0	We	_	_	O
1	previously	_	_	O
2	reported	_	_	O
3	that	_	_	O
4	treatment	_	_	O
5	of	_	_	O
6	patients	_	_	O
7	with	_	_	O
8	symptomatic	_	_	O
9	advanced	_	_	O
10	non-small	_	_	O
11	cell	_	_	O
12	lung	_	_	O
13	cancer	_	_	O
14	with	_	_	O
15	single	_	_	O
16	agent	_	_	O
17	Gemcitabine	_	_	O
18	(	_	_	O
19	GEM	_	_	O
20	)	_	_	O
21	resulted	_	_	O
22	in	_	_	O
23	a	_	_	O
24	superior	_	_	O
25	clinical-benefit	_	_	O
26	response	_	_	O
27	rate	_	_	O
28	(	_	_	O
29	RR	_	_	O
30	)	_	_	O
31	compared	_	_	O
32	to	_	_	O
33	cisplatin-based	_	_	O
34	combination	_	_	O
35	chemotherapy	_	_	O
36	.	_	_	O

37	We	_	_	O
38	now	_	_	O
39	report	_	_	O
40	the	_	_	O
41	detailed	_	_	O
42	individual	_	_	O
43	symptom	_	_	O
44	control	_	_	O
45	analysis	_	_	O
46	,	_	_	O
47	and	_	_	O
48	the	_	_	O
49	influence	_	_	O
50	of	_	_	O
51	cisplatin-use	_	_	O
52	,	_	_	O
53	age	_	_	O
54	,	_	_	O
55	performance	_	_	O
56	status	_	_	O
57	(	_	_	O
58	PS	_	_	O
59	)	_	_	O
60	and	_	_	O
61	duration	_	_	O
62	of	_	_	O
63	treatment	_	_	O
64	.	_	_	O

65	Patients	_	_	O
66	received	_	_	O
67	either	_	_	O
68	GEM	_	_	O
69	(	_	_	O
70	1000	_	_	O
71	mg/m	_	_	O
72	(	_	_	O
73	2	_	_	O
74	)	_	_	O
75	,	_	_	O
76	days	_	_	O
77	1	_	_	O
78	,	_	_	O
79	8	_	_	O
80	and	_	_	O
81	15	_	_	O
82	)	_	_	O
83	or	_	_	O
84	cisplatin	_	_	O
85	(	_	_	O
86	100	_	_	O
87	mg/m	_	_	O
88	(	_	_	O
89	2	_	_	O
90	)	_	_	O
91	,	_	_	O
92	day	_	_	O
93	1	_	_	O
94	)	_	_	O
95	plus	_	_	O
96	Vindesine	_	_	O
97	(	_	_	O
98	3	_	_	O
99	mg/m	_	_	O
100	(	_	_	O
101	2	_	_	O
102	)	_	_	O
103	,	_	_	O
104	days	_	_	O
105	1	_	_	O
106	and	_	_	O
107	15	_	_	O
108	)	_	_	O
109	(	_	_	O
110	PV	_	_	O
111	)	_	_	O
112	,	_	_	O
113	both	_	_	O
114	every	_	_	O
115	4	_	_	O
116	weeks	_	_	O
117	.	_	_	O

118	Scores	_	_	O
119	of	_	_	O
120	9	_	_	O
121	symptoms	_	_	O
122	were	_	_	O
123	listed	_	_	O
124	weekly	_	_	O
125	by	_	_	O
126	the	_	_	O
127	patient	_	_	O
128	on	_	_	O
129	visual	_	_	O
130	analogue	_	_	O
131	scales	_	_	O
132	.	_	_	O

133	Improvement	_	_	O
134	of	_	_	O
135	a	_	_	O
136	symptom	_	_	O
137	was	_	_	O
138	defined	_	_	O
139	as	_	_	O
140	2	_	_	O
141	consecutive	_	_	O
142	cycles	_	_	O
143	of	_	_	O
144	improvement	_	_	O
145	over	_	_	O
146	baseline	_	_	O
147	.	_	_	O

148	Baseline	_	_	O
149	symptoms	_	_	O
150	in	_	_	O
151	the	_	_	O
152	169	_	_	O
153	patients	_	_	O
154	were	_	_	O
155	well	_	_	O
156	balanced	_	_	O
157	between	_	_	O
158	the	_	_	O
159	2	_	_	O
160	arms	_	_	O
161	(	_	_	O
162	84	_	_	O
163	GEM	_	_	O
164	,	_	_	O
165	85	_	_	O
166	PV	_	_	O
167	)	_	_	O
168	.	_	_	O

169	Both	_	_	B-Premise
170	patients	_	_	I-Premise
171	with	_	_	I-Premise
172	objective	_	_	I-Premise
173	response	_	_	I-Premise
174	and	_	_	I-Premise
175	disease	_	_	I-Premise
176	stabilisation	_	_	I-Premise
177	had	_	_	I-Premise
178	clearly	_	_	I-Premise
179	better	_	_	I-Premise
180	symptom	_	_	I-Premise
181	control	_	_	I-Premise
182	than	_	_	I-Premise
183	those	_	_	I-Premise
184	with	_	_	I-Premise
185	disease	_	_	I-Premise
186	progression	_	_	I-Premise
187	.	_	_	I-Premise

188	Symptom	_	_	B-Premise
189	control	_	_	I-Premise
190	in	_	_	I-Premise
191	both	_	_	I-Premise
192	arms	_	_	I-Premise
193	was	_	_	I-Premise
194	similar	_	_	I-Premise
195	for	_	_	I-Premise
196	'disease-specific	_	_	I-Premise
197	'	_	_	I-Premise
198	symptoms	_	_	I-Premise
199	such	_	_	I-Premise
200	as	_	_	I-Premise
201	cough	_	_	I-Premise
202	,	_	_	I-Premise
203	dyspnea	_	_	I-Premise
204	,	_	_	I-Premise
205	pain	_	_	I-Premise
206	or	_	_	I-Premise
207	haemoptysis	_	_	I-Premise
208	.	_	_	I-Premise

209	Compared	_	_	B-Premise
210	to	_	_	I-Premise
211	PV	_	_	I-Premise
212	,	_	_	I-Premise
213	a	_	_	I-Premise
214	significantly	_	_	I-Premise
215	larger	_	_	I-Premise
216	number	_	_	I-Premise
217	of	_	_	I-Premise
218	GEM-patients	_	_	I-Premise
219	had	_	_	I-Premise
220	better	_	_	I-Premise
221	scores	_	_	I-Premise
222	for	_	_	I-Premise
223	'constitutional	_	_	I-Premise
224	'	_	_	I-Premise
225	items	_	_	I-Premise
226	such	_	_	I-Premise
227	as	_	_	I-Premise
228	anorexia	_	_	I-Premise
229	(	_	_	I-Premise
230	P=0.007	_	_	I-Premise
231	)	_	_	I-Premise
232	,	_	_	I-Premise
233	ability	_	_	I-Premise
234	to	_	_	I-Premise
235	carry	_	_	I-Premise
236	on	_	_	I-Premise
237	with	_	_	I-Premise
238	daily	_	_	I-Premise
239	activities	_	_	I-Premise
240	(	_	_	I-Premise
241	P=0.04	_	_	I-Premise
242	)	_	_	I-Premise
243	and	_	_	I-Premise
244	overall	_	_	I-Premise
245	impression	_	_	I-Premise
246	of	_	_	I-Premise
247	quality-of-life	_	_	I-Premise
248	(	_	_	I-Premise
249	P=0.008	_	_	I-Premise
250	)	_	_	I-Premise
251	.	_	_	I-Premise

252	Symptom	_	_	B-Premise
253	control	_	_	I-Premise
254	was	_	_	I-Premise
255	very	_	_	I-Premise
256	similar	_	_	I-Premise
257	in	_	_	I-Premise
258	younger	_	_	I-Premise
259	(	_	_	I-Premise
260	<	_	_	I-Premise
261	65	_	_	I-Premise
262	years	_	_	I-Premise
263	)	_	_	I-Premise
264	versus	_	_	I-Premise
265	older	_	_	I-Premise
266	(	_	_	I-Premise
267	>	_	_	I-Premise
268	/=65	_	_	I-Premise
269	years	_	_	I-Premise
270	)	_	_	I-Premise
271	patients	_	_	I-Premise
272	,	_	_	I-Premise
273	and	_	_	I-Premise
274	only	_	_	I-Premise
275	slightly	_	_	I-Premise
276	better	_	_	I-Premise
277	in	_	_	I-Premise
278	those	_	_	I-Premise
279	with	_	_	I-Premise
280	a	_	_	I-Premise
281	Karnofsky	_	_	I-Premise
282	PS	_	_	I-Premise
283	>	_	_	I-Premise
284	/=80	_	_	I-Premise
285	%	_	_	I-Premise
286	compared	_	_	I-Premise
287	to	_	_	I-Premise
288	those	_	_	I-Premise
289	<	_	_	I-Premise
290	80	_	_	I-Premise
291	%	_	_	I-Premise
292	.	_	_	I-Premise

293	Most	_	_	B-Premise
294	of	_	_	I-Premise
295	the	_	_	I-Premise
296	symptom	_	_	I-Premise
297	improvement	_	_	I-Premise
298	occurred	_	_	I-Premise
299	in	_	_	I-Premise
300	the	_	_	I-Premise
301	first	_	_	I-Premise
302	3	_	_	I-Premise
303	cycles	_	_	I-Premise
304	,	_	_	I-Premise
305	with	_	_	I-Premise
306	some	_	_	I-Premise
307	further	_	_	I-Premise
308	symptom	_	_	I-Premise
309	improvement	_	_	I-Premise
310	in	_	_	I-Premise
311	the	_	_	I-Premise
312	following	_	_	I-Premise
313	cycles	_	_	I-Premise
314	in	_	_	I-Premise
315	the	_	_	I-Premise
316	GEM-arm	_	_	I-Premise
317	only	_	_	I-Premise
318	.	_	_	I-Premise

319	Both	_	_	B-Claim
320	GEM	_	_	I-Claim
321	and	_	_	I-Claim
322	PV	_	_	I-Claim
323	yield	_	_	I-Claim
324	a	_	_	I-Claim
325	symptom	_	_	I-Claim
326	control	_	_	I-Claim
327	rate	_	_	I-Claim
328	much	_	_	I-Claim
329	higher	_	_	I-Claim
330	than	_	_	I-Claim
331	expected	_	_	I-Claim
332	by	_	_	I-Claim
333	the	_	_	I-Claim
334	objective	_	_	I-Claim
335	tumour	_	_	I-Claim
336	RR	_	_	I-Claim
337	.	_	_	I-Claim

338	GEM	_	_	B-Claim
339	is	_	_	I-Claim
340	equally	_	_	I-Claim
341	effective	_	_	I-Claim
342	in	_	_	I-Claim
343	controlling	_	_	I-Claim
344	'disease-specific	_	_	I-Claim
345	'	_	_	I-Claim
346	symptoms	_	_	I-Claim
347	,	_	_	I-Claim
348	but	_	_	I-Claim
349	superior	_	_	I-Claim
350	in	_	_	I-Claim
351	controlling	_	_	I-Claim
352	'constitutional	_	_	I-Claim
353	'	_	_	I-Claim
354	symptoms	_	_	I-Claim
355	.	_	_	I-Claim

356	Most	_	_	B-Premise
357	of	_	_	I-Premise
358	the	_	_	I-Premise
359	symptom	_	_	I-Premise
360	control	_	_	I-Premise
361	was	_	_	I-Premise
362	achieved	_	_	I-Premise
363	during	_	_	I-Premise
364	the	_	_	I-Premise
365	first	_	_	I-Premise
366	3	_	_	I-Premise
367	cycles	_	_	I-Premise
368	of	_	_	I-Premise
369	treatment	_	_	I-Premise
370	,	_	_	I-Premise
371	with	_	_	I-Premise
372	some	_	_	I-Premise
373	further	_	_	I-Premise
374	improvement	_	_	I-Premise
375	thereafter	_	_	I-Premise
376	in	_	_	I-Premise
377	the	_	_	I-Premise
378	GEM-arm	_	_	I-Premise
379	only	_	_	I-Premise
380	.	_	_	I-Premise


0	To	_	_	O
1	compare	_	_	O
2	1-year	_	_	O
3	outcomes	_	_	O
4	of	_	_	O
5	illuminated	_	_	O
6	microcatheter-assisted	_	_	O
7	circumferential	_	_	O
8	trabeculotomy	_	_	O
9	(	_	_	O
10	IMCT	_	_	O
11	)	_	_	O
12	vs	_	_	O
13	conventional	_	_	O
14	partial	_	_	O
15	trabeculotomy	_	_	O
16	(	_	_	O
17	CPT	_	_	O
18	)	_	_	O
19	for	_	_	O
20	primary	_	_	O
21	congenital	_	_	O
22	glaucoma	_	_	O
23	(	_	_	O
24	PCG	_	_	O
25	)	_	_	O
26	.	_	_	O

27	Forty	_	_	O
28	eyes	_	_	O
29	of	_	_	O
30	31	_	_	O
31	patients	_	_	O
32	with	_	_	O
33	unilateral	_	_	O
34	or	_	_	O
35	bilateral	_	_	O
36	primary	_	_	O
37	congenital	_	_	O
38	glaucoma	_	_	O
39	aged	_	_	O
40	less	_	_	O
41	than	_	_	O
42	2	_	_	O
43	years	_	_	O
44	were	_	_	O
45	randomized	_	_	O
46	to	_	_	O
47	undergo	_	_	O
48	IMCT	_	_	O
49	(	_	_	O
50	20	_	_	O
51	eyes	_	_	O
52	)	_	_	O
53	or	_	_	O
54	CPT	_	_	O
55	(	_	_	O
56	20	_	_	O
57	eyes	_	_	O
58	)	_	_	O
59	.	_	_	O

60	Primary	_	_	O
61	outcome	_	_	O
62	measure	_	_	O
63	was	_	_	O
64	intraocular	_	_	O
65	pressure	_	_	O
66	(	_	_	O
67	IOP	_	_	O
68	)	_	_	O
69	reduction	_	_	O
70	.	_	_	O

71	The	_	_	O
72	success	_	_	O
73	criterion	_	_	O
74	was	_	_	O
75	defined	_	_	O
76	as	_	_	O
77	IOP	_	_	O
78	≤	_	_	O
79	12	_	_	O
80	mm	_	_	O
81	Hg	_	_	O
82	without	_	_	O
83	and	_	_	O
84	with	_	_	O
85	antiglaucoma	_	_	O
86	medications	_	_	O
87	(	_	_	O
88	absolute	_	_	O
89	success	_	_	O
90	and	_	_	O
91	qualified	_	_	O
92	success	_	_	O
93	,	_	_	O
94	respectively	_	_	O
95	)	_	_	O
96	.	_	_	O

97	The	_	_	O
98	mean	_	_	O
99	age	_	_	O
100	of	_	_	O
101	our	_	_	O
102	study	_	_	O
103	population	_	_	O
104	was	_	_	O
105	8.35	_	_	O
106	±	_	_	O
107	1.2	_	_	O
108	months	_	_	O
109	.	_	_	O

110	The	_	_	O
111	mean	_	_	O
112	preoperative	_	_	O
113	IOP	_	_	O
114	was	_	_	O
115	24.70	_	_	O
116	±	_	_	O
117	3.90	_	_	O
118	mm	_	_	O
119	Hg	_	_	O
120	in	_	_	O
121	the	_	_	O
122	IMCT	_	_	O
123	group	_	_	O
124	and	_	_	O
125	24.60	_	_	O
126	±	_	_	O
127	3.31	_	_	O
128	mm	_	_	O
129	Hg	_	_	O
130	in	_	_	O
131	the	_	_	O
132	CPT	_	_	O
133	group	_	_	O
134	.	_	_	O

135	Both	_	_	O
136	groups	_	_	O
137	were	_	_	O
138	comparable	_	_	O
139	with	_	_	O
140	respect	_	_	O
141	to	_	_	O
142	preoperative	_	_	O
143	IOP	_	_	O
144	,	_	_	O
145	corneal	_	_	O
146	clarity	_	_	O
147	,	_	_	O
148	corneal	_	_	O
149	diameter	_	_	O
150	,	_	_	O
151	vertical	_	_	O
152	cup-to-disc	_	_	O
153	ratio	_	_	O
154	,	_	_	O
155	and	_	_	O
156	refractive	_	_	O
157	error	_	_	O
158	.	_	_	O

159	In	_	_	B-Premise
160	the	_	_	I-Premise
161	IMCT	_	_	I-Premise
162	group	_	_	I-Premise
163	,	_	_	I-Premise
164	360-degree	_	_	I-Premise
165	cannulation	_	_	I-Premise
166	was	_	_	I-Premise
167	achieved	_	_	I-Premise
168	in	_	_	I-Premise
169	80	_	_	I-Premise
170	%	_	_	I-Premise
171	(	_	_	I-Premise
172	16/20	_	_	I-Premise
173	)	_	_	I-Premise
174	of	_	_	I-Premise
175	eyes	_	_	I-Premise
176	.	_	_	I-Premise

177	For	_	_	B-Premise
178	the	_	_	I-Premise
179	IMCT	_	_	I-Premise
180	group	_	_	I-Premise
181	and	_	_	I-Premise
182	CPT	_	_	I-Premise
183	groups	_	_	I-Premise
184	,	_	_	I-Premise
185	respectively	_	_	I-Premise
186	,	_	_	I-Premise
187	the	_	_	I-Premise
188	absolute	_	_	I-Premise
189	success	_	_	I-Premise
190	rates	_	_	I-Premise
191	were	_	_	I-Premise
192	80	_	_	I-Premise
193	%	_	_	I-Premise
194	(	_	_	I-Premise
195	16/20	_	_	I-Premise
196	)	_	_	I-Premise
197	and	_	_	I-Premise
198	60	_	_	I-Premise
199	%	_	_	I-Premise
200	(	_	_	I-Premise
201	12/20	_	_	I-Premise
202	)	_	_	I-Premise
203	(	_	_	I-Premise
204	P	_	_	I-Premise
205	<	_	_	I-Premise
206	.001	_	_	I-Premise
207	)	_	_	I-Premise
208	and	_	_	I-Premise
209	qualified	_	_	I-Premise
210	success	_	_	I-Premise
211	rates	_	_	I-Premise
212	were	_	_	I-Premise
213	90	_	_	I-Premise
214	%	_	_	I-Premise
215	(	_	_	I-Premise
216	18/20	_	_	I-Premise
217	)	_	_	I-Premise
218	and	_	_	I-Premise
219	70	_	_	I-Premise
220	%	_	_	I-Premise
221	(	_	_	I-Premise
222	14/20	_	_	I-Premise
223	)	_	_	I-Premise
224	(	_	_	I-Premise
225	P	_	_	I-Premise
226	<	_	_	I-Premise
227	.001	_	_	I-Premise
228	)	_	_	I-Premise
229	.	_	_	I-Premise

230	Both	_	_	B-Claim
231	procedures	_	_	I-Claim
232	produced	_	_	I-Claim
233	a	_	_	I-Claim
234	statistically	_	_	I-Claim
235	significant	_	_	I-Claim
236	reduction	_	_	I-Claim
237	in	_	_	I-Claim
238	IOP	_	_	I-Claim
239	,	_	_	I-Claim
240	and	_	_	O
241	eyes	_	_	B-Premise
242	undergoing	_	_	I-Premise
243	IMCT	_	_	I-Premise
244	achieved	_	_	I-Premise
245	a	_	_	I-Premise
246	lower	_	_	I-Premise
247	IOP	_	_	I-Premise
248	than	_	_	I-Premise
249	CPT	_	_	I-Premise
250	group	_	_	I-Premise
251	eyes	_	_	I-Premise
252	at	_	_	I-Premise
253	12	_	_	I-Premise
254	months	_	_	I-Premise
255	follow-up	_	_	I-Premise
256	(	_	_	I-Premise
257	9.5	_	_	I-Premise
258	±	_	_	I-Premise
259	2.4	_	_	I-Premise
260	mm	_	_	I-Premise
261	Hg	_	_	I-Premise
262	and	_	_	I-Premise
263	11.7	_	_	I-Premise
264	±	_	_	I-Premise
265	2.1	_	_	I-Premise
266	mm	_	_	I-Premise
267	Hg	_	_	I-Premise
268	,	_	_	I-Premise
269	respectively	_	_	I-Premise
270	,	_	_	I-Premise
271	P	_	_	I-Premise
272	<	_	_	I-Premise
273	.001	_	_	I-Premise
274	)	_	_	I-Premise
275	.	_	_	I-Premise

276	In	_	_	B-Claim
277	primary	_	_	I-Claim
278	congential	_	_	I-Claim
279	glaucoma	_	_	I-Claim
280	,	_	_	I-Claim
281	illuminated	_	_	I-Claim
282	microcatheter-assisted	_	_	I-Claim
283	360-degree	_	_	I-Claim
284	circumferential	_	_	I-Claim
285	trabeculotomy	_	_	I-Claim
286	performed	_	_	I-Claim
287	better	_	_	I-Claim
288	than	_	_	I-Claim
289	conventional	_	_	I-Claim
290	partial	_	_	I-Claim
291	trabeculotomy	_	_	I-Claim
292	at	_	_	I-Claim
293	1	_	_	I-Claim
294	year	_	_	I-Claim
295	follow-up	_	_	I-Claim
296	and	_	_	I-Claim
297	resulted	_	_	I-Claim
298	in	_	_	I-Claim
299	significantly	_	_	I-Claim
300	lower	_	_	I-Claim
301	IOP	_	_	I-Claim
302	measurements	_	_	I-Claim
303	.	_	_	I-Claim


0	The	_	_	O
1	oral	_	_	O
2	Toll-like	_	_	O
3	receptor	_	_	O
4	(	_	_	O
5	TLR	_	_	O
6	)	_	_	O
7	7	_	_	O
8	agonist	_	_	O
9	GS-9620	_	_	O
10	has	_	_	O
11	antiviral	_	_	O
12	effects	_	_	O
13	in	_	_	O
14	woodchuck	_	_	O
15	and	_	_	O
16	chimpanzee	_	_	O
17	models	_	_	O
18	of	_	_	O
19	chronic	_	_	O
20	hepatitis	_	_	O
21	B	_	_	O
22	virus	_	_	O
23	(	_	_	O
24	HBV	_	_	O
25	)	_	_	O
26	infection	_	_	O
27	.	_	_	O

28	We	_	_	O
29	investigated	_	_	O
30	,	_	_	O
31	in	_	_	O
32	a	_	_	O
33	clinical	_	_	O
34	trial	_	_	O
35	,	_	_	O
36	the	_	_	O
37	capacity	_	_	O
38	of	_	_	O
39	this	_	_	O
40	agent	_	_	O
41	to	_	_	O
42	reconstitute	_	_	O
43	protective	_	_	O
44	immunity	_	_	O
45	in	_	_	O
46	patients	_	_	O
47	with	_	_	O
48	chronic	_	_	O
49	HBV	_	_	O
50	infection	_	_	O
51	.	_	_	O

52	We	_	_	O
53	performed	_	_	O
54	a	_	_	O
55	prospective	_	_	O
56	study	_	_	O
57	of	_	_	O
58	28	_	_	O
59	patients	_	_	O
60	with	_	_	O
61	suppression	_	_	O
62	of	_	_	O
63	HBV	_	_	O
64	infection	_	_	O
65	by	_	_	O
66	nucleos	_	_	O
67	(	_	_	O
68	t	_	_	O
69	)	_	_	O
70	ide	_	_	O
71	analogue	_	_	O
72	therapy	_	_	O
73	and	_	_	O
74	who	_	_	O
75	tested	_	_	O
76	negative	_	_	O
77	for	_	_	O
78	hepatitis	_	_	O
79	B	_	_	O
80	e	_	_	O
81	antigen	_	_	O
82	at	_	_	O
83	4	_	_	O
84	medical	_	_	O
85	centers	_	_	O
86	in	_	_	O
87	Italy	_	_	O
88	.	_	_	O

89	Patients	_	_	O
90	were	_	_	O
91	randomly	_	_	O
92	assigned	_	_	O
93	(	_	_	O
94	1:3:3:3	_	_	O
95	)	_	_	O
96	to	_	_	O
97	groups	_	_	O
98	given	_	_	O
99	placebo	_	_	O
100	or	_	_	O
101	different	_	_	O
102	doses	_	_	O
103	of	_	_	O
104	GS-9620	_	_	O
105	(	_	_	O
106	1	_	_	O
107	,	_	_	O
108	2	_	_	O
109	,	_	_	O
110	and	_	_	O
111	4	_	_	O
112	mg	_	_	O
113	,	_	_	O
114	weekly	_	_	O
115	for	_	_	O
116	12	_	_	O
117	weeks	_	_	O
118	)	_	_	O
119	.	_	_	O

120	We	_	_	O
121	added	_	_	O
122	data	_	_	O
123	from	_	_	O
124	8	_	_	O
125	patients	_	_	O
126	receiving	_	_	O
127	nucleos	_	_	O
128	(	_	_	O
129	t	_	_	O
130	)	_	_	O
131	ide	_	_	O
132	analogue	_	_	O
133	therapy	_	_	O
134	to	_	_	O
135	the	_	_	O
136	placebo	_	_	O
137	group	_	_	O
138	(	_	_	O
139	controls	_	_	O
140	)	_	_	O
141	;	_	_	O
142	13	_	_	O
143	treatment-naïve	_	_	O
144	patients	_	_	O
145	with	_	_	O
146	chronic	_	_	O
147	HBV	_	_	O
148	infection	_	_	O
149	and	_	_	O
150	15	_	_	O
151	subjects	_	_	O
152	who	_	_	O
153	spontaneously	_	_	O
154	recovered	_	_	O
155	from	_	_	O
156	an	_	_	O
157	acute	_	_	O
158	HBV	_	_	O
159	infection	_	_	O
160	served	_	_	O
161	as	_	_	O
162	additional	_	_	O
163	controls	_	_	O
164	.	_	_	O

165	Peripheral	_	_	O
166	blood	_	_	O
167	mononuclear	_	_	O
168	cells	_	_	O
169	were	_	_	O
170	collected	_	_	O
171	at	_	_	O
172	baseline	_	_	O
173	,	_	_	O
174	during	_	_	O
175	administration	_	_	O
176	of	_	_	O
177	GS-9620	_	_	O
178	or	_	_	O
179	placebo	_	_	O
180	,	_	_	O
181	and	_	_	O
182	12	_	_	O
183	weeks	_	_	O
184	afterward	_	_	O
185	.	_	_	O

186	Phenotype	_	_	O
187	and	_	_	O
188	function	_	_	O
189	of	_	_	O
190	natural	_	_	O
191	killer	_	_	O
192	(	_	_	O
193	NK	_	_	O
194	)	_	_	O
195	and	_	_	O
196	HBV-specific	_	_	O
197	T	_	_	O
198	cells	_	_	O
199	were	_	_	O
200	analyzed	_	_	O
201	by	_	_	O
202	flow	_	_	O
203	cytometry	_	_	O
204	.	_	_	O

205	T	_	_	O
206	cells	_	_	O
207	were	_	_	O
208	expanded	_	_	O
209	by	_	_	O
210	incubation	_	_	O
211	with	_	_	O
212	peptides	_	_	O
213	from	_	_	O
214	the	_	_	O
215	entire	_	_	O
216	HBV	_	_	O
217	proteome	_	_	O
218	and	_	_	O
219	studied	_	_	O
220	after	_	_	O
221	overnight	_	_	O
222	or	_	_	O
223	10	_	_	O
224	days	_	_	O
225	culture	_	_	O
226	.	_	_	O

227	NK-cell	_	_	O
228	inhibition	_	_	O
229	of	_	_	O
230	T-cell	_	_	O
231	responses	_	_	O
232	was	_	_	O
233	measured	_	_	O
234	by	_	_	O
235	assessing	_	_	O
236	cytokine	_	_	O
237	production	_	_	O
238	by	_	_	O
239	T	_	_	O
240	cells	_	_	O
241	stimulated	_	_	O
242	with	_	_	O
243	peptides	_	_	O
244	in	_	_	O
245	the	_	_	O
246	presence	_	_	O
247	or	_	_	O
248	absence	_	_	O
249	of	_	_	O
250	NK	_	_	O
251	cells	_	_	O
252	.	_	_	O

253	T	_	_	B-Premise
254	cells	_	_	I-Premise
255	collected	_	_	I-Premise
256	at	_	_	I-Premise
257	baseline	_	_	I-Premise
258	before	_	_	I-Premise
259	addition	_	_	I-Premise
260	of	_	_	I-Premise
261	GS-9620	_	_	I-Premise
262	,	_	_	I-Premise
263	when	_	_	I-Premise
264	patients	_	_	I-Premise
265	were	_	_	I-Premise
266	receiving	_	_	I-Premise
267	only	_	_	I-Premise
268	nucleos	_	_	I-Premise
269	(	_	_	I-Premise
270	t	_	_	I-Premise
271	)	_	_	I-Premise
272	ide	_	_	I-Premise
273	therapy	_	_	I-Premise
274	,	_	_	I-Premise
275	had	_	_	I-Premise
276	greater	_	_	I-Premise
277	responses	_	_	I-Premise
278	to	_	_	I-Premise
279	HBV	_	_	I-Premise
280	than	_	_	I-Premise
281	T	_	_	I-Premise
282	cells	_	_	I-Premise
283	from	_	_	I-Premise
284	treatment-naïve	_	_	I-Premise
285	patients	_	_	I-Premise
286	,	_	_	I-Premise
287	based	_	_	I-Premise
288	on	_	_	I-Premise
289	cytokine	_	_	I-Premise
290	production	_	_	I-Premise
291	in	_	_	I-Premise
292	response	_	_	I-Premise
293	to	_	_	I-Premise
294	HBV	_	_	I-Premise
295	peptides	_	_	I-Premise
296	.	_	_	I-Premise

297	However	_	_	B-Premise
298	,	_	_	I-Premise
299	during	_	_	I-Premise
300	or	_	_	I-Premise
301	after	_	_	I-Premise
302	administration	_	_	I-Premise
303	of	_	_	I-Premise
304	GS-9620	_	_	I-Premise
305	,	_	_	I-Premise
306	T	_	_	I-Premise
307	cells	_	_	I-Premise
308	produced	_	_	I-Premise
309	higher	_	_	I-Premise
310	levels	_	_	I-Premise
311	of	_	_	I-Premise
312	cytokines	_	_	I-Premise
313	compared	_	_	I-Premise
314	to	_	_	I-Premise
315	baseline	_	_	I-Premise
316	.	_	_	I-Premise

317	NK-cell	_	_	B-Premise
318	activation	_	_	I-Premise
319	and	_	_	I-Premise
320	function	_	_	I-Premise
321	increased	_	_	I-Premise
322	after	_	_	I-Premise
323	patients	_	_	I-Premise
324	were	_	_	I-Premise
325	given	_	_	I-Premise
326	GS-9620	_	_	I-Premise
327	,	_	_	I-Premise
328	but	_	_	I-Premise
329	the	_	_	I-Premise
330	ability	_	_	I-Premise
331	of	_	_	I-Premise
332	NK	_	_	I-Premise
333	cells	_	_	I-Premise
334	to	_	_	I-Premise
335	suppress	_	_	I-Premise
336	T-cell	_	_	I-Premise
337	responses	_	_	I-Premise
338	was	_	_	I-Premise
339	lower	_	_	I-Premise
340	during	_	_	I-Premise
341	GS-9620	_	_	I-Premise
342	therapy	_	_	I-Premise
343	than	_	_	I-Premise
344	before	_	_	I-Premise
345	.	_	_	I-Premise

346	Changes	_	_	B-Premise
347	in	_	_	I-Premise
348	T-cell	_	_	I-Premise
349	or	_	_	I-Premise
350	NK-cell	_	_	I-Premise
351	function	_	_	I-Premise
352	did	_	_	I-Premise
353	not	_	_	I-Premise
354	correlate	_	_	I-Premise
355	with	_	_	I-Premise
356	levels	_	_	I-Premise
357	of	_	_	I-Premise
358	hepatitis	_	_	I-Premise
359	B	_	_	I-Premise
360	surface	_	_	I-Premise
361	antigen	_	_	I-Premise
362	.	_	_	I-Premise

363	Serum	_	_	B-Premise
364	levels	_	_	I-Premise
365	of	_	_	I-Premise
366	hepatitis	_	_	I-Premise
367	B	_	_	I-Premise
368	surface	_	_	I-Premise
369	antigen	_	_	I-Premise
370	did	_	_	I-Premise
371	not	_	_	I-Premise
372	decrease	_	_	I-Premise
373	significantly	_	_	I-Premise
374	compared	_	_	I-Premise
375	to	_	_	I-Premise
376	baseline	_	_	I-Premise
377	in	_	_	I-Premise
378	patients	_	_	I-Premise
379	given	_	_	I-Premise
380	any	_	_	I-Premise
381	dose	_	_	I-Premise
382	of	_	_	I-Premise
383	GS-9620	_	_	I-Premise
384	.	_	_	I-Premise

385	Twelve	_	_	B-Claim
386	weeks	_	_	I-Claim
387	administration	_	_	I-Claim
388	of	_	_	I-Claim
389	GS-9620	_	_	I-Claim
390	had	_	_	I-Claim
391	no	_	_	I-Claim
392	significant	_	_	I-Claim
393	effect	_	_	I-Claim
394	on	_	_	I-Claim
395	serum	_	_	I-Claim
396	hepatitis	_	_	I-Claim
397	B	_	_	I-Claim
398	surface	_	_	I-Claim
399	antigen	_	_	I-Claim
400	levels	_	_	I-Claim
401	,	_	_	I-Claim
402	but	_	_	I-Claim
403	did	_	_	I-Claim
404	appear	_	_	I-Claim
405	to	_	_	I-Claim
406	increase	_	_	I-Claim
407	T-cell	_	_	I-Claim
408	and	_	_	I-Claim
409	NK-cell	_	_	I-Claim
410	responses	_	_	I-Claim
411	and	_	_	I-Claim
412	reduce	_	_	I-Claim
413	the	_	_	I-Claim
414	ability	_	_	I-Claim
415	of	_	_	I-Claim
416	NK	_	_	I-Claim
417	to	_	_	I-Claim
418	suppress	_	_	I-Claim
419	T	_	_	I-Claim
420	cells	_	_	I-Claim
421	.	_	_	I-Claim

422	GS-9620	_	_	B-Claim
423	might	_	_	I-Claim
424	therefore	_	_	I-Claim
425	be	_	_	I-Claim
426	included	_	_	I-Claim
427	in	_	_	I-Claim
428	therapies	_	_	I-Claim
429	to	_	_	I-Claim
430	increase	_	_	I-Claim
431	the	_	_	I-Claim
432	immune	_	_	I-Claim
433	response	_	_	I-Claim
434	to	_	_	I-Claim
435	HBV	_	_	I-Claim
436	.	_	_	I-Claim


0	Adherence	_	_	O
1	to	_	_	O
2	appropriate	_	_	O
3	nutrition	_	_	O
4	and	_	_	O
5	fluid	_	_	O
6	intake	_	_	O
7	is	_	_	O
8	one	_	_	O
9	of	_	_	O
10	the	_	_	O
11	essential	_	_	O
12	parts	_	_	O
13	of	_	_	O
14	chronic	_	_	O
15	renal	_	_	O
16	failure	_	_	O
17	treatment	_	_	O
18	for	_	_	O
19	achieving	_	_	O
20	the	_	_	O
21	desirable	_	_	O
22	results	_	_	O
23	among	_	_	O
24	the	_	_	O
25	patients	_	_	O
26	with	_	_	O
27	hemodialysis	_	_	O
28	.	_	_	O

29	Among	_	_	O
30	various	_	_	O
31	training	_	_	O
32	methods	_	_	O
33	,	_	_	O
34	the	_	_	O
35	"	_	_	O
36	small	_	_	O
37	groups	_	_	O
38	'	_	_	O
39	method	_	_	O
40	"	_	_	O
41	,	_	_	O
42	as	_	_	O
43	an	_	_	O
44	advanced	_	_	O
45	method	_	_	O
46	,	_	_	O
47	can	_	_	O
48	be	_	_	O
49	performed	_	_	O
50	by	_	_	O
51	nurses	_	_	O
52	in	_	_	O
53	achieving	_	_	O
54	desirable	_	_	O
55	therapeutic	_	_	O
56	results	_	_	O
57	.	_	_	O

58	The	_	_	O
59	present	_	_	O
60	study	_	_	O
61	was	_	_	O
62	aimed	_	_	O
63	to	_	_	O
64	investigate	_	_	O
65	the	_	_	O
66	effect	_	_	O
67	of	_	_	O
68	appropriate	_	_	O
69	nutrition	_	_	O
70	training	_	_	O
71	in	_	_	O
72	small	_	_	O
73	groups	_	_	O
74	on	_	_	O
75	laboratory	_	_	O
76	parameters	_	_	O
77	in	_	_	O
78	hemodialysis	_	_	O
79	patients	_	_	O
80	.	_	_	O

81	In	_	_	O
82	this	_	_	O
83	clinical	_	_	O
84	trial	_	_	O
85	,	_	_	O
86	64	_	_	O
87	patients	_	_	O
88	who	_	_	O
89	met	_	_	O
90	the	_	_	O
91	inclusion	_	_	O
92	criteria	_	_	O
93	were	_	_	O
94	randomly	_	_	O
95	selected	_	_	O
96	and	_	_	O
97	divided	_	_	O
98	into	_	_	O
99	an	_	_	O
100	intervention	_	_	O
101	group	_	_	O
102	and	_	_	O
103	a	_	_	O
104	control	_	_	O
105	group	_	_	O
106	.	_	_	O

107	Subsequently	_	_	O
108	,	_	_	O
109	an	_	_	O
110	appropriate	_	_	O
111	nutritional	_	_	O
112	training	_	_	O
113	program	_	_	O
114	,	_	_	O
115	including	_	_	O
116	lectures	_	_	O
117	along	_	_	O
118	with	_	_	O
119	appropriate	_	_	O
120	nutrition	_	_	O
121	pamphlets	_	_	O
122	in	_	_	O
123	three	_	_	O
124	one	_	_	O
125	hour	_	_	O
126	question	_	_	O
127	and	_	_	O
128	answer	_	_	O
129	sessions	_	_	O
130	were	_	_	O
131	performed	_	_	O
132	.	_	_	O

133	Thirty	_	_	O
134	two	_	_	O
135	patients	_	_	O
136	in	_	_	O
137	each	_	_	O
138	group	_	_	O
139	were	_	_	O
140	assigned	_	_	O
141	to	_	_	O
142	intervention	_	_	O
143	groups	_	_	O
144	of	_	_	O
145	five	_	_	O
146	.	_	_	O

147	Then	_	_	O
148	,	_	_	O
149	the	_	_	O
150	laboratory	_	_	O
151	indicators	_	_	O
152	for	_	_	O
153	each	_	_	O
154	patient	_	_	O
155	were	_	_	O
156	measured	_	_	O
157	in	_	_	O
158	each	_	_	O
159	group	_	_	O
160	one	_	_	O
161	month	_	_	O
162	after	_	_	O
163	training	_	_	O
164	.	_	_	O

165	Thereafter	_	_	O
166	,	_	_	O
167	data	_	_	O
168	analysis	_	_	O
169	was	_	_	O
170	performed	_	_	O
171	using	_	_	O
172	descriptive	_	_	O
173	and	_	_	O
174	analytical	_	_	O
175	statistics	_	_	O
176	(	_	_	O
177	statistical	_	_	O
178	tests	_	_	O
179	including	_	_	O
180	independent	_	_	O
181	t-test	_	_	O
182	,	_	_	O
183	paired	_	_	O
184	t-test	_	_	O
185	,	_	_	O
186	repeated	_	_	O
187	measures	_	_	O
188	,	_	_	O
189	and	_	_	O
190	ANOVA	_	_	O
191	)	_	_	O
192	in	_	_	O
193	SPSS	_	_	O
194	V.16	_	_	O
195	software	_	_	O
196	.	_	_	O

197	The	_	_	O
198	mean	_	_	O
199	age	_	_	O
200	of	_	_	O
201	the	_	_	O
202	patients	_	_	O
203	was	_	_	O
204	50.1	_	_	O
205	±	_	_	O
206	13.1	_	_	O
207	years	_	_	O
208	;	_	_	O
209	47.5	_	_	O
210	%	_	_	O
211	of	_	_	O
212	them	_	_	O
213	had	_	_	O
214	undergone	_	_	O
215	dialysis	_	_	O
216	due	_	_	O
217	to	_	_	O
218	hypertension	_	_	O
219	and	_	_	O
220	55.7	_	_	O
221	%	_	_	O
222	had	_	_	O
223	a	_	_	O
224	history	_	_	O
225	of	_	_	O
226	1-5	_	_	O
227	years	_	_	O
228	of	_	_	O
229	hemodialysis	_	_	O
230	.	_	_	O

231	There	_	_	B-Premise
232	was	_	_	I-Premise
233	a	_	_	I-Premise
234	significant	_	_	I-Premise
235	difference	_	_	I-Premise
236	in	_	_	I-Premise
237	post-intervention	_	_	I-Premise
238	levels	_	_	I-Premise
239	of	_	_	I-Premise
240	urea	_	_	I-Premise
241	,	_	_	I-Premise
242	creatinine	_	_	I-Premise
243	,	_	_	I-Premise
244	sodium	_	_	I-Premise
245	,	_	_	I-Premise
246	potassium	_	_	I-Premise
247	,	_	_	I-Premise
248	calcium	_	_	I-Premise
249	,	_	_	I-Premise
250	and	_	_	I-Premise
251	phosphorus	_	_	I-Premise
252	between	_	_	I-Premise
253	the	_	_	I-Premise
254	two	_	_	I-Premise
255	groups	_	_	I-Premise
256	.	_	_	I-Premise

257	Appropriate	_	_	B-Claim
258	nutrition	_	_	I-Claim
259	training	_	_	I-Claim
260	via	_	_	I-Claim
261	small-group	_	_	I-Claim
262	method	_	_	I-Claim
263	for	_	_	I-Claim
264	patients	_	_	I-Claim
265	on	_	_	I-Claim
266	hemodialysis	_	_	I-Claim
267	can	_	_	I-Claim
268	impose	_	_	I-Claim
269	positive	_	_	I-Claim
270	effects	_	_	I-Claim
271	on	_	_	I-Claim
272	laboratory	_	_	I-Claim
273	parameters	_	_	I-Claim
274	.	_	_	I-Claim


0	In	_	_	B-Claim
1	patients	_	_	I-Claim
2	with	_	_	I-Claim
3	chronic	_	_	I-Claim
4	hepatitis	_	_	I-Claim
5	B	_	_	I-Claim
6	,	_	_	I-Claim
7	tenofovir	_	_	I-Claim
8	disoproxil	_	_	I-Claim
9	fumarate	_	_	I-Claim
10	(	_	_	I-Claim
11	TDF	_	_	I-Claim
12	)	_	_	I-Claim
13	plus	_	_	I-Claim
14	pegylated	_	_	I-Claim
15	interferon	_	_	I-Claim
16	(	_	_	I-Claim
17	PEG-IFN	_	_	I-Claim
18	)	_	_	I-Claim
19	for	_	_	I-Claim
20	48-weeks	_	_	I-Claim
21	results	_	_	I-Claim
22	in	_	_	I-Claim
23	higher	_	_	I-Claim
24	rates	_	_	I-Claim
25	of	_	_	I-Claim
26	hepatitis	_	_	I-Claim
27	B	_	_	I-Claim
28	surface	_	_	I-Claim
29	antigen	_	_	I-Claim
30	(	_	_	I-Claim
31	HBsAg	_	_	I-Claim
32	)	_	_	I-Claim
33	loss	_	_	I-Claim
34	than	_	_	I-Claim
35	either	_	_	I-Claim
36	monotherapy	_	_	I-Claim
37	.	_	_	I-Claim

38	To	_	_	O
39	identify	_	_	O
40	baseline	_	_	O
41	and	_	_	O
42	on-treatment	_	_	O
43	factors	_	_	O
44	associated	_	_	O
45	with	_	_	O
46	HBsAg	_	_	O
47	loss	_	_	O
48	at	_	_	O
49	Week	_	_	O
50	72	_	_	O
51	and	_	_	O
52	provide	_	_	O
53	a	_	_	O
54	model	_	_	O
55	for	_	_	O
56	predicting	_	_	O
57	HBsAg	_	_	O
58	loss	_	_	O
59	in	_	_	O
60	patients	_	_	O
61	receiving	_	_	O
62	combination	_	_	O
63	therapy	_	_	O
64	for	_	_	O
65	48	_	_	O
66	weeks	_	_	O
67	.	_	_	O

68	A	_	_	O
69	secondary	_	_	O
70	analysis	_	_	O
71	of	_	_	O
72	data	_	_	O
73	from	_	_	O
74	an	_	_	O
75	open-label	_	_	O
76	study	_	_	O
77	where	_	_	O
78	patients	_	_	O
79	were	_	_	O
80	randomised	_	_	O
81	to	_	_	O
82	TDF	_	_	O
83	(	_	_	O
84	300	_	_	O
85	mg/day	_	_	O
86	,	_	_	O
87	oral	_	_	O
88	)	_	_	O
89	plus	_	_	O
90	PEG-IFN	_	_	O
91	(	_	_	O
92	PI	_	_	O
93	,	_	_	O
94	180	_	_	O
95	μg/week	_	_	O
96	,	_	_	O
97	subcutaneous	_	_	O
98	)	_	_	O
99	for	_	_	O
100	48	_	_	O
101	weeks	_	_	O
102	(	_	_	O
103	TDF/PI-48w	_	_	O
104	)	_	_	O
105	;	_	_	O
106	TDF	_	_	O
107	plus	_	_	O
108	PEG-IFN	_	_	O
109	for	_	_	O
110	16	_	_	O
111	weeks	_	_	O
112	,	_	_	O
113	TDF	_	_	O
114	for	_	_	O
115	32	_	_	O
116	weeks	_	_	O
117	(	_	_	O
118	TDF/PI-16w+TDF-32w	_	_	O
119	)	_	_	O
120	;	_	_	O
121	TDF	_	_	O
122	for	_	_	O
123	120	_	_	O
124	weeks	_	_	O
125	(	_	_	O
126	TDF-120w	_	_	O
127	)	_	_	O
128	or	_	_	O
129	PEG-IFN	_	_	O
130	for	_	_	O
131	48	_	_	O
132	weeks	_	_	O
133	(	_	_	O
134	PI-48w	_	_	O
135	)	_	_	O
136	.	_	_	O

137	Logistic	_	_	O
138	regression	_	_	O
139	methods	_	_	O
140	were	_	_	O
141	used	_	_	O
142	to	_	_	O
143	identify	_	_	O
144	models	_	_	O
145	that	_	_	O
146	best	_	_	O
147	predicted	_	_	O
148	HBsAg	_	_	O
149	loss	_	_	O
150	at	_	_	O
151	Week	_	_	O
152	72	_	_	O
153	.	_	_	O

154	Rates	_	_	B-Premise
155	of	_	_	I-Premise
156	HBsAg	_	_	I-Premise
157	loss	_	_	I-Premise
158	at	_	_	I-Premise
159	Week	_	_	I-Premise
160	72	_	_	I-Premise
161	were	_	_	I-Premise
162	significantly	_	_	I-Premise
163	higher	_	_	I-Premise
164	in	_	_	I-Premise
165	the	_	_	I-Premise
166	TDF/PI-48w	_	_	I-Premise
167	group	_	_	I-Premise
168	(	_	_	I-Premise
169	6.5	_	_	I-Premise
170	%	_	_	I-Premise
171	)	_	_	I-Premise
172	than	_	_	I-Premise
173	in	_	_	I-Premise
174	the	_	_	I-Premise
175	TDF/PI-16w+TDF-32w	_	_	I-Premise
176	(	_	_	I-Premise
177	0.5	_	_	I-Premise
178	%	_	_	I-Premise
179	)	_	_	I-Premise
180	,	_	_	I-Premise
181	TDF-120w	_	_	I-Premise
182	(	_	_	I-Premise
183	0	_	_	I-Premise
184	%	_	_	I-Premise
185	)	_	_	I-Premise
186	and	_	_	I-Premise
187	PI-48w	_	_	I-Premise
188	(	_	_	I-Premise
189	2.2	_	_	I-Premise
190	%	_	_	I-Premise
191	)	_	_	I-Premise
192	groups	_	_	I-Premise
193	(	_	_	I-Premise
194	P	_	_	I-Premise
195	=	_	_	I-Premise
196	0.09	_	_	I-Premise
197	)	_	_	I-Premise
198	.	_	_	I-Premise

199	The	_	_	O
200	only	_	_	O
201	baseline	_	_	O
202	factor	_	_	O
203	associated	_	_	O
204	with	_	_	O
205	response	_	_	O
206	was	_	_	O
207	genotype	_	_	O
208	A.	_	_	O
209	HBsAg	_	_	B-Premise
210	decline	_	_	I-Premise
211	at	_	_	I-Premise
212	Week	_	_	I-Premise
213	12	_	_	I-Premise
214	or	_	_	I-Premise
215	24	_	_	I-Premise
216	of	_	_	I-Premise
217	treatment	_	_	I-Premise
218	was	_	_	I-Premise
219	associated	_	_	I-Premise
220	with	_	_	I-Premise
221	HBsAg	_	_	I-Premise
222	loss	_	_	I-Premise
223	at	_	_	I-Premise
224	Week	_	_	I-Premise
225	72	_	_	I-Premise
226	(	_	_	I-Premise
227	P	_	_	I-Premise
228	<	_	_	I-Premise
229	0.001	_	_	I-Premise
230	)	_	_	I-Premise
231	.	_	_	I-Premise

232	HBsAg	_	_	B-Premise
233	decline	_	_	I-Premise
234	>	_	_	I-Premise
235	3.5	_	_	I-Premise
236	log10	_	_	I-Premise
237	IU/mL	_	_	I-Premise
238	at	_	_	I-Premise
239	Week	_	_	I-Premise
240	24	_	_	I-Premise
241	in	_	_	I-Premise
242	the	_	_	I-Premise
243	TDF/PI-48w	_	_	I-Premise
244	group	_	_	I-Premise
245	resulted	_	_	I-Premise
246	in	_	_	I-Premise
247	a	_	_	I-Premise
248	positive	_	_	I-Premise
249	predictive	_	_	I-Premise
250	value	_	_	I-Premise
251	of	_	_	I-Premise
252	85	_	_	I-Premise
253	%	_	_	I-Premise
254	and	_	_	I-Premise
255	a	_	_	I-Premise
256	negative	_	_	I-Premise
257	predictive	_	_	I-Premise
258	value	_	_	I-Premise
259	of	_	_	I-Premise
260	99	_	_	I-Premise
261	%	_	_	I-Premise
262	for	_	_	I-Premise
263	HBsAg	_	_	I-Premise
264	loss	_	_	I-Premise
265	at	_	_	I-Premise
266	Week	_	_	I-Premise
267	72	_	_	I-Premise
268	.	_	_	I-Premise

269	HBsAg	_	_	B-Claim
270	decline	_	_	I-Claim
271	at	_	_	I-Claim
272	Week	_	_	I-Claim
273	24	_	_	I-Claim
274	of	_	_	I-Claim
275	TDF	_	_	I-Claim
276	plus	_	_	I-Claim
277	PEG-IFN	_	_	I-Claim
278	combination	_	_	I-Claim
279	therapy	_	_	I-Claim
280	may	_	_	I-Claim
281	identify	_	_	I-Claim
282	patients	_	_	I-Claim
283	who	_	_	I-Claim
284	,	_	_	I-Claim
285	after	_	_	I-Claim
286	completing	_	_	I-Claim
287	48	_	_	I-Claim
288	weeks	_	_	I-Claim
289	of	_	_	I-Claim
290	treatment	_	_	I-Claim
291	,	_	_	I-Claim
292	have	_	_	I-Claim
293	a	_	_	I-Claim
294	better	_	_	I-Claim
295	chance	_	_	I-Claim
296	of	_	_	I-Claim
297	achieving	_	_	I-Claim
298	HBsAg	_	_	I-Claim
299	loss	_	_	I-Claim
300	at	_	_	I-Claim
301	Week	_	_	I-Claim
302	72	_	_	I-Claim
303	.	_	_	I-Claim


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	this	_	_	O
4	work	_	_	O
5	is	_	_	O
6	to	_	_	O
7	evaluate	_	_	O
8	efficacy	_	_	O
9	and	_	_	O
10	tolerability	_	_	O
11	of	_	_	O
12	preservative	_	_	O
13	containing	_	_	O
14	0.0015	_	_	O
15	%	_	_	O
16	tafluprost	_	_	O
17	and	_	_	O
18	preservative-free	_	_	O
19	0.0015	_	_	O
20	%	_	_	O
21	tafluprost	_	_	O
22	using	_	_	O
23	a	_	_	O
24	prospective	_	_	O
25	crossover	_	_	O
26	study	_	_	O
27	.	_	_	O

28	Primary	_	_	O
29	open	_	_	O
30	angle	_	_	O
31	glaucoma	_	_	O
32	(	_	_	O
33	POAG	_	_	O
34	)	_	_	O
35	and	_	_	O
36	normotensive	_	_	O
37	glaucoma	_	_	O
38	(	_	_	O
39	NTG	_	_	O
40	)	_	_	O
41	patients	_	_	O
42	were	_	_	O
43	randomized	_	_	O
44	enrolled	_	_	O
45	.	_	_	O

46	Group	_	_	O
47	1	_	_	O
48	(	_	_	O
49	"	_	_	O
50	NPT	_	_	O
51	to	_	_	O
52	PT	_	_	O
53	"	_	_	O
54	)	_	_	O
55	patients	_	_	O
56	used	_	_	O
57	preservative-free	_	_	O
58	0.0015	_	_	O
59	%	_	_	O
60	tafluprost	_	_	O
61	(	_	_	O
62	NPT	_	_	O
63	)	_	_	O
64	for	_	_	O
65	6	_	_	O
66	months	_	_	O
67	and	_	_	O
68	then	_	_	O
69	changed	_	_	O
70	to	_	_	O
71	preservative	_	_	O
72	containing	_	_	O
73	0.0015	_	_	O
74	%	_	_	O
75	tafluprost	_	_	O
76	(	_	_	O
77	PT	_	_	O
78	)	_	_	O
79	for	_	_	O
80	6	_	_	O
81	months	_	_	O
82	.	_	_	O

83	Group	_	_	O
84	2	_	_	O
85	(	_	_	O
86	"	_	_	O
87	PT	_	_	O
88	to	_	_	O
89	NPT	_	_	O
90	"	_	_	O
91	)	_	_	O
92	patients	_	_	O
93	used	_	_	O
94	preservative	_	_	O
95	containing	_	_	O
96	0.0015	_	_	O
97	%	_	_	O
98	tafluprost	_	_	O
99	for	_	_	O
100	6	_	_	O
101	months	_	_	O
102	and	_	_	O
103	changed	_	_	O
104	to	_	_	O
105	preservative-free	_	_	O
106	0.0015	_	_	O
107	%	_	_	O
108	tafluprost	_	_	O
109	for	_	_	O
110	6	_	_	O
111	months	_	_	O
112	.	_	_	O

113	At	_	_	O
114	1	_	_	O
115	,	_	_	O
116	3	_	_	O
117	,	_	_	O
118	6	_	_	O
119	,	_	_	O
120	7	_	_	O
121	,	_	_	O
122	9	_	_	O
123	,	_	_	O
124	and	_	_	O
125	12	_	_	O
126	months	_	_	O
127	,	_	_	O
128	we	_	_	O
129	measured	_	_	O
130	intraocular	_	_	O
131	pressure	_	_	O
132	for	_	_	O
133	efficacy	_	_	O
134	and	_	_	O
135	graded	_	_	O
136	corneal	_	_	O
137	erosion	_	_	O
138	,	_	_	O
139	tear	_	_	O
140	break-up	_	_	O
141	time	_	_	O
142	(	_	_	O
143	TBUT	_	_	O
144	)	_	_	O
145	,	_	_	O
146	and	_	_	O
147	subjective	_	_	O
148	discomfort	_	_	O
149	.	_	_	O

150	A	_	_	O
151	total	_	_	O
152	of	_	_	O
153	20	_	_	O
154	patients	_	_	O
155	and	_	_	O
156	20	_	_	O
157	eyes	_	_	O
158	were	_	_	O
159	enrolled	_	_	O
160	.	_	_	O

161	In	_	_	B-Premise
162	Group	_	_	I-Premise
163	1	_	_	I-Premise
164	and	_	_	I-Premise
165	2	_	_	I-Premise
166	,	_	_	I-Premise
167	intraocular	_	_	I-Premise
168	pressure	_	_	I-Premise
169	was	_	_	I-Premise
170	well	_	_	I-Premise
171	controlled	_	_	I-Premise
172	to	_	_	I-Premise
173	approximately	_	_	I-Premise
174	14	_	_	I-Premise
175	mmHg	_	_	I-Premise
176	(	_	_	I-Premise
177	9.38-18.46	_	_	I-Premise
178	%	_	_	I-Premise
179	decrease	_	_	I-Premise
180	)	_	_	I-Premise
181	.	_	_	I-Premise

182	Generally	_	_	B-Premise
183	,	_	_	I-Premise
184	subjective	_	_	I-Premise
185	satisfaction	_	_	I-Premise
186	was	_	_	I-Premise
187	improved	_	_	I-Premise
188	after	_	_	I-Premise
189	changing	_	_	I-Premise
190	from	_	_	I-Premise
191	PT	_	_	I-Premise
192	to	_	_	I-Premise
193	NPT	_	_	I-Premise
194	(	_	_	I-Premise
195	p	_	_	I-Premise
196	=	_	_	I-Premise
197	0.03	_	_	I-Premise
198	)	_	_	I-Premise
199	and	_	_	I-Premise
200	TBUT	_	_	I-Premise
201	using	_	_	I-Premise
202	PT	_	_	I-Premise
203	was	_	_	I-Premise
204	numerically	_	_	I-Premise
205	inferior	_	_	I-Premise
206	to	_	_	I-Premise
207	that	_	_	I-Premise
208	using	_	_	I-Premise
209	NPT	_	_	I-Premise
210	(	_	_	I-Premise
211	p	_	_	I-Premise
212	=	_	_	I-Premise
213	0.06	_	_	I-Premise
214	)	_	_	I-Premise
215	but	_	_	I-Premise
216	not	_	_	I-Premise
217	when	_	_	I-Premise
218	changing	_	_	I-Premise
219	from	_	_	I-Premise
220	NPT	_	_	I-Premise
221	to	_	_	I-Premise
222	PT	_	_	I-Premise
223	.	_	_	I-Premise

224	Both	_	_	B-Claim
225	preservative	_	_	I-Claim
226	containing	_	_	I-Claim
227	and	_	_	I-Claim
228	preservative-free	_	_	I-Claim
229	0.0015	_	_	I-Claim
230	%	_	_	I-Claim
231	tafluprost	_	_	I-Claim
232	reduced	_	_	I-Claim
233	intraocular	_	_	I-Claim
234	pressure	_	_	I-Claim
235	significantly	_	_	I-Claim
236	.	_	_	I-Claim

237	In	_	_	O
238	addition	_	_	O
239	,	_	_	O
240	changing	_	_	B-Claim
241	medication	_	_	I-Claim
242	from	_	_	I-Claim
243	PT	_	_	I-Claim
244	to	_	_	I-Claim
245	NPT	_	_	I-Claim
246	might	_	_	I-Claim
247	improve	_	_	I-Claim
248	subjective	_	_	I-Claim
249	satisfaction	_	_	I-Claim
250	and	_	_	I-Claim
251	tear	_	_	I-Claim
252	break	_	_	I-Claim
253	up	_	_	I-Claim
254	time	_	_	I-Claim
255	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	phacoemulsification	_	_	O
3	versus	_	_	O
4	trabeculectomy	_	_	O
5	with	_	_	O
6	adjunctive	_	_	O
7	mitomycin	_	_	O
8	C	_	_	O
9	in	_	_	O
10	medically	_	_	O
11	uncontrolled	_	_	O
12	chronic	_	_	O
13	angle-closure	_	_	O
14	glaucoma	_	_	O
15	(	_	_	O
16	CACG	_	_	O
17	)	_	_	O
18	without	_	_	O
19	cataract	_	_	O
20	.	_	_	O

21	Prospective	_	_	O
22	,	_	_	O
23	randomized	_	_	O
24	clinical	_	_	O
25	trial	_	_	O
26	.	_	_	O

27	Fifty	_	_	O
28	medically	_	_	O
29	uncontrolled	_	_	O
30	CACG	_	_	O
31	eyes	_	_	O
32	without	_	_	O
33	cataract	_	_	O
34	of	_	_	O
35	50	_	_	O
36	patients	_	_	O
37	.	_	_	O

38	Patients	_	_	O
39	were	_	_	O
40	randomized	_	_	O
41	into	_	_	O
42	undergoing	_	_	O
43	either	_	_	O
44	phacoemulsification	_	_	O
45	or	_	_	O
46	trabeculectomy	_	_	O
47	with	_	_	O
48	adjunctive	_	_	O
49	mitomycin	_	_	O
50	C.	_	_	O
51	After	_	_	O
52	surgery	_	_	O
53	,	_	_	O
54	patients	_	_	O
55	were	_	_	O
56	followed	_	_	O
57	up	_	_	O
58	every	_	_	O
59	3	_	_	O
60	months	_	_	O
61	for	_	_	O
62	2	_	_	O
63	years	_	_	O
64	.	_	_	O

65	Intraocular	_	_	O
66	pressure	_	_	O
67	(	_	_	O
68	IOP	_	_	O
69	)	_	_	O
70	and	_	_	O
71	requirement	_	_	O
72	for	_	_	O
73	glaucoma	_	_	O
74	drugs	_	_	O
75	.	_	_	O

76	Twenty-six	_	_	O
77	CACG	_	_	O
78	eyes	_	_	O
79	were	_	_	O
80	randomized	_	_	O
81	to	_	_	O
82	receive	_	_	O
83	phacoemulsification	_	_	O
84	,	_	_	O
85	and	_	_	O
86	24	_	_	O
87	eyes	_	_	O
88	underwent	_	_	O
89	trabeculectomy	_	_	O
90	with	_	_	O
91	mitomycin	_	_	O
92	C.	_	_	O
93	Phacoemulsification	_	_	B-Premise
94	and	_	_	I-Premise
95	trabeculectomy	_	_	I-Premise
96	resulted	_	_	I-Premise
97	in	_	_	I-Premise
98	significant	_	_	I-Premise
99	and	_	_	I-Premise
100	comparable	_	_	I-Premise
101	IOP	_	_	I-Premise
102	reduction	_	_	I-Premise
103	at	_	_	I-Premise
104	24	_	_	I-Premise
105	months	_	_	I-Premise
106	after	_	_	I-Premise
107	surgery	_	_	I-Premise
108	(	_	_	I-Premise
109	reduction	_	_	I-Premise
110	of	_	_	I-Premise
111	8.4	_	_	I-Premise
112	mmHg	_	_	I-Premise
113	or	_	_	I-Premise
114	34	_	_	I-Premise
115	%	_	_	I-Premise
116	for	_	_	I-Premise
117	phacoemulsification	_	_	I-Premise
118	vs	_	_	I-Premise
119	8.9	_	_	I-Premise
120	mmHg	_	_	I-Premise
121	or	_	_	I-Premise
122	36	_	_	I-Premise
123	%	_	_	I-Premise
124	for	_	_	I-Premise
125	trabeculectomy	_	_	I-Premise
126	;	_	_	I-Premise
127	P=0.76	_	_	I-Premise
128	)	_	_	I-Premise
129	.	_	_	I-Premise

130	Over	_	_	B-Premise
131	first	_	_	I-Premise
132	24	_	_	I-Premise
133	months	_	_	I-Premise
134	,	_	_	I-Premise
135	trabeculectomy-treated	_	_	I-Premise
136	eyes	_	_	I-Premise
137	required	_	_	I-Premise
138	on	_	_	I-Premise
139	average	_	_	I-Premise
140	1.1	_	_	I-Premise
141	fewer	_	_	I-Premise
142	drugs	_	_	I-Premise
143	than	_	_	I-Premise
144	phacoemulsification-treated	_	_	I-Premise
145	eyes	_	_	I-Premise
146	(	_	_	I-Premise
147	P	_	_	I-Premise
148	<	_	_	I-Premise
149	0.001	_	_	I-Premise
150	)	_	_	I-Premise
151	.	_	_	I-Premise

152	However	_	_	O
153	,	_	_	O
154	trabeculectomy	_	_	B-Premise
155	was	_	_	I-Premise
156	associated	_	_	I-Premise
157	with	_	_	I-Premise
158	significantly	_	_	I-Premise
159	more	_	_	I-Premise
160	surgical	_	_	I-Premise
161	complications	_	_	I-Premise
162	than	_	_	I-Premise
163	phacoemulsification	_	_	I-Premise
164	(	_	_	I-Premise
165	46	_	_	I-Premise
166	%	_	_	I-Premise
167	vs	_	_	I-Premise
168	4	_	_	I-Premise
169	%	_	_	I-Premise
170	;	_	_	I-Premise
171	P=0.001	_	_	I-Premise
172	)	_	_	I-Premise
173	.	_	_	I-Premise

174	Eight	_	_	B-Premise
175	(	_	_	I-Premise
176	33	_	_	I-Premise
177	%	_	_	I-Premise
178	)	_	_	I-Premise
179	of	_	_	I-Premise
180	24	_	_	I-Premise
181	trabeculectomy	_	_	I-Premise
182	eyes	_	_	I-Premise
183	demonstrated	_	_	I-Premise
184	cataract	_	_	I-Premise
185	during	_	_	I-Premise
186	follow-up	_	_	I-Premise
187	.	_	_	I-Premise

188	Both	_	_	B-Claim
189	phacoemulsification	_	_	I-Claim
190	and	_	_	I-Claim
191	trabeculectomy	_	_	I-Claim
192	are	_	_	I-Claim
193	effective	_	_	I-Claim
194	in	_	_	I-Claim
195	reducing	_	_	I-Claim
196	IOP	_	_	I-Claim
197	in	_	_	I-Claim
198	medically	_	_	I-Claim
199	uncontrolled	_	_	I-Claim
200	CACG	_	_	I-Claim
201	eyes	_	_	I-Claim
202	without	_	_	I-Claim
203	cataract	_	_	I-Claim
204	.	_	_	I-Claim

205	Trabeculectomy	_	_	B-Claim
206	is	_	_	I-Claim
207	more	_	_	I-Claim
208	effective	_	_	I-Claim
209	than	_	_	I-Claim
210	phacoemulsification	_	_	I-Claim
211	in	_	_	I-Claim
212	reducing	_	_	I-Claim
213	dependence	_	_	I-Claim
214	on	_	_	I-Claim
215	glaucoma	_	_	I-Claim
216	drugs	_	_	I-Claim
217	,	_	_	I-Claim
218	but	_	_	I-Claim
219	is	_	_	I-Claim
220	associated	_	_	I-Claim
221	with	_	_	I-Claim
222	more	_	_	I-Claim
223	complications	_	_	I-Claim
224	.	_	_	I-Claim


0	Uncontrolled	_	_	O
1	hypertension	_	_	O
2	is	_	_	O
3	a	_	_	O
4	major	_	_	O
5	problem	_	_	O
6	among	_	_	O
7	non-Hispanic	_	_	O
8	black	_	_	O
9	men	_	_	O
10	,	_	_	O
11	who	_	_	O
12	are	_	_	O
13	underrepresented	_	_	O
14	in	_	_	O
15	pharmacist	_	_	O
16	intervention	_	_	O
17	trials	_	_	O
18	in	_	_	O
19	traditional	_	_	O
20	health	_	_	O
21	care	_	_	O
22	settings	_	_	O
23	.	_	_	O

24	We	_	_	O
25	enrolled	_	_	O
26	a	_	_	O
27	cohort	_	_	O
28	of	_	_	O
29	319	_	_	O
30	black	_	_	O
31	male	_	_	O
32	patrons	_	_	O
33	with	_	_	O
34	systolic	_	_	O
35	blood	_	_	O
36	pressure	_	_	O
37	of	_	_	O
38	140	_	_	O
39	mm	_	_	O
40	Hg	_	_	O
41	or	_	_	O
42	more	_	_	O
43	from	_	_	O
44	52	_	_	O
45	black-owned	_	_	O
46	barbershops	_	_	O
47	(	_	_	O
48	nontraditional	_	_	O
49	health	_	_	O
50	care	_	_	O
51	setting	_	_	O
52	)	_	_	O
53	in	_	_	O
54	a	_	_	O
55	cluster-randomized	_	_	O
56	trial	_	_	O
57	in	_	_	O
58	which	_	_	O
59	barbershops	_	_	O
60	were	_	_	O
61	assigned	_	_	O
62	to	_	_	O
63	a	_	_	O
64	pharmacist-led	_	_	O
65	intervention	_	_	O
66	(	_	_	O
67	in	_	_	O
68	which	_	_	O
69	barbers	_	_	O
70	encouraged	_	_	O
71	meetings	_	_	O
72	in	_	_	O
73	barbershops	_	_	O
74	with	_	_	O
75	specialty-trained	_	_	O
76	pharmacists	_	_	O
77	who	_	_	O
78	prescribed	_	_	O
79	drug	_	_	O
80	therapy	_	_	O
81	under	_	_	O
82	a	_	_	O
83	collaborative	_	_	O
84	practice	_	_	O
85	agreement	_	_	O
86	with	_	_	O
87	the	_	_	O
88	participants	_	_	O
89	’	_	_	O
90	doctors	_	_	O
91	)	_	_	O
92	or	_	_	O
93	to	_	_	O
94	an	_	_	O
95	active	_	_	O
96	control	_	_	O
97	approach	_	_	O
98	(	_	_	O
99	in	_	_	O
100	which	_	_	O
101	barbers	_	_	O
102	encouraged	_	_	O
103	lifestyle	_	_	O
104	modification	_	_	O
105	and	_	_	O
106	doctor	_	_	O
107	appointments	_	_	O
108	)	_	_	O
109	.	_	_	O

110	The	_	_	O
111	primary	_	_	O
112	outcome	_	_	O
113	was	_	_	O
114	reduction	_	_	O
115	in	_	_	O
116	systolic	_	_	O
117	blood	_	_	O
118	pressure	_	_	O
119	at	_	_	O
120	6	_	_	O
121	months	_	_	O
122	.	_	_	O

123	At	_	_	O
124	baseline	_	_	O
125	,	_	_	O
126	the	_	_	O
127	mean	_	_	O
128	systolic	_	_	O
129	blood	_	_	O
130	pressure	_	_	O
131	was	_	_	O
132	152.8	_	_	O
133	mm	_	_	O
134	Hg	_	_	O
135	in	_	_	O
136	the	_	_	O
137	intervention	_	_	O
138	group	_	_	O
139	and	_	_	O
140	154.6	_	_	O
141	mm	_	_	O
142	Hg	_	_	O
143	in	_	_	O
144	the	_	_	O
145	control	_	_	O
146	group	_	_	O
147	.	_	_	O

148	At	_	_	B-Premise
149	6	_	_	I-Premise
150	months	_	_	I-Premise
151	,	_	_	I-Premise
152	the	_	_	I-Premise
153	mean	_	_	I-Premise
154	systolic	_	_	I-Premise
155	blood	_	_	I-Premise
156	pressure	_	_	I-Premise
157	fell	_	_	I-Premise
158	by	_	_	I-Premise
159	27.0	_	_	I-Premise
160	mm	_	_	I-Premise
161	Hg	_	_	I-Premise
162	(	_	_	I-Premise
163	to	_	_	I-Premise
164	125.8	_	_	I-Premise
165	mm	_	_	I-Premise
166	Hg	_	_	I-Premise
167	)	_	_	I-Premise
168	in	_	_	I-Premise
169	the	_	_	I-Premise
170	intervention	_	_	I-Premise
171	group	_	_	I-Premise
172	and	_	_	I-Premise
173	by	_	_	I-Premise
174	9.3	_	_	I-Premise
175	mm	_	_	I-Premise
176	Hg	_	_	I-Premise
177	(	_	_	I-Premise
178	to	_	_	I-Premise
179	145.4	_	_	I-Premise
180	mm	_	_	I-Premise
181	Hg	_	_	I-Premise
182	)	_	_	I-Premise
183	in	_	_	I-Premise
184	the	_	_	I-Premise
185	control	_	_	I-Premise
186	group	_	_	I-Premise
187	;	_	_	I-Premise
188	the	_	_	I-Premise
189	mean	_	_	I-Premise
190	reduction	_	_	I-Premise
191	was	_	_	I-Premise
192	21.6	_	_	I-Premise
193	mm	_	_	I-Premise
194	Hg	_	_	I-Premise
195	greater	_	_	I-Premise
196	with	_	_	I-Premise
197	the	_	_	I-Premise
198	intervention	_	_	I-Premise
199	(	_	_	I-Premise
200	95	_	_	I-Premise
201	%	_	_	I-Premise
202	confidence	_	_	I-Premise
203	interval	_	_	I-Premise
204	,	_	_	I-Premise
205	14.7	_	_	I-Premise
206	to	_	_	I-Premise
207	28.4	_	_	I-Premise
208	;	_	_	I-Premise
209	P	_	_	I-Premise
210	<	_	_	I-Premise
211	0.001	_	_	I-Premise
212	)	_	_	I-Premise
213	.	_	_	I-Premise

214	A	_	_	B-Premise
215	blood-pressure	_	_	I-Premise
216	level	_	_	I-Premise
217	of	_	_	I-Premise
218	less	_	_	I-Premise
219	than	_	_	I-Premise
220	130/80	_	_	I-Premise
221	mm	_	_	I-Premise
222	Hg	_	_	I-Premise
223	was	_	_	I-Premise
224	achieved	_	_	I-Premise
225	among	_	_	I-Premise
226	63.6	_	_	I-Premise
227	%	_	_	I-Premise
228	of	_	_	I-Premise
229	the	_	_	I-Premise
230	participants	_	_	I-Premise
231	in	_	_	I-Premise
232	the	_	_	I-Premise
233	intervention	_	_	I-Premise
234	group	_	_	I-Premise
235	versus	_	_	I-Premise
236	11.7	_	_	I-Premise
237	%	_	_	I-Premise
238	of	_	_	I-Premise
239	the	_	_	I-Premise
240	participants	_	_	I-Premise
241	in	_	_	I-Premise
242	the	_	_	I-Premise
243	control	_	_	I-Premise
244	group	_	_	I-Premise
245	(	_	_	I-Premise
246	P	_	_	I-Premise
247	<	_	_	I-Premise
248	0.001	_	_	I-Premise
249	)	_	_	I-Premise
250	.	_	_	I-Premise

251	In	_	_	B-Premise
252	the	_	_	I-Premise
253	intervention	_	_	I-Premise
254	group	_	_	I-Premise
255	,	_	_	I-Premise
256	the	_	_	I-Premise
257	rate	_	_	I-Premise
258	of	_	_	I-Premise
259	cohort	_	_	I-Premise
260	retention	_	_	I-Premise
261	was	_	_	I-Premise
262	95	_	_	I-Premise
263	%	_	_	I-Premise
264	,	_	_	I-Premise
265	and	_	_	I-Premise
266	there	_	_	I-Premise
267	were	_	_	I-Premise
268	few	_	_	I-Premise
269	adverse	_	_	I-Premise
270	events	_	_	I-Premise
271	(	_	_	I-Premise
272	three	_	_	I-Premise
273	cases	_	_	I-Premise
274	of	_	_	I-Premise
275	acute	_	_	I-Premise
276	kidney	_	_	I-Premise
277	injury	_	_	I-Premise
278	)	_	_	I-Premise
279	.	_	_	I-Premise

280	Among	_	_	B-Claim
281	black	_	_	I-Claim
282	male	_	_	I-Claim
283	barbershop	_	_	I-Claim
284	patrons	_	_	I-Claim
285	with	_	_	I-Claim
286	uncontrolled	_	_	I-Claim
287	hypertension	_	_	I-Claim
288	,	_	_	I-Claim
289	health	_	_	I-Claim
290	promotion	_	_	I-Claim
291	by	_	_	I-Claim
292	barbers	_	_	I-Claim
293	resulted	_	_	I-Claim
294	in	_	_	I-Claim
295	larger	_	_	I-Claim
296	blood-pressure	_	_	I-Claim
297	reduction	_	_	I-Claim
298	when	_	_	I-Claim
299	coupled	_	_	I-Claim
300	with	_	_	I-Claim
301	medication	_	_	I-Claim
302	management	_	_	I-Claim
303	in	_	_	I-Claim
304	barbershops	_	_	I-Claim
305	by	_	_	I-Claim
306	specialty-trained	_	_	I-Claim
307	pharmacists	_	_	I-Claim
308	.	_	_	I-Claim


0	Treatment-related	_	_	B-Claim
1	quality	_	_	I-Claim
2	of	_	_	I-Claim
3	life	_	_	I-Claim
4	(	_	_	I-Claim
5	QOL	_	_	I-Claim
6	)	_	_	I-Claim
7	is	_	_	I-Claim
8	an	_	_	I-Claim
9	important	_	_	I-Claim
10	aspect	_	_	I-Claim
11	of	_	_	I-Claim
12	diabetes	_	_	I-Claim
13	management	_	_	I-Claim
14	.	_	_	I-Claim

15	However	_	_	O
16	,	_	_	O
17	no	_	_	O
18	studies	_	_	O
19	have	_	_	O
20	compared	_	_	O
21	the	_	_	O
22	influence	_	_	O
23	of	_	_	O
24	dipeptidyl	_	_	O
25	peptidase-4	_	_	O
26	inhibitors	_	_	O
27	versus	_	_	O
28	alpha-glucosidase	_	_	O
29	inhibitors	_	_	O
30	on	_	_	O
31	treatment-related	_	_	O
32	QOL	_	_	O
33	.	_	_	O

34	This	_	_	O
35	prespecified	_	_	O
36	sub-analysis	_	_	O
37	of	_	_	O
38	the	_	_	O
39	Linagliptin	_	_	O
40	Study	_	_	O
41	of	_	_	O
42	Effects	_	_	O
43	on	_	_	O
44	Postprandial	_	_	O
45	blood	_	_	O
46	glucose	_	_	O
47	(	_	_	O
48	L-STEP	_	_	O
49	)	_	_	O
50	compared	_	_	O
51	the	_	_	O
52	effects	_	_	O
53	of	_	_	O
54	linagliptin	_	_	O
55	(	_	_	O
56	5	_	_	O
57	mg	_	_	O
58	once	_	_	O
59	daily	_	_	O
60	)	_	_	O
61	and	_	_	O
62	voglibose	_	_	O
63	(	_	_	O
64	0.2	_	_	O
65	mg/meal	_	_	O
66	thrice	_	_	O
67	daily	_	_	O
68	)	_	_	O
69	on	_	_	O
70	treatment-related	_	_	O
71	QOL	_	_	O
72	in	_	_	O
73	Japanese	_	_	O
74	patients	_	_	O
75	with	_	_	O
76	type	_	_	O
77	2	_	_	O
78	diabetes	_	_	O
79	(	_	_	O
80	T2DM	_	_	O
81	)	_	_	O
82	inadequately	_	_	O
83	controlled	_	_	O
84	with	_	_	O
85	diet	_	_	O
86	and	_	_	O
87	exercise	_	_	O
88	therapy	_	_	O
89	.	_	_	O

90	Among	_	_	O
91	366	_	_	O
92	subjects	_	_	O
93	in	_	_	O
94	the	_	_	O
95	original	_	_	O
96	study	_	_	O
97	,	_	_	O
98	182	_	_	O
99	in	_	_	O
100	the	_	_	O
101	linagliptin	_	_	O
102	group	_	_	O
103	and	_	_	O
104	173	_	_	O
105	in	_	_	O
106	the	_	_	O
107	voglibose	_	_	O
108	group	_	_	O
109	were	_	_	O
110	included	_	_	O
111	in	_	_	O
112	this	_	_	O
113	analysis	_	_	O
114	.	_	_	O

115	The	_	_	O
116	outcome	_	_	O
117	of	_	_	O
118	this	_	_	O
119	study	_	_	O
120	was	_	_	O
121	change	_	_	O
122	in	_	_	O
123	QOL	_	_	O
124	as	_	_	O
125	assessed	_	_	O
126	by	_	_	O
127	the	_	_	O
128	Diabetes	_	_	O
129	Therapy-Related	_	_	O
130	Quality	_	_	O
131	of	_	_	O
132	Life	_	_	O
133	17	_	_	O
134	(	_	_	O
135	DTR-QOL17	_	_	O
136	)	_	_	O
137	questionnaire	_	_	O
138	from	_	_	O
139	baseline	_	_	O
140	to	_	_	O
141	week	_	_	O
142	12	_	_	O
143	.	_	_	O

144	Compared	_	_	B-Premise
145	with	_	_	I-Premise
146	baseline	_	_	I-Premise
147	data	_	_	I-Premise
148	,	_	_	I-Premise
149	total	_	_	I-Premise
150	DTR-QOL17	_	_	I-Premise
151	scores	_	_	I-Premise
152	were	_	_	I-Premise
153	significantly	_	_	I-Premise
154	higher	_	_	I-Premise
155	after	_	_	I-Premise
156	12	_	_	I-Premise
157	weeks	_	_	I-Premise
158	of	_	_	I-Premise
159	linagliptin	_	_	I-Premise
160	and	_	_	I-Premise
161	voglibose	_	_	I-Premise
162	treatment	_	_	I-Premise
163	.	_	_	I-Premise

164	The	_	_	B-Premise
165	change	_	_	I-Premise
166	in	_	_	I-Premise
167	the	_	_	I-Premise
168	total	_	_	I-Premise
169	DTR-QOL17	_	_	I-Premise
170	score	_	_	I-Premise
171	and	_	_	I-Premise
172	the	_	_	I-Premise
173	score	_	_	I-Premise
174	of	_	_	I-Premise
175	one	_	_	I-Premise
176	domain	_	_	I-Premise
177	,	_	_	I-Premise
178	burden	_	_	I-Premise
179	on	_	_	I-Premise
180	social	_	_	I-Premise
181	activities	_	_	I-Premise
182	and	_	_	I-Premise
183	daily	_	_	I-Premise
184	activities	_	_	I-Premise
185	,	_	_	I-Premise
186	was	_	_	I-Premise
187	significantly	_	_	I-Premise
188	greater	_	_	I-Premise
189	in	_	_	I-Premise
190	the	_	_	I-Premise
191	linagliptin	_	_	I-Premise
192	group	_	_	I-Premise
193	than	_	_	I-Premise
194	in	_	_	I-Premise
195	the	_	_	I-Premise
196	voglibose	_	_	I-Premise
197	group	_	_	I-Premise
198	.	_	_	I-Premise

199	In	_	_	B-Premise
200	addition	_	_	I-Premise
201	,	_	_	I-Premise
202	only	_	_	I-Premise
203	linagliptin	_	_	I-Premise
204	treatment	_	_	I-Premise
205	was	_	_	I-Premise
206	identified	_	_	I-Premise
207	as	_	_	I-Premise
208	a	_	_	I-Premise
209	factor	_	_	I-Premise
210	associated	_	_	I-Premise
211	with	_	_	I-Premise
212	an	_	_	I-Premise
213	increased	_	_	I-Premise
214	total	_	_	I-Premise
215	DTR-QOL17	_	_	I-Premise
216	score	_	_	I-Premise
217	.	_	_	I-Premise

218	Linagliptin	_	_	B-Claim
219	is	_	_	I-Claim
220	superior	_	_	I-Claim
221	to	_	_	I-Claim
222	voglibose	_	_	I-Claim
223	in	_	_	I-Claim
224	terms	_	_	I-Claim
225	of	_	_	I-Claim
226	improving	_	_	I-Claim
227	treatment-related	_	_	I-Claim
228	QOL	_	_	I-Claim
229	in	_	_	I-Claim
230	Japanese	_	_	I-Claim
231	patients	_	_	I-Claim
232	with	_	_	I-Claim
233	T2DM	_	_	I-Claim
234	.	_	_	I-Claim


0	Long-term	_	_	O
1	treatment	_	_	O
2	with	_	_	O
3	tenofovir	_	_	O
4	disoproxil	_	_	O
5	fumarate	_	_	O
6	(	_	_	O
7	TDF	_	_	O
8	)	_	_	O
9	alone	_	_	O
10	,	_	_	O
11	or	_	_	O
12	in	_	_	O
13	combination	_	_	O
14	with	_	_	O
15	emtricitabine	_	_	O
16	(	_	_	O
17	FTC	_	_	O
18	)	_	_	O
19	is	_	_	O
20	associated	_	_	O
21	with	_	_	O
22	sustained	_	_	O
23	viral	_	_	O
24	suppression	_	_	O
25	in	_	_	O
26	patients	_	_	O
27	with	_	_	O
28	lamivudine	_	_	O
29	resistant	_	_	O
30	(	_	_	O
31	LAM-R	_	_	O
32	)	_	_	O
33	chronic	_	_	O
34	hepatitis	_	_	O
35	B	_	_	O
36	(	_	_	O
37	CHB	_	_	O
38	)	_	_	O
39	.	_	_	O

40	LAM-R	_	_	O
41	CHB	_	_	O
42	patients	_	_	O
43	were	_	_	O
44	randomised	_	_	O
45	1:1	_	_	O
46	to	_	_	O
47	receive	_	_	O
48	TDF	_	_	O
49	300mg	_	_	O
50	or	_	_	O
51	FTC	_	_	O
52	200mg	_	_	O
53	and	_	_	O
54	TDF	_	_	O
55	300mg	_	_	O
56	once	_	_	O
57	daily	_	_	O
58	in	_	_	O
59	a	_	_	O
60	prospective	_	_	O
61	,	_	_	O
62	double	_	_	O
63	blind	_	_	O
64	,	_	_	O
65	study	_	_	O
66	.	_	_	O

67	The	_	_	O
68	proportion	_	_	O
69	of	_	_	O
70	patients	_	_	O
71	with	_	_	O
72	plasma	_	_	O
73	hepatitis	_	_	O
74	B	_	_	O
75	virus	_	_	O
76	(	_	_	O
77	HBV	_	_	O
78	)	_	_	O
79	DNA	_	_	O
80	<	_	_	O
81	69IU/ml	_	_	O
82	(	_	_	O
83	<	_	_	O
84	400copies/ml	_	_	O
85	)	_	_	O
86	at	_	_	O
87	week	_	_	O
88	96	_	_	O
89	(	_	_	O
90	primary	_	_	O
91	efficacy	_	_	O
92	endpoint	_	_	O
93	)	_	_	O
94	was	_	_	O
95	reported	_	_	O
96	previously	_	_	O
97	.	_	_	O

98	Here	_	_	O
99	we	_	_	O
100	present	_	_	O
101	week	_	_	O
102	240	_	_	O
103	follow-up	_	_	O
104	data	_	_	O
105	.	_	_	O

106	Overall	_	_	O
107	,	_	_	O
108	280	_	_	O
109	patients	_	_	O
110	were	_	_	O
111	randomised	_	_	O
112	to	_	_	O
113	receive	_	_	O
114	TDF	_	_	O
115	(	_	_	O
116	n=141	_	_	O
117	)	_	_	O
118	or	_	_	O
119	FTC/TDF	_	_	O
120	(	_	_	O
121	n=139	_	_	O
122	)	_	_	O
123	,	_	_	O
124	and	_	_	O
125	85.4	_	_	O
126	%	_	_	O
127	completed	_	_	O
128	240	_	_	O
129	weeks	_	_	O
130	of	_	_	O
131	treatment	_	_	O
132	.	_	_	O

133	At	_	_	B-Premise
134	week	_	_	I-Premise
135	240	_	_	I-Premise
136	,	_	_	I-Premise
137	83.0	_	_	I-Premise
138	%	_	_	I-Premise
139	of	_	_	I-Premise
140	patients	_	_	I-Premise
141	in	_	_	I-Premise
142	the	_	_	I-Premise
143	TDF	_	_	I-Premise
144	arm	_	_	I-Premise
145	,	_	_	I-Premise
146	and	_	_	I-Premise
147	82.7	_	_	I-Premise
148	%	_	_	I-Premise
149	of	_	_	I-Premise
150	patients	_	_	I-Premise
151	in	_	_	I-Premise
152	the	_	_	I-Premise
153	FTC/TDF	_	_	I-Premise
154	treatment	_	_	I-Premise
155	arm	_	_	I-Premise
156	had	_	_	I-Premise
157	HBV	_	_	I-Premise
158	DNA	_	_	I-Premise
159	<	_	_	I-Premise
160	69IU/ml	_	_	I-Premise
161	(	_	_	I-Premise
162	p=0.96	_	_	I-Premise
163	)	_	_	I-Premise
164	.	_	_	I-Premise

165	Rates	_	_	B-Premise
166	of	_	_	I-Premise
167	normal	_	_	I-Premise
168	alanine	_	_	I-Premise
169	aminotransferase	_	_	I-Premise
170	(	_	_	I-Premise
171	ALT	_	_	I-Premise
172	)	_	_	I-Premise
173	and	_	_	I-Premise
174	normalised	_	_	I-Premise
175	ALT	_	_	I-Premise
176	were	_	_	I-Premise
177	similar	_	_	I-Premise
178	between	_	_	I-Premise
179	groups	_	_	I-Premise
180	(	_	_	I-Premise
181	p=0.41	_	_	I-Premise
182	and	_	_	I-Premise
183	p=0.97	_	_	I-Premise
184	respectively	_	_	I-Premise
185	)	_	_	I-Premise
186	.	_	_	I-Premise

187	Hepatitis	_	_	B-Premise
188	B	_	_	I-Premise
189	e	_	_	I-Premise
190	antigen	_	_	I-Premise
191	loss	_	_	I-Premise
192	and	_	_	I-Premise
193	seroconversion	_	_	I-Premise
194	at	_	_	I-Premise
195	week	_	_	I-Premise
196	240	_	_	I-Premise
197	were	_	_	I-Premise
198	similar	_	_	I-Premise
199	between	_	_	I-Premise
200	groups	_	_	I-Premise
201	,	_	_	I-Premise
202	(	_	_	I-Premise
203	p=0.41	_	_	I-Premise
204	and	_	_	I-Premise
205	p=0.67	_	_	I-Premise
206	respectively	_	_	I-Premise
207	)	_	_	I-Premise
208	.	_	_	I-Premise

209	Overall	_	_	B-Premise
210	,	_	_	I-Premise
211	six	_	_	I-Premise
212	patients	_	_	I-Premise
213	achieved	_	_	I-Premise
214	hepatitis	_	_	I-Premise
215	B	_	_	I-Premise
216	surface	_	_	I-Premise
217	antigen	_	_	I-Premise
218	(	_	_	I-Premise
219	HBsAg	_	_	I-Premise
220	)	_	_	I-Premise
221	loss	_	_	I-Premise
222	and	_	_	I-Premise
223	one	_	_	I-Premise
224	patient	_	_	I-Premise
225	(	_	_	I-Premise
226	FTC/TDF	_	_	I-Premise
227	arm	_	_	I-Premise
228	)	_	_	I-Premise
229	had	_	_	I-Premise
230	HBsAg	_	_	I-Premise
231	seroconversion	_	_	I-Premise
232	by	_	_	I-Premise
233	week	_	_	I-Premise
234	240	_	_	I-Premise
235	.	_	_	I-Premise

236	No	_	_	B-Premise
237	TDF	_	_	I-Premise
238	resistance	_	_	I-Premise
239	was	_	_	I-Premise
240	observed	_	_	I-Premise
241	up	_	_	I-Premise
242	to	_	_	I-Premise
243	week	_	_	I-Premise
244	240	_	_	I-Premise
245	.	_	_	I-Premise

246	Treatment	_	_	B-Premise
247	was	_	_	I-Premise
248	generally	_	_	I-Premise
249	well	_	_	I-Premise
250	tolerated	_	_	I-Premise
251	,	_	_	I-Premise
252	and	_	_	I-Premise
253	renal	_	_	I-Premise
254	events	_	_	I-Premise
255	were	_	_	I-Premise
256	mild	_	_	I-Premise
257	and	_	_	I-Premise
258	infrequent	_	_	I-Premise
259	(	_	_	I-Premise
260	∼8.6	_	_	I-Premise
261	%	_	_	I-Premise
262	)	_	_	I-Premise
263	.	_	_	I-Premise

264	The	_	_	B-Premise
265	mean	_	_	I-Premise
266	change	_	_	I-Premise
267	in	_	_	I-Premise
268	bone	_	_	I-Premise
269	mineral	_	_	I-Premise
270	density	_	_	I-Premise
271	at	_	_	I-Premise
272	week	_	_	I-Premise
273	240	_	_	I-Premise
274	was	_	_	I-Premise
275	-0.98	_	_	I-Premise
276	%	_	_	I-Premise
277	and	_	_	I-Premise
278	-2.54	_	_	I-Premise
279	%	_	_	I-Premise
280	at	_	_	I-Premise
281	the	_	_	I-Premise
282	spine	_	_	I-Premise
283	and	_	_	I-Premise
284	hip	_	_	I-Premise
285	,	_	_	I-Premise
286	respectively	_	_	I-Premise
287	.	_	_	I-Premise

288	TDF	_	_	B-Claim
289	monotherapy	_	_	I-Claim
290	was	_	_	I-Claim
291	effective	_	_	I-Claim
292	and	_	_	I-Claim
293	well	_	_	I-Claim
294	tolerated	_	_	I-Claim
295	in	_	_	I-Claim
296	LAM-R	_	_	I-Claim
297	CHB	_	_	I-Claim
298	patients	_	_	I-Claim
299	for	_	_	I-Claim
300	up	_	_	I-Claim
301	to	_	_	I-Claim
302	240	_	_	I-Claim
303	weeks	_	_	I-Claim
304	.	_	_	I-Claim

305	The	_	_	O
306	goal	_	_	O
307	of	_	_	O
308	oral	_	_	O
309	antiviral	_	_	O
310	treatment	_	_	O
311	for	_	_	O
312	chronic	_	_	O
313	hepatitis	_	_	O
314	B	_	_	O
315	(	_	_	O
316	CHB	_	_	O
317	)	_	_	O
318	is	_	_	O
319	to	_	_	O
320	achieve	_	_	O
321	and	_	_	O
322	maintain	_	_	O
323	undetectable	_	_	O
324	HBV	_	_	O
325	DNA	_	_	O
326	levels	_	_	O
327	.	_	_	O

328	Treatment	_	_	O
329	options	_	_	O
330	with	_	_	O
331	enhanced	_	_	O
332	potency	_	_	O
333	,	_	_	O
334	and	_	_	O
335	low	_	_	O
336	risk	_	_	O
337	of	_	_	O
338	resistance	_	_	O
339	development	_	_	O
340	for	_	_	O
341	patients	_	_	O
342	infected	_	_	O
343	with	_	_	O
344	lamivudine	_	_	O
345	resistant	_	_	O
346	(	_	_	O
347	LAM-R	_	_	O
348	)	_	_	O
349	HBV	_	_	O
350	are	_	_	O
351	required	_	_	O
352	.	_	_	O

353	Tenofovir	_	_	B-Claim
354	disoproxil	_	_	I-Claim
355	fumarate	_	_	I-Claim
356	(	_	_	I-Claim
357	TDF	_	_	I-Claim
358	)	_	_	I-Claim
359	monotherapy	_	_	I-Claim
360	was	_	_	I-Claim
361	effective	_	_	I-Claim
362	and	_	_	I-Claim
363	well	_	_	I-Claim
364	tolerated	_	_	I-Claim
365	without	_	_	I-Claim
366	TDF	_	_	I-Claim
367	resistance	_	_	I-Claim
368	development	_	_	I-Claim
369	in	_	_	I-Claim
370	CHB	_	_	I-Claim
371	patients	_	_	I-Claim
372	with	_	_	I-Claim
373	LAM-R	_	_	I-Claim
374	,	_	_	I-Claim
375	for	_	_	I-Claim
376	up	_	_	I-Claim
377	to	_	_	I-Claim
378	240weeks	_	_	I-Claim
379	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	outcome	_	_	O
4	of	_	_	O
5	trabeculectomy	_	_	O
6	using	_	_	O
7	adjunctive	_	_	O
8	intracameral	_	_	O
9	bevacizumab	_	_	O
10	versus	_	_	O
11	intraoperative	_	_	O
12	mitomycin	_	_	O
13	C	_	_	O
14	(	_	_	O
15	MMC	_	_	O
16	)	_	_	O
17	.	_	_	O

18	In	_	_	O
19	this	_	_	O
20	double-blind	_	_	O
21	,	_	_	O
22	randomized	_	_	O
23	clinical	_	_	O
24	trial	_	_	O
25	87	_	_	O
26	eyes	_	_	O
27	of	_	_	O
28	87	_	_	O
29	patients	_	_	O
30	with	_	_	O
31	primary	_	_	O
32	open-angle	_	_	O
33	or	_	_	O
34	pseudoexfoliation	_	_	O
35	glaucoma	_	_	O
36	were	_	_	O
37	assigned	_	_	O
38	to	_	_	O
39	each	_	_	O
40	treatment	_	_	O
41	group	_	_	O
42	(	_	_	O
43	44	_	_	O
44	cases	_	_	O
45	received	_	_	O
46	1.25	_	_	O
47	mg	_	_	O
48	intracameral	_	_	O
49	bevacizumab	_	_	O
50	at	_	_	O
51	the	_	_	O
52	end	_	_	O
53	of	_	_	O
54	operation	_	_	O
55	and	_	_	O
56	in	_	_	O
57	43	_	_	O
58	cases	_	_	O
59	MMC	_	_	O
60	was	_	_	O
61	applied	_	_	O
62	during	_	_	O
63	surgery	_	_	O
64	)	_	_	O
65	.	_	_	O

66	Success	_	_	O
67	was	_	_	O
68	defined	_	_	O
69	as	_	_	O
70	intraocular	_	_	O
71	pressure	_	_	O
72	(	_	_	O
73	IOP	_	_	O
74	)	_	_	O
75	between	_	_	O
76	6	_	_	O
77	and	_	_	O
78	21	_	_	O
79	mm	_	_	O
80	Hg	_	_	O
81	and	_	_	O
82	at	_	_	O
83	least	_	_	O
84	30	_	_	O
85	%	_	_	O
86	IOP	_	_	O
87	drop	_	_	O
88	with	_	_	O
89	(	_	_	O
90	qualified	_	_	O
91	)	_	_	O
92	or	_	_	O
93	without	_	_	O
94	(	_	_	O
95	complete	_	_	O
96	)	_	_	O
97	glaucoma	_	_	O
98	medications	_	_	O
99	without	_	_	O
100	additional	_	_	O
101	glaucoma	_	_	O
102	surgery	_	_	O
103	.	_	_	O

104	The	_	_	O
105	follow-up	_	_	O
106	time	_	_	O
107	was	_	_	O
108	17.12±2.58	_	_	O
109	months	_	_	O
110	in	_	_	O
111	the	_	_	O
112	bevacizumab	_	_	O
113	group	_	_	O
114	and	_	_	O
115	17.23±2.42	_	_	O
116	months	_	_	O
117	in	_	_	O
118	the	_	_	O
119	MMC	_	_	O
120	group	_	_	O
121	(	_	_	O
122	P=0.845	_	_	O
123	)	_	_	O
124	.	_	_	O

125	The	_	_	B-Premise
126	preoperative	_	_	I-Premise
127	IOP	_	_	I-Premise
128	was	_	_	I-Premise
129	29.17±3.94	_	_	I-Premise
130	and	_	_	I-Premise
131	28.8±4.08	_	_	I-Premise
132	mm	_	_	I-Premise
133	Hg	_	_	I-Premise
134	in	_	_	I-Premise
135	the	_	_	I-Premise
136	bevacizumab	_	_	I-Premise
137	and	_	_	I-Premise
138	MMC	_	_	I-Premise
139	groups	_	_	I-Premise
140	,	_	_	I-Premise
141	respectively	_	_	I-Premise
142	(	_	_	I-Premise
143	P=0.689	_	_	I-Premise
144	)	_	_	I-Premise
145	.	_	_	I-Premise

146	Last	_	_	B-Premise
147	visit	_	_	I-Premise
148	IOP	_	_	I-Premise
149	was	_	_	I-Premise
150	17.41±3.11	_	_	I-Premise
151	mm	_	_	I-Premise
152	Hg	_	_	I-Premise
153	in	_	_	I-Premise
154	the	_	_	I-Premise
155	bevacizumab	_	_	I-Premise
156	group	_	_	I-Premise
157	and	_	_	I-Premise
158	15.34±3.62	_	_	I-Premise
159	mm	_	_	I-Premise
160	Hg	_	_	I-Premise
161	in	_	_	I-Premise
162	the	_	_	I-Premise
163	MMC	_	_	I-Premise
164	group	_	_	I-Premise
165	(	_	_	I-Premise
166	P	_	_	I-Premise
167	<	_	_	I-Premise
168	0.009	_	_	I-Premise
169	)	_	_	I-Premise
170	.	_	_	I-Premise

171	Compared	_	_	B-Premise
172	with	_	_	I-Premise
173	baseline	_	_	I-Premise
174	,	_	_	I-Premise
175	IOP	_	_	I-Premise
176	drop	_	_	I-Premise
177	at	_	_	I-Premise
178	last	_	_	I-Premise
179	visit	_	_	I-Premise
180	was	_	_	I-Premise
181	11.76±5.51	_	_	I-Premise
182	and	_	_	I-Premise
183	13.43±5.92	_	_	I-Premise
184	in	_	_	I-Premise
185	the	_	_	I-Premise
186	bevacizumab	_	_	I-Premise
187	and	_	_	I-Premise
188	MMC	_	_	I-Premise
189	groups	_	_	I-Premise
190	,	_	_	I-Premise
191	respectively	_	_	I-Premise
192	(	_	_	I-Premise
193	P=0.207	_	_	I-Premise
194	)	_	_	I-Premise
195	.	_	_	I-Premise

196	At	_	_	B-Premise
197	last	_	_	I-Premise
198	visit	_	_	I-Premise
199	,	_	_	I-Premise
200	complete	_	_	I-Premise
201	success	_	_	I-Premise
202	was	_	_	I-Premise
203	achieved	_	_	I-Premise
204	in	_	_	I-Premise
205	25	_	_	I-Premise
206	cases	_	_	I-Premise
207	(	_	_	I-Premise
208	61	_	_	I-Premise
209	%	_	_	I-Premise
210	)	_	_	I-Premise
211	of	_	_	I-Premise
212	bevacizumab	_	_	I-Premise
213	group	_	_	I-Premise
214	and	_	_	I-Premise
215	23	_	_	I-Premise
216	cases	_	_	I-Premise
217	(	_	_	I-Premise
218	66	_	_	I-Premise
219	%	_	_	I-Premise
220	)	_	_	I-Premise
221	of	_	_	I-Premise
222	MMC	_	_	I-Premise
223	group	_	_	I-Premise
224	(	_	_	I-Premise
225	P=0.669	_	_	I-Premise
226	)	_	_	I-Premise
227	.	_	_	I-Premise

228	Early	_	_	B-Premise
229	filtering	_	_	I-Premise
230	bleb	_	_	I-Premise
231	leak	_	_	I-Premise
232	was	_	_	I-Premise
233	more	_	_	I-Premise
234	prevalent	_	_	I-Premise
235	in	_	_	I-Premise
236	bevacizumab	_	_	I-Premise
237	group	_	_	I-Premise
238	(	_	_	I-Premise
239	29	_	_	I-Premise
240	%	_	_	I-Premise
241	vs.	_	_	I-Premise
242	11	_	_	I-Premise
243	%	_	_	I-Premise
244	)	_	_	I-Premise
245	.	_	_	I-Premise

246	A	_	_	B-Claim
247	single	_	_	I-Claim
248	1.25	_	_	I-Claim
249	mg	_	_	I-Claim
250	dose	_	_	I-Claim
251	of	_	_	I-Claim
252	intracameral	_	_	I-Claim
253	bevacizumab	_	_	I-Claim
254	improves	_	_	I-Claim
255	the	_	_	I-Claim
256	success	_	_	I-Claim
257	of	_	_	I-Claim
258	trabeculectomy	_	_	I-Claim
259	comparable	_	_	I-Claim
260	with	_	_	I-Claim
261	MMC	_	_	I-Claim
262	;	_	_	I-Claim
263	however	_	_	B-Claim
264	,	_	_	I-Claim
265	it	_	_	I-Claim
266	increases	_	_	I-Claim
267	the	_	_	I-Claim
268	risk	_	_	I-Claim
269	of	_	_	I-Claim
270	early	_	_	I-Claim
271	filtering	_	_	I-Claim
272	bleb	_	_	I-Claim
273	leakage	_	_	I-Claim
274	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	tolerability	_	_	O
6	of	_	_	O
7	two	_	_	O
8	doses	_	_	O
9	of	_	_	O
10	gefitinib	_	_	O
11	(	_	_	O
12	Iressa	_	_	O
13	[	_	_	O
14	ZD1839	_	_	O
15	]	_	_	O
16	;	_	_	O
17	AstraZeneca	_	_	O
18	,	_	_	O
19	Wilmington	_	_	O
20	,	_	_	O
21	DE	_	_	O
22	)	_	_	O
23	,	_	_	O
24	a	_	_	O
25	novel	_	_	O
26	epidermal	_	_	O
27	growth	_	_	O
28	factor	_	_	O
29	receptor	_	_	O
30	tyrosine	_	_	O
31	kinase	_	_	O
32	inhibitor	_	_	O
33	,	_	_	O
34	in	_	_	O
35	patients	_	_	O
36	with	_	_	O
37	pretreated	_	_	O
38	advanced	_	_	O
39	non-small-cell	_	_	O
40	lung	_	_	O
41	cancer	_	_	O
42	(	_	_	O
43	NSCLC	_	_	O
44	)	_	_	O
45	.	_	_	O

46	This	_	_	O
47	was	_	_	O
48	a	_	_	O
49	randomized	_	_	O
50	,	_	_	O
51	double-blind	_	_	O
52	,	_	_	O
53	parallel-group	_	_	O
54	,	_	_	O
55	multicenter	_	_	O
56	phase	_	_	O
57	II	_	_	O
58	trial	_	_	O
59	.	_	_	O

60	Two	_	_	O
61	hundred	_	_	O
62	ten	_	_	O
63	patients	_	_	O
64	with	_	_	O
65	advanced	_	_	O
66	NSCLC	_	_	O
67	who	_	_	O
68	were	_	_	O
69	previously	_	_	O
70	treated	_	_	O
71	with	_	_	O
72	one	_	_	O
73	or	_	_	O
74	two	_	_	O
75	chemotherapy	_	_	O
76	regimens	_	_	O
77	(	_	_	O
78	at	_	_	O
79	least	_	_	O
80	one	_	_	O
81	containing	_	_	O
82	platinum	_	_	O
83	)	_	_	O
84	were	_	_	O
85	randomly	_	_	O
86	assigned	_	_	O
87	to	_	_	O
88	receive	_	_	O
89	either	_	_	O
90	250-mg	_	_	O
91	or	_	_	O
92	500-mg	_	_	O
93	oral	_	_	O
94	doses	_	_	O
95	of	_	_	O
96	gefitinib	_	_	O
97	once	_	_	O
98	daily	_	_	O
99	.	_	_	O

100	Efficacy	_	_	B-Premise
101	was	_	_	I-Premise
102	similar	_	_	I-Premise
103	for	_	_	I-Premise
104	the	_	_	I-Premise
105	250-	_	_	I-Premise
106	and	_	_	I-Premise
107	500-mg/d	_	_	I-Premise
108	groups	_	_	I-Premise
109	.	_	_	I-Premise

110	Objective	_	_	B-Premise
111	tumor	_	_	I-Premise
112	response	_	_	I-Premise
113	rates	_	_	I-Premise
114	were	_	_	I-Premise
115	18.4	_	_	I-Premise
116	%	_	_	I-Premise
117	(	_	_	I-Premise
118	95	_	_	I-Premise
119	%	_	_	I-Premise
120	confidence	_	_	I-Premise
121	interval	_	_	I-Premise
122	[	_	_	I-Premise
123	CI	_	_	I-Premise
124	]	_	_	I-Premise
125	,	_	_	I-Premise
126	11.5	_	_	I-Premise
127	to	_	_	I-Premise
128	27.3	_	_	I-Premise
129	)	_	_	I-Premise
130	and	_	_	I-Premise
131	19.0	_	_	I-Premise
132	%	_	_	I-Premise
133	(	_	_	I-Premise
134	95	_	_	I-Premise
135	%	_	_	I-Premise
136	CI	_	_	I-Premise
137	,	_	_	I-Premise
138	12.1	_	_	I-Premise
139	to	_	_	I-Premise
140	27.9	_	_	I-Premise
141	)	_	_	I-Premise
142	;	_	_	I-Premise
143	among	_	_	I-Premise
144	evaluable	_	_	I-Premise
145	patients	_	_	I-Premise
146	,	_	_	I-Premise
147	symptom	_	_	I-Premise
148	improvement	_	_	I-Premise
149	rates	_	_	I-Premise
150	were	_	_	I-Premise
151	40.3	_	_	I-Premise
152	%	_	_	I-Premise
153	(	_	_	I-Premise
154	95	_	_	I-Premise
155	%	_	_	I-Premise
156	CI	_	_	I-Premise
157	,	_	_	I-Premise
158	28.5	_	_	I-Premise
159	to	_	_	I-Premise
160	53.0	_	_	I-Premise
161	)	_	_	I-Premise
162	and	_	_	I-Premise
163	37.0	_	_	I-Premise
164	%	_	_	I-Premise
165	(	_	_	I-Premise
166	95	_	_	I-Premise
167	%	_	_	I-Premise
168	CI	_	_	I-Premise
169	,	_	_	I-Premise
170	26.0	_	_	I-Premise
171	to	_	_	I-Premise
172	49.1	_	_	I-Premise
173	)	_	_	I-Premise
174	;	_	_	I-Premise
175	median	_	_	I-Premise
176	progression-free	_	_	I-Premise
177	survival	_	_	I-Premise
178	times	_	_	I-Premise
179	were	_	_	I-Premise
180	2.7	_	_	I-Premise
181	and	_	_	I-Premise
182	2.8	_	_	I-Premise
183	months	_	_	I-Premise
184	;	_	_	I-Premise
185	and	_	_	I-Premise
186	median	_	_	I-Premise
187	overall	_	_	I-Premise
188	survival	_	_	I-Premise
189	times	_	_	I-Premise
190	were	_	_	I-Premise
191	7.6	_	_	I-Premise
192	and	_	_	I-Premise
193	8.0	_	_	I-Premise
194	months	_	_	I-Premise
195	,	_	_	I-Premise
196	respectively	_	_	I-Premise
197	.	_	_	I-Premise

198	Symptom	_	_	B-Premise
199	improvements	_	_	I-Premise
200	were	_	_	I-Premise
201	recorded	_	_	I-Premise
202	for	_	_	I-Premise
203	69.2	_	_	I-Premise
204	%	_	_	I-Premise
205	(	_	_	I-Premise
206	250	_	_	I-Premise
207	mg/d	_	_	I-Premise
208	)	_	_	I-Premise
209	and	_	_	I-Premise
210	85.7	_	_	I-Premise
211	%	_	_	I-Premise
212	(	_	_	I-Premise
213	500	_	_	I-Premise
214	mg/d	_	_	I-Premise
215	)	_	_	I-Premise
216	of	_	_	I-Premise
217	patients	_	_	I-Premise
218	with	_	_	I-Premise
219	a	_	_	I-Premise
220	tumor	_	_	I-Premise
221	response	_	_	I-Premise
222	.	_	_	I-Premise

223	Adverse	_	_	B-Premise
224	events	_	_	I-Premise
225	(	_	_	I-Premise
226	AEs	_	_	I-Premise
227	)	_	_	I-Premise
228	at	_	_	I-Premise
229	both	_	_	I-Premise
230	dose	_	_	I-Premise
231	levels	_	_	I-Premise
232	were	_	_	I-Premise
233	generally	_	_	I-Premise
234	mild	_	_	I-Premise
235	(	_	_	I-Premise
236	grade	_	_	I-Premise
237	1	_	_	I-Premise
238	or	_	_	I-Premise
239	2	_	_	I-Premise
240	)	_	_	I-Premise
241	and	_	_	I-Premise
242	consisted	_	_	I-Premise
243	mainly	_	_	I-Premise
244	of	_	_	I-Premise
245	skin	_	_	I-Premise
246	reactions	_	_	I-Premise
247	and	_	_	I-Premise
248	diarrhea	_	_	I-Premise
249	.	_	_	I-Premise

250	Drug-related	_	_	B-Premise
251	toxicities	_	_	I-Premise
252	were	_	_	I-Premise
253	more	_	_	I-Premise
254	frequent	_	_	I-Premise
255	in	_	_	I-Premise
256	the	_	_	I-Premise
257	higher-dose	_	_	I-Premise
258	group	_	_	I-Premise
259	.	_	_	I-Premise

260	Withdrawal	_	_	B-Premise
261	due	_	_	I-Premise
262	to	_	_	I-Premise
263	drug-related	_	_	I-Premise
264	AEs	_	_	I-Premise
265	was	_	_	I-Premise
266	1.9	_	_	I-Premise
267	%	_	_	I-Premise
268	and	_	_	I-Premise
269	9.4	_	_	I-Premise
270	%	_	_	I-Premise
271	for	_	_	I-Premise
272	patients	_	_	I-Premise
273	receiving	_	_	I-Premise
274	gefitinib	_	_	I-Premise
275	250	_	_	I-Premise
276	and	_	_	I-Premise
277	500	_	_	I-Premise
278	mg/d	_	_	I-Premise
279	,	_	_	I-Premise
280	respectively	_	_	I-Premise
281	.	_	_	I-Premise

282	Gefitinib	_	_	B-Claim
283	showed	_	_	I-Claim
284	clinically	_	_	I-Claim
285	meaningful	_	_	I-Claim
286	antitumor	_	_	I-Claim
287	activity	_	_	I-Claim
288	and	_	_	I-Claim
289	provided	_	_	I-Claim
290	symptom	_	_	I-Claim
291	relief	_	_	I-Claim
292	as	_	_	I-Claim
293	second-	_	_	I-Claim
294	and	_	_	I-Claim
295	third-line	_	_	I-Claim
296	treatment	_	_	I-Claim
297	in	_	_	I-Claim
298	these	_	_	I-Claim
299	patients	_	_	I-Claim
300	.	_	_	I-Claim

301	At	_	_	B-Claim
302	250	_	_	I-Claim
303	mg/d	_	_	I-Claim
304	,	_	_	I-Claim
305	gefitinib	_	_	I-Claim
306	had	_	_	I-Claim
307	a	_	_	I-Claim
308	favorable	_	_	I-Claim
309	AE	_	_	I-Claim
310	profile	_	_	I-Claim
311	.	_	_	I-Claim

312	Gefitinib	_	_	B-Claim
313	250	_	_	I-Claim
314	mg/d	_	_	I-Claim
315	is	_	_	I-Claim
316	an	_	_	I-Claim
317	important	_	_	I-Claim
318	,	_	_	I-Claim
319	novel	_	_	I-Claim
320	treatment	_	_	I-Claim
321	option	_	_	I-Claim
322	for	_	_	I-Claim
323	patients	_	_	I-Claim
324	with	_	_	I-Claim
325	pretreated	_	_	I-Claim
326	advanced	_	_	I-Claim
327	NSCLC	_	_	I-Claim
328	.	_	_	I-Claim


0	Multiple	_	_	B-Claim
1	studies	_	_	I-Claim
2	have	_	_	I-Claim
3	evaluated	_	_	I-Claim
4	the	_	_	I-Claim
5	hypoglycemic	_	_	I-Claim
6	effect	_	_	I-Claim
7	of	_	_	I-Claim
8	cinnamon	_	_	I-Claim
9	in	_	_	I-Claim
10	patients	_	_	I-Claim
11	with	_	_	I-Claim
12	diabetes	_	_	I-Claim
13	mellitus	_	_	I-Claim
14	(	_	_	I-Claim
15	DM	_	_	I-Claim
16	)	_	_	I-Claim
17	type	_	_	I-Claim
18	II	_	_	I-Claim
19	,	_	_	I-Claim
20	with	_	_	I-Claim
21	conflicting	_	_	I-Claim
22	results	_	_	I-Claim
23	.	_	_	I-Claim

24	Differences	_	_	O
25	in	_	_	O
26	Baseline	_	_	O
27	Body	_	_	O
28	Mass	_	_	O
29	Index	_	_	O
30	(	_	_	O
31	BMI	_	_	O
32	)	_	_	O
33	of	_	_	O
34	patients	_	_	O
35	may	_	_	O
36	be	_	_	O
37	able	_	_	O
38	to	_	_	O
39	explain	_	_	O
40	the	_	_	O
41	observed	_	_	O
42	differences	_	_	O
43	in	_	_	O
44	the	_	_	O
45	results	_	_	O
46	.	_	_	O

47	This	_	_	O
48	study	_	_	O
49	was	_	_	O
50	designed	_	_	O
51	to	_	_	O
52	evaluate	_	_	O
53	the	_	_	O
54	effect	_	_	O
55	of	_	_	O
56	cinnamon	_	_	O
57	supplementation	_	_	O
58	on	_	_	O
59	anthropometric	_	_	O
60	,	_	_	O
61	glycemic	_	_	O
62	and	_	_	O
63	lipid	_	_	O
64	outcomes	_	_	O
65	of	_	_	O
66	patients	_	_	O
67	with	_	_	O
68	DM	_	_	O
69	type	_	_	O
70	II	_	_	O
71	based	_	_	O
72	on	_	_	O
73	their	_	_	O
74	baseline	_	_	O
75	BMI	_	_	O
76	.	_	_	O

77	The	_	_	O
78	study	_	_	O
79	was	_	_	O
80	designed	_	_	O
81	as	_	_	O
82	a	_	_	O
83	triple-blind	_	_	O
84	placebo-controlled	_	_	O
85	randomized	_	_	O
86	clinical	_	_	O
87	trial	_	_	O
88	,	_	_	O
89	using	_	_	O
90	a	_	_	O
91	parallel	_	_	O
92	design	_	_	O
93	.	_	_	O

94	One	_	_	O
95	hundred	_	_	O
96	and	_	_	O
97	forty	_	_	O
98	patients	_	_	O
99	referred	_	_	O
100	to	_	_	O
101	Diabetes	_	_	O
102	Clinic	_	_	O
103	of	_	_	O
104	Yazd	_	_	O
105	University	_	_	O
106	of	_	_	O
107	Medical	_	_	O
108	Sciences	_	_	O
109	with	_	_	O
110	diagnosis	_	_	O
111	of	_	_	O
112	DM	_	_	O
113	type	_	_	O
114	II	_	_	O
115	were	_	_	O
116	randomly	_	_	O
117	assigned	_	_	O
118	in	_	_	O
119	four	_	_	O
120	groups	_	_	O
121	:	_	_	O
122	cinnamon	_	_	O
123	(	_	_	O
124	BMI	_	_	O
125	≥	_	_	O
126	27	_	_	O
127	,	_	_	O
128	BMI	_	_	O
129	<	_	_	O
130	27	_	_	O
131	)	_	_	O
132	and	_	_	O
133	Placebo	_	_	O
134	(	_	_	O
135	BMI	_	_	O
136	≥	_	_	O
137	27	_	_	O
138	,	_	_	O
139	BMI	_	_	O
140	<	_	_	O
141	27	_	_	O
142	)	_	_	O
143	.	_	_	O

144	Patients	_	_	O
145	received	_	_	O
146	cinnamon	_	_	O
147	bark	_	_	O
148	powder	_	_	O
149	or	_	_	O
150	placebo	_	_	O
151	in	_	_	O
152	500	_	_	O
153	mg	_	_	O
154	capsules	_	_	O
155	twice	_	_	O
156	daily	_	_	O
157	for	_	_	O
158	3	_	_	O
159	months	_	_	O
160	.	_	_	O

161	Anthropometric	_	_	O
162	,	_	_	O
163	glycemic	_	_	O
164	and	_	_	O
165	lipid	_	_	O
166	outcomes	_	_	O
167	were	_	_	O
168	measured	_	_	O
169	before	_	_	O
170	and	_	_	O
171	after	_	_	O
172	the	_	_	O
173	intervention	_	_	O
174	.	_	_	O

175	Cinnamon	_	_	B-Premise
176	supplementation	_	_	I-Premise
177	led	_	_	I-Premise
178	to	_	_	I-Premise
179	improvement	_	_	I-Premise
180	of	_	_	I-Premise
181	all	_	_	I-Premise
182	anthropometric	_	_	I-Premise
183	(	_	_	I-Premise
184	BMI	_	_	I-Premise
185	,	_	_	I-Premise
186	body	_	_	I-Premise
187	fat	_	_	I-Premise
188	,	_	_	I-Premise
189	and	_	_	I-Premise
190	visceral	_	_	I-Premise
191	fat	_	_	I-Premise
192	)	_	_	I-Premise
193	,	_	_	I-Premise
194	glycemic	_	_	I-Premise
195	(	_	_	I-Premise
196	FPG	_	_	I-Premise
197	,	_	_	I-Premise
198	2hpp	_	_	I-Premise
199	,	_	_	I-Premise
200	HbA1C	_	_	I-Premise
201	,	_	_	I-Premise
202	Fasting	_	_	I-Premise
203	Insulin	_	_	I-Premise
204	,	_	_	I-Premise
205	and	_	_	I-Premise
206	Insulin	_	_	I-Premise
207	Resistance	_	_	I-Premise
208	)	_	_	I-Premise
209	,	_	_	I-Premise
210	and	_	_	I-Premise
211	lipids	_	_	I-Premise
212	(	_	_	I-Premise
213	Cholesterol	_	_	I-Premise
214	Total	_	_	I-Premise
215	,	_	_	I-Premise
216	LDL-c	_	_	I-Premise
217	and	_	_	I-Premise
218	HDL-c	_	_	I-Premise
219	)	_	_	I-Premise
220	outcomes	_	_	I-Premise
221	(	_	_	I-Premise
222	except	_	_	I-Premise
223	for	_	_	I-Premise
224	triglycerides	_	_	I-Premise
225	level	_	_	I-Premise
226	)	_	_	I-Premise
227	.	_	_	I-Premise

228	All	_	_	B-Premise
229	observed	_	_	I-Premise
230	changes	_	_	I-Premise
231	(	_	_	I-Premise
232	except	_	_	I-Premise
233	for	_	_	I-Premise
234	Cholesterol	_	_	I-Premise
235	Total	_	_	I-Premise
236	and	_	_	I-Premise
237	LDL-c	_	_	I-Premise
238	)	_	_	I-Premise
239	were	_	_	I-Premise
240	significantly	_	_	I-Premise
241	more	_	_	I-Premise
242	prominent	_	_	I-Premise
243	in	_	_	I-Premise
244	patients	_	_	I-Premise
245	with	_	_	I-Premise
246	higher	_	_	I-Premise
247	baseline	_	_	I-Premise
248	BMI	_	_	I-Premise
249	(	_	_	I-Premise
250	BMI	_	_	I-Premise
251	≥	_	_	I-Premise
252	27	_	_	I-Premise
253	)	_	_	I-Premise
254	.	_	_	I-Premise

255	Based	_	_	B-Claim
256	on	_	_	I-Claim
257	the	_	_	I-Claim
258	study	_	_	I-Claim
259	findings	_	_	I-Claim
260	,	_	_	I-Claim
261	cinnamon	_	_	I-Claim
262	may	_	_	I-Claim
263	improve	_	_	I-Claim
264	anthropometric	_	_	I-Claim
265	parameters	_	_	I-Claim
266	,	_	_	I-Claim
267	glycemic	_	_	I-Claim
268	indices	_	_	I-Claim
269	and	_	_	I-Claim
270	lipid	_	_	I-Claim
271	profile	_	_	I-Claim
272	of	_	_	I-Claim
273	patients	_	_	I-Claim
274	with	_	_	I-Claim
275	type	_	_	I-Claim
276	II	_	_	I-Claim
277	diabetes	_	_	I-Claim
278	.	_	_	I-Claim

279	These	_	_	B-Claim
280	benefits	_	_	I-Claim
281	are	_	_	I-Claim
282	significantly	_	_	I-Claim
283	more	_	_	I-Claim
284	prominent	_	_	I-Claim
285	in	_	_	I-Claim
286	patients	_	_	I-Claim
287	with	_	_	I-Claim
288	higher	_	_	I-Claim
289	baseline	_	_	I-Claim
290	BMI	_	_	I-Claim
291	(	_	_	I-Claim
292	BMI	_	_	I-Claim
293	≥	_	_	I-Claim
294	27	_	_	I-Claim
295	)	_	_	I-Claim
296	.	_	_	I-Claim


0	Although	_	_	O
1	anthracyclines	_	_	B-Claim
2	are	_	_	I-Claim
3	effective	_	_	I-Claim
4	chemotherapeutic	_	_	I-Claim
5	agents	_	_	I-Claim
6	for	_	_	I-Claim
7	treating	_	_	I-Claim
8	B-cell	_	_	I-Claim
9	lymphoma	_	_	I-Claim
10	,	_	_	I-Claim
11	adverse	_	_	B-Claim
12	effects	_	_	I-Claim
13	,	_	_	I-Claim
14	such	_	_	I-Claim
15	as	_	_	I-Claim
16	bone	_	_	I-Claim
17	marrow	_	_	I-Claim
18	suppression	_	_	I-Claim
19	and	_	_	I-Claim
20	cardiotoxicity	_	_	I-Claim
21	,	_	_	I-Claim
22	limit	_	_	I-Claim
23	their	_	_	I-Claim
24	clinical	_	_	I-Claim
25	application	_	_	I-Claim
26	.	_	_	I-Claim

27	We	_	_	O
28	assessed	_	_	O
29	whether	_	_	O
30	anthracycline	_	_	O
31	treatment	_	_	O
32	also	_	_	O
33	increases	_	_	O
34	the	_	_	O
35	risk	_	_	O
36	for	_	_	O
37	diabetes	_	_	O
38	mellitus	_	_	O
39	in	_	_	O
40	patients	_	_	O
41	with	_	_	O
42	B-cell	_	_	O
43	lymphoma	_	_	O
44	.	_	_	O

45	Using	_	_	O
46	data	_	_	O
47	obtained	_	_	O
48	from	_	_	O
49	the	_	_	O
50	Taiwanese	_	_	O
51	National	_	_	O
52	Health	_	_	O
53	Insurance	_	_	O
54	Research	_	_	O
55	Database	_	_	O
56	from	_	_	O
57	2004	_	_	O
58	to	_	_	O
59	2011	_	_	O
60	,	_	_	O
61	we	_	_	O
62	compared	_	_	O
63	overall	_	_	O
64	survival	_	_	O
65	and	_	_	O
66	clinical	_	_	O
67	features	_	_	O
68	for	_	_	O
69	B-cell	_	_	O
70	lymphoma	_	_	O
71	patients	_	_	O
72	administered	_	_	O
73	anthracyclines	_	_	O
74	(	_	_	O
75	n	_	_	O
76	=	_	_	O
77	3147	_	_	O
78	)	_	_	O
79	and	_	_	O
80	those	_	_	O
81	not	_	_	O
82	administered	_	_	O
83	anthracyclines	_	_	O
84	(	_	_	O
85	n	_	_	O
86	=	_	_	O
87	837	_	_	O
88	)	_	_	O
89	.	_	_	O

90	The	_	_	O
91	impact	_	_	O
92	of	_	_	O
93	anthracycline	_	_	O
94	treatment	_	_	O
95	on	_	_	O
96	diabetes	_	_	O
97	risk	_	_	O
98	was	_	_	O
99	further	_	_	O
100	investigated	_	_	O
101	using	_	_	O
102	a	_	_	O
103	Gray	_	_	O
104	's	_	_	O
105	test	_	_	O
106	and	_	_	O
107	multivariate	_	_	O
108	competing-risk	_	_	O
109	regression	_	_	O
110	models	_	_	O
111	in	_	_	O
112	a	_	_	O
113	dose-dependent	_	_	O
114	manner	_	_	O
115	.	_	_	O

116	Anthracycline	_	_	B-Premise
117	administration	_	_	I-Premise
118	was	_	_	I-Premise
119	associated	_	_	I-Premise
120	with	_	_	I-Premise
121	a	_	_	I-Premise
122	higher	_	_	I-Premise
123	incidence	_	_	I-Premise
124	of	_	_	I-Premise
125	diabetes	_	_	I-Premise
126	(	_	_	I-Premise
127	HR	_	_	I-Premise
128	:	_	_	I-Premise
129	1.75	_	_	I-Premise
130	;	_	_	I-Premise
131	95	_	_	I-Premise
132	%	_	_	I-Premise
133	CI	_	_	I-Premise
134	1.11-2.75	_	_	I-Premise
135	;	_	_	I-Premise
136	p	_	_	I-Premise
137	=	_	_	I-Premise
138	0.0163	_	_	I-Premise
139	)	_	_	I-Premise
140	after	_	_	I-Premise
141	adjustments	_	_	I-Premise
142	for	_	_	I-Premise
143	age	_	_	I-Premise
144	,	_	_	I-Premise
145	gender	_	_	I-Premise
146	,	_	_	I-Premise
147	cumulative	_	_	I-Premise
148	dose	_	_	I-Premise
149	of	_	_	I-Premise
150	prednisolone	_	_	I-Premise
151	,	_	_	I-Premise
152	and	_	_	I-Premise
153	co-morbidities	_	_	I-Premise
154	.	_	_	I-Premise

155	Cumulative	_	_	B-Premise
156	anthracycline	_	_	I-Premise
157	doses	_	_	I-Premise
158	of	_	_	I-Premise
159	253-400	_	_	I-Premise
160	mg	_	_	I-Premise
161	(	_	_	I-Premise
162	HR	_	_	I-Premise
163	:	_	_	I-Premise
164	2.35	_	_	I-Premise
165	;	_	_	I-Premise
166	95	_	_	I-Premise
167	%	_	_	I-Premise
168	CI	_	_	I-Premise
169	1.41-3.91	_	_	I-Premise
170	;	_	_	I-Premise
171	p	_	_	I-Premise
172	=	_	_	I-Premise
173	0.0010	_	_	I-Premise
174	)	_	_	I-Premise
175	,	_	_	I-Premise
176	401-504	_	_	I-Premise
177	mg	_	_	I-Premise
178	(	_	_	I-Premise
179	HR	_	_	I-Premise
180	:	_	_	I-Premise
181	2.26	_	_	I-Premise
182	;	_	_	I-Premise
183	95	_	_	I-Premise
184	%	_	_	I-Premise
185	CI	_	_	I-Premise
186	1.26-4.05	_	_	I-Premise
187	;	_	_	I-Premise
188	p	_	_	I-Premise
189	=	_	_	I-Premise
190	0.0063	_	_	I-Premise
191	)	_	_	I-Premise
192	,	_	_	I-Premise
193	and	_	_	I-Premise
194	>	_	_	I-Premise
195	504	_	_	I-Premise
196	mg	_	_	I-Premise
197	(	_	_	I-Premise
198	HR	_	_	I-Premise
199	:	_	_	I-Premise
200	2.29	_	_	I-Premise
201	;	_	_	I-Premise
202	95	_	_	I-Premise
203	%	_	_	I-Premise
204	CI	_	_	I-Premise
205	1.25-4.18	_	_	I-Premise
206	;	_	_	I-Premise
207	p	_	_	I-Premise
208	=	_	_	I-Premise
209	0.0072	_	_	I-Premise
210	)	_	_	I-Premise
211	increased	_	_	I-Premise
212	the	_	_	I-Premise
213	incidence	_	_	I-Premise
214	density	_	_	I-Premise
215	of	_	_	I-Premise
216	diabetes	_	_	I-Premise
217	in	_	_	I-Premise
218	a	_	_	I-Premise
219	dose-dependent	_	_	I-Premise
220	manner	_	_	I-Premise
221	(	_	_	I-Premise
222	p	_	_	I-Premise
223	=	_	_	I-Premise
224	0.0006	_	_	I-Premise
225	)	_	_	I-Premise
226	.	_	_	I-Premise

227	The	_	_	B-Premise
228	annual	_	_	I-Premise
229	alteration	_	_	I-Premise
230	of	_	_	I-Premise
231	adapted	_	_	I-Premise
232	diabetes	_	_	I-Premise
233	complications	_	_	I-Premise
234	severity	_	_	I-Premise
235	index	_	_	I-Premise
236	score	_	_	I-Premise
237	was	_	_	I-Premise
238	not	_	_	I-Premise
239	significantly	_	_	I-Premise
240	different	_	_	I-Premise
241	between	_	_	I-Premise
242	B-cell	_	_	I-Premise
243	lymphoma	_	_	I-Premise
244	patients	_	_	I-Premise
245	with	_	_	I-Premise
246	or	_	_	I-Premise
247	without	_	_	I-Premise
248	anthracycline	_	_	I-Premise
249	treatment	_	_	I-Premise
250	(	_	_	I-Premise
251	p	_	_	I-Premise
252	=	_	_	I-Premise
253	0.4924	_	_	I-Premise
254	)	_	_	I-Premise
255	.	_	_	I-Premise

256	Anthracycline	_	_	B-Claim
257	therapy	_	_	I-Claim
258	increases	_	_	I-Claim
259	diabetes	_	_	I-Claim
260	risk	_	_	I-Claim
261	in	_	_	I-Claim
262	a	_	_	I-Claim
263	dose-dependent	_	_	I-Claim
264	manner	_	_	I-Claim
265	in	_	_	I-Claim
266	B-cell	_	_	I-Claim
267	lymphoma	_	_	I-Claim
268	patients	_	_	I-Claim
269	.	_	_	I-Claim

270	Intensive	_	_	B-Claim
271	blood	_	_	I-Claim
272	glucose	_	_	I-Claim
273	monitoring	_	_	I-Claim
274	and	_	_	I-Claim
275	control	_	_	I-Claim
276	should	_	_	I-Claim
277	be	_	_	I-Claim
278	recommended	_	_	I-Claim
279	for	_	_	I-Claim
280	B-cell	_	_	I-Claim
281	lymphoma	_	_	I-Claim
282	patients	_	_	I-Claim
283	receiving	_	_	I-Claim
284	anthracycline	_	_	I-Claim
285	treatment	_	_	I-Claim
286	.	_	_	I-Claim


0	Combination	_	_	O
1	therapy	_	_	O
2	has	_	_	O
3	been	_	_	O
4	recommended	_	_	O
5	for	_	_	O
6	the	_	_	O
7	treatment	_	_	O
8	of	_	_	O
9	patients	_	_	O
10	harboring	_	_	O
11	multiple	_	_	O
12	drug-resistant	_	_	O
13	hepatitis	_	_	O
14	B	_	_	O
15	virus	_	_	O
16	(	_	_	O
17	HBV	_	_	O
18	)	_	_	O
19	.	_	_	O

20	However	_	_	O
21	,	_	_	O
22	we	_	_	O
23	recently	_	_	O
24	demonstrated	_	_	O
25	that	_	_	O
26	monotherapy	_	_	O
27	with	_	_	O
28	tenofovir	_	_	O
29	disoproxil	_	_	O
30	fumarate	_	_	O
31	(	_	_	O
32	TDF	_	_	O
33	)	_	_	O
34	for	_	_	O
35	48	_	_	O
36	weeks	_	_	O
37	displayed	_	_	O
38	noninferior	_	_	O
39	efficacy	_	_	O
40	to	_	_	O
41	TDF	_	_	O
42	plus	_	_	O
43	entecavir	_	_	O
44	(	_	_	O
45	ETV	_	_	O
46	)	_	_	O
47	combination	_	_	O
48	therapy	_	_	O
49	in	_	_	O
50	patients	_	_	O
51	with	_	_	O
52	HBV	_	_	O
53	resistant	_	_	O
54	to	_	_	O
55	multiple	_	_	O
56	drugs	_	_	O
57	,	_	_	O
58	including	_	_	O
59	ETV	_	_	O
60	and	_	_	O
61	adefovir	_	_	O
62	.	_	_	O

63	Nonetheless	_	_	O
64	,	_	_	O
65	whether	_	_	O
66	prolonged	_	_	O
67	TDF	_	_	O
68	monotherapy	_	_	O
69	would	_	_	O
70	be	_	_	O
71	safe	_	_	O
72	and	_	_	O
73	increase	_	_	O
74	the	_	_	O
75	virologic	_	_	O
76	response	_	_	O
77	rate	_	_	O
78	in	_	_	O
79	these	_	_	O
80	patients	_	_	O
81	was	_	_	O
82	unclear	_	_	O
83	.	_	_	O

84	Among	_	_	O
85	192	_	_	O
86	patients	_	_	O
87	with	_	_	O
88	HBV-resistance	_	_	O
89	mutations	_	_	O
90	to	_	_	O
91	ETV	_	_	O
92	and/or	_	_	O
93	adefovir	_	_	O
94	,	_	_	O
95	who	_	_	O
96	were	_	_	O
97	randomized	_	_	O
98	to	_	_	O
99	receive	_	_	O
100	TDF	_	_	O
101	monotherapy	_	_	O
102	(	_	_	O
103	n	_	_	O
104	=	_	_	O
105	95	_	_	O
106	)	_	_	O
107	or	_	_	O
108	TDF/ETV	_	_	O
109	combination	_	_	O
110	therapy	_	_	O
111	(	_	_	O
112	n	_	_	O
113	=	_	_	O
114	97	_	_	O
115	)	_	_	O
116	for	_	_	O
117	48	_	_	O
118	weeks	_	_	O
119	,	_	_	O
120	189	_	_	O
121	agreed	_	_	O
122	to	_	_	O
123	continue	_	_	O
124	TDF	_	_	O
125	monotherapy	_	_	O
126	(	_	_	O
127	TDF-TDF	_	_	O
128	group	_	_	O
129	)	_	_	O
130	or	_	_	O
131	to	_	_	O
132	switch	_	_	O
133	to	_	_	O
134	TDF	_	_	O
135	monotherapy	_	_	O
136	(	_	_	O
137	TDF/ETV-TDF	_	_	O
138	group	_	_	O
139	)	_	_	O
140	and	_	_	O
141	180	_	_	O
142	(	_	_	O
143	93.8	_	_	O
144	%	_	_	O
145	)	_	_	O
146	completed	_	_	O
147	the	_	_	O
148	144-week	_	_	O
149	study	_	_	O
150	.	_	_	O

151	Serum	_	_	B-Premise
152	HBV	_	_	I-Premise
153	DNA	_	_	I-Premise
154	<	_	_	I-Premise
155	15	_	_	I-Premise
156	IU/mL	_	_	I-Premise
157	at	_	_	I-Premise
158	week	_	_	I-Premise
159	48	_	_	I-Premise
160	,	_	_	I-Premise
161	the	_	_	I-Premise
162	primary	_	_	I-Premise
163	efficacy	_	_	I-Premise
164	endpoint	_	_	I-Premise
165	,	_	_	I-Premise
166	was	_	_	I-Premise
167	achieved	_	_	I-Premise
168	in	_	_	I-Premise
169	66.3	_	_	I-Premise
170	%	_	_	I-Premise
171	in	_	_	I-Premise
172	the	_	_	I-Premise
173	TDF-TDF	_	_	I-Premise
174	group	_	_	I-Premise
175	and	_	_	I-Premise
176	68.0	_	_	I-Premise
177	%	_	_	I-Premise
178	in	_	_	I-Premise
179	the	_	_	I-Premise
180	TDF/ETV-TDF	_	_	I-Premise
181	group	_	_	I-Premise
182	(	_	_	I-Premise
183	P	_	_	I-Premise
184	=	_	_	I-Premise
185	0.80	_	_	I-Premise
186	)	_	_	I-Premise
187	.	_	_	I-Premise

188	At	_	_	B-Premise
189	week	_	_	I-Premise
190	144	_	_	I-Premise
191	,	_	_	I-Premise
192	the	_	_	I-Premise
193	proportion	_	_	I-Premise
194	with	_	_	I-Premise
195	HBV	_	_	I-Premise
196	DNA	_	_	I-Premise
197	<	_	_	I-Premise
198	15	_	_	I-Premise
199	IU/mL	_	_	I-Premise
200	increased	_	_	I-Premise
201	to	_	_	I-Premise
202	74.5	_	_	I-Premise
203	%	_	_	I-Premise
204	,	_	_	I-Premise
205	which	_	_	I-Premise
206	was	_	_	I-Premise
207	significantly	_	_	I-Premise
208	higher	_	_	I-Premise
209	compared	_	_	I-Premise
210	with	_	_	I-Premise
211	that	_	_	I-Premise
212	at	_	_	I-Premise
213	week	_	_	I-Premise
214	48	_	_	I-Premise
215	(	_	_	I-Premise
216	P	_	_	I-Premise
217	=	_	_	I-Premise
218	0.03	_	_	I-Premise
219	)	_	_	I-Premise
220	,	_	_	I-Premise
221	without	_	_	I-Premise
222	a	_	_	I-Premise
223	significant	_	_	I-Premise
224	difference	_	_	I-Premise
225	between	_	_	I-Premise
226	groups	_	_	I-Premise
227	(	_	_	I-Premise
228	P	_	_	I-Premise
229	=	_	_	I-Premise
230	0.46	_	_	I-Premise
231	)	_	_	I-Premise
232	.	_	_	I-Premise

233	By	_	_	B-Premise
234	on-treatment	_	_	I-Premise
235	analysis	_	_	I-Premise
236	,	_	_	I-Premise
237	a	_	_	I-Premise
238	total	_	_	I-Premise
239	of	_	_	I-Premise
240	79.4	_	_	I-Premise
241	%	_	_	I-Premise
242	had	_	_	I-Premise
243	HBV	_	_	I-Premise
244	DNA	_	_	I-Premise
245	<	_	_	I-Premise
246	15	_	_	I-Premise
247	IU/mL	_	_	I-Premise
248	at	_	_	I-Premise
249	week	_	_	I-Premise
250	144	_	_	I-Premise
251	.	_	_	I-Premise

252	Transient	_	_	B-Premise
253	virologic	_	_	I-Premise
254	breakthrough	_	_	I-Premise
255	occurred	_	_	I-Premise
256	in	_	_	I-Premise
257	6	_	_	I-Premise
258	patients	_	_	I-Premise
259	,	_	_	I-Premise
260	which	_	_	I-Premise
261	was	_	_	I-Premise
262	due	_	_	I-Premise
263	to	_	_	I-Premise
264	poor	_	_	I-Premise
265	drug	_	_	I-Premise
266	adherence	_	_	I-Premise
267	.	_	_	I-Premise

268	At	_	_	B-Premise
269	week	_	_	I-Premise
270	144	_	_	I-Premise
271	,	_	_	I-Premise
272	19	_	_	I-Premise
273	patients	_	_	I-Premise
274	who	_	_	I-Premise
275	had	_	_	I-Premise
276	HBV	_	_	I-Premise
277	DNA	_	_	I-Premise
278	levels	_	_	I-Premise
279	>	_	_	I-Premise
280	60	_	_	I-Premise
281	IU/mL	_	_	I-Premise
282	qualified	_	_	I-Premise
283	for	_	_	I-Premise
284	genotypic	_	_	I-Premise
285	resistance	_	_	I-Premise
286	analysis	_	_	I-Premise
287	,	_	_	I-Premise
288	and	_	_	I-Premise
289	6	_	_	I-Premise
290	retained	_	_	I-Premise
291	some	_	_	I-Premise
292	of	_	_	I-Premise
293	their	_	_	I-Premise
294	baseline	_	_	I-Premise
295	resistance	_	_	I-Premise
296	mutations	_	_	I-Premise
297	of	_	_	I-Premise
298	HBV	_	_	I-Premise
299	.	_	_	I-Premise

300	No	_	_	B-Premise
301	patients	_	_	I-Premise
302	developed	_	_	I-Premise
303	additional	_	_	I-Premise
304	resistance	_	_	I-Premise
305	mutations	_	_	I-Premise
306	throughout	_	_	I-Premise
307	the	_	_	I-Premise
308	study	_	_	I-Premise
309	period	_	_	I-Premise
310	.	_	_	I-Premise

311	TDF	_	_	B-Claim
312	monotherapy	_	_	I-Claim
313	was	_	_	I-Claim
314	efficacious	_	_	I-Claim
315	and	_	_	I-Claim
316	safe	_	_	I-Claim
317	for	_	_	I-Claim
318	up	_	_	I-Claim
319	to	_	_	I-Claim
320	144	_	_	I-Claim
321	weeks	_	_	I-Claim
322	,	_	_	I-Claim
323	providing	_	_	I-Claim
324	an	_	_	I-Claim
325	increasing	_	_	I-Claim
326	rate	_	_	I-Claim
327	of	_	_	I-Claim
328	virologic	_	_	I-Claim
329	response	_	_	I-Claim
330	in	_	_	I-Claim
331	heavily	_	_	I-Claim
332	pretreated	_	_	I-Claim
333	patients	_	_	I-Claim
334	with	_	_	I-Claim
335	multidrug-resistant	_	_	I-Claim
336	HBV	_	_	I-Claim
337	.	_	_	I-Claim


0	To	_	_	O
1	estimate	_	_	O
2	the	_	_	O
3	real-world	_	_	O
4	effects	_	_	O
5	of	_	_	O
6	offering	_	_	O
7	a	_	_	O
8	group-based	_	_	O
9	lifestyle	_	_	O
10	intervention	_	_	O
11	(	_	_	O
12	GLI	_	_	O
13	)	_	_	O
14	to	_	_	O
15	adults	_	_	O
16	with	_	_	O
17	diabetes	_	_	O
18	.	_	_	O

19	This	_	_	O
20	randomized	_	_	O
21	encouragement	_	_	O
22	trial	_	_	O
23	included	_	_	O
24	adult	_	_	O
25	primary	_	_	O
26	care	_	_	O
27	patients	_	_	O
28	in	_	_	O
29	metropolitan	_	_	O
30	Chicago	_	_	O
31	with	_	_	O
32	type	_	_	O
33	2	_	_	O
34	diabetes	_	_	O
35	and	_	_	O
36	body	_	_	O
37	mass	_	_	O
38	index	_	_	O
39	≥24	_	_	O
40	kg/m2	_	_	O
41	.	_	_	O

42	Participants	_	_	O
43	were	_	_	O
44	randomized	_	_	O
45	to	_	_	O
46	standard	_	_	O
47	care	_	_	O
48	(	_	_	O
49	brief	_	_	O
50	dietary	_	_	O
51	and	_	_	O
52	lifestyle	_	_	O
53	counseling	_	_	O
54	)	_	_	O
55	or	_	_	O
56	standard	_	_	O
57	care	_	_	O
58	plus	_	_	O
59	being	_	_	O
60	encouraged	_	_	O
61	,	_	_	O
62	but	_	_	O
63	not	_	_	O
64	required	_	_	O
65	,	_	_	O
66	to	_	_	O
67	participate	_	_	O
68	in	_	_	O
69	a	_	_	O
70	free-of-charge	_	_	O
71	GLI	_	_	O
72	offered	_	_	O
73	by	_	_	O
74	the	_	_	O
75	YMCA	_	_	O
76	.	_	_	O

77	The	_	_	O
78	GLI	_	_	O
79	was	_	_	O
80	a	_	_	O
81	group-based	_	_	O
82	adaptation	_	_	O
83	of	_	_	O
84	the	_	_	O
85	Look	_	_	O
86	AHEAD	_	_	O
87	lifestyle	_	_	O
88	intervention	_	_	O
89	.	_	_	O

90	Of	_	_	O
91	331	_	_	O
92	participants	_	_	O
93	,	_	_	O
94	167	_	_	O
95	were	_	_	O
96	randomized	_	_	O
97	to	_	_	O
98	standard	_	_	O
99	care	_	_	O
100	and	_	_	O
101	164	_	_	O
102	to	_	_	O
103	the	_	_	O
104	GLI	_	_	O
105	encouragement	_	_	O
106	arm	_	_	O
107	.	_	_	O

108	About	_	_	O
109	one	_	_	O
110	third	_	_	O
111	of	_	_	O
112	participants	_	_	O
113	were	_	_	O
114	non-Hispanic	_	_	O
115	White	_	_	O
116	(	_	_	O
117	34.4	_	_	O
118	%	_	_	O
119	)	_	_	O
120	.	_	_	O

121	In	_	_	O
122	the	_	_	O
123	GLI	_	_	O
124	arm	_	_	O
125	,	_	_	O
126	75	_	_	O
127	(	_	_	O
128	45.7	_	_	O
129	%	_	_	O
130	)	_	_	O
131	attended	_	_	O
132	≥1	_	_	O
133	GLI	_	_	O
134	visits	_	_	O
135	.	_	_	O

136	In	_	_	B-Premise
137	the	_	_	I-Premise
138	primary	_	_	I-Premise
139	intention-to-treat	_	_	I-Premise
140	analysis	_	_	I-Premise
141	,	_	_	I-Premise
142	the	_	_	I-Premise
143	effect	_	_	I-Premise
144	of	_	_	I-Premise
145	GLI	_	_	I-Premise
146	encouragement	_	_	I-Premise
147	was	_	_	I-Premise
148	0.95	_	_	I-Premise
149	%	_	_	I-Premise
150	weight	_	_	I-Premise
151	loss	_	_	I-Premise
152	at	_	_	I-Premise
153	six	_	_	I-Premise
154	months	_	_	I-Premise
155	(	_	_	I-Premise
156	95	_	_	I-Premise
157	%	_	_	I-Premise
158	confidence	_	_	I-Premise
159	interval	_	_	I-Premise
160	[	_	_	I-Premise
161	CI	_	_	I-Premise
162	]	_	_	I-Premise
163	,	_	_	I-Premise
164	0.13-1.77	_	_	I-Premise
165	%	_	_	I-Premise
166	;	_	_	I-Premise
167	P	_	_	I-Premise
168	=	_	_	I-Premise
169	0.02	_	_	I-Premise
170	)	_	_	I-Premise
171	,	_	_	I-Premise
172	and	_	_	I-Premise
173	1.20	_	_	I-Premise
174	%	_	_	I-Premise
175	weight	_	_	I-Premise
176	loss	_	_	I-Premise
177	at	_	_	I-Premise
178	12	_	_	I-Premise
179	months	_	_	I-Premise
180	(	_	_	I-Premise
181	95	_	_	I-Premise
182	%	_	_	I-Premise
183	CI	_	_	I-Premise
184	,	_	_	I-Premise
185	0.05-2.36	_	_	I-Premise
186	%	_	_	I-Premise
187	;	_	_	I-Premise
188	P	_	_	I-Premise
189	=	_	_	I-Premise
190	0.04	_	_	I-Premise
191	)	_	_	I-Premise
192	.	_	_	I-Premise

193	At	_	_	B-Premise
194	12	_	_	I-Premise
195	months	_	_	I-Premise
196	,	_	_	I-Premise
197	there	_	_	I-Premise
198	was	_	_	I-Premise
199	a	_	_	I-Premise
200	0.30	_	_	I-Premise
201	%	_	_	I-Premise
202	(	_	_	I-Premise
203	3.3	_	_	I-Premise
204	mmol/mol	_	_	I-Premise
205	)	_	_	I-Premise
206	reduction	_	_	I-Premise
207	in	_	_	I-Premise
208	hemoglobin	_	_	I-Premise
209	A1c	_	_	I-Premise
210	,	_	_	I-Premise
211	but	_	_	B-Premise
212	this	_	_	I-Premise
213	result	_	_	I-Premise
214	did	_	_	I-Premise
215	not	_	_	I-Premise
216	achieve	_	_	I-Premise
217	statistical	_	_	I-Premise
218	significance	_	_	I-Premise
219	(	_	_	I-Premise
220	P	_	_	I-Premise
221	=	_	_	I-Premise
222	0.054	_	_	I-Premise
223	)	_	_	I-Premise
224	.	_	_	I-Premise

225	In	_	_	B-Premise
226	instrumental	_	_	I-Premise
227	variable	_	_	I-Premise
228	analysis	_	_	I-Premise
229	estimating	_	_	I-Premise
230	effects	_	_	I-Premise
231	among	_	_	I-Premise
232	the	_	_	I-Premise
233	subgroup	_	_	I-Premise
234	of	_	_	I-Premise
235	participants	_	_	I-Premise
236	who	_	_	I-Premise
237	attended	_	_	I-Premise
238	any	_	_	I-Premise
239	GLI	_	_	I-Premise
240	visits	_	_	I-Premise
241	,	_	_	I-Premise
242	the	_	_	I-Premise
243	effect	_	_	I-Premise
244	of	_	_	I-Premise
245	GLI	_	_	I-Premise
246	attendance	_	_	I-Premise
247	was	_	_	I-Premise
248	2.30	_	_	I-Premise
249	%	_	_	I-Premise
250	weight	_	_	I-Premise
251	loss	_	_	I-Premise
252	at	_	_	I-Premise
253	six	_	_	I-Premise
254	months	_	_	I-Premise
255	(	_	_	I-Premise
256	95	_	_	I-Premise
257	%	_	_	I-Premise
258	CI	_	_	I-Premise
259	,	_	_	I-Premise
260	0.30-4.30	_	_	I-Premise
261	%	_	_	I-Premise
262	;	_	_	I-Premise
263	P	_	_	I-Premise
264	=	_	_	I-Premise
265	0.02	_	_	I-Premise
266	)	_	_	I-Premise
267	,	_	_	I-Premise
268	and	_	_	I-Premise
269	2.07	_	_	I-Premise
270	%	_	_	I-Premise
271	weight	_	_	I-Premise
272	loss	_	_	I-Premise
273	at	_	_	I-Premise
274	12	_	_	I-Premise
275	months	_	_	I-Premise
276	(	_	_	I-Premise
277	95	_	_	I-Premise
278	%	_	_	I-Premise
279	CI	_	_	I-Premise
280	,	_	_	I-Premise
281	0.25-3.88	_	_	I-Premise
282	%	_	_	I-Premise
283	;	_	_	I-Premise
284	P	_	_	I-Premise
285	=	_	_	I-Premise
286	0.02	_	_	I-Premise
287	)	_	_	I-Premise
288	.	_	_	I-Premise

289	We	_	_	O
290	detected	_	_	O
291	no	_	_	O
292	significant	_	_	O
293	blood	_	_	O
294	pressure	_	_	O
295	or	_	_	O
296	cholesterol	_	_	O
297	effects	_	_	O
298	.	_	_	O

299	Among	_	_	B-Claim
300	adults	_	_	I-Claim
301	with	_	_	I-Claim
302	type	_	_	I-Claim
303	2	_	_	I-Claim
304	diabetes	_	_	I-Claim
305	,	_	_	I-Claim
306	a	_	_	I-Claim
307	group-based	_	_	I-Claim
308	lifestyle	_	_	I-Claim
309	intervention	_	_	I-Claim
310	in	_	_	I-Claim
311	a	_	_	I-Claim
312	community-based	_	_	I-Claim
313	setting	_	_	I-Claim
314	achieved	_	_	I-Claim
315	modest	_	_	I-Claim
316	weight	_	_	I-Claim
317	loss	_	_	I-Claim
318	at	_	_	I-Claim
319	6	_	_	I-Claim
320	and	_	_	I-Claim
321	12	_	_	I-Claim
322	months	_	_	I-Claim
323	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	the	_	_	O
3	safety	_	_	O
4	and	_	_	O
5	efficacy	_	_	O
6	of	_	_	O
7	oral	_	_	O
8	bexarotene	_	_	O
9	(	_	_	O
10	Targretin	_	_	O
11	capsules	_	_	O
12	;	_	_	O
13	Ligand	_	_	O
14	Pharmaceuticals	_	_	O
15	Incorporated	_	_	O
16	,	_	_	O
17	San	_	_	O
18	Diego	_	_	O
19	,	_	_	O
20	Calif	_	_	O
21	)	_	_	O
22	.	_	_	O

23	The	_	_	O
24	effects	_	_	O
25	of	_	_	O
26	2	_	_	O
27	randomized	_	_	O
28	doses	_	_	O
29	of	_	_	O
30	6.5	_	_	O
31	mg/m	_	_	O
32	(	_	_	O
33	2	_	_	O
34	)	_	_	O
35	per	_	_	O
36	day	_	_	O
37	(	_	_	O
38	with	_	_	O
39	crossover	_	_	O
40	for	_	_	O
41	progression	_	_	O
42	)	_	_	O
43	vs	_	_	O
44	650	_	_	O
45	mg/m	_	_	O
46	(	_	_	O
47	2	_	_	O
48	)	_	_	O
49	per	_	_	O
50	day	_	_	O
51	(	_	_	O
52	later	_	_	O
53	modified	_	_	O
54	to	_	_	O
55	300	_	_	O
56	mg/m	_	_	O
57	(	_	_	O
58	2	_	_	O
59	)	_	_	O
60	per	_	_	O
61	day	_	_	O
62	)	_	_	O
63	were	_	_	O
64	evaluated	_	_	O
65	in	_	_	O
66	an	_	_	O
67	open-label	_	_	O
68	,	_	_	O
69	multicenter	_	_	O
70	,	_	_	O
71	phase	_	_	O
72	2	_	_	O
73	and	_	_	O
74	3	_	_	O
75	study	_	_	O
76	conducted	_	_	O
77	between	_	_	O
78	February	_	_	O
79	1997	_	_	O
80	and	_	_	O
81	November	_	_	O
82	1998	_	_	O
83	.	_	_	O

84	Eighteen	_	_	O
85	international	_	_	O
86	cutaneous	_	_	O
87	T-cell	_	_	O
88	lymphoma	_	_	O
89	clinics	_	_	O
90	at	_	_	O
91	academic	_	_	O
92	referral	_	_	O
93	centers	_	_	O
94	.	_	_	O

95	Fifty-eight	_	_	O
96	patients	_	_	O
97	with	_	_	O
98	biopsy-proven	_	_	O
99	stage	_	_	O
100	IA	_	_	O
101	through	_	_	O
102	IIA	_	_	O
103	cutaneous	_	_	O
104	T-cell	_	_	O
105	lymphoma	_	_	O
106	that	_	_	O
107	was	_	_	O
108	refractory	_	_	O
109	to	_	_	O
110	(	_	_	O
111	or	_	_	O
112	patients	_	_	O
113	were	_	_	O
114	intolerant	_	_	O
115	of	_	_	O
116	)	_	_	O
117	treatment	_	_	O
118	or	_	_	O
119	had	_	_	O
120	reached	_	_	O
121	at	_	_	O
122	least	_	_	O
123	a	_	_	O
124	6-month	_	_	O
125	response	_	_	O
126	plateau	_	_	O
127	under	_	_	O
128	at	_	_	O
129	least	_	_	O
130	2	_	_	O
131	forms	_	_	O
132	of	_	_	O
133	prior	_	_	O
134	therapy	_	_	O
135	(	_	_	O
136	median	_	_	O
137	of	_	_	O
138	3.5	_	_	O
139	prior	_	_	O
140	therapies	_	_	O
141	)	_	_	O
142	.	_	_	O

143	Bexarotene	_	_	O
144	(	_	_	O
145	Targretin	_	_	O
146	capsules	_	_	O
147	)	_	_	O
148	administered	_	_	O
149	once	_	_	O
150	daily	_	_	O
151	with	_	_	O
152	meal	_	_	O
153	for	_	_	O
154	16	_	_	O
155	weeks	_	_	O
156	or	_	_	O
157	longer	_	_	O
158	.	_	_	O

159	Primary	_	_	O
160	end	_	_	O
161	point	_	_	O
162	classification	_	_	O
163	of	_	_	O
164	overall	_	_	O
165	response	_	_	O
166	rate	_	_	O
167	of	_	_	O
168	complete	_	_	O
169	and	_	_	O
170	partial	_	_	O
171	remissions	_	_	O
172	determined	_	_	O
173	by	_	_	O
174	either	_	_	O
175	the	_	_	O
176	Physician	_	_	O
177	's	_	_	O
178	Global	_	_	O
179	Assessment	_	_	O
180	of	_	_	O
181	Clinical	_	_	O
182	Condition	_	_	O
183	or	_	_	O
184	the	_	_	O
185	objective	_	_	O
186	Composite	_	_	O
187	Assessment	_	_	O
188	of	_	_	O
189	Index	_	_	O
190	Lesion	_	_	O
191	Severity	_	_	O
192	.	_	_	O

193	Body	_	_	O
194	surface	_	_	O
195	area	_	_	O
196	,	_	_	O
197	time	_	_	O
198	to	_	_	O
199	response	_	_	O
200	,	_	_	O
201	duration	_	_	O
202	of	_	_	O
203	disease	_	_	O
204	control	_	_	O
205	,	_	_	O
206	time	_	_	O
207	to	_	_	O
208	disease	_	_	O
209	progression	_	_	O
210	,	_	_	O
211	individual	_	_	O
212	index	_	_	O
213	lesion	_	_	O
214	signs	_	_	O
215	and	_	_	O
216	symptoms	_	_	O
217	,	_	_	O
218	and	_	_	O
219	quality	_	_	O
220	of	_	_	O
221	life	_	_	O
222	parameters	_	_	O
223	were	_	_	O
224	secondary	_	_	O
225	outcomes	_	_	O
226	.	_	_	O

227	Responses	_	_	B-Premise
228	(	_	_	I-Premise
229	>	_	_	I-Premise
230	or	_	_	I-Premise
231	=	_	_	I-Premise
232	50	_	_	I-Premise
233	%	_	_	I-Premise
234	improvement	_	_	I-Premise
235	)	_	_	I-Premise
236	were	_	_	I-Premise
237	seen	_	_	I-Premise
238	in	_	_	I-Premise
239	3	_	_	I-Premise
240	(	_	_	I-Premise
241	20	_	_	I-Premise
242	%	_	_	I-Premise
243	)	_	_	I-Premise
244	of	_	_	I-Premise
245	15	_	_	I-Premise
246	patients	_	_	I-Premise
247	with	_	_	I-Premise
248	an	_	_	I-Premise
249	initial	_	_	I-Premise
250	dose	_	_	I-Premise
251	at	_	_	I-Premise
252	6.5	_	_	I-Premise
253	mg/m	_	_	I-Premise
254	(	_	_	I-Premise
255	2	_	_	I-Premise
256	)	_	_	I-Premise
257	per	_	_	I-Premise
258	day	_	_	I-Premise
259	(	_	_	I-Premise
260	95	_	_	I-Premise
261	%	_	_	I-Premise
262	confidence	_	_	I-Premise
263	interval	_	_	I-Premise
264	[	_	_	I-Premise
265	CI	_	_	I-Premise
266	]	_	_	I-Premise
267	,	_	_	I-Premise
268	0	_	_	I-Premise
269	%	_	_	I-Premise
270	-40	_	_	I-Premise
271	%	_	_	I-Premise
272	)	_	_	I-Premise
273	,	_	_	I-Premise
274	15	_	_	I-Premise
275	(	_	_	I-Premise
276	54	_	_	I-Premise
277	%	_	_	I-Premise
278	)	_	_	I-Premise
279	of	_	_	I-Premise
280	28	_	_	I-Premise
281	patients	_	_	I-Premise
282	at	_	_	I-Premise
283	300	_	_	I-Premise
284	mg/m	_	_	I-Premise
285	(	_	_	I-Premise
286	2	_	_	I-Premise
287	)	_	_	I-Premise
288	per	_	_	I-Premise
289	day	_	_	I-Premise
290	(	_	_	I-Premise
291	95	_	_	I-Premise
292	%	_	_	I-Premise
293	CI	_	_	I-Premise
294	,	_	_	I-Premise
295	35	_	_	I-Premise
296	%	_	_	I-Premise
297	-72	_	_	I-Premise
298	%	_	_	I-Premise
299	)	_	_	I-Premise
300	,	_	_	I-Premise
301	and	_	_	I-Premise
302	10	_	_	I-Premise
303	(	_	_	I-Premise
304	67	_	_	I-Premise
305	%	_	_	I-Premise
306	)	_	_	I-Premise
307	of	_	_	I-Premise
308	15	_	_	I-Premise
309	patients	_	_	I-Premise
310	at	_	_	I-Premise
311	above	_	_	I-Premise
312	300	_	_	I-Premise
313	mg/m	_	_	I-Premise
314	(	_	_	I-Premise
315	2	_	_	I-Premise
316	)	_	_	I-Premise
317	per	_	_	I-Premise
318	day	_	_	I-Premise
319	(	_	_	I-Premise
320	95	_	_	I-Premise
321	%	_	_	I-Premise
322	CI	_	_	I-Premise
323	,	_	_	I-Premise
324	43	_	_	I-Premise
325	%	_	_	I-Premise
326	-91	_	_	I-Premise
327	%	_	_	I-Premise
328	)	_	_	I-Premise
329	.	_	_	I-Premise

330	The	_	_	B-Premise
331	rate	_	_	I-Premise
332	of	_	_	I-Premise
333	progressive	_	_	I-Premise
334	disease	_	_	I-Premise
335	was	_	_	I-Premise
336	47	_	_	I-Premise
337	%	_	_	I-Premise
338	,	_	_	I-Premise
339	21	_	_	I-Premise
340	%	_	_	I-Premise
341	,	_	_	I-Premise
342	and	_	_	I-Premise
343	13	_	_	I-Premise
344	%	_	_	I-Premise
345	at	_	_	I-Premise
346	the	_	_	I-Premise
347	same	_	_	I-Premise
348	dose	_	_	I-Premise
349	levels	_	_	I-Premise
350	,	_	_	I-Premise
351	respectively	_	_	I-Premise
352	.	_	_	I-Premise

353	Eight	_	_	B-Premise
354	(	_	_	I-Premise
355	73	_	_	I-Premise
356	%	_	_	I-Premise
357	)	_	_	I-Premise
358	of	_	_	I-Premise
359	11	_	_	I-Premise
360	patients	_	_	I-Premise
361	crossing	_	_	I-Premise
362	over	_	_	I-Premise
363	from	_	_	I-Premise
364	6.5	_	_	I-Premise
365	mg/m	_	_	I-Premise
366	(	_	_	I-Premise
367	2	_	_	I-Premise
368	)	_	_	I-Premise
369	per	_	_	I-Premise
370	day	_	_	I-Premise
371	to	_	_	I-Premise
372	higher	_	_	I-Premise
373	doses	_	_	I-Premise
374	subsequently	_	_	I-Premise
375	responded	_	_	I-Premise
376	.	_	_	I-Premise

377	The	_	_	B-Premise
378	median	_	_	I-Premise
379	duration	_	_	I-Premise
380	of	_	_	I-Premise
381	response	_	_	I-Premise
382	from	_	_	I-Premise
383	start	_	_	I-Premise
384	of	_	_	I-Premise
385	therapy	_	_	I-Premise
386	could	_	_	I-Premise
387	not	_	_	I-Premise
388	be	_	_	I-Premise
389	estimated	_	_	I-Premise
390	for	_	_	I-Premise
391	the	_	_	I-Premise
392	15	_	_	I-Premise
393	patients	_	_	I-Premise
394	at	_	_	I-Premise
395	300	_	_	I-Premise
396	mg/m	_	_	I-Premise
397	(	_	_	I-Premise
398	2	_	_	I-Premise
399	)	_	_	I-Premise
400	per	_	_	I-Premise
401	day	_	_	I-Premise
402	owing	_	_	I-Premise
403	to	_	_	I-Premise
404	low	_	_	I-Premise
405	relapse	_	_	I-Premise
406	rates	_	_	I-Premise
407	in	_	_	I-Premise
408	2	_	_	I-Premise
409	patients	_	_	I-Premise
410	(	_	_	I-Premise
411	13	_	_	I-Premise
412	%	_	_	I-Premise
413	)	_	_	I-Premise
414	;	_	_	I-Premise
415	at	_	_	I-Premise
416	higher	_	_	I-Premise
417	doses	_	_	I-Premise
418	it	_	_	I-Premise
419	was	_	_	I-Premise
420	516	_	_	I-Premise
421	days	_	_	I-Premise
422	.	_	_	I-Premise

423	The	_	_	B-Premise
424	following	_	_	I-Premise
425	drug-related	_	_	I-Premise
426	adverse	_	_	I-Premise
427	effects	_	_	I-Premise
428	were	_	_	I-Premise
429	reversible	_	_	I-Premise
430	and	_	_	I-Premise
431	treatable	_	_	I-Premise
432	:	_	_	I-Premise
433	hypertriglyceridemia	_	_	I-Premise
434	(	_	_	I-Premise
435	46	_	_	I-Premise
436	patients	_	_	I-Premise
437	[	_	_	I-Premise
438	79	_	_	I-Premise
439	%	_	_	I-Premise
440	]	_	_	I-Premise
441	)	_	_	I-Premise
442	,	_	_	I-Premise
443	hypercholesterolemia	_	_	I-Premise
444	(	_	_	I-Premise
445	28	_	_	I-Premise
446	patients	_	_	I-Premise
447	[	_	_	I-Premise
448	48	_	_	I-Premise
449	%	_	_	I-Premise
450	]	_	_	I-Premise
451	)	_	_	I-Premise
452	,	_	_	I-Premise
453	headache	_	_	I-Premise
454	(	_	_	I-Premise
455	27	_	_	I-Premise
456	patients	_	_	I-Premise
457	[	_	_	I-Premise
458	47	_	_	I-Premise
459	%	_	_	I-Premise
460	]	_	_	I-Premise
461	)	_	_	I-Premise
462	,	_	_	I-Premise
463	central	_	_	I-Premise
464	hypothyroidism	_	_	I-Premise
465	(	_	_	I-Premise
466	23	_	_	I-Premise
467	patients	_	_	I-Premise
468	[	_	_	I-Premise
469	40	_	_	I-Premise
470	%	_	_	I-Premise
471	]	_	_	I-Premise
472	)	_	_	I-Premise
473	,	_	_	I-Premise
474	asthenia	_	_	I-Premise
475	(	_	_	I-Premise
476	21	_	_	I-Premise
477	patients	_	_	I-Premise
478	[	_	_	I-Premise
479	36	_	_	I-Premise
480	%	_	_	I-Premise
481	]	_	_	I-Premise
482	)	_	_	I-Premise
483	,	_	_	I-Premise
484	and	_	_	I-Premise
485	leukopenia	_	_	I-Premise
486	(	_	_	I-Premise
487	16	_	_	I-Premise
488	patients	_	_	I-Premise
489	[	_	_	I-Premise
490	28	_	_	I-Premise
491	%	_	_	I-Premise
492	]	_	_	I-Premise
493	)	_	_	I-Premise
494	.	_	_	I-Premise

495	No	_	_	B-Premise
496	cases	_	_	I-Premise
497	of	_	_	I-Premise
498	drug-related	_	_	I-Premise
499	neutropenic	_	_	I-Premise
500	fever	_	_	I-Premise
501	,	_	_	I-Premise
502	sepsis	_	_	I-Premise
503	,	_	_	I-Premise
504	or	_	_	I-Premise
505	death	_	_	I-Premise
506	occurred	_	_	I-Premise
507	.	_	_	I-Premise

508	Pancreatitis	_	_	B-Premise
509	occurred	_	_	I-Premise
510	in	_	_	I-Premise
511	3	_	_	I-Premise
512	patients	_	_	I-Premise
513	with	_	_	I-Premise
514	triglyceride	_	_	I-Premise
515	levels	_	_	I-Premise
516	higher	_	_	I-Premise
517	than	_	_	I-Premise
518	14.69	_	_	I-Premise
519	mmol/L	_	_	I-Premise
520	(	_	_	I-Premise
521	1300	_	_	I-Premise
522	mg/dL	_	_	I-Premise
523	)	_	_	I-Premise
524	,	_	_	I-Premise
525	all	_	_	I-Premise
526	of	_	_	I-Premise
527	whom	_	_	I-Premise
528	were	_	_	I-Premise
529	taking	_	_	I-Premise
530	300	_	_	I-Premise
531	mg/m	_	_	I-Premise
532	(	_	_	I-Premise
533	2	_	_	I-Premise
534	)	_	_	I-Premise
535	or	_	_	I-Premise
536	more	_	_	I-Premise
537	of	_	_	I-Premise
538	oral	_	_	I-Premise
539	bexarotene	_	_	I-Premise
540	per	_	_	I-Premise
541	day	_	_	I-Premise
542	.	_	_	I-Premise

543	Bexarotene	_	_	B-Claim
544	(	_	_	I-Claim
545	Targretin	_	_	I-Claim
546	capsules	_	_	I-Claim
547	)	_	_	I-Claim
548	(	_	_	I-Claim
549	the	_	_	I-Claim
550	first	_	_	I-Claim
551	retinoid	_	_	I-Claim
552	X	_	_	I-Claim
553	receptor-selective	_	_	I-Claim
554	rexinoid	_	_	I-Claim
555	)	_	_	I-Claim
556	was	_	_	I-Claim
557	well	_	_	I-Claim
558	tolerated	_	_	I-Claim
559	and	_	_	I-Claim
560	effective	_	_	I-Claim
561	as	_	_	I-Claim
562	an	_	_	I-Claim
563	oral	_	_	I-Claim
564	treatment	_	_	I-Claim
565	for	_	_	I-Claim
566	15	_	_	I-Claim
567	(	_	_	I-Claim
568	54	_	_	I-Claim
569	%	_	_	I-Claim
570	)	_	_	I-Claim
571	of	_	_	I-Claim
572	28	_	_	I-Claim
573	patients	_	_	I-Claim
574	with	_	_	I-Claim
575	refractory	_	_	I-Claim
576	or	_	_	I-Claim
577	persistent	_	_	I-Claim
578	early-stage	_	_	I-Claim
579	cutaneous	_	_	I-Claim
580	T-cell	_	_	I-Claim
581	lymphoma	_	_	I-Claim
582	at	_	_	I-Claim
583	doses	_	_	I-Claim
584	of	_	_	I-Claim
585	300	_	_	I-Claim
586	mg/m	_	_	I-Claim
587	(	_	_	I-Claim
588	2	_	_	I-Claim
589	)	_	_	I-Claim
590	per	_	_	I-Claim
591	day	_	_	I-Claim
592	.	_	_	I-Claim

593	Hypertriglyceridemia	_	_	B-Claim
594	and	_	_	I-Claim
595	hypothyroidism	_	_	I-Claim
596	require	_	_	I-Claim
597	monitoring	_	_	I-Claim
598	but	_	_	I-Claim
599	are	_	_	I-Claim
600	reversible	_	_	I-Claim
601	and	_	_	I-Claim
602	manageable	_	_	I-Claim
603	with	_	_	I-Claim
604	concomitant	_	_	I-Claim
605	medication	_	_	I-Claim
606	.	_	_	I-Claim


0	Few	_	_	O
1	controlled	_	_	O
2	clinical	_	_	O
3	trials	_	_	O
4	exist	_	_	O
5	to	_	_	O
6	support	_	_	O
7	oral	_	_	O
8	combination	_	_	O
9	therapy	_	_	O
10	in	_	_	O
11	pulmonary	_	_	O
12	arterial	_	_	O
13	hypertension	_	_	O
14	(	_	_	O
15	PAH	_	_	O
16	)	_	_	O
17	.	_	_	O

18	Patients	_	_	O
19	with	_	_	O
20	PAH	_	_	O
21	(	_	_	O
22	idiopathic	_	_	O
23	[	_	_	O
24	IPAH	_	_	O
25	]	_	_	O
26	or	_	_	O
27	associated	_	_	O
28	with	_	_	O
29	connective	_	_	O
30	tissue	_	_	O
31	disease	_	_	O
32	[	_	_	O
33	APAH-CTD	_	_	O
34	]	_	_	O
35	)	_	_	O
36	taking	_	_	O
37	bosentan	_	_	O
38	(	_	_	O
39	62.5	_	_	O
40	or	_	_	O
41	125	_	_	O
42	mg	_	_	O
43	twice	_	_	O
44	daily	_	_	O
45	at	_	_	O
46	a	_	_	O
47	stable	_	_	O
48	dose	_	_	O
49	for	_	_	O
50	≥3	_	_	O
51	months	_	_	O
52	)	_	_	O
53	were	_	_	O
54	randomized	_	_	O
55	(	_	_	O
56	1:1	_	_	O
57	)	_	_	O
58	to	_	_	O
59	sildenafil	_	_	O
60	(	_	_	O
61	20	_	_	O
62	mg	_	_	O
63	,	_	_	O
64	3	_	_	O
65	times	_	_	O
66	daily	_	_	O
67	;	_	_	O
68	n	_	_	O
69	=	_	_	O
70	50	_	_	O
71	)	_	_	O
72	or	_	_	O
73	placebo	_	_	O
74	(	_	_	O
75	n	_	_	O
76	=	_	_	O
77	53	_	_	O
78	)	_	_	O
79	.	_	_	O

80	The	_	_	O
81	primary	_	_	O
82	endpoint	_	_	O
83	was	_	_	O
84	change	_	_	O
85	from	_	_	O
86	baseline	_	_	O
87	in	_	_	O
88	6-min	_	_	O
89	walk	_	_	O
90	distance	_	_	O
91	(	_	_	O
92	6MWD	_	_	O
93	)	_	_	O
94	at	_	_	O
95	week	_	_	O
96	12	_	_	O
97	,	_	_	O
98	assessed	_	_	O
99	using	_	_	O
100	analysis	_	_	O
101	of	_	_	O
102	covariance	_	_	O
103	.	_	_	O

104	Patients	_	_	O
105	could	_	_	O
106	continue	_	_	O
107	in	_	_	O
108	a	_	_	O
109	52-week	_	_	O
110	extension	_	_	O
111	study	_	_	O
112	.	_	_	O

113	An	_	_	O
114	analysis	_	_	O
115	of	_	_	O
116	covariance	_	_	O
117	main-effects	_	_	O
118	model	_	_	O
119	was	_	_	O
120	used	_	_	O
121	,	_	_	O
122	which	_	_	O
123	included	_	_	O
124	categorical	_	_	O
125	terms	_	_	O
126	for	_	_	O
127	treatment	_	_	O
128	,	_	_	O
129	baseline	_	_	O
130	6MWD	_	_	O
131	(	_	_	O
132	<	_	_	O
133	325	_	_	O
134	m	_	_	O
135	;	_	_	O
136	≥325	_	_	O
137	m	_	_	O
138	)	_	_	O
139	,	_	_	O
140	and	_	_	O
141	baseline	_	_	O
142	aetiology	_	_	O
143	;	_	_	O
144	sensitivity	_	_	O
145	analyses	_	_	O
146	were	_	_	O
147	subsequently	_	_	O
148	performed	_	_	O
149	.	_	_	O

150	In	_	_	B-Premise
151	sildenafil	_	_	I-Premise
152	versus	_	_	I-Premise
153	placebo	_	_	I-Premise
154	arms	_	_	I-Premise
155	,	_	_	I-Premise
156	week-12	_	_	I-Premise
157	6MWD	_	_	I-Premise
158	increases	_	_	I-Premise
159	were	_	_	I-Premise
160	similar	_	_	I-Premise
161	(	_	_	I-Premise
162	least	_	_	I-Premise
163	squares	_	_	I-Premise
164	mean	_	_	I-Premise
165	difference	_	_	I-Premise
166	[	_	_	I-Premise
167	sildenafil-placebo	_	_	I-Premise
168	]	_	_	I-Premise
169	,	_	_	I-Premise
170	-2.4	_	_	I-Premise
171	m	_	_	I-Premise
172	[	_	_	I-Premise
173	90	_	_	I-Premise
174	%	_	_	I-Premise
175	CI	_	_	I-Premise
176	:	_	_	I-Premise
177	-21.8	_	_	I-Premise
178	to	_	_	I-Premise
179	17.1	_	_	I-Premise
180	m	_	_	I-Premise
181	]	_	_	I-Premise
182	;	_	_	I-Premise
183	P	_	_	I-Premise
184	=	_	_	I-Premise
185	0.6	_	_	I-Premise
186	)	_	_	I-Premise
187	;	_	_	I-Premise
188	mean	_	_	I-Premise
189	±	_	_	I-Premise
190	SD	_	_	I-Premise
191	changes	_	_	I-Premise
192	from	_	_	I-Premise
193	baseline	_	_	I-Premise
194	were	_	_	I-Premise
195	26.4	_	_	I-Premise
196	±	_	_	I-Premise
197	45.7	_	_	I-Premise
198	versus	_	_	I-Premise
199	11.8	_	_	I-Premise
200	±	_	_	I-Premise
201	57.4	_	_	I-Premise
202	m	_	_	I-Premise
203	,	_	_	I-Premise
204	respectively	_	_	I-Premise
205	,	_	_	I-Premise
206	in	_	_	I-Premise
207	IPAH	_	_	I-Premise
208	(	_	_	I-Premise
209	65	_	_	I-Premise
210	%	_	_	I-Premise
211	of	_	_	I-Premise
212	population	_	_	I-Premise
213	)	_	_	I-Premise
214	and	_	_	I-Premise
215	-18.3	_	_	I-Premise
216	±	_	_	I-Premise
217	82.0	_	_	I-Premise
218	versus	_	_	I-Premise
219	17.5	_	_	I-Premise
220	±	_	_	I-Premise
221	59.1	_	_	I-Premise
222	m	_	_	I-Premise
223	in	_	_	I-Premise
224	APAH-CTD	_	_	I-Premise
225	(	_	_	I-Premise
226	35	_	_	I-Premise
227	%	_	_	I-Premise
228	of	_	_	I-Premise
229	population	_	_	I-Premise
230	)	_	_	I-Premise
231	.	_	_	I-Premise

232	One-year	_	_	O
233	survival	_	_	O
234	was	_	_	O
235	96	_	_	O
236	%	_	_	O
237	;	_	_	O
238	patients	_	_	O
239	maintained	_	_	O
240	modest	_	_	O
241	6MWD	_	_	O
242	improvements	_	_	O
243	.	_	_	O

244	Changes	_	_	B-Premise
245	in	_	_	I-Premise
246	WHO	_	_	I-Premise
247	functional	_	_	I-Premise
248	class	_	_	I-Premise
249	and	_	_	I-Premise
250	Borg	_	_	I-Premise
251	dyspnoea	_	_	I-Premise
252	score	_	_	I-Premise
253	and	_	_	I-Premise
254	incidence	_	_	I-Premise
255	of	_	_	I-Premise
256	clinical	_	_	I-Premise
257	worsening	_	_	I-Premise
258	did	_	_	I-Premise
259	not	_	_	I-Premise
260	differ	_	_	I-Premise
261	.	_	_	I-Premise

262	Headache	_	_	B-Premise
263	,	_	_	I-Premise
264	diarrhoea	_	_	I-Premise
265	,	_	_	I-Premise
266	and	_	_	I-Premise
267	flushing	_	_	I-Premise
268	were	_	_	I-Premise
269	more	_	_	I-Premise
270	common	_	_	I-Premise
271	with	_	_	I-Premise
272	sildenafil	_	_	I-Premise
273	.	_	_	I-Premise

274	Sildenafil	_	_	B-Claim
275	,	_	_	I-Claim
276	in	_	_	I-Claim
277	addition	_	_	I-Claim
278	to	_	_	I-Claim
279	stable	_	_	I-Claim
280	(	_	_	I-Claim
281	≥3	_	_	I-Claim
282	months	_	_	I-Claim
283	)	_	_	I-Claim
284	bosentan	_	_	I-Claim
285	therapy	_	_	I-Claim
286	,	_	_	I-Claim
287	had	_	_	I-Claim
288	no	_	_	I-Claim
289	benefit	_	_	I-Claim
290	over	_	_	I-Claim
291	placebo	_	_	I-Claim
292	for	_	_	I-Claim
293	12-week	_	_	I-Claim
294	change	_	_	I-Claim
295	from	_	_	I-Claim
296	baseline	_	_	I-Claim
297	in	_	_	I-Claim
298	6MWD	_	_	I-Claim
299	.	_	_	I-Claim

300	The	_	_	O
301	influence	_	_	O
302	of	_	_	O
303	PAH	_	_	O
304	aetiology	_	_	O
305	warrants	_	_	O
306	future	_	_	O
307	study	_	_	O
308	.	_	_	O


0	Extranodal	_	_	O
1	natural	_	_	O
2	killer/T-cell	_	_	O
3	lymphoma	_	_	O
4	,	_	_	O
5	nasal	_	_	O
6	type	_	_	O
7	(	_	_	O
8	ENKTL	_	_	O
9	)	_	_	O
10	is	_	_	O
11	a	_	_	O
12	rare	_	_	O
13	subtype	_	_	O
14	of	_	_	O
15	lymphoma	_	_	O
16	that	_	_	O
17	is	_	_	O
18	often	_	_	O
19	associated	_	_	O
20	with	_	_	O
21	poor	_	_	O
22	clinical	_	_	O
23	prognosis	_	_	O
24	.	_	_	O

25	Several	_	_	O
26	studies	_	_	O
27	have	_	_	O
28	shown	_	_	O
29	that	_	_	O
30	hepatitis	_	_	O
31	B	_	_	O
32	virus	_	_	O
33	(	_	_	O
34	HBV	_	_	O
35	)	_	_	O
36	infection	_	_	O
37	may	_	_	O
38	be	_	_	O
39	associated	_	_	O
40	with	_	_	O
41	increased	_	_	O
42	risk	_	_	O
43	of	_	_	O
44	B-cell	_	_	O
45	non-Hodgkin	_	_	O
46	lymphoma	_	_	O
47	;	_	_	O
48	however	_	_	O
49	,	_	_	O
50	because	_	_	O
51	of	_	_	O
52	the	_	_	O
53	rarity	_	_	O
54	of	_	_	O
55	ENKTL	_	_	O
56	,	_	_	O
57	little	_	_	O
58	is	_	_	O
59	known	_	_	O
60	about	_	_	O
61	its	_	_	O
62	association	_	_	O
63	with	_	_	O
64	HBV	_	_	O
65	.	_	_	O

66	Our	_	_	O
67	study	_	_	O
68	aimed	_	_	O
69	to	_	_	O
70	assess	_	_	O
71	whether	_	_	O
72	HBV	_	_	O
73	infection	_	_	O
74	was	_	_	O
75	associated	_	_	O
76	with	_	_	O
77	increased	_	_	O
78	odds	_	_	O
79	of	_	_	O
80	ENKTL	_	_	O
81	.	_	_	O

82	We	_	_	O
83	conducted	_	_	O
84	a	_	_	O
85	hospital-based	_	_	O
86	case-control	_	_	O
87	study	_	_	O
88	including	_	_	O
89	417	_	_	O
90	ENKTL	_	_	O
91	cases	_	_	O
92	and	_	_	O
93	488	_	_	O
94	age-	_	_	O
95	and	_	_	O
96	sex-matched	_	_	O
97	subjects	_	_	O
98	with	_	_	O
99	nonmalignant	_	_	O
100	diseases	_	_	O
101	unrelated	_	_	O
102	to	_	_	O
103	HBV	_	_	O
104	infection	_	_	O
105	.	_	_	O

106	Multivariable	_	_	O
107	unconditional	_	_	O
108	logistic	_	_	O
109	regression	_	_	O
110	analyses	_	_	O
111	were	_	_	O
112	performed	_	_	O
113	to	_	_	O
114	estimate	_	_	O
115	adjusted	_	_	O
116	odds	_	_	O
117	ratios	_	_	O
118	[	_	_	O
119	AOR	_	_	O
120	]	_	_	O
121	and	_	_	O
122	their	_	_	O
123	corresponding	_	_	O
124	95	_	_	O
125	%	_	_	O
126	confidence	_	_	O
127	intervals	_	_	O
128	(	_	_	O
129	CI	_	_	O
130	)	_	_	O
131	.	_	_	O

132	The	_	_	B-Premise
133	results	_	_	I-Premise
134	of	_	_	I-Premise
135	the	_	_	I-Premise
136	multivariable	_	_	I-Premise
137	analysis	_	_	I-Premise
138	showed	_	_	I-Premise
139	that	_	_	I-Premise
140	after	_	_	I-Premise
141	adjustment	_	_	I-Premise
142	for	_	_	I-Premise
143	a	_	_	I-Premise
144	set	_	_	I-Premise
145	of	_	_	I-Premise
146	known	_	_	I-Premise
147	risk	_	_	I-Premise
148	factors	_	_	I-Premise
149	,	_	_	I-Premise
150	patients	_	_	I-Premise
151	previously	_	_	I-Premise
152	infected	_	_	I-Premise
153	with	_	_	I-Premise
154	HBV	_	_	I-Premise
155	(	_	_	I-Premise
156	HBsAg-seronegative/anti-HBc-seropositive	_	_	I-Premise
157	)	_	_	I-Premise
158	and	_	_	I-Premise
159	naturally	_	_	I-Premise
160	immune	_	_	I-Premise
161	to	_	_	I-Premise
162	HBV	_	_	I-Premise
163	(	_	_	I-Premise
164	anti-HBs-seropositive/anti-HBc-seropositive	_	_	I-Premise
165	)	_	_	I-Premise
166	were	_	_	I-Premise
167	at	_	_	I-Premise
168	significantly	_	_	I-Premise
169	greater	_	_	I-Premise
170	odds	_	_	I-Premise
171	of	_	_	I-Premise
172	being	_	_	I-Premise
173	diagnosed	_	_	I-Premise
174	with	_	_	I-Premise
175	ENKTL	_	_	I-Premise
176	(	_	_	I-Premise
177	AOR	_	_	I-Premise
178	,	_	_	I-Premise
179	1.497	_	_	I-Premise
180	;	_	_	I-Premise
181	95	_	_	I-Premise
182	%	_	_	I-Premise
183	CI	_	_	I-Premise
184	1.098-2.042	_	_	I-Premise
185	,	_	_	I-Premise
186	P=0.033	_	_	I-Premise
187	and	_	_	I-Premise
188	AOR	_	_	I-Premise
189	,	_	_	I-Premise
190	1.871	_	_	I-Premise
191	;	_	_	I-Premise
192	95	_	_	I-Premise
193	%	_	_	I-Premise
194	CI	_	_	I-Premise
195	1.302-2.689	_	_	I-Premise
196	,	_	_	I-Premise
197	P=0.001	_	_	I-Premise
198	,	_	_	I-Premise
199	respectively	_	_	I-Premise
200	)	_	_	I-Premise
201	.	_	_	I-Premise

202	After	_	_	B-Premise
203	adjusting	_	_	I-Premise
204	for	_	_	I-Premise
205	other	_	_	I-Premise
206	factors	_	_	I-Premise
207	,	_	_	I-Premise
208	significantly	_	_	I-Premise
209	greater	_	_	I-Premise
210	odds	_	_	I-Premise
211	of	_	_	I-Premise
212	being	_	_	I-Premise
213	diagnosed	_	_	I-Premise
214	with	_	_	I-Premise
215	ENKTL	_	_	I-Premise
216	were	_	_	I-Premise
217	observed	_	_	I-Premise
218	among	_	_	I-Premise
219	cases	_	_	I-Premise
220	who	_	_	I-Premise
221	reported	_	_	I-Premise
222	ever	_	_	I-Premise
223	drinking	_	_	I-Premise
224	alcohol	_	_	I-Premise
225	(	_	_	I-Premise
226	AOR	_	_	I-Premise
227	,	_	_	I-Premise
228	1.675	_	_	I-Premise
229	;	_	_	I-Premise
230	95	_	_	I-Premise
231	%	_	_	I-Premise
232	CI	_	_	I-Premise
233	1.054-2.660	_	_	I-Premise
234	,	_	_	I-Premise
235	P=0.029	_	_	I-Premise
236	)	_	_	I-Premise
237	.	_	_	I-Premise

238	The	_	_	B-Premise
239	odds	_	_	I-Premise
240	of	_	_	I-Premise
241	ENKTL	_	_	I-Premise
242	diagnosis	_	_	I-Premise
243	were	_	_	I-Premise
244	not	_	_	I-Premise
245	significantly	_	_	I-Premise
246	associated	_	_	I-Premise
247	with	_	_	I-Premise
248	ABO	_	_	I-Premise
249	blood	_	_	I-Premise
250	type	_	_	I-Premise
251	,	_	_	I-Premise
252	cigarette	_	_	I-Premise
253	smoking	_	_	I-Premise
254	status	_	_	I-Premise
255	or	_	_	I-Premise
256	family	_	_	I-Premise
257	history	_	_	I-Premise
258	of	_	_	I-Premise
259	cancer	_	_	I-Premise
260	.	_	_	I-Premise

261	The	_	_	B-Claim
262	results	_	_	I-Claim
263	of	_	_	I-Claim
264	our	_	_	I-Claim
265	study	_	_	I-Claim
266	suggest	_	_	I-Claim
267	that	_	_	I-Claim
268	patients	_	_	I-Claim
269	previously	_	_	I-Claim
270	infected	_	_	I-Claim
271	with	_	_	I-Claim
272	HBV	_	_	I-Claim
273	and	_	_	I-Claim
274	naturally	_	_	I-Claim
275	immune	_	_	I-Claim
276	to	_	_	I-Claim
277	HBV	_	_	I-Claim
278	were	_	_	I-Claim
279	at	_	_	I-Claim
280	greater	_	_	I-Claim
281	odds	_	_	I-Claim
282	of	_	_	I-Claim
283	being	_	_	I-Claim
284	diagnosed	_	_	I-Claim
285	with	_	_	I-Claim
286	ENKTL	_	_	I-Claim
287	.	_	_	I-Claim


0	We	_	_	O
1	assessed	_	_	O
2	bleb	_	_	O
3	morphology	_	_	O
4	and	_	_	O
5	the	_	_	O
6	intraocular	_	_	O
7	pressure	_	_	O
8	(	_	_	O
9	IOP	_	_	O
10	)	_	_	O
11	-lowering	_	_	O
12	effect	_	_	O
13	of	_	_	O
14	trabeculectomy	_	_	O
15	with	_	_	O
16	ologen	_	_	O
17	compared	_	_	O
18	to	_	_	O
19	mitomycin	_	_	O
20	C	_	_	O
21	(	_	_	O
22	MMC	_	_	O
23	)	_	_	O
24	in	_	_	O
25	juvenile	_	_	O
26	open-angle	_	_	O
27	glaucoma	_	_	O
28	(	_	_	O
29	JOAG	_	_	O
30	)	_	_	O
31	.This	_	_	O
32	is	_	_	O
33	a	_	_	O
34	prospective	_	_	O
35	interventional	_	_	O
36	comparative	_	_	O
37	study	_	_	O
38	conducted	_	_	O
39	on	_	_	O
40	40	_	_	O
41	eyes	_	_	O
42	(	_	_	O
43	20	_	_	O
44	patients	_	_	O
45	)	_	_	O
46	with	_	_	O
47	medically	_	_	O
48	uncontrolled	_	_	O
49	JOAG	_	_	O
50	,	_	_	O
51	randomly	_	_	O
52	operating	_	_	O
53	one	_	_	O
54	eye	_	_	O
55	for	_	_	O
56	trabeculectomy	_	_	O
57	with	_	_	O
58	ologen	_	_	O
59	(	_	_	O
60	group	_	_	O
61	A	_	_	O
62	:	_	_	O
63	20	_	_	O
64	eyes	_	_	O
65	)	_	_	O
66	and	_	_	O
67	the	_	_	O
68	other	_	_	O
69	with	_	_	O
70	MMC	_	_	O
71	(	_	_	O
72	group	_	_	O
73	B	_	_	O
74	:	_	_	O
75	20	_	_	O
76	eyes	_	_	O
77	)	_	_	O
78	.	_	_	O

79	IOP	_	_	O
80	measurement	_	_	O
81	,	_	_	O
82	SITA	_	_	O
83	standard	_	_	O
84	perimetry	_	_	O
85	,	_	_	O
86	and	_	_	O
87	spectral	_	_	O
88	domain	_	_	O
89	optical	_	_	O
90	coherence	_	_	O
91	tomography	_	_	O
92	(	_	_	O
93	OCT	_	_	O
94	)	_	_	O
95	for	_	_	O
96	retinal	_	_	O
97	nerve	_	_	O
98	fiber	_	_	O
99	layer	_	_	O
100	(	_	_	O
101	RNFL	_	_	O
102	)	_	_	O
103	thickness	_	_	O
104	were	_	_	O
105	all	_	_	O
106	done	_	_	O
107	pre-	_	_	O
108	and	_	_	O
109	postoperatively	_	_	O
110	.	_	_	O

111	Postoperative	_	_	O
112	blebs	_	_	O
113	were	_	_	O
114	assessed	_	_	O
115	clinically	_	_	O
116	using	_	_	O
117	the	_	_	O
118	Moorfields	_	_	O
119	bleb	_	_	O
120	grading	_	_	O
121	system	_	_	O
122	(	_	_	O
123	MBGS	_	_	O
124	)	_	_	O
125	and	_	_	O
126	anterior	_	_	O
127	segment	_	_	O
128	OCT	_	_	O
129	(	_	_	O
130	AS-OCT	_	_	O
131	)	_	_	O
132	.	_	_	O

133	All	_	_	O
134	patients	_	_	O
135	were	_	_	O
136	examined	_	_	O
137	for	_	_	O
138	up	_	_	O
139	to	_	_	O
140	1	_	_	O
141	year	_	_	O
142	postoperatively	_	_	O
143	.	_	_	O

144	The	_	_	B-Premise
145	mean	_	_	I-Premise
146	postoperative	_	_	I-Premise
147	IOP	_	_	I-Premise
148	was	_	_	I-Premise
149	statistically	_	_	I-Premise
150	significantly	_	_	I-Premise
151	lower	_	_	I-Premise
152	than	_	_	I-Premise
153	the	_	_	I-Premise
154	mean	_	_	I-Premise
155	preoperative	_	_	I-Premise
156	IOP	_	_	I-Premise
157	at	_	_	I-Premise
158	each	_	_	I-Premise
159	follow-up	_	_	I-Premise
160	in	_	_	I-Premise
161	each	_	_	I-Premise
162	group	_	_	I-Premise
163	.	_	_	I-Premise

164	At	_	_	B-Premise
165	1	_	_	I-Premise
166	year	_	_	I-Premise
167	,	_	_	I-Premise
168	the	_	_	I-Premise
169	mean	_	_	I-Premise
170	postoperative	_	_	I-Premise
171	IOP	_	_	I-Premise
172	was	_	_	I-Premise
173	significantly	_	_	I-Premise
174	lower	_	_	I-Premise
175	in	_	_	I-Premise
176	group	_	_	I-Premise
177	A	_	_	I-Premise
178	.	_	_	I-Premise

179	According	_	_	B-Premise
180	to	_	_	I-Premise
181	the	_	_	I-Premise
182	MBGS	_	_	I-Premise
183	,	_	_	I-Premise
184	blebs	_	_	I-Premise
185	with	_	_	I-Premise
186	an	_	_	I-Premise
187	ologen	_	_	I-Premise
188	implant	_	_	I-Premise
189	showed	_	_	I-Premise
190	significantly	_	_	I-Premise
191	better	_	_	I-Premise
192	scoring	_	_	I-Premise
193	than	_	_	I-Premise
194	those	_	_	I-Premise
195	with	_	_	I-Premise
196	MMC	_	_	I-Premise
197	.	_	_	I-Premise

198	AS-OCT	_	_	B-Premise
199	showed	_	_	I-Premise
200	that	_	_	I-Premise
201	ologen-induced	_	_	I-Premise
202	blebs	_	_	I-Premise
203	had	_	_	I-Premise
204	significantly	_	_	I-Premise
205	more	_	_	I-Premise
206	fluid-filled	_	_	I-Premise
207	spaces	_	_	I-Premise
208	,	_	_	I-Premise
209	cleavage	_	_	I-Premise
210	planes	_	_	I-Premise
211	,	_	_	I-Premise
212	and	_	_	I-Premise
213	less	_	_	I-Premise
214	fibrosis	_	_	I-Premise
215	.	_	_	I-Premise

216	Ologen	_	_	B-Claim
217	resulted	_	_	I-Claim
218	in	_	_	I-Claim
219	a	_	_	I-Claim
220	lower	_	_	I-Claim
221	long-term	_	_	I-Claim
222	postoperative	_	_	I-Claim
223	IOP	_	_	I-Claim
224	,	_	_	I-Claim
225	a	_	_	I-Claim
226	better	_	_	I-Claim
227	bleb	_	_	I-Claim
228	morphology	_	_	I-Claim
229	,	_	_	I-Claim
230	and	_	_	I-Claim
231	fewer	_	_	I-Claim
232	complications	_	_	I-Claim
233	.	_	_	I-Claim

234	Our	_	_	B-Claim
235	results	_	_	I-Claim
236	suggest	_	_	I-Claim
237	that	_	_	I-Claim
238	ologen	_	_	I-Claim
239	may	_	_	I-Claim
240	be	_	_	I-Claim
241	a	_	_	I-Claim
242	useful	_	_	I-Claim
243	alternative	_	_	I-Claim
244	to	_	_	I-Claim
245	MMC	_	_	I-Claim
246	in	_	_	I-Claim
247	JOAG	_	_	I-Claim
248	.	_	_	I-Claim


0	KAMUT	_	_	B-Claim
1	khorasan	_	_	I-Claim
2	is	_	_	I-Claim
3	an	_	_	I-Claim
4	ancient	_	_	I-Claim
5	grain	_	_	I-Claim
6	with	_	_	I-Claim
7	widely	_	_	I-Claim
8	acclaimed	_	_	I-Claim
9	health	_	_	I-Claim
10	benefits	_	_	I-Claim
11	.	_	_	I-Claim

12	The	_	_	O
13	aim	_	_	O
14	of	_	_	O
15	this	_	_	O
16	study	_	_	O
17	was	_	_	O
18	to	_	_	O
19	investigate	_	_	O
20	the	_	_	O
21	effects	_	_	O
22	of	_	_	O
23	a	_	_	O
24	replacement	_	_	O
25	diet	_	_	O
26	with	_	_	O
27	ancient	_	_	O
28	khorasan	_	_	O
29	wheat	_	_	O
30	products	_	_	O
31	in	_	_	O
32	patients	_	_	O
33	with	_	_	O
34	NAFLD	_	_	O
35	,	_	_	O
36	in	_	_	O
37	comparison	_	_	O
38	to	_	_	O
39	a	_	_	O
40	similar	_	_	O
41	replacement	_	_	O
42	diet	_	_	O
43	with	_	_	O
44	control	_	_	O
45	products	_	_	O
46	made	_	_	O
47	from	_	_	O
48	organic	_	_	O
49	semi-whole-grain	_	_	O
50	modern	_	_	O
51	wheat	_	_	O
52	.	_	_	O

53	Forty	_	_	O
54	NAFLD	_	_	O
55	patients	_	_	O
56	(	_	_	O
57	12	_	_	O
58	M/28	_	_	O
59	F	_	_	O
60	;	_	_	O
61	age	_	_	O
62	55.2	_	_	O
63	±	_	_	O
64	10.4	_	_	O
65	years	_	_	O
66	)	_	_	O
67	with	_	_	O
68	mild	_	_	O
69	to	_	_	O
70	moderate	_	_	O
71	liver	_	_	O
72	steatosis	_	_	O
73	were	_	_	O
74	included	_	_	O
75	.	_	_	O

76	The	_	_	O
77	experimental	_	_	O
78	design	_	_	O
79	was	_	_	O
80	a	_	_	O
81	randomized	_	_	O
82	,	_	_	O
83	double-blind	_	_	O
84	,	_	_	O
85	parallel-arm	_	_	O
86	study	_	_	O
87	with	_	_	O
88	20	_	_	O
89	participants	_	_	O
90	assigned	_	_	O
91	to	_	_	O
92	consume	_	_	O
93	either	_	_	O
94	KAMUT	_	_	O
95	khorasan	_	_	O
96	or	_	_	O
97	control	_	_	O
98	wheat	_	_	O
99	products	_	_	O
100	(	_	_	O
101	pasta	_	_	O
102	,	_	_	O
103	bread	_	_	O
104	,	_	_	O
105	crackers	_	_	O
106	,	_	_	O
107	biscuits	_	_	O
108	)	_	_	O
109	over	_	_	O
110	a	_	_	O
111	3-month	_	_	O
112	period	_	_	O
113	.	_	_	O

114	Anthropometric	_	_	O
115	measurements	_	_	O
116	,	_	_	O
117	blood	_	_	O
118	analyses	_	_	O
119	,	_	_	O
120	and	_	_	O
121	ultrasonography	_	_	O
122	examination	_	_	O
123	were	_	_	O
124	performed	_	_	O
125	at	_	_	O
126	both	_	_	O
127	the	_	_	O
128	beginning	_	_	O
129	and	_	_	O
130	end	_	_	O
131	of	_	_	O
132	each	_	_	O
133	dietary	_	_	O
134	intervention	_	_	O
135	.	_	_	O

136	After	_	_	B-Premise
137	the	_	_	I-Premise
138	implementation	_	_	I-Premise
139	of	_	_	I-Premise
140	a	_	_	I-Premise
141	general	_	_	I-Premise
142	linear	_	_	I-Premise
143	model	_	_	I-Premise
144	for	_	_	I-Premise
145	repeated	_	_	I-Premise
146	measurements	_	_	I-Premise
147	adjusted	_	_	I-Premise
148	for	_	_	I-Premise
149	baseline	_	_	I-Premise
150	demographic	_	_	I-Premise
151	details	_	_	I-Premise
152	,	_	_	I-Premise
153	risk	_	_	I-Premise
154	factors	_	_	I-Premise
155	,	_	_	I-Premise
156	and	_	_	I-Premise
157	medication	_	_	I-Premise
158	,	_	_	I-Premise
159	alanine	_	_	I-Premise
160	aminotransferase	_	_	I-Premise
161	(	_	_	I-Premise
162	ALT	_	_	I-Premise
163	)	_	_	I-Premise
164	was	_	_	I-Premise
165	significantly	_	_	I-Premise
166	reduced	_	_	I-Premise
167	by	_	_	I-Premise
168	12	_	_	I-Premise
169	%	_	_	I-Premise
170	,	_	_	I-Premise
171	aspartate	_	_	I-Premise
172	aminotransferase	_	_	I-Premise
173	(	_	_	I-Premise
174	AST	_	_	I-Premise
175	)	_	_	I-Premise
176	by	_	_	I-Premise
177	14	_	_	I-Premise
178	%	_	_	I-Premise
179	,	_	_	I-Premise
180	alkaline	_	_	I-Premise
181	phosphatase	_	_	I-Premise
182	(	_	_	I-Premise
183	ALP	_	_	I-Premise
184	)	_	_	I-Premise
185	by	_	_	I-Premise
186	8	_	_	I-Premise
187	%	_	_	I-Premise
188	,	_	_	I-Premise
189	and	_	_	I-Premise
190	cholesterol	_	_	I-Premise
191	by	_	_	I-Premise
192	6	_	_	I-Premise
193	%	_	_	I-Premise
194	only	_	_	I-Premise
195	in	_	_	I-Premise
196	the	_	_	I-Premise
197	khorasan	_	_	I-Premise
198	group	_	_	I-Premise
199	(	_	_	I-Premise
200	p	_	_	I-Premise
201	<	_	_	I-Premise
202	0.05	_	_	I-Premise
203	for	_	_	I-Premise
204	all	_	_	I-Premise
205	)	_	_	I-Premise
206	.	_	_	I-Premise

207	Similarly	_	_	O
208	,	_	_	O
209	significant	_	_	B-Premise
210	reductions	_	_	I-Premise
211	in	_	_	I-Premise
212	circulating	_	_	I-Premise
213	proinflammatory	_	_	I-Premise
214	tumor	_	_	I-Premise
215	necrosis	_	_	I-Premise
216	factor-alpha	_	_	I-Premise
217	by	_	_	I-Premise
218	50	_	_	I-Premise
219	%	_	_	I-Premise
220	,	_	_	I-Premise
221	interleukin	_	_	I-Premise
222	l-receptor	_	_	I-Premise
223	antagonist-alpha	_	_	I-Premise
224	by	_	_	I-Premise
225	37	_	_	I-Premise
226	%	_	_	I-Premise
227	,	_	_	I-Premise
228	interleukin-8	_	_	I-Premise
229	by	_	_	I-Premise
230	24	_	_	I-Premise
231	%	_	_	I-Premise
232	,	_	_	I-Premise
233	and	_	_	I-Premise
234	interferon	_	_	I-Premise
235	gamma	_	_	I-Premise
236	by	_	_	I-Premise
237	24	_	_	I-Premise
238	%	_	_	I-Premise
239	were	_	_	I-Premise
240	evident	_	_	I-Premise
241	only	_	_	I-Premise
242	in	_	_	I-Premise
243	participants	_	_	I-Premise
244	who	_	_	I-Premise
245	consumed	_	_	I-Premise
246	the	_	_	I-Premise
247	khorasan	_	_	I-Premise
248	products	_	_	I-Premise
249	(	_	_	I-Premise
250	p	_	_	I-Premise
251	<	_	_	I-Premise
252	0.05	_	_	I-Premise
253	for	_	_	I-Premise
254	all	_	_	I-Premise
255	)	_	_	I-Premise
256	.	_	_	I-Premise

257	Finally	_	_	O
258	,	_	_	O
259	significant	_	_	B-Premise
260	improvements	_	_	I-Premise
261	in	_	_	I-Premise
262	the	_	_	I-Premise
263	liver	_	_	I-Premise
264	steatosis	_	_	I-Premise
265	grading	_	_	I-Premise
266	,	_	_	I-Premise
267	Doppler	_	_	I-Premise
268	perfusion	_	_	I-Premise
269	index	_	_	I-Premise
270	values	_	_	I-Premise
271	,	_	_	I-Premise
272	and	_	_	I-Premise
273	reactive	_	_	I-Premise
274	oxygen	_	_	I-Premise
275	species	_	_	I-Premise
276	(	_	_	I-Premise
277	ROS	_	_	I-Premise
278	)	_	_	I-Premise
279	production	_	_	I-Premise
280	were	_	_	I-Premise
281	evident	_	_	I-Premise
282	after	_	_	I-Premise
283	consumption	_	_	I-Premise
284	of	_	_	I-Premise
285	both	_	_	I-Premise
286	the	_	_	I-Premise
287	khorasan	_	_	I-Premise
288	and	_	_	I-Premise
289	control	_	_	I-Premise
290	products	_	_	I-Premise
291	.	_	_	I-Premise

292	This	_	_	B-Claim
293	study	_	_	I-Claim
294	suggests	_	_	I-Claim
295	that	_	_	I-Claim
296	a	_	_	I-Claim
297	short-term	_	_	I-Claim
298	replacement	_	_	I-Claim
299	diet	_	_	I-Claim
300	with	_	_	I-Claim
301	ancient	_	_	I-Claim
302	KAMUT	_	_	I-Claim
303	khorasan	_	_	I-Claim
304	products	_	_	I-Claim
305	is	_	_	I-Claim
306	most	_	_	I-Claim
307	effective	_	_	I-Claim
308	in	_	_	I-Claim
309	reducing	_	_	I-Claim
310	metabolic	_	_	I-Claim
311	risk	_	_	I-Claim
312	factors	_	_	I-Claim
313	and	_	_	I-Claim
314	ameliorating	_	_	I-Claim
315	the	_	_	I-Claim
316	liver	_	_	I-Claim
317	profile	_	_	I-Claim
318	in	_	_	I-Claim
319	patients	_	_	I-Claim
320	with	_	_	I-Claim
321	NAFLD	_	_	I-Claim
322	.	_	_	I-Claim


0	The	_	_	O
1	role	_	_	O
2	of	_	_	O
3	gut	_	_	O
4	microbiota	_	_	O
5	in	_	_	O
6	the	_	_	O
7	management	_	_	O
8	of	_	_	O
9	diabetes	_	_	O
10	is	_	_	O
11	shown	_	_	O
12	.	_	_	O

13	In	_	_	O
14	this	_	_	O
15	randomized	_	_	O
16	clinical	_	_	O
17	trial	_	_	O
18	we	_	_	O
19	assessed	_	_	O
20	the	_	_	O
21	effects	_	_	O
22	of	_	_	O
23	synbiotic	_	_	O
24	supplementation	_	_	O
25	on	_	_	O
26	insulin	_	_	O
27	,	_	_	O
28	lipid	_	_	O
29	profile	_	_	O
30	and	_	_	O
31	antioxidative	_	_	O
32	status	_	_	O
33	among	_	_	O
34	women	_	_	O
35	with	_	_	O
36	gestational	_	_	O
37	diabetes	_	_	O
38	mellitus	_	_	O
39	(	_	_	O
40	GDM	_	_	O
41	)	_	_	O
42	.	_	_	O

43	Ninety	_	_	O
44	pregnant	_	_	O
45	women	_	_	O
46	with	_	_	O
47	GDM	_	_	O
48	were	_	_	O
49	randomly	_	_	O
50	assigned	_	_	O
51	into	_	_	O
52	two	_	_	O
53	groups	_	_	O
54	to	_	_	O
55	receive	_	_	O
56	either	_	_	O
57	a	_	_	O
58	daily	_	_	O
59	synbiotic	_	_	O
60	capsule	_	_	O
61	-	_	_	O
62	consisting	_	_	O
63	of	_	_	O
64	L.	_	_	O
65	acidophilus	_	_	O
66	,	_	_	O
67	L.	_	_	O
68	plantarum	_	_	O
69	,	_	_	O
70	L.	_	_	O
71	fermentum	_	_	O
72	,	_	_	O
73	L.	_	_	O
74	gasseri	_	_	O
75	(	_	_	O
76	1.5-7.0	_	_	O
77	×	_	_	O
78	109-10	_	_	O
79	CFU/g	_	_	O
80	)	_	_	O
81	-	_	_	O
82	with	_	_	O
83	fructooligosaccharide	_	_	O
84	(	_	_	O
85	38.5	_	_	O
86	mg	_	_	O
87	)	_	_	O
88	,	_	_	O
89	or	_	_	O
90	placebo	_	_	O
91	for	_	_	O
92	6	_	_	O
93	weeks	_	_	O
94	.	_	_	O

95	Fasting	_	_	O
96	plasma	_	_	O
97	glucose	_	_	O
98	(	_	_	O
99	FPG	_	_	O
100	)	_	_	O
101	,	_	_	O
102	insulin	_	_	O
103	,	_	_	O
104	homeostasis	_	_	O
105	model	_	_	O
106	assessment-insulin	_	_	O
107	resistance	_	_	O
108	(	_	_	O
109	HOMA-IR	_	_	O
110	)	_	_	O
111	,	_	_	O
112	quantitative	_	_	O
113	insulin	_	_	O
114	sensitivity	_	_	O
115	check	_	_	O
116	index	_	_	O
117	(	_	_	O
118	QUICKI	_	_	O
119	)	_	_	O
120	,	_	_	O
121	high-	_	_	O
122	and	_	_	O
123	low	_	_	O
124	density	_	_	O
125	lipoprotein	_	_	O
126	cholesterol	_	_	O
127	(	_	_	O
128	HDL-C	_	_	O
129	,	_	_	O
130	LDL-C	_	_	O
131	)	_	_	O
132	,	_	_	O
133	total	_	_	O
134	cholesterol	_	_	O
135	(	_	_	O
136	TC	_	_	O
137	)	_	_	O
138	,	_	_	O
139	triglycerides	_	_	O
140	(	_	_	O
141	TG	_	_	O
142	)	_	_	O
143	,	_	_	O
144	total	_	_	O
145	antioxidant	_	_	O
146	capacity	_	_	O
147	(	_	_	O
148	TAC	_	_	O
149	)	_	_	O
150	,	_	_	O
151	and	_	_	O
152	systolic	_	_	O
153	and	_	_	O
154	diastolic	_	_	O
155	blood	_	_	O
156	pressure	_	_	O
157	(	_	_	O
158	SBP	_	_	O
159	,	_	_	O
160	DSP	_	_	O
161	)	_	_	O
162	were	_	_	O
163	assessed	_	_	O
164	before	_	_	O
165	and	_	_	O
166	after	_	_	O
167	the	_	_	O
168	intervention	_	_	O
169	.	_	_	O

170	No	_	_	B-Premise
171	significant	_	_	I-Premise
172	changes	_	_	I-Premise
173	in	_	_	I-Premise
174	FPG	_	_	I-Premise
175	,	_	_	I-Premise
176	insulin	_	_	I-Premise
177	resistance/sensitivity	_	_	I-Premise
178	,	_	_	I-Premise
179	lipid	_	_	I-Premise
180	profile	_	_	I-Premise
181	and	_	_	I-Premise
182	TAC	_	_	I-Premise
183	indices	_	_	I-Premise
184	were	_	_	I-Premise
185	seen	_	_	I-Premise
186	in	_	_	I-Premise
187	synbiotic	_	_	I-Premise
188	group	_	_	I-Premise
189	compared	_	_	I-Premise
190	to	_	_	I-Premise
191	the	_	_	I-Premise
192	placebo	_	_	I-Premise
193	one	_	_	I-Premise
194	(	_	_	I-Premise
195	p	_	_	I-Premise
196	>	_	_	I-Premise
197	0.05	_	_	I-Premise
198	)	_	_	I-Premise
199	.	_	_	I-Premise

200	Significant	_	_	B-Premise
201	within	_	_	I-Premise
202	group	_	_	I-Premise
203	increases	_	_	I-Premise
204	for	_	_	I-Premise
205	HDL-C	_	_	I-Premise
206	and	_	_	I-Premise
207	TAC	_	_	I-Premise
208	levels	_	_	I-Premise
209	in	_	_	I-Premise
210	synbiotic	_	_	I-Premise
211	group	_	_	I-Premise
212	were	_	_	I-Premise
213	observed	_	_	I-Premise
214	(	_	_	I-Premise
215	p	_	_	I-Premise
216	<	_	_	I-Premise
217	0.05	_	_	I-Premise
218	)	_	_	I-Premise
219	.	_	_	I-Premise

220	LDL-C	_	_	B-Premise
221	showed	_	_	I-Premise
222	significant	_	_	I-Premise
223	increment	_	_	I-Premise
224	in	_	_	I-Premise
225	the	_	_	I-Premise
226	placebo	_	_	I-Premise
227	group	_	_	I-Premise
228	compared	_	_	I-Premise
229	to	_	_	I-Premise
230	the	_	_	I-Premise
231	baseline	_	_	I-Premise
232	of	_	_	I-Premise
233	the	_	_	I-Premise
234	study	_	_	I-Premise
235	(	_	_	I-Premise
236	6.9	_	_	I-Premise
237	mg/dL	_	_	I-Premise
238	,	_	_	I-Premise
239	p	_	_	I-Premise
240	<	_	_	I-Premise
241	0.05	_	_	I-Premise
242	)	_	_	I-Premise
243	.	_	_	I-Premise

244	Between	_	_	B-Premise
245	group	_	_	I-Premise
246	comparison	_	_	I-Premise
247	showed	_	_	I-Premise
248	significant	_	_	I-Premise
249	decrease	_	_	I-Premise
250	in	_	_	I-Premise
251	SBP	_	_	I-Premise
252	and	_	_	I-Premise
253	DBP	_	_	I-Premise
254	in	_	_	I-Premise
255	synbiotic	_	_	I-Premise
256	group	_	_	I-Premise
257	compared	_	_	I-Premise
258	to	_	_	I-Premise
259	placebo	_	_	I-Premise
260	(	_	_	I-Premise
261	-2.5	_	_	I-Premise
262	vs.	_	_	I-Premise
263	8.6	_	_	I-Premise
264	mmHg	_	_	I-Premise
265	,	_	_	I-Premise
266	and	_	_	I-Premise
267	-1.8	_	_	I-Premise
268	vs.	_	_	I-Premise
269	2.1	_	_	I-Premise
270	mmHg	_	_	I-Premise
271	,	_	_	I-Premise
272	p	_	_	I-Premise
273	<	_	_	I-Premise
274	0.05	_	_	I-Premise
275	)	_	_	I-Premise
276	.	_	_	I-Premise

277	The	_	_	B-Claim
278	results	_	_	I-Claim
279	showed	_	_	I-Claim
280	that	_	_	I-Claim
281	,	_	_	I-Claim
282	in	_	_	I-Claim
283	women	_	_	I-Claim
284	with	_	_	I-Claim
285	GDM	_	_	I-Claim
286	,	_	_	I-Claim
287	synbiotic	_	_	I-Claim
288	supplementation	_	_	I-Claim
289	had	_	_	I-Claim
290	no	_	_	I-Claim
291	effect	_	_	I-Claim
292	on	_	_	I-Claim
293	FPG	_	_	I-Claim
294	and	_	_	I-Claim
295	insulin	_	_	I-Claim
296	resistance/sensitivity	_	_	I-Claim
297	indices	_	_	I-Claim
298	.	_	_	I-Claim

299	Lipid	_	_	B-Claim
300	profile	_	_	I-Claim
301	and	_	_	I-Claim
302	TAC	_	_	I-Claim
303	status	_	_	I-Claim
304	may	_	_	I-Claim
305	be	_	_	I-Claim
306	affected	_	_	I-Claim
307	by	_	_	I-Claim
308	synbiotic	_	_	I-Claim
309	supplementation	_	_	I-Claim
310	.	_	_	I-Claim

311	Synbiotic	_	_	B-Claim
312	is	_	_	I-Claim
313	effective	_	_	I-Claim
314	in	_	_	I-Claim
315	reducing	_	_	I-Claim
316	of	_	_	I-Claim
317	blood	_	_	I-Claim
318	pressure	_	_	I-Claim
319	in	_	_	I-Claim
320	women	_	_	I-Claim
321	with	_	_	I-Claim
322	GDM	_	_	I-Claim
323	.	_	_	I-Claim


0	Hepatotoxicity	_	_	O
1	associated	_	_	O
2	with	_	_	O
3	isoniazid	_	_	O
4	preventive	_	_	O
5	therapy	_	_	O
6	(	_	_	O
7	IPT	_	_	O
8	)	_	_	O
9	and	_	_	O
10	antiretroviral	_	_	O
11	therapy	_	_	O
12	(	_	_	O
13	ART	_	_	O
14	)	_	_	O
15	has	_	_	O
16	not	_	_	O
17	been	_	_	O
18	well	_	_	O
19	studied	_	_	O
20	in	_	_	O
21	severely	_	_	O
22	immunosuppressed	_	_	O
23	people	_	_	O
24	with	_	_	O
25	HIV	_	_	O
26	.	_	_	O

27	Our	_	_	O
28	objective	_	_	O
29	was	_	_	O
30	to	_	_	O
31	determine	_	_	O
32	risk	_	_	O
33	factors	_	_	O
34	for	_	_	O
35	hepatotoxicity	_	_	O
36	in	_	_	O
37	severely	_	_	O
38	immunosuppressed	_	_	O
39	individuals	_	_	O
40	taking	_	_	O
41	IPT	_	_	O
42	and	_	_	O
43	ART	_	_	O
44	.	_	_	O

45	Multicenter	_	_	O
46	study	_	_	O
47	in	_	_	O
48	resource-limited	_	_	O
49	settings	_	_	O
50	with	_	_	O
51	high	_	_	O
52	burden	_	_	O
53	of	_	_	O
54	tuberculosis	_	_	O
55	.	_	_	O

56	We	_	_	O
57	conducted	_	_	O
58	a	_	_	O
59	secondary	_	_	O
60	analysis	_	_	O
61	of	_	_	O
62	data	_	_	O
63	from	_	_	O
64	1	_	_	O
65	randomized	_	_	O
66	arm	_	_	O
67	of	_	_	O
68	the	_	_	O
69	REMEMBER	_	_	O
70	trial	_	_	O
71	.	_	_	O

72	The	_	_	O
73	analysis	_	_	O
74	includes	_	_	O
75	participants	_	_	O
76	with	_	_	O
77	pre-ART	_	_	O
78	CD4	_	_	O
79	cell	_	_	O
80	counts	_	_	O
81	of	_	_	O
82	<	_	_	O
83	50	_	_	O
84	cells/μL	_	_	O
85	receiving	_	_	O
86	IPT	_	_	O
87	and	_	_	O
88	ART	_	_	O
89	for	_	_	O
90	24	_	_	O
91	weeks	_	_	O
92	.	_	_	O

93	Hepatotoxicity	_	_	O
94	was	_	_	O
95	defined	_	_	O
96	as	_	_	O
97	elevated	_	_	O
98	aspartate	_	_	O
99	aminotransferase	_	_	O
100	(	_	_	O
101	AST	_	_	O
102	)	_	_	O
103	or	_	_	O
104	alanine	_	_	O
105	aminotransferase	_	_	O
106	(	_	_	O
107	ALT	_	_	O
108	)	_	_	O
109	>	_	_	O
110	5	_	_	O
111	×	_	_	O
112	upper	_	_	O
113	limit	_	_	O
114	of	_	_	O
115	normal	_	_	O
116	or	_	_	O
117	symptomatic	_	_	O
118	hepatitis	_	_	O
119	during	_	_	O
120	IPT	_	_	O
121	and	_	_	O
122	ART	_	_	O
123	.	_	_	O

124	Logistic	_	_	O
125	regression	_	_	O
126	was	_	_	O
127	used	_	_	O
128	to	_	_	O
129	identify	_	_	O
130	baseline	_	_	O
131	risk	_	_	O
132	factors	_	_	O
133	for	_	_	O
134	hepatotoxicity	_	_	O
135	.	_	_	O

136	Time	_	_	O
137	to	_	_	O
138	occurrence	_	_	O
139	of	_	_	O
140	hepatotoxicity	_	_	O
141	was	_	_	O
142	estimated	_	_	O
143	by	_	_	O
144	the	_	_	O
145	Kaplan-Meier	_	_	O
146	method	_	_	O
147	.	_	_	O

148	Among	_	_	B-Premise
149	426	_	_	I-Premise
150	participants	_	_	I-Premise
151	(	_	_	I-Premise
152	53	_	_	I-Premise
153	%	_	_	I-Premise
154	male	_	_	I-Premise
155	,	_	_	I-Premise
156	median	_	_	I-Premise
157	age	_	_	I-Premise
158	35	_	_	I-Premise
159	years	_	_	I-Premise
160	,	_	_	I-Premise
161	median	_	_	I-Premise
162	CD4	_	_	I-Premise
163	count	_	_	I-Premise
164	19	_	_	I-Premise
165	cells/µL	_	_	I-Premise
166	)	_	_	I-Premise
167	,	_	_	I-Premise
168	31	_	_	I-Premise
169	developed	_	_	I-Premise
170	hepatotoxicity	_	_	I-Premise
171	(	_	_	I-Premise
172	7.3	_	_	I-Premise
173	%	_	_	I-Premise
174	)	_	_	I-Premise
175	.	_	_	I-Premise

176	Raised	_	_	B-Premise
177	pretreatment	_	_	I-Premise
178	AST/ALT	_	_	I-Premise
179	(	_	_	I-Premise
180	odds	_	_	I-Premise
181	ratio	_	_	I-Premise
182	[	_	_	I-Premise
183	OR	_	_	I-Premise
184	]	_	_	I-Premise
185	3.6	_	_	I-Premise
186	,	_	_	I-Premise
187	95	_	_	I-Premise
188	%	_	_	I-Premise
189	confidence	_	_	I-Premise
190	interval	_	_	I-Premise
191	[	_	_	I-Premise
192	CI	_	_	I-Premise
193	]	_	_	I-Premise
194	:	_	_	I-Premise
195	1.7	_	_	I-Premise
196	to	_	_	I-Premise
197	7.7	_	_	I-Premise
198	)	_	_	I-Premise
199	and	_	_	I-Premise
200	hepatitis	_	_	I-Premise
201	B	_	_	I-Premise
202	surface	_	_	I-Premise
203	antigen	_	_	I-Premise
204	(	_	_	I-Premise
205	HBsAg	_	_	I-Premise
206	)	_	_	I-Premise
207	seropositivity	_	_	I-Premise
208	at	_	_	I-Premise
209	baseline	_	_	I-Premise
210	(	_	_	I-Premise
211	OR	_	_	I-Premise
212	4.7	_	_	I-Premise
213	,	_	_	I-Premise
214	95	_	_	I-Premise
215	%	_	_	I-Premise
216	CI	_	_	I-Premise
217	:	_	_	I-Premise
218	1.7	_	_	I-Premise
219	to	_	_	I-Premise
220	12.9	_	_	I-Premise
221	)	_	_	I-Premise
222	were	_	_	I-Premise
223	significantly	_	_	I-Premise
224	associated	_	_	I-Premise
225	with	_	_	I-Premise
226	an	_	_	I-Premise
227	increased	_	_	I-Premise
228	risk	_	_	I-Premise
229	of	_	_	I-Premise
230	developing	_	_	I-Premise
231	hepatotoxicity	_	_	I-Premise
232	.	_	_	I-Premise

233	Participants	_	_	B-Premise
234	with	_	_	I-Premise
235	both	_	_	I-Premise
236	raised	_	_	I-Premise
237	AST/ALT	_	_	I-Premise
238	and	_	_	I-Premise
239	positive	_	_	I-Premise
240	HBsAg	_	_	I-Premise
241	had	_	_	I-Premise
242	a	_	_	I-Premise
243	higher	_	_	I-Premise
244	risk	_	_	I-Premise
245	(	_	_	I-Premise
246	OR	_	_	I-Premise
247	19.9	_	_	I-Premise
248	,	_	_	I-Premise
249	95	_	_	I-Premise
250	%	_	_	I-Premise
251	CI	_	_	I-Premise
252	:	_	_	I-Premise
253	5.3	_	_	I-Premise
254	to	_	_	I-Premise
255	74.3	_	_	I-Premise
256	)	_	_	I-Premise
257	and	_	_	I-Premise
258	earlier	_	_	I-Premise
259	onset	_	_	I-Premise
260	of	_	_	I-Premise
261	hepatotoxicity	_	_	I-Premise
262	than	_	_	I-Premise
263	participants	_	_	I-Premise
264	who	_	_	I-Premise
265	did	_	_	I-Premise
266	not	_	_	I-Premise
267	have	_	_	I-Premise
268	these	_	_	I-Premise
269	conditions	_	_	I-Premise
270	at	_	_	I-Premise
271	baseline	_	_	I-Premise
272	.	_	_	I-Premise

273	The	_	_	B-Claim
274	incidence	_	_	I-Claim
275	of	_	_	I-Claim
276	hepatotoxicity	_	_	I-Claim
277	during	_	_	I-Claim
278	IPT	_	_	I-Claim
279	and	_	_	I-Claim
280	ART	_	_	I-Claim
281	was	_	_	I-Claim
282	high	_	_	I-Claim
283	.	_	_	I-Claim

284	Severely	_	_	B-Claim
285	immunosuppressed	_	_	I-Claim
286	individuals	_	_	I-Claim
287	with	_	_	I-Claim
288	raised	_	_	I-Claim
289	pretreatment	_	_	I-Claim
290	AST/ALT	_	_	I-Claim
291	or	_	_	I-Claim
292	HBsAg	_	_	I-Claim
293	seropositivity	_	_	I-Claim
294	need	_	_	I-Claim
295	closer	_	_	I-Claim
296	monitoring	_	_	I-Claim
297	for	_	_	I-Claim
298	hepatotoxicity	_	_	I-Claim
299	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	predictors	_	_	O
3	of	_	_	O
4	serious	_	_	O
5	adverse	_	_	O
6	events	_	_	O
7	(	_	_	O
8	SAEs	_	_	O
9	)	_	_	O
10	involving	_	_	O
11	syncope	_	_	O
12	,	_	_	O
13	hypotension	_	_	O
14	,	_	_	O
15	and	_	_	O
16	falls	_	_	O
17	,	_	_	O
18	with	_	_	O
19	particular	_	_	O
20	attention	_	_	O
21	to	_	_	O
22	age	_	_	O
23	,	_	_	O
24	in	_	_	O
25	the	_	_	O
26	Systolic	_	_	O
27	Blood	_	_	O
28	Pressure	_	_	O
29	Intervention	_	_	O
30	Trial	_	_	O
31	.	_	_	O

32	Academic	_	_	O
33	and	_	_	O
34	private	_	_	O
35	practices	_	_	O
36	across	_	_	O
37	the	_	_	O
38	United	_	_	O
39	States	_	_	O
40	(	_	_	O
41	N	_	_	O
42	=	_	_	O
43	102	_	_	O
44	)	_	_	O
45	.	_	_	O

46	Adults	_	_	O
47	aged	_	_	O
48	50	_	_	O
49	and	_	_	O
50	older	_	_	O
51	with	_	_	O
52	a	_	_	O
53	systolic	_	_	O
54	blood	_	_	O
55	pressure	_	_	O
56	(	_	_	O
57	SBP	_	_	O
58	)	_	_	O
59	of	_	_	O
60	130	_	_	O
61	to	_	_	O
62	180	_	_	O
63	mmHg	_	_	O
64	at	_	_	O
65	high	_	_	O
66	risk	_	_	O
67	of	_	_	O
68	cardiovascular	_	_	O
69	disease	_	_	O
70	events	_	_	O
71	,	_	_	O
72	but	_	_	O
73	without	_	_	O
74	diabetes	_	_	O
75	,	_	_	O
76	history	_	_	O
77	of	_	_	O
78	stroke	_	_	O
79	,	_	_	O
80	symptomatic	_	_	O
81	heart	_	_	O
82	failure	_	_	O
83	or	_	_	O
84	ejection	_	_	O
85	fraction	_	_	O
86	less	_	_	O
87	than	_	_	O
88	35	_	_	O
89	%	_	_	O
90	,	_	_	O
91	dementia	_	_	O
92	,	_	_	O
93	or	_	_	O
94	standing	_	_	O
95	SBP	_	_	O
96	less	_	_	O
97	than	_	_	O
98	110	_	_	O
99	mmHg	_	_	O
100	(	_	_	O
101	N	_	_	O
102	=	_	_	O
103	9,361	_	_	O
104	)	_	_	O
105	.	_	_	O

106	Treatment	_	_	O
107	of	_	_	O
108	SBP	_	_	O
109	to	_	_	O
110	a	_	_	O
111	goal	_	_	O
112	of	_	_	O
113	less	_	_	O
114	than	_	_	O
115	120	_	_	O
116	mmHg	_	_	O
117	or	_	_	O
118	140	_	_	O
119	mmHg	_	_	O
120	.	_	_	O

121	Outcomes	_	_	O
122	were	_	_	O
123	SAEs	_	_	O
124	involving	_	_	O
125	syncope	_	_	O
126	,	_	_	O
127	hypotension	_	_	O
128	,	_	_	O
129	and	_	_	O
130	falls	_	_	O
131	.	_	_	O

132	Predictors	_	_	O
133	were	_	_	O
134	treatment	_	_	O
135	assignment	_	_	O
136	,	_	_	O
137	demographic	_	_	O
138	characteristics	_	_	O
139	,	_	_	O
140	comorbidities	_	_	O
141	,	_	_	O
142	baseline	_	_	O
143	measurements	_	_	O
144	,	_	_	O
145	and	_	_	O
146	baseline	_	_	O
147	use	_	_	O
148	of	_	_	O
149	cardiovascular	_	_	O
150	medications	_	_	O
151	.	_	_	O

152	One	_	_	O
153	hundred	_	_	O
154	seventy-two	_	_	O
155	(	_	_	O
156	1.8	_	_	O
157	%	_	_	O
158	)	_	_	O
159	participants	_	_	O
160	had	_	_	O
161	SAEs	_	_	O
162	involving	_	_	O
163	syncope	_	_	O
164	,	_	_	O
165	155	_	_	O
166	(	_	_	O
167	1.6	_	_	O
168	%	_	_	O
169	)	_	_	O
170	hypotension	_	_	O
171	,	_	_	O
172	and	_	_	O
173	203	_	_	O
174	(	_	_	O
175	2.2	_	_	O
176	%	_	_	O
177	)	_	_	O
178	falls	_	_	O
179	.	_	_	O

180	Randomization	_	_	B-Premise
181	to	_	_	I-Premise
182	intensive	_	_	I-Premise
183	SBP	_	_	I-Premise
184	control	_	_	I-Premise
185	was	_	_	I-Premise
186	associated	_	_	I-Premise
187	with	_	_	I-Premise
188	greater	_	_	I-Premise
189	risk	_	_	I-Premise
190	of	_	_	I-Premise
191	an	_	_	I-Premise
192	SAE	_	_	I-Premise
193	involving	_	_	I-Premise
194	hypotension	_	_	I-Premise
195	(	_	_	I-Premise
196	hazard	_	_	I-Premise
197	ratio	_	_	I-Premise
198	(	_	_	I-Premise
199	HR	_	_	I-Premise
200	)	_	_	I-Premise
201	=	_	_	I-Premise
202	1.67	_	_	I-Premise
203	,	_	_	I-Premise
204	95	_	_	I-Premise
205	%	_	_	I-Premise
206	confidence	_	_	I-Premise
207	interval	_	_	I-Premise
208	(	_	_	I-Premise
209	CI	_	_	I-Premise
210	)	_	_	I-Premise
211	=	_	_	I-Premise
212	1.21-2.32	_	_	I-Premise
213	,	_	_	I-Premise
214	P	_	_	I-Premise
215	=	_	_	I-Premise
216	.002	_	_	I-Premise
217	)	_	_	I-Premise
218	,	_	_	I-Premise
219	and	_	_	I-Premise
220	possibly	_	_	I-Premise
221	syncope	_	_	I-Premise
222	(	_	_	I-Premise
223	HR	_	_	I-Premise
224	=	_	_	I-Premise
225	1.32	_	_	I-Premise
226	,	_	_	I-Premise
227	95	_	_	I-Premise
228	%	_	_	I-Premise
229	CI	_	_	I-Premise
230	=	_	_	I-Premise
231	0.98-1.79	_	_	I-Premise
232	,	_	_	I-Premise
233	P	_	_	I-Premise
234	=	_	_	I-Premise
235	.07	_	_	I-Premise
236	)	_	_	I-Premise
237	,	_	_	I-Premise
238	but	_	_	I-Premise
239	not	_	_	I-Premise
240	falls	_	_	I-Premise
241	(	_	_	I-Premise
242	HR	_	_	I-Premise
243	=	_	_	I-Premise
244	0.98	_	_	I-Premise
245	,	_	_	I-Premise
246	95	_	_	I-Premise
247	%	_	_	I-Premise
248	CI	_	_	I-Premise
249	=	_	_	I-Premise
250	0.75-1.29	_	_	I-Premise
251	,	_	_	I-Premise
252	P	_	_	I-Premise
253	=	_	_	I-Premise
254	.90	_	_	I-Premise
255	)	_	_	I-Premise
256	.	_	_	I-Premise

257	Risk	_	_	B-Premise
258	of	_	_	I-Premise
259	all	_	_	I-Premise
260	three	_	_	I-Premise
261	outcomes	_	_	I-Premise
262	was	_	_	I-Premise
263	higher	_	_	I-Premise
264	for	_	_	I-Premise
265	participants	_	_	I-Premise
266	with	_	_	I-Premise
267	chronic	_	_	I-Premise
268	kidney	_	_	I-Premise
269	disease	_	_	I-Premise
270	or	_	_	I-Premise
271	frailty	_	_	I-Premise
272	.	_	_	I-Premise

273	Older	_	_	B-Premise
274	age	_	_	I-Premise
275	was	_	_	I-Premise
276	also	_	_	I-Premise
277	associated	_	_	I-Premise
278	with	_	_	I-Premise
279	greater	_	_	I-Premise
280	risk	_	_	I-Premise
281	of	_	_	I-Premise
282	syncope	_	_	I-Premise
283	,	_	_	I-Premise
284	hypotension	_	_	I-Premise
285	,	_	_	I-Premise
286	and	_	_	I-Premise
287	falls	_	_	I-Premise
288	,	_	_	I-Premise
289	but	_	_	I-Premise
290	there	_	_	I-Premise
291	was	_	_	I-Premise
292	no	_	_	I-Premise
293	age-by-treatment	_	_	I-Premise
294	interaction	_	_	I-Premise
295	for	_	_	I-Premise
296	any	_	_	I-Premise
297	of	_	_	I-Premise
298	the	_	_	I-Premise
299	SAE	_	_	I-Premise
300	outcomes	_	_	I-Premise
301	.	_	_	I-Premise

302	Participants	_	_	B-Claim
303	randomized	_	_	I-Claim
304	to	_	_	I-Claim
305	intensive	_	_	I-Claim
306	SBP	_	_	I-Claim
307	control	_	_	I-Claim
308	had	_	_	I-Claim
309	greater	_	_	I-Claim
310	risk	_	_	I-Claim
311	of	_	_	I-Claim
312	hypotension	_	_	I-Claim
313	and	_	_	I-Claim
314	possibly	_	_	I-Claim
315	syncope	_	_	I-Claim
316	,	_	_	I-Claim
317	but	_	_	I-Claim
318	not	_	_	I-Claim
319	falls	_	_	I-Claim
320	.	_	_	I-Claim

321	The	_	_	O
322	greater	_	_	O
323	risk	_	_	O
324	of	_	_	O
325	developing	_	_	O
326	these	_	_	O
327	events	_	_	O
328	associated	_	_	O
329	with	_	_	O
330	intensive	_	_	O
331	treatment	_	_	O
332	did	_	_	O
333	not	_	_	O
334	vary	_	_	O
335	according	_	_	O
336	to	_	_	O
337	age	_	_	O
338	.	_	_	O


0	Low	_	_	B-Claim
1	anterior	_	_	I-Claim
2	resection	_	_	I-Claim
3	with	_	_	I-Claim
4	coloanal	_	_	I-Claim
5	anastomosis	_	_	I-Claim
6	prevents	_	_	I-Claim
7	a	_	_	I-Claim
8	definitive	_	_	I-Claim
9	stoma	_	_	I-Claim
10	in	_	_	I-Claim
11	patients	_	_	I-Claim
12	with	_	_	I-Claim
13	distal	_	_	I-Claim
14	rectal	_	_	I-Claim
15	cancer	_	_	I-Claim
16	.	_	_	I-Claim

17	However	_	_	B-Premise
18	,	_	_	I-Premise
19	imperative	_	_	I-Premise
20	stool	_	_	I-Premise
21	urge	_	_	I-Premise
22	,	_	_	I-Premise
23	stool	_	_	I-Premise
24	fragmentation	_	_	I-Premise
25	,	_	_	I-Premise
26	prolonged	_	_	I-Premise
27	stooling	_	_	I-Premise
28	sessions	_	_	I-Premise
29	,	_	_	I-Premise
30	and	_	_	I-Premise
31	minor	_	_	I-Premise
32	problems	_	_	I-Premise
33	of	_	_	I-Premise
34	incontinence	_	_	I-Premise
35	are	_	_	I-Premise
36	frequently	_	_	I-Premise
37	observed	_	_	I-Premise
38	in	_	_	I-Premise
39	the	_	_	I-Premise
40	postoperative	_	_	I-Premise
41	situation	_	_	I-Premise
42	and	_	_	I-Premise
43	negatively	_	_	I-Premise
44	affect	_	_	I-Premise
45	quality	_	_	I-Premise
46	of	_	_	I-Premise
47	life	_	_	I-Premise
48	.	_	_	I-Premise

49	Therefore	_	_	O
50	,	_	_	O
51	the	_	_	O
52	colonic	_	_	O
53	J-pouch	_	_	O
54	was	_	_	O
55	originally	_	_	O
56	constructed	_	_	O
57	to	_	_	O
58	create	_	_	O
59	a	_	_	O
60	stool	_	_	O
61	reservoir	_	_	O
62	.	_	_	O

63	In	_	_	O
64	a	_	_	O
65	randomized	_	_	O
66	,	_	_	O
67	prospective	_	_	O
68	study	_	_	O
69	,	_	_	O
70	the	_	_	O
71	short	_	_	O
72	(	_	_	O
73	5	_	_	O
74	cm	_	_	O
75	)	_	_	O
76	colonic	_	_	O
77	J-pouch	_	_	O
78	was	_	_	O
79	tested	_	_	O
80	for	_	_	O
81	function	_	_	O
82	and	_	_	O
83	continence	_	_	O
84	vs.	_	_	O
85	straight	_	_	O
86	coloanal	_	_	O
87	anastomosis	_	_	O
88	.	_	_	O

89	Over	_	_	O
90	a	_	_	O
91	period	_	_	O
92	of	_	_	O
93	30	_	_	O
94	months	_	_	O
95	,	_	_	O
96	74	_	_	O
97	consecutive	_	_	O
98	patients	_	_	O
99	(	_	_	O
100	55	_	_	O
101	males	_	_	O
102	)	_	_	O
103	with	_	_	O
104	rectal	_	_	O
105	cancer	_	_	O
106	in	_	_	O
107	the	_	_	O
108	lower	_	_	O
109	and	_	_	O
110	middle	_	_	O
111	third	_	_	O
112	of	_	_	O
113	the	_	_	O
114	rectum	_	_	O
115	were	_	_	O
116	included	_	_	O
117	and	_	_	O
118	randomized	_	_	O
119	into	_	_	O
120	two	_	_	O
121	groups	_	_	O
122	.	_	_	O

123	Anastomosis	_	_	O
124	was	_	_	O
125	performed	_	_	O
126	either	_	_	O
127	as	_	_	O
128	a	_	_	O
129	coloanal	_	_	O
130	or	_	_	O
131	a	_	_	O
132	colon-pouch-anal	_	_	O
133	anastomosis	_	_	O
134	.	_	_	O

135	The	_	_	O
136	standardized	_	_	O
137	surgical	_	_	O
138	procedure	_	_	O
139	included	_	_	O
140	mobilization	_	_	O
141	of	_	_	O
142	the	_	_	O
143	left	_	_	O
144	hemicolon	_	_	O
145	,	_	_	O
146	central	_	_	O
147	ligation	_	_	O
148	of	_	_	O
149	the	_	_	O
150	inferior	_	_	O
151	mesenteric	_	_	O
152	artery	_	_	O
153	and	_	_	O
154	vein	_	_	O
155	,	_	_	O
156	preaortal	_	_	O
157	lymph	_	_	O
158	node	_	_	O
159	dissection	_	_	O
160	,	_	_	O
161	autonomic	_	_	O
162	nerve	_	_	O
163	preservation	_	_	O
164	,	_	_	O
165	and	_	_	O
166	total	_	_	O
167	mesorectal	_	_	O
168	excision	_	_	O
169	.	_	_	O

170	The	_	_	O
171	anastomosis	_	_	O
172	was	_	_	O
173	performed	_	_	O
174	at	_	_	O
175	the	_	_	O
176	upper	_	_	O
177	anal	_	_	O
178	canal	_	_	O
179	or	_	_	O
180	at	_	_	O
181	the	_	_	O
182	intersphincteric	_	_	O
183	level	_	_	O
184	.	_	_	O

185	All	_	_	O
186	patients	_	_	O
187	were	_	_	O
188	evaluated	_	_	O
189	preoperatively	_	_	O
190	and	_	_	O
191	six	_	_	O
192	months	_	_	O
193	postoperatively	_	_	O
194	for	_	_	O
195	fecal	_	_	O
196	continence	_	_	O
197	,	_	_	O
198	including	_	_	O
199	sphincter	_	_	O
200	manometry	_	_	O
201	and	_	_	O
202	defecation	_	_	O
203	habits	_	_	O
204	.	_	_	O

205	In	_	_	O
206	addition	_	_	O
207	,	_	_	O
208	quality	_	_	O
209	of	_	_	O
210	life	_	_	O
211	was	_	_	O
212	determined	_	_	O
213	by	_	_	O
214	use	_	_	O
215	of	_	_	O
216	a	_	_	O
217	standardized	_	_	O
218	questionnaire	_	_	O
219	(	_	_	O
220	European	_	_	O
221	Organization	_	_	O
222	for	_	_	O
223	Research	_	_	O
224	and	_	_	O
225	Treatment	_	_	O
226	of	_	_	O
227	Cancer	_	_	O
228	,	_	_	O
229	EORTC-QLQ-C30	_	_	O
230	)	_	_	O
231	.	_	_	O

232	Thirty-seven	_	_	O
233	patients	_	_	O
234	were	_	_	O
235	randomized	_	_	O
236	into	_	_	O
237	each	_	_	O
238	group	_	_	O
239	.	_	_	O

240	In	_	_	O
241	general	_	_	O
242	,	_	_	O
243	problems	_	_	B-Premise
244	with	_	_	I-Premise
245	continence	_	_	I-Premise
246	for	_	_	I-Premise
247	liquids	_	_	I-Premise
248	or	_	_	I-Premise
249	gas	_	_	I-Premise
250	occurred	_	_	I-Premise
251	less	_	_	I-Premise
252	frequently	_	_	I-Premise
253	in	_	_	I-Premise
254	the	_	_	I-Premise
255	colonic	_	_	I-Premise
256	J-pouch	_	_	I-Premise
257	group	_	_	I-Premise
258	6	_	_	I-Premise
259	months	_	_	I-Premise
260	after	_	_	I-Premise
261	surgery	_	_	I-Premise
262	.	_	_	I-Premise

263	The	_	_	B-Premise
264	frequency	_	_	I-Premise
265	of	_	_	I-Premise
266	bowel	_	_	I-Premise
267	movements	_	_	I-Premise
268	was	_	_	I-Premise
269	lower	_	_	I-Premise
270	in	_	_	I-Premise
271	the	_	_	I-Premise
272	J-pouch	_	_	I-Premise
273	group	_	_	I-Premise
274	(	_	_	I-Premise
275	2.5	_	_	I-Premise
276	per	_	_	I-Premise
277	day	_	_	I-Premise
278	)	_	_	I-Premise
279	than	_	_	I-Premise
280	in	_	_	I-Premise
281	the	_	_	I-Premise
282	coloanal	_	_	I-Premise
283	group	_	_	I-Premise
284	(	_	_	I-Premise
285	4.7	_	_	I-Premise
286	per	_	_	I-Premise
287	day	_	_	I-Premise
288	)	_	_	I-Premise
289	.	_	_	I-Premise

290	Importantly	_	_	O
291	,	_	_	O
292	in	_	_	B-Premise
293	a	_	_	I-Premise
294	manometric	_	_	I-Premise
295	study	_	_	I-Premise
296	at	_	_	I-Premise
297	the	_	_	I-Premise
298	same	_	_	I-Premise
299	postoperative	_	_	I-Premise
300	point	_	_	I-Premise
301	,	_	_	I-Premise
302	neorectal	_	_	I-Premise
303	capacity	_	_	I-Premise
304	was	_	_	I-Premise
305	decreased	_	_	I-Premise
306	to	_	_	I-Premise
307	a	_	_	I-Premise
308	similar	_	_	I-Premise
309	degree	_	_	I-Premise
310	in	_	_	I-Premise
311	both	_	_	I-Premise
312	groups	_	_	I-Premise
313	compared	_	_	I-Premise
314	with	_	_	I-Premise
315	the	_	_	I-Premise
316	preoperative	_	_	I-Premise
317	rectal	_	_	I-Premise
318	volume	_	_	I-Premise
319	.	_	_	I-Premise

320	Thus	_	_	O
321	,	_	_	O
322	the	_	_	B-Premise
323	expected	_	_	I-Premise
324	and	_	_	I-Premise
325	postulated	_	_	I-Premise
326	reservoir	_	_	I-Premise
327	effect	_	_	I-Premise
328	could	_	_	I-Premise
329	not	_	_	I-Premise
330	be	_	_	I-Premise
331	achieved	_	_	I-Premise
332	by	_	_	I-Premise
333	forming	_	_	I-Premise
334	a	_	_	I-Premise
335	5-cm	_	_	I-Premise
336	colonic	_	_	I-Premise
337	J-pouch	_	_	I-Premise
338	.	_	_	I-Premise

339	The	_	_	B-Claim
340	colonic	_	_	I-Claim
341	J-pouch	_	_	I-Claim
342	was	_	_	I-Claim
343	superior	_	_	I-Claim
344	with	_	_	I-Claim
345	regard	_	_	I-Claim
346	to	_	_	I-Claim
347	continence	_	_	I-Claim
348	for	_	_	I-Claim
349	gas	_	_	I-Claim
350	and	_	_	I-Claim
351	liquids	_	_	I-Claim
352	compared	_	_	I-Claim
353	with	_	_	I-Claim
354	a	_	_	I-Claim
355	straight	_	_	I-Claim
356	coloanal	_	_	I-Claim
357	anastomosis	_	_	I-Claim
358	.	_	_	I-Claim

359	Furthermore	_	_	O
360	,	_	_	O
361	stool	_	_	B-Claim
362	frequency	_	_	I-Claim
363	was	_	_	I-Claim
364	significantly	_	_	I-Claim
365	lower	_	_	I-Claim
366	in	_	_	I-Claim
367	the	_	_	I-Claim
368	J-pouch	_	_	I-Claim
369	group	_	_	I-Claim
370	than	_	_	I-Claim
371	in	_	_	I-Claim
372	the	_	_	I-Claim
373	coloanal	_	_	I-Claim
374	reconstruction	_	_	I-Claim
375	group	_	_	I-Claim
376	.	_	_	I-Claim

377	However	_	_	O
378	,	_	_	O
379	because	_	_	B-Premise
380	neorectal	_	_	I-Premise
381	capacity	_	_	I-Premise
382	decreased	_	_	I-Premise
383	equally	_	_	I-Premise
384	in	_	_	I-Premise
385	both	_	_	I-Premise
386	groups	_	_	I-Premise
387	,	_	_	I-Premise
388	we	_	_	B-Claim
389	speculate	_	_	I-Claim
390	that	_	_	I-Claim
391	the	_	_	I-Claim
392	advantage	_	_	I-Claim
393	of	_	_	I-Claim
394	the	_	_	I-Claim
395	colonic	_	_	I-Claim
396	J-pouch	_	_	I-Claim
397	is	_	_	I-Claim
398	not	_	_	I-Claim
399	in	_	_	I-Claim
400	the	_	_	I-Claim
401	creation	_	_	I-Claim
402	of	_	_	I-Claim
403	a	_	_	I-Claim
404	larger	_	_	I-Claim
405	neorectal	_	_	I-Claim
406	reservoir	_	_	I-Claim
407	but	_	_	I-Claim
408	rather	_	_	I-Claim
409	may	_	_	I-Claim
410	be	_	_	I-Claim
411	related	_	_	I-Claim
412	to	_	_	I-Claim
413	decreased	_	_	I-Claim
414	motility	_	_	I-Claim
415	.	_	_	I-Claim


0	To	_	_	O
1	observe	_	_	O
2	the	_	_	O
3	effect	_	_	O
4	of	_	_	O
5	the	_	_	O
6	combined	_	_	O
7	administration	_	_	O
8	of	_	_	O
9	entecavir	_	_	O
10	and	_	_	O
11	adefovir	_	_	O
12	dipivoxil	_	_	O
13	to	_	_	O
14	improve	_	_	O
15	hepatic	_	_	O
16	fibrosis	_	_	O
17	in	_	_	O
18	hepatitis	_	_	O
19	B	_	_	O
20	patients	_	_	O
21	with	_	_	O
22	interferon	_	_	O
23	resistance	_	_	O
24	.	_	_	O

25	This	_	_	O
26	study	_	_	O
27	comprised	_	_	O
28	90	_	_	O
29	hepatitis	_	_	O
30	B	_	_	O
31	patients	_	_	O
32	with	_	_	O
33	hepatic	_	_	O
34	fibrosis	_	_	O
35	and	_	_	O
36	interferon	_	_	O
37	(	_	_	O
38	IFN	_	_	O
39	)	_	_	O
40	resistance	_	_	O
41	who	_	_	O
42	were	_	_	O
43	admitted	_	_	O
44	in	_	_	O
45	the	_	_	O
46	hospital	_	_	O
47	's	_	_	O
48	department	_	_	O
49	of	_	_	O
50	infectious	_	_	O
51	disease	_	_	O
52	for	_	_	O
53	diagnosis	_	_	O
54	and	_	_	O
55	treatment	_	_	O
56	between	_	_	O
57	January	_	_	O
58	2013	_	_	O
59	and	_	_	O
60	September	_	_	O
61	2015	_	_	O
62	.	_	_	O

63	They	_	_	O
64	were	_	_	O
65	randomly	_	_	O
66	divided	_	_	O
67	into	_	_	O
68	two	_	_	O
69	groups	_	_	O
70	in	_	_	O
71	accordance	_	_	O
72	with	_	_	O
73	the	_	_	O
74	random	_	_	O
75	number	_	_	O
76	table	_	_	O
77	:	_	_	O
78	the	_	_	O
79	combination	_	_	O
80	treatment	_	_	O
81	group	_	_	O
82	(	_	_	O
83	N.=45	_	_	O
84	)	_	_	O
85	and	_	_	O
86	the	_	_	O
87	entecavir	_	_	O
88	group	_	_	O
89	(	_	_	O
90	N.=45	_	_	O
91	)	_	_	O
92	.	_	_	O

93	They	_	_	O
94	were	_	_	O
95	observed	_	_	O
96	for	_	_	O
97	any	_	_	O
98	variations	_	_	O
99	in	_	_	O
100	the	_	_	O
101	indexes	_	_	O
102	of	_	_	O
103	liver	_	_	O
104	function	_	_	O
105	and	_	_	O
106	fibrosis	_	_	O
107	,	_	_	O
108	as	_	_	O
109	well	_	_	O
110	as	_	_	O
111	the	_	_	O
112	Model	_	_	O
113	for	_	_	O
114	end-stage	_	_	O
115	liver	_	_	O
116	disease	_	_	O
117	(	_	_	O
118	MELD	_	_	O
119	)	_	_	O
120	scores	_	_	O
121	,	_	_	O
122	before	_	_	O
123	and	_	_	O
124	after	_	_	O
125	treatment	_	_	O
126	.	_	_	O

127	After	_	_	B-Premise
128	treatment	_	_	I-Premise
129	,	_	_	I-Premise
130	the	_	_	I-Premise
131	levels	_	_	I-Premise
132	of	_	_	I-Premise
133	the	_	_	I-Premise
134	indexes	_	_	I-Premise
135	in	_	_	I-Premise
136	both	_	_	I-Premise
137	groups	_	_	I-Premise
138	(	_	_	I-Premise
139	the	_	_	I-Premise
140	combination	_	_	I-Premise
141	treatment	_	_	I-Premise
142	group	_	_	I-Premise
143	vs.	_	_	I-Premise
144	the	_	_	I-Premise
145	entecavir	_	_	I-Premise
146	group	_	_	I-Premise
147	)	_	_	I-Premise
148	were	_	_	I-Premise
149	as	_	_	I-Premise
150	follows	_	_	I-Premise
151	:	_	_	I-Premise
152	bilirubin	_	_	I-Premise
153	(	_	_	I-Premise
154	67.5±7.7	_	_	I-Premise
155	vs.	_	_	I-Premise
156	82.4±13.5	_	_	I-Premise
157	μmol/L	_	_	I-Premise
158	)	_	_	I-Premise
159	;	_	_	I-Premise
160	International	_	_	I-Premise
161	Normalized	_	_	I-Premise
162	Ratio	_	_	I-Premise
163	(	_	_	I-Premise
164	INR	_	_	I-Premise
165	)	_	_	I-Premise
166	(	_	_	I-Premise
167	1.21±0.8	_	_	I-Premise
168	vs.	_	_	I-Premise
169	1.14±0.7	_	_	I-Premise
170	)	_	_	I-Premise
171	;	_	_	I-Premise
172	creatinine	_	_	I-Premise
173	(	_	_	I-Premise
174	147.3±12.4	_	_	I-Premise
175	vs.	_	_	I-Premise
176	287.4±21.6	_	_	I-Premise
177	mg/dL	_	_	I-Premise
178	)	_	_	I-Premise
179	;	_	_	I-Premise
180	GGT	_	_	I-Premise
181	(	_	_	I-Premise
182	67.4±23.2	_	_	I-Premise
183	vs.	_	_	I-Premise
184	88.4±23.7	_	_	I-Premise
185	U/L	_	_	I-Premise
186	)	_	_	I-Premise
187	;	_	_	I-Premise
188	and	_	_	I-Premise
189	ALT	_	_	I-Premise
190	(	_	_	I-Premise
191	63.4±40.8	_	_	I-Premise
192	vs.	_	_	I-Premise
193	96.5±23.5	_	_	I-Premise
194	U/L	_	_	I-Premise
195	)	_	_	I-Premise
196	.	_	_	I-Premise

197	In	_	_	B-Premise
198	comparison	_	_	I-Premise
199	of	_	_	I-Premise
200	the	_	_	I-Premise
201	indexes	_	_	I-Premise
202	of	_	_	I-Premise
203	hepatic	_	_	I-Premise
204	fibrosis	_	_	I-Premise
205	between	_	_	I-Premise
206	the	_	_	I-Premise
207	two	_	_	I-Premise
208	groups	_	_	I-Premise
209	,	_	_	I-Premise
210	we	_	_	I-Premise
211	found	_	_	I-Premise
212	the	_	_	I-Premise
213	following	_	_	I-Premise
214	differences	_	_	I-Premise
215	:	_	_	I-Premise
216	PCIII	_	_	I-Premise
217	(	_	_	I-Premise
218	67.5±7.7	_	_	I-Premise
219	vs.	_	_	I-Premise
220	82.4±13.5	_	_	I-Premise
221	μg/L	_	_	I-Premise
222	)	_	_	I-Premise
223	;	_	_	I-Premise
224	IV-C	_	_	I-Premise
225	(	_	_	I-Premise
226	61.3±18.7	_	_	I-Premise
227	vs.	_	_	I-Premise
228	74.5±17.9	_	_	I-Premise
229	μg/L	_	_	I-Premise
230	)	_	_	I-Premise
231	;	_	_	I-Premise
232	HA	_	_	I-Premise
233	(	_	_	I-Premise
234	147.3±12.4	_	_	I-Premise
235	vs.	_	_	I-Premise
236	87.4±31.6	_	_	I-Premise
237	μg/L	_	_	I-Premise
238	)	_	_	I-Premise
239	;	_	_	I-Premise
240	and	_	_	I-Premise
241	LN	_	_	I-Premise
242	(	_	_	I-Premise
243	88.7±13.2	_	_	I-Premise
244	vs	_	_	I-Premise
245	102.5±23.4	_	_	I-Premise
246	μg/L	_	_	I-Premise
247	)	_	_	I-Premise
248	.	_	_	I-Premise

249	The	_	_	B-Premise
250	results	_	_	I-Premise
251	showed	_	_	I-Premise
252	that	_	_	I-Premise
253	the	_	_	I-Premise
254	differences	_	_	I-Premise
255	in	_	_	I-Premise
256	comparison	_	_	I-Premise
257	of	_	_	I-Premise
258	the	_	_	I-Premise
259	indexes	_	_	I-Premise
260	before	_	_	I-Premise
261	and	_	_	I-Premise
262	after	_	_	I-Premise
263	the	_	_	I-Premise
264	treatment	_	_	I-Premise
265	were	_	_	I-Premise
266	statistically	_	_	I-Premise
267	significant	_	_	I-Premise
268	(	_	_	I-Premise
269	P	_	_	I-Premise
270	<	_	_	I-Premise
271	0.05	_	_	I-Premise
272	)	_	_	I-Premise
273	.	_	_	I-Premise

274	After	_	_	B-Premise
275	treatment	_	_	I-Premise
276	,	_	_	I-Premise
277	the	_	_	I-Premise
278	MELD	_	_	I-Premise
279	score	_	_	I-Premise
280	of	_	_	I-Premise
281	patients	_	_	I-Premise
282	in	_	_	I-Premise
283	the	_	_	I-Premise
284	combination	_	_	I-Premise
285	treatment	_	_	I-Premise
286	group	_	_	I-Premise
287	was	_	_	I-Premise
288	significantly	_	_	I-Premise
289	lower	_	_	I-Premise
290	than	_	_	I-Premise
291	that	_	_	I-Premise
292	in	_	_	I-Premise
293	the	_	_	I-Premise
294	entecavir	_	_	I-Premise
295	group	_	_	I-Premise
296	(	_	_	I-Premise
297	18.7±3.2	_	_	I-Premise
298	vs.	_	_	I-Premise
299	22.5±3.4	_	_	I-Premise
300	)	_	_	I-Premise
301	,	_	_	I-Premise
302	with	_	_	I-Premise
303	a	_	_	I-Premise
304	statistically	_	_	I-Premise
305	significant	_	_	I-Premise
306	difference	_	_	I-Premise
307	(	_	_	I-Premise
308	P	_	_	I-Premise
309	<	_	_	I-Premise
310	0.05	_	_	I-Premise
311	)	_	_	I-Premise
312	.	_	_	I-Premise

313	In	_	_	B-Claim
314	the	_	_	I-Claim
315	chronic	_	_	I-Claim
316	hepatitis	_	_	I-Claim
317	B	_	_	I-Claim
318	patients	_	_	I-Claim
319	with	_	_	I-Claim
320	interferon	_	_	I-Claim
321	resistance	_	_	I-Claim
322	,	_	_	I-Claim
323	the	_	_	I-Claim
324	combined	_	_	I-Claim
325	administration	_	_	I-Claim
326	of	_	_	I-Claim
327	entecavir	_	_	I-Claim
328	and	_	_	I-Claim
329	adefovir	_	_	I-Claim
330	dipivoxil	_	_	I-Claim
331	can	_	_	I-Claim
332	significantly	_	_	I-Claim
333	improve	_	_	I-Claim
334	liver	_	_	I-Claim
335	function	_	_	I-Claim
336	,	_	_	I-Claim
337	hepatic	_	_	I-Claim
338	fibrosis	_	_	I-Claim
339	and	_	_	I-Claim
340	MELD	_	_	I-Claim
341	scores	_	_	I-Claim
342	.	_	_	I-Claim

343	The	_	_	B-Claim
344	results	_	_	I-Claim
345	highlight	_	_	I-Claim
346	the	_	_	I-Claim
347	need	_	_	I-Claim
348	to	_	_	I-Claim
349	promote	_	_	I-Claim
350	the	_	_	I-Claim
351	benefits	_	_	I-Claim
352	of	_	_	I-Claim
353	this	_	_	I-Claim
354	drug	_	_	I-Claim
355	combination	_	_	I-Claim
356	in	_	_	I-Claim
357	helping	_	_	I-Claim
358	chronic	_	_	I-Claim
359	hepatitis	_	_	I-Claim
360	B	_	_	I-Claim
361	patients	_	_	I-Claim
362	with	_	_	I-Claim
363	interferon	_	_	I-Claim
364	resistance	_	_	I-Claim
365	,	_	_	I-Claim
366	and	_	_	I-Claim
367	to	_	_	I-Claim
368	promote	_	_	I-Claim
369	its	_	_	I-Claim
370	application	_	_	I-Claim
371	in	_	_	I-Claim
372	clinical	_	_	I-Claim
373	practices	_	_	I-Claim
374	.	_	_	I-Claim


0	In	_	_	O
1	China	_	_	O
2	,	_	_	O
3	the	_	_	O
4	clinical	_	_	O
5	management	_	_	O
6	of	_	_	O
7	chronic	_	_	O
8	hepatitis	_	_	O
9	B	_	_	O
10	(	_	_	O
11	CHB	_	_	O
12	)	_	_	O
13	is	_	_	O
14	complicated	_	_	O
15	by	_	_	O
16	the	_	_	O
17	use	_	_	O
18	of	_	_	O
19	various	_	_	O
20	nucleos	_	_	O
21	(	_	_	O
22	t	_	_	O
23	)	_	_	O
24	ide	_	_	O
25	analogue	_	_	O
26	(	_	_	O
27	NUC	_	_	O
28	)	_	_	O
29	regimens	_	_	O
30	in	_	_	O
31	treatment-naïve	_	_	O
32	patients	_	_	O
33	,	_	_	O
34	including	_	_	O
35	NUCs	_	_	O
36	with	_	_	O
37	low	_	_	O
38	genetic	_	_	O
39	barriers	_	_	O
40	to	_	_	O
41	resistance	_	_	O
42	,	_	_	O
43	with/without	_	_	O
44	add-on	_	_	O
45	therapy	_	_	O
46	and	_	_	O
47	de	_	_	O
48	novo	_	_	O
49	NUC	_	_	O
50	combinations	_	_	O
51	.	_	_	O

52	This	_	_	O
53	longitudinal	_	_	O
54	observational	_	_	O
55	study	_	_	O
56	therefore	_	_	O
57	investigated	_	_	O
58	the	_	_	O
59	real-world	_	_	O
60	clinical	_	_	O
61	management	_	_	O
62	and	_	_	O
63	efficacy	_	_	O
64	of	_	_	O
65	NUC	_	_	O
66	therapy	_	_	O
67	in	_	_	O
68	treatment-naïve	_	_	O
69	CHB	_	_	O
70	patients	_	_	O
71	in	_	_	O
72	China	_	_	O
73	.	_	_	O

74	Treatment-naïve	_	_	O
75	CHB	_	_	O
76	patients	_	_	O
77	initiated	_	_	O
78	on	_	_	O
79	NUC	_	_	O
80	therapy	_	_	O
81	were	_	_	O
82	enrolled	_	_	O
83	from	_	_	O
84	63	_	_	O
85	hospitals	_	_	O
86	in	_	_	O
87	tier-2	_	_	O
88	Chinese	_	_	O
89	cities	_	_	O
90	.	_	_	O

91	Demographic	_	_	O
92	and	_	_	O
93	treatment-specific	_	_	O
94	data	_	_	O
95	were	_	_	O
96	collected	_	_	O
97	,	_	_	O
98	with	_	_	O
99	the	_	_	O
100	objective	_	_	O
101	of	_	_	O
102	reporting	_	_	O
103	real-world	_	_	O
104	treatment	_	_	O
105	patterns	_	_	O
106	and	_	_	O
107	comparing	_	_	O
108	the	_	_	O
109	effectiveness	_	_	O
110	of	_	_	O
111	entecavir	_	_	O
112	(	_	_	O
113	ETV	_	_	O
114	)	_	_	O
115	treatment	_	_	O
116	and	_	_	O
117	lamivudine	_	_	O
118	(	_	_	O
119	LAM	_	_	O
120	)	_	_	O
121	-based	_	_	O
122	treatment	_	_	O
123	.	_	_	O

124	We	_	_	O
125	herein	_	_	O
126	report	_	_	O
127	the	_	_	O
128	first-year	_	_	O
129	data	_	_	O
130	.	_	_	O

131	3,408	_	_	O
132	NUC-naïve	_	_	O
133	patients	_	_	O
134	were	_	_	O
135	enrolled	_	_	O
136	and	_	_	O
137	treated	_	_	O
138	with	_	_	O
139	NUCs	_	_	O
140	(	_	_	O
141	53	_	_	O
142	%	_	_	O
143	ETV	_	_	O
144	,	_	_	O
145	18	_	_	O
146	%	_	_	O
147	LAM-based	_	_	O
148	,	_	_	O
149	29	_	_	O
150	%	_	_	O
151	other	_	_	O
152	)	_	_	O
153	.	_	_	O

154	Overall	_	_	B-Premise
155	,	_	_	I-Premise
156	6.6	_	_	I-Premise
157	%	_	_	I-Premise
158	of	_	_	I-Premise
159	patients	_	_	I-Premise
160	modified	_	_	I-Premise
161	their	_	_	I-Premise
162	initial	_	_	I-Premise
163	treatment	_	_	I-Premise
164	,	_	_	I-Premise
165	with	_	_	I-Premise
166	ETV	_	_	I-Premise
167	having	_	_	I-Premise
168	lower	_	_	I-Premise
169	rates	_	_	I-Premise
170	of	_	_	I-Premise
171	treatment	_	_	I-Premise
172	modification	_	_	I-Premise
173	than	_	_	I-Premise
174	other	_	_	I-Premise
175	major	_	_	I-Premise
176	NUCs	_	_	I-Premise
177	(	_	_	I-Premise
178	P	_	_	I-Premise
179	<	_	_	I-Premise
180	0.05	_	_	I-Premise
181	)	_	_	I-Premise
182	.	_	_	I-Premise

183	At	_	_	B-Premise
184	week	_	_	I-Premise
185	52	_	_	I-Premise
186	,	_	_	I-Premise
187	the	_	_	I-Premise
188	virologic	_	_	I-Premise
189	response	_	_	I-Premise
190	rate	_	_	I-Premise
191	was	_	_	I-Premise
192	higher	_	_	I-Premise
193	with	_	_	I-Premise
194	ETV	_	_	I-Premise
195	than	_	_	I-Premise
196	with	_	_	I-Premise
197	LAM-based	_	_	I-Premise
198	treatment	_	_	I-Premise
199	(	_	_	I-Premise
200	77.0	_	_	I-Premise
201	%	_	_	I-Premise
202	versus	_	_	I-Premise
203	61.4	_	_	I-Premise
204	%	_	_	I-Premise
205	,	_	_	I-Premise
206	P	_	_	I-Premise
207	<	_	_	I-Premise
208	0.0001	_	_	I-Premise
209	)	_	_	I-Premise
210	.	_	_	I-Premise

211	LAM-based	_	_	B-Premise
212	treatment	_	_	I-Premise
213	was	_	_	I-Premise
214	associated	_	_	I-Premise
215	with	_	_	I-Premise
216	a	_	_	I-Premise
217	higher	_	_	I-Premise
218	probability	_	_	I-Premise
219	of	_	_	I-Premise
220	virologic	_	_	I-Premise
221	breakthrough	_	_	I-Premise
222	and	_	_	I-Premise
223	genotypic	_	_	I-Premise
224	resistance	_	_	I-Premise
225	(	_	_	I-Premise
226	21.4	_	_	I-Premise
227	%	_	_	I-Premise
228	and	_	_	I-Premise
229	19.6	_	_	I-Premise
230	%	_	_	I-Premise
231	,	_	_	I-Premise
232	respectively	_	_	I-Premise
233	)	_	_	I-Premise
234	than	_	_	I-Premise
235	ETV	_	_	I-Premise
236	(	_	_	I-Premise
237	1.6	_	_	I-Premise
238	%	_	_	I-Premise
239	and	_	_	I-Premise
240	0.1	_	_	I-Premise
241	%	_	_	I-Premise
242	,	_	_	I-Premise
243	respectively	_	_	I-Premise
244	)	_	_	I-Premise
245	(	_	_	I-Premise
246	P	_	_	I-Premise
247	<	_	_	I-Premise
248	0.0001	_	_	I-Premise
249	)	_	_	I-Premise
250	.	_	_	I-Premise

251	Treatment-related	_	_	B-Premise
252	adverse	_	_	I-Premise
253	events	_	_	I-Premise
254	or	_	_	I-Premise
255	serious	_	_	I-Premise
256	adverse	_	_	I-Premise
257	events	_	_	I-Premise
258	were	_	_	I-Premise
259	uncommon	_	_	I-Premise
260	.	_	_	I-Premise

261	In	_	_	O
262	this	_	_	O
263	nationwide	_	_	O
264	observational	_	_	O
265	study	_	_	O
266	,	_	_	O
267	more	_	_	O
268	than	_	_	O
269	50	_	_	O
270	%	_	_	O
271	of	_	_	O
272	patients	_	_	O
273	with	_	_	O
274	CHB	_	_	O
275	in	_	_	O
276	tier-2	_	_	O
277	city	_	_	O
278	hospitals	_	_	O
279	in	_	_	O
280	China	_	_	O
281	initially	_	_	O
282	received	_	_	O
283	ETV	_	_	O
284	therapy	_	_	O
285	.	_	_	O

286	Consistent	_	_	B-Claim
287	with	_	_	I-Claim
288	clinical	_	_	I-Claim
289	trial	_	_	I-Claim
290	results	_	_	I-Claim
291	,	_	_	I-Claim
292	ETV	_	_	I-Claim
293	was	_	_	I-Claim
294	more	_	_	I-Claim
295	effective	_	_	I-Claim
296	than	_	_	I-Claim
297	LAM-based	_	_	I-Claim
298	treatments	_	_	I-Claim
299	in	_	_	I-Claim
300	a	_	_	I-Claim
301	real-world	_	_	I-Claim
302	setting	_	_	I-Claim
303	,	_	_	I-Claim
304	with	_	_	I-Claim
305	treatment	_	_	I-Claim
306	modification	_	_	I-Claim
307	being	_	_	I-Claim
308	relatively	_	_	I-Claim
309	low	_	_	I-Claim
310	in	_	_	I-Claim
311	ETV-treated	_	_	I-Claim
312	patients	_	_	I-Claim
313	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	postoperative	_	_	O
4	intraocular	_	_	O
5	pressure	_	_	O
6	(	_	_	O
7	IOP	_	_	O
8	)	_	_	O
9	and	_	_	O
10	incidence	_	_	O
11	of	_	_	O
12	early	_	_	O
13	complications	_	_	O
14	after	_	_	O
15	trabeculectomy	_	_	O
16	with	_	_	O
17	releasable	_	_	O
18	suture	_	_	O
19	to	_	_	O
20	standard	_	_	O
21	trabeculectomy	_	_	O
22	in	_	_	O
23	Chinese	_	_	O
24	patients	_	_	O
25	with	_	_	O
26	primary	_	_	O
27	angle-closure	_	_	O
28	glaucoma	_	_	O
29	.	_	_	O

30	One	_	_	O
31	hundred	_	_	O
32	seventy-five	_	_	O
33	patients	_	_	O
34	diagnosed	_	_	O
35	as	_	_	O
36	primary	_	_	O
37	angle-closure	_	_	O
38	glaucoma	_	_	O
39	with	_	_	O
40	6	_	_	O
41	clock-hours	_	_	O
42	or	_	_	O
43	more	_	_	O
44	of	_	_	O
45	peripheral	_	_	O
46	anterior	_	_	O
47	synechia	_	_	O
48	were	_	_	O
49	randomly	_	_	O
50	allocated	_	_	O
51	to	_	_	O
52	2	_	_	O
53	treatment	_	_	O
54	groups	_	_	O
55	:	_	_	O
56	87	_	_	O
57	underwent	_	_	O
58	standard	_	_	O
59	trabeculectomy	_	_	O
60	(	_	_	O
61	S	_	_	O
62	group	_	_	O
63	:	_	_	O
64	2	_	_	O
65	interrupted	_	_	O
66	permanent	_	_	O
67	sutures	_	_	O
68	to	_	_	O
69	the	_	_	O
70	scleral	_	_	O
71	flap	_	_	O
72	)	_	_	O
73	and	_	_	O
74	88	_	_	O
75	received	_	_	O
76	trabeculectomy	_	_	O
77	with	_	_	O
78	2	_	_	O
79	permanent	_	_	O
80	and	_	_	O
81	2	_	_	O
82	releasable	_	_	O
83	sutures	_	_	O
84	(	_	_	O
85	R	_	_	O
86	group	_	_	O
87	)	_	_	O
88	.	_	_	O

89	The	_	_	O
90	postoperative	_	_	O
91	IOP	_	_	O
92	and	_	_	O
93	complications	_	_	O
94	during	_	_	O
95	the	_	_	O
96	first	_	_	O
97	3	_	_	O
98	months	_	_	O
99	after	_	_	O
100	surgery	_	_	O
101	were	_	_	O
102	compared	_	_	O
103	.	_	_	O

104	One	_	_	O
105	hundred	_	_	O
106	seventy-one	_	_	O
107	patients	_	_	O
108	(	_	_	O
109	97.7	_	_	O
110	%	_	_	O
111	)	_	_	O
112	attended	_	_	O
113	the	_	_	O
114	3-month	_	_	O
115	visit	_	_	O
116	.	_	_	O

117	The	_	_	B-Premise
118	IOP	_	_	I-Premise
119	in	_	_	I-Premise
120	the	_	_	I-Premise
121	first	_	_	I-Premise
122	week	_	_	I-Premise
123	after	_	_	I-Premise
124	trabeculectomy	_	_	I-Premise
125	was	_	_	I-Premise
126	significantly	_	_	I-Premise
127	higher	_	_	I-Premise
128	in	_	_	I-Premise
129	the	_	_	I-Premise
130	R	_	_	I-Premise
131	group	_	_	I-Premise
132	:	_	_	I-Premise
133	day	_	_	I-Premise
134	1	_	_	I-Premise
135	,	_	_	I-Premise
136	17.3	_	_	I-Premise
137	±	_	_	I-Premise
138	8.6	_	_	I-Premise
139	versus	_	_	I-Premise
140	12.7	_	_	I-Premise
141	±	_	_	I-Premise
142	6.0	_	_	I-Premise
143	mm	_	_	I-Premise
144	Hg	_	_	I-Premise
145	(	_	_	I-Premise
146	P	_	_	I-Premise
147	<	_	_	I-Premise
148	0.001	_	_	I-Premise
149	)	_	_	I-Premise
150	;	_	_	I-Premise
151	day	_	_	I-Premise
152	3	_	_	I-Premise
153	,	_	_	I-Premise
154	18.0	_	_	I-Premise
155	±	_	_	I-Premise
156	7.3	_	_	I-Premise
157	versus	_	_	I-Premise
158	12.9	_	_	I-Premise
159	±	_	_	I-Premise
160	6.3	_	_	I-Premise
161	mm	_	_	I-Premise
162	Hg	_	_	I-Premise
163	(	_	_	I-Premise
164	P	_	_	I-Premise
165	<	_	_	I-Premise
166	0.001	_	_	I-Premise
167	)	_	_	I-Premise
168	;	_	_	I-Premise
169	day	_	_	I-Premise
170	7	_	_	I-Premise
171	,	_	_	I-Premise
172	14.8	_	_	I-Premise
173	±	_	_	I-Premise
174	6.3	_	_	I-Premise
175	versus	_	_	I-Premise
176	12.0	_	_	I-Premise
177	±	_	_	I-Premise
178	4.9	_	_	I-Premise
179	mm	_	_	I-Premise
180	Hg	_	_	I-Premise
181	(	_	_	I-Premise
182	P=0.001	_	_	I-Premise
183	)	_	_	I-Premise
184	,	_	_	I-Premise
185	but	_	_	O
186	no	_	_	B-Premise
187	difference	_	_	I-Premise
188	was	_	_	I-Premise
189	observed	_	_	I-Premise
190	after	_	_	I-Premise
191	the	_	_	I-Premise
192	second	_	_	I-Premise
193	week	_	_	I-Premise
194	(	_	_	I-Premise
195	P=0.659	_	_	I-Premise
196	to	_	_	I-Premise
197	0.753	_	_	I-Premise
198	)	_	_	I-Premise
199	.	_	_	I-Premise

200	The	_	_	B-Premise
201	incidence	_	_	I-Premise
202	of	_	_	I-Premise
203	transient	_	_	I-Premise
204	hypotony	_	_	I-Premise
205	was	_	_	I-Premise
206	higher	_	_	I-Premise
207	in	_	_	I-Premise
208	S	_	_	I-Premise
209	group	_	_	I-Premise
210	(	_	_	I-Premise
211	20.4	_	_	I-Premise
212	%	_	_	I-Premise
213	)	_	_	I-Premise
214	than	_	_	I-Premise
215	the	_	_	I-Premise
216	R	_	_	I-Premise
217	group	_	_	I-Premise
218	(	_	_	I-Premise
219	9.1	_	_	I-Premise
220	%	_	_	I-Premise
221	)	_	_	I-Premise
222	(	_	_	I-Premise
223	P=0.046	_	_	I-Premise
224	)	_	_	I-Premise
225	;	_	_	I-Premise
226	hypotony	_	_	B-Premise
227	recovered	_	_	I-Premise
228	in	_	_	I-Premise
229	80.8	_	_	I-Premise
230	%	_	_	I-Premise
231	(	_	_	I-Premise
232	21/26	_	_	I-Premise
233	)	_	_	I-Premise
234	within	_	_	I-Premise
235	1	_	_	I-Premise
236	week	_	_	I-Premise
237	.	_	_	I-Premise

238	There	_	_	B-Premise
239	was	_	_	I-Premise
240	no	_	_	I-Premise
241	difference	_	_	I-Premise
242	in	_	_	I-Premise
243	the	_	_	I-Premise
244	occurrence	_	_	I-Premise
245	of	_	_	I-Premise
246	shallow	_	_	I-Premise
247	chamber	_	_	I-Premise
248	,	_	_	I-Premise
249	choroidal	_	_	I-Premise
250	detachment	_	_	I-Premise
251	,	_	_	I-Premise
252	macular	_	_	I-Premise
253	edema	_	_	I-Premise
254	,	_	_	I-Premise
255	additional	_	_	I-Premise
256	surgery	_	_	I-Premise
257	,	_	_	I-Premise
258	or	_	_	I-Premise
259	hyphema	_	_	I-Premise
260	(	_	_	I-Premise
261	P=0.56	_	_	I-Premise
262	to	_	_	I-Premise
263	1.0	_	_	I-Premise
264	)	_	_	I-Premise
265	.	_	_	I-Premise

266	The	_	_	B-Claim
267	technique	_	_	I-Claim
268	of	_	_	I-Claim
269	releasable	_	_	I-Claim
270	sutures	_	_	I-Claim
271	for	_	_	I-Claim
272	trabeculectomy	_	_	I-Claim
273	used	_	_	I-Claim
274	in	_	_	I-Claim
275	this	_	_	I-Claim
276	study	_	_	I-Claim
277	did	_	_	I-Claim
278	not	_	_	I-Claim
279	demonstrate	_	_	I-Claim
280	significant	_	_	I-Claim
281	advantages	_	_	I-Claim
282	over	_	_	I-Claim
283	standard	_	_	I-Claim
284	trabeculectomy	_	_	I-Claim
285	.	_	_	I-Claim

286	Releasable	_	_	B-Claim
287	sutures	_	_	I-Claim
288	were	_	_	I-Claim
289	associated	_	_	I-Claim
290	with	_	_	I-Claim
291	some	_	_	I-Claim
292	decrease	_	_	I-Claim
293	in	_	_	I-Claim
294	visual	_	_	I-Claim
295	acuity	_	_	I-Claim
296	and	_	_	I-Claim
297	increase	_	_	I-Claim
298	in	_	_	I-Claim
299	postoperative	_	_	I-Claim
300	complaints	_	_	I-Claim
301	.	_	_	I-Claim


0	This	_	_	O
1	study	_	_	O
2	aimed	_	_	O
3	to	_	_	O
4	observe	_	_	O
5	and	_	_	O
6	compare	_	_	O
7	the	_	_	O
8	efficacy	_	_	O
9	and	_	_	O
10	safety	_	_	O
11	of	_	_	O
12	the	_	_	O
13	combined	_	_	O
14	therapy	_	_	O
15	and	_	_	O
16	two	_	_	O
17	different	_	_	O
18	optimized	_	_	O
19	therapies	_	_	O
20	of	_	_	O
21	lamivudine	_	_	O
22	(	_	_	O
23	LAM	_	_	O
24	)	_	_	O
25	and	_	_	O
26	adefovir	_	_	O
27	dipivoxil	_	_	O
28	(	_	_	O
29	ADV	_	_	O
30	)	_	_	O
31	,	_	_	O
32	as	_	_	O
33	well	_	_	O
34	as	_	_	O
35	entecavir	_	_	O
36	(	_	_	O
37	ETV	_	_	O
38	)	_	_	O
39	monotherapy	_	_	O
40	in	_	_	O
41	patients	_	_	O
42	with	_	_	O
43	hepatitis	_	_	O
44	B-induced	_	_	O
45	decompensated	_	_	O
46	cirrhosis	_	_	O
47	.	_	_	O

48	A	_	_	O
49	total	_	_	O
50	of	_	_	O
51	127	_	_	O
52	patients	_	_	O
53	with	_	_	O
54	decompensated	_	_	O
55	cirrhosis	_	_	O
56	were	_	_	O
57	divided	_	_	O
58	into	_	_	O
59	four	_	_	O
60	groups	_	_	O
61	,	_	_	O
62	and	_	_	O
63	each	_	_	O
64	group	_	_	O
65	received	_	_	O
66	different	_	_	O
67	doses	_	_	O
68	of	_	_	O
69	regimens	_	_	O
70	:	_	_	O
71	initial	_	_	O
72	combination	_	_	O
73	of	_	_	O
74	LAM	_	_	O
75	and	_	_	O
76	ADV	_	_	O
77	,	_	_	O
78	ADV	_	_	O
79	add-on	_	_	O
80	therapies	_	_	O
81	with	_	_	O
82	previous	_	_	O
83	12-week	_	_	O
84	LAM	_	_	O
85	,	_	_	O
86	ADV	_	_	O
87	add-on	_	_	O
88	therapies	_	_	O
89	with	_	_	O
90	previous	_	_	O
91	24-week	_	_	O
92	LAM	_	_	O
93	,	_	_	O
94	and	_	_	O
95	ETV	_	_	O
96	monotherapy	_	_	O
97	.	_	_	O

98	At	_	_	B-Premise
99	the	_	_	I-Premise
100	end	_	_	I-Premise
101	of	_	_	I-Premise
102	the	_	_	I-Premise
103	treatment	_	_	I-Premise
104	,	_	_	I-Premise
105	the	_	_	I-Premise
106	level	_	_	I-Premise
107	of	_	_	I-Premise
108	alanine	_	_	I-Premise
109	amino-transferase	_	_	I-Premise
110	(	_	_	I-Premise
111	ALT	_	_	I-Premise
112	)	_	_	I-Premise
113	,	_	_	I-Premise
114	albumin	_	_	I-Premise
115	(	_	_	I-Premise
116	ALB	_	_	I-Premise
117	)	_	_	I-Premise
118	and	_	_	I-Premise
119	total	_	_	I-Premise
120	bilirubin	_	_	I-Premise
121	(	_	_	I-Premise
122	TBIL	_	_	I-Premise
123	)	_	_	I-Premise
124	in	_	_	I-Premise
125	the	_	_	I-Premise
126	combination	_	_	I-Premise
127	therapy	_	_	I-Premise
128	group	_	_	I-Premise
129	and	_	_	I-Premise
130	12-week	_	_	I-Premise
131	optimized	_	_	I-Premise
132	therapy	_	_	I-Premise
133	group	_	_	I-Premise
134	were	_	_	I-Premise
135	significantly	_	_	I-Premise
136	improved	_	_	I-Premise
137	.	_	_	I-Premise

138	For	_	_	B-Premise
139	the	_	_	I-Premise
140	24-week	_	_	I-Premise
141	optimized	_	_	I-Premise
142	therapy	_	_	I-Premise
143	group	_	_	I-Premise
144	,	_	_	I-Premise
145	only	_	_	I-Premise
146	ALT	_	_	I-Premise
147	levels	_	_	I-Premise
148	revealed	_	_	I-Premise
149	a	_	_	I-Premise
150	significant	_	_	I-Premise
151	improvement	_	_	I-Premise
152	.	_	_	I-Premise

153	There	_	_	B-Premise
154	were	_	_	I-Premise
155	no	_	_	I-Premise
156	obvious	_	_	I-Premise
157	differences	_	_	I-Premise
158	in	_	_	I-Premise
159	the	_	_	I-Premise
160	normalization	_	_	I-Premise
161	rate	_	_	I-Premise
162	of	_	_	I-Premise
163	ALT	_	_	I-Premise
164	,	_	_	I-Premise
165	negative	_	_	I-Premise
166	conversion	_	_	I-Premise
167	rate	_	_	I-Premise
168	of	_	_	I-Premise
169	HBV	_	_	I-Premise
170	DNA	_	_	I-Premise
171	and	_	_	I-Premise
172	HBeAg	_	_	I-Premise
173	,	_	_	I-Premise
174	as	_	_	I-Premise
175	well	_	_	I-Premise
176	as	_	_	I-Premise
177	improvement	_	_	I-Premise
178	in	_	_	I-Premise
179	Child-Pugh	_	_	I-Premise
180	scores	_	_	I-Premise
181	among	_	_	I-Premise
182	the	_	_	I-Premise
183	combination	_	_	I-Premise
184	therapy	_	_	I-Premise
185	group	_	_	I-Premise
186	,	_	_	I-Premise
187	12-week	_	_	I-Premise
188	optimized	_	_	I-Premise
189	therapy	_	_	I-Premise
190	group	_	_	I-Premise
191	,	_	_	I-Premise
192	and	_	_	I-Premise
193	ETV	_	_	I-Premise
194	monotherapy	_	_	I-Premise
195	group	_	_	I-Premise
196	.	_	_	I-Premise

197	However	_	_	B-Premise
198	,	_	_	I-Premise
199	the	_	_	I-Premise
200	difference	_	_	I-Premise
201	among	_	_	I-Premise
202	these	_	_	I-Premise
203	three	_	_	I-Premise
204	groups	_	_	I-Premise
205	and	_	_	I-Premise
206	the	_	_	I-Premise
207	24-week	_	_	I-Premise
208	optimized	_	_	I-Premise
209	therapy	_	_	I-Premise
210	group	_	_	I-Premise
211	were	_	_	I-Premise
212	significant	_	_	I-Premise
213	.	_	_	I-Premise

214	Differences	_	_	B-Premise
215	were	_	_	I-Premise
216	not	_	_	I-Premise
217	observed	_	_	I-Premise
218	in	_	_	I-Premise
219	the	_	_	I-Premise
220	HBeAg	_	_	I-Premise
221	seroconversion	_	_	I-Premise
222	between	_	_	I-Premise
223	each	_	_	I-Premise
224	group	_	_	I-Premise
225	.	_	_	I-Premise

226	Differences	_	_	B-Premise
227	in	_	_	I-Premise
228	blood	_	_	I-Premise
229	urea	_	_	I-Premise
230	nitrogen	_	_	I-Premise
231	,	_	_	I-Premise
232	serum	_	_	I-Premise
233	creatinine	_	_	I-Premise
234	,	_	_	I-Premise
235	creatine	_	_	I-Premise
236	kinase	_	_	I-Premise
237	,	_	_	I-Premise
238	or	_	_	I-Premise
239	other	_	_	I-Premise
240	serious	_	_	I-Premise
241	adverse	_	_	I-Premise
242	effects	_	_	I-Premise
243	were	_	_	I-Premise
244	not	_	_	I-Premise
245	observed	_	_	I-Premise
246	in	_	_	I-Premise
247	each	_	_	I-Premise
248	group	_	_	I-Premise
249	at	_	_	I-Premise
250	the	_	_	I-Premise
251	end	_	_	I-Premise
252	of	_	_	I-Premise
253	the	_	_	I-Premise
254	96-week	_	_	I-Premise
255	treatment	_	_	I-Premise
256	.	_	_	I-Premise

257	Combination	_	_	B-Claim
258	therapy	_	_	I-Claim
259	and	_	_	I-Claim
260	early	_	_	I-Claim
261	ADV	_	_	I-Claim
262	addition	_	_	I-Claim
263	were	_	_	I-Claim
264	the	_	_	I-Claim
265	preferred	_	_	I-Claim
266	approaches	_	_	I-Claim
267	in	_	_	I-Claim
268	the	_	_	I-Claim
269	antiviral	_	_	I-Claim
270	strategy	_	_	I-Claim
271	for	_	_	I-Claim
272	the	_	_	I-Claim
273	treatment	_	_	I-Claim
274	of	_	_	I-Claim
275	hepatitis	_	_	I-Claim
276	B-induced	_	_	I-Claim
277	decompensated	_	_	I-Claim
278	cirrhosis	_	_	I-Claim
279	.	_	_	I-Claim


0	We	_	_	O
1	aimed	_	_	O
2	to	_	_	O
3	compare	_	_	O
4	a	_	_	O
5	combined	_	_	O
6	oral	_	_	O
7	contraceptive	_	_	O
8	(	_	_	O
9	COC	_	_	O
10	)	_	_	O
11	plus	_	_	O
12	the	_	_	O
13	antiandrogen	_	_	O
14	spironolactone	_	_	O
15	with	_	_	O
16	the	_	_	O
17	insulin	_	_	O
18	sensitizer	_	_	O
19	metformin	_	_	O
20	in	_	_	O
21	women	_	_	O
22	with	_	_	O
23	polycystic	_	_	O
24	ovary	_	_	O
25	syndrome	_	_	O
26	(	_	_	O
27	PCOS	_	_	O
28	)	_	_	O
29	.	_	_	O

30	We	_	_	O
31	conducted	_	_	O
32	a	_	_	O
33	randomized	_	_	O
34	,	_	_	O
35	parallel	_	_	O
36	,	_	_	O
37	open-label	_	_	O
38	,	_	_	O
39	clinical	_	_	O
40	trial	_	_	O
41	comparing	_	_	O
42	COC	_	_	O
43	(	_	_	O
44	30	_	_	O
45	μg	_	_	O
46	of	_	_	O
47	ethinylestradiol	_	_	O
48	and	_	_	O
49	150	_	_	O
50	μg	_	_	O
51	of	_	_	O
52	desogestrel	_	_	O
53	)	_	_	O
54	plus	_	_	O
55	spironolactone	_	_	O
56	(	_	_	O
57	100	_	_	O
58	mg/day	_	_	O
59	)	_	_	O
60	with	_	_	O
61	metformin	_	_	O
62	(	_	_	O
63	850	_	_	O
64	mg	_	_	O
65	b.i.d	_	_	O
66	.	_	_	O
67	)	_	_	O

68	for	_	_	O
69	one	_	_	O
70	year	_	_	O
71	in	_	_	O
72	women	_	_	O
73	with	_	_	O
74	PCOS	_	_	O
75	(	_	_	O
76	EudraCT2008-004531-38	_	_	O
77	)	_	_	O
78	.	_	_	O

79	The	_	_	O
80	composite	_	_	O
81	primary	_	_	O
82	outcome	_	_	O
83	included	_	_	O
84	efficacy	_	_	O
85	(	_	_	O
86	amelioration	_	_	O
87	of	_	_	O
88	hirsutism	_	_	O
89	,	_	_	O
90	androgen	_	_	O
91	excess	_	_	O
92	and	_	_	O
93	menstrual	_	_	O
94	dysfunction	_	_	O
95	)	_	_	O
96	and	_	_	O
97	cardiometabolic	_	_	O
98	safety	_	_	O
99	(	_	_	O
100	changes	_	_	O
101	in	_	_	O
102	the	_	_	O
103	frequencies	_	_	O
104	of	_	_	O
105	disorders	_	_	O
106	of	_	_	O
107	glucose	_	_	O
108	tolerance	_	_	O
109	,	_	_	O
110	dyslipidemia	_	_	O
111	and	_	_	O
112	hypertension	_	_	O
113	)	_	_	O
114	.	_	_	O

115	A	_	_	O
116	complete	_	_	O
117	anthropometric	_	_	O
118	,	_	_	O
119	biochemical	_	_	O
120	,	_	_	O
121	hormonal	_	_	O
122	and	_	_	O
123	metabolic	_	_	O
124	evaluation	_	_	O
125	was	_	_	O
126	conducted	_	_	O
127	every	_	_	O
128	three	_	_	O
129	months	_	_	O
130	and	_	_	O
131	data	_	_	O
132	were	_	_	O
133	submitted	_	_	O
134	to	_	_	O
135	intention-to-treat	_	_	O
136	analyses	_	_	O
137	.	_	_	O

138	Twenty-four	_	_	O
139	patients	_	_	O
140	were	_	_	O
141	assigned	_	_	O
142	to	_	_	O
143	COC	_	_	O
144	plus	_	_	O
145	spironolactone	_	_	O
146	and	_	_	O
147	22	_	_	O
148	patients	_	_	O
149	to	_	_	O
150	metformin	_	_	O
151	.	_	_	O

152	Compared	_	_	B-Premise
153	with	_	_	I-Premise
154	metformin	_	_	I-Premise
155	,	_	_	I-Premise
156	COC	_	_	I-Premise
157	plus	_	_	I-Premise
158	spironolactone	_	_	I-Premise
159	caused	_	_	I-Premise
160	larger	_	_	I-Premise
161	decreases	_	_	I-Premise
162	in	_	_	I-Premise
163	hirsutism	_	_	I-Premise
164	score	_	_	I-Premise
165	(	_	_	I-Premise
166	mean	_	_	I-Premise
167	difference	_	_	I-Premise
168	4.6	_	_	I-Premise
169	points	_	_	I-Premise
170	,	_	_	I-Premise
171	95	_	_	I-Premise
172	%	_	_	I-Premise
173	CI	_	_	I-Premise
174	:	_	_	I-Premise
175	2.6-6.7	_	_	I-Premise
176	)	_	_	I-Premise
177	,	_	_	I-Premise
178	total	_	_	I-Premise
179	testosterone	_	_	I-Premise
180	(	_	_	I-Premise
181	1.1	_	_	I-Premise
182	nmol/L	_	_	I-Premise
183	,	_	_	I-Premise
184	0.4-1.7	_	_	I-Premise
185	)	_	_	I-Premise
186	,	_	_	I-Premise
187	free	_	_	I-Premise
188	testosterone	_	_	I-Premise
189	(	_	_	I-Premise
190	25	_	_	I-Premise
191	pmol/L	_	_	I-Premise
192	,	_	_	I-Premise
193	12-39	_	_	I-Premise
194	)	_	_	I-Premise
195	,	_	_	I-Premise
196	androstenedione	_	_	I-Premise
197	(	_	_	I-Premise
198	5.5	_	_	I-Premise
199	nmol/L	_	_	I-Premise
200	,	_	_	I-Premise
201	1.8-9.2	_	_	I-Premise
202	)	_	_	I-Premise
203	and	_	_	I-Premise
204	dehydroepiandrosterone	_	_	I-Premise
205	sulfate	_	_	I-Premise
206	(	_	_	I-Premise
207	2.7	_	_	I-Premise
208	μmol/L	_	_	I-Premise
209	,	_	_	I-Premise
210	1.4-4.0	_	_	I-Premise
211	)	_	_	I-Premise
212	.	_	_	I-Premise

213	Menstrual	_	_	B-Premise
214	dysfunction	_	_	I-Premise
215	was	_	_	I-Premise
216	less	_	_	I-Premise
217	frequent	_	_	I-Premise
218	with	_	_	I-Premise
219	COC	_	_	I-Premise
220	plus	_	_	I-Premise
221	spironolactone	_	_	I-Premise
222	(	_	_	I-Premise
223	OR	_	_	I-Premise
224	:	_	_	I-Premise
225	0.06	_	_	I-Premise
226	,	_	_	I-Premise
227	95	_	_	I-Premise
228	%	_	_	I-Premise
229	CI	_	_	I-Premise
230	:	_	_	I-Premise
231	0.02-0.23	_	_	I-Premise
232	)	_	_	I-Premise
233	.	_	_	I-Premise

234	No	_	_	B-Premise
235	differences	_	_	I-Premise
236	were	_	_	I-Premise
237	found	_	_	I-Premise
238	in	_	_	I-Premise
239	frequencies	_	_	I-Premise
240	of	_	_	I-Premise
241	abnormal	_	_	I-Premise
242	glucose	_	_	I-Premise
243	tolerance	_	_	I-Premise
244	(	_	_	I-Premise
245	OR	_	_	I-Premise
246	:	_	_	I-Premise
247	1.7	_	_	I-Premise
248	,	_	_	I-Premise
249	95	_	_	I-Premise
250	%	_	_	I-Premise
251	CI	_	_	I-Premise
252	:	_	_	I-Premise
253	0.7-4.4	_	_	I-Premise
254	)	_	_	I-Premise
255	,	_	_	I-Premise
256	dyslipidemia	_	_	I-Premise
257	(	_	_	I-Premise
258	OR	_	_	I-Premise
259	:	_	_	I-Premise
260	0.6	_	_	I-Premise
261	,	_	_	I-Premise
262	95	_	_	I-Premise
263	%	_	_	I-Premise
264	CI	_	_	I-Premise
265	:	_	_	I-Premise
266	0.2-1.8	_	_	I-Premise
267	)	_	_	I-Premise
268	or	_	_	I-Premise
269	hypertension	_	_	I-Premise
270	(	_	_	I-Premise
271	OR	_	_	I-Premise
272	:	_	_	I-Premise
273	0.3	_	_	I-Premise
274	,	_	_	I-Premise
275	95	_	_	I-Premise
276	%	_	_	I-Premise
277	CI	_	_	I-Premise
278	:	_	_	I-Premise
279	0.5-2.0	_	_	I-Premise
280	)	_	_	I-Premise
281	.	_	_	I-Premise

282	No	_	_	B-Premise
283	major	_	_	I-Premise
284	adverse	_	_	I-Premise
285	events	_	_	I-Premise
286	occurred	_	_	I-Premise
287	and	_	_	I-Premise
288	biochemical	_	_	I-Premise
289	markers	_	_	I-Premise
290	were	_	_	I-Premise
291	similarly	_	_	I-Premise
292	safe	_	_	I-Premise
293	with	_	_	I-Premise
294	both	_	_	I-Premise
295	treatments	_	_	I-Premise
296	.	_	_	I-Premise

297	COC	_	_	B-Claim
298	plus	_	_	I-Claim
299	spironolactone	_	_	I-Claim
300	was	_	_	I-Claim
301	more	_	_	I-Claim
302	effective	_	_	I-Claim
303	than	_	_	I-Claim
304	metformin	_	_	I-Claim
305	for	_	_	I-Claim
306	symptoms	_	_	I-Claim
307	of	_	_	I-Claim
308	PCOS	_	_	I-Claim
309	showing	_	_	I-Claim
310	similar	_	_	I-Claim
311	safety	_	_	I-Claim
312	and	_	_	I-Claim
313	overall	_	_	I-Claim
314	neutral	_	_	I-Claim
315	effects	_	_	I-Claim
316	on	_	_	I-Claim
317	cardiometabolic	_	_	I-Claim
318	risk	_	_	I-Claim
319	factors	_	_	I-Claim
320	.	_	_	I-Claim


0	To	_	_	O
1	investigate	_	_	O
2	the	_	_	O
3	effect	_	_	O
4	of	_	_	O
5	recombinant	_	_	O
6	human	_	_	O
7	erythropoietin	_	_	O
8	(	_	_	O
9	epoetin	_	_	O
10	beta	_	_	O
11	)	_	_	O
12	on	_	_	O
13	anemia	_	_	O
14	,	_	_	O
15	transfusion	_	_	O
16	need	_	_	O
17	,	_	_	O
18	and	_	_	O
19	quality	_	_	O
20	of	_	_	O
21	life	_	_	O
22	(	_	_	O
23	QOL	_	_	O
24	)	_	_	O
25	in	_	_	O
26	severely	_	_	O
27	anemic	_	_	O
28	patients	_	_	O
29	with	_	_	O
30	low-grade	_	_	O
31	non-Hodgkin	_	_	O
32	's	_	_	O
33	lymphoma	_	_	O
34	(	_	_	O
35	NHL	_	_	O
36	)	_	_	O
37	,	_	_	O
38	chronic	_	_	O
39	lymphocytic	_	_	O
40	leukemia	_	_	O
41	(	_	_	O
42	CLL	_	_	O
43	)	_	_	O
44	,	_	_	O
45	or	_	_	O
46	multiple	_	_	O
47	myeloma	_	_	O
48	(	_	_	O
49	MM	_	_	O
50	)	_	_	O
51	.	_	_	O

52	Transfusion-dependent	_	_	O
53	patients	_	_	O
54	with	_	_	O
55	NHL	_	_	O
56	(	_	_	O
57	n	_	_	O
58	=	_	_	O
59	106	_	_	O
60	)	_	_	O
61	,	_	_	O
62	CLL	_	_	O
63	(	_	_	O
64	n	_	_	O
65	=	_	_	O
66	126	_	_	O
67	)	_	_	O
68	,	_	_	O
69	or	_	_	O
70	MM	_	_	O
71	(	_	_	O
72	n	_	_	O
73	=	_	_	O
74	117	_	_	O
75	)	_	_	O
76	and	_	_	O
77	a	_	_	O
78	low	_	_	O
79	serum	_	_	O
80	erythropoietin	_	_	O
81	concentration	_	_	O
82	were	_	_	O
83	randomized	_	_	O
84	to	_	_	O
85	receive	_	_	O
86	epoetin	_	_	O
87	beta	_	_	O
88	150	_	_	O
89	IU/kg	_	_	O
90	or	_	_	O
91	placebo	_	_	O
92	subcutaneously	_	_	O
93	three	_	_	O
94	times	_	_	O
95	a	_	_	O
96	week	_	_	O
97	for	_	_	O
98	16	_	_	O
99	weeks	_	_	O
100	.	_	_	O

101	Primary	_	_	O
102	efficacy	_	_	O
103	criteria	_	_	O
104	were	_	_	O
105	transfusion-free	_	_	O
106	and	_	_	O
107	transfusion-	_	_	O
108	and	_	_	O
109	severe	_	_	O
110	anemia-free	_	_	O
111	survival	_	_	O
112	(	_	_	O
113	hemoglobin	_	_	O
114	[	_	_	O
115	Hb	_	_	O
116	]	_	_	O
117	>	_	_	O
118	8.5	_	_	O
119	g/dL	_	_	O
120	)	_	_	O
121	between	_	_	O
122	weeks	_	_	O
123	5	_	_	O
124	to	_	_	O
125	16	_	_	O
126	.	_	_	O

127	Response	_	_	O
128	was	_	_	O
129	defined	_	_	O
130	as	_	_	O
131	an	_	_	O
132	increase	_	_	O
133	in	_	_	O
134	Hb	_	_	O
135	>	_	_	O
136	or	_	_	O
137	=	_	_	O
138	2	_	_	O
139	g/dL	_	_	O
140	with	_	_	O
141	elimination	_	_	O
142	of	_	_	O
143	transfusion	_	_	O
144	need	_	_	O
145	.	_	_	O

146	QOL	_	_	O
147	was	_	_	O
148	assessed	_	_	O
149	by	_	_	O
150	the	_	_	O
151	Functional	_	_	O
152	Assessment	_	_	O
153	of	_	_	O
154	Cancer	_	_	O
155	Therapy	_	_	O
156	scale	_	_	O
157	.	_	_	O

158	Transfusion-free	_	_	B-Premise
159	(	_	_	I-Premise
160	P	_	_	I-Premise
161	=.0012	_	_	I-Premise
162	)	_	_	I-Premise
163	survival	_	_	I-Premise
164	and	_	_	I-Premise
165	transfusion-	_	_	I-Premise
166	and	_	_	I-Premise
167	severe	_	_	I-Premise
168	anemia-free	_	_	I-Premise
169	survival	_	_	I-Premise
170	(	_	_	I-Premise
171	P	_	_	I-Premise
172	=.0001	_	_	I-Premise
173	)	_	_	I-Premise
174	were	_	_	I-Premise
175	significantly	_	_	I-Premise
176	greater	_	_	I-Premise
177	in	_	_	I-Premise
178	the	_	_	I-Premise
179	epoetin	_	_	I-Premise
180	beta	_	_	I-Premise
181	group	_	_	I-Premise
182	versus	_	_	I-Premise
183	placebo	_	_	I-Premise
184	(	_	_	I-Premise
185	Wald	_	_	I-Premise
186	chi	_	_	I-Premise
187	(	_	_	I-Premise
188	2	_	_	I-Premise
189	)	_	_	I-Premise
190	test	_	_	I-Premise
191	)	_	_	I-Premise
192	,	_	_	I-Premise
193	giving	_	_	I-Premise
194	a	_	_	I-Premise
195	relative	_	_	I-Premise
196	risk	_	_	I-Premise
197	reduction	_	_	I-Premise
198	of	_	_	I-Premise
199	43	_	_	I-Premise
200	%	_	_	I-Premise
201	and	_	_	I-Premise
202	51	_	_	I-Premise
203	%	_	_	I-Premise
204	,	_	_	I-Premise
205	respectively	_	_	I-Premise
206	.	_	_	I-Premise

207	The	_	_	B-Premise
208	response	_	_	I-Premise
209	rate	_	_	I-Premise
210	was	_	_	I-Premise
211	67	_	_	I-Premise
212	%	_	_	I-Premise
213	and	_	_	I-Premise
214	27	_	_	I-Premise
215	%	_	_	I-Premise
216	in	_	_	I-Premise
217	the	_	_	I-Premise
218	epoetin	_	_	I-Premise
219	beta	_	_	I-Premise
220	versus	_	_	I-Premise
221	the	_	_	I-Premise
222	placebo	_	_	I-Premise
223	group	_	_	I-Premise
224	,	_	_	I-Premise
225	respectively	_	_	I-Premise
226	(	_	_	I-Premise
227	P	_	_	I-Premise
228	<	_	_	I-Premise
229	.0001	_	_	I-Premise
230	)	_	_	I-Premise
231	.	_	_	I-Premise

232	After	_	_	B-Premise
233	12	_	_	I-Premise
234	and	_	_	I-Premise
235	16	_	_	I-Premise
236	weeks	_	_	I-Premise
237	of	_	_	I-Premise
238	treatment	_	_	I-Premise
239	,	_	_	I-Premise
240	QOL	_	_	I-Premise
241	significantly	_	_	I-Premise
242	improved	_	_	I-Premise
243	in	_	_	I-Premise
244	the	_	_	I-Premise
245	epoetin	_	_	I-Premise
246	beta	_	_	I-Premise
247	group	_	_	I-Premise
248	compared	_	_	I-Premise
249	with	_	_	I-Premise
250	placebo	_	_	I-Premise
251	(	_	_	I-Premise
252	P	_	_	I-Premise
253	<	_	_	I-Premise
254	.05	_	_	I-Premise
255	)	_	_	I-Premise
256	;	_	_	I-Premise
257	this	_	_	B-Premise
258	improvement	_	_	I-Premise
259	correlated	_	_	I-Premise
260	with	_	_	I-Premise
261	an	_	_	I-Premise
262	increase	_	_	I-Premise
263	in	_	_	I-Premise
264	Hb	_	_	I-Premise
265	concentration	_	_	I-Premise
266	(	_	_	I-Premise
267	>	_	_	I-Premise
268	or	_	_	I-Premise
269	=	_	_	I-Premise
270	2	_	_	I-Premise
271	g/dL	_	_	I-Premise
272	)	_	_	I-Premise
273	.	_	_	I-Premise

274	A	_	_	O
275	target	_	_	O
276	Hb	_	_	O
277	that	_	_	O
278	could	_	_	O
279	be	_	_	O
280	generally	_	_	O
281	recommended	_	_	O
282	could	_	_	O
283	not	_	_	O
284	be	_	_	O
285	identified	_	_	O
286	.	_	_	O

287	Many	_	_	B-Claim
288	severely	_	_	I-Claim
289	anemic	_	_	I-Claim
290	and	_	_	I-Claim
291	transfusion-dependent	_	_	I-Claim
292	patients	_	_	I-Claim
293	with	_	_	I-Claim
294	advanced	_	_	I-Claim
295	MM	_	_	I-Claim
296	,	_	_	I-Claim
297	NHL	_	_	I-Claim
298	,	_	_	I-Claim
299	and	_	_	I-Claim
300	CLL	_	_	I-Claim
301	and	_	_	I-Claim
302	a	_	_	I-Claim
303	low	_	_	I-Claim
304	performance	_	_	I-Claim
305	status	_	_	I-Claim
306	benefited	_	_	I-Claim
307	from	_	_	I-Claim
308	epoetin	_	_	I-Claim
309	therapy	_	_	I-Claim
310	,	_	_	I-Claim
311	with	_	_	I-Claim
312	elimination	_	_	I-Claim
313	of	_	_	I-Claim
314	severe	_	_	I-Claim
315	anemia	_	_	I-Claim
316	and	_	_	I-Claim
317	transfusion	_	_	I-Claim
318	need	_	_	I-Claim
319	,	_	_	I-Claim
320	and	_	_	I-Claim
321	improvement	_	_	I-Claim
322	in	_	_	I-Claim
323	QOL	_	_	I-Claim
324	.	_	_	I-Claim


0	Efficacy	_	_	O
1	of	_	_	O
2	sequential	_	_	O
3	therapy	_	_	O
4	with	_	_	O
5	nucleos	_	_	O
6	(	_	_	O
7	t	_	_	O
8	)	_	_	O
9	ide	_	_	O
10	analogues	_	_	O
11	and	_	_	O
12	interferons	_	_	O
13	versus	_	_	O
14	monotherapy	_	_	O
15	in	_	_	O
16	patients	_	_	O
17	with	_	_	O
18	hepatitis	_	_	O
19	B	_	_	O
20	e	_	_	O
21	antigen	_	_	O
22	(	_	_	O
23	HBeAg	_	_	O
24	)	_	_	O
25	-positive	_	_	O
26	chronic	_	_	O
27	hepatitis	_	_	O
28	B	_	_	O
29	(	_	_	O
30	CHB	_	_	O
31	)	_	_	O
32	remains	_	_	O
33	unexplored	_	_	O
34	.	_	_	O

35	We	_	_	O
36	aimed	_	_	O
37	to	_	_	O
38	assess	_	_	O
39	efficacy	_	_	O
40	and	_	_	O
41	safety	_	_	O
42	of	_	_	O
43	sequential	_	_	O
44	therapy	_	_	O
45	with	_	_	O
46	adefovir	_	_	O
47	(	_	_	O
48	ADV	_	_	O
49	)	_	_	O
50	or	_	_	O
51	entecavir	_	_	O
52	(	_	_	O
53	ETV	_	_	O
54	)	_	_	O
55	followed	_	_	O
56	by	_	_	O
57	peginterferon	_	_	O
58	(	_	_	O
59	PEG-IFN	_	_	O
60	)	_	_	O
61	alfa-2a	_	_	O
62	in	_	_	O
63	Taiwanese	_	_	O
64	patients	_	_	O
65	with	_	_	O
66	HBeAg-positive	_	_	O
67	.	_	_	O

68	This	_	_	O
69	randomized	_	_	O
70	,	_	_	O
71	placebo-controlled	_	_	O
72	,	_	_	O
73	double-blind	_	_	O
74	trial	_	_	O
75	was	_	_	O
76	conducted	_	_	O
77	at	_	_	O
78	nine	_	_	O
79	sites	_	_	O
80	in	_	_	O
81	Taiwan	_	_	O
82	from	_	_	O
83	April	_	_	O
84	2010	_	_	O
85	to	_	_	O
86	October	_	_	O
87	2013	_	_	O
88	.	_	_	O

89	Patients	_	_	O
90	(	_	_	O
91	N	_	_	O
92	=	_	_	O
93	280	_	_	O
94	)	_	_	O
95	were	_	_	O
96	randomized	_	_	O
97	1:1:1	_	_	O
98	to	_	_	O
99	receive	_	_	O
100	placebo	_	_	O
101	,	_	_	O
102	ETV	_	_	O
103	or	_	_	O
104	ADV	_	_	O
105	alone	_	_	O
106	for	_	_	O
107	four	_	_	O
108	weeks	_	_	O
109	,	_	_	O
110	combined	_	_	O
111	with	_	_	O
112	PEG-IFN	_	_	O
113	alfa-2a	_	_	O
114	for	_	_	O
115	two	_	_	O
116	weeks	_	_	O
117	,	_	_	O
118	then	_	_	O
119	PEG-IFN	_	_	O
120	alfa-2a	_	_	O
121	alone	_	_	O
122	for	_	_	O
123	46	_	_	O
124	weeks	_	_	O
125	.	_	_	O

126	The	_	_	O
127	primary	_	_	O
128	efficacy	_	_	O
129	end	_	_	O
130	point	_	_	O
131	was	_	_	O
132	HBeAg	_	_	O
133	seroconversion	_	_	O
134	at	_	_	O
135	48	_	_	O
136	weeks	_	_	O
137	post-treatment	_	_	O
138	.	_	_	O

139	No	_	_	B-Premise
140	significant	_	_	I-Premise
141	differences	_	_	I-Premise
142	were	_	_	I-Premise
143	observed	_	_	I-Premise
144	among	_	_	I-Premise
145	groups	_	_	I-Premise
146	for	_	_	I-Premise
147	HBeAg	_	_	I-Premise
148	seroconversion	_	_	I-Premise
149	(	_	_	I-Premise
150	PEG-IFN	_	_	I-Premise
151	alfa-2a+placebo	_	_	I-Premise
152	,	_	_	I-Premise
153	36.3	_	_	I-Premise
154	%	_	_	I-Premise
155	;	_	_	I-Premise
156	PEG-IFN	_	_	I-Premise
157	alfa-2a+ETV	_	_	I-Premise
158	,	_	_	I-Premise
159	29.5	_	_	I-Premise
160	%	_	_	I-Premise
161	;	_	_	I-Premise
162	and	_	_	I-Premise
163	PEG-IFN	_	_	I-Premise
164	alfa-2a+ADV	_	_	I-Premise
165	,	_	_	I-Premise
166	27.4	_	_	I-Premise
167	%	_	_	I-Premise
168	)	_	_	I-Premise
169	,	_	_	I-Premise
170	HBeAg	_	_	I-Premise
171	loss	_	_	I-Premise
172	(	_	_	I-Premise
173	37.4	_	_	I-Premise
174	%	_	_	I-Premise
175	,	_	_	I-Premise
176	32.2	_	_	I-Premise
177	%	_	_	I-Premise
178	,	_	_	I-Premise
179	and	_	_	I-Premise
180	28.6	_	_	I-Premise
181	%	_	_	I-Premise
182	,	_	_	I-Premise
183	respectively	_	_	I-Premise
184	)	_	_	I-Premise
185	or	_	_	I-Premise
186	change	_	_	I-Premise
187	in	_	_	I-Premise
188	hepatitis	_	_	I-Premise
189	B	_	_	I-Premise
190	surface	_	_	I-Premise
191	antigen	_	_	I-Premise
192	(	_	_	I-Premise
193	HBsAg	_	_	I-Premise
194	)	_	_	I-Premise
195	levels	_	_	I-Premise
196	from	_	_	I-Premise
197	baseline	_	_	I-Premise
198	(	_	_	I-Premise
199	-0.56	_	_	I-Premise
200	IU/mL	_	_	I-Premise
201	,	_	_	I-Premise
202	-0.60	_	_	I-Premise
203	IU/mL	_	_	I-Premise
204	,	_	_	I-Premise
205	and	_	_	I-Premise
206	-0.41	_	_	I-Premise
207	IU/mL	_	_	I-Premise
208	,	_	_	I-Premise
209	respectively	_	_	I-Premise
210	)	_	_	I-Premise
211	.	_	_	I-Premise

212	However	_	_	B-Premise
213	,	_	_	I-Premise
214	hepatitis	_	_	I-Premise
215	B	_	_	I-Premise
216	virus	_	_	I-Premise
217	DNA	_	_	I-Premise
218	levels	_	_	I-Premise
219	were	_	_	I-Premise
220	higher	_	_	I-Premise
221	with	_	_	I-Premise
222	PEG-IFN	_	_	I-Premise
223	alfa-2a+placebo	_	_	I-Premise
224	than	_	_	I-Premise
225	PEG-IFN	_	_	I-Premise
226	alfa+ETV	_	_	I-Premise
227	at	_	_	I-Premise
228	week	_	_	I-Premise
229	64	_	_	I-Premise
230	(	_	_	I-Premise
231	p	_	_	I-Premise
232	=	_	_	I-Premise
233	0.0412	_	_	I-Premise
234	)	_	_	I-Premise
235	,	_	_	I-Premise
236	76	_	_	I-Premise
237	(	_	_	I-Premise
238	p	_	_	I-Premise
239	=	_	_	I-Premise
240	0.0311	_	_	I-Premise
241	)	_	_	I-Premise
242	,	_	_	I-Premise
243	and	_	_	I-Premise
244	88	_	_	I-Premise
245	(	_	_	I-Premise
246	p	_	_	I-Premise
247	=	_	_	I-Premise
248	0.0113	_	_	I-Premise
249	)	_	_	I-Premise
250	,	_	_	I-Premise
251	and	_	_	I-Premise
252	alanine	_	_	I-Premise
253	aminotransferase	_	_	I-Premise
254	(	_	_	I-Premise
255	ALT	_	_	I-Premise
256	)	_	_	I-Premise
257	normalization	_	_	I-Premise
258	rate	_	_	I-Premise
259	was	_	_	I-Premise
260	higher	_	_	I-Premise
261	with	_	_	I-Premise
262	PEG-IFN	_	_	I-Premise
263	alfa-2a+placebo	_	_	I-Premise
264	than	_	_	I-Premise
265	PEG-IFN	_	_	I-Premise
266	alfa-2a+ADV	_	_	I-Premise
267	(	_	_	I-Premise
268	p	_	_	I-Premise
269	=	_	_	I-Premise
270	0.0283	_	_	I-Premise
271	)	_	_	I-Premise
272	or	_	_	I-Premise
273	PEG-IFN	_	_	I-Premise
274	alfa-2a+ETV	_	_	I-Premise
275	(	_	_	I-Premise
276	p	_	_	I-Premise
277	=	_	_	I-Premise
278	0.0369	_	_	I-Premise
279	)	_	_	I-Premise
280	at	_	_	I-Premise
281	week	_	_	I-Premise
282	88	_	_	I-Premise
283	.	_	_	I-Premise

284	Sub-analysis	_	_	B-Premise
285	of	_	_	I-Premise
286	results	_	_	I-Premise
287	revealed	_	_	I-Premise
288	an	_	_	I-Premise
289	association	_	_	I-Premise
290	between	_	_	I-Premise
291	on-treatment	_	_	I-Premise
292	HBsAg	_	_	I-Premise
293	and	_	_	I-Premise
294	ALT	_	_	I-Premise
295	levels	_	_	I-Premise
296	and	_	_	I-Premise
297	efficacy	_	_	I-Premise
298	48	_	_	I-Premise
299	weeks	_	_	I-Premise
300	post-treatment	_	_	I-Premise
301	.	_	_	I-Premise

302	Safety	_	_	B-Premise
303	was	_	_	I-Premise
304	comparable	_	_	I-Premise
305	among	_	_	I-Premise
306	treatment	_	_	I-Premise
307	groups	_	_	I-Premise
308	.	_	_	I-Premise

309	Pre-therapy	_	_	B-Claim
310	with	_	_	I-Claim
311	ADV	_	_	I-Claim
312	or	_	_	I-Claim
313	ETV	_	_	I-Claim
314	followed	_	_	I-Claim
315	by	_	_	I-Claim
316	PEG-IFN	_	_	I-Claim
317	alfa-2a	_	_	I-Claim
318	is	_	_	I-Claim
319	not	_	_	I-Claim
320	superior	_	_	I-Claim
321	to	_	_	I-Claim
322	PEG-IFN	_	_	I-Claim
323	alfa-2a	_	_	I-Claim
324	monotherapy	_	_	I-Claim
325	in	_	_	I-Claim
326	Taiwanese	_	_	I-Claim
327	patients	_	_	I-Claim
328	with	_	_	I-Claim
329	HBeAg-positive	_	_	I-Claim
330	CHB	_	_	I-Claim
331	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	comparatively	_	_	O
3	,	_	_	O
4	in	_	_	O
5	terms	_	_	O
6	of	_	_	O
7	quality-adjusted	_	_	O
8	survival	_	_	O
9	,	_	_	O
10	three	_	_	O
11	front-line	_	_	O
12	treatments	_	_	O
13	in	_	_	O
14	patients	_	_	O
15	with	_	_	O
16	stage	_	_	O
17	B-	_	_	O
18	or	_	_	O
19	C-chronic	_	_	O
20	lymphocytic	_	_	O
21	leukemia	_	_	O
22	(	_	_	O
23	CLL	_	_	O
24	)	_	_	O
25	.	_	_	O

26	To	_	_	O
27	describe	_	_	O
28	better	_	_	O
29	and	_	_	O
30	compare	_	_	O
31	the	_	_	O
32	survival	_	_	O
33	after	_	_	O
34	randomization	_	_	O
35	of	_	_	O
36	patients	_	_	O
37	from	_	_	O
38	the	_	_	O
39	CLL90	_	_	O
40	trial	_	_	O
41	that	_	_	O
42	randomly	_	_	O
43	compared	_	_	O
44	ChOP	_	_	O
45	(	_	_	O
46	cyclophosphamide	_	_	O
47	,	_	_	O
48	doxorubicin	_	_	O
49	,	_	_	O
50	oncovin	_	_	O
51	,	_	_	O
52	prednisone	_	_	O
53	)	_	_	O
54	,	_	_	O
55	CAP	_	_	O
56	(	_	_	O
57	cyclophosphamide	_	_	O
58	,	_	_	O
59	doxorubicin	_	_	O
60	,	_	_	O
61	prednisone	_	_	O
62	)	_	_	O
63	and	_	_	O
64	fludarabine	_	_	O
65	in	_	_	O
66	advanced	_	_	O
67	CLL	_	_	O
68	,	_	_	O
69	we	_	_	O
70	performed	_	_	O
71	a	_	_	O
72	quality-adjusted	_	_	O
73	survival	_	_	O
74	analysis	_	_	O
75	.	_	_	O

76	This	_	_	O
77	consisted	_	_	O
78	of	_	_	O
79	defining	_	_	O
80	four	_	_	O
81	clinical	_	_	O
82	states	_	_	O
83	(	_	_	O
84	toxicity	_	_	O
85	,	_	_	O
86	treatment	_	_	O
87	free	_	_	O
88	of	_	_	O
89	toxicity	_	_	O
90	,	_	_	O
91	no	_	_	O
92	treatment	_	_	O
93	nor	_	_	O
94	symptoms	_	_	O
95	,	_	_	O
96	relapse	_	_	O
97	)	_	_	O
98	,	_	_	O
99	then	_	_	O
100	summing	_	_	O
101	up	_	_	O
102	the	_	_	O
103	average	_	_	O
104	times	_	_	O
105	spent	_	_	O
106	in	_	_	O
107	each	_	_	O
108	state	_	_	O
109	weighted	_	_	O
110	by	_	_	O
111	utility	_	_	O
112	coefficients	_	_	O
113	that	_	_	O
114	reflect	_	_	O
115	relative	_	_	O
116	value	_	_	O
117	according	_	_	O
118	to	_	_	O
119	quality	_	_	O
120	of	_	_	O
121	life	_	_	O
122	.	_	_	O

123	The	_	_	O
124	resulting	_	_	O
125	quality-adjusted	_	_	O
126	time	_	_	O
127	without	_	_	O
128	symptoms	_	_	O
129	or	_	_	O
130	toxicity	_	_	O
131	(	_	_	O
132	Q-TWIST	_	_	O
133	)	_	_	O
134	was	_	_	O
135	compared	_	_	O
136	between	_	_	O
137	randomized	_	_	O
138	groups	_	_	O
139	,	_	_	O
140	and	_	_	O
141	sensitivity	_	_	O
142	(	_	_	O
143	threshold	_	_	O
144	)	_	_	O
145	analyses	_	_	O
146	to	_	_	O
147	the	_	_	O
148	choice	_	_	O
149	of	_	_	O
150	utility	_	_	O
151	coefficients	_	_	O
152	was	_	_	O
153	performed	_	_	O
154	.	_	_	O

155	Over	_	_	B-Premise
156	73	_	_	I-Premise
157	months	_	_	I-Premise
158	after	_	_	I-Premise
159	randomization	_	_	I-Premise
160	,	_	_	I-Premise
161	the	_	_	I-Premise
162	fludarabine	_	_	I-Premise
163	group	_	_	I-Premise
164	gained	_	_	I-Premise
165	a	_	_	I-Premise
166	mean	_	_	I-Premise
167	of	_	_	I-Premise
168	45	_	_	I-Premise
169	days	_	_	I-Premise
170	of	_	_	I-Premise
171	toxicity-free	_	_	I-Premise
172	survival	_	_	I-Premise
173	at	_	_	I-Premise
174	CAP	_	_	I-Premise
175	,	_	_	I-Premise
176	and	_	_	I-Premise
177	61	_	_	I-Premise
178	days	_	_	I-Premise
179	over	_	_	I-Premise
180	ChOP	_	_	I-Premise
181	.	_	_	I-Premise

182	The	_	_	B-Premise
183	mean	_	_	I-Premise
184	TWIST	_	_	I-Premise
185	was	_	_	I-Premise
186	27.05	_	_	I-Premise
187	months	_	_	I-Premise
188	with	_	_	I-Premise
189	CAP	_	_	I-Premise
190	,	_	_	I-Premise
191	31.5	_	_	I-Premise
192	months	_	_	I-Premise
193	with	_	_	I-Premise
194	ChOP	_	_	I-Premise
195	and	_	_	I-Premise
196	32.95	_	_	I-Premise
197	months	_	_	I-Premise
198	with	_	_	I-Premise
199	fludarabine	_	_	I-Premise
200	.	_	_	I-Premise

201	The	_	_	B-Premise
202	threshold	_	_	I-Premise
203	analyses	_	_	I-Premise
204	showed	_	_	I-Premise
205	that	_	_	I-Premise
206	,	_	_	I-Premise
207	whatever	_	_	I-Premise
208	the	_	_	I-Premise
209	utility	_	_	I-Premise
210	weights	_	_	I-Premise
211	,	_	_	I-Premise
212	the	_	_	I-Premise
213	mean	_	_	I-Premise
214	Q-TWIST	_	_	I-Premise
215	was	_	_	I-Premise
216	always	_	_	I-Premise
217	greater	_	_	I-Premise
218	with	_	_	I-Premise
219	ChOP	_	_	I-Premise
220	or	_	_	I-Premise
221	fludarabine	_	_	I-Premise
222	as	_	_	I-Premise
223	compared	_	_	I-Premise
224	to	_	_	I-Premise
225	CAP	_	_	I-Premise
226	.	_	_	I-Premise

227	Fludarabine	_	_	B-Claim
228	was	_	_	I-Claim
229	consistently	_	_	I-Claim
230	a	_	_	I-Claim
231	better	_	_	I-Claim
232	treatment	_	_	I-Claim
233	than	_	_	I-Claim
234	ChOP	_	_	I-Claim
235	,	_	_	I-Claim
236	except	_	_	B-Premise
237	in	_	_	I-Premise
238	the	_	_	I-Premise
239	unlikely	_	_	I-Premise
240	case	_	_	I-Premise
241	of	_	_	I-Premise
242	high	_	_	I-Premise
243	utility	_	_	I-Premise
244	weights	_	_	I-Premise
245	attributed	_	_	I-Premise
246	to	_	_	I-Premise
247	toxicity	_	_	I-Premise
248	and	_	_	I-Premise
249	low	_	_	I-Premise
250	utility	_	_	I-Premise
251	weights	_	_	I-Premise
252	attributed	_	_	I-Premise
253	to	_	_	I-Premise
254	treatment	_	_	I-Premise
255	.	_	_	I-Premise

256	Nevertheless	_	_	O
257	,	_	_	O
258	from	_	_	B-Premise
259	a	_	_	I-Premise
260	clinical	_	_	I-Premise
261	point	_	_	I-Premise
262	of	_	_	I-Premise
263	view	_	_	I-Premise
264	,	_	_	I-Premise
265	differences	_	_	I-Premise
266	between	_	_	I-Premise
267	ChOP	_	_	I-Premise
268	and	_	_	I-Premise
269	fludarabine	_	_	I-Premise
270	were	_	_	I-Premise
271	moderate	_	_	I-Premise
272	or	_	_	I-Premise
273	event	_	_	I-Premise
274	slight	_	_	I-Premise
275	(	_	_	I-Premise
276	mean	_	_	I-Premise
277	difference	_	_	I-Premise
278	in	_	_	I-Premise
279	TWIST	_	_	I-Premise
280	of	_	_	I-Premise
281	1.45	_	_	I-Premise
282	months	_	_	I-Premise
283	)	_	_	I-Premise
284	.	_	_	I-Premise

285	We	_	_	O
286	conclude	_	_	O
287	that	_	_	O
288	patients	_	_	B-Claim
289	with	_	_	I-Claim
290	advanced	_	_	I-Claim
291	CLL	_	_	I-Claim
292	have	_	_	I-Claim
293	a	_	_	I-Claim
294	moderate	_	_	I-Claim
295	benefit	_	_	I-Claim
296	in	_	_	I-Claim
297	terms	_	_	I-Claim
298	of	_	_	I-Claim
299	Q-TWIST	_	_	I-Claim
300	when	_	_	I-Claim
301	treated	_	_	I-Claim
302	with	_	_	I-Claim
303	fludarabine	_	_	I-Claim
304	over	_	_	I-Claim
305	ChOP	_	_	I-Claim
306	.	_	_	I-Claim

307	These	_	_	B-Claim
308	two	_	_	I-Claim
309	treatments	_	_	I-Claim
310	are	_	_	I-Claim
311	always	_	_	I-Claim
312	superior	_	_	I-Claim
313	to	_	_	I-Claim
314	CAP	_	_	I-Claim
315	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	of	_	_	O
5	bimatoprost/timolol	_	_	O
6	(	_	_	O
7	BTFC	_	_	O
8	)	_	_	O
9	or	_	_	O
10	travoprost/timolol	_	_	O
11	(	_	_	O
12	TTFC	_	_	O
13	)	_	_	O
14	fixed	_	_	O
15	combinations	_	_	O
16	on	_	_	O
17	intraocular	_	_	O
18	pressure	_	_	O
19	(	_	_	O
20	IOP	_	_	O
21	)	_	_	O
22	reduction	_	_	O
23	in	_	_	O
24	an	_	_	O
25	Egyptian	_	_	O
26	population	_	_	O
27	.	_	_	O

28	Patients	_	_	O
29	with	_	_	O
30	primary	_	_	O
31	open	_	_	O
32	angle	_	_	O
33	glaucoma	_	_	O
34	were	_	_	O
35	randomized	_	_	O
36	to	_	_	O
37	receive	_	_	O
38	either	_	_	O
39	BTFC	_	_	O
40	or	_	_	O
41	TTFC	_	_	O
42	.	_	_	O

43	IOPs	_	_	O
44	were	_	_	O
45	measured	_	_	O
46	at	_	_	O
47	baseline	_	_	O
48	,	_	_	O
49	2	_	_	O
50	weeks	_	_	O
51	,	_	_	O
52	and	_	_	O
53	1	_	_	O
54	,	_	_	O
55	2	_	_	O
56	,	_	_	O
57	4	_	_	O
58	,	_	_	O
59	and	_	_	O
60	6	_	_	O
61	months	_	_	O
62	.	_	_	O

63	The	_	_	O
64	primary	_	_	O
65	outcome	_	_	O
66	measure	_	_	O
67	was	_	_	O
68	the	_	_	O
69	mean	_	_	O
70	change	_	_	O
71	in	_	_	O
72	IOP	_	_	O
73	from	_	_	O
74	baseline	_	_	O
75	at	_	_	O
76	each	_	_	O
77	visit	_	_	O
78	.	_	_	O

79	Secondary	_	_	O
80	outcome	_	_	O
81	measures	_	_	O
82	included	_	_	O
83	the	_	_	O
84	incidence	_	_	O
85	of	_	_	O
86	adverse	_	_	O
87	events	_	_	O
88	.	_	_	O

89	Eighty	_	_	O
90	patients	_	_	O
91	(	_	_	O
92	80	_	_	O
93	eyes	_	_	O
94	)	_	_	O
95	were	_	_	O
96	included	_	_	O
97	finally	_	_	O
98	:	_	_	O
99	40	_	_	O
100	eyes	_	_	O
101	in	_	_	O
102	each	_	_	O
103	group	_	_	O
104	.	_	_	O

105	Baseline	_	_	O
106	mean	_	_	O
107	IOPs	_	_	O
108	were	_	_	O
109	24.78±3.53	_	_	O
110	and	_	_	O
111	25.26±3.51	_	_	O
112	mm	_	_	O
113	Hg	_	_	O
114	for	_	_	O
115	BTFC	_	_	O
116	and	_	_	O
117	TTFC	_	_	O
118	,	_	_	O
119	respectively	_	_	O
120	(	_	_	O
121	P=0.344	_	_	O
122	)	_	_	O
123	.	_	_	O

124	Both	_	_	B-Premise
125	drops	_	_	I-Premise
126	provided	_	_	I-Premise
127	statistically	_	_	I-Premise
128	significant	_	_	I-Premise
129	IOP	_	_	I-Premise
130	reductions	_	_	I-Premise
131	from	_	_	I-Premise
132	baseline	_	_	I-Premise
133	at	_	_	I-Premise
134	all	_	_	I-Premise
135	visits	_	_	I-Premise
136	(	_	_	I-Premise
137	P	_	_	I-Premise
138	<	_	_	I-Premise
139	0.001	_	_	I-Premise
140	)	_	_	I-Premise
141	.	_	_	I-Premise

142	BTFC	_	_	B-Premise
143	provided	_	_	I-Premise
144	greater	_	_	I-Premise
145	significant	_	_	I-Premise
146	mean	_	_	I-Premise
147	IOP	_	_	I-Premise
148	reductions	_	_	I-Premise
149	from	_	_	I-Premise
150	baseline	_	_	I-Premise
151	than	_	_	I-Premise
152	TTFC	_	_	I-Premise
153	at	_	_	I-Premise
154	each	_	_	I-Premise
155	visit	_	_	I-Premise
156	(	_	_	I-Premise
157	P	_	_	I-Premise
158	<	_	_	I-Premise
159	0.001	_	_	I-Premise
160	)	_	_	I-Premise
161	.	_	_	I-Premise

162	Mean	_	_	B-Premise
163	IOP	_	_	I-Premise
164	reductions	_	_	I-Premise
165	were	_	_	I-Premise
166	11.34	_	_	I-Premise
167	and	_	_	I-Premise
168	6.42	_	_	I-Premise
169	mm	_	_	I-Premise
170	Hg	_	_	I-Premise
171	at	_	_	I-Premise
172	2	_	_	I-Premise
173	weeks	_	_	I-Premise
174	(	_	_	I-Premise
175	P=0.000	_	_	I-Premise
176	)	_	_	I-Premise
177	,	_	_	I-Premise
178	and	_	_	I-Premise
179	11.17	_	_	I-Premise
180	and	_	_	I-Premise
181	7.89	_	_	I-Premise
182	mmHg	_	_	I-Premise
183	at	_	_	I-Premise
184	6	_	_	I-Premise
185	months	_	_	I-Premise
186	(	_	_	I-Premise
187	P=0.001	_	_	I-Premise
188	)	_	_	I-Premise
189	for	_	_	I-Premise
190	BTFC	_	_	I-Premise
191	and	_	_	I-Premise
192	TTFC	_	_	I-Premise
193	,	_	_	I-Premise
194	respectively	_	_	I-Premise
195	.	_	_	I-Premise

196	IOPs	_	_	B-Premise
197	at	_	_	I-Premise
198	2	_	_	I-Premise
199	weeks	_	_	I-Premise
200	were	_	_	I-Premise
201	18	_	_	I-Premise
202	mm	_	_	I-Premise
203	Hg	_	_	I-Premise
204	in	_	_	I-Premise
205	36	_	_	I-Premise
206	(	_	_	I-Premise
207	90.8	_	_	I-Premise
208	%	_	_	I-Premise
209	)	_	_	I-Premise
210	versus	_	_	I-Premise
211	22	_	_	I-Premise
212	(	_	_	I-Premise
213	55	_	_	I-Premise
214	%	_	_	I-Premise
215	)	_	_	I-Premise
216	eyes	_	_	I-Premise
217	and	_	_	I-Premise
218	16	_	_	I-Premise
219	mm	_	_	I-Premise
220	Hg	_	_	I-Premise
221	in	_	_	I-Premise
222	28	_	_	I-Premise
223	(	_	_	I-Premise
224	70	_	_	I-Premise
225	%	_	_	I-Premise
226	)	_	_	I-Premise
227	versus	_	_	I-Premise
228	16	_	_	I-Premise
229	(	_	_	I-Premise
230	40	_	_	I-Premise
231	%	_	_	I-Premise
232	)	_	_	I-Premise
233	eyes	_	_	I-Premise
234	(	_	_	I-Premise
235	P	_	_	I-Premise
236	<	_	_	I-Premise
237	0.001	_	_	I-Premise
238	)	_	_	I-Premise
239	,	_	_	I-Premise
240	and	_	_	I-Premise
241	at	_	_	I-Premise
242	6	_	_	I-Premise
243	months	_	_	I-Premise
244	,	_	_	I-Premise
245	18	_	_	I-Premise
246	mm	_	_	I-Premise
247	Hg	_	_	I-Premise
248	in	_	_	I-Premise
249	38	_	_	I-Premise
250	(	_	_	I-Premise
251	95	_	_	I-Premise
252	%	_	_	I-Premise
253	)	_	_	I-Premise
254	versus	_	_	I-Premise
255	28	_	_	I-Premise
256	(	_	_	I-Premise
257	70	_	_	I-Premise
258	%	_	_	I-Premise
259	)	_	_	I-Premise
260	eyes	_	_	I-Premise
261	and	_	_	I-Premise
262	16	_	_	I-Premise
263	mm	_	_	I-Premise
264	Hg	_	_	I-Premise
265	in	_	_	I-Premise
266	30	_	_	I-Premise
267	(	_	_	I-Premise
268	75	_	_	I-Premise
269	%	_	_	I-Premise
270	)	_	_	I-Premise
271	versus	_	_	I-Premise
272	18	_	_	I-Premise
273	(	_	_	I-Premise
274	45	_	_	I-Premise
275	%	_	_	I-Premise
276	)	_	_	I-Premise
277	eyes	_	_	I-Premise
278	for	_	_	I-Premise
279	BTFC	_	_	I-Premise
280	and	_	_	I-Premise
281	TTFC	_	_	I-Premise
282	,	_	_	I-Premise
283	respectively	_	_	I-Premise
284	(	_	_	I-Premise
285	P	_	_	I-Premise
286	<	_	_	I-Premise
287	0.001	_	_	I-Premise
288	)	_	_	I-Premise
289	.	_	_	I-Premise

290	Both	_	_	B-Claim
291	drops	_	_	I-Claim
292	provided	_	_	I-Claim
293	effective	_	_	I-Claim
294	IOP	_	_	I-Claim
295	reduction	_	_	I-Claim
296	that	_	_	I-Claim
297	was	_	_	I-Claim
298	greater	_	_	I-Claim
299	and	_	_	O
300	patients	_	_	B-Claim
301	were	_	_	I-Claim
302	more	_	_	I-Claim
303	likely	_	_	I-Claim
304	to	_	_	I-Claim
305	achieve	_	_	I-Claim
306	lower	_	_	I-Claim
307	target	_	_	I-Claim
308	pressures	_	_	I-Claim
309	with	_	_	I-Claim
310	BTFC	_	_	I-Claim
311	than	_	_	I-Claim
312	with	_	_	I-Claim
313	TTFC	_	_	I-Claim
314	.	_	_	I-Claim


0	Despite	_	_	O
1	the	_	_	O
2	lack	_	_	O
3	of	_	_	O
4	evidence	_	_	O
5	,	_	_	O
6	a	_	_	O
7	growing	_	_	O
8	number	_	_	O
9	of	_	_	O
10	people	_	_	O
11	are	_	_	O
12	using	_	_	O
13	herbal	_	_	O
14	medicine	_	_	O
15	to	_	_	O
16	attenuate	_	_	O
17	the	_	_	O
18	burden	_	_	O
19	of	_	_	O
20	diabetes	_	_	O
21	.	_	_	O

22	There	_	_	O
23	is	_	_	O
24	an	_	_	O
25	urgent	_	_	O
26	need	_	_	O
27	to	_	_	O
28	investigate	_	_	O
29	the	_	_	O
30	clinical	_	_	O
31	potential	_	_	O
32	of	_	_	O
33	herbs	_	_	O
34	.	_	_	O

35	Preliminary	_	_	O
36	observations	_	_	O
37	suggest	_	_	O
38	that	_	_	O
39	American	_	_	O
40	ginseng	_	_	O
41	(	_	_	O
42	Panax	_	_	O
43	quinquefolius	_	_	O
44	[	_	_	O
45	AG	_	_	O
46	]	_	_	O
47	)	_	_	O
48	may	_	_	O
49	reduce	_	_	O
50	postprandial	_	_	O
51	glycemia	_	_	O
52	.	_	_	O

53	Thus	_	_	O
54	,	_	_	O
55	we	_	_	O
56	aimed	_	_	O
57	to	_	_	O
58	evaluate	_	_	O
59	the	_	_	O
60	efficacy	_	_	O
61	and	_	_	O
62	safety	_	_	O
63	of	_	_	O
64	AG	_	_	O
65	as	_	_	O
66	an	_	_	O
67	add-on	_	_	O
68	therapy	_	_	O
69	in	_	_	O
70	individuals	_	_	O
71	with	_	_	O
72	type	_	_	O
73	2	_	_	O
74	diabetes	_	_	O
75	(	_	_	O
76	T2DM	_	_	O
77	)	_	_	O
78	controlled	_	_	O
79	by	_	_	O
80	conventional	_	_	O
81	treatment	_	_	O
82	.	_	_	O

83	24	_	_	O
84	individuals	_	_	O
85	living	_	_	O
86	with	_	_	O
87	T2DM	_	_	O
88	completed	_	_	O
89	the	_	_	O
90	study	_	_	O
91	(	_	_	O
92	F	_	_	O
93	:	_	_	O
94	M	_	_	O
95	=	_	_	O
96	11:13	_	_	O
97	;	_	_	O
98	age	_	_	O
99	=	_	_	O
100	64	_	_	O
101	±	_	_	O
102	7	_	_	O
103	year	_	_	O
104	;	_	_	O
105	BMI	_	_	O
106	=	_	_	O
107	27.8	_	_	O
108	±	_	_	O
109	4.6	_	_	O
110	kg/m2	_	_	O
111	;	_	_	O
112	HbA1c	_	_	O
113	=	_	_	O
114	7.1	_	_	O
115	±	_	_	O
116	1.2	_	_	O
117	%	_	_	O
118	)	_	_	O
119	.	_	_	O

120	Utilizing	_	_	O
121	a	_	_	O
122	double-blind	_	_	O
123	,	_	_	O
124	cross-over	_	_	O
125	design	_	_	O
126	,	_	_	O
127	the	_	_	O
128	participants	_	_	O
129	were	_	_	O
130	randomized	_	_	O
131	to	_	_	O
132	receive	_	_	O
133	either	_	_	O
134	1	_	_	O
135	g/meal	_	_	O
136	(	_	_	O
137	3	_	_	O
138	g/day	_	_	O
139	)	_	_	O
140	of	_	_	O
141	AG	_	_	O
142	extract	_	_	O
143	or	_	_	O
144	placebo	_	_	O
145	for	_	_	O
146	8	_	_	O
147	weeks	_	_	O
148	while	_	_	O
149	maintaining	_	_	O
150	their	_	_	O
151	original	_	_	O
152	treatment	_	_	O
153	.	_	_	O

154	Following	_	_	O
155	a	_	_	O
156	≥	_	_	O
157	4-week	_	_	O
158	washout	_	_	O
159	period	_	_	O
160	,	_	_	O
161	the	_	_	O
162	participants	_	_	O
163	were	_	_	O
164	crossed	_	_	O
165	over	_	_	O
166	to	_	_	O
167	the	_	_	O
168	opposite	_	_	O
169	8-week	_	_	O
170	treatment	_	_	O
171	arm	_	_	O
172	.	_	_	O

173	The	_	_	O
174	primary	_	_	O
175	objective	_	_	O
176	was	_	_	O
177	HbA1c	_	_	O
178	,	_	_	O
179	and	_	_	O
180	secondary	_	_	O
181	endpoints	_	_	O
182	included	_	_	O
183	fasting	_	_	O
184	blood	_	_	O
185	glucose	_	_	O
186	and	_	_	O
187	insulin	_	_	O
188	,	_	_	O
189	blood	_	_	O
190	pressure	_	_	O
191	,	_	_	O
192	plasma	_	_	O
193	lipids	_	_	O
194	,	_	_	O
195	serum	_	_	O
196	nitrates/nitrites	_	_	O
197	(	_	_	O
198	NOx	_	_	O
199	)	_	_	O
200	,	_	_	O
201	and	_	_	O
202	plasominogen-activating	_	_	O
203	factor-1	_	_	O
204	(	_	_	O
205	PAI-1	_	_	O
206	)	_	_	O
207	.	_	_	O

208	Safety	_	_	O
209	parameters	_	_	O
210	included	_	_	O
211	liver	_	_	O
212	and	_	_	O
213	kidney	_	_	O
214	function	_	_	O
215	.	_	_	O

216	Compared	_	_	B-Premise
217	to	_	_	I-Premise
218	placebo	_	_	I-Premise
219	,	_	_	I-Premise
220	AG	_	_	I-Premise
221	significantly	_	_	I-Premise
222	reduced	_	_	I-Premise
223	HbA1c	_	_	I-Premise
224	(	_	_	I-Premise
225	-	_	_	I-Premise
226	0.29	_	_	I-Premise
227	%	_	_	I-Premise
228	;	_	_	I-Premise
229	p	_	_	I-Premise
230	=	_	_	I-Premise
231	0.041	_	_	I-Premise
232	)	_	_	I-Premise
233	and	_	_	I-Premise
234	fasting	_	_	I-Premise
235	blood	_	_	I-Premise
236	glucose	_	_	I-Premise
237	(	_	_	I-Premise
238	-	_	_	I-Premise
239	0.71	_	_	I-Premise
240	mmol/L	_	_	I-Premise
241	;	_	_	I-Premise
242	p	_	_	I-Premise
243	=	_	_	I-Premise
244	0.008	_	_	I-Premise
245	)	_	_	I-Premise
246	.	_	_	I-Premise

247	Furthermore	_	_	O
248	,	_	_	O
249	AG	_	_	B-Premise
250	lowered	_	_	I-Premise
251	systolic	_	_	I-Premise
252	blood	_	_	I-Premise
253	pressure	_	_	I-Premise
254	(	_	_	I-Premise
255	-	_	_	I-Premise
256	5.6	_	_	I-Premise
257	±	_	_	I-Premise
258	2.7	_	_	I-Premise
259	mmHg	_	_	I-Premise
260	;	_	_	I-Premise
261	p	_	_	I-Premise
262	<	_	_	I-Premise
263	0.001	_	_	I-Premise
264	)	_	_	I-Premise
265	,	_	_	I-Premise
266	increased	_	_	I-Premise
267	NOx	_	_	I-Premise
268	(	_	_	I-Premise
269	+	_	_	I-Premise
270	1.85	_	_	I-Premise
271	±	_	_	I-Premise
272	2.13	_	_	I-Premise
273	µmol/L	_	_	I-Premise
274	;	_	_	I-Premise
275	p	_	_	I-Premise
276	<	_	_	I-Premise
277	0.03	_	_	I-Premise
278	)	_	_	I-Premise
279	,	_	_	I-Premise
280	and	_	_	I-Premise
281	produced	_	_	I-Premise
282	a	_	_	I-Premise
283	mean	_	_	I-Premise
284	percent	_	_	I-Premise
285	end-difference	_	_	I-Premise
286	of	_	_	I-Premise
287	-	_	_	I-Premise
288	12.3	_	_	I-Premise
289	±	_	_	I-Premise
290	3.9	_	_	I-Premise
291	%	_	_	I-Premise
292	in	_	_	I-Premise
293	LDL-C	_	_	I-Premise
294	and	_	_	I-Premise
295	-	_	_	I-Premise
296	13.9	_	_	I-Premise
297	±	_	_	I-Premise
298	5.8	_	_	I-Premise
299	%	_	_	I-Premise
300	in	_	_	I-Premise
301	LDL-C/HDL	_	_	I-Premise
302	.	_	_	I-Premise

303	The	_	_	O
304	safety	_	_	O
305	profiles	_	_	O
306	were	_	_	O
307	unaffected	_	_	O
308	.	_	_	O

309	AG	_	_	B-Claim
310	extract	_	_	I-Claim
311	added	_	_	I-Claim
312	to	_	_	I-Claim
313	conventional	_	_	I-Claim
314	treatment	_	_	I-Claim
315	provided	_	_	I-Claim
316	an	_	_	I-Claim
317	effective	_	_	I-Claim
318	and	_	_	I-Claim
319	safe	_	_	I-Claim
320	adjunct	_	_	I-Claim
321	in	_	_	I-Claim
322	the	_	_	I-Claim
323	management	_	_	I-Claim
324	of	_	_	I-Claim
325	T2DM	_	_	I-Claim
326	.	_	_	I-Claim

327	Larger	_	_	B-Claim
328	studies	_	_	I-Claim
329	using	_	_	I-Claim
330	physiologically	_	_	I-Claim
331	standardized	_	_	I-Claim
332	ginseng	_	_	I-Claim
333	preparations	_	_	I-Claim
334	are	_	_	I-Claim
335	warranted	_	_	I-Claim
336	to	_	_	I-Claim
337	substantiate	_	_	I-Claim
338	the	_	_	I-Claim
339	present	_	_	I-Claim
340	findings	_	_	I-Claim
341	and	_	_	I-Claim
342	to	_	_	I-Claim
343	demonstrate	_	_	I-Claim
344	therapeutic	_	_	I-Claim
345	effectiveness	_	_	I-Claim
346	of	_	_	I-Claim
347	AG	_	_	I-Claim
348	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	safety	_	_	O
6	of	_	_	O
7	a	_	_	O
8	slow-release	_	_	O
9	formulation	_	_	O
10	of	_	_	O
11	cytarabine	_	_	O
12	(	_	_	O
13	DepoCyt	_	_	O
14	;	_	_	O
15	Chiron	_	_	O
16	Corp	_	_	O
17	,	_	_	O
18	Emeryville	_	_	O
19	,	_	_	O
20	CA	_	_	O
21	,	_	_	O
22	and	_	_	O
23	Skye	_	_	O
24	Pharma	_	_	O
25	,	_	_	O
26	Inc	_	_	O
27	,	_	_	O
28	San	_	_	O
29	Diego	_	_	O
30	,	_	_	O
31	CA	_	_	O
32	)	_	_	O
33	that	_	_	O
34	maintains	_	_	O
35	cytotoxic	_	_	O
36	concentrations	_	_	O
37	of	_	_	O
38	cytarabine	_	_	O
39	(	_	_	O
40	ara-C	_	_	O
41	)	_	_	O
42	in	_	_	O
43	the	_	_	O
44	CSF	_	_	O
45	of	_	_	O
46	most	_	_	O
47	patients	_	_	O
48	for	_	_	O
49	more	_	_	O
50	than	_	_	O
51	14	_	_	O
52	days	_	_	O
53	.	_	_	O

54	Twenty-eight	_	_	O
55	patients	_	_	O
56	with	_	_	O
57	lymphoma	_	_	O
58	and	_	_	O
59	a	_	_	O
60	positive	_	_	O
61	CSF	_	_	O
62	cytology	_	_	O
63	were	_	_	O
64	randomized	_	_	O
65	to	_	_	O
66	receive	_	_	O
67	DepoCyt	_	_	O
68	50	_	_	O
69	mg	_	_	O
70	once	_	_	O
71	every	_	_	O
72	2	_	_	O
73	weeks	_	_	O
74	or	_	_	O
75	free	_	_	O
76	ara-C	_	_	O
77	50	_	_	O
78	mg	_	_	O
79	twice	_	_	O
80	a	_	_	O
81	week	_	_	O
82	for	_	_	O
83	1	_	_	O
84	month	_	_	O
85	.	_	_	O

86	Patients	_	_	O
87	whose	_	_	O
88	CSF	_	_	O
89	cytology	_	_	O
90	converted	_	_	O
91	to	_	_	O
92	negative	_	_	O
93	and	_	_	O
94	who	_	_	O
95	did	_	_	O
96	not	_	_	O
97	have	_	_	O
98	neurologic	_	_	O
99	progression	_	_	O
100	received	_	_	O
101	an	_	_	O
102	additional	_	_	O
103	3	_	_	O
104	months	_	_	O
105	of	_	_	O
106	consolidation	_	_	O
107	therapy	_	_	O
108	and	_	_	O
109	then	_	_	O
110	4	_	_	O
111	months	_	_	O
112	of	_	_	O
113	maintenance	_	_	O
114	therapy	_	_	O
115	.	_	_	O

116	All	_	_	O
117	patients	_	_	O
118	received	_	_	O
119	dexamethasone	_	_	O
120	4	_	_	O
121	mg	_	_	O
122	orally	_	_	O
123	bid	_	_	O
124	on	_	_	O
125	days	_	_	O
126	1	_	_	O
127	through	_	_	O
128	5	_	_	O
129	of	_	_	O
130	each	_	_	O
131	2-week	_	_	O
132	cycle	_	_	O
133	.	_	_	O

134	The	_	_	B-Premise
135	response	_	_	I-Premise
136	rate	_	_	I-Premise
137	was	_	_	I-Premise
138	71	_	_	I-Premise
139	%	_	_	I-Premise
140	for	_	_	I-Premise
141	DepoCyt	_	_	I-Premise
142	and	_	_	I-Premise
143	15	_	_	I-Premise
144	%	_	_	I-Premise
145	for	_	_	I-Premise
146	ara-C	_	_	I-Premise
147	on	_	_	I-Premise
148	an	_	_	I-Premise
149	intent-to-treat	_	_	I-Premise
150	basis	_	_	I-Premise
151	(	_	_	I-Premise
152	P	_	_	I-Premise
153	=.006	_	_	I-Premise
154	)	_	_	I-Premise
155	.	_	_	I-Premise

156	All	_	_	B-Premise
157	of	_	_	I-Premise
158	the	_	_	I-Premise
159	patients	_	_	I-Premise
160	on	_	_	I-Premise
161	the	_	_	I-Premise
162	DepoCyt	_	_	I-Premise
163	arm	_	_	I-Premise
164	but	_	_	I-Premise
165	only	_	_	I-Premise
166	53	_	_	I-Premise
167	%	_	_	I-Premise
168	of	_	_	I-Premise
169	those	_	_	I-Premise
170	on	_	_	I-Premise
171	the	_	_	I-Premise
172	ara-C	_	_	I-Premise
173	arm	_	_	I-Premise
174	were	_	_	I-Premise
175	able	_	_	I-Premise
176	to	_	_	I-Premise
177	complete	_	_	I-Premise
178	the	_	_	I-Premise
179	planned	_	_	I-Premise
180	1-month	_	_	I-Premise
181	induction	_	_	I-Premise
182	therapy	_	_	I-Premise
183	regimen	_	_	I-Premise
184	.	_	_	I-Premise

185	Time	_	_	B-Premise
186	to	_	_	I-Premise
187	neurologic	_	_	I-Premise
188	progression	_	_	I-Premise
189	and	_	_	I-Premise
190	survival	_	_	I-Premise
191	trend	_	_	I-Premise
192	in	_	_	I-Premise
193	favor	_	_	I-Premise
194	of	_	_	I-Premise
195	DepoCyt	_	_	I-Premise
196	(	_	_	I-Premise
197	median	_	_	I-Premise
198	,	_	_	I-Premise
199	78.5	_	_	I-Premise
200	v	_	_	I-Premise
201	42	_	_	I-Premise
202	days	_	_	I-Premise
203	and	_	_	I-Premise
204	99.5	_	_	I-Premise
205	v	_	_	I-Premise
206	63	_	_	I-Premise
207	days	_	_	I-Premise
208	,	_	_	I-Premise
209	respectively	_	_	I-Premise
210	;	_	_	I-Premise
211	P	_	_	I-Premise
212	>	_	_	I-Premise
213	.05	_	_	I-Premise
214	)	_	_	I-Premise
215	.	_	_	I-Premise

216	DepoCyt	_	_	B-Premise
217	treatment	_	_	I-Premise
218	was	_	_	I-Premise
219	associated	_	_	I-Premise
220	with	_	_	I-Premise
221	an	_	_	I-Premise
222	improved	_	_	I-Premise
223	mean	_	_	I-Premise
224	change	_	_	I-Premise
225	in	_	_	I-Premise
226	Karnofsky	_	_	I-Premise
227	performance	_	_	I-Premise
228	score	_	_	I-Premise
229	at	_	_	I-Premise
230	the	_	_	I-Premise
231	end	_	_	I-Premise
232	of	_	_	I-Premise
233	induction	_	_	I-Premise
234	(	_	_	I-Premise
235	P	_	_	I-Premise
236	=.041	_	_	I-Premise
237	)	_	_	I-Premise
238	.	_	_	I-Premise

239	The	_	_	B-Premise
240	major	_	_	I-Premise
241	adverse	_	_	I-Premise
242	events	_	_	I-Premise
243	on	_	_	I-Premise
244	both	_	_	I-Premise
245	arms	_	_	I-Premise
246	were	_	_	I-Premise
247	headache	_	_	I-Premise
248	and	_	_	I-Premise
249	arachnoiditis	_	_	I-Premise
250	,	_	_	I-Premise
251	which	_	_	I-Premise
252	were	_	_	I-Premise
253	often	_	_	I-Premise
254	caused	_	_	I-Premise
255	by	_	_	I-Premise
256	the	_	_	I-Premise
257	underlying	_	_	I-Premise
258	disease	_	_	I-Premise
259	.	_	_	I-Premise

260	DepoCyt	_	_	B-Claim
261	injected	_	_	I-Claim
262	once	_	_	I-Claim
263	every	_	_	I-Claim
264	2	_	_	I-Claim
265	weeks	_	_	I-Claim
266	produced	_	_	I-Claim
267	a	_	_	I-Claim
268	high	_	_	I-Claim
269	response	_	_	I-Claim
270	rate	_	_	I-Claim
271	and	_	_	I-Claim
272	a	_	_	I-Claim
273	better	_	_	I-Claim
274	quality	_	_	I-Claim
275	of	_	_	I-Claim
276	life	_	_	I-Claim
277	as	_	_	I-Claim
278	measured	_	_	I-Claim
279	by	_	_	I-Claim
280	Karnofsky	_	_	I-Claim
281	score	_	_	I-Claim
282	relative	_	_	I-Claim
283	to	_	_	I-Claim
284	that	_	_	I-Claim
285	produced	_	_	I-Claim
286	by	_	_	I-Claim
287	free	_	_	I-Claim
288	ara-C	_	_	I-Claim
289	injected	_	_	I-Claim
290	twice	_	_	I-Claim
291	a	_	_	I-Claim
292	week	_	_	I-Claim
293	.	_	_	I-Claim


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	this	_	_	O
4	2-group	_	_	O
5	,	_	_	O
6	parallel	_	_	O
7	,	_	_	O
8	double	_	_	O
9	blind	_	_	O
10	single-centre	_	_	O
11	RCT	_	_	O
12	was	_	_	O
13	to	_	_	O
14	evaluate	_	_	O
15	the	_	_	O
16	acute	_	_	O
17	and	_	_	O
18	chronic	_	_	O
19	impacts	_	_	O
20	of	_	_	O
21	high	_	_	O
22	flavanol	_	_	O
23	high	_	_	O
24	theobromine	_	_	O
25	(	_	_	O
26	HFHT	_	_	O
27	)	_	_	O
28	chocolate	_	_	O
29	consumption	_	_	O
30	on	_	_	O
31	endothelial	_	_	O
32	function	_	_	O
33	,	_	_	O
34	arterial	_	_	O
35	stiffness	_	_	O
36	and	_	_	O
37	blood	_	_	O
38	pressure	_	_	O
39	(	_	_	O
40	BP	_	_	O
41	)	_	_	O
42	in	_	_	O
43	women	_	_	O
44	at	_	_	O
45	risk	_	_	O
46	of	_	_	O
47	preeclampsia	_	_	O
48	.	_	_	O

49	131	_	_	O
50	pregnant	_	_	O
51	women	_	_	O
52	considered	_	_	O
53	at	_	_	O
54	risk	_	_	O
55	of	_	_	O
56	preeclampsia	_	_	O
57	based	_	_	O
58	on	_	_	O
59	uterine	_	_	O
60	artery	_	_	O
61	Doppler	_	_	O
62	ultrasound	_	_	O
63	were	_	_	O
64	divided	_	_	O
65	into	_	_	O
66	two	_	_	O
67	groups	_	_	O
68	(	_	_	O
69	HFHT	_	_	O
70	or	_	_	O
71	low	_	_	O
72	flavanol	_	_	O
73	and	_	_	O
74	theobromine	_	_	O
75	chocolate	_	_	O
76	(	_	_	O
77	LFLT	_	_	O
78	)	_	_	O
79	.	_	_	O

80	Acute	_	_	O
81	changes	_	_	O
82	in	_	_	O
83	plasma	_	_	O
84	flavanol	_	_	O
85	and	_	_	O
86	theobromine	_	_	O
87	,	_	_	O
88	peripheral	_	_	O
89	arterial	_	_	O
90	tonometry	_	_	O
91	and	_	_	O
92	BP	_	_	O
93	were	_	_	O
94	evaluated	_	_	O
95	at	_	_	O
96	randomization	_	_	O
97	(	_	_	O
98	0	_	_	O
99	,	_	_	O
100	60	_	_	O
101	and	_	_	O
102	120	_	_	O
103	min	_	_	O
104	after	_	_	O
105	a	_	_	O
106	single	_	_	O
107	40-g	_	_	O
108	dose	_	_	O
109	of	_	_	O
110	chocolate	_	_	O
111	)	_	_	O
112	and	_	_	O
113	again	_	_	O
114	6	_	_	O
115	and	_	_	O
116	12	_	_	O
117	weeks	_	_	O
118	after	_	_	O
119	daily	_	_	O
120	30-g	_	_	O
121	chocolate	_	_	O
122	intake	_	_	O
123	.	_	_	O

124	The	_	_	O
125	EndoPAT	_	_	O
126	2000	_	_	O
127	provided	_	_	O
128	reactive	_	_	O
129	hyperemia	_	_	O
130	index	_	_	O
131	(	_	_	O
132	RHI	_	_	O
133	)	_	_	O
134	and	_	_	O
135	adjusted	_	_	O
136	augmentation	_	_	O
137	index	_	_	O
138	(	_	_	O
139	AIx	_	_	O
140	)	_	_	O
141	as	_	_	O
142	markers	_	_	O
143	for	_	_	O
144	endothelial	_	_	O
145	function	_	_	O
146	and	_	_	O
147	arterial	_	_	O
148	stiffness	_	_	O
149	,	_	_	O
150	respectively	_	_	O
151	.	_	_	O

152	Compared	_	_	B-Premise
153	with	_	_	I-Premise
154	LFLT	_	_	I-Premise
155	,	_	_	I-Premise
156	acute	_	_	I-Premise
157	HFHT	_	_	I-Premise
158	intake	_	_	I-Premise
159	significantly	_	_	I-Premise
160	increased	_	_	I-Premise
161	plasma	_	_	I-Premise
162	epicatechin	_	_	I-Premise
163	and	_	_	I-Premise
164	theobromine	_	_	I-Premise
165	(	_	_	I-Premise
166	p	_	_	I-Premise
167	<	_	_	I-Premise
168	0.0001	_	_	I-Premise
169	)	_	_	I-Premise
170	,	_	_	I-Premise
171	decreased	_	_	I-Premise
172	AIx	_	_	I-Premise
173	(	_	_	I-Premise
174	p	_	_	I-Premise
175	<	_	_	I-Premise
176	0.0001	_	_	I-Premise
177	)	_	_	I-Premise
178	and	_	_	I-Premise
179	increased	_	_	I-Premise
180	diastolic	_	_	I-Premise
181	BP	_	_	I-Premise
182	(	_	_	I-Premise
183	3.49	_	_	I-Premise
184	±	_	_	I-Premise
185	3.40	_	_	I-Premise
186	mmHg	_	_	I-Premise
187	increase	_	_	I-Premise
188	in	_	_	I-Premise
189	HFHT	_	_	I-Premise
190	group	_	_	I-Premise
191	vs	_	_	I-Premise
192	1.55	_	_	I-Premise
193	±	_	_	I-Premise
194	2.59	_	_	I-Premise
195	mmHg	_	_	I-Premise
196	increase	_	_	I-Premise
197	in	_	_	I-Premise
198	LFLT	_	_	I-Premise
199	group	_	_	I-Premise
200	,	_	_	I-Premise
201	p	_	_	I-Premise
202	=	_	_	I-Premise
203	0.0008	_	_	I-Premise
204	)	_	_	I-Premise
205	.	_	_	I-Premise

206	Chronic	_	_	B-Premise
207	HFHT	_	_	I-Premise
208	compared	_	_	I-Premise
209	with	_	_	I-Premise
210	LFLT	_	_	I-Premise
211	intake	_	_	I-Premise
212	significantly	_	_	I-Premise
213	increased	_	_	I-Premise
214	plasma	_	_	I-Premise
215	theobromine	_	_	I-Premise
216	(	_	_	I-Premise
217	p	_	_	I-Premise
218	<	_	_	I-Premise
219	0.0001	_	_	I-Premise
220	)	_	_	I-Premise
221	.	_	_	I-Premise

222	No	_	_	O
223	other	_	_	O
224	significant	_	_	O
225	within	_	_	O
226	group	_	_	O
227	or	_	_	O
228	between	_	_	O
229	group	_	_	O
230	changes	_	_	O
231	were	_	_	O
232	observed	_	_	O
233	.	_	_	O

234	Acute	_	_	B-Claim
235	consumption	_	_	I-Claim
236	of	_	_	I-Claim
237	HFHT	_	_	I-Claim
238	,	_	_	I-Claim
239	compared	_	_	I-Claim
240	to	_	_	I-Claim
241	LFLT	_	_	I-Claim
242	,	_	_	I-Claim
243	increased	_	_	I-Claim
244	plasma	_	_	I-Claim
245	epicatechin	_	_	I-Claim
246	and	_	_	I-Claim
247	theobromine	_	_	I-Claim
248	concentrations	_	_	I-Claim
249	and	_	_	I-Claim
250	decreased	_	_	I-Claim
251	arterial	_	_	I-Claim
252	stiffness	_	_	I-Claim
253	,	_	_	I-Claim
254	with	_	_	I-Claim
255	no	_	_	I-Claim
256	effect	_	_	I-Claim
257	on	_	_	I-Claim
258	endothelial	_	_	I-Claim
259	function	_	_	I-Claim
260	and	_	_	I-Claim
261	a	_	_	I-Claim
262	marginal	_	_	I-Claim
263	increase	_	_	I-Claim
264	in	_	_	I-Claim
265	diastolic	_	_	I-Claim
266	BP	_	_	I-Claim
267	.	_	_	I-Claim

268	Chronic	_	_	B-Claim
269	HFHT	_	_	I-Claim
270	intake	_	_	I-Claim
271	increased	_	_	I-Claim
272	plasma	_	_	I-Claim
273	theobromine	_	_	I-Claim
274	,	_	_	I-Claim
275	though	_	_	I-Claim
276	it	_	_	I-Claim
277	did	_	_	I-Claim
278	not	_	_	I-Claim
279	have	_	_	I-Claim
280	positive	_	_	I-Claim
281	impacts	_	_	I-Claim
282	on	_	_	I-Claim
283	endothelial	_	_	I-Claim
284	function	_	_	I-Claim
285	,	_	_	I-Claim
286	arterial	_	_	I-Claim
287	stiffness	_	_	I-Claim
288	or	_	_	I-Claim
289	BP	_	_	I-Claim
290	when	_	_	I-Claim
291	compared	_	_	I-Claim
292	to	_	_	I-Claim
293	LFLT	_	_	I-Claim
294	in	_	_	I-Claim
295	pregnant	_	_	I-Claim
296	women	_	_	I-Claim
297	at	_	_	I-Claim
298	risk	_	_	I-Claim
299	of	_	_	I-Claim
300	PE	_	_	I-Claim
301	.	_	_	I-Claim


0	The	_	_	O
1	authors	_	_	O
2	tested	_	_	O
3	the	_	_	O
4	hypothesis	_	_	O
5	that	_	_	O
6	a	_	_	O
7	valsartan/cilnidipine	_	_	B-Claim
8	combination	_	_	I-Claim
9	would	_	_	I-Claim
10	suppress	_	_	I-Claim
11	the	_	_	I-Claim
12	home	_	_	I-Claim
13	morning	_	_	I-Claim
14	blood	_	_	I-Claim
15	pressure	_	_	I-Claim
16	(	_	_	I-Claim
17	BP	_	_	I-Claim
18	)	_	_	I-Claim
19	surge	_	_	I-Claim
20	(	_	_	I-Claim
21	HMBPS	_	_	I-Claim
22	)	_	_	I-Claim
23	more	_	_	I-Claim
24	effectively	_	_	I-Claim
25	than	_	_	I-Claim
26	a	_	_	I-Claim
27	valsartan/hydrochlorothiazide	_	_	I-Claim
28	combination	_	_	I-Claim
29	in	_	_	I-Claim
30	patients	_	_	I-Claim
31	with	_	_	I-Claim
32	morning	_	_	I-Claim
33	hypertension	_	_	I-Claim
34	,	_	_	O
35	defined	_	_	O
36	as	_	_	O
37	systolic	_	_	O
38	BP	_	_	O
39	(	_	_	O
40	SBP	_	_	O
41	)	_	_	O
42	≥135	_	_	O
43	mm	_	_	O
44	Hg	_	_	O
45	or	_	_	O
46	diastolic	_	_	O
47	BP	_	_	O
48	≥85	_	_	O
49	mm	_	_	O
50	Hg	_	_	O
51	assessed	_	_	O
52	by	_	_	O
53	a	_	_	O
54	self-measuring	_	_	O
55	information	_	_	O
56	and	_	_	O
57	communication	_	_	O
58	technology-based	_	_	O
59	home	_	_	O
60	BP	_	_	O
61	monitoring	_	_	O
62	device	_	_	O
63	more	_	_	O
64	than	_	_	O
65	three	_	_	O
66	times	_	_	O
67	before	_	_	O
68	either	_	_	O
69	combination	_	_	O
70	's	_	_	O
71	administration	_	_	O
72	.	_	_	O

73	This	_	_	O
74	was	_	_	O
75	an	_	_	O
76	8-week	_	_	O
77	prospective	_	_	O
78	,	_	_	O
79	multicenter	_	_	O
80	,	_	_	O
81	randomized	_	_	O
82	,	_	_	O
83	open-label	_	_	O
84	clinical	_	_	O
85	trial	_	_	O
86	.	_	_	O

87	The	_	_	O
88	HMBPS	_	_	O
89	,	_	_	O
90	which	_	_	O
91	is	_	_	O
92	a	_	_	O
93	new	_	_	O
94	index	_	_	O
95	,	_	_	O
96	was	_	_	O
97	defined	_	_	O
98	as	_	_	O
99	the	_	_	O
100	mean	_	_	O
101	morning	_	_	O
102	SBP	_	_	O
103	minus	_	_	O
104	the	_	_	O
105	mean	_	_	O
106	nocturnal	_	_	O
107	SBP	_	_	O
108	,	_	_	O
109	both	_	_	O
110	measured	_	_	O
111	on	_	_	O
112	the	_	_	O
113	same	_	_	O
114	day	_	_	O
115	.	_	_	O

116	The	_	_	O
117	authors	_	_	O
118	randomly	_	_	O
119	allocated	_	_	O
120	129	_	_	O
121	patients	_	_	O
122	to	_	_	O
123	the	_	_	O
124	valsartan/cilnidipine	_	_	O
125	(	_	_	O
126	63	_	_	O
127	patients	_	_	O
128	;	_	_	O
129	mean	_	_	O
130	68.4	_	_	O
131	years	_	_	O
132	)	_	_	O
133	or	_	_	O
134	valsartan/hydrochlorothiazide	_	_	O
135	(	_	_	O
136	66	_	_	O
137	patients	_	_	O
138	;	_	_	O
139	mean	_	_	O
140	67.3	_	_	O
141	years	_	_	O
142	)	_	_	O
143	combination	_	_	O
144	groups	_	_	O
145	,	_	_	O
146	and	_	_	O
147	the	_	_	O
148	baseline	_	_	O
149	HMBPS	_	_	O
150	values	_	_	O
151	were	_	_	O
152	17.4	_	_	O
153	mm	_	_	O
154	Hg	_	_	O
155	vs	_	_	O
156	16.9	_	_	O
157	mm	_	_	O
158	Hg	_	_	O
159	,	_	_	O
160	respectively	_	_	O
161	(	_	_	O
162	P	_	_	O
163	=	_	_	O
164	.820	_	_	O
165	)	_	_	O
166	.	_	_	O

167	At	_	_	B-Premise
168	the	_	_	I-Premise
169	end	_	_	I-Premise
170	of	_	_	I-Premise
171	the	_	_	I-Premise
172	treatment	_	_	I-Premise
173	period	_	_	I-Premise
174	,	_	_	I-Premise
175	the	_	_	I-Premise
176	changes	_	_	I-Premise
177	in	_	_	I-Premise
178	nocturnal	_	_	I-Premise
179	SBP	_	_	I-Premise
180	and	_	_	I-Premise
181	morning	_	_	I-Premise
182	SBP	_	_	I-Premise
183	from	_	_	I-Premise
184	baseline	_	_	I-Premise
185	were	_	_	I-Premise
186	significant	_	_	I-Premise
187	in	_	_	I-Premise
188	both	_	_	I-Premise
189	the	_	_	I-Premise
190	valsartan/cilnidipine	_	_	I-Premise
191	and	_	_	I-Premise
192	valsartan/hydrochlorothiazide	_	_	I-Premise
193	groups	_	_	I-Premise
194	(	_	_	I-Premise
195	P	_	_	I-Premise
196	<	_	_	I-Premise
197	.001	_	_	I-Premise
198	)	_	_	I-Premise
199	:	_	_	I-Premise
200	-5.0	_	_	I-Premise
201	vs	_	_	I-Premise
202	-10.0	_	_	I-Premise
203	mm	_	_	I-Premise
204	Hg	_	_	I-Premise
205	(	_	_	I-Premise
206	P	_	_	I-Premise
207	=	_	_	I-Premise
208	.035	_	_	I-Premise
209	)	_	_	I-Premise
210	and	_	_	I-Premise
211	-10.7	_	_	I-Premise
212	vs	_	_	I-Premise
213	-13.6	_	_	I-Premise
214	mm	_	_	I-Premise
215	Hg	_	_	I-Premise
216	(	_	_	I-Premise
217	P	_	_	I-Premise
218	=	_	_	I-Premise
219	.142	_	_	I-Premise
220	)	_	_	I-Premise
221	,	_	_	I-Premise
222	respectively	_	_	I-Premise
223	.	_	_	I-Premise

224	HMBPS	_	_	B-Premise
225	was	_	_	I-Premise
226	significantly	_	_	I-Premise
227	decreased	_	_	I-Premise
228	from	_	_	I-Premise
229	baseline	_	_	I-Premise
230	in	_	_	I-Premise
231	both	_	_	I-Premise
232	groups	_	_	I-Premise
233	(	_	_	I-Premise
234	P	_	_	I-Premise
235	<	_	_	I-Premise
236	.001	_	_	I-Premise
237	)	_	_	I-Premise
238	,	_	_	I-Premise
239	but	_	_	I-Premise
240	there	_	_	I-Premise
241	was	_	_	I-Premise
242	no	_	_	I-Premise
243	significant	_	_	I-Premise
244	difference	_	_	I-Premise
245	between	_	_	I-Premise
246	the	_	_	I-Premise
247	two	_	_	I-Premise
248	groups	_	_	I-Premise
249	:	_	_	I-Premise
250	14.4	_	_	I-Premise
251	mm	_	_	I-Premise
252	Hg	_	_	I-Premise
253	vs	_	_	I-Premise
254	14.0	_	_	I-Premise
255	mm	_	_	I-Premise
256	Hg	_	_	I-Premise
257	,	_	_	I-Premise
258	respectively	_	_	I-Premise
259	(	_	_	I-Premise
260	P	_	_	I-Premise
261	=	_	_	I-Premise
262	.892	_	_	I-Premise
263	)	_	_	I-Premise
264	.	_	_	I-Premise

265	Valsartan/cilnidipine	_	_	B-Claim
266	could	_	_	I-Claim
267	not	_	_	I-Claim
268	significantly	_	_	I-Claim
269	suppress	_	_	I-Claim
270	HMBPS	_	_	I-Claim
271	compared	_	_	I-Claim
272	with	_	_	I-Claim
273	valsartan/hydrochlorothiazide	_	_	I-Claim
274	.	_	_	I-Claim

275	Large-scale	_	_	O
276	randomized	_	_	O
277	controlled	_	_	O
278	studies	_	_	O
279	are	_	_	O
280	needed	_	_	O
281	to	_	_	O
282	assess	_	_	O
283	how	_	_	O
284	reducing	_	_	O
285	HMBPS	_	_	O
286	will	_	_	O
287	affect	_	_	O
288	future	_	_	O
289	cardiovascular	_	_	O
290	outcomes	_	_	O
291	.	_	_	O

292	The	_	_	O
293	information	_	_	O
294	and	_	_	O
295	communication	_	_	O
296	technology-based	_	_	O
297	home	_	_	O
298	BP	_	_	O
299	monitoring	_	_	O
300	device	_	_	O
301	may	_	_	O
302	become	_	_	O
303	an	_	_	O
304	alternative	_	_	O
305	to	_	_	O
306	ambulatory	_	_	O
307	BP	_	_	O
308	monitoring	_	_	O
309	,	_	_	O
310	which	_	_	O
311	has	_	_	O
312	been	_	_	O
313	a	_	_	O
314	gold	_	_	O
315	standard	_	_	O
316	to	_	_	O
317	measure	_	_	O
318	nocturnal	_	_	O
319	BP	_	_	O
320	and	_	_	O
321	the	_	_	O
322	morning	_	_	O
323	BP	_	_	O
324	surge	_	_	O
325	.	_	_	O


0	To	_	_	O
1	report	_	_	O
2	1-year	_	_	O
3	treatment	_	_	O
4	outcomes	_	_	O
5	in	_	_	O
6	the	_	_	O
7	Primary	_	_	O
8	Tube	_	_	O
9	Versus	_	_	O
10	Trabeculectomy	_	_	O
11	(	_	_	O
12	PTVT	_	_	O
13	)	_	_	O
14	Study	_	_	O
15	.	_	_	O

16	Two	_	_	O
17	hundred	_	_	O
18	forty-two	_	_	O
19	eyes	_	_	O
20	of	_	_	O
21	242	_	_	O
22	patients	_	_	O
23	with	_	_	O
24	medically	_	_	O
25	uncontrolled	_	_	O
26	glaucoma	_	_	O
27	and	_	_	O
28	no	_	_	O
29	previous	_	_	O
30	incisional	_	_	O
31	ocular	_	_	O
32	surgery	_	_	O
33	,	_	_	O
34	including	_	_	O
35	125	_	_	O
36	in	_	_	O
37	the	_	_	O
38	tube	_	_	O
39	group	_	_	O
40	and	_	_	O
41	117	_	_	O
42	in	_	_	O
43	the	_	_	O
44	trabeculectomy	_	_	O
45	group	_	_	O
46	.	_	_	O

47	Patients	_	_	O
48	were	_	_	O
49	enrolled	_	_	O
50	at	_	_	O
51	16	_	_	O
52	clinical	_	_	O
53	centers	_	_	O
54	and	_	_	O
55	assigned	_	_	O
56	randomly	_	_	O
57	to	_	_	O
58	treatment	_	_	O
59	with	_	_	O
60	a	_	_	O
61	tube	_	_	O
62	shunt	_	_	O
63	(	_	_	O
64	350-mm2	_	_	O
65	Baerveldt	_	_	O
66	glaucoma	_	_	O
67	implant	_	_	O
68	)	_	_	O
69	or	_	_	O
70	trabeculectomy	_	_	O
71	with	_	_	O
72	mitomycin	_	_	O
73	C	_	_	O
74	(	_	_	O
75	MMC	_	_	O
76	;	_	_	O
77	0.4	_	_	O
78	mg/ml	_	_	O
79	for	_	_	O
80	2	_	_	O
81	minutes	_	_	O
82	)	_	_	O
83	.	_	_	O

84	Intraocular	_	_	O
85	pressure	_	_	O
86	(	_	_	O
87	IOP	_	_	O
88	)	_	_	O
89	,	_	_	O
90	glaucoma	_	_	O
91	medical	_	_	O
92	therapy	_	_	O
93	,	_	_	O
94	visual	_	_	O
95	acuity	_	_	O
96	,	_	_	O
97	visual	_	_	O
98	fields	_	_	O
99	,	_	_	O
100	surgical	_	_	O
101	complications	_	_	O
102	,	_	_	O
103	and	_	_	O
104	failure	_	_	O
105	(	_	_	O
106	IOP	_	_	O
107	of	_	_	O
108	more	_	_	O
109	than	_	_	O
110	21	_	_	O
111	mmHg	_	_	O
112	or	_	_	O
113	reduced	_	_	O
114	by	_	_	O
115	less	_	_	O
116	than	_	_	O
117	20	_	_	O
118	%	_	_	O
119	from	_	_	O
120	baseline	_	_	O
121	,	_	_	O
122	IOP	_	_	O
123	of	_	_	O
124	5	_	_	O
125	mmHg	_	_	O
126	or	_	_	O
127	less	_	_	O
128	,	_	_	O
129	reoperation	_	_	O
130	for	_	_	O
131	glaucoma	_	_	O
132	,	_	_	O
133	or	_	_	O
134	loss	_	_	O
135	of	_	_	O
136	light	_	_	O
137	perception	_	_	O
138	vision	_	_	O
139	)	_	_	O
140	.	_	_	O

141	The	_	_	B-Premise
142	cumulative	_	_	I-Premise
143	probability	_	_	I-Premise
144	of	_	_	I-Premise
145	failure	_	_	I-Premise
146	during	_	_	I-Premise
147	the	_	_	I-Premise
148	first	_	_	I-Premise
149	year	_	_	I-Premise
150	of	_	_	I-Premise
151	follow-up	_	_	I-Premise
152	was	_	_	I-Premise
153	17.3	_	_	I-Premise
154	%	_	_	I-Premise
155	in	_	_	I-Premise
156	the	_	_	I-Premise
157	tube	_	_	I-Premise
158	group	_	_	I-Premise
159	and	_	_	I-Premise
160	7.9	_	_	I-Premise
161	%	_	_	I-Premise
162	in	_	_	I-Premise
163	the	_	_	I-Premise
164	trabeculectomy	_	_	I-Premise
165	group	_	_	I-Premise
166	(	_	_	I-Premise
167	P	_	_	I-Premise
168	=	_	_	I-Premise
169	0.01	_	_	I-Premise
170	;	_	_	I-Premise
171	hazard	_	_	I-Premise
172	ratio	_	_	I-Premise
173	,	_	_	I-Premise
174	2.59	_	_	I-Premise
175	;	_	_	I-Premise
176	95	_	_	I-Premise
177	%	_	_	I-Premise
178	confidence	_	_	I-Premise
179	interval	_	_	I-Premise
180	,	_	_	I-Premise
181	1.20-5.60	_	_	I-Premise
182	)	_	_	I-Premise
183	.	_	_	I-Premise

184	Mean	_	_	B-Premise
185	±	_	_	I-Premise
186	standard	_	_	I-Premise
187	deviation	_	_	I-Premise
188	IOP	_	_	I-Premise
189	was	_	_	I-Premise
190	13.8±4.1	_	_	I-Premise
191	mmHg	_	_	I-Premise
192	in	_	_	I-Premise
193	the	_	_	I-Premise
194	tube	_	_	I-Premise
195	group	_	_	I-Premise
196	and	_	_	I-Premise
197	12.4±4.4	_	_	I-Premise
198	mmHg	_	_	I-Premise
199	in	_	_	I-Premise
200	the	_	_	I-Premise
201	trabeculectomy	_	_	I-Premise
202	group	_	_	I-Premise
203	at	_	_	I-Premise
204	1	_	_	I-Premise
205	year	_	_	I-Premise
206	(	_	_	I-Premise
207	P	_	_	I-Premise
208	=	_	_	I-Premise
209	0.01	_	_	I-Premise
210	)	_	_	I-Premise
211	,	_	_	I-Premise
212	and	_	_	I-Premise
213	the	_	_	I-Premise
214	number	_	_	I-Premise
215	of	_	_	I-Premise
216	glaucoma	_	_	I-Premise
217	medications	_	_	I-Premise
218	was	_	_	I-Premise
219	2.1±1.4	_	_	I-Premise
220	in	_	_	I-Premise
221	the	_	_	I-Premise
222	tube	_	_	I-Premise
223	group	_	_	I-Premise
224	and	_	_	I-Premise
225	0.9±1.4	_	_	I-Premise
226	in	_	_	I-Premise
227	the	_	_	I-Premise
228	trabeculectomy	_	_	I-Premise
229	group	_	_	I-Premise
230	(	_	_	I-Premise
231	P	_	_	I-Premise
232	<	_	_	I-Premise
233	0.001	_	_	I-Premise
234	)	_	_	I-Premise
235	.	_	_	I-Premise

236	Postoperative	_	_	B-Premise
237	complications	_	_	I-Premise
238	developed	_	_	I-Premise
239	in	_	_	I-Premise
240	36	_	_	I-Premise
241	patients	_	_	I-Premise
242	(	_	_	I-Premise
243	29	_	_	I-Premise
244	%	_	_	I-Premise
245	)	_	_	I-Premise
246	in	_	_	I-Premise
247	the	_	_	I-Premise
248	tube	_	_	I-Premise
249	group	_	_	I-Premise
250	and	_	_	I-Premise
251	48	_	_	I-Premise
252	patients	_	_	I-Premise
253	(	_	_	I-Premise
254	41	_	_	I-Premise
255	%	_	_	I-Premise
256	)	_	_	I-Premise
257	in	_	_	I-Premise
258	the	_	_	I-Premise
259	trabeculectomy	_	_	I-Premise
260	group	_	_	I-Premise
261	(	_	_	I-Premise
262	P	_	_	I-Premise
263	=	_	_	I-Premise
264	0.06	_	_	I-Premise
265	)	_	_	I-Premise
266	.	_	_	I-Premise

267	Serious	_	_	B-Premise
268	complications	_	_	I-Premise
269	requiring	_	_	I-Premise
270	reoperation	_	_	I-Premise
271	or	_	_	I-Premise
272	producing	_	_	I-Premise
273	a	_	_	I-Premise
274	loss	_	_	I-Premise
275	of	_	_	I-Premise
276	2	_	_	I-Premise
277	Snellen	_	_	I-Premise
278	lines	_	_	I-Premise
279	or	_	_	I-Premise
280	more	_	_	I-Premise
281	occurred	_	_	I-Premise
282	in	_	_	I-Premise
283	1	_	_	I-Premise
284	patient	_	_	I-Premise
285	(	_	_	I-Premise
286	1	_	_	I-Premise
287	%	_	_	I-Premise
288	)	_	_	I-Premise
289	in	_	_	I-Premise
290	the	_	_	I-Premise
291	tube	_	_	I-Premise
292	group	_	_	I-Premise
293	and	_	_	I-Premise
294	8	_	_	I-Premise
295	patients	_	_	I-Premise
296	(	_	_	I-Premise
297	7	_	_	I-Premise
298	%	_	_	I-Premise
299	)	_	_	I-Premise
300	in	_	_	I-Premise
301	the	_	_	I-Premise
302	trabeculectomy	_	_	I-Premise
303	group	_	_	I-Premise
304	(	_	_	I-Premise
305	P	_	_	I-Premise
306	=	_	_	I-Premise
307	0.03	_	_	I-Premise
308	)	_	_	I-Premise
309	.	_	_	I-Premise

310	Trabeculectomy	_	_	B-Claim
311	with	_	_	I-Claim
312	MMC	_	_	I-Claim
313	had	_	_	I-Claim
314	a	_	_	I-Claim
315	higher	_	_	I-Claim
316	surgical	_	_	I-Claim
317	success	_	_	I-Claim
318	rate	_	_	I-Claim
319	than	_	_	I-Claim
320	tube	_	_	I-Claim
321	shunt	_	_	I-Claim
322	implantation	_	_	I-Claim
323	after	_	_	I-Claim
324	1	_	_	I-Claim
325	year	_	_	I-Claim
326	in	_	_	I-Claim
327	the	_	_	I-Claim
328	PTVT	_	_	I-Claim
329	Study	_	_	I-Claim
330	.	_	_	I-Claim

331	Lower	_	_	B-Claim
332	IOP	_	_	I-Claim
333	with	_	_	I-Claim
334	use	_	_	I-Claim
335	of	_	_	I-Claim
336	fewer	_	_	I-Claim
337	glaucoma	_	_	I-Claim
338	medications	_	_	I-Claim
339	was	_	_	I-Claim
340	achieved	_	_	I-Claim
341	after	_	_	I-Claim
342	trabeculectomy	_	_	I-Claim
343	with	_	_	I-Claim
344	MMC	_	_	I-Claim
345	compared	_	_	I-Claim
346	with	_	_	I-Claim
347	tube	_	_	I-Claim
348	shunt	_	_	I-Claim
349	surgery	_	_	I-Claim
350	during	_	_	I-Claim
351	the	_	_	I-Claim
352	first	_	_	I-Claim
353	year	_	_	I-Claim
354	of	_	_	I-Claim
355	follow-up	_	_	I-Claim
356	.	_	_	I-Claim

357	The	_	_	B-Claim
358	frequency	_	_	I-Claim
359	of	_	_	I-Claim
360	serious	_	_	I-Claim
361	complications	_	_	I-Claim
362	producing	_	_	I-Claim
363	vision	_	_	I-Claim
364	loss	_	_	I-Claim
365	or	_	_	I-Claim
366	requiring	_	_	I-Claim
367	reoperation	_	_	I-Claim
368	was	_	_	I-Claim
369	lower	_	_	I-Claim
370	after	_	_	I-Claim
371	tube	_	_	I-Claim
372	shunt	_	_	I-Claim
373	surgery	_	_	I-Claim
374	relative	_	_	I-Claim
375	to	_	_	I-Claim
376	trabeculectomy	_	_	I-Claim
377	with	_	_	I-Claim
378	MMC	_	_	I-Claim
379	.	_	_	I-Claim


0	For	_	_	B-Claim
1	several	_	_	I-Claim
2	decades	_	_	I-Claim
3	,	_	_	I-Claim
4	both	_	_	I-Claim
5	preoperative	_	_	I-Claim
6	intra-arterial	_	_	I-Claim
7	chemotherapy	_	_	I-Claim
8	and	_	_	I-Claim
9	preoperative	_	_	I-Claim
10	irradiation	_	_	I-Claim
11	have	_	_	I-Claim
12	been	_	_	I-Claim
13	accepted	_	_	I-Claim
14	treatments	_	_	I-Claim
15	for	_	_	I-Claim
16	patients	_	_	I-Claim
17	with	_	_	I-Claim
18	tumors	_	_	I-Claim
19	of	_	_	I-Claim
20	the	_	_	I-Claim
21	head	_	_	I-Claim
22	and	_	_	I-Claim
23	neck	_	_	I-Claim
24	.	_	_	I-Claim

25	Unfortunately	_	_	O
26	,	_	_	O
27	arguments	_	_	O
28	have	_	_	O
29	often	_	_	O
30	been	_	_	O
31	put	_	_	O
32	forward	_	_	O
33	in	_	_	O
34	favor	_	_	O
35	of	_	_	O
36	one	_	_	O
37	or	_	_	O
38	other	_	_	O
39	of	_	_	O
40	the	_	_	O
41	two	_	_	O
42	methods	_	_	O
43	,	_	_	O
44	but	_	_	O
45	without	_	_	O
46	the	_	_	O
47	performance	_	_	O
48	of	_	_	O
49	an	_	_	O
50	objective	_	_	O
51	,	_	_	O
52	randomized	_	_	O
53	investigation	_	_	O
54	.	_	_	O

55	To	_	_	O
56	resolve	_	_	O
57	this	_	_	O
58	situation	_	_	O
59	,	_	_	O
60	the	_	_	O
61	authors	_	_	O
62	have	_	_	O
63	carried	_	_	O
64	out	_	_	O
65	a	_	_	O
66	multicenter	_	_	O
67	,	_	_	O
68	randomized	_	_	O
69	prospective	_	_	O
70	study	_	_	O
71	of	_	_	O
72	selected	_	_	O
73	patients	_	_	O
74	with	_	_	O
75	a	_	_	O
76	view	_	_	O
77	to	_	_	O
78	deciding	_	_	O
79	which	_	_	O
80	method	_	_	O
81	affords	_	_	O
82	better	_	_	O
83	results	_	_	O
84	in	_	_	O
85	complex	_	_	O
86	tumor	_	_	O
87	therapy	_	_	O
88	from	_	_	O
89	the	_	_	O
90	aspects	_	_	O
91	of	_	_	O
92	survival	_	_	O
93	and	_	_	O
94	postoperative	_	_	O
95	quality	_	_	O
96	of	_	_	O
97	life	_	_	O
98	.	_	_	O

99	One	_	_	O
100	hundred	_	_	O
101	thirty-one	_	_	O
102	patients	_	_	O
103	with	_	_	O
104	operable	_	_	O
105	sublingual	_	_	O
106	or	_	_	O
107	lingual	_	_	O
108	squamous	_	_	O
109	cell	_	_	O
110	carcinoma	_	_	O
111	in	_	_	O
112	stages	_	_	O
113	T2NXM0	_	_	O
114	to	_	_	O
115	T4MXM0	_	_	O
116	were	_	_	O
117	randomized	_	_	O
118	into	_	_	O
119	2	_	_	O
120	groups	_	_	O
121	:	_	_	O
122	1	_	_	O
123	group	_	_	O
124	participated	_	_	O
125	in	_	_	O
126	preoperative	_	_	O
127	chemotherapy	_	_	O
128	with	_	_	O
129	cisplatin	_	_	O
130	and	_	_	O
131	epirubicin	_	_	O
132	(	_	_	O
133	total	_	_	O
134	doses	_	_	O
135	:	_	_	O
136	200	_	_	O
137	mg	_	_	O
138	cisplatin	_	_	O
139	,	_	_	O
140	120	_	_	O
141	mg	_	_	O
142	epirubicin	_	_	O
143	)	_	_	O
144	via	_	_	O
145	the	_	_	O
146	external	_	_	O
147	carotid	_	_	O
148	artery	_	_	O
149	,	_	_	O
150	whereas	_	_	O
151	the	_	_	O
152	other	_	_	O
153	group	_	_	O
154	received	_	_	O
155	preoperative	_	_	O
156	radiation	_	_	O
157	therapy	_	_	O
158	(	_	_	O
159	46	_	_	O
160	grays	_	_	O
161	)	_	_	O
162	.	_	_	O

163	Following	_	_	O
164	subsequent	_	_	O
165	radical	_	_	O
166	surgery	_	_	O
167	,	_	_	O
168	the	_	_	O
169	patients	_	_	O
170	received	_	_	O
171	regular	_	_	O
172	follow-up	_	_	O
173	for	_	_	O
174	5	_	_	O
175	years	_	_	O
176	.	_	_	O

177	By	_	_	O
178	the	_	_	O
179	end	_	_	O
180	of	_	_	O
181	the	_	_	O
182	5	_	_	O
183	years	_	_	O
184	,	_	_	O
185	95	_	_	O
186	of	_	_	O
187	the	_	_	O
188	131	_	_	O
189	patients	_	_	O
190	had	_	_	O
191	conformed	_	_	O
192	to	_	_	O
193	the	_	_	O
194	protocol	_	_	O
195	.	_	_	O

196	Of	_	_	O
197	those	_	_	O
198	95	_	_	O
199	,	_	_	O
200	47	_	_	O
201	had	_	_	O
202	received	_	_	O
203	preoperative	_	_	O
204	chemotherapy	_	_	O
205	and	_	_	O
206	48	_	_	O
207	preoperative	_	_	O
208	irradiation	_	_	O
209	.	_	_	O

210	After	_	_	B-Premise
211	5	_	_	I-Premise
212	years	_	_	I-Premise
213	,	_	_	I-Premise
214	18	_	_	I-Premise
215	of	_	_	I-Premise
216	the	_	_	I-Premise
217	47	_	_	I-Premise
218	patients	_	_	I-Premise
219	who	_	_	I-Premise
220	received	_	_	I-Premise
221	chemotherapy	_	_	I-Premise
222	and	_	_	I-Premise
223	15	_	_	I-Premise
224	of	_	_	I-Premise
225	the	_	_	I-Premise
226	48	_	_	I-Premise
227	patients	_	_	I-Premise
228	who	_	_	I-Premise
229	received	_	_	I-Premise
230	irradiation	_	_	I-Premise
231	were	_	_	I-Premise
232	still	_	_	I-Premise
233	alive	_	_	I-Premise
234	and	_	_	I-Premise
235	tumor	_	_	I-Premise
236	free	_	_	I-Premise
237	.	_	_	I-Premise

238	A	_	_	B-Premise
239	few	_	_	I-Premise
240	more	_	_	I-Premise
241	patients	_	_	I-Premise
242	had	_	_	I-Premise
243	died	_	_	I-Premise
244	of	_	_	I-Premise
245	recurrence	_	_	I-Premise
246	or	_	_	I-Premise
247	regional	_	_	I-Premise
248	metastasis	_	_	I-Premise
249	in	_	_	I-Premise
250	the	_	_	I-Premise
251	chemotherapy	_	_	I-Premise
252	group	_	_	I-Premise
253	(	_	_	I-Premise
254	23	_	_	I-Premise
255	patients	_	_	I-Premise
256	)	_	_	I-Premise
257	than	_	_	I-Premise
258	in	_	_	I-Premise
259	the	_	_	I-Premise
260	irradiation	_	_	I-Premise
261	group	_	_	I-Premise
262	(	_	_	I-Premise
263	20	_	_	I-Premise
264	patients	_	_	I-Premise
265	)	_	_	I-Premise
266	.	_	_	I-Premise

267	Occurrence	_	_	B-Premise
268	of	_	_	I-Premise
269	a	_	_	I-Premise
270	second	_	_	I-Premise
271	carcinoma	_	_	I-Premise
272	was	_	_	I-Premise
273	3	_	_	I-Premise
274	times	_	_	I-Premise
275	as	_	_	I-Premise
276	frequent	_	_	I-Premise
277	in	_	_	I-Premise
278	the	_	_	I-Premise
279	irradiation	_	_	I-Premise
280	group	_	_	I-Premise
281	(	_	_	I-Premise
282	9	_	_	I-Premise
283	patients	_	_	I-Premise
284	)	_	_	I-Premise
285	as	_	_	I-Premise
286	in	_	_	I-Premise
287	the	_	_	I-Premise
288	chemotherapy	_	_	I-Premise
289	group	_	_	I-Premise
290	(	_	_	I-Premise
291	3	_	_	I-Premise
292	patients	_	_	I-Premise
293	)	_	_	I-Premise
294	.	_	_	I-Premise

295	Overall	_	_	O
296	,	_	_	O
297	the	_	_	B-Claim
298	survival	_	_	I-Claim
299	rates	_	_	I-Claim
300	were	_	_	I-Claim
301	by-and-large	_	_	I-Claim
302	the	_	_	I-Claim
303	same	_	_	I-Claim
304	for	_	_	I-Claim
305	the	_	_	I-Claim
306	two	_	_	I-Claim
307	groups	_	_	I-Claim
308	.	_	_	I-Claim

309	Regarding	_	_	B-Claim
310	postoperative	_	_	I-Claim
311	quality	_	_	I-Claim
312	of	_	_	I-Claim
313	life	_	_	I-Claim
314	,	_	_	I-Claim
315	the	_	_	I-Claim
316	chemotherapy	_	_	I-Claim
317	group	_	_	I-Claim
318	presented	_	_	I-Claim
319	a	_	_	I-Claim
320	more	_	_	I-Claim
321	favorable	_	_	I-Claim
322	picture	_	_	I-Claim
323	.	_	_	I-Claim

324	The	_	_	B-Claim
325	long	_	_	I-Claim
326	term	_	_	I-Claim
327	survival	_	_	I-Claim
328	results	_	_	I-Claim
329	subsequent	_	_	I-Claim
330	to	_	_	I-Claim
331	preoperative	_	_	I-Claim
332	intra-arterial	_	_	I-Claim
333	chemotherapy	_	_	I-Claim
334	or	_	_	I-Claim
335	preoperative	_	_	I-Claim
336	radiotherapy	_	_	I-Claim
337	were	_	_	I-Claim
338	practically	_	_	I-Claim
339	the	_	_	I-Claim
340	same	_	_	I-Claim
341	.	_	_	I-Claim

342	Regarding	_	_	B-Claim
343	postoperative	_	_	I-Claim
344	quality	_	_	I-Claim
345	of	_	_	I-Claim
346	life	_	_	I-Claim
347	,	_	_	I-Claim
348	patients	_	_	I-Claim
349	who	_	_	I-Claim
350	underwent	_	_	I-Claim
351	intra-arterial	_	_	I-Claim
352	chemotherapy	_	_	I-Claim
353	appeared	_	_	I-Claim
354	to	_	_	I-Claim
355	be	_	_	I-Claim
356	in	_	_	I-Claim
357	a	_	_	I-Claim
358	slightly	_	_	I-Claim
359	more	_	_	I-Claim
360	favorable	_	_	I-Claim
361	situation	_	_	I-Claim
362	.	_	_	I-Claim

363	The	_	_	O
364	authors	_	_	O
365	consider	_	_	O
366	it	_	_	O
367	important	_	_	O
368	to	_	_	O
369	stress	_	_	O
370	these	_	_	O
371	findings	_	_	O
372	,	_	_	O
373	as	_	_	O
374	they	_	_	O
375	are	_	_	O
376	not	_	_	O
377	aware	_	_	O
378	of	_	_	O
379	a	_	_	O
380	similar	_	_	O
381	randomized	_	_	O
382	study	_	_	O
383	of	_	_	O
384	patients	_	_	O
385	with	_	_	O
386	tumors	_	_	O
387	of	_	_	O
388	the	_	_	O
389	oral	_	_	O
390	cavity	_	_	O
391	.	_	_	O


0	Vesatolimod	_	_	O
1	(	_	_	O
2	GS-9620	_	_	O
3	)	_	_	O
4	is	_	_	O
5	an	_	_	O
6	oral	_	_	O
7	agonist	_	_	O
8	of	_	_	O
9	toll-like	_	_	O
10	receptor	_	_	O
11	7	_	_	O
12	,	_	_	O
13	an	_	_	O
14	activator	_	_	O
15	of	_	_	O
16	innate	_	_	O
17	and	_	_	O
18	adaptive	_	_	O
19	immune	_	_	O
20	responses	_	_	O
21	.	_	_	O

22	Herein	_	_	O
23	the	_	_	O
24	safety	_	_	O
25	and	_	_	O
26	efficacy	_	_	O
27	of	_	_	O
28	vesatolimod	_	_	O
29	is	_	_	O
30	assessed	_	_	O
31	after	_	_	O
32	once-weekly	_	_	O
33	treatment	_	_	O
34	in	_	_	O
35	patients	_	_	O
36	with	_	_	O
37	chronic	_	_	O
38	hepatitis	_	_	O
39	B	_	_	O
40	(	_	_	O
41	CHB	_	_	O
42	)	_	_	O
43	infection	_	_	O
44	suppressed	_	_	O
45	on	_	_	O
46	oral	_	_	O
47	antiviral	_	_	O
48	treatment	_	_	O
49	.	_	_	O

50	In	_	_	O
51	a	_	_	O
52	phase	_	_	O
53	II	_	_	O
54	,	_	_	O
55	double-blind	_	_	O
56	,	_	_	O
57	randomized	_	_	O
58	,	_	_	O
59	placebo	_	_	O
60	(	_	_	O
61	PBO	_	_	O
62	)	_	_	O
63	-controlled	_	_	O
64	study	_	_	O
65	,	_	_	O
66	162	_	_	O
67	patients	_	_	O
68	stratified	_	_	O
69	by	_	_	O
70	hepatitis	_	_	O
71	B	_	_	O
72	surface	_	_	O
73	antigen	_	_	O
74	(	_	_	O
75	HBsAg	_	_	O
76	)	_	_	O
77	levels	_	_	O
78	and	_	_	O
79	serum	_	_	O
80	hepatitis	_	_	O
81	B	_	_	O
82	e	_	_	O
83	antigen	_	_	O
84	(	_	_	O
85	HBeAg	_	_	O
86	)	_	_	O
87	status	_	_	O
88	were	_	_	O
89	randomized	_	_	O
90	1:3:3:3	_	_	O
91	to	_	_	O
92	once-weekly	_	_	O
93	oral	_	_	O
94	PBO	_	_	O
95	or	_	_	O
96	vesatolimod	_	_	O
97	(	_	_	O
98	1-	_	_	O
99	,	_	_	O
100	2-	_	_	O
101	,	_	_	O
102	or	_	_	O
103	4-mg	_	_	O
104	doses	_	_	O
105	)	_	_	O
106	for	_	_	O
107	4	_	_	O
108	,	_	_	O
109	8	_	_	O
110	or	_	_	O
111	12	_	_	O
112	weeks	_	_	O
113	per	_	_	O
114	cohort	_	_	O
115	.	_	_	O

116	Efficacy	_	_	O
117	was	_	_	O
118	assessed	_	_	O
119	by	_	_	O
120	change	_	_	O
121	in	_	_	O
122	baseline	_	_	O
123	HBsAg	_	_	O
124	(	_	_	O
125	log10	_	_	O
126	IU/ml	_	_	O
127	)	_	_	O
128	at	_	_	O
129	the	_	_	O
130	primary	_	_	O
131	endpoint	_	_	O
132	(	_	_	O
133	Week	_	_	O
134	24	_	_	O
135	)	_	_	O
136	.	_	_	O

137	Safety	_	_	O
138	assessments	_	_	O
139	included	_	_	O
140	adverse	_	_	O
141	events	_	_	O
142	(	_	_	O
143	AE	_	_	O
144	)	_	_	O
145	and	_	_	O
146	laboratory	_	_	O
147	abnormality	_	_	O
148	monitoring	_	_	O
149	.	_	_	O

150	Pharmacodynamic	_	_	O
151	assessments	_	_	O
152	included	_	_	O
153	peripheral	_	_	O
154	cytokine	_	_	O
155	level	_	_	O
156	quantification	_	_	O
157	and	_	_	O
158	interferon-stimulated	_	_	O
159	gene	_	_	O
160	(	_	_	O
161	ISG	_	_	O
162	)	_	_	O
163	mRNA	_	_	O
164	expression	_	_	O
165	evaluation	_	_	O
166	.	_	_	O

167	The	_	_	O
168	majority	_	_	O
169	of	_	_	O
170	patients	_	_	O
171	were	_	_	O
172	male	_	_	O
173	(	_	_	O
174	76	_	_	O
175	%	_	_	O
176	)	_	_	O
177	and	_	_	O
178	HBeAg-negative	_	_	O
179	(	_	_	O
180	79	_	_	O
181	%	_	_	O
182	)	_	_	O
183	at	_	_	O
184	baseline	_	_	O
185	.	_	_	O

186	Most	_	_	B-Premise
187	(	_	_	I-Premise
188	41-80	_	_	I-Premise
189	%	_	_	I-Premise
190	)	_	_	I-Premise
191	experienced	_	_	I-Premise
192	≥1	_	_	I-Premise
193	AE	_	_	I-Premise
194	during	_	_	I-Premise
195	the	_	_	I-Premise
196	study	_	_	I-Premise
197	with	_	_	I-Premise
198	the	_	_	I-Premise
199	majority	_	_	I-Premise
200	of	_	_	I-Premise
201	AEs	_	_	I-Premise
202	mild	_	_	I-Premise
203	or	_	_	I-Premise
204	moderate	_	_	I-Premise
205	in	_	_	I-Premise
206	severity	_	_	I-Premise
207	.	_	_	I-Premise

208	No	_	_	B-Premise
209	significant	_	_	I-Premise
210	declines	_	_	I-Premise
211	in	_	_	I-Premise
212	HBsAg	_	_	I-Premise
213	were	_	_	I-Premise
214	observed	_	_	I-Premise
215	at	_	_	I-Premise
216	the	_	_	I-Premise
217	primary	_	_	I-Premise
218	(	_	_	I-Premise
219	Week	_	_	I-Premise
220	24	_	_	I-Premise
221	)	_	_	I-Premise
222	or	_	_	I-Premise
223	secondary	_	_	I-Premise
224	endpoints	_	_	I-Premise
225	(	_	_	I-Premise
226	Weeks	_	_	I-Premise
227	4	_	_	I-Premise
228	,	_	_	I-Premise
229	8	_	_	I-Premise
230	,	_	_	I-Premise
231	12	_	_	I-Premise
232	,	_	_	I-Premise
233	and	_	_	I-Premise
234	48	_	_	I-Premise
235	)	_	_	I-Premise
236	.	_	_	I-Premise

237	ISG15	_	_	B-Premise
238	induction	_	_	I-Premise
239	was	_	_	I-Premise
240	dose-dependent	_	_	I-Premise
241	and	_	_	I-Premise
242	consistent	_	_	I-Premise
243	after	_	_	I-Premise
244	repeat	_	_	I-Premise
245	dosing	_	_	I-Premise
246	,	_	_	I-Premise
247	returning	_	_	I-Premise
248	closer	_	_	I-Premise
249	to	_	_	I-Premise
250	baseline	_	_	I-Premise
251	by	_	_	I-Premise
252	one	_	_	I-Premise
253	week	_	_	I-Premise
254	after	_	_	I-Premise
255	treatment	_	_	I-Premise
256	at	_	_	I-Premise
257	all	_	_	I-Premise
258	dose	_	_	I-Premise
259	levels	_	_	I-Premise
260	;	_	_	I-Premise
261	no	_	_	B-Premise
262	patient	_	_	I-Premise
263	demonstrated	_	_	I-Premise
264	significant	_	_	I-Premise
265	serum	_	_	I-Premise
266	interferon	_	_	I-Premise
267	alpha	_	_	I-Premise
268	(	_	_	I-Premise
269	IFNα	_	_	I-Premise
270	)	_	_	I-Premise
271	expression	_	_	I-Premise
272	at	_	_	I-Premise
273	any	_	_	I-Premise
274	timepoint	_	_	I-Premise
275	evaluated	_	_	I-Premise
276	.	_	_	I-Premise

277	Multivariate	_	_	B-Premise
278	analyses	_	_	I-Premise
279	showed	_	_	I-Premise
280	that	_	_	I-Premise
281	≥2-fold	_	_	I-Premise
282	ISG15	_	_	I-Premise
283	induction	_	_	I-Premise
284	is	_	_	I-Premise
285	associated	_	_	I-Premise
286	with	_	_	I-Premise
287	2-	_	_	I-Premise
288	or	_	_	I-Premise
289	4-mg	_	_	I-Premise
290	vesatolimod	_	_	I-Premise
291	dose	_	_	I-Premise
292	and	_	_	I-Premise
293	female	_	_	I-Premise
294	sex	_	_	I-Premise
295	.	_	_	I-Premise

296	Vesatolimod	_	_	B-Claim
297	was	_	_	I-Claim
298	safe	_	_	I-Claim
299	and	_	_	I-Claim
300	well-tolerated	_	_	I-Claim
301	in	_	_	I-Claim
302	patients	_	_	I-Claim
303	with	_	_	I-Claim
304	CHB	_	_	I-Claim
305	,	_	_	I-Claim
306	demonstrating	_	_	I-Claim
307	consistent	_	_	I-Claim
308	dose-dependent	_	_	I-Claim
309	pharmacodynamic	_	_	I-Claim
310	induction	_	_	I-Claim
311	of	_	_	I-Claim
312	ISG15	_	_	I-Claim
313	without	_	_	I-Claim
314	significant	_	_	I-Claim
315	systemic	_	_	I-Claim
316	induction	_	_	I-Claim
317	of	_	_	I-Claim
318	IFNα	_	_	I-Claim
319	expression	_	_	I-Claim
320	or	_	_	I-Claim
321	related	_	_	I-Claim
322	symptoms	_	_	I-Claim
323	.	_	_	I-Claim

324	However	_	_	O
325	,	_	_	O
326	no	_	_	O
327	significant	_	_	O
328	HBsAg	_	_	O
329	declines	_	_	O
330	were	_	_	O
331	observed	_	_	O
332	.	_	_	O


0	The	_	_	O
1	potential	_	_	O
2	protective	_	_	O
3	effects	_	_	O
4	of	_	_	O
5	remote	_	_	O
6	ischemic	_	_	O
7	preconditioning	_	_	O
8	(	_	_	O
9	RIPC	_	_	O
10	)	_	_	O
11	on	_	_	O
12	contrast-induced	_	_	O
13	nephropathy	_	_	O
14	(	_	_	O
15	CIN	_	_	O
16	)	_	_	O
17	after	_	_	O
18	percutaneous	_	_	O
19	coronary	_	_	O
20	intervention	_	_	O
21	(	_	_	O
22	PCI	_	_	O
23	)	_	_	O
24	remain	_	_	O
25	to	_	_	O
26	be	_	_	O
27	defined	_	_	O
28	.	_	_	O

29	A	_	_	O
30	double	_	_	O
31	blind	_	_	O
32	,	_	_	O
33	randomized	_	_	O
34	,	_	_	O
35	placebo	_	_	O
36	controlled	_	_	O
37	multicenter	_	_	O
38	study	_	_	O
39	was	_	_	O
40	performed	_	_	O
41	.	_	_	O

42	Patients	_	_	O
43	younger	_	_	O
44	than	_	_	O
45	85years	_	_	O
46	old	_	_	O
47	,	_	_	O
48	with	_	_	O
49	a	_	_	O
50	renal	_	_	O
51	clearance	_	_	O
52	of	_	_	O
53	30-60ml/min/1.73m2	_	_	O
54	,	_	_	O
55	who	_	_	O
56	were	_	_	O
57	candidates	_	_	O
58	for	_	_	O
59	PCI	_	_	O
60	for	_	_	O
61	all	_	_	O
62	clinical	_	_	O
63	indications	_	_	O
64	except	_	_	O
65	for	_	_	O
66	primary	_	_	O
67	PCI	_	_	O
68	,	_	_	O
69	were	_	_	O
70	allocated	_	_	O
71	1:1	_	_	O
72	to	_	_	O
73	RIPC	_	_	O
74	or	_	_	O
75	to	_	_	O
76	standard	_	_	O
77	therapy	_	_	O
78	.	_	_	O

79	The	_	_	O
80	primary	_	_	O
81	endpoint	_	_	O
82	was	_	_	O
83	incidence	_	_	O
84	of	_	_	O
85	CIN	_	_	O
86	.	_	_	O

87	The	_	_	O
88	secondary	_	_	O
89	endpoint	_	_	O
90	was	_	_	O
91	incidence	_	_	O
92	of	_	_	O
93	peri-procedural	_	_	O
94	myocardial	_	_	O
95	infarction	_	_	O
96	(	_	_	O
97	PMI	_	_	O
98	)	_	_	O
99	.	_	_	O

100	From	_	_	O
101	February	_	_	O
102	2013	_	_	O
103	to	_	_	O
104	April	_	_	O
105	2014	_	_	O
106	,	_	_	O
107	3108	_	_	O
108	patients	_	_	O
109	who	_	_	O
110	were	_	_	O
111	scheduled	_	_	O
112	for	_	_	O
113	coronary	_	_	O
114	angiography	_	_	O
115	were	_	_	O
116	screened	_	_	O
117	for	_	_	O
118	the	_	_	O
119	study	_	_	O
120	.	_	_	O

121	442	_	_	O
122	fulfilled	_	_	O
123	the	_	_	O
124	inclusion	_	_	O
125	criteria	_	_	O
126	and	_	_	O
127	223	_	_	O
128	received	_	_	O
129	PCI	_	_	O
130	.	_	_	O

131	These	_	_	O
132	patients	_	_	O
133	were	_	_	O
134	randomized	_	_	O
135	to	_	_	O
136	sham	_	_	O
137	RIPC	_	_	O
138	(	_	_	O
139	n=107	_	_	O
140	)	_	_	O
141	or	_	_	O
142	treatment	_	_	O
143	group	_	_	O
144	(	_	_	O
145	n=116	_	_	O
146	)	_	_	O
147	.	_	_	O

148	The	_	_	O
149	only	_	_	O
150	pre-specified	_	_	O
151	subgroup	_	_	O
152	of	_	_	O
153	diabetic	_	_	O
154	patients	_	_	O
155	included	_	_	O
156	85	_	_	O
157	(	_	_	O
158	38	_	_	O
159	%	_	_	O
160	)	_	_	O
161	cases	_	_	O
162	.	_	_	O

163	RIPC	_	_	B-Premise
164	significantly	_	_	I-Premise
165	reduced	_	_	I-Premise
166	CIN	_	_	I-Premise
167	incidence	_	_	I-Premise
168	in	_	_	I-Premise
169	the	_	_	I-Premise
170	overall	_	_	I-Premise
171	population	_	_	I-Premise
172	(	_	_	I-Premise
173	12.1	_	_	I-Premise
174	%	_	_	I-Premise
175	vs.	_	_	I-Premise
176	26.1	_	_	I-Premise
177	%	_	_	I-Premise
178	,	_	_	I-Premise
179	p=0.01	_	_	I-Premise
180	,	_	_	I-Premise
181	with	_	_	I-Premise
182	a	_	_	I-Premise
183	NNT=9	_	_	I-Premise
184	)	_	_	I-Premise
185	and	_	_	I-Premise
186	in	_	_	I-Premise
187	non-diabetic	_	_	I-Premise
188	patients	_	_	I-Premise
189	(	_	_	I-Premise
190	9.2	_	_	I-Premise
191	%	_	_	I-Premise
192	vs.	_	_	I-Premise
193	25.0	_	_	I-Premise
194	%	_	_	I-Premise
195	,	_	_	I-Premise
196	p=0.02	_	_	I-Premise
197	)	_	_	I-Premise
198	,	_	_	I-Premise
199	but	_	_	I-Premise
200	showed	_	_	I-Premise
201	no	_	_	I-Premise
202	benefit	_	_	I-Premise
203	in	_	_	I-Premise
204	diabetics	_	_	I-Premise
205	(	_	_	I-Premise
206	16.7	_	_	I-Premise
207	%	_	_	I-Premise
208	vs.	_	_	I-Premise
209	28.2	_	_	I-Premise
210	%	_	_	I-Premise
211	,	_	_	I-Premise
212	p=0.21	_	_	I-Premise
213	)	_	_	I-Premise
214	.	_	_	I-Premise

215	A	_	_	B-Premise
216	trend	_	_	I-Premise
217	for	_	_	I-Premise
218	lower	_	_	I-Premise
219	PMI	_	_	I-Premise
220	was	_	_	I-Premise
221	seen	_	_	I-Premise
222	in	_	_	I-Premise
223	the	_	_	I-Premise
224	intervention	_	_	I-Premise
225	arm	_	_	I-Premise
226	(	_	_	I-Premise
227	creatine	_	_	I-Premise
228	kinase	_	_	I-Premise
229	-	_	_	I-Premise
230	muscle	_	_	I-Premise
231	brain	_	_	I-Premise
232	>	_	_	I-Premise
233	5	_	_	I-Premise
234	URL	_	_	I-Premise
235	;	_	_	I-Premise
236	8.4	_	_	I-Premise
237	%	_	_	I-Premise
238	vs.	_	_	I-Premise
239	16.4	_	_	I-Premise
240	%	_	_	I-Premise
241	,	_	_	I-Premise
242	p=0.07	_	_	I-Premise
243	;	_	_	I-Premise
244	troponin	_	_	I-Premise
245	T	_	_	I-Premise
246	>	_	_	I-Premise
247	5	_	_	I-Premise
248	URL	_	_	I-Premise
249	;	_	_	I-Premise
250	27	_	_	I-Premise
251	%	_	_	I-Premise
252	vs.	_	_	I-Premise
253	38	_	_	I-Premise
254	%	_	_	I-Premise
255	,	_	_	I-Premise
256	p=0.21	_	_	I-Premise
257	)	_	_	I-Premise
258	.	_	_	I-Premise

259	Remote	_	_	B-Claim
260	ischemic	_	_	I-Claim
261	preconditioning	_	_	I-Claim
262	significantly	_	_	I-Claim
263	reduces	_	_	I-Claim
264	the	_	_	I-Claim
265	incidence	_	_	I-Claim
266	of	_	_	I-Claim
267	acute	_	_	I-Claim
268	kidney	_	_	I-Claim
269	injury	_	_	I-Claim
270	in	_	_	I-Claim
271	non-diabetic	_	_	I-Claim
272	patients	_	_	I-Claim
273	undergoing	_	_	I-Claim
274	PCI	_	_	I-Claim
275	.	_	_	I-Claim

276	Larger	_	_	B-Claim
277	sample	_	_	I-Claim
278	size	_	_	I-Claim
279	is	_	_	I-Claim
280	presumably	_	_	I-Claim
281	needed	_	_	I-Claim
282	to	_	_	I-Claim
283	assess	_	_	I-Claim
284	the	_	_	I-Claim
285	effect	_	_	I-Claim
286	of	_	_	I-Claim
287	RIPC	_	_	I-Claim
288	for	_	_	I-Claim
289	patients	_	_	I-Claim
290	with	_	_	I-Claim
291	diabetes	_	_	I-Claim
292	mellitus	_	_	I-Claim
293	.	_	_	I-Claim


0	Hypertension	_	_	B-Claim
1	is	_	_	I-Claim
2	a	_	_	I-Claim
3	generally	_	_	I-Claim
4	accepted	_	_	I-Claim
5	atherogenic	_	_	I-Claim
6	risk	_	_	I-Claim
7	factor	_	_	I-Claim
8	.	_	_	I-Claim

9	The	_	_	O
10	aim	_	_	O
11	of	_	_	O
12	this	_	_	O
13	prospective	_	_	O
14	longitudinal	_	_	O
15	study	_	_	O
16	was	_	_	O
17	to	_	_	O
18	evaluate	_	_	O
19	changes	_	_	O
20	in	_	_	O
21	carotid	_	_	O
22	intima-media	_	_	O
23	thickness	_	_	O
24	(	_	_	O
25	c-IMT	_	_	O
26	)	_	_	O
27	and	_	_	O
28	explore	_	_	O
29	the	_	_	O
30	association	_	_	O
31	of	_	_	O
32	cardiovascular	_	_	O
33	risk	_	_	O
34	factors	_	_	O
35	and	_	_	O
36	the	_	_	O
37	carotid	_	_	O
38	intima	_	_	O
39	thickness	_	_	O
40	in	_	_	O
41	adults	_	_	O
42	with	_	_	O
43	hypertension	_	_	O
44	using	_	_	O
45	standardized	_	_	O
46	methods	_	_	O
47	.	_	_	O

48	We	_	_	O
49	used	_	_	O
50	data	_	_	O
51	from	_	_	O
52	a	_	_	O
53	subgroup	_	_	O
54	of	_	_	O
55	Beijing	_	_	O
56	Vascular	_	_	O
57	Disease	_	_	O
58	Patients	_	_	O
59	Evaluation	_	_	O
60	Study	_	_	O
61	(	_	_	O
62	BEST	_	_	O
63	)	_	_	O
64	,	_	_	O
65	a	_	_	O
66	population-based	_	_	O
67	study	_	_	O
68	of	_	_	O
69	community-dwelling	_	_	O
70	adults	_	_	O
71	.	_	_	O

72	The	_	_	O
73	c-IMT	_	_	O
74	,	_	_	O
75	biomarkers	_	_	O
76	,	_	_	O
77	and	_	_	O
78	carotid-femoral-pulse	_	_	O
79	wave	_	_	O
80	velocity	_	_	O
81	(	_	_	O
82	PWV	_	_	O
83	)	_	_	O
84	were	_	_	O
85	measured	_	_	O
86	at	_	_	O
87	baseline	_	_	O
88	,	_	_	O
89	and	_	_	O
90	lifestyles	_	_	O
91	such	_	_	O
92	as	_	_	O
93	smoking	_	_	O
94	status	_	_	O
95	,	_	_	O
96	sleeping	_	_	O
97	habits	_	_	O
98	,	_	_	O
99	and	_	_	O
100	oil	_	_	O
101	or	_	_	O
102	salt	_	_	O
103	intake	_	_	O
104	level	_	_	O
105	were	_	_	O
106	determined	_	_	O
107	with	_	_	O
108	the	_	_	O
109	use	_	_	O
110	of	_	_	O
111	a	_	_	O
112	validated	_	_	O
113	questionnaire	_	_	O
114	in	_	_	O
115	the	_	_	O
116	follow-up	_	_	O
117	.	_	_	O

118	We	_	_	O
119	reevaluated	_	_	O
120	c-IMT	_	_	O
121	in	_	_	O
122	all	_	_	O
123	the	_	_	O
124	initial	_	_	O
125	1284	_	_	O
126	(	_	_	O
127	540	_	_	O
128	female	_	_	O
129	and	_	_	O
130	744	_	_	O
131	male	_	_	O
132	)	_	_	O
133	patients	_	_	O
134	with	_	_	O
135	hypertension	_	_	O
136	after	_	_	O
137	4	_	_	O
138	years	_	_	O
139	.	_	_	O

140	At	_	_	O
141	reevaluation	_	_	O
142	,	_	_	O
143	mean	_	_	O
144	(	_	_	O
145	±	_	_	O
146	SD	_	_	O
147	)	_	_	O
148	age	_	_	O
149	was	_	_	O
150	66	_	_	O
151	±	_	_	O
152	1.2	_	_	O
153	years	_	_	O
154	,	_	_	O
155	systolic	_	_	O
156	blood	_	_	O
157	pressure	_	_	O
158	was	_	_	O
159	138	_	_	O
160	±	_	_	O
161	19	_	_	O
162	mmHg	_	_	O
163	,	_	_	O
164	and	_	_	O
165	diastolic	_	_	O
166	blood	_	_	O
167	pressure	_	_	O
168	was	_	_	O
169	91	_	_	O
170	±	_	_	O
171	10	_	_	O
172	mmHg	_	_	O
173	.	_	_	O

174	The	_	_	B-Premise
175	results	_	_	I-Premise
176	showed	_	_	I-Premise
177	that	_	_	I-Premise
178	mean	_	_	I-Premise
179	c-IMT	_	_	I-Premise
180	z-scores	_	_	I-Premise
181	increased	_	_	I-Premise
182	significantly	_	_	I-Premise
183	during	_	_	I-Premise
184	4	_	_	I-Premise
185	years	_	_	I-Premise
186	(	_	_	I-Premise
187	0.002	_	_	I-Premise
188	±	_	_	I-Premise
189	0.003	_	_	I-Premise
190	,	_	_	I-Premise
191	p	_	_	I-Premise
192	<	_	_	I-Premise
193	0.001	_	_	I-Premise
194	)	_	_	I-Premise
195	as	_	_	I-Premise
196	well	_	_	I-Premise
197	as	_	_	I-Premise
198	carotid-femoral	_	_	I-Premise
199	PWV	_	_	I-Premise
200	(	_	_	I-Premise
201	13.99	_	_	I-Premise
202	±	_	_	I-Premise
203	2.74	_	_	I-Premise
204	,	_	_	I-Premise
205	p	_	_	I-Premise
206	<	_	_	I-Premise
207	0.01	_	_	I-Premise
208	)	_	_	I-Premise
209	and	_	_	I-Premise
210	total	_	_	I-Premise
211	cholesterol	_	_	I-Premise
212	(	_	_	I-Premise
213	6.97	_	_	I-Premise
214	±	_	_	I-Premise
215	1.08	_	_	I-Premise
216	,	_	_	I-Premise
217	p	_	_	I-Premise
218	<	_	_	I-Premise
219	0.001	_	_	I-Premise
220	)	_	_	I-Premise
221	.	_	_	I-Premise

222	Linear	_	_	B-Premise
223	regression	_	_	I-Premise
224	showed	_	_	I-Premise
225	statistically	_	_	I-Premise
226	significant	_	_	I-Premise
227	associations	_	_	I-Premise
228	between	_	_	I-Premise
229	systolic	_	_	I-Premise
230	blood	_	_	I-Premise
231	pressure	_	_	I-Premise
232	,	_	_	I-Premise
233	diastolic	_	_	I-Premise
234	blood	_	_	I-Premise
235	pressure	_	_	I-Premise
236	,	_	_	I-Premise
237	C-reactive	_	_	I-Premise
238	protein	_	_	I-Premise
239	,	_	_	I-Premise
240	lip-line	_	_	I-Premise
241	,	_	_	I-Premise
242	and	_	_	I-Premise
243	heart	_	_	I-Premise
244	rate	_	_	I-Premise
245	with	_	_	I-Premise
246	c-IMT	_	_	I-Premise
247	z-scores	_	_	I-Premise
248	of	_	_	I-Premise
249	>	_	_	I-Premise
250	1.5SD	_	_	I-Premise
251	in	_	_	I-Premise
252	the	_	_	I-Premise
253	fully	_	_	I-Premise
254	adjusted	_	_	I-Premise
255	models	_	_	I-Premise
256	and	_	_	I-Premise
257	the	_	_	I-Premise
258	p	_	_	I-Premise
259	values	_	_	I-Premise
260	were	_	_	I-Premise
261	0.000	_	_	I-Premise
262	,	_	_	I-Premise
263	0.000	_	_	I-Premise
264	,	_	_	I-Premise
265	0.017	_	_	I-Premise
266	,	_	_	I-Premise
267	0.001	_	_	I-Premise
268	,	_	_	I-Premise
269	and	_	_	I-Premise
270	0.044	_	_	I-Premise
271	,	_	_	I-Premise
272	respectively	_	_	I-Premise
273	.	_	_	I-Premise

274	There	_	_	O
275	were	_	_	O
276	significant	_	_	O
277	predictors	_	_	O
278	for	_	_	O
279	the	_	_	O
280	mean	_	_	O
281	effect	_	_	O
282	on	_	_	O
283	c-IMT	_	_	O
284	z-score	_	_	O
285	.	_	_	O

286	In	_	_	B-Premise
287	a	_	_	I-Premise
288	full-model	_	_	I-Premise
289	logistic	_	_	I-Premise
290	regression	_	_	I-Premise
291	,	_	_	I-Premise
292	significant	_	_	I-Premise
293	risk	_	_	I-Premise
294	factors	_	_	I-Premise
295	for	_	_	I-Premise
296	an	_	_	I-Premise
297	increase	_	_	I-Premise
298	in	_	_	I-Premise
299	IMT	_	_	I-Premise
300	of	_	_	I-Premise
301	≥1.5	_	_	I-Premise
302	z-scores	_	_	I-Premise
303	were	_	_	I-Premise
304	carotid-femoral	_	_	I-Premise
305	PWV	_	_	I-Premise
306	(	_	_	I-Premise
307	odds	_	_	I-Premise
308	ratio	_	_	I-Premise
309	:	_	_	I-Premise
310	1.119	_	_	I-Premise
311	,	_	_	I-Premise
312	confidence	_	_	I-Premise
313	interval	_	_	I-Premise
314	:	_	_	I-Premise
315	1.018	_	_	I-Premise
316	,	_	_	I-Premise
317	1.230	_	_	I-Premise
318	,	_	_	I-Premise
319	p	_	_	I-Premise
320	=	_	_	I-Premise
321	0.020	_	_	I-Premise
322	<	_	_	I-Premise
323	0.05	_	_	I-Premise
324	)	_	_	I-Premise
325	at	_	_	I-Premise
326	first	_	_	I-Premise
327	measurement	_	_	I-Premise
328	.	_	_	I-Premise

329	The	_	_	B-Claim
330	conclusion	_	_	I-Claim
331	of	_	_	I-Claim
332	the	_	_	I-Claim
333	study	_	_	I-Claim
334	was	_	_	I-Claim
335	that	_	_	I-Claim
336	longitudinal	_	_	I-Claim
337	c-IMT	_	_	I-Claim
338	measurements	_	_	I-Claim
339	revealed	_	_	I-Claim
340	progression	_	_	I-Claim
341	in	_	_	I-Claim
342	subclinical	_	_	I-Claim
343	atherosclerosis	_	_	I-Claim
344	during	_	_	I-Claim
345	a	_	_	I-Claim
346	four-year	_	_	I-Claim
347	period	_	_	I-Claim
348	in	_	_	I-Claim
349	a	_	_	I-Claim
350	hypertensive	_	_	I-Claim
351	old-aged	_	_	I-Claim
352	cohort	_	_	I-Claim
353	.	_	_	I-Claim

354	Systolic	_	_	B-Claim
355	or	_	_	I-Claim
356	diastolic	_	_	I-Claim
357	blood	_	_	I-Claim
358	pressure	_	_	I-Claim
359	,	_	_	I-Claim
360	homocysteine	_	_	I-Claim
361	,	_	_	I-Claim
362	carotid-femoral	_	_	I-Claim
363	PWV	_	_	I-Claim
364	,	_	_	I-Claim
365	and	_	_	I-Claim
366	waistline	_	_	I-Claim
367	were	_	_	I-Claim
368	significantly	_	_	I-Claim
369	related	_	_	I-Claim
370	to	_	_	I-Claim
371	c-IMT	_	_	I-Claim
372	increment	_	_	I-Claim
373	.	_	_	I-Claim

374	By	_	_	B-Claim
375	lifestyle	_	_	I-Claim
376	and	_	_	I-Claim
377	medical	_	_	I-Claim
378	intervention	_	_	I-Claim
379	to	_	_	I-Claim
380	control	_	_	I-Claim
381	these	_	_	I-Claim
382	risk	_	_	I-Claim
383	factors	_	_	I-Claim
384	may	_	_	I-Claim
385	prevent	_	_	I-Claim
386	progression	_	_	I-Claim
387	of	_	_	I-Claim
388	c-IMT	_	_	I-Claim
389	in	_	_	I-Claim
390	old-aged	_	_	I-Claim
391	cohort	_	_	I-Claim
392	with	_	_	I-Claim
393	hypertension	_	_	I-Claim
394	.	_	_	I-Claim


0	The	_	_	B-Claim
1	immunosuppressive	_	_	I-Claim
2	drug	_	_	I-Claim
3	rapamycin	_	_	I-Claim
4	may	_	_	I-Claim
5	influence	_	_	I-Claim
6	insulin	_	_	I-Claim
7	sensitivity	_	_	I-Claim
8	in	_	_	I-Claim
9	insulin-responsive	_	_	I-Claim
10	tissues	_	_	I-Claim
11	.	_	_	I-Claim

12	This	_	_	O
13	study	_	_	O
14	aimed	_	_	O
15	at	_	_	O
16	evaluating	_	_	O
17	the	_	_	O
18	effectiveness	_	_	O
19	of	_	_	O
20	rapamycin	_	_	O
21	pre-treatment	_	_	O
22	before	_	_	O
23	pancreatic	_	_	O
24	islet	_	_	O
25	allotransplantation	_	_	O
26	(	_	_	O
27	ITx	_	_	O
28	)	_	_	O
29	in	_	_	O
30	patients	_	_	O
31	with	_	_	O
32	type	_	_	O
33	1	_	_	O
34	diabetes	_	_	O
35	mellitus	_	_	O
36	(	_	_	O
37	T1DM	_	_	O
38	)	_	_	O
39	.	_	_	O

40	Forty-one	_	_	O
41	T1DM	_	_	O
42	patients	_	_	O
43	were	_	_	O
44	studied	_	_	O
45	.	_	_	O

46	Thirteen	_	_	O
47	patients	_	_	O
48	with	_	_	O
49	poor	_	_	O
50	glycemic	_	_	O
51	control	_	_	O
52	underwent	_	_	O
53	a	_	_	O
54	short-term	_	_	O
55	rapamycin	_	_	O
56	treatment	_	_	O
57	before	_	_	O
58	ITx	_	_	O
59	(	_	_	O
60	Group	_	_	O
61	1	_	_	O
62	)	_	_	O
63	,	_	_	O
64	and	_	_	O
65	they	_	_	O
66	were	_	_	O
67	compared	_	_	O
68	to	_	_	O
69	28	_	_	O
70	patients	_	_	O
71	undergoing	_	_	O
72	ITx	_	_	O
73	without	_	_	O
74	rapamycin	_	_	O
75	pre-treatment	_	_	O
76	(	_	_	O
77	Group	_	_	O
78	2	_	_	O
79	)	_	_	O
80	.	_	_	O

81	Outcomes	_	_	O
82	were	_	_	O
83	daily	_	_	O
84	insulin	_	_	O
85	requirement	_	_	O
86	(	_	_	O
87	DIR	_	_	O
88	)	_	_	O
89	,	_	_	O
90	fasting	_	_	O
91	blood	_	_	O
92	glucose	_	_	O
93	,	_	_	O
94	HbA1c	_	_	O
95	,	_	_	O
96	C-peptide	_	_	O
97	and	_	_	O
98	the	_	_	O
99	SUITO	_	_	O
100	index	_	_	O
101	of	_	_	O
102	beta-cell	_	_	O
103	function	_	_	O
104	.	_	_	O

105	A	_	_	O
106	subgroup	_	_	O
107	of	_	_	O
108	patients	_	_	O
109	pre-treated	_	_	O
110	with	_	_	O
111	rapamycin	_	_	O
112	before	_	_	O
113	ITx	_	_	O
114	underwent	_	_	O
115	euglycemic	_	_	O
116	hyperinsulinemic	_	_	O
117	clamp	_	_	O
118	with	_	_	O
119	[	_	_	O
120	6,6-2H2	_	_	O
121	]	_	_	O
122	glucose	_	_	O
123	before	_	_	O
124	and	_	_	O
125	after	_	_	O
126	ITx	_	_	O
127	to	_	_	O
128	evaluate	_	_	O
129	insulin	_	_	O
130	sensitivity	_	_	O
131	.	_	_	O

132	We	_	_	B-Premise
133	found	_	_	I-Premise
134	a	_	_	I-Premise
135	significant	_	_	I-Premise
136	reduction	_	_	I-Premise
137	in	_	_	I-Premise
138	DIR	_	_	I-Premise
139	after	_	_	I-Premise
140	rapamycin	_	_	I-Premise
141	pre-treatment	_	_	I-Premise
142	(	_	_	I-Premise
143	-	_	_	I-Premise
144	8	_	_	I-Premise
145	±	_	_	I-Premise
146	6	_	_	I-Premise
147	U/day	_	_	I-Premise
148	,	_	_	I-Premise
149	mean	_	_	I-Premise
150	±	_	_	I-Premise
151	SD	_	_	I-Premise
152	,	_	_	I-Premise
153	p	_	_	I-Premise
154	<	_	_	I-Premise
155	0.001	_	_	I-Premise
156	)	_	_	I-Premise
157	and	_	_	I-Premise
158	1	_	_	I-Premise
159	year	_	_	I-Premise
160	after	_	_	I-Premise
161	ITx	_	_	I-Premise
162	.	_	_	I-Premise

163	DIR	_	_	B-Premise
164	reduction	_	_	I-Premise
165	1	_	_	I-Premise
166	year	_	_	I-Premise
167	after	_	_	I-Premise
168	ITx	_	_	I-Premise
169	was	_	_	I-Premise
170	greater	_	_	I-Premise
171	in	_	_	I-Premise
172	Group	_	_	I-Premise
173	1	_	_	I-Premise
174	as	_	_	I-Premise
175	compared	_	_	I-Premise
176	to	_	_	I-Premise
177	Group	_	_	I-Premise
178	2	_	_	I-Premise
179	(	_	_	I-Premise
180	-	_	_	I-Premise
181	37	_	_	I-Premise
182	±	_	_	I-Premise
183	15	_	_	I-Premise
184	vs.	_	_	I-Premise
185	-	_	_	I-Premise
186	19	_	_	I-Premise
187	±	_	_	I-Premise
188	13	_	_	I-Premise
189	U/day	_	_	I-Premise
190	,	_	_	I-Premise
191	p	_	_	I-Premise
192	=	_	_	I-Premise
193	0.005	_	_	I-Premise
194	)	_	_	I-Premise
195	and	_	_	I-Premise
196	remained	_	_	I-Premise
197	significant	_	_	I-Premise
198	after	_	_	I-Premise
199	adjusting	_	_	I-Premise
200	for	_	_	I-Premise
201	gender	_	_	I-Premise
202	,	_	_	I-Premise
203	age	_	_	I-Premise
204	,	_	_	I-Premise
205	glucose	_	_	I-Premise
206	and	_	_	I-Premise
207	baseline	_	_	I-Premise
208	HbA1c	_	_	I-Premise
209	(	_	_	I-Premise
210	beta	_	_	I-Premise
211	=	_	_	I-Premise
212	18.2	_	_	I-Premise
213	±	_	_	I-Premise
214	5.9	_	_	I-Premise
215	,	_	_	I-Premise
216	p	_	_	I-Premise
217	=	_	_	I-Premise
218	0.006	_	_	I-Premise
219	)	_	_	I-Premise
220	.	_	_	I-Premise

221	Fasting	_	_	B-Premise
222	glucose	_	_	I-Premise
223	and	_	_	I-Premise
224	HbA1c	_	_	I-Premise
225	significantly	_	_	I-Premise
226	decreased	_	_	I-Premise
227	1	_	_	I-Premise
228	year	_	_	I-Premise
229	after	_	_	I-Premise
230	ITx	_	_	I-Premise
231	in	_	_	I-Premise
232	Group	_	_	I-Premise
233	1	_	_	I-Premise
234	(	_	_	I-Premise
235	HbA1c	_	_	I-Premise
236	:	_	_	I-Premise
237	-	_	_	I-Premise
238	2.1	_	_	I-Premise
239	±	_	_	I-Premise
240	1.4	_	_	I-Premise
241	%	_	_	I-Premise
242	,	_	_	I-Premise
243	p	_	_	I-Premise
244	=	_	_	I-Premise
245	0.002	_	_	I-Premise
246	)	_	_	I-Premise
247	,	_	_	I-Premise
248	while	_	_	O
249	fasting	_	_	B-Premise
250	C-peptide	_	_	I-Premise
251	(	_	_	I-Premise
252	+0.5	_	_	I-Premise
253	±	_	_	I-Premise
254	0.3	_	_	I-Premise
255	nmol/l	_	_	I-Premise
256	,	_	_	I-Premise
257	p	_	_	I-Premise
258	=	_	_	I-Premise
259	0.002	_	_	I-Premise
260	)	_	_	I-Premise
261	and	_	_	I-Premise
262	SUITO	_	_	I-Premise
263	index	_	_	I-Premise
264	increased	_	_	I-Premise
265	(	_	_	I-Premise
266	+57.4	_	_	I-Premise
267	±	_	_	I-Premise
268	39.7	_	_	I-Premise
269	,	_	_	I-Premise
270	p	_	_	I-Premise
271	=	_	_	I-Premise
272	0.016	_	_	I-Premise
273	)	_	_	I-Premise
274	,	_	_	I-Premise
275	without	_	_	I-Premise
276	differences	_	_	I-Premise
277	between	_	_	I-Premise
278	the	_	_	I-Premise
279	two	_	_	I-Premise
280	groups	_	_	I-Premise
281	.	_	_	I-Premise

282	Hepatic	_	_	B-Premise
283	glucose	_	_	I-Premise
284	production	_	_	I-Premise
285	decreased	_	_	I-Premise
286	after	_	_	I-Premise
287	rapamycin	_	_	I-Premise
288	pre-treatment	_	_	I-Premise
289	(	_	_	I-Premise
290	-	_	_	I-Premise
291	1.1	_	_	I-Premise
292	±	_	_	I-Premise
293	1.1	_	_	I-Premise
294	mg/kg/min	_	_	I-Premise
295	,	_	_	I-Premise
296	p	_	_	I-Premise
297	=	_	_	I-Premise
298	0.04	_	_	I-Premise
299	)	_	_	I-Premise
300	and	_	_	I-Premise
301	after	_	_	I-Premise
302	ITx	_	_	I-Premise
303	(	_	_	I-Premise
304	-	_	_	I-Premise
305	1.6	_	_	I-Premise
306	±	_	_	I-Premise
307	0.6	_	_	I-Premise
308	mg/kg/min	_	_	I-Premise
309	,	_	_	I-Premise
310	p	_	_	I-Premise
311	=	_	_	I-Premise
312	0.015	_	_	I-Premise
313	)	_	_	I-Premise
314	,	_	_	I-Premise
315	while	_	_	O
316	no	_	_	B-Premise
317	changes	_	_	I-Premise
318	in	_	_	I-Premise
319	peripheral	_	_	I-Premise
320	glucose	_	_	I-Premise
321	disposal	_	_	I-Premise
322	were	_	_	I-Premise
323	observed	_	_	I-Premise
324	.	_	_	I-Premise

325	Rapamycin	_	_	B-Claim
326	pre-treatment	_	_	I-Claim
327	before	_	_	I-Claim
328	ITx	_	_	I-Claim
329	succeeds	_	_	I-Claim
330	in	_	_	I-Claim
331	reducing	_	_	I-Claim
332	insulin	_	_	I-Claim
333	requirement	_	_	I-Claim
334	,	_	_	I-Claim
335	enhancing	_	_	I-Claim
336	hepatic	_	_	I-Claim
337	insulin	_	_	I-Claim
338	sensitivity	_	_	I-Claim
339	.	_	_	I-Claim

340	This	_	_	B-Claim
341	treatment	_	_	I-Claim
342	may	_	_	I-Claim
343	improve	_	_	I-Claim
344	short-term	_	_	I-Claim
345	ITx	_	_	I-Claim
346	outcomes	_	_	I-Claim
347	,	_	_	I-Claim
348	possibly	_	_	I-Claim
349	in	_	_	I-Claim
350	selected	_	_	I-Claim
351	patients	_	_	I-Claim
352	with	_	_	I-Claim
353	T1DM	_	_	I-Claim
354	complicated	_	_	I-Claim
355	by	_	_	I-Claim
356	insulin	_	_	I-Claim
357	resistance	_	_	I-Claim
358	.	_	_	I-Claim


0	The	_	_	O
1	hepatitis	_	_	O
2	B	_	_	O
3	is	_	_	O
4	most	_	_	O
5	prevalent	_	_	O
6	diseases	_	_	O
7	(	_	_	O
8	along	_	_	O
9	with	_	_	O
10	morbidities	_	_	O
11	)	_	_	O
12	in	_	_	O
13	Asian	_	_	O
14	countries	_	_	O
15	.	_	_	O

16	This	_	_	O
17	research	_	_	O
18	study	_	_	O
19	has	_	_	O
20	been	_	_	O
21	conducted	_	_	O
22	to	_	_	O
23	provide	_	_	O
24	an	_	_	O
25	alternative	_	_	O
26	treatment	_	_	O
27	which	_	_	O
28	is	_	_	O
29	safe	_	_	O
30	,	_	_	O
31	effective	_	_	O
32	and	_	_	O
33	cost-effective	_	_	O
34	to	_	_	O
35	comprehend	_	_	O
36	relations	_	_	O
37	of	_	_	O
38	disease	_	_	O
39	,	_	_	O
40	symptoms	_	_	O
41	,	_	_	O
42	patients	_	_	O
43	response	_	_	O
44	and	_	_	O
45	the	_	_	O
46	clinical	_	_	O
47	response	_	_	O
48	via	_	_	O
49	better	_	_	O
50	management	_	_	O
51	of	_	_	O
52	hepatitis	_	_	O
53	B	_	_	O
54	.	_	_	O

55	The	_	_	O
56	goal	_	_	O
57	of	_	_	O
58	this	_	_	O
59	research	_	_	O
60	is	_	_	O
61	to	_	_	O
62	evaluate	_	_	O
63	efficacy	_	_	O
64	and	_	_	O
65	safety	_	_	O
66	of	_	_	O
67	herbal	_	_	O
68	medicine	_	_	O
69	as	_	_	O
70	compared	_	_	O
71	to	_	_	O
72	allopathic	_	_	O
73	medicine	_	_	O
74	in	_	_	O
75	patients	_	_	O
76	suffering	_	_	O
77	from	_	_	O
78	hepatitis	_	_	O
79	B	_	_	O
80	.	_	_	O

81	This	_	_	O
82	was	_	_	O
83	a	_	_	O
84	single	_	_	O
85	blind	_	_	O
86	,	_	_	O
87	randomized	_	_	O
88	controlled	_	_	O
89	clinical	_	_	O
90	trial	_	_	O
91	conducted	_	_	O
92	at	_	_	O
93	Shifa-ul-Mulk	_	_	O
94	Memorial	_	_	O
95	Hospital	_	_	O
96	Hamdard	_	_	O
97	University	_	_	O
98	,	_	_	O
99	Karachi	_	_	O
100	and	_	_	O
101	Dar	_	_	O
102	ul	_	_	O
103	Shifa	_	_	O
104	Unani	_	_	O
105	Dawakhana	_	_	O
106	Karachi	_	_	O
107	,	_	_	O
108	Pakistan	_	_	O
109	.	_	_	O

110	The	_	_	O
111	patients	_	_	O
112	of	_	_	O
113	both	_	_	O
114	genders	_	_	O
115	ranging	_	_	O
116	from	_	_	O
117	25	_	_	O
118	to	_	_	O
119	50	_	_	O
120	years	_	_	O
121	with	_	_	O
122	symptoms	_	_	O
123	and	_	_	O
124	diagnosed	_	_	O
125	for	_	_	O
126	hepatitis	_	_	O
127	B	_	_	O
128	that	_	_	O
129	fulfilled	_	_	O
130	the	_	_	O
131	criteria	_	_	O
132	for	_	_	O
133	membership	_	_	O
134	,	_	_	O
135	and	_	_	O
136	consented	_	_	O
137	for	_	_	O
138	participation	_	_	O
139	were	_	_	O
140	registered	_	_	O
141	.	_	_	O

142	Ethical	_	_	O
143	committee	_	_	O
144	clearance	_	_	O
145	and	_	_	O
146	permission	_	_	O
147	was	_	_	O
148	obtained	_	_	O
149	from	_	_	O
150	the	_	_	O
151	concerned	_	_	O
152	committee	_	_	O
153	at	_	_	O
154	Faculty	_	_	O
155	of	_	_	O
156	Eastern	_	_	O
157	Medicine	_	_	O
158	,	_	_	O
159	Hamdard	_	_	O
160	University	_	_	O
161	,	_	_	O
162	Karachi	_	_	O
163	,	_	_	O
164	Pakistan	_	_	O
165	.	_	_	O

166	No	_	_	B-Premise
167	significant	_	_	I-Premise
168	difference	_	_	I-Premise
169	was	_	_	I-Premise
170	identified	_	_	I-Premise
171	after	_	_	I-Premise
172	treatment	_	_	I-Premise
173	and	_	_	I-Premise
174	it	_	_	I-Premise
175	was	_	_	I-Premise
176	found	_	_	I-Premise
177	that	_	_	I-Premise
178	the	_	_	I-Premise
179	efficacy	_	_	I-Premise
180	of	_	_	I-Premise
181	Alpha	_	_	I-Premise
182	(	_	_	I-Premise
183	Control	_	_	I-Premise
184	drug	_	_	I-Premise
185	)	_	_	I-Premise
186	is	_	_	I-Premise
187	same	_	_	I-Premise
188	as	_	_	I-Premise
189	Safoof	_	_	I-Premise
190	akseer	_	_	I-Premise
191	e	_	_	I-Premise
192	jigar	_	_	I-Premise
193	(	_	_	I-Premise
194	Test	_	_	I-Premise
195	drug	_	_	I-Premise
196	)	_	_	I-Premise
197	.	_	_	I-Premise

198	The	_	_	B-Claim
199	data	_	_	I-Claim
200	offered	_	_	I-Claim
201	support	_	_	I-Claim
202	to	_	_	I-Claim
203	the	_	_	I-Claim
204	null	_	_	I-Claim
205	hypothesis	_	_	I-Claim
206	and	_	_	I-Claim
207	therefore	_	_	I-Claim
208	research	_	_	I-Claim
209	hypothesis	_	_	I-Claim
210	was	_	_	I-Claim
211	rejected	_	_	I-Claim
212	.	_	_	I-Claim

213	According	_	_	B-Premise
214	to	_	_	I-Premise
215	the	_	_	I-Premise
216	statistical	_	_	I-Premise
217	analysis	_	_	I-Premise
218	by	_	_	I-Premise
219	chi	_	_	I-Premise
220	square	_	_	I-Premise
221	,	_	_	I-Premise
222	hepatitis	_	_	I-Premise
223	B	_	_	I-Premise
224	was	_	_	I-Premise
225	recorded	_	_	I-Premise
226	as	_	_	I-Premise
227	negative	_	_	I-Premise
228	in	_	_	I-Premise
229	26	_	_	I-Premise
230	patients	_	_	I-Premise
231	(	_	_	I-Premise
232	57.77	_	_	I-Premise
233	%	_	_	I-Premise
234	)	_	_	I-Premise
235	out	_	_	I-Premise
236	of	_	_	I-Premise
237	45	_	_	I-Premise
238	patients	_	_	I-Premise
239	by	_	_	I-Premise
240	the	_	_	I-Premise
241	use	_	_	I-Premise
242	of	_	_	I-Premise
243	Interferon	_	_	I-Premise
244	Alpha	_	_	I-Premise
245	(	_	_	I-Premise
246	control	_	_	I-Premise
247	therapy	_	_	I-Premise
248	)	_	_	I-Premise
249	and	_	_	I-Premise
250	in	_	_	I-Premise
251	27	_	_	I-Premise
252	patients	_	_	I-Premise
253	(	_	_	I-Premise
254	64.28	_	_	I-Premise
255	%	_	_	I-Premise
256	)	_	_	I-Premise
257	out	_	_	I-Premise
258	of	_	_	I-Premise
259	42	_	_	I-Premise
260	patients	_	_	I-Premise
261	by	_	_	I-Premise
262	the	_	_	I-Premise
263	use	_	_	I-Premise
264	of	_	_	I-Premise
265	Safoof	_	_	I-Premise
266	akseer	_	_	I-Premise
267	e	_	_	I-Premise
268	jigar	_	_	I-Premise
269	(	_	_	I-Premise
270	test	_	_	I-Premise
271	drug	_	_	I-Premise
272	)	_	_	I-Premise
273	.	_	_	I-Premise

274	Comparison	_	_	B-Premise
275	of	_	_	I-Premise
276	the	_	_	I-Premise
277	data	_	_	I-Premise
278	recorded	_	_	I-Premise
279	of	_	_	I-Premise
280	the	_	_	I-Premise
281	patients	_	_	I-Premise
282	was	_	_	I-Premise
283	determined	_	_	I-Premise
284	as	_	_	I-Premise
285	both	_	_	I-Premise
286	drugs	_	_	I-Premise
287	showed	_	_	I-Premise
288	significant	_	_	I-Premise
289	improvement	_	_	I-Premise
290	and	_	_	I-Premise
291	p	_	_	I-Premise
292	value	_	_	I-Premise
293	>	_	_	I-Premise
294	0.05	_	_	I-Premise
295	.	_	_	I-Premise

296	The	_	_	B-Claim
297	efficacy	_	_	I-Claim
298	response	_	_	I-Claim
299	is	_	_	I-Claim
300	equal	_	_	I-Claim
301	in	_	_	I-Claim
302	both	_	_	I-Claim
303	drugs	_	_	I-Claim
304	while	_	_	I-Claim
305	test	_	_	I-Claim
306	drug	_	_	I-Claim
307	showed	_	_	I-Claim
308	more	_	_	I-Claim
309	safety	_	_	I-Claim
310	response	_	_	I-Claim
311	.	_	_	I-Claim

312	It	_	_	B-Claim
313	is	_	_	I-Claim
314	concluded	_	_	I-Claim
315	that	_	_	I-Claim
316	Safoof	_	_	I-Claim
317	akseer	_	_	I-Claim
318	e	_	_	I-Claim
319	jigar	_	_	I-Claim
320	possesses	_	_	I-Claim
321	as	_	_	I-Claim
322	effective	_	_	I-Claim
323	a	_	_	I-Claim
324	therapeutic	_	_	I-Claim
325	value	_	_	I-Claim
326	in	_	_	I-Claim
327	treating	_	_	I-Claim
328	hepatitis	_	_	I-Claim
329	B	_	_	I-Claim
330	as	_	_	I-Claim
331	allopathic	_	_	I-Claim
332	medicine	_	_	I-Claim
333	.	_	_	I-Claim


0	Observational	_	_	B-Claim
1	data	_	_	I-Claim
2	support	_	_	I-Claim
3	a	_	_	I-Claim
4	role	_	_	I-Claim
5	for	_	_	I-Claim
6	vitamin	_	_	I-Claim
7	D	_	_	I-Claim
8	in	_	_	I-Claim
9	type	_	_	I-Claim
10	2	_	_	I-Claim
11	diabetes	_	_	I-Claim
12	,	_	_	I-Claim
13	but	_	_	B-Claim
14	evidence	_	_	I-Claim
15	from	_	_	I-Claim
16	trials	_	_	I-Claim
17	is	_	_	I-Claim
18	inconclusive	_	_	I-Claim
19	.	_	_	I-Claim

20	To	_	_	O
21	evaluate	_	_	O
22	the	_	_	O
23	effect	_	_	O
24	of	_	_	O
25	vitamin	_	_	O
26	D	_	_	O
27	supplementation	_	_	O
28	on	_	_	O
29	β-cell	_	_	O
30	function	_	_	O
31	and	_	_	O
32	hemoglobin	_	_	O
33	A1c	_	_	O
34	(	_	_	O
35	HbA1c	_	_	O
36	)	_	_	O
37	in	_	_	O
38	patients	_	_	O
39	with	_	_	O
40	well-controlled	_	_	O
41	type	_	_	O
42	2	_	_	O
43	diabetes	_	_	O
44	.	_	_	O

45	Double-blind	_	_	O
46	,	_	_	O
47	randomized	_	_	O
48	,	_	_	O
49	placebo-controlled	_	_	O
50	clinical	_	_	O
51	trial	_	_	O
52	.	_	_	O

53	Tufts	_	_	O
54	Medical	_	_	O
55	Center	_	_	O
56	,	_	_	O
57	Boston	_	_	O
58	,	_	_	O
59	MA	_	_	O
60	;	_	_	O
61	VA	_	_	O
62	Medical	_	_	O
63	Center	_	_	O
64	,	_	_	O
65	Cincinnati	_	_	O
66	,	_	_	O
67	OH	_	_	O
68	.	_	_	O

69	A	_	_	O
70	total	_	_	O
71	of	_	_	O
72	127	_	_	O
73	patients	_	_	O
74	(	_	_	O
75	mean	_	_	O
76	age	_	_	O
77	,	_	_	O
78	60	_	_	O
79	years	_	_	O
80	)	_	_	O
81	with	_	_	O
82	stable	_	_	O
83	(	_	_	O
84	HbA1c	_	_	O
85	≤7.5	_	_	O
86	%	_	_	O
87	)	_	_	O
88	diabetes	_	_	O
89	managed	_	_	O
90	with	_	_	O
91	lifestyle	_	_	O
92	only	_	_	O
93	or	_	_	O
94	lifestyle	_	_	O
95	plus	_	_	O
96	metformin	_	_	O
97	.	_	_	O

98	Subjects	_	_	O
99	were	_	_	O
100	given	_	_	O
101	4000	_	_	O
102	units	_	_	O
103	of	_	_	O
104	vitamin	_	_	O
105	D3	_	_	O
106	(	_	_	O
107	cholecalciferol	_	_	O
108	)	_	_	O
109	daily	_	_	O
110	or	_	_	O
111	placebo	_	_	O
112	for	_	_	O
113	48	_	_	O
114	weeks	_	_	O
115	.	_	_	O

116	Insulin	_	_	O
117	secretion	_	_	O
118	rate	_	_	O
119	(	_	_	O
120	ISR	_	_	O
121	)	_	_	O
122	was	_	_	O
123	estimated	_	_	O
124	from	_	_	O
125	peripheral	_	_	O
126	plasma	_	_	O
127	C-peptide	_	_	O
128	levels	_	_	O
129	after	_	_	O
130	a	_	_	O
131	3-hour	_	_	O
132	75-g	_	_	O
133	oral	_	_	O
134	glucose	_	_	O
135	tolerance	_	_	O
136	test	_	_	O
137	done	_	_	O
138	at	_	_	O
139	baseline	_	_	O
140	and	_	_	O
141	week	_	_	O
142	24	_	_	O
143	.	_	_	O

144	Changes	_	_	O
145	in	_	_	O
146	HbA1c	_	_	O
147	were	_	_	O
148	assessed	_	_	O
149	at	_	_	O
150	16	_	_	O
151	,	_	_	O
152	24	_	_	O
153	,	_	_	O
154	36	_	_	O
155	,	_	_	O
156	and	_	_	O
157	48	_	_	O
158	weeks	_	_	O
159	.	_	_	O

160	Baseline	_	_	O
161	mean	_	_	O
162	plasma	_	_	O
163	25-hydroxyvitamin	_	_	O
164	D	_	_	O
165	[	_	_	O
166	25	_	_	O
167	(	_	_	O
168	OH	_	_	O
169	)	_	_	O
170	D	_	_	O
171	]	_	_	O
172	concentration	_	_	O
173	was	_	_	O
174	26.6	_	_	O
175	ng/mL	_	_	O
176	,	_	_	O
177	mean	_	_	O
178	HbA1c	_	_	O
179	was	_	_	O
180	6.6	_	_	O
181	%	_	_	O
182	,	_	_	O
183	and	_	_	O
184	78	_	_	O
185	%	_	_	O
186	of	_	_	O
187	patients	_	_	O
188	were	_	_	O
189	on	_	_	O
190	metformin	_	_	O
191	.	_	_	O

192	At	_	_	B-Premise
193	week	_	_	I-Premise
194	24	_	_	I-Premise
195	,	_	_	I-Premise
196	mean	_	_	I-Premise
197	25	_	_	I-Premise
198	(	_	_	I-Premise
199	OH	_	_	I-Premise
200	)	_	_	I-Premise
201	D	_	_	I-Premise
202	changed	_	_	I-Premise
203	by	_	_	I-Premise
204	20.5	_	_	I-Premise
205	and	_	_	I-Premise
206	-1.6	_	_	I-Premise
207	ng/mL	_	_	I-Premise
208	in	_	_	I-Premise
209	the	_	_	I-Premise
210	vitamin	_	_	I-Premise
211	D	_	_	I-Premise
212	and	_	_	I-Premise
213	placebo	_	_	I-Premise
214	groups	_	_	I-Premise
215	,	_	_	I-Premise
216	respectively	_	_	I-Premise
217	(	_	_	I-Premise
218	P	_	_	I-Premise
219	<	_	_	I-Premise
220	0.001	_	_	I-Premise
221	)	_	_	I-Premise
222	.	_	_	I-Premise

223	The	_	_	B-Premise
224	vitamin	_	_	I-Premise
225	D	_	_	I-Premise
226	and	_	_	I-Premise
227	placebo	_	_	I-Premise
228	groups	_	_	I-Premise
229	did	_	_	I-Premise
230	not	_	_	I-Premise
231	differ	_	_	I-Premise
232	in	_	_	I-Premise
233	change	_	_	I-Premise
234	in	_	_	I-Premise
235	ISR	_	_	I-Premise
236	or	_	_	I-Premise
237	HbA1c	_	_	I-Premise
238	.	_	_	I-Premise

239	Among	_	_	B-Premise
240	patients	_	_	I-Premise
241	treated	_	_	I-Premise
242	with	_	_	I-Premise
243	lifestyle	_	_	I-Premise
244	only	_	_	I-Premise
245	(	_	_	I-Premise
246	n	_	_	I-Premise
247	=	_	_	I-Premise
248	28	_	_	I-Premise
249	)	_	_	I-Premise
250	,	_	_	I-Premise
251	vitamin	_	_	I-Premise
252	D	_	_	I-Premise
253	supplementation	_	_	I-Premise
254	reduced	_	_	I-Premise
255	HbA1c	_	_	I-Premise
256	compared	_	_	I-Premise
257	with	_	_	I-Premise
258	placebo	_	_	I-Premise
259	(	_	_	I-Premise
260	-0.1	_	_	I-Premise
261	%	_	_	I-Premise
262	vs	_	_	I-Premise
263	0.3	_	_	I-Premise
264	%	_	_	I-Premise
265	,	_	_	I-Premise
266	respectively	_	_	I-Premise
267	;	_	_	I-Premise
268	P	_	_	I-Premise
269	=	_	_	I-Premise
270	0.034	_	_	I-Premise
271	)	_	_	I-Premise
272	at	_	_	I-Premise
273	week	_	_	I-Premise
274	24	_	_	I-Premise
275	.	_	_	I-Premise

276	This	_	_	O
277	result	_	_	O
278	was	_	_	O
279	not	_	_	O
280	observed	_	_	O
281	at	_	_	O
282	the	_	_	O
283	other	_	_	O
284	time	_	_	O
285	points	_	_	O
286	and	_	_	O
287	could	_	_	O
288	be	_	_	O
289	due	_	_	O
290	to	_	_	O
291	chance	_	_	O
292	.	_	_	O

293	Vitamin	_	_	B-Premise
294	D3	_	_	I-Premise
295	at	_	_	I-Premise
296	4000	_	_	I-Premise
297	IU/d	_	_	I-Premise
298	did	_	_	I-Premise
299	not	_	_	I-Premise
300	change	_	_	I-Premise
301	ISR	_	_	I-Premise
302	or	_	_	I-Premise
303	HbA1c	_	_	I-Premise
304	in	_	_	I-Premise
305	patients	_	_	I-Premise
306	with	_	_	I-Premise
307	well-controlled	_	_	I-Premise
308	type	_	_	I-Premise
309	2	_	_	I-Premise
310	diabetes	_	_	I-Premise
311	on	_	_	I-Premise
312	metformin	_	_	I-Premise
313	not	_	_	I-Premise
314	selected	_	_	I-Premise
315	for	_	_	I-Premise
316	vitamin	_	_	I-Premise
317	D	_	_	I-Premise
318	deficiency	_	_	I-Premise
319	.	_	_	I-Premise


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	outcomes	_	_	O
4	of	_	_	O
5	microcatheter-assisted	_	_	O
6	circumferential	_	_	O
7	trabeculotomy	_	_	O
8	to	_	_	O
9	standard	_	_	O
10	rigid	_	_	O
11	probe	_	_	O
12	trabeculotomy	_	_	O
13	in	_	_	O
14	childhood	_	_	O
15	glaucomas	_	_	O
16	.	_	_	O

17	Eyes	_	_	O
18	of	_	_	O
19	children	_	_	O
20	requiring	_	_	O
21	trabeculotomy	_	_	O
22	for	_	_	O
23	primary	_	_	O
24	congenital	_	_	O
25	or	_	_	O
26	secondary	_	_	O
27	paediatric	_	_	O
28	glaucoma	_	_	O
29	were	_	_	O
30	randomized	_	_	O
31	to	_	_	O
32	undergo	_	_	O
33	either	_	_	O
34	trabeculotomy	_	_	O
35	using	_	_	O
36	the	_	_	O
37	Glaucolight	_	_	O
38	illuminated	_	_	O
39	microcatheter	_	_	O
40	,	_	_	O
41	or	_	_	O
42	a	_	_	O
43	rigid	_	_	O
44	probe	_	_	O
45	trabeculotomy	_	_	O
46	.	_	_	O

47	Complete	_	_	O
48	success	_	_	O
49	was	_	_	O
50	defined	_	_	O
51	as	_	_	O
52	an	_	_	O
53	intraocular	_	_	O
54	pressure	_	_	O
55	(	_	_	O
56	IOP	_	_	O
57	)	_	_	O
58	of	_	_	O
59	<	_	_	O
60	18	_	_	O
61	mmHg	_	_	O
62	without	_	_	O
63	medications	_	_	O
64	.	_	_	O

65	A	_	_	O
66	total	_	_	O
67	of	_	_	O
68	62	_	_	O
69	eyes	_	_	O
70	of	_	_	O
71	62	_	_	O
72	patients	_	_	O
73	were	_	_	O
74	included	_	_	O
75	.	_	_	O

76	Of	_	_	O
77	these	_	_	O
78	30	_	_	O
79	eyes	_	_	O
80	of	_	_	O
81	30	_	_	O
82	patients	_	_	O
83	aged	_	_	O
84	5.6	_	_	O
85	±	_	_	O
86	4.8	_	_	O
87	months	_	_	O
88	underwent	_	_	O
89	microcatheter-assisted	_	_	O
90	trabeculotomy	_	_	O
91	,	_	_	O
92	with	_	_	O
93	15	_	_	O
94	eyes	_	_	O
95	(	_	_	O
96	50	_	_	O
97	%	_	_	O
98	)	_	_	O
99	having	_	_	O
100	a	_	_	O
101	complete	_	_	O
102	360°	_	_	O
103	cut	_	_	O
104	,	_	_	O
105	while	_	_	O
106	15	_	_	O
107	eyes	_	_	O
108	(	_	_	O
109	50	_	_	O
110	%	_	_	O
111	)	_	_	O
112	had	_	_	O
113	an	_	_	O
114	incomplete	_	_	O
115	cut	_	_	O
116	ranging	_	_	O
117	from	_	_	O
118	250	_	_	O
119	to	_	_	O
120	350	_	_	O
121	degrees	_	_	O
122	.	_	_	O

123	The	_	_	O
124	rigid	_	_	O
125	probe	_	_	O
126	trabeculotomy	_	_	O
127	group	_	_	O
128	included	_	_	O
129	32	_	_	O
130	eyes	_	_	O
131	of	_	_	O
132	32	_	_	O
133	patients	_	_	O
134	aged	_	_	O
135	4.4	_	_	O
136	±	_	_	O
137	3.8	_	_	O
138	months	_	_	O
139	.	_	_	O

140	At	_	_	B-Premise
141	the	_	_	I-Premise
142	end	_	_	I-Premise
143	of	_	_	I-Premise
144	the	_	_	I-Premise
145	2-year	_	_	I-Premise
146	follow-up	_	_	I-Premise
147	period	_	_	I-Premise
148	,	_	_	I-Premise
149	the	_	_	I-Premise
150	complete	_	_	I-Premise
151	success	_	_	I-Premise
152	and	_	_	I-Premise
153	the	_	_	I-Premise
154	failure	_	_	I-Premise
155	rates	_	_	I-Premise
156	were	_	_	I-Premise
157	67	_	_	I-Premise
158	%	_	_	I-Premise
159	and	_	_	I-Premise
160	15	_	_	I-Premise
161	%	_	_	I-Premise
162	,	_	_	I-Premise
163	respectively	_	_	I-Premise
164	,	_	_	I-Premise
165	in	_	_	I-Premise
166	the	_	_	I-Premise
167	microcatheter-assisted	_	_	I-Premise
168	group	_	_	I-Premise
169	versus	_	_	I-Premise
170	47	_	_	I-Premise
171	%	_	_	I-Premise
172	and	_	_	I-Premise
173	50	_	_	I-Premise
174	%	_	_	I-Premise
175	in	_	_	I-Premise
176	the	_	_	I-Premise
177	rigid	_	_	I-Premise
178	probe	_	_	I-Premise
179	trabeculotomy	_	_	I-Premise
180	group	_	_	I-Premise
181	(	_	_	I-Premise
182	p	_	_	I-Premise
183	=	_	_	I-Premise
184	0.006	_	_	I-Premise
185	)	_	_	I-Premise
186	.	_	_	I-Premise

187	There	_	_	B-Premise
188	was	_	_	I-Premise
189	a	_	_	I-Premise
190	tendency	_	_	I-Premise
191	towards	_	_	I-Premise
192	lower	_	_	I-Premise
193	IOP	_	_	I-Premise
194	in	_	_	I-Premise
195	the	_	_	I-Premise
196	microcatheter	_	_	I-Premise
197	group	_	_	I-Premise
198	at	_	_	I-Premise
199	1	_	_	I-Premise
200	,	_	_	I-Premise
201	3	_	_	I-Premise
202	,	_	_	I-Premise
203	6	_	_	I-Premise
204	,	_	_	I-Premise
205	12	_	_	I-Premise
206	and	_	_	I-Premise
207	24	_	_	I-Premise
208	months	_	_	I-Premise
209	postoperatively	_	_	I-Premise
210	,	_	_	I-Premise
211	with	_	_	I-Premise
212	the	_	_	I-Premise
213	difference	_	_	I-Premise
214	in	_	_	I-Premise
215	IOP	_	_	I-Premise
216	reaching	_	_	I-Premise
217	statistical	_	_	I-Premise
218	significance	_	_	I-Premise
219	at	_	_	I-Premise
220	6	_	_	I-Premise
221	months	_	_	I-Premise
222	(	_	_	I-Premise
223	p	_	_	I-Premise
224	=	_	_	I-Premise
225	0.004	_	_	I-Premise
226	)	_	_	I-Premise
227	.	_	_	I-Premise

228	The	_	_	B-Premise
229	mean	_	_	I-Premise
230	survival	_	_	I-Premise
231	time	_	_	I-Premise
232	was	_	_	I-Premise
233	significantly	_	_	I-Premise
234	longer	_	_	I-Premise
235	for	_	_	I-Premise
236	the	_	_	I-Premise
237	microcatheter	_	_	I-Premise
238	group	_	_	I-Premise
239	(	_	_	I-Premise
240	p	_	_	I-Premise
241	=	_	_	I-Premise
242	0.01	_	_	I-Premise
243	)	_	_	I-Premise
244	.	_	_	I-Premise

245	At	_	_	B-Claim
246	2	_	_	I-Claim
247	years	_	_	I-Claim
248	postoperatively	_	_	I-Claim
249	,	_	_	I-Claim
250	microcatheter-assisted	_	_	I-Claim
251	trabeculotomy	_	_	I-Claim
252	still	_	_	I-Claim
253	yielded	_	_	I-Claim
254	superior	_	_	I-Claim
255	results	_	_	I-Claim
256	in	_	_	I-Claim
257	terms	_	_	I-Claim
258	of	_	_	I-Claim
259	IOP	_	_	I-Claim
260	control	_	_	I-Claim
261	and	_	_	I-Claim
262	success	_	_	I-Claim
263	rates	_	_	I-Claim
264	in	_	_	I-Claim
265	children	_	_	I-Claim
266	with	_	_	I-Claim
267	primary	_	_	I-Claim
268	congenital	_	_	I-Claim
269	glaucoma	_	_	I-Claim
270	.	_	_	I-Claim

271	The	_	_	B-Premise
272	need	_	_	I-Premise
273	for	_	_	I-Premise
274	reoperation	_	_	I-Premise
275	for	_	_	I-Premise
276	glaucoma	_	_	I-Premise
277	was	_	_	I-Premise
278	significantly	_	_	I-Premise
279	lower	_	_	I-Premise
280	in	_	_	I-Premise
281	the	_	_	I-Premise
282	microcatheter	_	_	I-Premise
283	group	_	_	I-Premise
284	.	_	_	I-Premise


0	Cardiovascular	_	_	B-Claim
1	complications	_	_	I-Claim
2	are	_	_	I-Claim
3	one	_	_	I-Claim
4	of	_	_	I-Claim
5	main	_	_	I-Claim
6	cause	_	_	I-Claim
7	of	_	_	I-Claim
8	increased	_	_	I-Claim
9	mortality	_	_	I-Claim
10	and	_	_	I-Claim
11	morbidity	_	_	I-Claim
12	among	_	_	I-Claim
13	Diabetes	_	_	I-Claim
14	Mellitus	_	_	I-Claim
15	(	_	_	I-Claim
16	DM	_	_	I-Claim
17	)	_	_	I-Claim
18	patients	_	_	I-Claim
19	.	_	_	I-Claim

20	Altered	_	_	B-Claim
21	metabolism	_	_	I-Claim
22	of	_	_	I-Claim
23	sulphur	_	_	I-Claim
24	amino	_	_	I-Claim
25	acids	_	_	I-Claim
26	in	_	_	I-Claim
27	diabetes	_	_	I-Claim
28	reflected	_	_	I-Claim
29	as	_	_	I-Claim
30	increases	_	_	I-Claim
31	in	_	_	I-Claim
32	concentration	_	_	I-Claim
33	of	_	_	I-Claim
34	methionine	_	_	I-Claim
35	and	_	_	I-Claim
36	cysteine/cystine	_	_	I-Claim
37	in	_	_	I-Claim
38	the	_	_	I-Claim
39	blood	_	_	I-Claim
40	which	_	_	I-Claim
41	known	_	_	I-Claim
42	as	_	_	I-Claim
43	a	_	_	I-Claim
44	markers	_	_	I-Claim
45	of	_	_	I-Claim
46	Cardiovascular	_	_	I-Claim
47	Diseases	_	_	I-Claim
48	(	_	_	I-Claim
49	CVD	_	_	I-Claim
50	)	_	_	I-Claim
51	.	_	_	I-Claim

52	The	_	_	O
53	aim	_	_	O
54	of	_	_	O
55	present	_	_	O
56	study	_	_	O
57	was	_	_	O
58	to	_	_	O
59	determine	_	_	O
60	the	_	_	O
61	effect	_	_	O
62	of	_	_	O
63	Eicosapentaenoic	_	_	O
64	acid	_	_	O
65	(	_	_	O
66	EPA	_	_	O
67	)	_	_	O
68	supplementation	_	_	O
69	on	_	_	O
70	sulfhydryl	_	_	O
71	amino	_	_	O
72	acids	_	_	O
73	and	_	_	O
74	Atherogenic	_	_	O
75	Index	_	_	O
76	of	_	_	O
77	Plasma	_	_	O
78	(	_	_	O
79	AIP	_	_	O
80	)	_	_	O
81	in	_	_	O
82	patients	_	_	O
83	with	_	_	O
84	type	_	_	O
85	2	_	_	O
86	DM	_	_	O
87	(	_	_	O
88	T2DM	_	_	O
89	)	_	_	O
90	.	_	_	O

91	A	_	_	O
92	randomized	_	_	O
93	,	_	_	O
94	double-blind	_	_	O
95	,	_	_	O
96	placebo-controlled	_	_	O
97	clinical	_	_	O
98	trial	_	_	O
99	was	_	_	O
100	performed	_	_	O
101	in	_	_	O
102	36	_	_	O
103	control	_	_	O
104	and	_	_	O
105	patients	_	_	O
106	with	_	_	O
107	DM	_	_	O
108	.	_	_	O

109	The	_	_	O
110	subjects	_	_	O
111	were	_	_	O
112	randomly	_	_	O
113	assigned	_	_	O
114	to	_	_	O
115	obtain	_	_	O
116	2	_	_	O
117	g/d	_	_	O
118	EPA	_	_	O
119	(	_	_	O
120	n	_	_	O
121	=	_	_	O
122	18	_	_	O
123	)	_	_	O
124	or	_	_	O
125	placebo	_	_	O
126	(	_	_	O
127	n	_	_	O
128	=	_	_	O
129	18	_	_	O
130	)	_	_	O
131	for	_	_	O
132	8	_	_	O
133	weeks	_	_	O
134	.	_	_	O

135	Fasting	_	_	O
136	serum	_	_	O
137	level	_	_	O
138	of	_	_	O
139	Cystein	_	_	O
140	and	_	_	O
141	Methionine	_	_	O
142	were	_	_	O
143	measured	_	_	O
144	using	_	_	O
145	HPLC	_	_	O
146	method	_	_	O
147	and	_	_	O
148	atherogenic	_	_	O
149	index	_	_	O
150	of	_	_	O
151	plasma	_	_	O
152	(	_	_	O
153	AIP	_	_	O
154	)	_	_	O
155	as	_	_	O
156	a	_	_	O
157	proxy	_	_	O
158	measure	_	_	O
159	of	_	_	O
160	atherosclerosis	_	_	O
161	was	_	_	O
162	computed	_	_	O
163	.	_	_	O

164	Eight	_	_	B-Premise
165	weeks	_	_	I-Premise
166	supplementation	_	_	I-Premise
167	with	_	_	I-Premise
168	EPA	_	_	I-Premise
169	led	_	_	I-Premise
170	to	_	_	I-Premise
171	significant	_	_	I-Premise
172	reductions	_	_	I-Premise
173	in	_	_	I-Premise
174	Met	_	_	I-Premise
175	(	_	_	I-Premise
176	p	_	_	I-Premise
177	<	_	_	I-Premise
178	0.002	_	_	I-Premise
179	)	_	_	I-Premise
180	and	_	_	I-Premise
181	Cys	_	_	I-Premise
182	(	_	_	I-Premise
183	p	_	_	I-Premise
184	<	_	_	I-Premise
185	0.001	_	_	I-Premise
186	)	_	_	I-Premise
187	compared	_	_	I-Premise
188	with	_	_	I-Premise
189	the	_	_	I-Premise
190	placebo	_	_	I-Premise
191	(	_	_	I-Premise
192	p	_	_	I-Premise
193	<	_	_	I-Premise
194	0.06	_	_	I-Premise
195	)	_	_	I-Premise
196	.	_	_	I-Premise

197	In	_	_	O
198	addition	_	_	O
199	,	_	_	O
200	compared	_	_	B-Premise
201	to	_	_	I-Premise
202	placebo	_	_	I-Premise
203	a	_	_	I-Premise
204	significant	_	_	I-Premise
205	reduction	_	_	I-Premise
206	in	_	_	I-Premise
207	AIP	_	_	I-Premise
208	were	_	_	I-Premise
209	seen	_	_	I-Premise
210	after	_	_	I-Premise
211	taking	_	_	I-Premise
212	EPA	_	_	I-Premise
213	(	_	_	I-Premise
214	p	_	_	I-Premise
215	<	_	_	I-Premise
216	0.04	_	_	I-Premise
217	)	_	_	I-Premise
218	.	_	_	I-Premise

219	EPA	_	_	B-Claim
220	supplementation	_	_	I-Claim
221	in	_	_	I-Claim
222	patients	_	_	I-Claim
223	with	_	_	I-Claim
224	T2DM	_	_	I-Claim
225	for	_	_	I-Claim
226	eight	_	_	I-Claim
227	weeks	_	_	I-Claim
228	had	_	_	I-Claim
229	beneficial	_	_	I-Claim
230	effects	_	_	I-Claim
231	on	_	_	I-Claim
232	Met	_	_	I-Claim
233	,	_	_	I-Claim
234	Cys	_	_	I-Claim
235	and	_	_	I-Claim
236	AIP	_	_	I-Claim
237	,	_	_	I-Claim
238	which	_	_	I-Claim
239	may	_	_	I-Claim
240	attribute	_	_	I-Claim
241	to	_	_	I-Claim
242	the	_	_	I-Claim
243	prevention	_	_	I-Claim
244	of	_	_	I-Claim
245	vascular	_	_	I-Claim
246	complications	_	_	I-Claim
247	in	_	_	I-Claim
248	the	_	_	I-Claim
249	T2DM	_	_	I-Claim
250	patients	_	_	I-Claim
251	.	_	_	I-Claim


0	The	_	_	O
1	standard	_	_	O
2	treatment	_	_	O
3	for	_	_	O
4	patients	_	_	O
5	with	_	_	O
6	clinically	_	_	O
7	resectable	_	_	O
8	rectal	_	_	O
9	cancer	_	_	O
10	is	_	_	O
11	surgery	_	_	O
12	.	_	_	O

13	Postoperative	_	_	B-Claim
14	radiochemotherapy	_	_	I-Claim
15	is	_	_	I-Claim
16	recommended	_	_	I-Claim
17	for	_	_	I-Claim
18	patients	_	_	I-Claim
19	with	_	_	I-Claim
20	advanced	_	_	I-Claim
21	disease	_	_	I-Claim
22	(	_	_	I-Claim
23	pT3/4	_	_	I-Claim
24	or	_	_	I-Claim
25	pN+	_	_	I-Claim
26	)	_	_	I-Claim
27	.	_	_	I-Claim

28	In	_	_	B-Claim
29	recent	_	_	I-Claim
30	years	_	_	I-Claim
31	,	_	_	I-Claim
32	encouraging	_	_	I-Claim
33	results	_	_	I-Claim
34	of	_	_	I-Claim
35	preoperative	_	_	I-Claim
36	radiotherapy	_	_	I-Claim
37	have	_	_	I-Claim
38	been	_	_	I-Claim
39	reported	_	_	I-Claim
40	.	_	_	I-Claim

41	This	_	_	O
42	prospective	_	_	O
43	randomized	_	_	O
44	phase-III	_	_	O
45	trial	_	_	O
46	(	_	_	O
47	CAO/ARO/AIO-94	_	_	O
48	)	_	_	O
49	compares	_	_	O
50	the	_	_	O
51	efficacy	_	_	O
52	of	_	_	O
53	neoadjuvant	_	_	O
54	radiochemotherapy	_	_	O
55	to	_	_	O
56	standard	_	_	O
57	postoperative	_	_	O
58	radiochemotherapy	_	_	O
59	.	_	_	O

60	We	_	_	O
61	report	_	_	O
62	on	_	_	O
63	the	_	_	O
64	design	_	_	O
65	of	_	_	O
66	the	_	_	O
67	study	_	_	O
68	and	_	_	O
69	first	_	_	O
70	results	_	_	O
71	with	_	_	O
72	regard	_	_	O
73	to	_	_	O
74	toxicity	_	_	O
75	of	_	_	O
76	radiochemotherapy	_	_	O
77	and	_	_	O
78	postoperative	_	_	O
79	morbidity	_	_	O
80	.	_	_	O

81	Patients	_	_	O
82	with	_	_	O
83	locally	_	_	O
84	advanced	_	_	O
85	operable	_	_	O
86	rectal	_	_	O
87	cancer	_	_	O
88	(	_	_	O
89	uT3/4	_	_	O
90	or	_	_	O
91	uN+	_	_	O
92	,	_	_	O
93	Mason	_	_	O
94	CS	_	_	O
95	III/IV	_	_	O
96	)	_	_	O
97	were	_	_	O
98	randomly	_	_	O
99	assigned	_	_	O
100	to	_	_	O
101	pre-	_	_	O
102	or	_	_	O
103	postoperative	_	_	O
104	radiochemotherapy	_	_	O
105	:	_	_	O
106	A	_	_	O
107	total	_	_	O
108	dose	_	_	O
109	of	_	_	O
110	50.4	_	_	O
111	Gy	_	_	O
112	(	_	_	O
113	single	_	_	O
114	dose	_	_	O
115	1.8	_	_	O
116	Gy	_	_	O
117	)	_	_	O
118	was	_	_	O
119	applied	_	_	O
120	to	_	_	O
121	the	_	_	O
122	tumor	_	_	O
123	and	_	_	O
124	the	_	_	O
125	pelvic	_	_	O
126	lymph	_	_	O
127	nodes	_	_	O
128	.	_	_	O

129	5-FU	_	_	O
130	(	_	_	O
131	1,000	_	_	O
132	mg/m2/d	_	_	O
133	)	_	_	O
134	was	_	_	O
135	administered	_	_	O
136	concomitantly	_	_	O
137	in	_	_	O
138	the	_	_	O
139	first	_	_	O
140	and	_	_	O
141	fifth	_	_	O
142	week	_	_	O
143	of	_	_	O
144	radiation	_	_	O
145	as	_	_	O
146	120-h	_	_	O
147	continuous	_	_	O
148	infusion	_	_	O
149	.	_	_	O

150	Four	_	_	O
151	additional	_	_	O
152	cycles	_	_	O
153	of	_	_	O
154	5-FU	_	_	O
155	chemotherapy	_	_	O
156	(	_	_	O
157	500	_	_	O
158	mg/m2/d	_	_	O
159	,	_	_	O
160	i.v	_	_	O
161	.	_	_	O

162	bolus	_	_	O
163	)	_	_	O
164	were	_	_	O
165	applied	_	_	O
166	.	_	_	O

167	Radiochemotherapy	_	_	O
168	was	_	_	O
169	identical	_	_	O
170	in	_	_	O
171	both	_	_	O
172	arms	_	_	O
173	except	_	_	O
174	for	_	_	O
175	a	_	_	O
176	small-volume	_	_	O
177	boost	_	_	O
178	of	_	_	O
179	5.4	_	_	O
180	Gy	_	_	O
181	in	_	_	O
182	the	_	_	O
183	postoperative	_	_	O
184	setting	_	_	O
185	.	_	_	O

186	Time	_	_	O
187	interval	_	_	O
188	between	_	_	O
189	radiochemotherapy	_	_	O
190	and	_	_	O
191	surgery	_	_	O
192	was	_	_	O
193	4-6	_	_	O
194	weeks	_	_	O
195	in	_	_	O
196	both	_	_	O
197	arms	_	_	O
198	.	_	_	O

199	Techniques	_	_	O
200	of	_	_	O
201	surgery	_	_	O
202	were	_	_	O
203	standardized	_	_	O
204	and	_	_	O
205	included	_	_	O
206	total	_	_	O
207	mesorectal	_	_	O
208	excision	_	_	O
209	.	_	_	O

210	In	_	_	O
211	addition	_	_	O
212	,	_	_	O
213	stratification	_	_	O
214	according	_	_	O
215	to	_	_	O
216	surgeons	_	_	O
217	involved	_	_	O
218	has	_	_	O
219	been	_	_	O
220	provided	_	_	O
221	for	_	_	O
222	.	_	_	O

223	Primary	_	_	O
224	endpoints	_	_	O
225	of	_	_	O
226	the	_	_	O
227	study	_	_	O
228	are	_	_	O
229	5-year	_	_	O
230	overall-survival	_	_	O
231	,	_	_	O
232	local	_	_	O
233	and	_	_	O
234	distant	_	_	O
235	control	_	_	O
236	,	_	_	O
237	secondary	_	_	O
238	endpoints	_	_	O
239	include	_	_	O
240	rate	_	_	O
241	of	_	_	O
242	curative	_	_	O
243	(	_	_	O
244	R0	_	_	O
245	)	_	_	O
246	resections	_	_	O
247	and	_	_	O
248	sphincter	_	_	O
249	saving	_	_	O
250	procedures	_	_	O
251	,	_	_	O
252	toxicity	_	_	O
253	of	_	_	O
254	radiochemotherapy	_	_	O
255	,	_	_	O
256	surgical	_	_	O
257	complications	_	_	O
258	and	_	_	O
259	quality	_	_	O
260	of	_	_	O
261	life	_	_	O
262	.	_	_	O

263	As	_	_	O
264	of	_	_	O
265	15th	_	_	O
266	November	_	_	O
267	2000	_	_	O
268	,	_	_	O
269	628	_	_	O
270	patients	_	_	O
271	were	_	_	O
272	randomized	_	_	O
273	from	_	_	O
274	26	_	_	O
275	participating	_	_	O
276	institutions	_	_	O
277	:	_	_	O
278	310	_	_	O
279	patients	_	_	O
280	were	_	_	O
281	randomized	_	_	O
282	to	_	_	O
283	postoperative	_	_	O
284	radiochemotherapy	_	_	O
285	,	_	_	O
286	318	_	_	O
287	patients	_	_	O
288	to	_	_	O
289	preoperative	_	_	O
290	radiochemotherapy	_	_	O
291	.	_	_	O

292	Acute	_	_	B-Premise
293	toxicity	_	_	I-Premise
294	(	_	_	I-Premise
295	WHO	_	_	I-Premise
296	)	_	_	I-Premise
297	of	_	_	I-Premise
298	radiochemotherapy	_	_	I-Premise
299	was	_	_	I-Premise
300	low	_	_	I-Premise
301	,	_	_	I-Premise
302	with	_	_	I-Premise
303	less	_	_	I-Premise
304	than	_	_	I-Premise
305	15	_	_	I-Premise
306	%	_	_	I-Premise
307	of	_	_	I-Premise
308	patients	_	_	I-Premise
309	experiencing	_	_	I-Premise
310	Grade	_	_	I-Premise
311	3	_	_	I-Premise
312	or	_	_	I-Premise
313	higher	_	_	I-Premise
314	toxicity	_	_	I-Premise
315	:	_	_	O
316	The	_	_	B-Premise
317	principal	_	_	I-Premise
318	toxicity	_	_	I-Premise
319	was	_	_	I-Premise
320	diarrhea	_	_	I-Premise
321	,	_	_	I-Premise
322	with	_	_	I-Premise
323	12	_	_	I-Premise
324	%	_	_	I-Premise
325	in	_	_	I-Premise
326	the	_	_	I-Premise
327	postoperative	_	_	I-Premise
328	radiochemotherapy	_	_	I-Premise
329	arm	_	_	I-Premise
330	and	_	_	I-Premise
331	10	_	_	I-Premise
332	%	_	_	I-Premise
333	in	_	_	I-Premise
334	the	_	_	I-Premise
335	preoperative	_	_	I-Premise
336	radiochemotherapy	_	_	I-Premise
337	arm	_	_	I-Premise
338	having	_	_	I-Premise
339	Grade-3	_	_	I-Premise
340	,	_	_	I-Premise
341	and	_	_	I-Premise
342	1	_	_	I-Premise
343	%	_	_	I-Premise
344	in	_	_	I-Premise
345	either	_	_	I-Premise
346	arm	_	_	I-Premise
347	having	_	_	I-Premise
348	Grade-4	_	_	I-Premise
349	diarrhea	_	_	I-Premise
350	.	_	_	I-Premise

351	Erythema	_	_	B-Premise
352	,	_	_	I-Premise
353	nausea	_	_	I-Premise
354	and	_	_	I-Premise
355	leukopenia	_	_	I-Premise
356	were	_	_	I-Premise
357	the	_	_	I-Premise
358	next	_	_	I-Premise
359	common	_	_	I-Premise
360	toxicities	_	_	I-Premise
361	,	_	_	I-Premise
362	with	_	_	I-Premise
363	less	_	_	I-Premise
364	than	_	_	I-Premise
365	3	_	_	I-Premise
366	%	_	_	I-Premise
367	of	_	_	I-Premise
368	patients	_	_	I-Premise
369	in	_	_	I-Premise
370	either	_	_	I-Premise
371	arm	_	_	I-Premise
372	suffering	_	_	I-Premise
373	Grade	_	_	I-Premise
374	3	_	_	I-Premise
375	or	_	_	I-Premise
376	greater	_	_	I-Premise
377	leukopenia	_	_	I-Premise
378	or	_	_	I-Premise
379	nausea	_	_	I-Premise
380	.	_	_	I-Premise

381	Postoperative	_	_	B-Premise
382	complication	_	_	I-Premise
383	rates	_	_	I-Premise
384	were	_	_	I-Premise
385	similar	_	_	I-Premise
386	in	_	_	I-Premise
387	both	_	_	I-Premise
388	arms	_	_	I-Premise
389	,	_	_	I-Premise
390	with	_	_	I-Premise
391	12	_	_	I-Premise
392	%	_	_	I-Premise
393	(	_	_	I-Premise
394	postoperative	_	_	I-Premise
395	radiochemotherapy	_	_	I-Premise
396	)	_	_	I-Premise
397	and	_	_	I-Premise
398	13	_	_	I-Premise
399	%	_	_	I-Premise
400	(	_	_	I-Premise
401	preoperative	_	_	I-Premise
402	radiochemotherapy	_	_	I-Premise
403	)	_	_	I-Premise
404	of	_	_	I-Premise
405	patients	_	_	I-Premise
406	,	_	_	I-Premise
407	respectively	_	_	I-Premise
408	,	_	_	I-Premise
409	suffering	_	_	I-Premise
410	from	_	_	I-Premise
411	anastomotic	_	_	I-Premise
412	leakage	_	_	I-Premise
413	,	_	_	I-Premise
414	4	_	_	I-Premise
415	%	_	_	I-Premise
416	(	_	_	I-Premise
417	postoperative	_	_	I-Premise
418	radiochemotherapy	_	_	I-Premise
419	)	_	_	I-Premise
420	and	_	_	I-Premise
421	3	_	_	I-Premise
422	%	_	_	I-Premise
423	(	_	_	I-Premise
424	preoperative	_	_	I-Premise
425	radiochemotherapy	_	_	I-Premise
426	)	_	_	I-Premise
427	from	_	_	I-Premise
428	postoperative	_	_	I-Premise
429	bleeding	_	_	I-Premise
430	,	_	_	I-Premise
431	and	_	_	I-Premise
432	6	_	_	I-Premise
433	%	_	_	I-Premise
434	(	_	_	I-Premise
435	postoperative	_	_	I-Premise
436	radiochemotherapy	_	_	I-Premise
437	)	_	_	I-Premise
438	and	_	_	I-Premise
439	5	_	_	I-Premise
440	%	_	_	I-Premise
441	(	_	_	I-Premise
442	preoperative	_	_	I-Premise
443	radiochemotherapy	_	_	I-Premise
444	)	_	_	I-Premise
445	from	_	_	I-Premise
446	delayed	_	_	I-Premise
447	wound	_	_	I-Premise
448	healing	_	_	I-Premise
449	.	_	_	I-Premise

450	The	_	_	B-Claim
451	patient	_	_	I-Claim
452	accrual	_	_	I-Claim
453	of	_	_	I-Claim
454	our	_	_	I-Claim
455	trial	_	_	I-Claim
456	is	_	_	I-Claim
457	satisfactory	_	_	I-Claim
458	,	_	_	I-Claim
459	neoadjuvant	_	_	B-Claim
460	radiochemotherapy	_	_	I-Claim
461	is	_	_	I-Claim
462	well	_	_	I-Claim
463	tolerated	_	_	I-Claim
464	and	_	_	I-Claim
465	bears	_	_	I-Claim
466	no	_	_	I-Claim
467	higher	_	_	I-Claim
468	risk	_	_	I-Claim
469	for	_	_	I-Claim
470	postoperative	_	_	I-Claim
471	morbidity	_	_	I-Claim
472	.	_	_	I-Claim


0	Imatinib	_	_	B-Claim
1	(	_	_	I-Claim
2	Gleevec	_	_	I-Claim
3	)	_	_	I-Claim
4	,	_	_	I-Claim
5	a	_	_	I-Claim
6	highly	_	_	I-Claim
7	effective	_	_	I-Claim
8	specific	_	_	I-Claim
9	tyrosine	_	_	I-Claim
10	kinase	_	_	I-Claim
11	inhibitor	_	_	I-Claim
12	,	_	_	I-Claim
13	demonstrates	_	_	I-Claim
14	a	_	_	I-Claim
15	better	_	_	I-Claim
16	side	_	_	I-Claim
17	effect	_	_	I-Claim
18	profile	_	_	I-Claim
19	than	_	_	I-Claim
20	interferon-alpha	_	_	I-Claim
21	(	_	_	I-Claim
22	IFN	_	_	I-Claim
23	)	_	_	I-Claim
24	,	_	_	I-Claim
25	which	_	_	I-Claim
26	impairs	_	_	I-Claim
27	patients	_	_	I-Claim
28	'	_	_	I-Claim
29	quality	_	_	I-Claim
30	of	_	_	I-Claim
31	life	_	_	I-Claim
32	(	_	_	I-Claim
33	QoL	_	_	I-Claim
34	)	_	_	I-Claim
35	.	_	_	I-Claim

36	This	_	_	O
37	phase	_	_	O
38	III	_	_	O
39	international	_	_	O
40	study	_	_	O
41	evaluated	_	_	O
42	QoL	_	_	O
43	outcomes	_	_	O
44	in	_	_	O
45	1,106	_	_	O
46	newly	_	_	O
47	diagnosed	_	_	O
48	patients	_	_	O
49	with	_	_	O
50	chronic-phase	_	_	O
51	chronic	_	_	O
52	myeloid	_	_	O
53	leukemia	_	_	O
54	(	_	_	O
55	CML	_	_	O
56	)	_	_	O
57	who	_	_	O
58	were	_	_	O
59	randomized	_	_	O
60	to	_	_	O
61	receive	_	_	O
62	either	_	_	O
63	imatinib	_	_	O
64	400	_	_	O
65	mg	_	_	O
66	daily	_	_	O
67	or	_	_	O
68	IFN	_	_	O
69	up	_	_	O
70	to	_	_	O
71	5	_	_	O
72	MU/m	_	_	O
73	(	_	_	O
74	2	_	_	O
75	)	_	_	O
76	/d	_	_	O
77	with	_	_	O
78	cytarabine	_	_	O
79	(	_	_	O
80	Ara-C	_	_	O
81	)	_	_	O
82	20	_	_	O
83	mg/m	_	_	O
84	(	_	_	O
85	2	_	_	O
86	)	_	_	O
87	/d	_	_	O
88	added	_	_	O
89	for	_	_	O
90	10	_	_	O
91	days	_	_	O
92	every	_	_	O
93	month	_	_	O
94	(	_	_	O
95	IFN	_	_	O
96	+	_	_	O
97	LDAC	_	_	O
98	)	_	_	O
99	.	_	_	O

100	Crossover	_	_	O
101	to	_	_	O
102	the	_	_	O
103	other	_	_	O
104	treatment	_	_	O
105	arm	_	_	O
106	was	_	_	O
107	permitted	_	_	O
108	due	_	_	O
109	to	_	_	O
110	a	_	_	O
111	lack	_	_	O
112	of	_	_	O
113	efficacy	_	_	O
114	or	_	_	O
115	treatment	_	_	O
116	intolerance	_	_	O
117	.	_	_	O

118	QoL	_	_	O
119	was	_	_	O
120	assessed	_	_	O
121	with	_	_	O
122	the	_	_	O
123	Functional	_	_	O
124	Assessment	_	_	O
125	of	_	_	O
126	Cancer	_	_	O
127	Therapy-Biologic	_	_	O
128	Response	_	_	O
129	Modifiers	_	_	O
130	(	_	_	O
131	FACT-BRM	_	_	O
132	)	_	_	O
133	at	_	_	O
134	baseline	_	_	O
135	,	_	_	O
136	monthly	_	_	O
137	for	_	_	O
138	6	_	_	O
139	months	_	_	O
140	and	_	_	O
141	then	_	_	O
142	at	_	_	O
143	months	_	_	O
144	9	_	_	O
145	,	_	_	O
146	12	_	_	O
147	,	_	_	O
148	and	_	_	O
149	18	_	_	O
150	.	_	_	O

151	The	_	_	O
152	Trial	_	_	O
153	Outcome	_	_	O
154	Index	_	_	O
155	(	_	_	O
156	TOI	_	_	O
157	;	_	_	O
158	a	_	_	O
159	composite	_	_	O
160	endpoint	_	_	O
161	of	_	_	O
162	physical/functional/treatment-specific	_	_	O
163	subscales	_	_	O
164	)	_	_	O
165	was	_	_	O
166	the	_	_	O
167	primary	_	_	O
168	endpoint	_	_	O
169	.	_	_	O

170	Secondary	_	_	O
171	endpoints	_	_	O
172	measured	_	_	O
173	were	_	_	O
174	social/family	_	_	O
175	well-being	_	_	O
176	(	_	_	O
177	SFWB	_	_	O
178	)	_	_	O
179	and	_	_	O
180	emotional	_	_	O
181	well-being	_	_	O
182	(	_	_	O
183	EWB	_	_	O
184	)	_	_	O
185	.	_	_	O

186	QoL	_	_	O
187	was	_	_	O
188	analyzed	_	_	O
189	for	_	_	O
190	the	_	_	O
191	first	_	_	O
192	18	_	_	O
193	months	_	_	O
194	of	_	_	O
195	treatment	_	_	O
196	using	_	_	O
197	mixed	_	_	O
198	effects	_	_	O
199	growth	_	_	O
200	curve	_	_	O
201	models	_	_	O
202	.	_	_	O

203	The	_	_	O
204	primary	_	_	O
205	analyses	_	_	O
206	were	_	_	O
207	intention-to-treat	_	_	O
208	(	_	_	O
209	ITT	_	_	O
210	)	_	_	O
211	;	_	_	O
212	secondary	_	_	O
213	analyses	_	_	O
214	incorporated	_	_	O
215	crossover	_	_	O
216	as	_	_	O
217	a	_	_	O
218	time-dependent	_	_	O
219	covariate	_	_	O
220	.	_	_	O

221	A	_	_	O
222	total	_	_	O
223	of	_	_	O
224	1,049	_	_	O
225	patients	_	_	O
226	completed	_	_	O
227	at	_	_	O
228	least	_	_	O
229	one	_	_	O
230	QoL	_	_	O
231	assessment	_	_	O
232	.	_	_	O

233	Two	_	_	B-Premise
234	hundred	_	_	I-Premise
235	sixty-one	_	_	I-Premise
236	patients	_	_	I-Premise
237	(	_	_	I-Premise
238	50	_	_	I-Premise
239	%	_	_	I-Premise
240	)	_	_	I-Premise
241	crossed	_	_	I-Premise
242	over	_	_	I-Premise
243	from	_	_	I-Premise
244	IFN	_	_	I-Premise
245	to	_	_	I-Premise
246	imatinib	_	_	I-Premise
247	and	_	_	I-Premise
248	11	_	_	I-Premise
249	(	_	_	I-Premise
250	2	_	_	I-Premise
251	%	_	_	I-Premise
252	)	_	_	I-Premise
253	crossed	_	_	I-Premise
254	over	_	_	I-Premise
255	from	_	_	I-Premise
256	imatinib	_	_	I-Premise
257	to	_	_	I-Premise
258	IFN	_	_	I-Premise
259	.	_	_	I-Premise

260	There	_	_	B-Premise
261	was	_	_	I-Premise
262	a	_	_	I-Premise
263	significant	_	_	I-Premise
264	decline	_	_	I-Premise
265	in	_	_	I-Premise
266	TOI	_	_	I-Premise
267	scores	_	_	I-Premise
268	for	_	_	I-Premise
269	the	_	_	I-Premise
270	IFN	_	_	I-Premise
271	treatment	_	_	I-Premise
272	arm	_	_	I-Premise
273	compared	_	_	I-Premise
274	with	_	_	I-Premise
275	preservation	_	_	I-Premise
276	of	_	_	I-Premise
277	baseline	_	_	I-Premise
278	TOI	_	_	I-Premise
279	scores	_	_	I-Premise
280	in	_	_	I-Premise
281	the	_	_	I-Premise
282	imatinib	_	_	I-Premise
283	arm	_	_	I-Premise
284	(	_	_	I-Premise
285	P	_	_	I-Premise
286	<	_	_	I-Premise
287	.001	_	_	I-Premise
288	,	_	_	I-Premise
289	ITT	_	_	I-Premise
290	)	_	_	I-Premise
291	.	_	_	I-Premise

292	Mean	_	_	B-Premise
293	social/family	_	_	I-Premise
294	and	_	_	I-Premise
295	EWB	_	_	I-Premise
296	scores	_	_	I-Premise
297	were	_	_	I-Premise
298	22.8	_	_	I-Premise
299	and	_	_	I-Premise
300	19.5	_	_	I-Premise
301	,	_	_	I-Premise
302	respectively	_	_	I-Premise
303	,	_	_	I-Premise
304	for	_	_	I-Premise
305	imatinib	_	_	I-Premise
306	and	_	_	I-Premise
307	21.6	_	_	I-Premise
308	and	_	_	I-Premise
309	17.6	_	_	I-Premise
310	,	_	_	I-Premise
311	respectively	_	_	I-Premise
312	,	_	_	I-Premise
313	for	_	_	I-Premise
314	IFN	_	_	I-Premise
315	(	_	_	I-Premise
316	P	_	_	I-Premise
317	<	_	_	I-Premise
318	.001	_	_	I-Premise
319	,	_	_	I-Premise
320	ITT	_	_	I-Premise
321	)	_	_	I-Premise
322	.	_	_	I-Premise

323	After	_	_	B-Premise
324	crossing	_	_	I-Premise
325	over	_	_	I-Premise
326	from	_	_	I-Premise
327	IFN	_	_	I-Premise
328	to	_	_	I-Premise
329	imatinib	_	_	I-Premise
330	,	_	_	I-Premise
331	patients	_	_	I-Premise
332	experienced	_	_	I-Premise
333	a	_	_	I-Premise
334	significant	_	_	I-Premise
335	(	_	_	I-Premise
336	P	_	_	I-Premise
337	<	_	_	I-Premise
338	.001	_	_	I-Premise
339	)	_	_	I-Premise
340	increase	_	_	I-Premise
341	in	_	_	I-Premise
342	TOI	_	_	I-Premise
343	scores	_	_	I-Premise
344	.	_	_	I-Premise

345	Imatinib	_	_	B-Claim
346	offers	_	_	I-Claim
347	clear	_	_	I-Claim
348	QoL	_	_	I-Claim
349	advantages	_	_	I-Claim
350	over	_	_	I-Claim
351	IFN	_	_	I-Claim
352	as	_	_	I-Claim
353	first-line	_	_	I-Claim
354	treatment	_	_	I-Claim
355	of	_	_	I-Claim
356	chronic-phase	_	_	I-Claim
357	CML	_	_	I-Claim
358	.	_	_	I-Claim

359	In	_	_	O
360	addition	_	_	O
361	,	_	_	O
362	patients	_	_	B-Claim
363	who	_	_	I-Claim
364	crossed	_	_	I-Claim
365	over	_	_	I-Claim
366	to	_	_	I-Claim
367	imatinib	_	_	I-Claim
368	reported	_	_	I-Claim
369	higher	_	_	I-Claim
370	QoL	_	_	I-Claim
371	than	_	_	I-Claim
372	those	_	_	I-Claim
373	who	_	_	I-Claim
374	remained	_	_	I-Claim
375	on	_	_	I-Claim
376	IFN	_	_	I-Claim
377	.	_	_	I-Claim


0	Recently	_	_	O
1	,	_	_	O
2	there	_	_	B-Claim
3	has	_	_	I-Claim
4	been	_	_	I-Claim
5	an	_	_	I-Claim
6	increasing	_	_	I-Claim
7	interest	_	_	I-Claim
8	in	_	_	I-Claim
9	the	_	_	I-Claim
10	influence	_	_	I-Claim
11	of	_	_	I-Claim
12	antioxidant	_	_	I-Claim
13	vitamins	_	_	I-Claim
14	on	_	_	I-Claim
15	the	_	_	I-Claim
16	efficacy	_	_	I-Claim
17	of	_	_	I-Claim
18	oral	_	_	I-Claim
19	hypoglycemic	_	_	I-Claim
20	therapy	_	_	I-Claim
21	in	_	_	I-Claim
22	type	_	_	I-Claim
23	2	_	_	I-Claim
24	diabetic	_	_	I-Claim
25	patients	_	_	I-Claim
26	(	_	_	I-Claim
27	T2DM	_	_	I-Claim
28	)	_	_	I-Claim
29	.	_	_	I-Claim

30	This	_	_	O
31	single-blinded	_	_	O
32	randomized	_	_	O
33	controlled	_	_	O
34	clinical	_	_	O
35	trial	_	_	O
36	aimed	_	_	O
37	to	_	_	O
38	investigate	_	_	O
39	the	_	_	O
40	effect	_	_	O
41	of	_	_	O
42	vitamin	_	_	O
43	C	_	_	O
44	and/or	_	_	O
45	E	_	_	O
46	supplementation	_	_	O
47	on	_	_	O
48	the	_	_	O
49	efficacy	_	_	O
50	of	_	_	O
51	oral	_	_	O
52	hypoglycemic	_	_	O
53	therapy	_	_	O
54	in	_	_	O
55	T2DM	_	_	O
56	Palestinian	_	_	O
57	male	_	_	O
58	patients	_	_	O
59	from	_	_	O
60	the	_	_	O
61	Gaza	_	_	O
62	Strip	_	_	O
63	.	_	_	O

64	Forty	_	_	O
65	T2DM	_	_	O
66	male	_	_	O
67	patients	_	_	O
68	aged	_	_	O
69	40-60	_	_	O
70	years	_	_	O
71	on	_	_	O
72	metformin	_	_	O
73	treatment	_	_	O
74	were	_	_	O
75	randomly	_	_	O
76	divided	_	_	O
77	into	_	_	O
78	four	_	_	O
79	groups	_	_	O
80	,	_	_	O
81	each	_	_	O
82	group	_	_	O
83	received	_	_	O
84	an	_	_	O
85	additional	_	_	O
86	one	_	_	O
87	of	_	_	O
88	the	_	_	O
89	following	_	_	O
90	daily	_	_	O
91	oral	_	_	O
92	supplements	_	_	O
93	for	_	_	O
94	90	_	_	O
95	days	_	_	O
96	:	_	_	O
97	placebo	_	_	O
98	;	_	_	O
99	vitamin	_	_	O
100	C	_	_	O
101	;	_	_	O
102	vitamin	_	_	O
103	E	_	_	O
104	and	_	_	O
105	vitamin	_	_	O
106	C	_	_	O
107	plus	_	_	O
108	vitamin	_	_	O
109	E.	_	_	O
110	After	_	_	O
111	overnight	_	_	O
112	fasting	_	_	O
113	,	_	_	O
114	venous	_	_	O
115	blood	_	_	O
116	specimens	_	_	O
117	were	_	_	O
118	collected	_	_	O
119	from	_	_	O
120	all	_	_	O
121	individuals	_	_	O
122	into	_	_	O
123	K3-EDTA	_	_	O
124	tubes	_	_	O
125	and	_	_	O
126	serum	_	_	O
127	tubes	_	_	O
128	for	_	_	O
129	measuring	_	_	O
130	the	_	_	O
131	biochemical	_	_	O
132	and	_	_	O
133	hematological	_	_	O
134	parameters	_	_	O
135	of	_	_	O
136	the	_	_	O
137	study	_	_	O
138	at	_	_	O
139	baseline	_	_	O
140	and	_	_	O
141	after	_	_	O
142	90	_	_	O
143	days	_	_	O
144	of	_	_	O
145	vitamins	_	_	O
146	supplementation	_	_	O
147	.	_	_	O

148	The	_	_	O
149	results	_	_	O
150	revealed	_	_	O
151	that	_	_	O
152	vitamin	_	_	B-Premise
153	C	_	_	I-Premise
154	and/or	_	_	I-Premise
155	E	_	_	I-Premise
156	improve	_	_	I-Premise
157	fasting	_	_	I-Premise
158	blood	_	_	I-Premise
159	sugar	_	_	I-Premise
160	(	_	_	I-Premise
161	FBS	_	_	I-Premise
162	)	_	_	I-Premise
163	,	_	_	I-Premise
164	HbA1c	_	_	I-Premise
165	,	_	_	I-Premise
166	lipid	_	_	I-Premise
167	profile	_	_	I-Premise
168	,	_	_	I-Premise
169	insulin	_	_	I-Premise
170	,	_	_	I-Premise
171	homeostasis	_	_	I-Premise
172	model	_	_	I-Premise
173	assessment	_	_	I-Premise
174	of	_	_	I-Premise
175	insulin	_	_	I-Premise
176	resistance	_	_	I-Premise
177	(	_	_	I-Premise
178	HOMA-IR	_	_	I-Premise
179	)	_	_	I-Premise
180	,	_	_	I-Premise
181	reduced	_	_	I-Premise
182	glutathione	_	_	I-Premise
183	(	_	_	I-Premise
184	GSH	_	_	I-Premise
185	)	_	_	I-Premise
186	;	_	_	I-Premise
187	and	_	_	I-Premise
188	Quantitative	_	_	I-Premise
189	Insulin	_	_	I-Premise
190	Sensitivity	_	_	I-Premise
191	Check	_	_	I-Premise
192	Index	_	_	I-Premise
193	(	_	_	I-Premise
194	QISCI	_	_	I-Premise
195	)	_	_	I-Premise
196	compared	_	_	I-Premise
197	with	_	_	I-Premise
198	diabetic	_	_	I-Premise
199	patients	_	_	I-Premise
200	group	_	_	I-Premise
201	that	_	_	I-Premise
202	received	_	_	I-Premise
203	placebo	_	_	I-Premise
204	.	_	_	I-Premise

205	This	_	_	B-Claim
206	study	_	_	I-Claim
207	provided	_	_	I-Claim
208	additional	_	_	I-Claim
209	evidence	_	_	I-Claim
210	on	_	_	I-Claim
211	the	_	_	I-Claim
212	beneficial	_	_	I-Claim
213	effects	_	_	I-Claim
214	of	_	_	I-Claim
215	supplementing	_	_	I-Claim
216	antioxidant	_	_	I-Claim
217	vitamins	_	_	I-Claim
218	in	_	_	I-Claim
219	T2DM	_	_	I-Claim
220	which	_	_	I-Claim
221	could	_	_	I-Claim
222	improve	_	_	I-Claim
223	the	_	_	I-Claim
224	clinical	_	_	I-Claim
225	condition	_	_	I-Claim
226	and	_	_	I-Claim
227	attenuate	_	_	I-Claim
228	or	_	_	I-Claim
229	prevent	_	_	I-Claim
230	diabetic	_	_	I-Claim
231	pathogenesis	_	_	I-Claim
232	and	_	_	I-Claim
233	complications	_	_	I-Claim
234	that	_	_	I-Claim
235	,	_	_	I-Claim
236	secondly	_	_	I-Claim
237	to	_	_	I-Claim
238	poor	_	_	I-Claim
239	glycemic	_	_	I-Claim
240	control	_	_	I-Claim
241	,	_	_	I-Claim
242	could	_	_	I-Claim
243	attribute	_	_	I-Claim
244	to	_	_	I-Claim
245	the	_	_	I-Claim
246	imbalance	_	_	I-Claim
247	between	_	_	I-Claim
248	the	_	_	I-Claim
249	decline	_	_	I-Claim
250	in	_	_	I-Claim
251	the	_	_	I-Claim
252	endogenous	_	_	I-Claim
253	antioxidants	_	_	I-Claim
254	and	_	_	I-Claim
255	increasing	_	_	I-Claim
256	production	_	_	I-Claim
257	of	_	_	I-Claim
258	the	_	_	I-Claim
259	reactive	_	_	I-Claim
260	oxygen	_	_	I-Claim
261	species	_	_	I-Claim
262	leading	_	_	I-Claim
263	to	_	_	I-Claim
264	the	_	_	I-Claim
265	oxidant-mediated	_	_	I-Claim
266	damage	_	_	I-Claim
267	present	_	_	I-Claim
268	in	_	_	I-Claim
269	the	_	_	I-Claim
270	diabetic	_	_	I-Claim
271	context	_	_	I-Claim
272	.	_	_	I-Claim


0	Cutaneous	_	_	B-Claim
1	T-cell	_	_	I-Claim
2	lymphoma	_	_	I-Claim
3	(	_	_	I-Claim
4	CTCL	_	_	I-Claim
5	)	_	_	I-Claim
6	can	_	_	I-Claim
7	be	_	_	I-Claim
8	associated	_	_	I-Claim
9	with	_	_	I-Claim
10	painful	_	_	I-Claim
11	,	_	_	I-Claim
12	pruritic	_	_	I-Claim
13	,	_	_	I-Claim
14	disfiguring	_	_	I-Claim
15	lesions	_	_	I-Claim
16	.	_	_	I-Claim

17	As	_	_	O
18	part	_	_	O
19	of	_	_	O
20	a	_	_	O
21	multicenter	_	_	O
22	,	_	_	O
23	randomized	_	_	O
24	phase	_	_	O
25	III	_	_	O
26	trial	_	_	O
27	in	_	_	O
28	patients	_	_	O
29	with	_	_	O
30	heavily	_	_	O
31	pretreated	_	_	O
32	advanced	_	_	O
33	and/or	_	_	O
34	recurrent	_	_	O
35	CTCL	_	_	O
36	,	_	_	O
37	the	_	_	O
38	effects	_	_	O
39	of	_	_	O
40	an	_	_	O
41	interleukin-2	_	_	O
42	receptor-targeted	_	_	O
43	fusion	_	_	O
44	protein	_	_	O
45	,	_	_	O
46	denileukin	_	_	O
47	diftitox	_	_	O
48	(	_	_	O
49	DAB389IL-2	_	_	O
50	,	_	_	O
51	ONTAK	_	_	O
52	)	_	_	O
53	,	_	_	O
54	on	_	_	O
55	patient-rated	_	_	O
56	overall	_	_	O
57	quality	_	_	O
58	of	_	_	O
59	life	_	_	O
60	(	_	_	O
61	QOL	_	_	O
62	)	_	_	O
63	,	_	_	O
64	skin	_	_	O
65	appearance	_	_	O
66	,	_	_	O
67	and	_	_	O
68	pruritus	_	_	O
69	severity	_	_	O
70	were	_	_	O
71	evaluated	_	_	O
72	.	_	_	O

73	A	_	_	O
74	total	_	_	O
75	of	_	_	O
76	71	_	_	O
77	patients	_	_	O
78	with	_	_	O
79	stage	_	_	O
80	IB-IVA	_	_	O
81	CTCL	_	_	O
82	received	_	_	O
83	intravenous	_	_	O
84	denileukin	_	_	O
85	diftitox	_	_	O
86	9	_	_	O
87	microg/kg/day	_	_	O
88	or	_	_	O
89	18	_	_	O
90	microg/kg/day	_	_	O
91	over	_	_	O
92	15-60	_	_	O
93	minutes	_	_	O
94	for	_	_	O
95	5	_	_	O
96	consecutive	_	_	O
97	days	_	_	O
98	on	_	_	O
99	an	_	_	O
100	outpatient	_	_	O
101	basis	_	_	O
102	;	_	_	O
103	cycles	_	_	O
104	were	_	_	O
105	planned	_	_	O
106	for	_	_	O
107	every	_	_	O
108	21	_	_	O
109	days	_	_	O
110	for	_	_	O
111	a	_	_	O
112	total	_	_	O
113	of	_	_	O
114	8	_	_	O
115	cycles	_	_	O
116	over	_	_	O
117	6	_	_	O
118	months	_	_	O
119	.	_	_	O

120	Prior	_	_	O
121	to	_	_	O
122	each	_	_	O
123	treatment	_	_	O
124	cycle	_	_	O
125	,	_	_	O
126	patients	_	_	O
127	were	_	_	O
128	evaluated	_	_	O
129	for	_	_	O
130	disease	_	_	O
131	response	_	_	O
132	and	_	_	O
133	were	_	_	O
134	asked	_	_	O
135	to	_	_	O
136	self-rate	_	_	O
137	their	_	_	O
138	overall	_	_	O
139	QOL	_	_	O
140	via	_	_	O
141	the	_	_	O
142	Functional	_	_	O
143	Assessment	_	_	O
144	of	_	_	O
145	Cancer	_	_	O
146	Therapy-General	_	_	O
147	(	_	_	O
148	FACT-G	_	_	O
149	)	_	_	O
150	questionnaire	_	_	O
151	,	_	_	O
152	skin	_	_	O
153	appearance	_	_	O
154	(	_	_	O
155	7-point	_	_	O
156	scale	_	_	O
157	)	_	_	O
158	,	_	_	O
159	and	_	_	O
160	pruritus	_	_	O
161	severity	_	_	O
162	(	_	_	O
163	10-cm	_	_	O
164	visual	_	_	O
165	analogue	_	_	O
166	scale	_	_	O
167	)	_	_	O
168	.	_	_	O

169	Composite	_	_	B-Premise
170	FACT-G	_	_	I-Premise
171	and	_	_	I-Premise
172	most	_	_	I-Premise
173	individual	_	_	I-Premise
174	subscale	_	_	I-Premise
175	scores	_	_	I-Premise
176	(	_	_	I-Premise
177	physical	_	_	I-Premise
178	,	_	_	I-Premise
179	social/family	_	_	I-Premise
180	,	_	_	I-Premise
181	emotional	_	_	I-Premise
182	,	_	_	I-Premise
183	and	_	_	I-Premise
184	functional	_	_	I-Premise
185	well	_	_	I-Premise
186	being	_	_	I-Premise
187	)	_	_	I-Premise
188	in	_	_	I-Premise
189	documented	_	_	I-Premise
190	responders	_	_	I-Premise
191	(	_	_	I-Premise
192	n	_	_	I-Premise
193	=	_	_	I-Premise
194	21	_	_	I-Premise
195	)	_	_	I-Premise
196	gradually	_	_	I-Premise
197	increased	_	_	I-Premise
198	during	_	_	I-Premise
199	the	_	_	I-Premise
200	study	_	_	I-Premise
201	period	_	_	I-Premise
202	,	_	_	I-Premise
203	generally	_	_	I-Premise
204	reaching	_	_	I-Premise
205	statistical	_	_	I-Premise
206	significance	_	_	I-Premise
207	(	_	_	I-Premise
208	P	_	_	I-Premise
209	<	_	_	I-Premise
210	0.05	_	_	I-Premise
211	)	_	_	I-Premise
212	by	_	_	I-Premise
213	cycle	_	_	I-Premise
214	3	_	_	I-Premise
215	,	_	_	I-Premise
216	and	_	_	I-Premise
217	were	_	_	I-Premise
218	significantly	_	_	I-Premise
219	(	_	_	I-Premise
220	P	_	_	I-Premise
221	<	_	_	I-Premise
222	or	_	_	I-Premise
223	=	_	_	I-Premise
224	0.041	_	_	I-Premise
225	)	_	_	I-Premise
226	higher	_	_	I-Premise
227	than	_	_	I-Premise
228	the	_	_	I-Premise
229	scores	_	_	I-Premise
230	of	_	_	I-Premise
231	nonresponders	_	_	I-Premise
232	at	_	_	I-Premise
233	endpoint	_	_	I-Premise
234	.	_	_	I-Premise

235	Additionally	_	_	B-Premise
236	for	_	_	I-Premise
237	responders	_	_	I-Premise
238	,	_	_	I-Premise
239	assessments	_	_	I-Premise
240	of	_	_	I-Premise
241	skin	_	_	I-Premise
242	severity	_	_	I-Premise
243	and	_	_	I-Premise
244	pruritus	_	_	I-Premise
245	severity	_	_	I-Premise
246	showed	_	_	I-Premise
247	significant	_	_	I-Premise
248	(	_	_	I-Premise
249	P	_	_	I-Premise
250	<	_	_	I-Premise
251	or	_	_	I-Premise
252	=	_	_	I-Premise
253	0.05	_	_	I-Premise
254	)	_	_	I-Premise
255	improvements	_	_	I-Premise
256	at	_	_	I-Premise
257	study	_	_	I-Premise
258	endpoint	_	_	I-Premise
259	compared	_	_	I-Premise
260	with	_	_	I-Premise
261	baseline	_	_	I-Premise
262	.	_	_	I-Premise

263	Adverse	_	_	B-Premise
264	transfusion-related	_	_	I-Premise
265	events	_	_	I-Premise
266	(	_	_	I-Premise
267	eg	_	_	I-Premise
268	,	_	_	I-Premise
269	hypersensitivity	_	_	I-Premise
270	reactions	_	_	I-Premise
271	,	_	_	I-Premise
272	flu-like	_	_	I-Premise
273	syndrome	_	_	I-Premise
274	)	_	_	I-Premise
275	were	_	_	I-Premise
276	common	_	_	I-Premise
277	during	_	_	I-Premise
278	cycles	_	_	I-Premise
279	1	_	_	I-Premise
280	and	_	_	I-Premise
281	2	_	_	I-Premise
282	,	_	_	I-Premise
283	and	_	_	I-Premise
284	vascular-leak	_	_	I-Premise
285	syndrome	_	_	I-Premise
286	occurred	_	_	I-Premise
287	in	_	_	I-Premise
288	25	_	_	I-Premise
289	%	_	_	I-Premise
290	of	_	_	I-Premise
291	patients	_	_	I-Premise
292	.	_	_	I-Premise

293	Denileukin	_	_	B-Claim
294	diftitox	_	_	I-Claim
295	was	_	_	I-Claim
296	not	_	_	I-Claim
297	associated	_	_	I-Claim
298	with	_	_	I-Claim
299	any	_	_	I-Claim
300	clinically	_	_	I-Claim
301	significant	_	_	I-Claim
302	myelosuppression	_	_	I-Claim
303	.	_	_	I-Claim

304	Heavily	_	_	B-Claim
305	pretreated	_	_	I-Claim
306	patients	_	_	I-Claim
307	with	_	_	I-Claim
308	advanced	_	_	I-Claim
309	and/or	_	_	I-Claim
310	recurrent	_	_	I-Claim
311	CTCL	_	_	I-Claim
312	who	_	_	I-Claim
313	responded	_	_	I-Claim
314	to	_	_	I-Claim
315	denileukin	_	_	I-Claim
316	diftitox	_	_	I-Claim
317	therapy	_	_	I-Claim
318	showed	_	_	I-Claim
319	significant	_	_	I-Claim
320	improvements	_	_	I-Claim
321	in	_	_	I-Claim
322	self-rated	_	_	I-Claim
323	overall	_	_	I-Claim
324	QOL	_	_	I-Claim
325	,	_	_	I-Claim
326	skin	_	_	I-Claim
327	appearance	_	_	I-Claim
328	,	_	_	I-Claim
329	and	_	_	I-Claim
330	pruritus	_	_	I-Claim
331	severity	_	_	I-Claim
332	.	_	_	I-Claim


0	The	_	_	O
1	blood	_	_	O
2	pressure-lowering	_	_	O
3	effect	_	_	O
4	of	_	_	O
5	fermented	_	_	O
6	milk	_	_	O
7	with	_	_	O
8	Lactococcus	_	_	O
9	lactis	_	_	O
10	NRRL	_	_	O
11	B-50571	_	_	O
12	was	_	_	O
13	evaluated	_	_	O
14	in	_	_	O
15	a	_	_	O
16	double-blind	_	_	O
17	randomized	_	_	O
18	controlled	_	_	O
19	clinical	_	_	O
20	trial	_	_	O
21	with	_	_	O
22	prehypertensive	_	_	O
23	subjects	_	_	O
24	.	_	_	O

25	Participants	_	_	O
26	were	_	_	O
27	randomized	_	_	O
28	into	_	_	O
29	2	_	_	O
30	groups	_	_	O
31	(	_	_	O
32	n	_	_	O
33	=	_	_	O
34	18	_	_	O
35	each	_	_	O
36	group	_	_	O
37	)	_	_	O
38	:	_	_	O
39	one	_	_	O
40	group	_	_	O
41	treated	_	_	O
42	with	_	_	O
43	fermented	_	_	O
44	milk	_	_	O
45	with	_	_	O
46	Lactococcus	_	_	O
47	lactis	_	_	O
48	NRRL	_	_	O
49	B-50571	_	_	O
50	and	_	_	O
51	a	_	_	O
52	control	_	_	O
53	group	_	_	O
54	treated	_	_	O
55	with	_	_	O
56	artificially	_	_	O
57	acidified	_	_	O
58	milk	_	_	O
59	.	_	_	O

60	Results	_	_	B-Premise
61	revealed	_	_	I-Premise
62	that	_	_	I-Premise
63	during	_	_	I-Premise
64	daily	_	_	I-Premise
65	consumption	_	_	I-Premise
66	of	_	_	I-Premise
67	fermented	_	_	I-Premise
68	milk	_	_	I-Premise
69	for	_	_	I-Premise
70	5	_	_	I-Premise
71	wk	_	_	I-Premise
72	,	_	_	I-Premise
73	systolic	_	_	I-Premise
74	[	_	_	I-Premise
75	(	_	_	I-Premise
76	116.55	_	_	I-Premise
77	±	_	_	I-Premise
78	12.26	_	_	I-Premise
79	mmHg	_	_	I-Premise
80	vs.	_	_	I-Premise
81	124.77	_	_	I-Premise
82	±	_	_	I-Premise
83	11.04	_	_	I-Premise
84	mmHg	_	_	I-Premise
85	)	_	_	I-Premise
86	and	_	_	I-Premise
87	diastolic	_	_	I-Premise
88	blood	_	_	I-Premise
89	pressure	_	_	I-Premise
90	(	_	_	I-Premise
91	80.7	_	_	I-Premise
92	±	_	_	I-Premise
93	9	_	_	I-Premise
94	vs.	_	_	I-Premise
95	84.5	_	_	I-Premise
96	±	_	_	I-Premise
97	8.5	_	_	I-Premise
98	mmHg	_	_	I-Premise
99	)	_	_	I-Premise
100	]	_	_	I-Premise
101	from	_	_	I-Premise
102	the	_	_	I-Premise
103	fermented	_	_	I-Premise
104	milk	_	_	I-Premise
105	group	_	_	I-Premise
106	was	_	_	I-Premise
107	lower	_	_	I-Premise
108	than	_	_	I-Premise
109	the	_	_	I-Premise
110	control	_	_	I-Premise
111	group	_	_	I-Premise
112	.	_	_	I-Premise

113	Additionally	_	_	B-Premise
114	,	_	_	I-Premise
115	triglyceride	_	_	I-Premise
116	,	_	_	I-Premise
117	total	_	_	I-Premise
118	cholesterol	_	_	I-Premise
119	,	_	_	I-Premise
120	and	_	_	I-Premise
121	low-density	_	_	I-Premise
122	lipoprotein	_	_	I-Premise
123	in	_	_	I-Premise
124	blood	_	_	I-Premise
125	serum	_	_	I-Premise
126	were	_	_	I-Premise
127	lower	_	_	I-Premise
128	in	_	_	I-Premise
129	the	_	_	I-Premise
130	fermented	_	_	I-Premise
131	milk	_	_	I-Premise
132	group	_	_	I-Premise
133	than	_	_	I-Premise
134	in	_	_	I-Premise
135	the	_	_	I-Premise
136	control	_	_	I-Premise
137	group	_	_	I-Premise
138	.	_	_	I-Premise

139	Results	_	_	B-Claim
140	demonstrated	_	_	I-Claim
141	that	_	_	I-Claim
142	daily	_	_	I-Claim
143	consumption	_	_	I-Claim
144	of	_	_	I-Claim
145	fermented	_	_	I-Claim
146	milk	_	_	I-Claim
147	with	_	_	I-Claim
148	Lactococcus	_	_	I-Claim
149	lactis	_	_	I-Claim
150	(	_	_	I-Claim
151	NRRL	_	_	I-Claim
152	B-50571	_	_	I-Claim
153	)	_	_	I-Claim
154	had	_	_	I-Claim
155	a	_	_	I-Claim
156	blood	_	_	I-Claim
157	pressure-lowering	_	_	I-Claim
158	effect	_	_	I-Claim
159	on	_	_	I-Claim
160	prehypertensive	_	_	I-Claim
161	subjects	_	_	I-Claim
162	.	_	_	I-Claim

163	Regular	_	_	B-Claim
164	consumption	_	_	I-Claim
165	of	_	_	I-Claim
166	this	_	_	I-Claim
167	product	_	_	I-Claim
168	may	_	_	I-Claim
169	be	_	_	I-Claim
170	used	_	_	I-Claim
171	as	_	_	I-Claim
172	a	_	_	I-Claim
173	potential	_	_	I-Claim
174	functional	_	_	I-Claim
175	food	_	_	I-Claim
176	.	_	_	I-Claim


0	Antiretroviral	_	_	O
1	treatment	_	_	O
2	(	_	_	O
3	ART	_	_	O
4	)	_	_	O
5	interruptions	_	_	O
6	increase	_	_	O
7	the	_	_	O
8	risk	_	_	O
9	of	_	_	O
10	severe	_	_	O
11	morbidity/mortality	_	_	O
12	in	_	_	O
13	human	_	_	O
14	immunodeficiency	_	_	O
15	virus	_	_	O
16	(	_	_	O
17	HIV	_	_	O
18	)	_	_	O
19	-infected	_	_	O
20	individuals	_	_	O
21	from	_	_	O
22	subSaharan	_	_	O
23	Africa	_	_	O
24	.	_	_	O

25	We	_	_	O
26	aimed	_	_	O
27	to	_	_	O
28	determine	_	_	O
29	whether	_	_	O
30	the	_	_	O
31	risk	_	_	O
32	is	_	_	O
33	further	_	_	O
34	increased	_	_	O
35	among	_	_	O
36	HIV-hepatitis	_	_	O
37	B	_	_	O
38	virus	_	_	O
39	(	_	_	O
40	HBV	_	_	O
41	)	_	_	O
42	co-infected	_	_	O
43	patients	_	_	O
44	in	_	_	O
45	this	_	_	O
46	setting	_	_	O
47	.	_	_	O

48	In	_	_	O
49	this	_	_	O
50	sub-analysis	_	_	O
51	of	_	_	O
52	a	_	_	O
53	randomized-control	_	_	O
54	trial	_	_	O
55	,	_	_	O
56	632	_	_	O
57	participants	_	_	O
58	from	_	_	O
59	Côte	_	_	O
60	d'Ivoire	_	_	O
61	randomized	_	_	O
62	to	_	_	O
63	receive	_	_	O
64	continuous-ART	_	_	O
65	(	_	_	O
66	C-ART	_	_	O
67	)	_	_	O
68	,	_	_	O
69	structured	_	_	O
70	ART	_	_	O
71	interruptions	_	_	O
72	of	_	_	O
73	2-months	_	_	O
74	off	_	_	O
75	,	_	_	O
76	4-months	_	_	O
77	on	_	_	O
78	(	_	_	O
79	2/4-ART	_	_	O
80	)	_	_	O
81	,	_	_	O
82	and	_	_	O
83	CD4-guided	_	_	O
84	ART	_	_	O
85	interruptions	_	_	O
86	(	_	_	O
87	CD4GT	_	_	O
88	,	_	_	O
89	interruption	_	_	O
90	at	_	_	O
91	350/mm3	_	_	O
92	and	_	_	O
93	reintroduction	_	_	O
94	at	_	_	O
95	250/mm3	_	_	O
96	)	_	_	O
97	were	_	_	O
98	analyzed	_	_	O
99	.	_	_	O

100	Incidence	_	_	O
101	rates	_	_	O
102	(	_	_	O
103	IR	_	_	O
104	)	_	_	O
105	of	_	_	O
106	serious	_	_	O
107	HIV-	_	_	O
108	and	_	_	O
109	non-HIV-related	_	_	O
110	morbidity	_	_	O
111	were	_	_	O
112	compared	_	_	O
113	between	_	_	O
114	patients	_	_	O
115	stratified	_	_	O
116	on	_	_	O
117	hepatitis	_	_	O
118	B	_	_	O
119	surface	_	_	O
120	antigen	_	_	O
121	(	_	_	O
122	HBsAg	_	_	O
123	)	_	_	O
124	status	_	_	O
125	.	_	_	O

126	Overall	_	_	O
127	,	_	_	O
128	65	_	_	O
129	(	_	_	O
130	10.3	_	_	O
131	%	_	_	O
132	)	_	_	O
133	were	_	_	O
134	HBsAg-positive	_	_	O
135	,	_	_	O
136	29	_	_	O
137	(	_	_	O
138	44.6	_	_	O
139	%	_	_	O
140	)	_	_	O
141	of	_	_	O
142	whom	_	_	O
143	had	_	_	O
144	HBV-DNA	_	_	O
145	levels	_	_	O
146	>	_	_	O
147	10,000	_	_	O
148	copies/mL	_	_	O
149	.	_	_	O

150	After	_	_	B-Premise
151	a	_	_	I-Premise
152	median	_	_	I-Premise
153	2.0	_	_	I-Premise
154	year	_	_	I-Premise
155	(	_	_	I-Premise
156	range	_	_	I-Premise
157	=	_	_	I-Premise
158	0.2-3.1	_	_	I-Premise
159	)	_	_	I-Premise
160	follow-up	_	_	I-Premise
161	,	_	_	I-Premise
162	≥	_	_	I-Premise
163	1	_	_	I-Premise
164	serious	_	_	I-Premise
165	HIV-related	_	_	I-Premise
166	events	_	_	I-Premise
167	occurred	_	_	I-Premise
168	in	_	_	I-Premise
169	101	_	_	I-Premise
170	HIV	_	_	I-Premise
171	mono-infected	_	_	I-Premise
172	and	_	_	I-Premise
173	15	_	_	I-Premise
174	HIV-HBV	_	_	I-Premise
175	co-infected	_	_	I-Premise
176	patients	_	_	I-Premise
177	(	_	_	I-Premise
178	IR	_	_	I-Premise
179	=	_	_	I-Premise
180	10.0	_	_	I-Premise
181	versus	_	_	I-Premise
182	13.2/100	_	_	I-Premise
183	person/years	_	_	I-Premise
184	,	_	_	I-Premise
185	respectively	_	_	I-Premise
186	,	_	_	I-Premise
187	P	_	_	I-Premise
188	=	_	_	I-Premise
189	0.3	_	_	I-Premise
190	)	_	_	I-Premise
191	,	_	_	O
192	whereas	_	_	O
193	the	_	_	O
194	highest	_	_	O
195	incidence	_	_	O
196	was	_	_	O
197	observed	_	_	O
198	in	_	_	O
199	co-infected	_	_	O
200	patients	_	_	O
201	with	_	_	O
202	baseline	_	_	O
203	HBV-replication	_	_	O
204	>	_	_	O
205	10,000	_	_	O
206	copies/mL	_	_	O
207	(	_	_	O
208	IR	_	_	O
209	=	_	_	O
210	24.0/100	_	_	O
211	person/years	_	_	O
212	,	_	_	O
213	P	_	_	O
214	versus	_	_	O
215	HIV	_	_	O
216	mono-infected	_	_	O
217	=	_	_	O
218	0.002	_	_	O
219	)	_	_	O
220	.	_	_	O

221	Incidence	_	_	B-Premise
222	of	_	_	I-Premise
223	bacterial	_	_	I-Premise
224	infections	_	_	I-Premise
225	was	_	_	I-Premise
226	also	_	_	I-Premise
227	highest	_	_	I-Premise
228	in	_	_	I-Premise
229	the	_	_	I-Premise
230	co-infected	_	_	I-Premise
231	group	_	_	I-Premise
232	with	_	_	I-Premise
233	HBV-replication	_	_	I-Premise
234	>	_	_	I-Premise
235	10,000	_	_	I-Premise
236	copies/mL	_	_	I-Premise
237	(	_	_	I-Premise
238	IR	_	_	I-Premise
239	=	_	_	I-Premise
240	12.9	_	_	I-Premise
241	versus	_	_	I-Premise
242	3.3/100	_	_	I-Premise
243	person/years	_	_	I-Premise
244	in	_	_	I-Premise
245	HIV	_	_	I-Premise
246	mono-infected	_	_	I-Premise
247	patients	_	_	I-Premise
248	,	_	_	I-Premise
249	P	_	_	I-Premise
250	=	_	_	I-Premise
251	0.001	_	_	I-Premise
252	)	_	_	I-Premise
253	.	_	_	I-Premise

254	The	_	_	B-Premise
255	relative	_	_	I-Premise
256	effect	_	_	I-Premise
257	of	_	_	I-Premise
258	CD4GT	_	_	I-Premise
259	or	_	_	I-Premise
260	2/4-ART	_	_	I-Premise
261	versus	_	_	I-Premise
262	C-ART	_	_	I-Premise
263	was	_	_	I-Premise
264	not	_	_	I-Premise
265	different	_	_	I-Premise
266	between	_	_	I-Premise
267	infection	_	_	I-Premise
268	groups	_	_	I-Premise
269	(	_	_	I-Premise
270	P	_	_	I-Premise
271	for	_	_	I-Premise
272	interaction	_	_	I-Premise
273	=	_	_	I-Premise
274	0.4	_	_	I-Premise
275	)	_	_	I-Premise
276	.	_	_	I-Premise

277	No	_	_	B-Premise
278	increase	_	_	I-Premise
279	in	_	_	I-Premise
280	the	_	_	I-Premise
281	incidence	_	_	I-Premise
282	of	_	_	I-Premise
283	non-HIV-related	_	_	I-Premise
284	morbidity	_	_	I-Premise
285	was	_	_	I-Premise
286	observed	_	_	I-Premise
287	for	_	_	I-Premise
288	co-infected	_	_	I-Premise
289	patients	_	_	I-Premise
290	(	_	_	I-Premise
291	P	_	_	I-Premise
292	=	_	_	I-Premise
293	0.5	_	_	I-Premise
294	)	_	_	I-Premise
295	,	_	_	I-Premise
296	even	_	_	I-Premise
297	at	_	_	I-Premise
298	HBV-replication	_	_	I-Premise
299	levels	_	_	I-Premise
300	>	_	_	I-Premise
301	10,000	_	_	I-Premise
302	copies/mL	_	_	I-Premise
303	(	_	_	I-Premise
304	P	_	_	I-Premise
305	=	_	_	I-Premise
306	0.7	_	_	I-Premise
307	)	_	_	I-Premise
308	.	_	_	I-Premise

309	In	_	_	B-Claim
310	conclusion	_	_	I-Claim
311	,	_	_	I-Claim
312	co-infected	_	_	I-Claim
313	patients	_	_	I-Claim
314	with	_	_	I-Claim
315	elevated	_	_	I-Claim
316	HBV-replication	_	_	I-Claim
317	at	_	_	I-Claim
318	ART-initiation	_	_	I-Claim
319	are	_	_	I-Claim
320	more	_	_	I-Claim
321	susceptible	_	_	I-Claim
322	to	_	_	I-Claim
323	HIV-related	_	_	I-Claim
324	morbidity	_	_	I-Claim
325	,	_	_	I-Claim
326	especially	_	_	I-Claim
327	invasive	_	_	I-Claim
328	bacterial	_	_	I-Claim
329	diseases	_	_	I-Claim
330	,	_	_	I-Claim
331	during	_	_	I-Claim
332	treatment	_	_	I-Claim
333	interruption	_	_	I-Claim
334	.	_	_	I-Claim


0	Hepatitis	_	_	O
1	B	_	_	O
2	virus	_	_	O
3	(	_	_	O
4	HBV	_	_	O
5	)	_	_	O
6	reactivation	_	_	O
7	in	_	_	O
8	patients	_	_	O
9	with	_	_	O
10	resolved	_	_	O
11	HBV	_	_	O
12	infection	_	_	O
13	(	_	_	O
14	HBsAg	_	_	O
15	negative	_	_	O
16	,	_	_	O
17	antiHBc	_	_	O
18	positive	_	_	O
19	)	_	_	O
20	is	_	_	O
21	uncommon	_	_	O
22	,	_	_	O
23	but	_	_	O
24	potentially	_	_	O
25	fatal	_	_	O
26	.	_	_	O

27	The	_	_	O
28	role	_	_	O
29	of	_	_	O
30	HBV	_	_	O
31	prophylaxis	_	_	O
32	in	_	_	O
33	this	_	_	O
34	setting	_	_	O
35	is	_	_	O
36	uncertain	_	_	O
37	.	_	_	O

38	The	_	_	O
39	aim	_	_	O
40	of	_	_	O
41	this	_	_	O
42	study	_	_	O
43	was	_	_	O
44	to	_	_	O
45	compare	_	_	O
46	the	_	_	O
47	efficacy	_	_	O
48	of	_	_	O
49	tenofovir	_	_	O
50	disoproxil	_	_	O
51	fumarate	_	_	O
52	(	_	_	O
53	TDF	_	_	O
54	)	_	_	O
55	prophylaxis	_	_	O
56	versus	_	_	O
57	close	_	_	O
58	monitoring	_	_	O
59	in	_	_	O
60	antiHBc-positive	_	_	O
61	,	_	_	O
62	HBsAg-negative	_	_	O
63	patients	_	_	O
64	under	_	_	O
65	treatment	_	_	O
66	with	_	_	O
67	rituximab	_	_	O
68	(	_	_	O
69	RTX	_	_	O
70	)	_	_	O
71	-based	_	_	O
72	regimens	_	_	O
73	for	_	_	O
74	hematologic	_	_	O
75	malignancy	_	_	O
76	.	_	_	O

77	PREBLIN	_	_	O
78	is	_	_	O
79	a	_	_	O
80	phase	_	_	O
81	IV	_	_	O
82	,	_	_	O
83	randomized	_	_	O
84	,	_	_	O
85	prospective	_	_	O
86	,	_	_	O
87	open-label	_	_	O
88	,	_	_	O
89	multicenter	_	_	O
90	,	_	_	O
91	parallel-group	_	_	O
92	trial	_	_	O
93	conducted	_	_	O
94	in	_	_	O
95	17	_	_	O
96	hospitals	_	_	O
97	throughout	_	_	O
98	Spain	_	_	O
99	.	_	_	O

100	Anti-HBc-positive	_	_	O
101	,	_	_	O
102	HBsAg-negative	_	_	O
103	patients	_	_	O
104	with	_	_	O
105	undetectable	_	_	O
106	HBV	_	_	O
107	DNA	_	_	O
108	were	_	_	O
109	randomized	_	_	O
110	to	_	_	O
111	receive	_	_	O
112	TDF	_	_	O
113	300	_	_	O
114	mg	_	_	O
115	once	_	_	O
116	daily	_	_	O
117	(	_	_	O
118	Group	_	_	O
119	I	_	_	O
120	)	_	_	O
121	or	_	_	O
122	observation	_	_	O
123	(	_	_	O
124	Group	_	_	O
125	II	_	_	O
126	)	_	_	O
127	.	_	_	O

128	The	_	_	O
129	primary	_	_	O
130	endpoint	_	_	O
131	was	_	_	O
132	the	_	_	O
133	percentage	_	_	O
134	of	_	_	O
135	patients	_	_	O
136	showing	_	_	O
137	HBV	_	_	O
138	reactivation	_	_	O
139	during	_	_	O
140	18	_	_	O
141	months	_	_	O
142	following	_	_	O
143	initiation	_	_	O
144	of	_	_	O
145	RTX	_	_	O
146	treatment	_	_	O
147	.	_	_	O

148	Patients	_	_	O
149	with	_	_	O
150	detectable	_	_	O
151	HBV	_	_	O
152	DNA	_	_	O
153	(	_	_	O
154	Group	_	_	O
155	III	_	_	O
156	)	_	_	O
157	received	_	_	O
158	the	_	_	O
159	same	_	_	O
160	dose	_	_	O
161	of	_	_	O
162	TDF	_	_	O
163	and	_	_	O
164	were	_	_	O
165	analyzed	_	_	O
166	together	_	_	O
167	with	_	_	O
168	Group	_	_	O
169	I	_	_	O
170	to	_	_	O
171	investigate	_	_	O
172	TDF	_	_	O
173	safety	_	_	O
174	.	_	_	O

175	Sixty-one	_	_	O
176	patients	_	_	O
177	were	_	_	O
178	enrolled	_	_	O
179	in	_	_	O
180	the	_	_	O
181	study	_	_	O
182	,	_	_	O
183	33	_	_	O
184	in	_	_	O
185	the	_	_	O
186	TDF	_	_	O
187	treatment	_	_	O
188	group	_	_	O
189	and	_	_	O
190	28	_	_	O
191	in	_	_	O
192	the	_	_	O
193	observation	_	_	O
194	group	_	_	O
195	.	_	_	O

196	By	_	_	B-Premise
197	ITT	_	_	I-Premise
198	analysis	_	_	I-Premise
199	,	_	_	I-Premise
200	HBV	_	_	I-Premise
201	reactivation	_	_	I-Premise
202	was	_	_	I-Premise
203	0	_	_	I-Premise
204	%	_	_	I-Premise
205	(	_	_	I-Premise
206	0/33	_	_	I-Premise
207	)	_	_	I-Premise
208	in	_	_	I-Premise
209	the	_	_	I-Premise
210	study	_	_	I-Premise
211	group	_	_	I-Premise
212	and	_	_	I-Premise
213	10.7	_	_	I-Premise
214	%	_	_	I-Premise
215	(	_	_	I-Premise
216	3/28	_	_	I-Premise
217	)	_	_	I-Premise
218	in	_	_	I-Premise
219	the	_	_	I-Premise
220	observation	_	_	I-Premise
221	group	_	_	I-Premise
222	(	_	_	I-Premise
223	p	_	_	I-Premise
224	=	_	_	I-Premise
225	0.091	_	_	I-Premise
226	)	_	_	I-Premise
227	.	_	_	I-Premise

228	None	_	_	B-Premise
229	of	_	_	I-Premise
230	the	_	_	I-Premise
231	patients	_	_	I-Premise
232	in	_	_	I-Premise
233	either	_	_	I-Premise
234	group	_	_	I-Premise
235	showed	_	_	I-Premise
236	significant	_	_	I-Premise
237	differences	_	_	I-Premise
238	in	_	_	I-Premise
239	liver	_	_	I-Premise
240	function	_	_	I-Premise
241	parameters	_	_	I-Premise
242	between	_	_	I-Premise
243	baseline	_	_	I-Premise
244	and	_	_	I-Premise
245	the	_	_	I-Premise
246	last	_	_	I-Premise
247	follow-up	_	_	I-Premise
248	sample	_	_	I-Premise
249	.	_	_	I-Premise

250	TDF	_	_	B-Claim
251	was	_	_	I-Claim
252	generally	_	_	I-Claim
253	well	_	_	I-Claim
254	tolerated	_	_	I-Claim
255	and	_	_	I-Claim
256	there	_	_	I-Claim
257	were	_	_	I-Claim
258	no	_	_	I-Claim
259	severe	_	_	I-Claim
260	treatment-related	_	_	I-Claim
261	adverse	_	_	I-Claim
262	events	_	_	I-Claim
263	.	_	_	I-Claim

264	In	_	_	B-Claim
265	patients	_	_	I-Claim
266	with	_	_	I-Claim
267	hematological	_	_	I-Claim
268	malignancy	_	_	I-Claim
269	and	_	_	I-Claim
270	resolved	_	_	I-Claim
271	hepatitis	_	_	I-Claim
272	B	_	_	I-Claim
273	infection	_	_	I-Claim
274	receiving	_	_	I-Claim
275	RTX-based	_	_	I-Claim
276	regimens	_	_	I-Claim
277	,	_	_	I-Claim
278	HBV	_	_	I-Claim
279	reactivation	_	_	I-Claim
280	did	_	_	I-Claim
281	not	_	_	I-Claim
282	occur	_	_	I-Claim
283	in	_	_	I-Claim
284	patients	_	_	I-Claim
285	given	_	_	I-Claim
286	TDF	_	_	I-Claim
287	prophylaxis	_	_	I-Claim
288	.	_	_	I-Claim


0	Chronic	_	_	O
1	hepatitis	_	_	O
2	B	_	_	O
3	management	_	_	O
4	is	_	_	O
5	commonly	_	_	O
6	targeted	_	_	O
7	at	_	_	O
8	reducing	_	_	O
9	viral	_	_	O
10	replication	_	_	O
11	.	_	_	O

12	However	_	_	O
13	,	_	_	O
14	the	_	_	O
15	currently	_	_	O
16	available	_	_	O
17	antiviral	_	_	O
18	therapies	_	_	O
19	are	_	_	O
20	associated	_	_	O
21	with	_	_	O
22	some	_	_	O
23	problems	_	_	O
24	,	_	_	O
25	including	_	_	O
26	resistance	_	_	O
27	and	_	_	O
28	numerous	_	_	O
29	adverse	_	_	O
30	effects	_	_	O
31	.	_	_	O

32	Ginseng	_	_	O
33	has	_	_	O
34	been	_	_	O
35	reported	_	_	O
36	to	_	_	O
37	be	_	_	O
38	effective	_	_	O
39	for	_	_	O
40	treating	_	_	O
41	viral	_	_	O
42	infections	_	_	O
43	such	_	_	O
44	as	_	_	O
45	influenza	_	_	O
46	and	_	_	O
47	human	_	_	O
48	immunodeficiency	_	_	O
49	virus	_	_	O
50	.	_	_	O

51	However	_	_	O
52	,	_	_	O
53	there	_	_	O
54	are	_	_	O
55	currently	_	_	O
56	few	_	_	O
57	studies	_	_	O
58	on	_	_	O
59	the	_	_	O
60	effects	_	_	O
61	of	_	_	O
62	ginseng	_	_	O
63	in	_	_	O
64	chronic	_	_	O
65	hepatitis	_	_	O
66	B	_	_	O
67	.	_	_	O

68	Thus	_	_	O
69	,	_	_	O
70	this	_	_	O
71	study	_	_	O
72	investigated	_	_	O
73	the	_	_	O
74	effects	_	_	O
75	of	_	_	O
76	ginseng	_	_	O
77	together	_	_	O
78	with	_	_	O
79	antiviral	_	_	O
80	agents	_	_	O
81	in	_	_	O
82	chronic	_	_	O
83	hepatitis	_	_	O
84	B	_	_	O
85	.	_	_	O

86	This	_	_	O
87	was	_	_	O
88	a	_	_	O
89	prospective	_	_	O
90	,	_	_	O
91	single-blinded	_	_	O
92	,	_	_	O
93	randomized	_	_	O
94	controlled	_	_	O
95	trial	_	_	O
96	,	_	_	O
97	and	_	_	O
98	single-center	_	_	O
99	study	_	_	O
100	.	_	_	O

101	Thirty-eight	_	_	O
102	patients	_	_	O
103	were	_	_	O
104	enrolled	_	_	O
105	.	_	_	O

106	The	_	_	O
107	control	_	_	O
108	group	_	_	O
109	(	_	_	O
110	n	_	_	O
111	=	_	_	O
112	19	_	_	O
113	)	_	_	O
114	was	_	_	O
115	administered	_	_	O
116	antiviral	_	_	O
117	agents	_	_	O
118	alone	_	_	O
119	.	_	_	O

120	The	_	_	O
121	experimental	_	_	O
122	group	_	_	O
123	(	_	_	O
124	n	_	_	O
125	=	_	_	O
126	19	_	_	O
127	)	_	_	O
128	was	_	_	O
129	administered	_	_	O
130	antiviral	_	_	O
131	agents	_	_	O
132	along	_	_	O
133	with	_	_	O
134	Korean	_	_	O
135	Red	_	_	O
136	Ginseng	_	_	O
137	powder	_	_	O
138	capsules	_	_	O
139	(	_	_	O
140	each	_	_	O
141	dose	_	_	O
142	is	_	_	O
143	1	_	_	O
144	gram	_	_	O
145	(	_	_	O
146	two	_	_	O
147	capsules	_	_	O
148	)	_	_	O
149	,	_	_	O
150	a	_	_	O
151	one-day	_	_	O
152	dose	_	_	O
153	is	_	_	O
154	3	_	_	O
155	grams	_	_	O
156	)	_	_	O
157	.	_	_	O

158	The	_	_	O
159	baseline	_	_	O
160	characteristics	_	_	O
161	did	_	_	O
162	not	_	_	O
163	differ	_	_	O
164	between	_	_	O
165	the	_	_	O
166	two	_	_	O
167	groups	_	_	O
168	.	_	_	O

169	Differences	_	_	B-Premise
170	in	_	_	I-Premise
171	several	_	_	I-Premise
172	non-invasive	_	_	I-Premise
173	fibrosis	_	_	I-Premise
174	serologic	_	_	I-Premise
175	markers	_	_	I-Premise
176	(	_	_	I-Premise
177	type	_	_	I-Premise
178	IV	_	_	I-Premise
179	collagen	_	_	I-Premise
180	,	_	_	I-Premise
181	hyaluronic	_	_	I-Premise
182	acid	_	_	I-Premise
183	,	_	_	I-Premise
184	transforming	_	_	I-Premise
185	growth	_	_	I-Premise
186	factor-β	_	_	I-Premise
187	)	_	_	I-Premise
188	and	_	_	I-Premise
189	in	_	_	I-Premise
190	the	_	_	I-Premise
191	hepatitis	_	_	I-Premise
192	B	_	_	I-Premise
193	virus	_	_	I-Premise
194	DNA	_	_	I-Premise
195	levels	_	_	I-Premise
196	were	_	_	I-Premise
197	compared	_	_	I-Premise
198	between	_	_	I-Premise
199	the	_	_	I-Premise
200	groups	_	_	I-Premise
201	.	_	_	I-Premise

202	The	_	_	B-Premise
203	non-invasive	_	_	I-Premise
204	fibrosis	_	_	I-Premise
205	serologic	_	_	I-Premise
206	markers	_	_	I-Premise
207	were	_	_	I-Premise
208	further	_	_	I-Premise
209	decreased	_	_	I-Premise
210	in	_	_	I-Premise
211	the	_	_	I-Premise
212	experimental	_	_	I-Premise
213	group	_	_	I-Premise
214	,	_	_	I-Premise
215	with	_	_	I-Premise
216	significant	_	_	I-Premise
217	differences	_	_	I-Premise
218	after	_	_	I-Premise
219	treatment	_	_	I-Premise
220	observed	_	_	I-Premise
221	for	_	_	I-Premise
222	hyaluronic	_	_	I-Premise
223	acid	_	_	I-Premise
224	(	_	_	I-Premise
225	p	_	_	I-Premise
226	=	_	_	I-Premise
227	0.032	_	_	I-Premise
228	)	_	_	I-Premise
229	and	_	_	I-Premise
230	transforming	_	_	I-Premise
231	growth	_	_	I-Premise
232	factor-β	_	_	I-Premise
233	(	_	_	I-Premise
234	p	_	_	I-Premise
235	=	_	_	I-Premise
236	0.008	_	_	I-Premise
237	)	_	_	I-Premise
238	,	_	_	I-Premise
239	but	_	_	I-Premise
240	not	_	_	I-Premise
241	for	_	_	I-Premise
242	type	_	_	I-Premise
243	IV	_	_	I-Premise
244	collagen	_	_	I-Premise
245	(	_	_	I-Premise
246	p	_	_	I-Premise
247	=	_	_	I-Premise
248	0.174	_	_	I-Premise
249	)	_	_	I-Premise
250	.	_	_	I-Premise

251	This	_	_	B-Claim
252	study	_	_	I-Claim
253	suggests	_	_	I-Claim
254	the	_	_	I-Claim
255	possibility	_	_	I-Claim
256	of	_	_	I-Claim
257	Korean	_	_	I-Claim
258	Red	_	_	I-Claim
259	Ginseng	_	_	I-Claim
260	as	_	_	I-Claim
261	a	_	_	I-Claim
262	complementary	_	_	I-Claim
263	therapy	_	_	I-Claim
264	for	_	_	I-Claim
265	chronic	_	_	I-Claim
266	hepatitis	_	_	I-Claim
267	B	_	_	I-Claim
268	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	intraocular	_	_	O
4	pressure	_	_	O
5	(	_	_	O
6	IOP	_	_	O
7	)	_	_	O
8	-lowering	_	_	O
9	efficacy	_	_	O
10	and	_	_	O
11	safety	_	_	O
12	of	_	_	O
13	fixed-combination	_	_	O
14	brimonidine	_	_	O
15	0.2	_	_	O
16	%	_	_	O
17	-timolol	_	_	O
18	0.5	_	_	O
19	%	_	_	O
20	compared	_	_	O
21	with	_	_	O
22	latanoprost	_	_	O
23	0.005	_	_	O
24	%	_	_	O
25	in	_	_	O
26	patients	_	_	O
27	with	_	_	O
28	glaucoma	_	_	O
29	or	_	_	O
30	ocular	_	_	O
31	hypertension	_	_	O
32	.	_	_	O

33	This	_	_	O
34	was	_	_	O
35	a	_	_	O
36	prospective	_	_	O
37	,	_	_	O
38	randomized	_	_	O
39	,	_	_	O
40	multicenter	_	_	O
41	,	_	_	O
42	investigator-masked	_	_	O
43	clinical	_	_	O
44	trial	_	_	O
45	.	_	_	O

46	After	_	_	O
47	washout	_	_	O
48	of	_	_	O
49	any	_	_	O
50	previous	_	_	O
51	IOP-lowering	_	_	O
52	medications	_	_	O
53	,	_	_	O
54	patients	_	_	O
55	with	_	_	O
56	IOP	_	_	O
57	of	_	_	O
58	24	_	_	O
59	mmHg	_	_	O
60	or	_	_	O
61	higher	_	_	O
62	were	_	_	O
63	randomized	_	_	O
64	to	_	_	O
65	twice-daily	_	_	O
66	fixed-combination	_	_	O
67	brimonidine	_	_	O
68	0.2	_	_	O
69	%	_	_	O
70	-timolol	_	_	O
71	0.5	_	_	O
72	%	_	_	O
73	(	_	_	O
74	n	_	_	O
75	=	_	_	O
76	73	_	_	O
77	)	_	_	O
78	or	_	_	O
79	once-daily	_	_	O
80	latanoprost	_	_	O
81	0.005	_	_	O
82	%	_	_	O
83	(	_	_	O
84	n	_	_	O
85	=	_	_	O
86	75	_	_	O
87	,	_	_	O
88	dosed	_	_	O
89	in	_	_	O
90	the	_	_	O
91	evening	_	_	O
92	,	_	_	O
93	with	_	_	O
94	vehicle	_	_	O
95	control	_	_	O
96	in	_	_	O
97	the	_	_	O
98	morning	_	_	O
99	to	_	_	O
100	maintain	_	_	O
101	masking	_	_	O
102	)	_	_	O
103	for	_	_	O
104	12	_	_	O
105	weeks	_	_	O
106	.	_	_	O

107	IOP	_	_	O
108	was	_	_	O
109	measured	_	_	O
110	at	_	_	O
111	8	_	_	O
112	a.m.	_	_	O
113	(	_	_	O
114	before	_	_	O
115	dosing	_	_	O
116	)	_	_	O
117	,	_	_	O
118	10	_	_	O
119	a.m.	_	_	O
120	,	_	_	O
121	and	_	_	O
122	3	_	_	O
123	p.m.	_	_	O
124	at	_	_	O
125	baseline	_	_	O
126	,	_	_	O
127	week	_	_	O
128	6	_	_	O
129	,	_	_	O
130	and	_	_	O
131	week	_	_	O
132	12	_	_	O
133	.	_	_	O

134	The	_	_	O
135	primary	_	_	O
136	efficacy	_	_	O
137	endpoint	_	_	O
138	was	_	_	O
139	diurnal	_	_	O
140	IOP	_	_	O
141	(	_	_	O
142	averaged	_	_	O
143	over	_	_	O
144	8	_	_	O
145	a.m.	_	_	O
146	,	_	_	O
147	10	_	_	O
148	a.m.	_	_	O
149	,	_	_	O
150	and	_	_	O
151	3	_	_	O
152	p.m.	_	_	O
153	)	_	_	O
154	at	_	_	O
155	week	_	_	O
156	12	_	_	O
157	.	_	_	O

158	Safety	_	_	O
159	measures	_	_	O
160	included	_	_	O
161	biomicroscopy	_	_	O
162	.	_	_	O

163	There	_	_	O
164	was	_	_	O
165	no	_	_	O
166	statistically	_	_	O
167	significant	_	_	O
168	difference	_	_	O
169	between	_	_	O
170	the	_	_	O
171	treatment	_	_	O
172	groups	_	_	O
173	in	_	_	O
174	mean	_	_	O
175	diurnal	_	_	O
176	IOP	_	_	O
177	at	_	_	O
178	baseline	_	_	O
179	(	_	_	O
180	p	_	_	O
181	=	_	_	O
182	0.118	_	_	O
183	)	_	_	O
184	.	_	_	O

185	At	_	_	B-Premise
186	week	_	_	I-Premise
187	12	_	_	I-Premise
188	,	_	_	I-Premise
189	the	_	_	I-Premise
190	mean	_	_	I-Premise
191	(	_	_	I-Premise
192	SD	_	_	I-Premise
193	)	_	_	I-Premise
194	diurnal	_	_	I-Premise
195	IOP	_	_	I-Premise
196	was	_	_	I-Premise
197	17.8	_	_	I-Premise
198	(	_	_	I-Premise
199	2.9	_	_	I-Premise
200	)	_	_	I-Premise
201	mmHg	_	_	I-Premise
202	with	_	_	I-Premise
203	brimonidine-timolol	_	_	I-Premise
204	and	_	_	I-Premise
205	17.9	_	_	I-Premise
206	(	_	_	I-Premise
207	3.9	_	_	I-Premise
208	)	_	_	I-Premise
209	mmHg	_	_	I-Premise
210	with	_	_	I-Premise
211	latanoprost	_	_	I-Premise
212	(	_	_	I-Premise
213	p	_	_	I-Premise
214	=	_	_	I-Premise
215	0.794	_	_	I-Premise
216	)	_	_	I-Premise
217	.	_	_	I-Premise

218	The	_	_	B-Premise
219	percentage	_	_	I-Premise
220	of	_	_	I-Premise
221	patients	_	_	I-Premise
222	achieving	_	_	I-Premise
223	at	_	_	I-Premise
224	least	_	_	I-Premise
225	a	_	_	I-Premise
226	20	_	_	I-Premise
227	%	_	_	I-Premise
228	decrease	_	_	I-Premise
229	from	_	_	I-Premise
230	baseline	_	_	I-Premise
231	diurnal	_	_	I-Premise
232	IOP	_	_	I-Premise
233	at	_	_	I-Premise
234	week	_	_	I-Premise
235	12	_	_	I-Premise
236	was	_	_	I-Premise
237	87.7	_	_	I-Premise
238	%	_	_	I-Premise
239	in	_	_	I-Premise
240	the	_	_	I-Premise
241	brimonidine-timolol	_	_	I-Premise
242	group	_	_	I-Premise
243	and	_	_	I-Premise
244	77.3	_	_	I-Premise
245	%	_	_	I-Premise
246	in	_	_	I-Premise
247	the	_	_	I-Premise
248	latanoprost	_	_	I-Premise
249	group	_	_	I-Premise
250	(	_	_	I-Premise
251	p	_	_	I-Premise
252	=	_	_	I-Premise
253	0.131	_	_	I-Premise
254	)	_	_	I-Premise
255	.	_	_	I-Premise

256	Measured	_	_	B-Premise
257	biomicroscopic	_	_	I-Premise
258	changes	_	_	I-Premise
259	from	_	_	I-Premise
260	baseline	_	_	I-Premise
261	to	_	_	I-Premise
262	week	_	_	I-Premise
263	12	_	_	I-Premise
264	were	_	_	I-Premise
265	infrequent	_	_	I-Premise
266	in	_	_	I-Premise
267	both	_	_	I-Premise
268	groups	_	_	I-Premise
269	.	_	_	I-Premise

270	Fixed-combination	_	_	B-Claim
271	brimonidine-timolol	_	_	I-Claim
272	was	_	_	I-Claim
273	as	_	_	I-Claim
274	effective	_	_	I-Claim
275	as	_	_	I-Claim
276	latanoprost	_	_	I-Claim
277	in	_	_	I-Claim
278	reducing	_	_	I-Claim
279	IOP	_	_	I-Claim
280	in	_	_	I-Claim
281	patients	_	_	I-Claim
282	with	_	_	I-Claim
283	glaucoma	_	_	I-Claim
284	or	_	_	I-Claim
285	ocular	_	_	I-Claim
286	hypertension	_	_	I-Claim
287	.	_	_	I-Claim

288	Both	_	_	B-Claim
289	treatments	_	_	I-Claim
290	demonstrated	_	_	I-Claim
291	favorable	_	_	I-Claim
292	ocular	_	_	I-Claim
293	tolerability	_	_	I-Claim
294	.	_	_	I-Claim

295	The	_	_	O
296	duration	_	_	O
297	of	_	_	O
298	the	_	_	O
299	study	_	_	O
300	was	_	_	O
301	12	_	_	O
302	weeks	_	_	O
303	,	_	_	O
304	and	_	_	O
305	additional	_	_	O
306	studies	_	_	O
307	will	_	_	O
308	be	_	_	O
309	needed	_	_	O
310	to	_	_	O
311	compare	_	_	O
312	the	_	_	O
313	efficacy	_	_	O
314	and	_	_	O
315	safety	_	_	O
316	of	_	_	O
317	fixed-combination	_	_	O
318	brimonidine-timolol	_	_	O
319	and	_	_	O
320	latanoprost	_	_	O
321	during	_	_	O
322	long-term	_	_	O
323	treatment	_	_	O
324	.	_	_	O


0	We	_	_	O
1	compared	_	_	O
2	the	_	_	O
3	clinical	_	_	O
4	effects	_	_	O
5	and	_	_	O
6	impact	_	_	O
7	on	_	_	O
8	quality	_	_	O
9	of	_	_	O
10	life	_	_	O
11	(	_	_	O
12	QOL	_	_	O
13	)	_	_	O
14	of	_	_	O
15	patients	_	_	O
16	who	_	_	O
17	received	_	_	O
18	a	_	_	O
19	3-month	_	_	O
20	course	_	_	O
21	of	_	_	O
22	flutamide	_	_	O
23	monotherapy	_	_	O
24	before	_	_	O
25	radical	_	_	O
26	prostatectomy	_	_	O
27	with	_	_	O
28	those	_	_	O
29	who	_	_	O
30	received	_	_	O
31	a	_	_	O
32	3-month	_	_	O
33	course	_	_	O
34	of	_	_	O
35	luteinizing	_	_	O
36	hormone-releasing	_	_	O
37	hormone	_	_	O
38	(	_	_	O
39	LHRH	_	_	O
40	)	_	_	O
41	agonist	_	_	O
42	monotherapy	_	_	O
43	.	_	_	O

44	Thirty-seven	_	_	O
45	patients	_	_	O
46	with	_	_	O
47	non-metastatic	_	_	O
48	prostate	_	_	O
49	cancer	_	_	O
50	were	_	_	O
51	enrolled	_	_	O
52	in	_	_	O
53	this	_	_	O
54	study	_	_	O
55	(	_	_	O
56	19	_	_	O
57	,	_	_	O
58	flutamide	_	_	O
59	;	_	_	O
60	18	_	_	O
61	,	_	_	O
62	LHRH	_	_	O
63	agonist	_	_	O
64	)	_	_	O
65	.	_	_	O

66	The	_	_	O
67	rates	_	_	O
68	of	_	_	O
69	change	_	_	O
70	of	_	_	O
71	serum	_	_	O
72	prostate-specific	_	_	O
73	antigen	_	_	O
74	(	_	_	O
75	PSA	_	_	O
76	)	_	_	O
77	and	_	_	O
78	testosterone	_	_	O
79	levels	_	_	O
80	,	_	_	O
81	downsizing	_	_	O
82	of	_	_	O
83	prostate	_	_	O
84	volume	_	_	O
85	,	_	_	O
86	the	_	_	O
87	rate	_	_	O
88	of	_	_	O
89	organ	_	_	O
90	confined	_	_	O
91	disease	_	_	O
92	,	_	_	O
93	adverse	_	_	O
94	effects	_	_	O
95	and	_	_	O
96	perioperative	_	_	O
97	scores	_	_	O
98	measured	_	_	O
99	using	_	_	O
100	the	_	_	O
101	European	_	_	O
102	Organization	_	_	O
103	for	_	_	O
104	Research	_	_	O
105	and	_	_	O
106	Treatment	_	_	O
107	of	_	_	O
108	Cancer	_	_	O
109	Prostate	_	_	O
110	Cancer	_	_	O
111	Quality	_	_	O
112	of	_	_	O
113	Life	_	_	O
114	Questionnaire	_	_	O
115	(	_	_	O
116	EORTC-P	_	_	O
117	)	_	_	O
118	and	_	_	O
119	the	_	_	O
120	Sapporo	_	_	O
121	Medical	_	_	O
122	University	_	_	O
123	Sexual	_	_	O
124	Function	_	_	O
125	Questionnaire	_	_	O
126	(	_	_	O
127	SMUF	_	_	O
128	)	_	_	O
129	were	_	_	O
130	analyzed	_	_	O
131	.	_	_	O

132	At	_	_	B-Premise
133	radical	_	_	I-Premise
134	prostatectomy	_	_	I-Premise
135	,	_	_	I-Premise
136	pathological	_	_	I-Premise
137	variables	_	_	I-Premise
138	were	_	_	I-Premise
139	not	_	_	I-Premise
140	significantly	_	_	I-Premise
141	different	_	_	I-Premise
142	in	_	_	I-Premise
143	the	_	_	I-Premise
144	two	_	_	I-Premise
145	groups	_	_	I-Premise
146	.	_	_	I-Premise

147	Serum	_	_	B-Premise
148	testosterone	_	_	I-Premise
149	level	_	_	I-Premise
150	was	_	_	I-Premise
151	significantly	_	_	I-Premise
152	higher	_	_	I-Premise
153	(	_	_	I-Premise
154	mean	_	_	I-Premise
155	359.2	_	_	I-Premise
156	compared	_	_	I-Premise
157	to	_	_	I-Premise
158	10.5	_	_	I-Premise
159	,	_	_	I-Premise
160	P	_	_	I-Premise
161	<	_	_	I-Premise
162	0.001	_	_	I-Premise
163	)	_	_	I-Premise
164	,	_	_	I-Premise
165	complete	_	_	B-Premise
166	response	_	_	I-Premise
167	rate	_	_	I-Premise
168	of	_	_	I-Premise
169	PSA	_	_	I-Premise
170	(	_	_	I-Premise
171	13	_	_	I-Premise
172	%	_	_	I-Premise
173	compared	_	_	I-Premise
174	to	_	_	I-Premise
175	57	_	_	I-Premise
176	%	_	_	I-Premise
177	,	_	_	I-Premise
178	P	_	_	I-Premise
179	=	_	_	I-Premise
180	0.028	_	_	I-Premise
181	)	_	_	I-Premise
182	and	_	_	I-Premise
183	rate	_	_	I-Premise
184	of	_	_	I-Premise
185	downsizing	_	_	I-Premise
186	of	_	_	I-Premise
187	prostate	_	_	I-Premise
188	volume	_	_	I-Premise
189	(	_	_	I-Premise
190	mean	_	_	I-Premise
191	,	_	_	I-Premise
192	-17.7	_	_	I-Premise
193	%	_	_	I-Premise
194	compared	_	_	I-Premise
195	to	_	_	I-Premise
196	-35.4	_	_	I-Premise
197	%	_	_	I-Premise
198	,	_	_	I-Premise
199	P	_	_	I-Premise
200	=	_	_	I-Premise
201	0.038	_	_	I-Premise
202	)	_	_	I-Premise
203	were	_	_	I-Premise
204	significantly	_	_	I-Premise
205	lower	_	_	I-Premise
206	in	_	_	I-Premise
207	the	_	_	I-Premise
208	flutamide	_	_	I-Premise
209	group	_	_	I-Premise
210	than	_	_	I-Premise
211	in	_	_	I-Premise
212	the	_	_	I-Premise
213	LHRH	_	_	I-Premise
214	group	_	_	I-Premise
215	.	_	_	I-Premise

216	After	_	_	B-Premise
217	neoadjuvant	_	_	I-Premise
218	hormone	_	_	I-Premise
219	therapy	_	_	I-Premise
220	,	_	_	I-Premise
221	the	_	_	I-Premise
222	scores	_	_	I-Premise
223	on	_	_	I-Premise
224	the	_	_	I-Premise
225	sexual	_	_	I-Premise
226	problem	_	_	I-Premise
227	domain	_	_	I-Premise
228	of	_	_	I-Premise
229	EORTC-P	_	_	I-Premise
230	(	_	_	I-Premise
231	P	_	_	I-Premise
232	=	_	_	I-Premise
233	0.033	_	_	I-Premise
234	)	_	_	I-Premise
235	and	_	_	I-Premise
236	sexual	_	_	I-Premise
237	desire	_	_	I-Premise
238	score	_	_	I-Premise
239	of	_	_	I-Premise
240	SMUF	_	_	I-Premise
241	(	_	_	I-Premise
242	P	_	_	I-Premise
243	=	_	_	I-Premise
244	0.021	_	_	I-Premise
245	)	_	_	I-Premise
246	were	_	_	I-Premise
247	significantly	_	_	I-Premise
248	higher	_	_	I-Premise
249	in	_	_	I-Premise
250	the	_	_	I-Premise
251	flutamide	_	_	I-Premise
252	group	_	_	I-Premise
253	than	_	_	I-Premise
254	in	_	_	I-Premise
255	the	_	_	I-Premise
256	LHRH	_	_	I-Premise
257	group	_	_	I-Premise
258	.	_	_	I-Premise

259	At	_	_	B-Premise
260	a	_	_	I-Premise
261	median	_	_	I-Premise
262	follow-up	_	_	I-Premise
263	of	_	_	I-Premise
264	34	_	_	I-Premise
265	months	_	_	I-Premise
266	after	_	_	I-Premise
267	prostatectomy	_	_	I-Premise
268	,	_	_	I-Premise
269	biochemical	_	_	I-Premise
270	failure-free	_	_	I-Premise
271	survival	_	_	I-Premise
272	rate	_	_	I-Premise
273	in	_	_	I-Premise
274	the	_	_	I-Premise
275	flutamide	_	_	I-Premise
276	group	_	_	I-Premise
277	did	_	_	I-Premise
278	not	_	_	I-Premise
279	differ	_	_	I-Premise
280	from	_	_	I-Premise
281	that	_	_	I-Premise
282	in	_	_	I-Premise
283	the	_	_	I-Premise
284	LHRH	_	_	I-Premise
285	group	_	_	I-Premise
286	.	_	_	I-Premise

287	This	_	_	B-Claim
288	study	_	_	I-Claim
289	suggests	_	_	I-Claim
290	that	_	_	I-Claim
291	flutamide	_	_	I-Claim
292	monotherapy	_	_	I-Claim
293	can	_	_	I-Claim
294	be	_	_	I-Claim
295	an	_	_	I-Claim
296	acceptable	_	_	I-Claim
297	modality	_	_	I-Claim
298	as	_	_	I-Claim
299	an	_	_	I-Claim
300	option	_	_	I-Claim
301	for	_	_	I-Claim
302	neoadjuvant	_	_	I-Claim
303	hormone	_	_	I-Claim
304	therapy	_	_	I-Claim
305	.	_	_	I-Claim


0	Increasing	_	_	O
1	evidence	_	_	O
2	suggests	_	_	O
3	that	_	_	O
4	iron-containing	_	_	B-Claim
5	multiple	_	_	I-Claim
6	micronutrient	_	_	I-Claim
7	may	_	_	I-Claim
8	reduce	_	_	I-Claim
9	the	_	_	I-Claim
10	risk	_	_	I-Claim
11	of	_	_	I-Claim
12	pregnancy-induced	_	_	I-Claim
13	hypertension	_	_	I-Claim
14	including	_	_	I-Claim
15	gestational	_	_	I-Claim
16	hypertension	_	_	I-Claim
17	or	_	_	I-Claim
18	preeclampsia	_	_	I-Claim
19	.	_	_	I-Claim

20	We	_	_	O
21	aimed	_	_	O
22	to	_	_	O
23	examine	_	_	O
24	whether	_	_	O
25	30	_	_	O
26	mg	_	_	O
27	iron	_	_	O
28	plus	_	_	O
29	folic	_	_	O
30	acid	_	_	O
31	or	_	_	O
32	multiple	_	_	O
33	micronutrients	_	_	O
34	during	_	_	O
35	pregnancy	_	_	O
36	reduces	_	_	O
37	the	_	_	O
38	risk	_	_	O
39	of	_	_	O
40	pregnancy-induced	_	_	O
41	hypertension	_	_	O
42	.	_	_	O

43	We	_	_	O
44	conducted	_	_	O
45	a	_	_	O
46	secondary	_	_	O
47	data	_	_	O
48	analysis	_	_	O
49	by	_	_	O
50	the	_	_	O
51	dataset	_	_	O
52	from	_	_	O
53	a	_	_	O
54	double-blind	_	_	O
55	randomized	_	_	O
56	controlled	_	_	O
57	trial	_	_	O
58	in	_	_	O
59	China	_	_	O
60	from	_	_	O
61	2006	_	_	O
62	to	_	_	O
63	2009	_	_	O
64	that	_	_	O
65	was	_	_	O
66	conducted	_	_	O
67	to	_	_	O
68	investigate	_	_	O
69	the	_	_	O
70	effects	_	_	O
71	of	_	_	O
72	multiple	_	_	O
73	micronutrient	_	_	O
74	supplements	_	_	O
75	on	_	_	O
76	adverse	_	_	O
77	pregnancy	_	_	O
78	outcomes	_	_	O
79	when	_	_	O
80	provided	_	_	O
81	to	_	_	O
82	pregnant	_	_	O
83	women	_	_	O
84	with	_	_	O
85	no/mild	_	_	O
86	anemia	_	_	O
87	.	_	_	O

88	We	_	_	O
89	used	_	_	O
90	logistic	_	_	O
91	regression	_	_	O
92	to	_	_	O
93	estimate	_	_	O
94	the	_	_	O
95	adjusted	_	_	O
96	odds	_	_	O
97	ratio	_	_	O
98	and	_	_	O
99	95	_	_	O
100	%	_	_	O
101	confidence	_	_	O
102	interval	_	_	O
103	and	_	_	O
104	test	_	_	O
105	for	_	_	O
106	effect	_	_	O
107	modification	_	_	O
108	.	_	_	O

109	The	_	_	B-Premise
110	incidence	_	_	I-Premise
111	of	_	_	I-Premise
112	pregnancy-induced	_	_	I-Premise
113	hypertension	_	_	I-Premise
114	was	_	_	I-Premise
115	7.1	_	_	I-Premise
116	%	_	_	I-Premise
117	(	_	_	I-Premise
118	423/5923	_	_	I-Premise
119	)	_	_	I-Premise
120	,	_	_	I-Premise
121	6.3	_	_	I-Premise
122	%	_	_	I-Premise
123	(	_	_	I-Premise
124	374/5933	_	_	I-Premise
125	)	_	_	I-Premise
126	and	_	_	I-Premise
127	6.3	_	_	I-Premise
128	%	_	_	I-Premise
129	(	_	_	I-Premise
130	372/5914	_	_	I-Premise
131	)	_	_	I-Premise
132	among	_	_	I-Premise
133	the	_	_	I-Premise
134	pregnant	_	_	I-Premise
135	women	_	_	I-Premise
136	who	_	_	I-Premise
137	took	_	_	I-Premise
138	folic	_	_	I-Premise
139	acid	_	_	I-Premise
140	only	_	_	I-Premise
141	,	_	_	I-Premise
142	iron-folic	_	_	I-Premise
143	acid	_	_	I-Premise
144	and	_	_	I-Premise
145	multiple	_	_	I-Premise
146	micronutrient	_	_	I-Premise
147	supplements	_	_	I-Premise
148	,	_	_	I-Premise
149	respectively	_	_	I-Premise
150	.	_	_	I-Premise

151	The	_	_	B-Premise
152	adjusted	_	_	I-Premise
153	odds	_	_	I-Premise
154	ratios	_	_	I-Premise
155	associated	_	_	I-Premise
156	with	_	_	I-Premise
157	iron-folic	_	_	I-Premise
158	acid	_	_	I-Premise
159	supplements	_	_	I-Premise
160	and	_	_	I-Premise
161	multiple	_	_	I-Premise
162	micronutrient	_	_	I-Premise
163	supplements	_	_	I-Premise
164	for	_	_	I-Premise
165	pregnancy-induced	_	_	I-Premise
166	hypertension	_	_	I-Premise
167	were	_	_	I-Premise
168	both	_	_	I-Premise
169	nearly	_	_	I-Premise
170	0.88	_	_	I-Premise
171	(	_	_	I-Premise
172	95	_	_	I-Premise
173	%	_	_	I-Premise
174	confidence	_	_	I-Premise
175	interval	_	_	I-Premise
176	,	_	_	I-Premise
177	0.76-1.02	_	_	I-Premise
178	)	_	_	I-Premise
179	,	_	_	I-Premise
180	compared	_	_	I-Premise
181	with	_	_	I-Premise
182	folic	_	_	I-Premise
183	acid	_	_	I-Premise
184	supplements	_	_	I-Premise
185	only	_	_	I-Premise
186	.	_	_	I-Premise

187	Among	_	_	B-Premise
188	pregnant	_	_	I-Premise
189	women	_	_	I-Premise
190	aged	_	_	I-Premise
191	20-24	_	_	I-Premise
192	years	_	_	I-Premise
193	,	_	_	I-Premise
194	iron-folic	_	_	I-Premise
195	acid	_	_	I-Premise
196	(	_	_	I-Premise
197	adjusted	_	_	I-Premise
198	odds	_	_	I-Premise
199	ratios	_	_	I-Premise
200	:	_	_	I-Premise
201	0.81	_	_	I-Premise
202	,	_	_	I-Premise
203	95	_	_	I-Premise
204	%	_	_	I-Premise
205	confidence	_	_	I-Premise
206	interval	_	_	I-Premise
207	:	_	_	I-Premise
208	0.67-0.96	_	_	I-Premise
209	)	_	_	I-Premise
210	or	_	_	I-Premise
211	multiple	_	_	I-Premise
212	micronutrient	_	_	I-Premise
213	supplementation	_	_	I-Premise
214	(	_	_	I-Premise
215	adjusted	_	_	I-Premise
216	odds	_	_	I-Premise
217	ratios	_	_	I-Premise
218	:	_	_	I-Premise
219	0.83	_	_	I-Premise
220	,	_	_	I-Premise
221	95	_	_	I-Premise
222	%	_	_	I-Premise
223	confidence	_	_	I-Premise
224	interval	_	_	I-Premise
225	:	_	_	I-Premise
226	0.70-0.99	_	_	I-Premise
227	)	_	_	I-Premise
228	can	_	_	I-Premise
229	significantly	_	_	I-Premise
230	reduce	_	_	I-Premise
231	the	_	_	I-Premise
232	risk	_	_	I-Premise
233	of	_	_	I-Premise
234	pregnancy-induced	_	_	I-Premise
235	hypertension	_	_	I-Premise
236	compared	_	_	I-Premise
237	to	_	_	I-Premise
238	folic	_	_	I-Premise
239	acid	_	_	I-Premise
240	supplementation	_	_	I-Premise
241	.	_	_	I-Premise

242	Overall	_	_	O
243	,	_	_	O
244	there	_	_	O
245	were	_	_	O
246	no	_	_	O
247	significant	_	_	O
248	differences	_	_	O
249	in	_	_	O
250	pregnancy-induced	_	_	O
251	hypertension	_	_	O
252	across	_	_	O
253	supplement	_	_	O
254	groups	_	_	O
255	.	_	_	O

256	However	_	_	O
257	,	_	_	O
258	among	_	_	B-Claim
259	pregnant	_	_	I-Claim
260	women	_	_	I-Claim
261	aged	_	_	I-Claim
262	20-24	_	_	I-Claim
263	years	_	_	I-Claim
264	,	_	_	I-Claim
265	iron-containing	_	_	I-Claim
266	multiple	_	_	I-Claim
267	micronutrient	_	_	I-Claim
268	supplementation	_	_	I-Claim
269	was	_	_	I-Claim
270	associated	_	_	I-Claim
271	with	_	_	I-Claim
272	a	_	_	I-Claim
273	reduced	_	_	I-Claim
274	risk	_	_	I-Claim
275	of	_	_	I-Claim
276	pregnancy-induced	_	_	I-Claim
277	hypertension	_	_	I-Claim
278	compared	_	_	I-Claim
279	with	_	_	I-Claim
280	folic	_	_	I-Claim
281	acid	_	_	I-Claim
282	supplements	_	_	I-Claim
283	only	_	_	I-Claim
284	.	_	_	I-Claim


0	To	_	_	O
1	investigate	_	_	O
2	whether	_	_	O
3	docetaxel	_	_	O
4	plus	_	_	O
5	platinum	_	_	O
6	regimens	_	_	O
7	improve	_	_	O
8	survival	_	_	O
9	and	_	_	O
10	affect	_	_	O
11	quality	_	_	O
12	of	_	_	O
13	life	_	_	O
14	(	_	_	O
15	QoL	_	_	O
16	)	_	_	O
17	in	_	_	O
18	advanced	_	_	O
19	non-small-cell	_	_	O
20	lung	_	_	O
21	cancer	_	_	O
22	(	_	_	O
23	NSCLC	_	_	O
24	)	_	_	O
25	compared	_	_	O
26	with	_	_	O
27	vinorelbine	_	_	O
28	plus	_	_	O
29	cisplatin	_	_	O
30	as	_	_	O
31	first-line	_	_	O
32	chemotherapy	_	_	O
33	.	_	_	O

34	Patients	_	_	O
35	(	_	_	O
36	n	_	_	O
37	=	_	_	O
38	1,218	_	_	O
39	)	_	_	O
40	with	_	_	O
41	stage	_	_	O
42	IIIB	_	_	O
43	to	_	_	O
44	IV	_	_	O
45	NSCLC	_	_	O
46	were	_	_	O
47	randomly	_	_	O
48	assigned	_	_	O
49	to	_	_	O
50	receive	_	_	O
51	docetaxel	_	_	O
52	75	_	_	O
53	mg/m2	_	_	O
54	and	_	_	O
55	cisplatin	_	_	O
56	75	_	_	O
57	mg/m2	_	_	O
58	every	_	_	O
59	3	_	_	O
60	weeks	_	_	O
61	(	_	_	O
62	DC	_	_	O
63	)	_	_	O
64	;	_	_	O
65	docetaxel	_	_	O
66	75	_	_	O
67	mg/m2	_	_	O
68	and	_	_	O
69	carboplatin	_	_	O
70	area	_	_	O
71	under	_	_	O
72	the	_	_	O
73	curve	_	_	O
74	of	_	_	O
75	6	_	_	O
76	mg/mL	_	_	O
77	*	_	_	O
78	min	_	_	O
79	every	_	_	O
80	3	_	_	O
81	weeks	_	_	O
82	(	_	_	O
83	DCb	_	_	O
84	)	_	_	O
85	;	_	_	O
86	or	_	_	O
87	vinorelbine	_	_	O
88	25	_	_	O
89	mg/m2/wk	_	_	O
90	and	_	_	O
91	cisplatin	_	_	O
92	100	_	_	O
93	mg/m2	_	_	O
94	every	_	_	O
95	4	_	_	O
96	weeks	_	_	O
97	(	_	_	O
98	VC	_	_	O
99	)	_	_	O
100	.	_	_	O

101	Patients	_	_	B-Premise
102	treated	_	_	I-Premise
103	with	_	_	I-Premise
104	DC	_	_	I-Premise
105	had	_	_	I-Premise
106	a	_	_	I-Premise
107	median	_	_	I-Premise
108	survival	_	_	I-Premise
109	of	_	_	I-Premise
110	11.3	_	_	I-Premise
111	v	_	_	I-Premise
112	10.1	_	_	I-Premise
113	months	_	_	I-Premise
114	for	_	_	I-Premise
115	VC-treated	_	_	I-Premise
116	patients	_	_	I-Premise
117	(	_	_	I-Premise
118	P	_	_	I-Premise
119	=.044	_	_	I-Premise
120	;	_	_	I-Premise
121	hazard	_	_	I-Premise
122	ratio	_	_	I-Premise
123	,	_	_	I-Premise
124	1.183	_	_	I-Premise
125	[	_	_	I-Premise
126	97.2	_	_	I-Premise
127	%	_	_	I-Premise
128	confidence	_	_	I-Premise
129	interval	_	_	I-Premise
130	,	_	_	I-Premise
131	0.989	_	_	I-Premise
132	to	_	_	I-Premise
133	1.416	_	_	I-Premise
134	]	_	_	I-Premise
135	)	_	_	I-Premise
136	.	_	_	I-Premise

137	The	_	_	B-Premise
138	2-year	_	_	I-Premise
139	survival	_	_	I-Premise
140	rate	_	_	I-Premise
141	was	_	_	I-Premise
142	21	_	_	I-Premise
143	%	_	_	I-Premise
144	for	_	_	I-Premise
145	DC-treated	_	_	I-Premise
146	patients	_	_	I-Premise
147	and	_	_	I-Premise
148	14	_	_	I-Premise
149	%	_	_	I-Premise
150	for	_	_	I-Premise
151	VC-treated	_	_	I-Premise
152	patients	_	_	I-Premise
153	.	_	_	I-Premise

154	Overall	_	_	B-Premise
155	response	_	_	I-Premise
156	rate	_	_	I-Premise
157	was	_	_	I-Premise
158	31.6	_	_	I-Premise
159	%	_	_	I-Premise
160	for	_	_	I-Premise
161	DC-treated	_	_	I-Premise
162	patients	_	_	I-Premise
163	v	_	_	I-Premise
164	24.5	_	_	I-Premise
165	%	_	_	I-Premise
166	for	_	_	I-Premise
167	VC-treated	_	_	I-Premise
168	patients	_	_	I-Premise
169	(	_	_	I-Premise
170	P	_	_	I-Premise
171	=.029	_	_	I-Premise
172	)	_	_	I-Premise
173	.	_	_	I-Premise

174	Median	_	_	B-Premise
175	survival	_	_	I-Premise
176	(	_	_	I-Premise
177	9.4	_	_	I-Premise
178	v	_	_	I-Premise
179	9.9	_	_	I-Premise
180	months	_	_	I-Premise
181	[	_	_	I-Premise
182	for	_	_	I-Premise
183	VC	_	_	I-Premise
184	]	_	_	I-Premise
185	;	_	_	I-Premise
186	P	_	_	I-Premise
187	=.657	_	_	I-Premise
188	;	_	_	I-Premise
189	hazard	_	_	I-Premise
190	ratio	_	_	I-Premise
191	,	_	_	I-Premise
192	1.048	_	_	I-Premise
193	[	_	_	I-Premise
194	97.2	_	_	I-Premise
195	confidence	_	_	I-Premise
196	interval	_	_	I-Premise
197	,	_	_	I-Premise
198	0.877	_	_	I-Premise
199	to	_	_	I-Premise
200	1.253	_	_	I-Premise
201	]	_	_	I-Premise
202	)	_	_	I-Premise
203	and	_	_	I-Premise
204	response	_	_	I-Premise
205	(	_	_	I-Premise
206	23.9	_	_	I-Premise
207	%	_	_	I-Premise
208	)	_	_	I-Premise
209	with	_	_	I-Premise
210	DCb	_	_	I-Premise
211	were	_	_	I-Premise
212	similar	_	_	I-Premise
213	to	_	_	I-Premise
214	those	_	_	I-Premise
215	results	_	_	I-Premise
216	for	_	_	I-Premise
217	VC	_	_	I-Premise
218	.	_	_	I-Premise

219	Neutropenia	_	_	B-Premise
220	,	_	_	I-Premise
221	thrombocytopenia	_	_	I-Premise
222	,	_	_	I-Premise
223	infection	_	_	I-Premise
224	,	_	_	I-Premise
225	and	_	_	I-Premise
226	febrile	_	_	I-Premise
227	neutropenia	_	_	I-Premise
228	were	_	_	I-Premise
229	similar	_	_	I-Premise
230	with	_	_	I-Premise
231	all	_	_	I-Premise
232	three	_	_	I-Premise
233	regimens	_	_	I-Premise
234	.	_	_	I-Premise

235	Grade	_	_	B-Premise
236	3	_	_	I-Premise
237	to	_	_	I-Premise
238	4	_	_	I-Premise
239	anemia	_	_	I-Premise
240	,	_	_	I-Premise
241	nausea	_	_	I-Premise
242	,	_	_	I-Premise
243	and	_	_	I-Premise
244	vomiting	_	_	I-Premise
245	were	_	_	I-Premise
246	more	_	_	I-Premise
247	common	_	_	I-Premise
248	(	_	_	I-Premise
249	P	_	_	I-Premise
250	<	_	_	I-Premise
251	.01	_	_	I-Premise
252	)	_	_	I-Premise
253	with	_	_	I-Premise
254	VC	_	_	I-Premise
255	than	_	_	I-Premise
256	with	_	_	I-Premise
257	DC	_	_	I-Premise
258	or	_	_	I-Premise
259	DCb	_	_	I-Premise
260	.	_	_	I-Premise

261	Patients	_	_	B-Premise
262	treated	_	_	I-Premise
263	with	_	_	I-Premise
264	either	_	_	I-Premise
265	docetaxel	_	_	I-Premise
266	regimen	_	_	I-Premise
267	had	_	_	I-Premise
268	consistently	_	_	I-Premise
269	improved	_	_	I-Premise
270	QoL	_	_	I-Premise
271	compared	_	_	I-Premise
272	with	_	_	I-Premise
273	VC-treated	_	_	I-Premise
274	patients	_	_	I-Premise
275	,	_	_	I-Premise
276	who	_	_	I-Premise
277	experienced	_	_	I-Premise
278	deterioration	_	_	I-Premise
279	in	_	_	I-Premise
280	QoL	_	_	I-Premise
281	.	_	_	I-Premise

282	DC	_	_	B-Claim
283	resulted	_	_	I-Claim
284	in	_	_	I-Claim
285	a	_	_	I-Claim
286	more	_	_	I-Claim
287	favorable	_	_	I-Claim
288	overall	_	_	I-Claim
289	response	_	_	I-Claim
290	and	_	_	I-Claim
291	survival	_	_	I-Claim
292	rate	_	_	I-Claim
293	than	_	_	I-Claim
294	VC	_	_	I-Claim
295	.	_	_	I-Claim

296	Both	_	_	B-Claim
297	DC	_	_	I-Claim
298	and	_	_	I-Claim
299	DCb	_	_	I-Claim
300	were	_	_	I-Claim
301	better	_	_	I-Claim
302	tolerated	_	_	I-Claim
303	and	_	_	I-Claim
304	provided	_	_	I-Claim
305	patients	_	_	I-Claim
306	with	_	_	I-Claim
307	consistently	_	_	I-Claim
308	improved	_	_	I-Claim
309	QoL	_	_	I-Claim
310	compared	_	_	I-Claim
311	with	_	_	I-Claim
312	VC	_	_	I-Claim
313	.	_	_	I-Claim

314	These	_	_	B-Claim
315	findings	_	_	I-Claim
316	demonstrate	_	_	I-Claim
317	that	_	_	I-Claim
318	a	_	_	I-Claim
319	docetaxel	_	_	I-Claim
320	plus	_	_	I-Claim
321	platinum	_	_	I-Claim
322	combination	_	_	I-Claim
323	is	_	_	I-Claim
324	an	_	_	I-Claim
325	effective	_	_	I-Claim
326	treatment	_	_	I-Claim
327	option	_	_	I-Claim
328	with	_	_	I-Claim
329	a	_	_	I-Claim
330	favorable	_	_	I-Claim
331	therapeutic	_	_	I-Claim
332	index	_	_	I-Claim
333	for	_	_	I-Claim
334	first-line	_	_	I-Claim
335	treatment	_	_	I-Claim
336	of	_	_	I-Claim
337	advanced	_	_	I-Claim
338	or	_	_	I-Claim
339	metastatic	_	_	I-Claim
340	NSCLC	_	_	I-Claim
341	.	_	_	I-Claim


0	Pulmonary	_	_	O
1	arterial	_	_	O
2	hypertension	_	_	O
3	(	_	_	O
4	PAH	_	_	O
5	)	_	_	O
6	is	_	_	O
7	a	_	_	O
8	rare	_	_	O
9	and	_	_	O
10	life-threatening	_	_	O
11	disease	_	_	O
12	well-marked	_	_	O
13	by	_	_	O
14	under	_	_	O
15	diagnosis	_	_	O
16	,	_	_	O
17	delayed	_	_	O
18	diagnosis	_	_	O
19	and	_	_	O
20	atypical	_	_	O
21	treatments	_	_	O
22	.	_	_	O

23	Few	_	_	O
24	data	_	_	O
25	are	_	_	O
26	available	_	_	O
27	on	_	_	O
28	the	_	_	O
29	quality	_	_	O
30	of	_	_	O
31	life	_	_	O
32	(	_	_	O
33	QoL	_	_	O
34	)	_	_	O
35	and	_	_	O
36	psychosocial	_	_	O
37	characteristics	_	_	O
38	of	_	_	O
39	patients	_	_	O
40	with	_	_	O
41	PAH	_	_	O
42	.	_	_	O

43	Our	_	_	O
44	aim	_	_	O
45	is	_	_	O
46	to	_	_	O
47	describe	_	_	O
48	the	_	_	O
49	impact	_	_	O
50	of	_	_	O
51	psychological	_	_	O
52	factors	_	_	O
53	on	_	_	O
54	the	_	_	O
55	health-related	_	_	O
56	quality	_	_	O
57	of	_	_	O
58	life	_	_	O
59	(	_	_	O
60	HRQoL	_	_	O
61	)	_	_	O
62	of	_	_	O
63	treated	_	_	O
64	PAH	_	_	O
65	patients	_	_	O
66	in	_	_	O
67	a	_	_	O
68	cross-sectional	_	_	O
69	study	_	_	O
70	.	_	_	O

71	Consecutive	_	_	O
72	patients	_	_	O
73	presenting	_	_	O
74	at	_	_	O
75	our	_	_	O
76	Competency	_	_	O
77	Centre	_	_	O
78	for	_	_	O
79	PAH	_	_	O
80	were	_	_	O
81	recruited	_	_	O
82	.	_	_	O

83	The	_	_	O
84	aetiology	_	_	O
85	,	_	_	O
86	New	_	_	O
87	York	_	_	O
88	Heart	_	_	O
89	Association	_	_	O
90	(	_	_	O
91	NYHA	_	_	O
92	)	_	_	O
93	stage	_	_	O
94	,	_	_	O
95	haemodynamics	_	_	O
96	,	_	_	O
97	6-min	_	_	O
98	walk	_	_	O
99	distance	_	_	O
100	(	_	_	O
101	6MWD	_	_	O
102	)	_	_	O
103	,	_	_	O
104	delta	_	_	O
105	SPO2	_	_	O
106	(	_	_	O
107	Pulse	_	_	O
108	oximeter	_	_	O
109	oxygen	_	_	O
110	saturation	_	_	O
111	;	_	_	O
112	baseline	_	_	O
113	lowest	_	_	O
114	value	_	_	O
115	during	_	_	O
116	6-min	_	_	O
117	walk	_	_	O
118	test	_	_	O
119	(	_	_	O
120	6MWT	_	_	O
121	)	_	_	O
122	,	_	_	O
123	current	_	_	O
124	treatments	_	_	O
125	and	_	_	O
126	psychological	_	_	O
127	history	_	_	O
128	were	_	_	O
129	recorded	_	_	O
130	.	_	_	O

131	HRQoL	_	_	O
132	,	_	_	O
133	anxiety	_	_	O
134	,	_	_	O
135	depression	_	_	O
136	and	_	_	O
137	coping	_	_	O
138	strategies	_	_	O
139	were	_	_	O
140	explored	_	_	O
141	using	_	_	O
142	self-administered	_	_	O
143	questionnaires	_	_	O
144	(	_	_	O
145	SF-36	_	_	O
146	,	_	_	O
147	HADS	_	_	O
148	,	_	_	O
149	STAI-Y	_	_	O
150	,	_	_	O
151	CHIP	_	_	O
152	and	_	_	O
153	WCC	_	_	O
154	)	_	_	O
155	.	_	_	O

156	A	_	_	O
157	total	_	_	O
158	of	_	_	O
159	55	_	_	O
160	patients	_	_	O
161	were	_	_	O
162	included	_	_	O
163	.	_	_	O

164	The	_	_	O
165	HRQoL	_	_	O
166	of	_	_	O
167	PAH	_	_	O
168	patients	_	_	O
169	was	_	_	O
170	poor	_	_	O
171	with	_	_	O
172	altered	_	_	O
173	results	_	_	O
174	on	_	_	O
175	several	_	_	O
176	scales	_	_	O
177	.	_	_	O

178	Anxiety	_	_	O
179	and	_	_	O
180	depression	_	_	O
181	were	_	_	O
182	high	_	_	O
183	and	_	_	O
184	coping	_	_	O
185	was	_	_	O
186	focused	_	_	O
187	on	_	_	O
188	medical	_	_	O
189	information	_	_	O
190	strategies	_	_	O
191	.	_	_	O

192	Multivariate	_	_	B-Premise
193	analysis	_	_	I-Premise
194	indicated	_	_	I-Premise
195	a	_	_	I-Premise
196	positive	_	_	I-Premise
197	relationship	_	_	I-Premise
198	between	_	_	I-Premise
199	6MWD	_	_	I-Premise
200	and	_	_	I-Premise
201	the	_	_	I-Premise
202	Physical	_	_	I-Premise
203	Composite	_	_	I-Premise
204	Score	_	_	I-Premise
205	for	_	_	I-Premise
206	QoL	_	_	I-Premise
207	(	_	_	I-Premise
208	p=0.004	_	_	I-Premise
209	)	_	_	I-Premise
210	,	_	_	I-Premise
211	as	_	_	O
212	well	_	_	O
213	as	_	_	O
214	a	_	_	O
215	negative	_	_	B-Premise
216	relationship	_	_	I-Premise
217	between	_	_	I-Premise
218	delta	_	_	I-Premise
219	SPO2	_	_	I-Premise
220	and	_	_	I-Premise
221	the	_	_	I-Premise
222	Mental	_	_	I-Premise
223	Composite	_	_	I-Premise
224	Score	_	_	I-Premise
225	(	_	_	I-Premise
226	p=0.02	_	_	I-Premise
227	)	_	_	I-Premise
228	,	_	_	I-Premise
229	irrespective	_	_	I-Premise
230	of	_	_	I-Premise
231	other	_	_	I-Premise
232	known	_	_	I-Premise
233	prognostic	_	_	I-Premise
234	factors	_	_	I-Premise
235	(	_	_	I-Premise
236	such	_	_	I-Premise
237	as	_	_	I-Premise
238	haemodynamics	_	_	I-Premise
239	at	_	_	I-Premise
240	right	_	_	I-Premise
241	heart	_	_	I-Premise
242	catheterization	_	_	I-Premise
243	)	_	_	I-Premise
244	.	_	_	I-Premise

245	Depression	_	_	B-Premise
246	and	_	_	I-Premise
247	Trait-Anxiety	_	_	I-Premise
248	were	_	_	I-Premise
249	associated	_	_	I-Premise
250	with	_	_	I-Premise
251	a	_	_	I-Premise
252	lower	_	_	I-Premise
253	physical	_	_	I-Premise
254	(	_	_	I-Premise
255	p=0.001	_	_	I-Premise
256	)	_	_	I-Premise
257	and	_	_	I-Premise
258	mental	_	_	I-Premise
259	(	_	_	I-Premise
260	p	_	_	I-Premise
261	<	_	_	I-Premise
262	0.001	_	_	I-Premise
263	)	_	_	I-Premise
264	QoL	_	_	I-Premise
265	,	_	_	I-Premise
266	respectively	_	_	I-Premise
267	.	_	_	I-Premise

268	Psychological	_	_	B-Claim
269	factors	_	_	I-Claim
270	impact	_	_	I-Claim
271	the	_	_	I-Claim
272	HRQoL	_	_	I-Claim
273	of	_	_	I-Claim
274	treated	_	_	I-Claim
275	patients	_	_	I-Claim
276	.	_	_	I-Claim

277	A	_	_	B-Claim
278	longitudinal	_	_	I-Claim
279	and	_	_	I-Claim
280	qualitative	_	_	I-Claim
281	study	_	_	I-Claim
282	should	_	_	I-Claim
283	refine	_	_	I-Claim
284	these	_	_	I-Claim
285	results	_	_	I-Claim
286	.	_	_	I-Claim


0	Data	_	_	O
1	are	_	_	O
2	insufficient	_	_	O
3	regarding	_	_	O
4	the	_	_	O
5	survival	_	_	O
6	benefit	_	_	O
7	of	_	_	O
8	surveillance	_	_	O
9	for	_	_	O
10	hepatocellular	_	_	O
11	carcinoma	_	_	O
12	(	_	_	O
13	HCC	_	_	O
14	)	_	_	O
15	.	_	_	O

16	To	_	_	O
17	investigate	_	_	O
18	the	_	_	O
19	effectiveness	_	_	O
20	of	_	_	O
21	HCC	_	_	O
22	surveillance	_	_	O
23	in	_	_	O
24	a	_	_	O
25	hepatitis	_	_	O
26	B-endemic	_	_	O
27	population	_	_	O
28	.	_	_	O

29	This	_	_	O
30	retrospective	_	_	O
31	cohort	_	_	O
32	study	_	_	O
33	included	_	_	O
34	1402	_	_	O
35	consecutive	_	_	O
36	patients	_	_	O
37	who	_	_	O
38	were	_	_	O
39	newly	_	_	O
40	diagnosed	_	_	O
41	with	_	_	O
42	HCC	_	_	O
43	between	_	_	O
44	2005	_	_	O
45	and	_	_	O
46	2012	_	_	O
47	at	_	_	O
48	a	_	_	O
49	single	_	_	O
50	tertiary	_	_	O
51	hospital	_	_	O
52	in	_	_	O
53	Korea	_	_	O
54	.	_	_	O

55	The	_	_	O
56	primary	_	_	O
57	endpoint	_	_	O
58	was	_	_	O
59	overall	_	_	O
60	survival	_	_	O
61	.	_	_	O

62	Lead-time	_	_	O
63	and	_	_	O
64	length-time	_	_	O
65	biases	_	_	O
66	were	_	_	O
67	adjusted	_	_	O
68	(	_	_	O
69	sojourn	_	_	O
70	time	_	_	O
71	=	_	_	O
72	140	_	_	O
73	days	_	_	O
74	)	_	_	O
75	and	_	_	O
76	sensitivity	_	_	O
77	analyses	_	_	O
78	were	_	_	O
79	performed	_	_	O
80	.	_	_	O

81	The	_	_	O
82	most	_	_	O
83	common	_	_	O
84	aetiology	_	_	O
85	was	_	_	O
86	hepatitis	_	_	O
87	B	_	_	O
88	(	_	_	O
89	80.4	_	_	O
90	%	_	_	O
91	)	_	_	O
92	.	_	_	O

93	Cirrhosis	_	_	O
94	was	_	_	O
95	present	_	_	O
96	in	_	_	O
97	78.2	_	_	O
98	%	_	_	O
99	.	_	_	O

100	HCC	_	_	O
101	was	_	_	O
102	diagnosed	_	_	O
103	during	_	_	O
104	regular	_	_	O
105	surveillance	_	_	O
106	(	_	_	O
107	defined	_	_	O
108	as	_	_	O
109	mean	_	_	O
110	interval	_	_	O
111	of	_	_	O
112	ultrasonography	_	_	O
113	<	_	_	O
114	8	_	_	O
115	months	_	_	O
116	,	_	_	O
117	n	_	_	O
118	=	_	_	O
119	834	_	_	O
120	)	_	_	O
121	,	_	_	O
122	irregular	_	_	O
123	surveillance	_	_	O
124	(	_	_	O
125	n	_	_	O
126	=	_	_	O
127	104	_	_	O
128	)	_	_	O
129	or	_	_	O
130	nonsurveillance	_	_	O
131	(	_	_	O
132	n	_	_	O
133	=	_	_	O
134	464	_	_	O
135	)	_	_	O
136	.	_	_	O

137	Patients	_	_	B-Premise
138	in	_	_	I-Premise
139	the	_	_	I-Premise
140	regular	_	_	I-Premise
141	surveillance	_	_	I-Premise
142	group	_	_	I-Premise
143	were	_	_	I-Premise
144	diagnosed	_	_	I-Premise
145	at	_	_	I-Premise
146	earlier	_	_	I-Premise
147	stages	_	_	I-Premise
148	(	_	_	I-Premise
149	[	_	_	I-Premise
150	very	_	_	I-Premise
151	]	_	_	I-Premise
152	early	_	_	I-Premise
153	stage	_	_	I-Premise
154	,	_	_	I-Premise
155	64.4	_	_	I-Premise
156	%	_	_	I-Premise
157	)	_	_	I-Premise
158	than	_	_	I-Premise
159	the	_	_	I-Premise
160	irregular	_	_	I-Premise
161	surveillance	_	_	I-Premise
162	(	_	_	I-Premise
163	40.4	_	_	I-Premise
164	%	_	_	I-Premise
165	)	_	_	I-Premise
166	or	_	_	I-Premise
167	nonsurveillance	_	_	I-Premise
168	(	_	_	I-Premise
169	26.9	_	_	I-Premise
170	%	_	_	I-Premise
171	)	_	_	I-Premise
172	groups	_	_	I-Premise
173	and	_	_	I-Premise
174	had	_	_	I-Premise
175	more	_	_	I-Premise
176	chance	_	_	I-Premise
177	for	_	_	I-Premise
178	curative	_	_	I-Premise
179	treatments	_	_	I-Premise
180	(	_	_	I-Premise
181	52.4	_	_	I-Premise
182	%	_	_	I-Premise
183	)	_	_	I-Premise
184	than	_	_	I-Premise
185	the	_	_	I-Premise
186	irregular	_	_	I-Premise
187	surveillance	_	_	I-Premise
188	(	_	_	I-Premise
189	39.4	_	_	I-Premise
190	%	_	_	I-Premise
191	)	_	_	I-Premise
192	or	_	_	I-Premise
193	nonsurveillance	_	_	I-Premise
194	(	_	_	I-Premise
195	23.3	_	_	I-Premise
196	%	_	_	I-Premise
197	)	_	_	I-Premise
198	groups	_	_	I-Premise
199	(	_	_	I-Premise
200	all	_	_	I-Premise
201	P	_	_	I-Premise
202	<	_	_	I-Premise
203	0.001	_	_	I-Premise
204	)	_	_	I-Premise
205	.	_	_	I-Premise

206	Mortality	_	_	B-Premise
207	risk	_	_	I-Premise
208	was	_	_	I-Premise
209	significantly	_	_	I-Premise
210	lower	_	_	I-Premise
211	in	_	_	I-Premise
212	the	_	_	I-Premise
213	regular	_	_	I-Premise
214	surveillance	_	_	I-Premise
215	group	_	_	I-Premise
216	(	_	_	I-Premise
217	adjusted	_	_	I-Premise
218	hazard	_	_	I-Premise
219	ratio	_	_	I-Premise
220	[	_	_	I-Premise
221	aHR	_	_	I-Premise
222	]	_	_	I-Premise
223	,	_	_	I-Premise
224	0.69	_	_	I-Premise
225	;	_	_	I-Premise
226	95	_	_	I-Premise
227	%	_	_	I-Premise
228	[	_	_	I-Premise
229	CI	_	_	I-Premise
230	]	_	_	I-Premise
231	,	_	_	I-Premise
232	0.57-0.83	_	_	I-Premise
233	)	_	_	I-Premise
234	but	_	_	I-Premise
235	not	_	_	I-Premise
236	in	_	_	I-Premise
237	the	_	_	I-Premise
238	irregular	_	_	I-Premise
239	surveillance	_	_	I-Premise
240	group	_	_	I-Premise
241	(	_	_	I-Premise
242	aHR	_	_	I-Premise
243	,	_	_	I-Premise
244	0.94	_	_	I-Premise
245	;	_	_	I-Premise
246	95	_	_	I-Premise
247	%	_	_	I-Premise
248	CI	_	_	I-Premise
249	,	_	_	I-Premise
250	0.69-1.28	_	_	I-Premise
251	)	_	_	I-Premise
252	compared	_	_	I-Premise
253	with	_	_	I-Premise
254	the	_	_	I-Premise
255	nonsurveillance	_	_	I-Premise
256	group	_	_	I-Premise
257	after	_	_	I-Premise
258	adjusting	_	_	I-Premise
259	for	_	_	I-Premise
260	confounding	_	_	I-Premise
261	factors	_	_	I-Premise
262	and	_	_	I-Premise
263	lead-time	_	_	I-Premise
264	.	_	_	I-Premise

265	When	_	_	B-Premise
266	the	_	_	I-Premise
267	subjects	_	_	I-Premise
268	were	_	_	I-Premise
269	restricted	_	_	I-Premise
270	to	_	_	I-Premise
271	cirrhotic	_	_	I-Premise
272	patients	_	_	I-Premise
273	or	_	_	I-Premise
274	Child-Pugh	_	_	I-Premise
275	class	_	_	I-Premise
276	A/B	_	_	I-Premise
277	patients	_	_	I-Premise
278	,	_	_	I-Premise
279	similar	_	_	I-Premise
280	results	_	_	I-Premise
281	were	_	_	I-Premise
282	obtained	_	_	I-Premise
283	for	_	_	I-Premise
284	mortality	_	_	I-Premise
285	risk	_	_	I-Premise
286	reduction	_	_	I-Premise
287	between	_	_	I-Premise
288	groups	_	_	I-Premise
289	.	_	_	I-Premise

290	HCC	_	_	B-Claim
291	surveillance	_	_	I-Claim
292	was	_	_	I-Claim
293	associated	_	_	I-Claim
294	with	_	_	I-Claim
295	longer	_	_	I-Claim
296	survival	_	_	I-Claim
297	owing	_	_	I-Claim
298	to	_	_	I-Claim
299	earlier	_	_	I-Claim
300	diagnosis	_	_	I-Claim
301	and	_	_	I-Claim
302	curative	_	_	I-Claim
303	treatment	_	_	I-Claim
304	.	_	_	I-Claim

305	Survival	_	_	B-Claim
306	advantage	_	_	I-Claim
307	was	_	_	I-Claim
308	significant	_	_	I-Claim
309	with	_	_	I-Claim
310	regular	_	_	I-Claim
311	surveillance	_	_	I-Claim
312	but	_	_	I-Claim
313	not	_	_	I-Claim
314	with	_	_	I-Claim
315	irregular	_	_	I-Claim
316	surveillance	_	_	I-Claim
317	.	_	_	I-Claim


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	is	_	_	O
6	to	_	_	O
7	compare	_	_	O
8	spironolactone	_	_	O
9	versus	_	_	O
10	clonidine	_	_	O
11	as	_	_	O
12	the	_	_	O
13	fourth	_	_	O
14	drug	_	_	O
15	in	_	_	O
16	patients	_	_	O
17	with	_	_	O
18	resistant	_	_	O
19	hypertension	_	_	O
20	in	_	_	O
21	a	_	_	O
22	multicenter	_	_	O
23	,	_	_	O
24	randomized	_	_	O
25	trial	_	_	O
26	.	_	_	O

27	Medical	_	_	O
28	therapy	_	_	O
29	adherence	_	_	O
30	was	_	_	O
31	checked	_	_	O
32	by	_	_	O
33	pill	_	_	O
34	counting	_	_	O
35	.	_	_	O

36	Patients	_	_	O
37	with	_	_	O
38	resistant	_	_	O
39	hypertension	_	_	O
40	(	_	_	O
41	no	_	_	O
42	office	_	_	O
43	and	_	_	O
44	ambulatory	_	_	O
45	blood	_	_	O
46	pressure	_	_	O
47	[	_	_	O
48	BP	_	_	O
49	]	_	_	O
50	monitoring	_	_	O
51	control	_	_	O
52	,	_	_	O
53	despite	_	_	O
54	treatment	_	_	O
55	with	_	_	O
56	3	_	_	O
57	drugs	_	_	O
58	,	_	_	O
59	including	_	_	O
60	a	_	_	O
61	diuretic	_	_	O
62	,	_	_	O
63	for	_	_	O
64	12	_	_	O
65	weeks	_	_	O
66	)	_	_	O
67	were	_	_	O
68	randomized	_	_	O
69	to	_	_	O
70	an	_	_	O
71	additional	_	_	O
72	12-week	_	_	O
73	treatment	_	_	O
74	with	_	_	O
75	spironolactone	_	_	O
76	(	_	_	O
77	12.5-50	_	_	O
78	mg	_	_	O
79	QD	_	_	O
80	)	_	_	O
81	or	_	_	O
82	clonidine	_	_	O
83	(	_	_	O
84	0.1-0.3	_	_	O
85	mg	_	_	O
86	BID	_	_	O
87	)	_	_	O
88	.	_	_	O

89	The	_	_	O
90	primary	_	_	O
91	end	_	_	O
92	point	_	_	O
93	was	_	_	O
94	BP	_	_	O
95	control	_	_	O
96	during	_	_	O
97	office	_	_	O
98	(	_	_	O
99	<	_	_	O
100	140/90	_	_	O
101	mm	_	_	O
102	Hg	_	_	O
103	)	_	_	O
104	and	_	_	O
105	24-h	_	_	O
106	ambulatory	_	_	O
107	(	_	_	O
108	<	_	_	O
109	130/80	_	_	O
110	mm	_	_	O
111	Hg	_	_	O
112	)	_	_	O
113	BP	_	_	O
114	monitoring	_	_	O
115	.	_	_	O

116	Secondary	_	_	O
117	end	_	_	O
118	points	_	_	O
119	included	_	_	O
120	BP	_	_	O
121	control	_	_	O
122	from	_	_	O
123	each	_	_	O
124	method	_	_	O
125	and	_	_	O
126	absolute	_	_	O
127	BP	_	_	O
128	reduction	_	_	O
129	.	_	_	O

130	From	_	_	O
131	1597	_	_	O
132	patients	_	_	O
133	recruited	_	_	O
134	,	_	_	O
135	11.7	_	_	O
136	%	_	_	O
137	(	_	_	O
138	187	_	_	O
139	patients	_	_	O
140	)	_	_	O
141	fulfilled	_	_	O
142	the	_	_	O
143	resistant	_	_	O
144	hypertension	_	_	O
145	criteria	_	_	O
146	.	_	_	O

147	Compared	_	_	B-Premise
148	with	_	_	I-Premise
149	the	_	_	I-Premise
150	spironolactone	_	_	I-Premise
151	group	_	_	I-Premise
152	(	_	_	I-Premise
153	n=95	_	_	I-Premise
154	)	_	_	I-Premise
155	,	_	_	I-Premise
156	the	_	_	I-Premise
157	clonidine	_	_	I-Premise
158	group	_	_	I-Premise
159	(	_	_	I-Premise
160	n=92	_	_	I-Premise
161	)	_	_	I-Premise
162	presented	_	_	I-Premise
163	similar	_	_	I-Premise
164	rates	_	_	I-Premise
165	of	_	_	I-Premise
166	achieving	_	_	I-Premise
167	the	_	_	I-Premise
168	primary	_	_	I-Premise
169	end	_	_	I-Premise
170	point	_	_	I-Premise
171	(	_	_	I-Premise
172	20.5	_	_	I-Premise
173	%	_	_	I-Premise
174	versus	_	_	I-Premise
175	20.8	_	_	I-Premise
176	%	_	_	I-Premise
177	,	_	_	I-Premise
178	respectively	_	_	I-Premise
179	;	_	_	I-Premise
180	relative	_	_	I-Premise
181	risk	_	_	I-Premise
182	,	_	_	I-Premise
183	1.01	_	_	I-Premise
184	[	_	_	I-Premise
185	0.55-1.88	_	_	I-Premise
186	]	_	_	I-Premise
187	;	_	_	I-Premise
188	P=1.00	_	_	I-Premise
189	)	_	_	I-Premise
190	.	_	_	I-Premise

191	Secondary	_	_	B-Premise
192	end	_	_	I-Premise
193	point	_	_	I-Premise
194	analysis	_	_	I-Premise
195	showed	_	_	I-Premise
196	similar	_	_	I-Premise
197	office	_	_	I-Premise
198	BP	_	_	I-Premise
199	(	_	_	I-Premise
200	33.3	_	_	I-Premise
201	%	_	_	I-Premise
202	versus	_	_	I-Premise
203	29.3	_	_	I-Premise
204	%	_	_	I-Premise
205	)	_	_	I-Premise
206	and	_	_	I-Premise
207	ambulatory	_	_	I-Premise
208	BP	_	_	I-Premise
209	monitoring	_	_	I-Premise
210	(	_	_	I-Premise
211	44	_	_	I-Premise
212	%	_	_	I-Premise
213	versus	_	_	I-Premise
214	46.2	_	_	I-Premise
215	%	_	_	I-Premise
216	)	_	_	I-Premise
217	control	_	_	I-Premise
218	for	_	_	I-Premise
219	spironolactone	_	_	I-Premise
220	and	_	_	I-Premise
221	clonidine	_	_	I-Premise
222	,	_	_	I-Premise
223	respectively	_	_	I-Premise
224	.	_	_	I-Premise

225	However	_	_	O
226	,	_	_	O
227	spironolactone	_	_	B-Premise
228	promoted	_	_	I-Premise
229	greater	_	_	I-Premise
230	decrease	_	_	I-Premise
231	in	_	_	I-Premise
232	24-h	_	_	I-Premise
233	systolic	_	_	I-Premise
234	and	_	_	I-Premise
235	diastolic	_	_	I-Premise
236	BP	_	_	I-Premise
237	and	_	_	I-Premise
238	diastolic	_	_	I-Premise
239	daytime	_	_	I-Premise
240	ambulatory	_	_	I-Premise
241	BP	_	_	I-Premise
242	than	_	_	I-Premise
243	clonidine	_	_	I-Premise
244	.	_	_	I-Premise

245	Per-protocol	_	_	O
246	analysis	_	_	O
247	(	_	_	O
248	limited	_	_	O
249	to	_	_	O
250	patients	_	_	O
251	with	_	_	O
252	≥80	_	_	O
253	%	_	_	O
254	adherence	_	_	O
255	to	_	_	O
256	spironolactone/clonidine	_	_	O
257	treatment	_	_	O
258	)	_	_	O
259	showed	_	_	O
260	similar	_	_	O
261	results	_	_	O
262	regarding	_	_	O
263	the	_	_	O
264	primary	_	_	O
265	end	_	_	O
266	point	_	_	O
267	.	_	_	O

268	In	_	_	O
269	conclusion	_	_	O
270	,	_	_	O
271	clonidine	_	_	B-Claim
272	was	_	_	I-Claim
273	not	_	_	I-Claim
274	superior	_	_	I-Claim
275	to	_	_	I-Claim
276	spironolactone	_	_	I-Claim
277	in	_	_	I-Claim
278	true	_	_	I-Claim
279	resistant	_	_	I-Claim
280	hypertensive	_	_	I-Claim
281	patients	_	_	I-Claim
282	,	_	_	I-Claim
283	but	_	_	I-Claim
284	the	_	_	I-Claim
285	overall	_	_	I-Claim
286	BP	_	_	I-Claim
287	control	_	_	I-Claim
288	was	_	_	I-Claim
289	low	_	_	I-Claim
290	(	_	_	I-Claim
291	≈21	_	_	I-Claim
292	%	_	_	I-Claim
293	)	_	_	I-Claim
294	.	_	_	I-Claim

295	Considering	_	_	O
296	easier	_	_	O
297	posology	_	_	O
298	and	_	_	O
299	greater	_	_	O
300	decrease	_	_	O
301	in	_	_	O
302	secondary	_	_	O
303	end	_	_	O
304	points	_	_	O
305	,	_	_	O
306	spironolactone	_	_	B-Claim
307	is	_	_	I-Claim
308	preferable	_	_	I-Claim
309	for	_	_	I-Claim
310	the	_	_	I-Claim
311	fourth-drug	_	_	I-Claim
312	therapy	_	_	I-Claim
313	.	_	_	I-Claim


0	Low	_	_	B-Claim
1	serum	_	_	I-Claim
2	vitamin	_	_	I-Claim
3	D	_	_	I-Claim
4	has	_	_	I-Claim
5	been	_	_	I-Claim
6	associated	_	_	I-Claim
7	with	_	_	I-Claim
8	metabolic	_	_	I-Claim
9	syndrome	_	_	I-Claim
10	and	_	_	I-Claim
11	Non-alcoholic	_	_	I-Claim
12	fatty	_	_	I-Claim
13	liver	_	_	I-Claim
14	disease	_	_	I-Claim
15	(	_	_	I-Claim
16	NAFLD	_	_	I-Claim
17	)	_	_	I-Claim
18	.	_	_	I-Claim

19	This	_	_	O
20	study	_	_	O
21	aimed	_	_	O
22	to	_	_	O
23	investigate	_	_	O
24	the	_	_	O
25	impact	_	_	O
26	of	_	_	O
27	vitamin	_	_	O
28	D	_	_	O
29	supplementation	_	_	O
30	in	_	_	O
31	treatment	_	_	O
32	of	_	_	O
33	patients	_	_	O
34	with	_	_	O
35	NAFLD	_	_	O
36	.	_	_	O

37	In	_	_	O
38	a	_	_	O
39	double	_	_	O
40	blind	_	_	O
41	,	_	_	O
42	randomized	_	_	O
43	,	_	_	O
44	placebo	_	_	O
45	controlled	_	_	O
46	trial	_	_	O
47	patients	_	_	O
48	with	_	_	O
49	NAFLD	_	_	O
50	were	_	_	O
51	randomized	_	_	O
52	to	_	_	O
53	receive	_	_	O
54	one	_	_	O
55	weekly	_	_	O
56	pearl	_	_	O
57	of	_	_	O
58	placebo	_	_	O
59	,	_	_	O
60	50,000	_	_	O
61	U	_	_	O
62	vitamin	_	_	O
63	D3	_	_	O
64	(	_	_	O
65	cholecalciferol	_	_	O
66	)	_	_	O
67	pearl	_	_	O
68	per	_	_	O
69	week	_	_	O
70	and	_	_	O
71	0.25	_	_	O
72	mg	_	_	O
73	calcitriol	_	_	O
74	(	_	_	O
75	1,25	_	_	O
76	dihydroxycholecalciferol	_	_	O
77	)	_	_	O
78	pearl	_	_	O
79	per	_	_	O
80	day	_	_	O
81	for	_	_	O
82	3	_	_	O
83	months	_	_	O
84	.	_	_	O

85	106	_	_	O
86	NAFLD	_	_	O
87	patients	_	_	O
88	were	_	_	O
89	randomized	_	_	O
90	to	_	_	O
91	receive	_	_	O
92	calcitriol	_	_	O
93	,	_	_	O
94	vitamin	_	_	O
95	D3	_	_	O
96	and	_	_	O
97	placebo	_	_	O
98	pearls	_	_	O
99	for	_	_	O
100	12	_	_	O
101	weeks	_	_	O
102	and	_	_	O
103	data	_	_	O
104	for	_	_	O
105	91	_	_	O
106	patients	_	_	O
107	were	_	_	O
108	analyzed	_	_	O
109	.	_	_	O

110	After	_	_	B-Premise
111	12	_	_	I-Premise
112	weeks	_	_	I-Premise
113	of	_	_	I-Premise
114	treatment	_	_	I-Premise
115	,	_	_	I-Premise
116	serum	_	_	I-Premise
117	alkaline	_	_	I-Premise
118	phosphatase	_	_	I-Premise
119	levels	_	_	I-Premise
120	was	_	_	I-Premise
121	significantly	_	_	I-Premise
122	decreased	_	_	I-Premise
123	from	_	_	I-Premise
124	baseline	_	_	I-Premise
125	levels	_	_	I-Premise
126	in	_	_	I-Premise
127	vitamin	_	_	I-Premise
128	D	_	_	I-Premise
129	and	_	_	I-Premise
130	calcitriol	_	_	I-Premise
131	treated	_	_	I-Premise
132	groups	_	_	I-Premise
133	(	_	_	I-Premise
134	P	_	_	I-Premise
135	<	_	_	I-Premise
136	0.05	_	_	I-Premise
137	)	_	_	I-Premise
138	.	_	_	I-Premise

139	Serum	_	_	B-Premise
140	and	_	_	I-Premise
141	gamma	_	_	I-Premise
142	glutamyl	_	_	I-Premise
143	transferase	_	_	I-Premise
144	(	_	_	I-Premise
145	GGT	_	_	I-Premise
146	)	_	_	I-Premise
147	level	_	_	I-Premise
148	was	_	_	I-Premise
149	also	_	_	I-Premise
150	significantly	_	_	I-Premise
151	decreased	_	_	I-Premise
152	compared	_	_	I-Premise
153	to	_	_	I-Premise
154	the	_	_	I-Premise
155	baseline	_	_	I-Premise
156	levels	_	_	I-Premise
157	after	_	_	I-Premise
158	12	_	_	I-Premise
159	weeks	_	_	I-Premise
160	of	_	_	I-Premise
161	treatment	_	_	I-Premise
162	with	_	_	I-Premise
163	vitamin	_	_	I-Premise
164	D.	_	_	I-Premise
165	There	_	_	B-Premise
166	was	_	_	I-Premise
167	no	_	_	I-Premise
168	statistically	_	_	I-Premise
169	significant	_	_	I-Premise
170	difference	_	_	I-Premise
171	between	_	_	I-Premise
172	placebo	_	_	I-Premise
173	,	_	_	I-Premise
174	calcitriol	_	_	I-Premise
175	,	_	_	I-Premise
176	vitamin	_	_	I-Premise
177	D	_	_	I-Premise
178	groups	_	_	I-Premise
179	in	_	_	I-Premise
180	terms	_	_	I-Premise
181	of	_	_	I-Premise
182	serum	_	_	I-Premise
183	aminotransferase	_	_	I-Premise
184	,	_	_	I-Premise
185	alkaline	_	_	I-Premise
186	phosphatase	_	_	I-Premise
187	,	_	_	I-Premise
188	serum	_	_	I-Premise
189	GGT	_	_	I-Premise
190	and	_	_	I-Premise
191	lipid	_	_	I-Premise
192	profile	_	_	I-Premise
193	(	_	_	I-Premise
194	P	_	_	I-Premise
195	>	_	_	I-Premise
196	0.05	_	_	I-Premise
197	)	_	_	I-Premise
198	.	_	_	I-Premise

199	While	_	_	O
200	significant	_	_	B-Claim
201	reduction	_	_	I-Claim
202	of	_	_	I-Claim
203	serum	_	_	I-Claim
204	alkaline	_	_	I-Claim
205	phosphatase	_	_	I-Claim
206	and	_	_	I-Claim
207	GGT	_	_	I-Claim
208	were	_	_	I-Claim
209	seen	_	_	I-Claim
210	with	_	_	I-Claim
211	vitamin	_	_	I-Claim
212	D	_	_	I-Claim
213	and	_	_	I-Claim
214	calcitriol	_	_	I-Claim
215	supplementation	_	_	I-Claim
216	from	_	_	I-Claim
217	baseline	_	_	I-Claim
218	levels	_	_	I-Claim
219	,	_	_	I-Claim
220	no	_	_	B-Claim
221	beneficial	_	_	I-Claim
222	effects	_	_	I-Claim
223	was	_	_	I-Claim
224	seen	_	_	I-Claim
225	when	_	_	I-Claim
226	comparing	_	_	I-Claim
227	vitamin	_	_	I-Claim
228	D	_	_	I-Claim
229	,	_	_	I-Claim
230	calcitriol	_	_	I-Claim
231	and	_	_	I-Claim
232	placebo	_	_	I-Claim
233	groups	_	_	I-Claim
234	at	_	_	I-Claim
235	the	_	_	I-Claim
236	end	_	_	I-Claim
237	of	_	_	I-Claim
238	trial	_	_	I-Claim
239	.	_	_	I-Claim


0	Emerging	_	_	O
1	genetic	_	_	O
2	,	_	_	O
3	ex-vivo	_	_	O
4	,	_	_	O
5	and	_	_	O
6	clinical	_	_	O
7	trial	_	_	O
8	evidence	_	_	O
9	indicates	_	_	O
10	that	_	_	O
11	calcium	_	_	O
12	channel	_	_	O
13	blockers	_	_	O
14	(	_	_	O
15	CCB	_	_	O
16	)	_	_	O
17	can	_	_	O
18	improve	_	_	O
19	mood	_	_	O
20	and	_	_	O
21	cognitive	_	_	O
22	function	_	_	O
23	.	_	_	O

24	The	_	_	O
25	objective	_	_	O
26	of	_	_	O
27	this	_	_	O
28	study	_	_	O
29	was	_	_	O
30	to	_	_	O
31	examine	_	_	O
32	the	_	_	O
33	effect	_	_	O
34	of	_	_	O
35	selective	_	_	O
36	serotonin	_	_	O
37	reuptake	_	_	O
38	inhibitor	_	_	O
39	(	_	_	O
40	SSRI	_	_	O
41	)	_	_	O
42	therapy	_	_	O
43	augmented	_	_	O
44	with	_	_	O
45	CCB	_	_	O
46	on	_	_	O
47	depression	_	_	O
48	and	_	_	O
49	cognitive	_	_	O
50	decline	_	_	O
51	in	_	_	O
52	an	_	_	O
53	elderly	_	_	O
54	population	_	_	O
55	with	_	_	O
56	hypertension	_	_	O
57	.	_	_	O

58	Prospective	_	_	O
59	study	_	_	O
60	of	_	_	O
61	296	_	_	O
62	persons	_	_	O
63	treated	_	_	O
64	with	_	_	O
65	SSRI	_	_	O
66	and	_	_	O
67	antihypertensive	_	_	O
68	drugs	_	_	O
69	.	_	_	O

70	Baseline	_	_	O
71	and	_	_	O
72	two	_	_	O
73	year	_	_	O
74	clinic	_	_	O
75	assessments	_	_	O
76	were	_	_	O
77	used	_	_	O
78	to	_	_	O
79	categorize	_	_	O
80	participants	_	_	O
81	as	_	_	O
82	users	_	_	O
83	of	_	_	O
84	SSRI	_	_	O
85	+	_	_	O
86	CCB	_	_	O
87	(	_	_	O
88	n	_	_	O
89	=	_	_	O
90	53	_	_	O
91	)	_	_	O
92	or	_	_	O
93	users	_	_	O
94	of	_	_	O
95	SSRI	_	_	O
96	+	_	_	O
97	other	_	_	O
98	antihypertensives	_	_	O
99	(	_	_	O
100	n	_	_	O
101	=	_	_	O
102	243	_	_	O
103	)	_	_	O
104	.	_	_	O

105	Clinic	_	_	O
106	visits	_	_	O
107	were	_	_	O
108	performed	_	_	O
109	up	_	_	O
110	to	_	_	O
111	four	_	_	O
112	times	_	_	O
113	in	_	_	O
114	a	_	_	O
115	ten-year	_	_	O
116	period	_	_	O
117	to	_	_	O
118	assess	_	_	O
119	depression	_	_	O
120	and	_	_	O
121	cognitive	_	_	O
122	function	_	_	O
123	.	_	_	O

124	The	_	_	O
125	sample	_	_	O
126	mean	_	_	O
127	age	_	_	O
128	was	_	_	O
129	75.2	_	_	O
130	±	_	_	O
131	5.47	_	_	O
132	years	_	_	O
133	and	_	_	O
134	78	_	_	O
135	%	_	_	O
136	of	_	_	O
137	participants	_	_	O
138	were	_	_	O
139	female	_	_	O
140	.	_	_	O

141	At	_	_	B-Premise
142	two	_	_	I-Premise
143	year	_	_	I-Premise
144	follow-up	_	_	I-Premise
145	there	_	_	I-Premise
146	was	_	_	I-Premise
147	a	_	_	I-Premise
148	significant	_	_	I-Premise
149	group	_	_	I-Premise
150	by	_	_	I-Premise
151	time	_	_	I-Premise
152	interaction	_	_	I-Premise
153	showing	_	_	I-Premise
154	lower	_	_	I-Premise
155	Center	_	_	I-Premise
156	for	_	_	I-Premise
157	Epidemiological	_	_	I-Premise
158	Studies-Depression	_	_	I-Premise
159	(	_	_	I-Premise
160	CESD	_	_	I-Premise
161	)	_	_	I-Premise
162	scores	_	_	I-Premise
163	in	_	_	I-Premise
164	the	_	_	I-Premise
165	SSRI	_	_	I-Premise
166	+	_	_	I-Premise
167	CCB	_	_	I-Premise
168	group	_	_	I-Premise
169	,	_	_	I-Premise
170	F	_	_	I-Premise
171	(	_	_	I-Premise
172	1,291	_	_	I-Premise
173	)	_	_	I-Premise
174	=	_	_	I-Premise
175	4.13	_	_	I-Premise
176	,	_	_	I-Premise
177	p	_	_	I-Premise
178	=	_	_	I-Premise
179	0.043	_	_	I-Premise
180	,	_	_	I-Premise
181	η2	_	_	I-Premise
182	p	_	_	I-Premise
183	=	_	_	I-Premise
184	0.014	_	_	I-Premise
185	.	_	_	I-Premise

186	Over	_	_	B-Premise
187	ten-years	_	_	I-Premise
188	follow-up	_	_	I-Premise
189	,	_	_	I-Premise
190	SSRI	_	_	I-Premise
191	+	_	_	I-Premise
192	CCB	_	_	I-Premise
193	use	_	_	I-Premise
194	was	_	_	I-Premise
195	associated	_	_	I-Premise
196	with	_	_	I-Premise
197	improved	_	_	I-Premise
198	general	_	_	I-Premise
199	cognitive	_	_	I-Premise
200	function	_	_	I-Premise
201	(	_	_	I-Premise
202	Mini-Mental	_	_	I-Premise
203	State	_	_	I-Premise
204	Examination	_	_	I-Premise
205	:	_	_	I-Premise
206	β	_	_	I-Premise
207	=	_	_	I-Premise
208	0.97	_	_	I-Premise
209	;	_	_	I-Premise
210	95	_	_	I-Premise
211	%	_	_	I-Premise
212	CI	_	_	I-Premise
213	0.14	_	_	I-Premise
214	to	_	_	I-Premise
215	1.81	_	_	I-Premise
216	,	_	_	I-Premise
217	p	_	_	I-Premise
218	=	_	_	I-Premise
219	0.023	_	_	I-Premise
220	)	_	_	I-Premise
221	and	_	_	I-Premise
222	immediate	_	_	I-Premise
223	visual	_	_	I-Premise
224	memory	_	_	I-Premise
225	(	_	_	I-Premise
226	Boston	_	_	I-Premise
227	Visual	_	_	I-Premise
228	Retention	_	_	I-Premise
229	Test	_	_	I-Premise
230	:	_	_	I-Premise
231	β	_	_	I-Premise
232	=	_	_	I-Premise
233	0.69	_	_	I-Premise
234	;	_	_	I-Premise
235	95	_	_	I-Premise
236	%	_	_	I-Premise
237	CI	_	_	I-Premise
238	0.06	_	_	I-Premise
239	to	_	_	I-Premise
240	1.32	_	_	I-Premise
241	,	_	_	I-Premise
242	p	_	_	I-Premise
243	=	_	_	I-Premise
244	0.033	_	_	I-Premise
245	)	_	_	I-Premise
246	.	_	_	I-Premise

247	The	_	_	B-Claim
248	findings	_	_	I-Claim
249	provide	_	_	I-Claim
250	general	_	_	I-Claim
251	population	_	_	I-Claim
252	evidence	_	_	I-Claim
253	that	_	_	I-Claim
254	SSRI	_	_	I-Claim
255	augmentation	_	_	I-Claim
256	with	_	_	I-Claim
257	CCB	_	_	I-Claim
258	may	_	_	I-Claim
259	improve	_	_	I-Claim
260	depression	_	_	I-Claim
261	and	_	_	I-Claim
262	cognitive	_	_	I-Claim
263	function	_	_	I-Claim
264	.	_	_	I-Claim


0	This	_	_	O
1	randomised	_	_	O
2	trial	_	_	O
3	compared	_	_	O
4	three	_	_	O
5	chemotherapy	_	_	O
6	regimens	_	_	O
7	in	_	_	O
8	the	_	_	O
9	first-line	_	_	O
10	treatment	_	_	O
11	of	_	_	O
12	advanced	_	_	O
13	colorectal	_	_	O
14	cancer	_	_	O
15	,	_	_	O
16	in	_	_	O
17	terms	_	_	O
18	of	_	_	O
19	their	_	_	O
20	effect	_	_	O
21	on	_	_	O
22	overall	_	_	O
23	and	_	_	O
24	progression-free	_	_	O
25	survival	_	_	O
26	;	_	_	O
27	other	_	_	O
28	endpoints	_	_	O
29	included	_	_	O
30	toxicity	_	_	O
31	,	_	_	O
32	symptom	_	_	O
33	palliation	_	_	O
34	,	_	_	O
35	and	_	_	O
36	quality	_	_	O
37	of	_	_	O
38	life	_	_	O
39	.	_	_	O

40	905	_	_	O
41	patients	_	_	O
42	were	_	_	O
43	randomly	_	_	O
44	assigned	_	_	O
45	the	_	_	O
46	de	_	_	O
47	Gramont	_	_	O
48	regimen	_	_	O
49	(	_	_	O
50	n=303	_	_	O
51	;	_	_	O
52	folinic	_	_	O
53	acid	_	_	O
54	200	_	_	O
55	mg/m	_	_	O
56	(	_	_	O
57	2	_	_	O
58	)	_	_	O
59	,	_	_	O
60	fluorouracil	_	_	O
61	bolus	_	_	O
62	400	_	_	O
63	mg/m	_	_	O
64	(	_	_	O
65	2	_	_	O
66	)	_	_	O
67	,	_	_	O
68	and	_	_	O
69	infusion	_	_	O
70	600	_	_	O
71	mg/m	_	_	O
72	(	_	_	O
73	2	_	_	O
74	)	_	_	O
75	on	_	_	O
76	days	_	_	O
77	1	_	_	O
78	and	_	_	O
79	2	_	_	O
80	,	_	_	O
81	repeated	_	_	O
82	every	_	_	O
83	14	_	_	O
84	days	_	_	O
85	)	_	_	O
86	,	_	_	O
87	the	_	_	O
88	Lokich	_	_	O
89	regimen	_	_	O
90	(	_	_	O
91	n=301	_	_	O
92	;	_	_	O
93	protracted	_	_	O
94	venous	_	_	O
95	infusion	_	_	O
96	of	_	_	O
97	fluorouracil	_	_	O
98	300	_	_	O
99	mg/m	_	_	O
100	(	_	_	O
101	2	_	_	O
102	)	_	_	O
103	daily	_	_	O
104	)	_	_	O
105	,	_	_	O
106	or	_	_	O
107	raltitrexed	_	_	O
108	(	_	_	O
109	n=301	_	_	O
110	;	_	_	O
111	3	_	_	O
112	mg/m	_	_	O
113	(	_	_	O
114	2	_	_	O
115	)	_	_	O
116	intravenously	_	_	O
117	every	_	_	O
118	21	_	_	O
119	days	_	_	O
120	)	_	_	O
121	.	_	_	O

122	Analyses	_	_	O
123	were	_	_	O
124	by	_	_	O
125	intention	_	_	O
126	to	_	_	O
127	treat	_	_	O
128	.	_	_	O

129	Median	_	_	O
130	follow-up	_	_	O
131	of	_	_	O
132	survivors	_	_	O
133	was	_	_	O
134	67	_	_	O
135	weeks	_	_	O
136	.	_	_	O

137	For	_	_	B-Premise
138	the	_	_	I-Premise
139	de	_	_	I-Premise
140	Gramont	_	_	I-Premise
141	,	_	_	I-Premise
142	Lokich	_	_	I-Premise
143	,	_	_	I-Premise
144	and	_	_	I-Premise
145	raltitrexed	_	_	I-Premise
146	groups	_	_	I-Premise
147	,	_	_	I-Premise
148	respectively	_	_	I-Premise
149	,	_	_	I-Premise
150	median	_	_	I-Premise
151	survival	_	_	I-Premise
152	was	_	_	I-Premise
153	294	_	_	I-Premise
154	,	_	_	I-Premise
155	302	_	_	I-Premise
156	,	_	_	I-Premise
157	and	_	_	I-Premise
158	266	_	_	I-Premise
159	days	_	_	I-Premise
160	.	_	_	I-Premise

161	The	_	_	B-Premise
162	hazard	_	_	I-Premise
163	ratios	_	_	I-Premise
164	for	_	_	I-Premise
165	overall	_	_	I-Premise
166	survival	_	_	I-Premise
167	were	_	_	I-Premise
168	0.88	_	_	I-Premise
169	(	_	_	I-Premise
170	95	_	_	I-Premise
171	%	_	_	I-Premise
172	CI	_	_	I-Premise
173	0.70-1.12	_	_	I-Premise
174	,	_	_	I-Premise
175	p=0.17	_	_	I-Premise
176	)	_	_	I-Premise
177	for	_	_	I-Premise
178	de	_	_	I-Premise
179	Gramont	_	_	I-Premise
180	versus	_	_	I-Premise
181	Lokich	_	_	I-Premise
182	,	_	_	I-Premise
183	and	_	_	I-Premise
184	0.99	_	_	I-Premise
185	(	_	_	I-Premise
186	0.79-1.25	_	_	I-Premise
187	,	_	_	I-Premise
188	p=0.94	_	_	I-Premise
189	)	_	_	I-Premise
190	for	_	_	I-Premise
191	de	_	_	I-Premise
192	Gramont	_	_	I-Premise
193	versus	_	_	I-Premise
194	raltitrexed	_	_	I-Premise
195	.	_	_	I-Premise

196	An	_	_	B-Premise
197	increase	_	_	I-Premise
198	in	_	_	I-Premise
199	treatment-related	_	_	I-Premise
200	deaths	_	_	I-Premise
201	was	_	_	I-Premise
202	seen	_	_	I-Premise
203	on	_	_	I-Premise
204	raltitrexed	_	_	I-Premise
205	(	_	_	I-Premise
206	de	_	_	I-Premise
207	Gramont	_	_	I-Premise
208	one	_	_	I-Premise
209	,	_	_	I-Premise
210	Lokich	_	_	I-Premise
211	two	_	_	I-Premise
212	,	_	_	I-Premise
213	raltitrexed	_	_	I-Premise
214	18	_	_	I-Premise
215	)	_	_	I-Premise
216	due	_	_	I-Premise
217	to	_	_	I-Premise
218	combined	_	_	I-Premise
219	gastrointestinal	_	_	I-Premise
220	and	_	_	I-Premise
221	haematological	_	_	I-Premise
222	toxicity	_	_	I-Premise
223	.	_	_	I-Premise

224	Patients	_	_	B-Premise
225	'	_	_	I-Premise
226	assessment	_	_	I-Premise
227	of	_	_	I-Premise
228	quality	_	_	I-Premise
229	of	_	_	I-Premise
230	life	_	_	I-Premise
231	showed	_	_	I-Premise
232	that	_	_	I-Premise
233	raltitrexed	_	_	I-Premise
234	was	_	_	I-Premise
235	inferior	_	_	I-Premise
236	to	_	_	I-Premise
237	the	_	_	I-Premise
238	fluorouracil-based	_	_	I-Premise
239	regimens	_	_	I-Premise
240	,	_	_	I-Premise
241	especially	_	_	I-Premise
242	in	_	_	I-Premise
243	terms	_	_	I-Premise
244	of	_	_	I-Premise
245	palliation	_	_	I-Premise
246	and	_	_	I-Premise
247	functioning	_	_	I-Premise
248	.	_	_	I-Premise

249	The	_	_	B-Claim
250	deGramont	_	_	I-Claim
251	and	_	_	I-Claim
252	Lokich	_	_	I-Claim
253	regimens	_	_	I-Claim
254	were	_	_	I-Claim
255	similar	_	_	I-Claim
256	in	_	_	I-Claim
257	terms	_	_	I-Claim
258	of	_	_	I-Claim
259	survival	_	_	I-Claim
260	,	_	_	I-Claim
261	quality	_	_	I-Claim
262	of	_	_	I-Claim
263	life	_	_	I-Claim
264	,	_	_	I-Claim
265	and	_	_	I-Claim
266	response	_	_	I-Claim
267	rates	_	_	I-Claim
268	.	_	_	I-Claim

269	The	_	_	B-Claim
270	Lokich	_	_	I-Claim
271	regimen	_	_	I-Claim
272	was	_	_	I-Claim
273	associated	_	_	I-Claim
274	with	_	_	I-Claim
275	more	_	_	I-Claim
276	central	_	_	I-Claim
277	line	_	_	I-Claim
278	complications	_	_	I-Claim
279	and	_	_	I-Claim
280	hand-foot	_	_	I-Claim
281	syndrome	_	_	I-Claim
282	.	_	_	I-Claim

283	Raltitrexed	_	_	B-Claim
284	showed	_	_	I-Claim
285	similar	_	_	I-Claim
286	response	_	_	I-Claim
287	rates	_	_	I-Claim
288	and	_	_	I-Claim
289	overall	_	_	I-Claim
290	survival	_	_	I-Claim
291	to	_	_	I-Claim
292	the	_	_	I-Claim
293	de	_	_	I-Claim
294	Gramont	_	_	I-Claim
295	regimen	_	_	I-Claim
296	and	_	_	I-Claim
297	was	_	_	I-Claim
298	easier	_	_	I-Claim
299	to	_	_	I-Claim
300	administer	_	_	I-Claim
301	,	_	_	I-Claim
302	but	_	_	B-Claim
303	resulted	_	_	I-Claim
304	in	_	_	I-Claim
305	greater	_	_	I-Claim
306	toxicity	_	_	I-Claim
307	and	_	_	I-Claim
308	inferior	_	_	I-Claim
309	quality	_	_	I-Claim
310	of	_	_	I-Claim
311	life	_	_	I-Claim
312	.	_	_	I-Claim


0	Blood	_	_	O
1	pressure	_	_	O
2	(	_	_	O
3	BP	_	_	O
4	)	_	_	O
5	lowering	_	_	O
6	is	_	_	O
7	considered	_	_	O
8	neuroprotective	_	_	O
9	in	_	_	O
10	patients	_	_	O
11	with	_	_	O
12	cerebral	_	_	O
13	small	_	_	O
14	vessel	_	_	O
15	disease	_	_	O
16	;	_	_	O
17	however	_	_	O
18	,	_	_	O
19	more	_	_	O
20	intensive	_	_	O
21	regimens	_	_	O
22	may	_	_	O
23	increase	_	_	O
24	cerebral	_	_	O
25	hypoperfusion	_	_	O
26	.	_	_	O

27	This	_	_	O
28	study	_	_	O
29	examined	_	_	O
30	the	_	_	O
31	effect	_	_	O
32	of	_	_	O
33	standard	_	_	O
34	vs	_	_	O
35	intensive	_	_	O
36	BP	_	_	O
37	treatment	_	_	O
38	on	_	_	O
39	cerebral	_	_	O
40	perfusion	_	_	O
41	in	_	_	O
42	patients	_	_	O
43	with	_	_	O
44	severe	_	_	O
45	small	_	_	O
46	vessel	_	_	O
47	disease	_	_	O
48	.	_	_	O

49	To	_	_	O
50	investigate	_	_	O
51	whether	_	_	O
52	standard	_	_	O
53	vs	_	_	O
54	intensive	_	_	O
55	BP	_	_	O
56	lowering	_	_	O
57	over	_	_	O
58	3	_	_	O
59	months	_	_	O
60	causes	_	_	O
61	decreased	_	_	O
62	cerebral	_	_	O
63	perfusion	_	_	O
64	in	_	_	O
65	small	_	_	O
66	vessel	_	_	O
67	disease	_	_	O
68	.	_	_	O

69	This	_	_	O
70	randomized	_	_	O
71	clinical	_	_	O
72	trial	_	_	O
73	took	_	_	O
74	place	_	_	O
75	at	_	_	O
76	2	_	_	O
77	English	_	_	O
78	university	_	_	O
79	medical	_	_	O
80	centers	_	_	O
81	.	_	_	O

82	Patients	_	_	O
83	were	_	_	O
84	randomized	_	_	O
85	via	_	_	O
86	a	_	_	O
87	central	_	_	O
88	online	_	_	O
89	system	_	_	O
90	(	_	_	O
91	in	_	_	O
92	a	_	_	O
93	1:1	_	_	O
94	ratio	_	_	O
95	)	_	_	O
96	.	_	_	O

97	Seventy	_	_	O
98	patients	_	_	O
99	with	_	_	O
100	hypertension	_	_	O
101	and	_	_	O
102	with	_	_	O
103	magnetic	_	_	O
104	resonance	_	_	O
105	imaging-confirmed	_	_	O
106	symptomatic	_	_	O
107	lacunar	_	_	O
108	infarct	_	_	O
109	and	_	_	O
110	confluent	_	_	O
111	white	_	_	O
112	matter	_	_	O
113	hyperintensities	_	_	O
114	were	_	_	O
115	recruited	_	_	O
116	between	_	_	O
117	February	_	_	O
118	29	_	_	O
119	,	_	_	O
120	2012	_	_	O
121	,	_	_	O
122	and	_	_	O
123	October	_	_	O
124	21	_	_	O
125	,	_	_	O
126	2015	_	_	O
127	,	_	_	O
128	and	_	_	O
129	randomized	_	_	O
130	(	_	_	O
131	36	_	_	O
132	in	_	_	O
133	the	_	_	O
134	standard	_	_	O
135	group	_	_	O
136	and	_	_	O
137	34	_	_	O
138	in	_	_	O
139	the	_	_	O
140	intensive	_	_	O
141	group	_	_	O
142	)	_	_	O
143	.	_	_	O

144	Analyzable	_	_	O
145	data	_	_	O
146	were	_	_	O
147	available	_	_	O
148	in	_	_	O
149	62	_	_	O
150	patients	_	_	O
151	,	_	_	O
152	33	_	_	O
153	in	_	_	O
154	the	_	_	O
155	standard	_	_	O
156	group	_	_	O
157	and	_	_	O
158	29	_	_	O
159	in	_	_	O
160	the	_	_	O
161	intensive	_	_	O
162	group	_	_	O
163	,	_	_	O
164	for	_	_	O
165	intent-to-treat	_	_	O
166	analysis	_	_	O
167	.	_	_	O

168	This	_	_	O
169	experiment	_	_	O
170	examines	_	_	O
171	the	_	_	O
172	3-month	_	_	O
173	follow-up	_	_	O
174	period	_	_	O
175	.	_	_	O

176	Patients	_	_	O
177	were	_	_	O
178	randomized	_	_	O
179	to	_	_	O
180	standard	_	_	O
181	(	_	_	O
182	systolic	_	_	O
183	,	_	_	O
184	130-140	_	_	O
185	mm	_	_	O
186	Hg	_	_	O
187	)	_	_	O
188	or	_	_	O
189	intensive	_	_	O
190	(	_	_	O
191	systolic	_	_	O
192	,	_	_	O
193	<	_	_	O
194	125	_	_	O
195	mm	_	_	O
196	Hg	_	_	O
197	)	_	_	O
198	BP	_	_	O
199	targets	_	_	O
200	,	_	_	O
201	to	_	_	O
202	be	_	_	O
203	achieved	_	_	O
204	through	_	_	O
205	medication	_	_	O
206	changes	_	_	O
207	.	_	_	O

208	Cerebral	_	_	O
209	perfusion	_	_	O
210	was	_	_	O
211	measured	_	_	O
212	using	_	_	O
213	arterial	_	_	O
214	spin	_	_	O
215	labeling	_	_	O
216	;	_	_	O
217	the	_	_	O
218	primary	_	_	O
219	end	_	_	O
220	point	_	_	O
221	was	_	_	O
222	change	_	_	O
223	in	_	_	O
224	global	_	_	O
225	perfusion	_	_	O
226	between	_	_	O
227	baseline	_	_	O
228	and	_	_	O
229	3	_	_	O
230	months	_	_	O
231	,	_	_	O
232	compared	_	_	O
233	between	_	_	O
234	treatment	_	_	O
235	groups	_	_	O
236	by	_	_	O
237	analysis	_	_	O
238	of	_	_	O
239	variance	_	_	O
240	.	_	_	O

241	Linear	_	_	O
242	regression	_	_	O
243	compared	_	_	O
244	change	_	_	O
245	in	_	_	O
246	perfusion	_	_	O
247	against	_	_	O
248	change	_	_	O
249	in	_	_	O
250	BP	_	_	O
251	.	_	_	O

252	Magnetic	_	_	O
253	resonance	_	_	O
254	imaging	_	_	O
255	scan	_	_	O
256	analysis	_	_	O
257	was	_	_	O
258	masked	_	_	O
259	to	_	_	O
260	treatment	_	_	O
261	group	_	_	O
262	.	_	_	O

263	Among	_	_	O
264	62	_	_	O
265	analyzable	_	_	O
266	patients	_	_	O
267	,	_	_	O
268	the	_	_	O
269	mean	_	_	O
270	age	_	_	O
271	was	_	_	O
272	69.3	_	_	O
273	years	_	_	O
274	,	_	_	O
275	and	_	_	O
276	60	_	_	O
277	%	_	_	O
278	(	_	_	O
279	n	_	_	O
280	=	_	_	O
281	37	_	_	O
282	)	_	_	O
283	were	_	_	O
284	male	_	_	O
285	.	_	_	O

286	The	_	_	B-Premise
287	mean	_	_	I-Premise
288	(	_	_	I-Premise
289	SD	_	_	I-Premise
290	)	_	_	I-Premise
291	systolic	_	_	I-Premise
292	BP	_	_	I-Premise
293	decreased	_	_	I-Premise
294	by	_	_	I-Premise
295	8	_	_	I-Premise
296	(	_	_	I-Premise
297	12	_	_	I-Premise
298	)	_	_	I-Premise
299	mm	_	_	I-Premise
300	Hg	_	_	I-Premise
301	in	_	_	I-Premise
302	the	_	_	I-Premise
303	standard	_	_	I-Premise
304	group	_	_	I-Premise
305	and	_	_	I-Premise
306	by	_	_	I-Premise
307	27	_	_	I-Premise
308	(	_	_	I-Premise
309	17	_	_	I-Premise
310	)	_	_	I-Premise
311	mm	_	_	I-Premise
312	Hg	_	_	I-Premise
313	in	_	_	I-Premise
314	the	_	_	I-Premise
315	intensive	_	_	I-Premise
316	group	_	_	I-Premise
317	(	_	_	I-Premise
318	P	_	_	I-Premise
319	<	_	_	I-Premise
320	.001	_	_	I-Premise
321	)	_	_	I-Premise
322	,	_	_	I-Premise
323	with	_	_	I-Premise
324	mean	_	_	I-Premise
325	(	_	_	I-Premise
326	SD	_	_	I-Premise
327	)	_	_	I-Premise
328	achieved	_	_	I-Premise
329	pressures	_	_	I-Premise
330	of	_	_	I-Premise
331	141	_	_	I-Premise
332	(	_	_	I-Premise
333	13	_	_	I-Premise
334	)	_	_	I-Premise
335	and	_	_	I-Premise
336	126	_	_	I-Premise
337	(	_	_	I-Premise
338	10	_	_	I-Premise
339	)	_	_	I-Premise
340	mm	_	_	I-Premise
341	Hg	_	_	I-Premise
342	,	_	_	I-Premise
343	respectively	_	_	I-Premise
344	.	_	_	I-Premise

345	Change	_	_	B-Premise
346	in	_	_	I-Premise
347	global	_	_	I-Premise
348	perfusion	_	_	I-Premise
349	did	_	_	I-Premise
350	not	_	_	I-Premise
351	differ	_	_	I-Premise
352	between	_	_	I-Premise
353	treatment	_	_	I-Premise
354	groups	_	_	I-Premise
355	:	_	_	I-Premise
356	the	_	_	I-Premise
357	mean	_	_	I-Premise
358	(	_	_	I-Premise
359	SD	_	_	I-Premise
360	)	_	_	I-Premise
361	change	_	_	I-Premise
362	was	_	_	I-Premise
363	-0.5	_	_	I-Premise
364	(	_	_	I-Premise
365	9.4	_	_	I-Premise
366	)	_	_	I-Premise
367	mL/min/100	_	_	I-Premise
368	g	_	_	I-Premise
369	in	_	_	I-Premise
370	the	_	_	I-Premise
371	standard	_	_	I-Premise
372	group	_	_	I-Premise
373	vs	_	_	I-Premise
374	0.7	_	_	I-Premise
375	(	_	_	I-Premise
376	8.6	_	_	I-Premise
377	)	_	_	I-Premise
378	mL/min/100	_	_	I-Premise
379	g	_	_	I-Premise
380	in	_	_	I-Premise
381	the	_	_	I-Premise
382	intensive	_	_	I-Premise
383	group	_	_	I-Premise
384	(	_	_	I-Premise
385	partial	_	_	I-Premise
386	η2	_	_	I-Premise
387	,	_	_	I-Premise
388	0.004	_	_	I-Premise
389	;	_	_	I-Premise
390	95	_	_	I-Premise
391	%	_	_	I-Premise
392	CI	_	_	I-Premise
393	,	_	_	I-Premise
394	-3.551	_	_	I-Premise
395	to	_	_	I-Premise
396	5.818	_	_	I-Premise
397	;	_	_	I-Premise
398	P	_	_	I-Premise
399	=	_	_	I-Premise
400	.63	_	_	I-Premise
401	)	_	_	I-Premise
402	.	_	_	I-Premise

403	No	_	_	B-Premise
404	differences	_	_	I-Premise
405	were	_	_	I-Premise
406	observed	_	_	I-Premise
407	when	_	_	I-Premise
408	the	_	_	I-Premise
409	analysis	_	_	I-Premise
410	examined	_	_	I-Premise
411	gray	_	_	I-Premise
412	or	_	_	I-Premise
413	white	_	_	I-Premise
414	matter	_	_	I-Premise
415	only	_	_	I-Premise
416	or	_	_	I-Premise
417	was	_	_	I-Premise
418	confined	_	_	I-Premise
419	to	_	_	I-Premise
420	those	_	_	I-Premise
421	achieving	_	_	I-Premise
422	target	_	_	I-Premise
423	BP	_	_	I-Premise
424	.	_	_	I-Premise

425	The	_	_	B-Premise
426	number	_	_	I-Premise
427	of	_	_	I-Premise
428	adverse	_	_	I-Premise
429	events	_	_	I-Premise
430	did	_	_	I-Premise
431	not	_	_	I-Premise
432	differ	_	_	I-Premise
433	between	_	_	I-Premise
434	treatment	_	_	I-Premise
435	groups	_	_	I-Premise
436	,	_	_	I-Premise
437	with	_	_	I-Premise
438	a	_	_	I-Premise
439	mean	_	_	I-Premise
440	(	_	_	I-Premise
441	SD	_	_	I-Premise
442	)	_	_	I-Premise
443	of	_	_	I-Premise
444	0.21	_	_	I-Premise
445	(	_	_	I-Premise
446	0.65	_	_	I-Premise
447	)	_	_	I-Premise
448	for	_	_	I-Premise
449	the	_	_	I-Premise
450	standard	_	_	I-Premise
451	group	_	_	I-Premise
452	and	_	_	I-Premise
453	0.32	_	_	I-Premise
454	(	_	_	I-Premise
455	0.75	_	_	I-Premise
456	)	_	_	I-Premise
457	for	_	_	I-Premise
458	the	_	_	I-Premise
459	intensive	_	_	I-Premise
460	group	_	_	I-Premise
461	(	_	_	I-Premise
462	P	_	_	I-Premise
463	=	_	_	I-Premise
464	.44	_	_	I-Premise
465	)	_	_	I-Premise
466	.	_	_	I-Premise

467	Intensive	_	_	B-Claim
468	BP	_	_	I-Claim
469	lowering	_	_	I-Claim
470	did	_	_	I-Claim
471	not	_	_	I-Claim
472	reduce	_	_	I-Claim
473	cerebral	_	_	I-Claim
474	perfusion	_	_	I-Claim
475	in	_	_	I-Claim
476	severe	_	_	I-Claim
477	small	_	_	I-Claim
478	vessel	_	_	I-Claim
479	disease	_	_	I-Claim
480	.	_	_	I-Claim


1	Ocular	_	_	O
2	blood	_	_	O
3	flow	_	_	O
4	dysregulation	_	_	O
5	has	_	_	O
6	been	_	_	O
7	implicated	_	_	O
8	in	_	_	O
9	the	_	_	O
10	pathogenesis	_	_	O
11	of	_	_	O
12	glaucoma	_	_	O
13	.	_	_	O

14	Whereas	_	_	O
15	the	_	_	O
16	effect	_	_	O
17	of	_	_	O
18	single	_	_	O
19	antiglaucoma	_	_	O
20	substances	_	_	O
21	on	_	_	O
22	ocular	_	_	O
23	blood	_	_	O
24	flow	_	_	O
25	has	_	_	O
26	been	_	_	O
27	addressed	_	_	O
28	in	_	_	O
29	various	_	_	O
30	experiments	_	_	O
31	,	_	_	O
32	evidence	_	_	O
33	for	_	_	O
34	fixed	_	_	O
35	combinations	_	_	O
36	is	_	_	O
37	sparse	_	_	O
38	.	_	_	O

39	In	_	_	O
40	the	_	_	O
41	present	_	_	O
42	study	_	_	O
43	,	_	_	O
44	we	_	_	O
45	set	_	_	O
46	out	_	_	O
47	to	_	_	O
48	compare	_	_	O
49	the	_	_	O
50	effects	_	_	O
51	of	_	_	O
52	latanoprost	_	_	O
53	0.005	_	_	O
54	%	_	_	O
55	/timolol	_	_	O
56	0.5	_	_	O
57	%	_	_	O
58	(	_	_	O
59	LT	_	_	O
60	)	_	_	O
61	fixed	_	_	O
62	combination	_	_	O
63	and	_	_	O
64	brimonidine	_	_	O
65	0.2	_	_	O
66	%	_	_	O
67	/timolol	_	_	O
68	0.5	_	_	O
69	%	_	_	O
70	(	_	_	O
71	BT	_	_	O
72	)	_	_	O
73	fixed	_	_	O
74	combination	_	_	O
75	on	_	_	O
76	intraocular	_	_	O
77	pressure	_	_	O
78	(	_	_	O
79	IOP	_	_	O
80	)	_	_	O
81	and	_	_	O
82	ocular	_	_	O
83	blood	_	_	O
84	flow	_	_	O
85	.	_	_	O

86	In	_	_	O
87	the	_	_	O
88	present	_	_	O
89	study	_	_	O
90	,	_	_	O
91	which	_	_	O
92	followed	_	_	O
93	a	_	_	O
94	randomized	_	_	O
95	,	_	_	O
96	double-masked	_	_	O
97	2-way	_	_	O
98	crossover	_	_	O
99	design	_	_	O
100	,	_	_	O
101	16	_	_	O
102	patients	_	_	O
103	with	_	_	O
104	primary	_	_	O
105	open-angle	_	_	O
106	glaucoma	_	_	O
107	and	_	_	O
108	2	_	_	O
109	patients	_	_	O
110	with	_	_	O
111	ocular	_	_	O
112	hypertension	_	_	O
113	were	_	_	O
114	included	_	_	O
115	.	_	_	O

116	The	_	_	O
117	patients	_	_	O
118	underwent	_	_	O
119	a	_	_	O
120	6-week	_	_	O
121	treatment	_	_	O
122	with	_	_	O
123	LT	_	_	O
124	and	_	_	O
125	a	_	_	O
126	6-week	_	_	O
127	treatment	_	_	O
128	with	_	_	O
129	BT	_	_	O
130	after	_	_	O
131	a	_	_	O
132	washout	_	_	O
133	for	_	_	O
134	previous	_	_	O
135	antiglaucoma	_	_	O
136	medication	_	_	O
137	.	_	_	O

138	Optic	_	_	O
139	nerve	_	_	O
140	head	_	_	O
141	blood	_	_	O
142	flow	_	_	O
143	(	_	_	O
144	ONHBF	_	_	O
145	)	_	_	O
146	was	_	_	O
147	measured	_	_	O
148	using	_	_	O
149	laser	_	_	O
150	Doppler	_	_	O
151	flowmetry	_	_	O
152	;	_	_	O
153	retrobulbar	_	_	O
154	flow	_	_	O
155	velocities	_	_	O
156	were	_	_	O
157	measured	_	_	O
158	using	_	_	O
159	color	_	_	O
160	Doppler	_	_	O
161	imaging	_	_	O
162	in	_	_	O
163	the	_	_	O
164	ophthalmic	_	_	O
165	artery	_	_	O
166	,	_	_	O
167	the	_	_	O
168	central	_	_	O
169	retinal	_	_	O
170	artery	_	_	O
171	,	_	_	O
172	and	_	_	O
173	the	_	_	O
174	posterior	_	_	O
175	ciliary	_	_	O
176	arteries	_	_	O
177	.	_	_	O

178	IOP	_	_	O
179	was	_	_	O
180	measured	_	_	O
181	at	_	_	O
182	8	_	_	O
183	AM	_	_	O
184	,	_	_	O
185	12	_	_	O
186	PM	_	_	O
187	,	_	_	O
188	and	_	_	O
189	4	_	_	O
190	PM	_	_	O
191	.	_	_	O

192	The	_	_	O
193	mean	_	_	O
194	baseline	_	_	O
195	IOP	_	_	O
196	was	_	_	O
197	25.3	_	_	O
198	±2.8	_	_	O
199	mmHg	_	_	O
200	.	_	_	O

201	Both	_	_	B-Premise
202	drugs	_	_	I-Premise
203	were	_	_	I-Premise
204	equally	_	_	I-Premise
205	effective	_	_	I-Premise
206	in	_	_	I-Premise
207	reducing	_	_	I-Premise
208	IOP	_	_	I-Premise
209	(	_	_	I-Premise
210	LT	_	_	I-Premise
211	:	_	_	I-Premise
212	-35.0	_	_	I-Premise
213	%	_	_	I-Premise
214	±10.0	_	_	I-Premise
215	%	_	_	I-Premise
216	;	_	_	I-Premise
217	BT	_	_	I-Premise
218	:	_	_	I-Premise
219	-33.6	_	_	I-Premise
220	%	_	_	I-Premise
221	±8.8	_	_	I-Premise
222	%	_	_	I-Premise
223	,	_	_	I-Premise
224	P=0.463	_	_	I-Premise
225	between	_	_	I-Premise
226	groups	_	_	I-Premise
227	)	_	_	I-Premise
228	.	_	_	I-Premise

229	In	_	_	O
230	addition	_	_	O
231	,	_	_	O
232	no	_	_	B-Premise
233	difference	_	_	I-Premise
234	in	_	_	I-Premise
235	ocular	_	_	I-Premise
236	perfusion	_	_	I-Premise
237	pressure	_	_	I-Premise
238	was	_	_	I-Premise
239	observed	_	_	I-Premise
240	between	_	_	I-Premise
241	the	_	_	I-Premise
242	2	_	_	I-Premise
243	treatment	_	_	I-Premise
244	groups	_	_	I-Premise
245	(	_	_	I-Premise
246	P=0.1	_	_	I-Premise
247	,	_	_	I-Premise
248	between	_	_	I-Premise
249	groups	_	_	I-Premise
250	)	_	_	I-Premise
251	.	_	_	I-Premise

252	Neither	_	_	B-Premise
253	LT	_	_	I-Premise
254	nor	_	_	I-Premise
255	BT	_	_	I-Premise
256	altered	_	_	I-Premise
257	ONHBF	_	_	I-Premise
258	(	_	_	I-Premise
259	P=0.4	_	_	I-Premise
260	,	_	_	I-Premise
261	baseline	_	_	I-Premise
262	vs.	_	_	I-Premise
263	treatment	_	_	I-Premise
264	)	_	_	I-Premise
265	and	_	_	O
266	no	_	_	B-Premise
267	effect	_	_	I-Premise
268	on	_	_	I-Premise
269	flow	_	_	I-Premise
270	velocities	_	_	I-Premise
271	in	_	_	I-Premise
272	the	_	_	I-Premise
273	retrobulbar	_	_	I-Premise
274	vessels	_	_	I-Premise
275	was	_	_	I-Premise
276	seen	_	_	I-Premise
277	with	_	_	I-Premise
278	either	_	_	I-Premise
279	of	_	_	I-Premise
280	the	_	_	I-Premise
281	2	_	_	I-Premise
282	treatments	_	_	I-Premise
283	.	_	_	I-Premise

284	In	_	_	O
285	the	_	_	O
286	present	_	_	O
287	study	_	_	O
288	,	_	_	O
289	a	_	_	B-Claim
290	6-week	_	_	I-Claim
291	treatment	_	_	I-Claim
292	with	_	_	I-Claim
293	LT	_	_	I-Claim
294	or	_	_	I-Claim
295	BT	_	_	I-Claim
296	was	_	_	I-Claim
297	equally	_	_	I-Claim
298	effective	_	_	I-Claim
299	in	_	_	I-Claim
300	reducing	_	_	I-Claim
301	IOP	_	_	I-Claim
302	.	_	_	I-Claim

303	In	_	_	O
304	addition	_	_	O
305	,	_	_	O
306	none	_	_	B-Claim
307	of	_	_	I-Claim
308	the	_	_	I-Claim
309	administered	_	_	I-Claim
310	drugs	_	_	I-Claim
311	induced	_	_	I-Claim
312	a	_	_	I-Claim
313	significant	_	_	I-Claim
314	effect	_	_	I-Claim
315	on	_	_	I-Claim
316	ocular	_	_	I-Claim
317	blood	_	_	I-Claim
318	flow	_	_	I-Claim
319	parameters	_	_	I-Claim
320	.	_	_	I-Claim


0	The	_	_	O
1	REVEAL	_	_	O
2	risk	_	_	O
3	score	_	_	O
4	(	_	_	O
5	RRS	_	_	O
6	)	_	_	O
7	was	_	_	O
8	developed	_	_	O
9	to	_	_	O
10	predict	_	_	O
11	survival	_	_	O
12	in	_	_	O
13	patients	_	_	O
14	with	_	_	O
15	pulmonary	_	_	O
16	arterial	_	_	O
17	hypertension	_	_	O
18	(	_	_	O
19	PAH	_	_	O
20	)	_	_	O
21	,	_	_	O
22	based	_	_	O
23	on	_	_	O
24	multiple	_	_	O
25	patient	_	_	O
26	characteristics	_	_	O
27	.	_	_	O

28	Herein	_	_	O
29	we	_	_	O
30	calculated	_	_	O
31	RRS	_	_	O
32	for	_	_	O
33	patients	_	_	O
34	in	_	_	O
35	the	_	_	O
36	randomized	_	_	O
37	CHEST-1	_	_	O
38	study	_	_	O
39	and	_	_	O
40	open-label	_	_	O
41	CHEST-2	_	_	O
42	extension	_	_	O
43	study	_	_	O
44	of	_	_	O
45	riociguat	_	_	O
46	in	_	_	O
47	inoperable	_	_	O
48	or	_	_	O
49	persistent/recurrent	_	_	O
50	chronic	_	_	O
51	thromboembolic	_	_	O
52	pulmonary	_	_	O
53	hypertension	_	_	O
54	(	_	_	O
55	CTEPH	_	_	O
56	)	_	_	O
57	.	_	_	O

58	We	_	_	O
59	investigated	_	_	O
60	the	_	_	O
61	effect	_	_	O
62	of	_	_	O
63	riociguat	_	_	O
64	vs	_	_	O
65	placebo	_	_	O
66	on	_	_	O
67	RRS	_	_	O
68	in	_	_	O
69	the	_	_	O
70	CHEST-1	_	_	O
71	study	_	_	O
72	,	_	_	O
73	and	_	_	O
74	the	_	_	O
75	relationship	_	_	O
76	between	_	_	O
77	RRS	_	_	O
78	and	_	_	O
79	long-term	_	_	O
80	outcomes	_	_	O
81	in	_	_	O
82	the	_	_	O
83	CHEST-2	_	_	O
84	study	_	_	O
85	.	_	_	O

86	RRS	_	_	O
87	was	_	_	O
88	calculated	_	_	O
89	post	_	_	O
90	hoc	_	_	O
91	for	_	_	O
92	baseline	_	_	O
93	and	_	_	O
94	Week	_	_	O
95	16	_	_	O
96	of	_	_	O
97	CHEST-1	_	_	O
98	and	_	_	O
99	Week	_	_	O
100	12	_	_	O
101	of	_	_	O
102	CHEST-2	_	_	O
103	,	_	_	O
104	based	_	_	O
105	on	_	_	O
106	9	_	_	O
107	evaluable	_	_	O
108	elements	_	_	O
109	.	_	_	O

110	Patients	_	_	O
111	were	_	_	O
112	grouped	_	_	O
113	into	_	_	O
114	risk	_	_	O
115	strata	_	_	O
116	by	_	_	O
117	RRS	_	_	O
118	.	_	_	O

119	Relationships	_	_	O
120	between	_	_	O
121	RRS	_	_	O
122	and	_	_	O
123	both	_	_	O
124	survival	_	_	O
125	and	_	_	O
126	clinical	_	_	O
127	worsening-free	_	_	O
128	survival	_	_	O
129	were	_	_	O
130	examined	_	_	O
131	by	_	_	O
132	Kaplan-Meier	_	_	O
133	and	_	_	O
134	Cox	_	_	O
135	proportional	_	_	O
136	hazards	_	_	O
137	analyses	_	_	O
138	.	_	_	O

139	Overall	_	_	O
140	,	_	_	O
141	237	_	_	O
142	patients	_	_	O
143	completed	_	_	O
144	CHEST-1	_	_	O
145	and	_	_	O
146	entered	_	_	O
147	CHEST-2	_	_	O
148	.	_	_	O

149	In	_	_	B-Premise
150	CHEST-1	_	_	I-Premise
151	,	_	_	I-Premise
152	riociguat	_	_	I-Premise
153	significantly	_	_	I-Premise
154	improved	_	_	I-Premise
155	RRS	_	_	I-Premise
156	(	_	_	I-Premise
157	p	_	_	I-Premise
158	<	_	_	I-Premise
159	0.0001	_	_	I-Premise
160	)	_	_	I-Premise
161	and	_	_	I-Premise
162	risk	_	_	I-Premise
163	stratum	_	_	I-Premise
164	(	_	_	I-Premise
165	p	_	_	I-Premise
166	<	_	_	I-Premise
167	0.001	_	_	I-Premise
168	)	_	_	I-Premise
169	vs	_	_	I-Premise
170	placebo	_	_	I-Premise
171	from	_	_	I-Premise
172	baseline	_	_	I-Premise
173	to	_	_	I-Premise
174	Week	_	_	I-Premise
175	16	_	_	I-Premise
176	.	_	_	I-Premise

177	RRS	_	_	B-Premise
178	at	_	_	I-Premise
179	baseline	_	_	I-Premise
180	,	_	_	I-Premise
181	and	_	_	I-Premise
182	at	_	_	I-Premise
183	Week	_	_	I-Premise
184	16	_	_	I-Premise
185	,	_	_	I-Premise
186	and	_	_	I-Premise
187	change	_	_	I-Premise
188	in	_	_	I-Premise
189	RRS	_	_	I-Premise
190	during	_	_	I-Premise
191	CHEST-1	_	_	I-Premise
192	were	_	_	I-Premise
193	significantly	_	_	I-Premise
194	associated	_	_	I-Premise
195	with	_	_	I-Premise
196	survival	_	_	I-Premise
197	(	_	_	I-Premise
198	hazard	_	_	I-Premise
199	ratios	_	_	I-Premise
200	for	_	_	I-Premise
201	a	_	_	I-Premise
202	1-point	_	_	I-Premise
203	reduction	_	_	I-Premise
204	in	_	_	I-Premise
205	RRS	_	_	I-Premise
206	:	_	_	I-Premise
207	0.702	_	_	I-Premise
208	,	_	_	I-Premise
209	0.692	_	_	I-Premise
210	,	_	_	I-Premise
211	and	_	_	I-Premise
212	0.682	_	_	I-Premise
213	,	_	_	I-Premise
214	respectively	_	_	I-Premise
215	)	_	_	I-Premise
216	and	_	_	I-Premise
217	clinical	_	_	I-Premise
218	worsening-free	_	_	I-Premise
219	survival	_	_	I-Premise
220	(	_	_	I-Premise
221	hazard	_	_	I-Premise
222	ratios	_	_	I-Premise
223	:	_	_	I-Premise
224	0.697	_	_	I-Premise
225	,	_	_	I-Premise
226	0.719	_	_	I-Premise
227	,	_	_	I-Premise
228	and	_	_	I-Premise
229	0.754	_	_	I-Premise
230	,	_	_	I-Premise
231	respectively	_	_	I-Premise
232	)	_	_	I-Premise
233	over	_	_	I-Premise
234	2	_	_	I-Premise
235	years	_	_	I-Premise
236	in	_	_	I-Premise
237	CHEST-2	_	_	I-Premise
238	.	_	_	I-Premise

239	Riociguat	_	_	B-Premise
240	improved	_	_	I-Premise
241	RRS	_	_	I-Premise
242	in	_	_	I-Premise
243	patients	_	_	I-Premise
244	with	_	_	I-Premise
245	inoperable	_	_	I-Premise
246	and	_	_	I-Premise
247	persistent/recurrent	_	_	I-Premise
248	CTEPH	_	_	I-Premise
249	.	_	_	I-Premise

250	RRS	_	_	B-Premise
251	at	_	_	I-Premise
252	baseline	_	_	I-Premise
253	and	_	_	I-Premise
254	Week	_	_	I-Premise
255	16	_	_	I-Premise
256	,	_	_	I-Premise
257	and	_	_	I-Premise
258	change	_	_	I-Premise
259	in	_	_	I-Premise
260	RRS	_	_	I-Premise
261	from	_	_	I-Premise
262	baseline	_	_	I-Premise
263	,	_	_	I-Premise
264	predicted	_	_	I-Premise
265	survival	_	_	I-Premise
266	and	_	_	I-Premise
267	clinical	_	_	I-Premise
268	worsening-free	_	_	I-Premise
269	survival	_	_	I-Premise
270	.	_	_	I-Premise

271	This	_	_	B-Claim
272	analysis	_	_	I-Claim
273	of	_	_	I-Claim
274	RRS	_	_	I-Claim
275	in	_	_	I-Claim
276	patients	_	_	I-Claim
277	with	_	_	I-Claim
278	inoperable	_	_	I-Claim
279	or	_	_	I-Claim
280	persistent/recurrent	_	_	I-Claim
281	CTEPH	_	_	I-Claim
282	suggests	_	_	I-Claim
283	utility	_	_	I-Claim
284	for	_	_	I-Claim
285	the	_	_	I-Claim
286	RRS	_	_	I-Claim
287	in	_	_	I-Claim
288	indications	_	_	I-Claim
289	beyond	_	_	I-Claim
290	PAH	_	_	I-Claim
291	.	_	_	I-Claim


0	High	_	_	O
1	blood	_	_	O
2	pressure	_	_	O
3	(	_	_	O
4	BP	_	_	O
5	)	_	_	O
6	is	_	_	O
7	a	_	_	O
8	common	_	_	O
9	chronic	_	_	O
10	disease	_	_	O
11	needs	_	_	O
12	long	_	_	O
13	life	_	_	O
14	drug	_	_	O
15	consumption	_	_	O
16	to	_	_	O
17	control	_	_	O
18	.	_	_	O

19	Spironolactone	_	_	B-Claim
20	could	_	_	I-Claim
21	be	_	_	I-Claim
22	used	_	_	I-Claim
23	as	_	_	I-Claim
24	the	_	_	I-Claim
25	fourth-line	_	_	I-Claim
26	therapy	_	_	I-Claim
27	in	_	_	I-Claim
28	patients	_	_	I-Claim
29	with	_	_	I-Claim
30	resistant	_	_	I-Claim
31	hypertension	_	_	I-Claim
32	.	_	_	I-Claim

33	However	_	_	O
34	,	_	_	O
35	there	_	_	O
36	is	_	_	O
37	no	_	_	O
38	study	_	_	O
39	to	_	_	O
40	determine	_	_	O
41	the	_	_	O
42	effects	_	_	O
43	of	_	_	O
44	low	_	_	O
45	dose	_	_	O
46	spironolactone	_	_	O
47	as	_	_	O
48	a	_	_	O
49	first	_	_	O
50	line	_	_	O
51	therapy	_	_	O
52	in	_	_	O
53	treatment	_	_	O
54	of	_	_	O
55	essential	_	_	O
56	hypertension	_	_	O
57	.	_	_	O

58	The	_	_	O
59	aim	_	_	O
60	of	_	_	O
61	this	_	_	O
62	study	_	_	O
63	is	_	_	O
64	to	_	_	O
65	investigate	_	_	O
66	the	_	_	O
67	effect	_	_	O
68	of	_	_	O
69	low	_	_	O
70	dose	_	_	O
71	spironolactone	_	_	O
72	monotherapy	_	_	O
73	in	_	_	O
74	management	_	_	O
75	of	_	_	O
76	essential	_	_	O
77	hypertension	_	_	O
78	.	_	_	O

79	In	_	_	O
80	this	_	_	O
81	double	_	_	O
82	blind	_	_	O
83	randomized	_	_	O
84	clinical	_	_	O
85	trial	_	_	O
86	,	_	_	O
87	40	_	_	O
88	patients	_	_	O
89	who	_	_	O
90	had	_	_	O
91	stage	_	_	O
92	I	_	_	O
93	essential	_	_	O
94	hypertension	_	_	O
95	were	_	_	O
96	randomly	_	_	O
97	divided	_	_	O
98	into	_	_	O
99	two	_	_	O
100	groups	_	_	O
101	:	_	_	O
102	intervention	_	_	O
103	group	_	_	O
104	received	_	_	O
105	spironolactone	_	_	O
106	25	_	_	O
107	milligram	_	_	O
108	once	_	_	O
109	daily	_	_	O
110	for	_	_	O
111	one	_	_	O
112	month	_	_	O
113	and	_	_	O
114	control	_	_	O
115	group	_	_	O
116	received	_	_	O
117	placebo	_	_	O
118	once	_	_	O
119	daily	_	_	O
120	.	_	_	O

121	At	_	_	O
122	the	_	_	O
123	baseline	_	_	O
124	and	_	_	O
125	after	_	_	O
126	one	_	_	O
127	month	_	_	O
128	,	_	_	O
129	24-hour	_	_	O
130	BP	_	_	O
131	holter-monitoring	_	_	O
132	and	_	_	O
133	serum	_	_	O
134	potassium	_	_	O
135	assay	_	_	O
136	were	_	_	O
137	done	_	_	O
138	.	_	_	O

139	Systolic	_	_	B-Premise
140	BP	_	_	I-Premise
141	was	_	_	I-Premise
142	reduced	_	_	I-Premise
143	from	_	_	I-Premise
144	143.5	_	_	I-Premise
145	±	_	_	I-Premise
146	8.2	_	_	I-Premise
147	mmHg	_	_	I-Premise
148	to	_	_	I-Premise
149	137.10	_	_	I-Premise
150	±	_	_	I-Premise
151	7.57	_	_	I-Premise
152	mmHg	_	_	I-Premise
153	in	_	_	I-Premise
154	the	_	_	I-Premise
155	intervention	_	_	I-Premise
156	group	_	_	I-Premise
157	,	_	_	I-Premise
158	while	_	_	I-Premise
159	it	_	_	I-Premise
160	did	_	_	I-Premise
161	not	_	_	I-Premise
162	change	_	_	I-Premise
163	significantly	_	_	I-Premise
164	in	_	_	I-Premise
165	control	_	_	I-Premise
166	(	_	_	I-Premise
167	between	_	_	I-Premise
168	group	_	_	I-Premise
169	treatment	_	_	I-Premise
170	difference	_	_	I-Premise
171	=	_	_	I-Premise
172	-4.5	_	_	I-Premise
173	mmHg	_	_	I-Premise
174	,	_	_	I-Premise
175	p	_	_	I-Premise
176	=	_	_	I-Premise
177	0.004	_	_	I-Premise
178	)	_	_	I-Premise
179	.	_	_	I-Premise

180	There	_	_	B-Premise
181	was	_	_	I-Premise
182	no	_	_	I-Premise
183	significant	_	_	I-Premise
184	reduction	_	_	I-Premise
185	of	_	_	I-Premise
186	diastolic	_	_	I-Premise
187	BP	_	_	I-Premise
188	in	_	_	I-Premise
189	the	_	_	I-Premise
190	intervention	_	_	I-Premise
191	group	_	_	I-Premise
192	in	_	_	I-Premise
193	comparison	_	_	I-Premise
194	to	_	_	I-Premise
195	placebo	_	_	I-Premise
196	group	_	_	I-Premise
197	(	_	_	I-Premise
198	between	_	_	I-Premise
199	group	_	_	I-Premise
200	treatment	_	_	I-Premise
201	difference	_	_	I-Premise
202	=	_	_	I-Premise
203	-1.3	_	_	I-Premise
204	mmHg	_	_	I-Premise
205	,	_	_	I-Premise
206	p	_	_	I-Premise
207	=	_	_	I-Premise
208	0.099	_	_	I-Premise
209	)	_	_	I-Premise
210	.	_	_	I-Premise

211	Short	_	_	B-Claim
212	course	_	_	I-Claim
213	monotherapy	_	_	I-Claim
214	with	_	_	I-Claim
215	low	_	_	I-Claim
216	dose	_	_	I-Claim
217	spironolactone	_	_	I-Claim
218	is	_	_	I-Claim
219	effective	_	_	I-Claim
220	in	_	_	I-Claim
221	reducing	_	_	I-Claim
222	systolic	_	_	I-Claim
223	BP	_	_	I-Claim
224	in	_	_	I-Claim
225	patients	_	_	I-Claim
226	with	_	_	I-Claim
227	stage	_	_	I-Claim
228	I	_	_	I-Claim
229	essential	_	_	I-Claim
230	hypertension	_	_	I-Claim
231	.	_	_	I-Claim


0	Chronic	_	_	O
1	infection	_	_	O
2	with	_	_	O
3	hepatitis	_	_	O
4	B	_	_	O
5	virus	_	_	O
6	(	_	_	O
7	HBV	_	_	O
8	)	_	_	O
9	in	_	_	O
10	children	_	_	O
11	is	_	_	O
12	a	_	_	O
13	serious	_	_	O
14	health	_	_	O
15	problem	_	_	O
16	worldwide	_	_	O
17	.	_	_	O

18	How	_	_	O
19	to	_	_	O
20	treat	_	_	O
21	children	_	_	O
22	with	_	_	O
23	immune-tolerant	_	_	O
24	chronic	_	_	O
25	hepatitis	_	_	O
26	B	_	_	O
27	infection	_	_	O
28	,	_	_	O
29	commonly	_	_	O
30	characterized	_	_	O
31	by	_	_	O
32	hepatitis	_	_	O
33	B	_	_	O
34	e	_	_	O
35	antigen	_	_	O
36	(	_	_	O
37	HBeAg	_	_	O
38	)	_	_	O
39	positivity	_	_	O
40	,	_	_	O
41	high	_	_	O
42	viral	_	_	O
43	load	_	_	O
44	,	_	_	O
45	normal	_	_	O
46	or	_	_	O
47	mildly	_	_	O
48	elevated	_	_	O
49	alanine	_	_	O
50	aminotransferase	_	_	O
51	and	_	_	O
52	no	_	_	O
53	or	_	_	O
54	minimal	_	_	O
55	inflammation	_	_	O
56	in	_	_	O
57	liver	_	_	O
58	histology	_	_	O
59	,	_	_	O
60	remains	_	_	O
61	unresolved	_	_	O
62	.	_	_	O

63	This	_	_	O
64	trial	_	_	O
65	aims	_	_	O
66	to	_	_	O
67	study	_	_	O
68	the	_	_	O
69	benefits	_	_	O
70	of	_	_	O
71	antiviral	_	_	O
72	therapy	_	_	O
73	in	_	_	O
74	children	_	_	O
75	with	_	_	O
76	these	_	_	O
77	characteristics	_	_	O
78	.	_	_	O

79	This	_	_	O
80	is	_	_	O
81	a	_	_	O
82	pilot	_	_	O
83	open-label	_	_	O
84	randomized	_	_	O
85	controlled	_	_	O
86	study	_	_	O
87	.	_	_	O

88	From	_	_	O
89	May	_	_	O
90	2014	_	_	O
91	to	_	_	O
92	April	_	_	O
93	2015	_	_	O
94	,	_	_	O
95	69	_	_	O
96	treatment-naive	_	_	O
97	chronically	_	_	O
98	HBV-infected	_	_	O
99	children	_	_	O
100	,	_	_	O
101	aged	_	_	O
102	1	_	_	O
103	to	_	_	O
104	16	_	_	O
105	years	_	_	O
106	,	_	_	O
107	who	_	_	O
108	had	_	_	O
109	immune-tolerant	_	_	O
110	characteristics	_	_	O
111	were	_	_	O
112	recruited	_	_	O
113	to	_	_	O
114	this	_	_	O
115	trial	_	_	O
116	and	_	_	O
117	randomly	_	_	O
118	assigned	_	_	O
119	,	_	_	O
120	in	_	_	O
121	a	_	_	O
122	2:1	_	_	O
123	ratio	_	_	O
124	,	_	_	O
125	to	_	_	O
126	treatment	_	_	O
127	group	_	_	O
128	and	_	_	O
129	control	_	_	O
130	group	_	_	O
131	.	_	_	O

132	Patients	_	_	O
133	in	_	_	O
134	the	_	_	O
135	treatment	_	_	O
136	group	_	_	O
137	received	_	_	O
138	either	_	_	O
139	interferon-α	_	_	O
140	(	_	_	O
141	IFN	_	_	O
142	)	_	_	O
143	monotherapy	_	_	O
144	or	_	_	O
145	consecutively	_	_	O
146	received	_	_	O
147	IFN	_	_	O
148	monotherapy	_	_	O
149	,	_	_	O
150	combination	_	_	O
151	therapy	_	_	O
152	of	_	_	O
153	IFN	_	_	O
154	and	_	_	O
155	lamivudine	_	_	O
156	(	_	_	O
157	LAM	_	_	O
158	)	_	_	O
159	,	_	_	O
160	and	_	_	O
161	LAM	_	_	O
162	therapy	_	_	O
163	alone	_	_	O
164	.	_	_	O

165	All	_	_	O
166	patients	_	_	O
167	were	_	_	O
168	observed	_	_	O
169	until	_	_	O
170	week	_	_	O
171	96	_	_	O
172	.	_	_	O

173	At	_	_	O
174	baseline	_	_	O
175	,	_	_	O
176	epidemiological	_	_	O
177	,	_	_	O
178	biochemical	_	_	O
179	,	_	_	O
180	serological	_	_	O
181	,	_	_	O
182	virological	_	_	O
183	and	_	_	O
184	histological	_	_	O
185	indices	_	_	O
186	were	_	_	O
187	consistent	_	_	O
188	across	_	_	O
189	the	_	_	O
190	treatment	_	_	O
191	and	_	_	O
192	control	_	_	O
193	groups	_	_	O
194	.	_	_	O

195	Of	_	_	B-Premise
196	the	_	_	I-Premise
197	46	_	_	I-Premise
198	patients	_	_	I-Premise
199	in	_	_	I-Premise
200	the	_	_	I-Premise
201	treatment	_	_	I-Premise
202	group	_	_	I-Premise
203	,	_	_	I-Premise
204	73.91	_	_	I-Premise
205	%	_	_	I-Premise
206	had	_	_	I-Premise
207	undetectable	_	_	I-Premise
208	serum	_	_	I-Premise
209	HBV	_	_	I-Premise
210	DNA	_	_	I-Premise
211	,	_	_	I-Premise
212	32.61	_	_	I-Premise
213	%	_	_	I-Premise
214	achieved	_	_	I-Premise
215	HBeAg	_	_	I-Premise
216	seroconversion	_	_	I-Premise
217	and	_	_	I-Premise
218	21.74	_	_	I-Premise
219	%	_	_	I-Premise
220	lost	_	_	I-Premise
221	hepatitis	_	_	I-Premise
222	B	_	_	I-Premise
223	surface	_	_	I-Premise
224	antigen	_	_	I-Premise
225	(	_	_	I-Premise
226	HBsAg	_	_	I-Premise
227	)	_	_	I-Premise
228	at	_	_	I-Premise
229	the	_	_	I-Premise
230	endpoint	_	_	I-Premise
231	.	_	_	I-Premise

232	No	_	_	B-Premise
233	LAM	_	_	I-Premise
234	resistance	_	_	I-Premise
235	emerged	_	_	I-Premise
236	at	_	_	I-Premise
237	week	_	_	I-Premise
238	96	_	_	I-Premise
239	.	_	_	I-Premise

240	In	_	_	B-Premise
241	the	_	_	I-Premise
242	control	_	_	I-Premise
243	group	_	_	I-Premise
244	,	_	_	I-Premise
245	only	_	_	I-Premise
246	one	_	_	I-Premise
247	(	_	_	I-Premise
248	4.35	_	_	I-Premise
249	%	_	_	I-Premise
250	)	_	_	I-Premise
251	patient	_	_	I-Premise
252	underwent	_	_	I-Premise
253	spontaneous	_	_	I-Premise
254	HBeAg	_	_	I-Premise
255	seroconversion	_	_	I-Premise
256	and	_	_	I-Premise
257	had	_	_	I-Premise
258	undetectable	_	_	I-Premise
259	serum	_	_	I-Premise
260	HBV	_	_	I-Premise
261	DNA	_	_	I-Premise
262	during	_	_	I-Premise
263	observation	_	_	I-Premise
264	,	_	_	I-Premise
265	and	_	_	I-Premise
266	moreover	_	_	I-Premise
267	,	_	_	I-Premise
268	none	_	_	I-Premise
269	developed	_	_	I-Premise
270	HBsAg	_	_	I-Premise
271	clearance	_	_	I-Premise
272	.	_	_	I-Premise

273	For	_	_	B-Premise
274	all	_	_	I-Premise
275	patients	_	_	I-Premise
276	,	_	_	I-Premise
277	no	_	_	I-Premise
278	serious	_	_	I-Premise
279	adverse	_	_	I-Premise
280	events	_	_	I-Premise
281	were	_	_	I-Premise
282	observed	_	_	I-Premise
283	.	_	_	I-Premise

284	Antiviral	_	_	B-Premise
285	treatment	_	_	I-Premise
286	with	_	_	I-Premise
287	a	_	_	I-Premise
288	sequential	_	_	I-Premise
289	combination	_	_	I-Premise
290	of	_	_	I-Premise
291	IFN	_	_	I-Premise
292	and	_	_	I-Premise
293	LAM	_	_	I-Premise
294	resulted	_	_	I-Premise
295	in	_	_	I-Premise
296	a	_	_	I-Premise
297	significant	_	_	I-Premise
298	improvement	_	_	I-Premise
299	in	_	_	I-Premise
300	the	_	_	I-Premise
301	rates	_	_	I-Premise
302	of	_	_	I-Premise
303	undetectable	_	_	I-Premise
304	serum	_	_	I-Premise
305	HBV	_	_	I-Premise
306	DNA	_	_	I-Premise
307	,	_	_	I-Premise
308	HBeAg	_	_	I-Premise
309	seroconversion	_	_	I-Premise
310	and	_	_	I-Premise
311	HBsAg	_	_	I-Premise
312	loss	_	_	I-Premise
313	in	_	_	I-Premise
314	children	_	_	I-Premise
315	with	_	_	I-Premise
316	chronic	_	_	I-Premise
317	HBV	_	_	I-Premise
318	infection	_	_	I-Premise
319	and	_	_	I-Premise
320	immune-tolerant	_	_	I-Premise
321	characteristics	_	_	I-Premise
322	.	_	_	I-Premise

323	There	_	_	O
324	is	_	_	O
325	a	_	_	O
326	lack	_	_	O
327	of	_	_	O
328	data	_	_	O
329	regarding	_	_	O
330	treatment	_	_	O
331	of	_	_	O
332	immune-tolerant	_	_	O
333	chronic	_	_	O
334	hepatitis	_	_	O
335	B	_	_	O
336	(	_	_	O
337	CHB	_	_	O
338	)	_	_	O
339	.	_	_	O

340	It	_	_	B-Claim
341	remains	_	_	I-Claim
342	unresolved	_	_	I-Claim
343	how	_	_	I-Claim
344	children	_	_	I-Claim
345	with	_	_	I-Claim
346	immune-tolerant	_	_	I-Claim
347	CHB	_	_	I-Claim
348	should	_	_	I-Claim
349	be	_	_	I-Claim
350	treated	_	_	I-Claim
351	.	_	_	I-Claim

352	This	_	_	O
353	paper	_	_	O
354	reports	_	_	O
355	the	_	_	O
356	outcomes	_	_	O
357	from	_	_	O
358	a	_	_	O
359	pilot	_	_	O
360	open-label	_	_	O
361	randomized	_	_	O
362	controlled	_	_	O
363	trial	_	_	O
364	on	_	_	O
365	antiviral	_	_	O
366	therapy	_	_	O
367	in	_	_	O
368	children	_	_	O
369	with	_	_	O
370	immune-tolerant	_	_	O
371	characteristics	_	_	O
372	.	_	_	O

373	It	_	_	B-Claim
374	shows	_	_	I-Claim
375	that	_	_	I-Claim
376	a	_	_	I-Claim
377	sequential	_	_	I-Claim
378	combination	_	_	I-Claim
379	of	_	_	I-Claim
380	interferon-α	_	_	I-Claim
381	and	_	_	I-Claim
382	lamivudine	_	_	I-Claim
383	was	_	_	I-Claim
384	beneficial	_	_	I-Claim
385	.	_	_	I-Claim


0	The	_	_	O
1	carbonic	_	_	O
2	anhydrase	_	_	O
3	inhibitor	_	_	O
4	acetazolamide	_	_	O
5	(	_	_	O
6	AZT	_	_	O
7	)	_	_	O
8	modulates	_	_	O
9	blood	_	_	O
10	pressure	_	_	O
11	at	_	_	O
12	high	_	_	O
13	altitude	_	_	O
14	and	_	_	O
15	reduces	_	_	O
16	sleep-disordered	_	_	O
17	breathing	_	_	O
18	in	_	_	O
19	patients	_	_	O
20	with	_	_	O
21	obstructive	_	_	O
22	sleep	_	_	O
23	apnea	_	_	O
24	(	_	_	O
25	OSA	_	_	O
26	)	_	_	O
27	.	_	_	O

28	We	_	_	O
29	aimed	_	_	O
30	to	_	_	O
31	investigate	_	_	O
32	the	_	_	O
33	treatment	_	_	O
34	effect	_	_	O
35	of	_	_	O
36	AZT	_	_	O
37	and	_	_	O
38	in	_	_	O
39	combination	_	_	O
40	with	_	_	O
41	continuous	_	_	O
42	positive	_	_	O
43	airway	_	_	O
44	pressure	_	_	O
45	(	_	_	O
46	CPAP	_	_	O
47	)	_	_	O
48	on	_	_	O
49	blood	_	_	O
50	pressure	_	_	O
51	in	_	_	O
52	patients	_	_	O
53	with	_	_	O
54	hypertension	_	_	O
55	and	_	_	O
56	OSA	_	_	O
57	.	_	_	O

58	In	_	_	O
59	a	_	_	O
60	prospective	_	_	O
61	,	_	_	O
62	randomized	_	_	O
63	,	_	_	O
64	three-way	_	_	O
65	crossover	_	_	O
66	study	_	_	O
67	,	_	_	O
68	13	_	_	O
69	male	_	_	O
70	patients	_	_	O
71	with	_	_	O
72	hypertension	_	_	O
73	and	_	_	O
74	moderate	_	_	O
75	to	_	_	O
76	severe	_	_	O
77	OSA	_	_	O
78	(	_	_	O
79	age	_	_	O
80	64	_	_	O
81	±	_	_	O
82	7	_	_	O
83	years	_	_	O
84	,	_	_	O
85	body	_	_	O
86	mass	_	_	O
87	index	_	_	O
88	29	_	_	O
89	±	_	_	O
90	4	_	_	O
91	kg/m2	_	_	O
92	,	_	_	O
93	and	_	_	O
94	mean	_	_	O
95	apnea-hypopnea	_	_	O
96	index	_	_	O
97	37	_	_	O
98	±	_	_	O
99	23	_	_	O
100	events/h	_	_	O
101	)	_	_	O
102	received	_	_	O
103	AZT	_	_	O
104	,	_	_	O
105	CPAP	_	_	O
106	,	_	_	O
107	or	_	_	O
108	AZT	_	_	O
109	plus	_	_	O
110	CPAP	_	_	O
111	for	_	_	O
112	2-week	_	_	O
113	periods	_	_	O
114	.	_	_	O

115	Antihypertensive	_	_	O
116	medication	_	_	O
117	was	_	_	O
118	washed	_	_	O
119	out	_	_	O
120	.	_	_	O

121	Office	_	_	O
122	and	_	_	O
123	24-hour	_	_	O
124	blood	_	_	O
125	pressure	_	_	O
126	,	_	_	O
127	arterial	_	_	O
128	stiffness	_	_	O
129	,	_	_	O
130	polygraphic	_	_	O
131	sleep	_	_	O
132	study	_	_	O
133	data	_	_	O
134	,	_	_	O
135	and	_	_	O
136	blood	_	_	O
137	chemistry	_	_	O
138	were	_	_	O
139	compared	_	_	O
140	.	_	_	O

141	AZT	_	_	O
142	alone	_	_	O
143	and	_	_	O
144	AZT	_	_	O
145	plus	_	_	O
146	CPAP	_	_	O
147	,	_	_	O
148	but	_	_	O
149	not	_	_	O
150	CPAP	_	_	O
151	alone	_	_	O
152	,	_	_	O
153	reduced	_	_	O
154	office	_	_	O
155	mean	_	_	O
156	arterial	_	_	O
157	pressure	_	_	O
158	compared	_	_	O
159	to	_	_	O
160	baseline	_	_	O
161	(	_	_	O
162	-7	_	_	O
163	[	_	_	O
164	95	_	_	O
165	%	_	_	O
166	CI	_	_	O
167	-11	_	_	O
168	to	_	_	O
169	-4	_	_	O
170	]	_	_	O
171	,	_	_	O
172	-7	_	_	O
173	[	_	_	O
174	95	_	_	O
175	%	_	_	O
176	CI	_	_	O
177	-11	_	_	O
178	to	_	_	O
179	-4	_	_	O
180	]	_	_	O
181	and	_	_	O
182	-1	_	_	O
183	[	_	_	O
184	95	_	_	O
185	%	_	_	O
186	CI	_	_	O
187	-5	_	_	O
188	to	_	_	O
189	4	_	_	O
190	]	_	_	O
191	mmHg	_	_	O
192	,	_	_	O
193	respectively	_	_	O
194	;	_	_	O
195	repeated-	_	_	O
196	measures	_	_	O
197	analysis	_	_	O
198	of	_	_	O
199	variance	_	_	O
200	(	_	_	O
201	RM-ANOVA	_	_	O
202	;	_	_	O
203	P	_	_	O
204	=	_	_	O
205	.015	_	_	O
206	)	_	_	O
207	.	_	_	O

208	Aortic	_	_	B-Premise
209	systolic	_	_	I-Premise
210	pressure	_	_	I-Premise
211	and	_	_	I-Premise
212	augmentation	_	_	I-Premise
213	index	_	_	I-Premise
214	,	_	_	I-Premise
215	assessed	_	_	I-Premise
216	by	_	_	I-Premise
217	radial	_	_	I-Premise
218	artery	_	_	I-Premise
219	oscillatory	_	_	I-Premise
220	tonometry	_	_	I-Premise
221	,	_	_	I-Premise
222	were	_	_	I-Premise
223	unaffected	_	_	I-Premise
224	by	_	_	I-Premise
225	CPAP	_	_	I-Premise
226	but	_	_	I-Premise
227	decreased	_	_	I-Premise
228	after	_	_	I-Premise
229	AZT	_	_	I-Premise
230	and	_	_	I-Premise
231	AZT	_	_	I-Premise
232	plus	_	_	I-Premise
233	CPAP	_	_	I-Premise
234	(	_	_	I-Premise
235	RM-ANOVA	_	_	I-Premise
236	P	_	_	I-Premise
237	=	_	_	I-Premise
238	.030	_	_	I-Premise
239	and	_	_	I-Premise
240	.031	_	_	I-Premise
241	,	_	_	I-Premise
242	respectively	_	_	I-Premise
243	)	_	_	I-Premise
244	.	_	_	I-Premise

245	The	_	_	B-Premise
246	apnea-hypopnea	_	_	I-Premise
247	index	_	_	I-Premise
248	was	_	_	I-Premise
249	significantly	_	_	I-Premise
250	reduced	_	_	I-Premise
251	in	_	_	I-Premise
252	all	_	_	I-Premise
253	three	_	_	I-Premise
254	treatment	_	_	I-Premise
255	arms	_	_	I-Premise
256	,	_	_	I-Premise
257	most	_	_	I-Premise
258	prominently	_	_	I-Premise
259	by	_	_	I-Premise
260	AZT	_	_	I-Premise
261	plus	_	_	I-Premise
262	CPAP	_	_	I-Premise
263	(	_	_	I-Premise
264	RM-ANOVA	_	_	I-Premise
265	P	_	_	I-Premise
266	=	_	_	I-Premise
267	.003	_	_	I-Premise
268	)	_	_	I-Premise
269	.	_	_	I-Premise

270	The	_	_	B-Premise
271	reduction	_	_	I-Premise
272	of	_	_	I-Premise
273	venous	_	_	I-Premise
274	bicarbonate	_	_	I-Premise
275	concentration	_	_	I-Premise
276	following	_	_	I-Premise
277	AZT	_	_	I-Premise
278	was	_	_	I-Premise
279	correlated	_	_	I-Premise
280	with	_	_	I-Premise
281	the	_	_	I-Premise
282	change	_	_	I-Premise
283	of	_	_	I-Premise
284	apnea-hypopnea	_	_	I-Premise
285	index	_	_	I-Premise
286	(	_	_	I-Premise
287	r	_	_	I-Premise
288	=	_	_	I-Premise
289	0.66	_	_	I-Premise
290	,	_	_	I-Premise
291	P	_	_	I-Premise
292	=	_	_	I-Premise
293	.013	_	_	I-Premise
294	)	_	_	I-Premise
295	.	_	_	I-Premise

296	AZT	_	_	B-Claim
297	reduced	_	_	I-Claim
298	blood	_	_	I-Claim
299	pressure	_	_	I-Claim
300	,	_	_	I-Claim
301	vascular	_	_	I-Claim
302	stiffness	_	_	I-Claim
303	,	_	_	I-Claim
304	and	_	_	I-Claim
305	sleep-disordered	_	_	I-Claim
306	breathing	_	_	I-Claim
307	in	_	_	I-Claim
308	patients	_	_	I-Claim
309	with	_	_	I-Claim
310	OSA	_	_	I-Claim
311	and	_	_	I-Claim
312	comorbid	_	_	I-Claim
313	hypertension	_	_	I-Claim
314	.	_	_	I-Claim

315	Carbonic	_	_	B-Claim
316	anhydrase	_	_	I-Claim
317	inhibition	_	_	I-Claim
318	may	_	_	I-Claim
319	constitute	_	_	I-Claim
320	a	_	_	I-Claim
321	potential	_	_	I-Claim
322	target	_	_	I-Claim
323	for	_	_	I-Claim
324	drug	_	_	I-Claim
325	therapy	_	_	I-Claim
326	in	_	_	I-Claim
327	patients	_	_	I-Claim
328	with	_	_	I-Claim
329	sleep	_	_	I-Claim
330	apnea	_	_	I-Claim
331	and	_	_	I-Claim
332	comorbid	_	_	I-Claim
333	hypertension	_	_	I-Claim
334	.	_	_	I-Claim


0	The	_	_	O
1	purpose	_	_	O
2	of	_	_	O
3	this	_	_	O
4	review	_	_	O
5	is	_	_	O
6	to	_	_	O
7	correlate	_	_	O
8	predictions	_	_	O
9	based	_	_	O
10	on	_	_	O
11	pre-clinical	_	_	O
12	data	_	_	O
13	with	_	_	O
14	outcomes	_	_	O
15	from	_	_	O
16	clinical	_	_	O
17	trials	_	_	O
18	that	_	_	O
19	examine	_	_	O
20	the	_	_	O
21	effects	_	_	O
22	of	_	_	O
23	incretin-based	_	_	O
24	diabetes	_	_	O
25	treatments	_	_	O
26	on	_	_	O
27	the	_	_	O
28	kidney	_	_	O
29	.	_	_	O

30	The	_	_	O
31	incretin-based	_	_	O
32	treatments	_	_	O
33	include	_	_	O
34	agonists	_	_	O
35	of	_	_	O
36	the	_	_	O
37	glucagon-like	_	_	O
38	peptide	_	_	O
39	1	_	_	O
40	receptor	_	_	O
41	(	_	_	O
42	GLP-1R	_	_	O
43	)	_	_	O
44	and	_	_	O
45	inhibitors	_	_	O
46	of	_	_	O
47	the	_	_	O
48	enzyme	_	_	O
49	,	_	_	O
50	dipeptidyl	_	_	O
51	peptidase-4	_	_	O
52	(	_	_	O
53	DPP-4	_	_	O
54	)	_	_	O
55	.	_	_	O

56	In	_	_	O
57	addition	_	_	O
58	,	_	_	O
59	what	_	_	O
60	is	_	_	O
61	known	_	_	O
62	about	_	_	O
63	the	_	_	O
64	incretin-based	_	_	O
65	therapies	_	_	O
66	will	_	_	O
67	be	_	_	O
68	compared	_	_	O
69	to	_	_	O
70	what	_	_	O
71	is	_	_	O
72	known	_	_	O
73	about	_	_	O
74	the	_	_	O
75	renal	_	_	O
76	effects	_	_	O
77	of	_	_	O
78	SGLT2	_	_	O
79	inhibitors	_	_	O
80	.	_	_	O

81	Large-scale	_	_	O
82	clinical	_	_	O
83	trials	_	_	O
84	have	_	_	O
85	shown	_	_	O
86	that	_	_	O
87	SGLT2	_	_	O
88	inhibitors	_	_	O
89	reduce	_	_	O
90	albuminuria	_	_	O
91	and	_	_	O
92	preserve	_	_	O
93	estimated	_	_	O
94	glomerular	_	_	O
95	filtration	_	_	O
96	rate	_	_	O
97	(	_	_	O
98	eGFR	_	_	O
99	)	_	_	O
100	in	_	_	O
101	patients	_	_	O
102	with	_	_	O
103	diabetic	_	_	O
104	nephropathy	_	_	O
105	.	_	_	O

106	A	_	_	O
107	concise	_	_	O
108	and	_	_	O
109	plausible	_	_	O
110	hemodynamic	_	_	O
111	mechanism	_	_	O
112	is	_	_	O
113	supported	_	_	O
114	by	_	_	O
115	pre-clinical	_	_	O
116	research	_	_	O
117	on	_	_	O
118	the	_	_	O
119	physiology	_	_	O
120	and	_	_	O
121	pharmacology	_	_	O
122	of	_	_	O
123	SGLT2	_	_	O
124	.	_	_	O

125	Large-scale	_	_	B-Premise
126	clinical	_	_	I-Premise
127	trials	_	_	I-Premise
128	have	_	_	I-Premise
129	shown	_	_	I-Premise
130	that	_	_	I-Premise
131	incretin-based	_	_	I-Premise
132	therapies	_	_	I-Premise
133	mitigate	_	_	I-Premise
134	albuminuria	_	_	I-Premise
135	but	_	_	B-Premise
136	have	_	_	I-Premise
137	not	_	_	I-Premise
138	shown	_	_	I-Premise
139	beneficial	_	_	I-Premise
140	effects	_	_	I-Premise
141	on	_	_	I-Premise
142	eGFR	_	_	I-Premise
143	.	_	_	I-Premise

144	Research	_	_	B-Premise
145	on	_	_	I-Premise
146	the	_	_	I-Premise
147	incretin-based	_	_	I-Premise
148	therapies	_	_	I-Premise
149	has	_	_	I-Premise
150	yielded	_	_	I-Premise
151	a	_	_	I-Premise
152	diverse	_	_	I-Premise
153	array	_	_	I-Premise
154	of	_	_	I-Premise
155	direct	_	_	I-Premise
156	effects	_	_	I-Premise
157	throughout	_	_	I-Premise
158	the	_	_	I-Premise
159	body	_	_	I-Premise
160	,	_	_	I-Premise
161	which	_	_	I-Premise
162	fuels	_	_	I-Premise
163	speculation	_	_	I-Premise
164	as	_	_	I-Premise
165	to	_	_	I-Premise
166	how	_	_	I-Premise
167	these	_	_	I-Premise
168	drugs	_	_	I-Premise
169	might	_	_	I-Premise
170	benefit	_	_	I-Premise
171	the	_	_	I-Premise
172	diabetic	_	_	I-Premise
173	kidney	_	_	I-Premise
174	and	_	_	I-Premise
175	affect	_	_	I-Premise
176	its	_	_	I-Premise
177	function	_	_	I-Premise
178	(	_	_	I-Premise
179	s	_	_	I-Premise
180	)	_	_	I-Premise
181	.	_	_	I-Premise

182	But	_	_	B-Premise
183	in	_	_	I-Premise
184	vivo	_	_	I-Premise
185	experiments	_	_	I-Premise
186	have	_	_	I-Premise
187	yet	_	_	I-Premise
188	to	_	_	I-Premise
189	confirm	_	_	I-Premise
190	that	_	_	I-Premise
191	the	_	_	I-Premise
192	proposed	_	_	I-Premise
193	mechanisms	_	_	I-Premise
194	underlying	_	_	I-Premise
195	emergent	_	_	I-Premise
196	phenomena	_	_	I-Premise
197	,	_	_	I-Premise
198	such	_	_	I-Premise
199	as	_	_	I-Premise
200	proximal	_	_	I-Premise
201	tubular	_	_	I-Premise
202	fluid	_	_	I-Premise
203	reabsorption	_	_	I-Premise
204	,	_	_	I-Premise
205	are	_	_	I-Premise
206	the	_	_	I-Premise
207	ones	_	_	I-Premise
208	predicted	_	_	I-Premise
209	by	_	_	I-Premise
210	cell	_	_	I-Premise
211	and	_	_	I-Premise
212	molecular	_	_	I-Premise
213	experiments	_	_	I-Premise
214	.	_	_	I-Premise

215	There	_	_	B-Claim
216	may	_	_	I-Claim
217	be	_	_	I-Claim
218	salutary	_	_	I-Claim
219	effects	_	_	I-Claim
220	of	_	_	I-Claim
221	incretin-based	_	_	I-Claim
222	treatments	_	_	I-Claim
223	on	_	_	I-Claim
224	the	_	_	I-Claim
225	diabetic	_	_	I-Claim
226	kidney	_	_	I-Claim
227	,	_	_	I-Claim
228	but	_	_	B-Claim
229	the	_	_	I-Claim
230	system	_	_	I-Claim
231	is	_	_	I-Claim
232	complex	_	_	I-Claim
233	and	_	_	I-Claim
234	not	_	_	I-Claim
235	amenable	_	_	I-Claim
236	to	_	_	I-Claim
237	simple	_	_	I-Claim
238	explanation	_	_	I-Claim
239	or	_	_	I-Claim
240	prior	_	_	I-Claim
241	prediction	_	_	I-Claim
242	.	_	_	I-Claim

243	This	_	_	B-Claim
244	contrasts	_	_	I-Claim
245	with	_	_	I-Claim
246	the	_	_	I-Claim
247	renal	_	_	I-Claim
248	effects	_	_	I-Claim
249	of	_	_	I-Claim
250	SGLT2	_	_	I-Claim
251	inhibitors	_	_	I-Claim
252	,	_	_	I-Claim
253	which	_	_	I-Claim
254	can	_	_	I-Claim
255	be	_	_	I-Claim
256	explained	_	_	I-Claim
257	concisely	_	_	I-Claim
258	.	_	_	I-Claim


1	To	_	_	O
2	compare	_	_	O
3	efficacy	_	_	O
4	(	_	_	O
5	intraocular	_	_	O
6	pressure	_	_	O
7	(	_	_	O
8	IOP	_	_	O
9	)	_	_	O
10	reduction	_	_	O
11	)	_	_	O
12	and	_	_	O
13	safety	_	_	O
14	of	_	_	O
15	preservative-free	_	_	O
16	latanoprost	_	_	O
17	(	_	_	O
18	T2345	_	_	O
19	)	_	_	O
20	to	_	_	O
21	benzalkonium	_	_	O
22	chloride	_	_	O
23	(	_	_	O
24	BAK	_	_	O
25	)	_	_	O
26	-preserved	_	_	O
27	latanoprost	_	_	O
28	(	_	_	O
29	BPL	_	_	O
30	;	_	_	O
31	Xalatan	_	_	O
32	)	_	_	O
33	in	_	_	O
34	ocular	_	_	O
35	hypertension	_	_	O
36	(	_	_	O
37	OHT	_	_	O
38	)	_	_	O
39	or	_	_	O
40	primary	_	_	O
41	open	_	_	O
42	angle	_	_	O
43	glaucoma	_	_	O
44	(	_	_	O
45	POAG	_	_	O
46	)	_	_	O
47	patients	_	_	O
48	.	_	_	O

49	Prospective	_	_	O
50	,	_	_	O
51	international	_	_	O
52	,	_	_	O
53	multicentre	_	_	O
54	,	_	_	O
55	randomised	_	_	O
56	,	_	_	O
57	investigator-masked	_	_	O
58	,	_	_	O
59	parallel-group	_	_	O
60	trial	_	_	O
61	.	_	_	O

62	After	_	_	O
63	a	_	_	O
64	wash-out	_	_	O
65	period	_	_	O
66	,	_	_	O
67	POAG	_	_	O
68	or	_	_	O
69	OHT	_	_	O
70	patients	_	_	O
71	,	_	_	O
72	previously	_	_	O
73	managed	_	_	O
74	by	_	_	O
75	BPL	_	_	O
76	monotherapy	_	_	O
77	,	_	_	O
78	randomly	_	_	O
79	received	_	_	O
80	T2345	_	_	O
81	or	_	_	O
82	BPL	_	_	O
83	(	_	_	O
84	one	_	_	O
85	drop	_	_	O
86	into	_	_	O
87	the	_	_	O
88	affected	_	_	O
89	eye	_	_	O
90	(	_	_	O
91	s	_	_	O
92	)	_	_	O
93	)	_	_	O
94	once	_	_	O
95	daily	_	_	O
96	from	_	_	O
97	D0	_	_	O
98	to	_	_	O
99	D84	_	_	O
100	.	_	_	O

101	Change	_	_	O
102	in	_	_	O
103	IOP	_	_	O
104	was	_	_	O
105	measured	_	_	O
106	at	_	_	O
107	09:00	_	_	O
108	(	_	_	O
109	±1	_	_	O
110	h	_	_	O
111	)	_	_	O
112	from	_	_	O
113	D0	_	_	O
114	to	_	_	O
115	D84	_	_	O
116	in	_	_	O
117	the	_	_	O
118	worse	_	_	O
119	eye	_	_	O
120	.	_	_	O

121	Mean	_	_	B-Premise
122	IOP	_	_	I-Premise
123	reduction	_	_	I-Premise
124	(	_	_	I-Premise
125	D0-D84	_	_	I-Premise
126	)	_	_	I-Premise
127	was	_	_	I-Premise
128	-8.6	_	_	I-Premise
129	±2.6	_	_	I-Premise
130	mm	_	_	I-Premise
131	Hg	_	_	I-Premise
132	(	_	_	I-Premise
133	-36	_	_	I-Premise
134	%	_	_	I-Premise
135	)	_	_	I-Premise
136	on	_	_	I-Premise
137	T2345	_	_	I-Premise
138	and	_	_	I-Premise
139	-9.0	_	_	I-Premise
140	±2.4	_	_	I-Premise
141	mm	_	_	I-Premise
142	Hg	_	_	I-Premise
143	(	_	_	I-Premise
144	-38	_	_	I-Premise
145	%	_	_	I-Premise
146	)	_	_	I-Premise
147	on	_	_	I-Premise
148	BPL	_	_	I-Premise
149	,	_	_	I-Premise
150	confirming	_	_	I-Premise
151	non-inferiority	_	_	I-Premise
152	of	_	_	I-Premise
153	T2345	_	_	I-Premise
154	to	_	_	I-Premise
155	BPL	_	_	I-Premise
156	.	_	_	I-Premise

157	Non-inferiority	_	_	O
158	of	_	_	O
159	T2345	_	_	O
160	was	_	_	O
161	observed	_	_	O
162	from	_	_	O
163	D15	_	_	O
164	.	_	_	O

165	The	_	_	B-Premise
166	most	_	_	I-Premise
167	frequent	_	_	I-Premise
168	ocular	_	_	I-Premise
169	adverse	_	_	I-Premise
170	event	_	_	I-Premise
171	,	_	_	I-Premise
172	drug	_	_	I-Premise
173	intolerance	_	_	I-Premise
174	,	_	_	I-Premise
175	was	_	_	I-Premise
176	reported	_	_	I-Premise
177	in	_	_	I-Premise
178	1	_	_	I-Premise
179	(	_	_	I-Premise
180	0.5	_	_	I-Premise
181	%	_	_	I-Premise
182	)	_	_	I-Premise
183	patient	_	_	I-Premise
184	on	_	_	I-Premise
185	T2345	_	_	I-Premise
186	versus	_	_	I-Premise
187	4	_	_	I-Premise
188	(	_	_	I-Premise
189	2.1	_	_	I-Premise
190	%	_	_	I-Premise
191	)	_	_	I-Premise
192	patients	_	_	I-Premise
193	on	_	_	I-Premise
194	BPL	_	_	I-Premise
195	.	_	_	I-Premise

196	Moderate	_	_	B-Premise
197	to	_	_	I-Premise
198	severe	_	_	I-Premise
199	conjunctival	_	_	I-Premise
200	hyperaemia	_	_	I-Premise
201	was	_	_	I-Premise
202	less	_	_	I-Premise
203	frequent	_	_	I-Premise
204	on	_	_	I-Premise
205	T2345	_	_	I-Premise
206	than	_	_	I-Premise
207	on	_	_	I-Premise
208	BPL	_	_	I-Premise
209	at	_	_	I-Premise
210	D42	_	_	I-Premise
211	(	_	_	I-Premise
212	20.2	_	_	I-Premise
213	%	_	_	I-Premise
214	vs	_	_	I-Premise
215	30.6	_	_	I-Premise
216	%	_	_	I-Premise
217	;	_	_	I-Premise
218	p=0.003	_	_	I-Premise
219	)	_	_	I-Premise
220	and	_	_	I-Premise
221	D84	_	_	I-Premise
222	(	_	_	I-Premise
223	21.4	_	_	I-Premise
224	%	_	_	I-Premise
225	vs	_	_	I-Premise
226	29.1	_	_	I-Premise
227	%	_	_	I-Premise
228	;	_	_	I-Premise
229	p=0.02	_	_	I-Premise
230	)	_	_	I-Premise
231	.	_	_	I-Premise

232	Upon	_	_	B-Premise
233	instillation	_	_	I-Premise
234	,	_	_	I-Premise
235	the	_	_	I-Premise
236	global	_	_	I-Premise
237	subjective	_	_	I-Premise
238	ocular	_	_	I-Premise
239	symptom	_	_	I-Premise
240	score	_	_	I-Premise
241	was	_	_	I-Premise
242	significantly	_	_	I-Premise
243	lower	_	_	I-Premise
244	on	_	_	I-Premise
245	T2345	_	_	I-Premise
246	than	_	_	I-Premise
247	BPL	_	_	I-Premise
248	on	_	_	I-Premise
249	D42	_	_	I-Premise
250	(	_	_	I-Premise
251	0.15	_	_	I-Premise
252	vs	_	_	I-Premise
253	0.41	_	_	I-Premise
254	;	_	_	I-Premise
255	p=0.001	_	_	I-Premise
256	)	_	_	I-Premise
257	and	_	_	I-Premise
258	D84	_	_	I-Premise
259	(	_	_	I-Premise
260	0.18	_	_	I-Premise
261	vs	_	_	I-Premise
262	0.46	_	_	I-Premise
263	;	_	_	I-Premise
264	p=0.001	_	_	I-Premise
265	)	_	_	I-Premise
266	.	_	_	I-Premise

267	Preservative-free	_	_	B-Claim
268	latanoprost	_	_	I-Claim
269	has	_	_	I-Claim
270	the	_	_	I-Claim
271	same	_	_	I-Claim
272	efficacy	_	_	I-Claim
273	as	_	_	I-Claim
274	BPL	_	_	I-Claim
275	,	_	_	I-Claim
276	with	_	_	I-Claim
277	improved	_	_	I-Claim
278	local	_	_	I-Claim
279	tolerance	_	_	I-Claim
280	.	_	_	I-Claim


0	Intradialytic	_	_	O
1	hypotension	_	_	O
2	(	_	_	O
3	IDH	_	_	O
4	)	_	_	O
5	is	_	_	O
6	an	_	_	O
7	important	_	_	O
8	cause	_	_	O
9	of	_	_	O
10	morbidity	_	_	O
11	and	_	_	O
12	mortality	_	_	O
13	among	_	_	O
14	hemodialysis	_	_	O
15	patients	_	_	O
16	.	_	_	O

17	We	_	_	O
18	used	_	_	O
19	an	_	_	O
20	immersion	_	_	O
21	model	_	_	O
22	to	_	_	O
23	evaluate	_	_	O
24	the	_	_	O
25	role	_	_	O
26	of	_	_	O
27	reduced	_	_	O
28	effective	_	_	O
29	circulating	_	_	O
30	volume	_	_	O
31	,	_	_	O
32	and	_	_	O
33	to	_	_	O
34	examine	_	_	O
35	whether	_	_	O
36	facilitated	_	_	O
37	refilling	_	_	O
38	can	_	_	O
39	prevent	_	_	O
40	IDH	_	_	O
41	.	_	_	O

42	Ten	_	_	O
43	male	_	_	O
44	hemodialysis	_	_	O
45	patients	_	_	O
46	who	_	_	O
47	had	_	_	O
48	frequent	_	_	O
49	episodes	_	_	O
50	of	_	_	O
51	IDH	_	_	O
52	were	_	_	O
53	randomized	_	_	O
54	to	_	_	O
55	a	_	_	O
56	mid-week	_	_	O
57	"	_	_	O
58	wet	_	_	O
59	"	_	_	O
60	or	_	_	O
61	"	_	_	O
62	dry	_	_	O
63	"	_	_	O
64	hemodialysis	_	_	O
65	session	_	_	O
66	,	_	_	O
67	and	_	_	O
68	subsequently	_	_	O
69	underwent	_	_	O
70	the	_	_	O
71	other	_	_	O
72	session	_	_	O
73	in	_	_	O
74	a	_	_	O
75	crossover	_	_	O
76	manner	_	_	O
77	.	_	_	O

78	The	_	_	O
79	wet	_	_	O
80	sessions	_	_	O
81	were	_	_	O
82	performed	_	_	O
83	while	_	_	O
84	immersed	_	_	O
85	up	_	_	O
86	to	_	_	O
87	the	_	_	O
88	neck	_	_	O
89	in	_	_	O
90	a	_	_	O
91	34	_	_	O
92	to	_	_	O
93	35°C	_	_	O
94	bath	_	_	O
95	,	_	_	O
96	and	_	_	O
97	the	_	_	O
98	dry	_	_	O
99	session	_	_	O
100	was	_	_	O
101	standard	_	_	O
102	hemodialysis	_	_	O
103	.	_	_	O

104	Ultrafiltration	_	_	O
105	goals	_	_	O
106	were	_	_	O
107	determined	_	_	O
108	as	_	_	O
109	the	_	_	O
110	mean	_	_	O
111	ultrafiltration	_	_	O
112	during	_	_	O
113	the	_	_	O
114	10	_	_	O
115	sessions	_	_	O
116	preceding	_	_	O
117	the	_	_	O
118	first	_	_	O
119	study	_	_	O
120	session	_	_	O
121	±	_	_	O
122	10	_	_	O
123	%	_	_	O
124	.	_	_	O

125	Mean	_	_	O
126	ultrafiltration	_	_	O
127	was	_	_	O
128	similar	_	_	O
129	for	_	_	O
130	the	_	_	O
131	wet	_	_	O
132	and	_	_	O
133	dry	_	_	O
134	sessions	_	_	O
135	(	_	_	O
136	2.99	_	_	O
137	±	_	_	O
138	0.64	_	_	O
139	kg	_	_	O
140	vs.	_	_	O
141	2.96	_	_	O
142	±	_	_	O
143	0.74	_	_	O
144	kg	_	_	O
145	)	_	_	O
146	.	_	_	O

147	Symptomatic	_	_	B-Premise
148	hypotension	_	_	I-Premise
149	did	_	_	I-Premise
150	not	_	_	I-Premise
151	develop	_	_	I-Premise
152	in	_	_	I-Premise
153	any	_	_	I-Premise
154	of	_	_	I-Premise
155	the	_	_	I-Premise
156	patients	_	_	I-Premise
157	during	_	_	I-Premise
158	the	_	_	I-Premise
159	wet	_	_	I-Premise
160	session	_	_	I-Premise
161	,	_	_	I-Premise
162	compared	_	_	I-Premise
163	to	_	_	I-Premise
164	4	_	_	I-Premise
165	(	_	_	I-Premise
166	40	_	_	I-Premise
167	%	_	_	I-Premise
168	)	_	_	I-Premise
169	during	_	_	I-Premise
170	the	_	_	I-Premise
171	dry	_	_	I-Premise
172	session	_	_	I-Premise
173	.	_	_	I-Premise

174	Systolic	_	_	B-Premise
175	blood	_	_	I-Premise
176	pressure	_	_	I-Premise
177	adjusted	_	_	I-Premise
178	to	_	_	I-Premise
179	ultrafiltration	_	_	I-Premise
180	was	_	_	I-Premise
181	stable	_	_	I-Premise
182	during	_	_	I-Premise
183	the	_	_	I-Premise
184	wet	_	_	I-Premise
185	session	_	_	I-Premise
186	,	_	_	I-Premise
187	0.22	_	_	I-Premise
188	mmHg/15	_	_	I-Premise
189	min	_	_	I-Premise
190	(	_	_	I-Premise
191	95	_	_	I-Premise
192	%	_	_	I-Premise
193	CI	_	_	I-Premise
194	-0.27	_	_	I-Premise
195	to	_	_	I-Premise
196	0.70	_	_	I-Premise
197	)	_	_	I-Premise
198	,	_	_	I-Premise
199	P	_	_	I-Premise
200	=	_	_	I-Premise
201	0.38	_	_	I-Premise
202	,	_	_	I-Premise
203	and	_	_	I-Premise
204	significantly	_	_	I-Premise
205	decreased	_	_	I-Premise
206	during	_	_	I-Premise
207	the	_	_	I-Premise
208	dry	_	_	I-Premise
209	session	_	_	I-Premise
210	,	_	_	I-Premise
211	-0.68	_	_	I-Premise
212	mmHg/15	_	_	I-Premise
213	min	_	_	I-Premise
214	(	_	_	I-Premise
215	95	_	_	I-Premise
216	%	_	_	I-Premise
217	CI	_	_	I-Premise
218	-1.24	_	_	I-Premise
219	to	_	_	I-Premise
220	-0.11	_	_	I-Premise
221	)	_	_	I-Premise
222	,	_	_	I-Premise
223	P	_	_	I-Premise
224	=	_	_	I-Premise
225	0.02	_	_	I-Premise
226	.	_	_	I-Premise

227	Diastolic	_	_	B-Premise
228	blood	_	_	I-Premise
229	pressure	_	_	I-Premise
230	did	_	_	I-Premise
231	not	_	_	I-Premise
232	change	_	_	I-Premise
233	during	_	_	I-Premise
234	the	_	_	I-Premise
235	sessions	_	_	I-Premise
236	.	_	_	I-Premise

237	Mean	_	_	B-Premise
238	atrial	_	_	I-Premise
239	natriuretic	_	_	I-Premise
240	peptide	_	_	I-Premise
241	significantly	_	_	I-Premise
242	increased	_	_	I-Premise
243	in	_	_	I-Premise
244	the	_	_	I-Premise
245	wet	_	_	I-Premise
246	session	_	_	I-Premise
247	,	_	_	I-Premise
248	by	_	_	I-Premise
249	31.36	_	_	I-Premise
250	pgr/mL	_	_	I-Premise
251	(	_	_	I-Premise
252	95	_	_	I-Premise
253	%	_	_	I-Premise
254	CI	_	_	I-Premise
255	8.73-53.99	_	_	I-Premise
256	)	_	_	I-Premise
257	,	_	_	I-Premise
258	P	_	_	I-Premise
259	=	_	_	I-Premise
260	0.007	_	_	I-Premise
261	,	_	_	I-Premise
262	and	_	_	I-Premise
263	slightly	_	_	I-Premise
264	and	_	_	I-Premise
265	insignificantly	_	_	I-Premise
266	decreased	_	_	I-Premise
267	in	_	_	I-Premise
268	the	_	_	I-Premise
269	dry	_	_	I-Premise
270	session	_	_	I-Premise
271	,	_	_	I-Premise
272	by	_	_	I-Premise
273	21.66	_	_	I-Premise
274	pgr/mL	_	_	I-Premise
275	(	_	_	I-Premise
276	95	_	_	I-Premise
277	%	_	_	I-Premise
278	CI	_	_	I-Premise
279	-52.59	_	_	I-Premise
280	to	_	_	I-Premise
281	9.25	_	_	I-Premise
282	)	_	_	I-Premise
283	,	_	_	I-Premise
284	P	_	_	I-Premise
285	=	_	_	I-Premise
286	0.167	_	_	I-Premise
287	.	_	_	I-Premise

288	Aldosterone	_	_	B-Premise
289	blood	_	_	I-Premise
290	levels	_	_	I-Premise
291	did	_	_	I-Premise
292	not	_	_	I-Premise
293	change	_	_	I-Premise
294	.	_	_	I-Premise

295	Reduced	_	_	B-Claim
296	effective	_	_	I-Claim
297	circulating	_	_	I-Claim
298	volume	_	_	I-Claim
299	is	_	_	I-Claim
300	a	_	_	I-Claim
301	major	_	_	I-Claim
302	cause	_	_	I-Claim
303	for	_	_	I-Claim
304	IDH	_	_	I-Claim
305	,	_	_	I-Claim
306	which	_	_	I-Claim
307	can	_	_	I-Claim
308	be	_	_	I-Claim
309	prevented	_	_	I-Claim
310	using	_	_	I-Claim
311	head-out	_	_	I-Claim
312	water	_	_	I-Claim
313	immersion	_	_	I-Claim
314	facilitated	_	_	I-Claim
315	redistribution	_	_	I-Claim
316	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	intraocular	_	_	O
3	pressure	_	_	O
4	(	_	_	O
5	IOP	_	_	O
6	)	_	_	O
7	over	_	_	O
8	time	_	_	O
9	after	_	_	O
10	standard	_	_	O
11	trabeculectomy	_	_	O
12	vs	_	_	O
13	Ex-PRESS	_	_	O
14	implantation	_	_	O
15	in	_	_	O
16	patients	_	_	O
17	with	_	_	O
18	bilateral	_	_	O
19	primary	_	_	O
20	open-angle	_	_	O
21	glaucoma	_	_	O
22	(	_	_	O
23	POAG	_	_	O
24	)	_	_	O
25	.	_	_	O

26	Prospective	_	_	O
27	,	_	_	O
28	randomised	_	_	O
29	study	_	_	O
30	.	_	_	O

31	This	_	_	O
32	study	_	_	O
33	included	_	_	O
34	adult	_	_	O
35	patients	_	_	O
36	with	_	_	O
37	bilateral	_	_	O
38	POAG	_	_	O
39	necessitating	_	_	O
40	surgery	_	_	O
41	.	_	_	O

42	Each	_	_	O
43	patient	_	_	O
44	underwent	_	_	O
45	trabeculectomy	_	_	O
46	in	_	_	O
47	one	_	_	O
48	eye	_	_	O
49	and	_	_	O
50	Ex-PRESS	_	_	O
51	implantation	_	_	O
52	under	_	_	O
53	a	_	_	O
54	scleral	_	_	O
55	flap	_	_	O
56	in	_	_	O
57	the	_	_	O
58	other	_	_	O
59	eye	_	_	O
60	according	_	_	O
61	to	_	_	O
62	randomised	_	_	O
63	contralateral	_	_	O
64	allocations	_	_	O
65	.	_	_	O

66	Efficacy	_	_	O
67	was	_	_	O
68	assessed	_	_	O
69	by	_	_	O
70	IOP	_	_	O
71	values	_	_	O
72	and	_	_	O
73	success	_	_	O
74	rates	_	_	O
75	(	_	_	O
76	IOP	_	_	O
77	threshold	_	_	O
78	and/or	_	_	O
79	need	_	_	O
80	for	_	_	O
81	topical	_	_	O
82	glaucoma	_	_	O
83	medication	_	_	O
84	)	_	_	O
85	during	_	_	O
86	30	_	_	O
87	months	_	_	O
88	.	_	_	O

89	Statistical	_	_	O
90	analysis	_	_	O
91	included	_	_	O
92	Generalised	_	_	O
93	Estimate	_	_	O
94	Equation	_	_	O
95	and	_	_	O
96	Cox	_	_	O
97	Survival	_	_	O
98	models	_	_	O
99	,	_	_	O
100	and	_	_	O
101	paired	_	_	O
102	t-tests	_	_	O
103	.	_	_	O

104	Thirty	_	_	O
105	eyes	_	_	O
106	of	_	_	O
107	15	_	_	O
108	patients	_	_	O
109	were	_	_	O
110	studied	_	_	O
111	for	_	_	O
112	a	_	_	O
113	mean	_	_	O
114	of	_	_	O
115	23.6	_	_	O
116	months	_	_	O
117	(	_	_	O
118	SD	_	_	O
119	,	_	_	O
120	±	_	_	O
121	6.9	_	_	O
122	)	_	_	O
123	.	_	_	O

124	At	_	_	B-Premise
125	the	_	_	I-Premise
126	last	_	_	I-Premise
127	follow-up	_	_	I-Premise
128	visit	_	_	I-Premise
129	,	_	_	I-Premise
130	mean	_	_	I-Premise
131	pre-operative	_	_	I-Premise
132	IOP	_	_	I-Premise
133	decreased	_	_	I-Premise
134	from	_	_	I-Premise
135	31.1	_	_	I-Premise
136	(	_	_	I-Premise
137	±	_	_	I-Premise
138	14.2	_	_	I-Premise
139	)	_	_	I-Premise
140	to	_	_	I-Premise
141	16.2	_	_	I-Premise
142	(	_	_	I-Premise
143	±	_	_	I-Premise
144	1.5	_	_	I-Premise
145	)	_	_	I-Premise
146	mm	_	_	I-Premise
147	Hg	_	_	I-Premise
148	after	_	_	I-Premise
149	trabeculectomy	_	_	I-Premise
150	,	_	_	I-Premise
151	and	_	_	I-Premise
152	from	_	_	I-Premise
153	28.1	_	_	I-Premise
154	(	_	_	I-Premise
155	±	_	_	I-Premise
156	9.0	_	_	I-Premise
157	)	_	_	I-Premise
158	to	_	_	I-Premise
159	15.7	_	_	I-Premise
160	(	_	_	I-Premise
161	±	_	_	I-Premise
162	1.8	_	_	I-Premise
163	)	_	_	I-Premise
164	mm	_	_	I-Premise
165	Hg	_	_	I-Premise
166	after	_	_	I-Premise
167	Ex-PRESS	_	_	I-Premise
168	implantation	_	_	I-Premise
169	(	_	_	I-Premise
170	P=0.001	_	_	I-Premise
171	)	_	_	I-Premise
172	.	_	_	I-Premise

173	The	_	_	B-Premise
174	mean	_	_	I-Premise
175	number	_	_	I-Premise
176	of	_	_	I-Premise
177	anti-glaucoma	_	_	I-Premise
178	medicines	_	_	I-Premise
179	prescribed	_	_	I-Premise
180	at	_	_	I-Premise
181	the	_	_	I-Premise
182	last	_	_	I-Premise
183	follow-up	_	_	I-Premise
184	decreased	_	_	I-Premise
185	from	_	_	I-Premise
186	3.7	_	_	I-Premise
187	pre-operatively	_	_	I-Premise
188	(	_	_	I-Premise
189	both	_	_	I-Premise
190	groups	_	_	I-Premise
191	)	_	_	I-Premise
192	to	_	_	I-Premise
193	0.9	_	_	I-Premise
194	after	_	_	I-Premise
195	trabeculectomy	_	_	I-Premise
196	vs	_	_	I-Premise
197	0.3	_	_	I-Premise
198	after	_	_	I-Premise
199	Ex-PRESS	_	_	I-Premise
200	implantation	_	_	I-Premise
201	(	_	_	I-Premise
202	P=0.001	_	_	I-Premise
203	)	_	_	I-Premise
204	.	_	_	I-Premise

205	Complete	_	_	B-Premise
206	success	_	_	I-Premise
207	rates	_	_	I-Premise
208	(	_	_	I-Premise
209	5	_	_	I-Premise
210	<	_	_	I-Premise
211	IOP	_	_	I-Premise
212	<	_	_	I-Premise
213	18	_	_	I-Premise
214	mm	_	_	I-Premise
215	Hg	_	_	I-Premise
216	without	_	_	I-Premise
217	medications	_	_	I-Premise
218	)	_	_	I-Premise
219	were	_	_	I-Premise
220	higher	_	_	I-Premise
221	with	_	_	I-Premise
222	Ex-PRESS	_	_	I-Premise
223	compared	_	_	I-Premise
224	with	_	_	I-Premise
225	trabeculectomy	_	_	I-Premise
226	(	_	_	I-Premise
227	P=0.0024	_	_	I-Premise
228	)	_	_	I-Premise
229	.	_	_	I-Premise

230	Postoperative	_	_	B-Premise
231	complications	_	_	I-Premise
232	were	_	_	I-Premise
233	more	_	_	I-Premise
234	frequent	_	_	I-Premise
235	after	_	_	I-Premise
236	trabeculectomy	_	_	I-Premise
237	(	_	_	I-Premise
238	33	_	_	I-Premise
239	%	_	_	I-Premise
240	)	_	_	I-Premise
241	compared	_	_	I-Premise
242	with	_	_	I-Premise
243	Ex-PRESS	_	_	I-Premise
244	(	_	_	I-Premise
245	20	_	_	I-Premise
246	%	_	_	I-Premise
247	)	_	_	I-Premise
248	,	_	_	I-Premise
249	with	_	_	I-Premise
250	four	_	_	I-Premise
251	trabeculectomy	_	_	I-Premise
252	eyes	_	_	I-Premise
253	(	_	_	I-Premise
254	27	_	_	I-Premise
255	%	_	_	I-Premise
256	)	_	_	I-Premise
257	needing	_	_	I-Premise
258	postoperative	_	_	I-Premise
259	interventions	_	_	I-Premise
260	,	_	_	I-Premise
261	compared	_	_	I-Premise
262	with	_	_	I-Premise
263	none	_	_	I-Premise
264	with	_	_	I-Premise
265	Ex-PRESS	_	_	I-Premise
266	.	_	_	I-Premise

267	Trabeculectomy	_	_	B-Claim
268	and	_	_	I-Claim
269	Ex-PRESS	_	_	I-Claim
270	implantation	_	_	I-Claim
271	provided	_	_	I-Claim
272	similar	_	_	I-Claim
273	IOP	_	_	I-Claim
274	control	_	_	I-Claim
275	,	_	_	I-Claim
276	but	_	_	O
277	the	_	_	B-Claim
278	Ex-PRESS	_	_	I-Claim
279	group	_	_	I-Claim
280	had	_	_	I-Claim
281	a	_	_	I-Claim
282	lower	_	_	I-Claim
283	rate	_	_	I-Claim
284	of	_	_	I-Claim
285	complications	_	_	I-Claim
286	,	_	_	I-Claim
287	fewer	_	_	I-Claim
288	postoperative	_	_	I-Claim
289	interventions	_	_	I-Claim
290	,	_	_	I-Claim
291	and	_	_	I-Claim
292	needed	_	_	I-Claim
293	less	_	_	I-Claim
294	glaucoma	_	_	I-Claim
295	medications	_	_	I-Claim
296	.	_	_	I-Claim


0	Sodium	_	_	B-Claim
1	nitrite	_	_	I-Claim
2	has	_	_	I-Claim
3	been	_	_	I-Claim
4	reported	_	_	I-Claim
5	to	_	_	I-Claim
6	be	_	_	I-Claim
7	effective	_	_	I-Claim
8	in	_	_	I-Claim
9	reducing	_	_	I-Claim
10	chronic	_	_	I-Claim
11	peripheral	_	_	I-Claim
12	pain	_	_	I-Claim
13	.	_	_	I-Claim

14	To	_	_	O
15	evaluate	_	_	O
16	the	_	_	O
17	safety	_	_	O
18	and	_	_	O
19	efficacy	_	_	O
20	of	_	_	O
21	40	_	_	O
22	and	_	_	O
23	80	_	_	O
24	mg	_	_	O
25	,	_	_	O
26	BID	_	_	O
27	,	_	_	O
28	of	_	_	O
29	an	_	_	O
30	oral	_	_	O
31	sustained	_	_	O
32	release	_	_	O
33	formulation	_	_	O
34	of	_	_	O
35	sodium	_	_	O
36	nitrite	_	_	O
37	(	_	_	O
38	SR-nitrite	_	_	O
39	)	_	_	O
40	in	_	_	O
41	patients	_	_	O
42	suffering	_	_	O
43	from	_	_	O
44	diabetic	_	_	O
45	neuropathy	_	_	O
46	,	_	_	O
47	and	_	_	O
48	to	_	_	O
49	determine	_	_	O
50	whether	_	_	O
51	SR-nitrite	_	_	O
52	would	_	_	O
53	reduce	_	_	O
54	the	_	_	O
55	frequency	_	_	O
56	of	_	_	O
57	headaches	_	_	O
58	reported	_	_	O
59	previously	_	_	O
60	by	_	_	O
61	subjects	_	_	O
62	receiving	_	_	O
63	the	_	_	O
64	same	_	_	O
65	doses	_	_	O
66	of	_	_	O
67	an	_	_	O
68	immediate	_	_	O
69	release	_	_	O
70	formulation	_	_	O
71	.	_	_	O

72	Phase	_	_	O
73	II	_	_	O
74	,	_	_	O
75	single-center	_	_	O
76	,	_	_	O
77	randomized	_	_	O
78	,	_	_	O
79	double-blind	_	_	O
80	,	_	_	O
81	placebo	_	_	O
82	controlled	_	_	O
83	clinical	_	_	O
84	trial	_	_	O
85	.	_	_	O

86	Twenty-four	_	_	O
87	patients	_	_	O
88	were	_	_	O
89	randomized	_	_	O
90	to	_	_	O
91	40	_	_	O
92	mg	_	_	O
93	or	_	_	O
94	80	_	_	O
95	mg	_	_	O
96	SR-nitrite	_	_	O
97	or	_	_	O
98	placebo	_	_	O
99	twice	_	_	O
100	daily	_	_	O
101	for	_	_	O
102	12	_	_	O
103	weeks	_	_	O
104	.	_	_	O

105	The	_	_	O
106	primary	_	_	O
107	objective	_	_	O
108	was	_	_	O
109	to	_	_	O
110	determine	_	_	O
111	whether	_	_	O
112	headaches	_	_	O
113	would	_	_	O
114	be	_	_	O
115	reduced	_	_	O
116	using	_	_	O
117	SR-nitrite	_	_	O
118	.	_	_	O

119	The	_	_	O
120	primary	_	_	O
121	efficacy	_	_	O
122	endpoint	_	_	O
123	was	_	_	O
124	the	_	_	O
125	mean	_	_	O
126	difference	_	_	O
127	in	_	_	O
128	the	_	_	O
129	change	_	_	O
130	of	_	_	O
131	the	_	_	O
132	Neuropathic	_	_	O
133	Pain	_	_	O
134	Symptom	_	_	O
135	Inventory	_	_	O
136	(	_	_	O
137	NPSI	_	_	O
138	)	_	_	O
139	pain	_	_	O
140	score	_	_	O
141	from	_	_	O
142	baseline	_	_	O
143	to	_	_	O
144	that	_	_	O
145	reported	_	_	O
146	after	_	_	O
147	12	_	_	O
148	weeks	_	_	O
149	of	_	_	O
150	treatment	_	_	O
151	.	_	_	O

152	Secondary	_	_	O
153	endpoints	_	_	O
154	included	_	_	O
155	changes	_	_	O
156	from	_	_	O
157	baseline	_	_	O
158	for	_	_	O
159	the	_	_	O
160	Brief	_	_	O
161	Pain	_	_	O
162	Inventory	_	_	O
163	(	_	_	O
164	BPI	_	_	O
165	)	_	_	O
166	Scale	_	_	O
167	,	_	_	O
168	the	_	_	O
169	RAND	_	_	O
170	36	_	_	O
171	questionnaire	_	_	O
172	,	_	_	O
173	Short	_	_	O
174	Form	_	_	O
175	McGill	_	_	O
176	Questionnaire	_	_	O
177	,	_	_	O
178	daily	_	_	O
179	patient	_	_	O
180	reported	_	_	O
181	score	_	_	O
182	for	_	_	O
183	neuropathic	_	_	O
184	pain	_	_	O
185	,	_	_	O
186	changes	_	_	O
187	in	_	_	O
188	HbA1c	_	_	O
189	,	_	_	O
190	PulseOx	_	_	O
191	and	_	_	O
192	quantitative	_	_	O
193	sensory	_	_	O
194	testing	_	_	O
195	.	_	_	O

196	The	_	_	B-Premise
197	number	_	_	I-Premise
198	of	_	_	I-Premise
199	subjects	_	_	I-Premise
200	reporting	_	_	I-Premise
201	adverse	_	_	I-Premise
202	events	_	_	I-Premise
203	and	_	_	I-Premise
204	the	_	_	I-Premise
205	number	_	_	I-Premise
206	of	_	_	I-Premise
207	adverse	_	_	I-Premise
208	events	_	_	I-Premise
209	did	_	_	I-Premise
210	not	_	_	I-Premise
211	change	_	_	I-Premise
212	with	_	_	I-Premise
213	dose	_	_	I-Premise
214	.	_	_	I-Premise

215	There	_	_	B-Premise
216	were	_	_	I-Premise
217	no	_	_	I-Premise
218	reports	_	_	I-Premise
219	of	_	_	I-Premise
220	treatment-related	_	_	I-Premise
221	headaches	_	_	I-Premise
222	.	_	_	I-Premise

223	Although	_	_	O
224	no	_	_	O
225	significant	_	_	O
226	differences	_	_	O
227	were	_	_	O
228	identified	_	_	O
229	in	_	_	O
230	patient	_	_	O
231	responses	_	_	O
232	to	_	_	O
233	the	_	_	O
234	questionnaires	_	_	O
235	,	_	_	O
236	a	_	_	O
237	trend	_	_	O
238	was	_	_	O
239	observed	_	_	O
240	.	_	_	O

241	In	_	_	B-Premise
242	the	_	_	I-Premise
243	NPSI	_	_	I-Premise
244	assessment	_	_	I-Premise
245	,	_	_	I-Premise
246	patients	_	_	I-Premise
247	in	_	_	I-Premise
248	the	_	_	I-Premise
249	40	_	_	I-Premise
250	mg	_	_	I-Premise
251	and	_	_	I-Premise
252	80	_	_	I-Premise
253	mg	_	_	I-Premise
254	dose	_	_	I-Premise
255	group	_	_	I-Premise
256	reported	_	_	I-Premise
257	a	_	_	I-Premise
258	12.7	_	_	I-Premise
259	%	_	_	I-Premise
260	and	_	_	I-Premise
261	22.0	_	_	I-Premise
262	%	_	_	I-Premise
263	reduction	_	_	I-Premise
264	in	_	_	I-Premise
265	pain	_	_	I-Premise
266	,	_	_	I-Premise
267	respectively	_	_	I-Premise
268	,	_	_	I-Premise
269	compared	_	_	I-Premise
270	to	_	_	I-Premise
271	an	_	_	I-Premise
272	8.4	_	_	I-Premise
273	%	_	_	I-Premise
274	reduction	_	_	I-Premise
275	by	_	_	I-Premise
276	patients	_	_	I-Premise
277	in	_	_	I-Premise
278	the	_	_	I-Premise
279	placebo	_	_	I-Premise
280	group	_	_	I-Premise
281	.	_	_	I-Premise

282	A	_	_	O
283	trend	_	_	O
284	was	_	_	O
285	also	_	_	O
286	observed	_	_	O
287	with	_	_	O
288	the	_	_	O
289	BPI	_	_	O
290	total	_	_	O
291	severity	_	_	O
292	score	_	_	O
293	.	_	_	O

294	However	_	_	O
295	,	_	_	O
296	the	_	_	B-Premise
297	40	_	_	I-Premise
298	mg	_	_	I-Premise
299	dosing	_	_	I-Premise
300	group	_	_	I-Premise
301	reported	_	_	I-Premise
302	the	_	_	I-Premise
303	greatest	_	_	I-Premise
304	reduction	_	_	I-Premise
305	in	_	_	I-Premise
306	pain	_	_	I-Premise
307	using	_	_	I-Premise
308	the	_	_	I-Premise
309	McGill	_	_	I-Premise
310	Pain	_	_	I-Premise
311	index	_	_	I-Premise
312	and	_	_	I-Premise
313	via	_	_	I-Premise
314	patient	_	_	I-Premise
315	logs	_	_	I-Premise
316	of	_	_	I-Premise
317	daily	_	_	I-Premise
318	pain	_	_	I-Premise
319	scores	_	_	I-Premise
320	,	_	_	I-Premise
321	where	_	_	O
322	the	_	_	B-Premise
323	mean	_	_	I-Premise
324	of	_	_	I-Premise
325	pain	_	_	I-Premise
326	scores	_	_	I-Premise
327	reported	_	_	I-Premise
328	by	_	_	I-Premise
329	subjects	_	_	I-Premise
330	in	_	_	I-Premise
331	the	_	_	I-Premise
332	40	_	_	I-Premise
333	mg	_	_	I-Premise
334	group	_	_	I-Premise
335	dropped	_	_	I-Premise
336	by	_	_	I-Premise
337	day	_	_	I-Premise
338	41	_	_	I-Premise
339	and	_	_	I-Premise
340	generally	_	_	I-Premise
341	stayed	_	_	I-Premise
342	lower	_	_	I-Premise
343	than	_	_	I-Premise
344	the	_	_	I-Premise
345	mean	_	_	I-Premise
346	of	_	_	I-Premise
347	scores	_	_	I-Premise
348	reported	_	_	I-Premise
349	by	_	_	I-Premise
350	subjects	_	_	I-Premise
351	in	_	_	I-Premise
352	either	_	_	I-Premise
353	of	_	_	I-Premise
354	the	_	_	I-Premise
355	other	_	_	I-Premise
356	two	_	_	I-Premise
357	groups	_	_	I-Premise
358	.	_	_	I-Premise

359	Patients	_	_	B-Premise
360	in	_	_	I-Premise
361	the	_	_	I-Premise
362	80	_	_	I-Premise
363	mg	_	_	I-Premise
364	SR-nitrite	_	_	I-Premise
365	group	_	_	I-Premise
366	had	_	_	I-Premise
367	an	_	_	I-Premise
368	improvement	_	_	I-Premise
369	in	_	_	I-Premise
370	both	_	_	I-Premise
371	Nerve	_	_	I-Premise
372	Sensory	_	_	I-Premise
373	Conductance	_	_	I-Premise
374	and	_	_	I-Premise
375	Nerve	_	_	I-Premise
376	Sensory	_	_	I-Premise
377	Velocity	_	_	I-Premise
378	.	_	_	I-Premise

379	No	_	_	B-Premise
380	changes	_	_	I-Premise
381	were	_	_	I-Premise
382	observed	_	_	I-Premise
383	in	_	_	I-Premise
384	HbA1c	_	_	I-Premise
385	levels	_	_	I-Premise
386	or	_	_	I-Premise
387	PulseOx	_	_	I-Premise
388	.	_	_	I-Premise

389	Sustained	_	_	B-Claim
390	release	_	_	I-Claim
391	sodium	_	_	I-Claim
392	nitrite	_	_	I-Claim
393	prevents	_	_	I-Claim
394	the	_	_	I-Claim
395	prevalent	_	_	I-Claim
396	reports	_	_	I-Claim
397	of	_	_	I-Claim
398	headaches	_	_	I-Claim
399	by	_	_	I-Claim
400	patients	_	_	I-Claim
401	treated	_	_	I-Claim
402	with	_	_	I-Claim
403	an	_	_	I-Claim
404	immediate	_	_	I-Claim
405	release	_	_	I-Claim
406	formulation	_	_	I-Claim
407	of	_	_	I-Claim
408	sodium	_	_	I-Claim
409	nitrite	_	_	I-Claim
410	.	_	_	I-Claim

411	In	_	_	B-Premise
412	a	_	_	I-Premise
413	previous	_	_	I-Premise
414	study	_	_	I-Premise
415	of	_	_	I-Premise
416	patients	_	_	I-Premise
417	with	_	_	I-Premise
418	peripheral	_	_	I-Premise
419	arterial	_	_	I-Premise
420	disease	_	_	I-Premise
421	(	_	_	I-Premise
422	PAD	_	_	I-Premise
423	)	_	_	I-Premise
424	,	_	_	I-Premise
425	40	_	_	I-Premise
426	mg	_	_	I-Premise
427	BID	_	_	I-Premise
428	treatment	_	_	I-Premise
429	led	_	_	I-Premise
430	to	_	_	I-Premise
431	a	_	_	I-Premise
432	statistically	_	_	I-Premise
433	significant	_	_	I-Premise
434	reduction	_	_	I-Premise
435	in	_	_	I-Premise
436	reported	_	_	I-Premise
437	pain	_	_	I-Premise
438	,	_	_	I-Premise
439	similar	_	_	I-Premise
440	trends	_	_	I-Premise
441	were	_	_	I-Premise
442	observed	_	_	I-Premise
443	at	_	_	I-Premise
444	the	_	_	I-Premise
445	end	_	_	I-Premise
446	of	_	_	I-Premise
447	the	_	_	I-Premise
448	trial	_	_	I-Premise
449	period	_	_	I-Premise
450	for	_	_	I-Premise
451	most	_	_	I-Premise
452	of	_	_	I-Premise
453	the	_	_	I-Premise
454	pain	_	_	I-Premise
455	questionnaires	_	_	I-Premise
456	used	_	_	I-Premise
457	in	_	_	I-Premise
458	the	_	_	I-Premise
459	study	_	_	I-Premise
460	.	_	_	I-Premise

461	The	_	_	B-Premise
462	80	_	_	I-Premise
463	mg	_	_	I-Premise
464	BID	_	_	I-Premise
465	treatment	_	_	I-Premise
466	had	_	_	I-Premise
467	the	_	_	I-Premise
468	more	_	_	I-Premise
469	pronounced	_	_	I-Premise
470	affect	_	_	I-Premise
471	on	_	_	I-Premise
472	bioactivity	_	_	I-Premise
473	(	_	_	I-Premise
474	quantitative	_	_	I-Premise
475	sensory	_	_	I-Premise
476	testing	_	_	I-Premise
477	)	_	_	I-Premise
478	,	_	_	I-Premise
479	which	_	_	I-Premise
480	was	_	_	I-Premise
481	similar	_	_	I-Premise
482	to	_	_	I-Premise
483	the	_	_	I-Premise
484	PAD	_	_	I-Premise
485	study	_	_	I-Premise
486	,	_	_	I-Premise
487	where	_	_	I-Premise
488	this	_	_	I-Premise
489	dose	_	_	I-Premise
490	group	_	_	I-Premise
491	had	_	_	I-Premise
492	the	_	_	I-Premise
493	greatest	_	_	I-Premise
494	improvement	_	_	I-Premise
495	in	_	_	I-Premise
496	FMD	_	_	I-Premise
497	{	_	_	I-Premise
498	AU	_	_	I-Premise
499	:	_	_	I-Premise
500	spell	_	_	I-Premise
501	out	_	_	I-Premise
502	FMD	_	_	I-Premise
503	}	_	_	I-Premise
504	.	_	_	I-Premise

505	The	_	_	B-Claim
506	ability	_	_	I-Claim
507	to	_	_	I-Claim
508	alleviate	_	_	I-Claim
509	pain	_	_	I-Claim
510	with	_	_	I-Claim
511	BID	_	_	I-Claim
512	treatment	_	_	I-Claim
513	of	_	_	I-Claim
514	SR-nitrite	_	_	I-Claim
515	offers	_	_	I-Claim
516	promise	_	_	I-Claim
517	for	_	_	I-Claim
518	a	_	_	I-Claim
519	new	_	_	I-Claim
520	non-addictive	_	_	I-Claim
521	,	_	_	I-Claim
522	non-sedating	_	_	I-Claim
523	treatment	_	_	I-Claim
524	of	_	_	I-Claim
525	chronic	_	_	I-Claim
526	pain	_	_	I-Claim
527	and	_	_	I-Claim
528	warrants	_	_	I-Claim
529	further	_	_	I-Claim
530	study	_	_	I-Claim
531	.	_	_	I-Claim


0	We	_	_	O
1	investigated	_	_	O
2	the	_	_	O
3	effects	_	_	O
4	of	_	_	O
5	high-Ca	_	_	O
6	fat-free	_	_	O
7	milk	_	_	O
8	phase	_	_	O
9	(	_	_	O
10	MD	_	_	O
11	)	_	_	O
12	(	_	_	O
13	prescription	_	_	O
14	of	_	_	O
15	approximately	_	_	O
16	1500	_	_	O
17	mg	_	_	O
18	of	_	_	O
19	Ca/d	_	_	O
20	)	_	_	O
21	v.	_	_	O
22	low-Ca	_	_	O
23	phase	_	_	O
24	(	_	_	O
25	CD	_	_	O
26	)	_	_	O
27	(	_	_	O
28	prescription	_	_	O
29	of	_	_	O
30	approximately	_	_	O
31	800	_	_	O
32	mg	_	_	O
33	of	_	_	O
34	Ca/d	_	_	O
35	)	_	_	O
36	in	_	_	O
37	an	_	_	O
38	energy-restricted	_	_	O
39	diet	_	_	O
40	on	_	_	O
41	the	_	_	O
42	metabolic	_	_	O
43	syndrome	_	_	O
44	(	_	_	O
45	MetS	_	_	O
46	)	_	_	O
47	and	_	_	O
48	cardiometabolic	_	_	O
49	measures	_	_	O
50	in	_	_	O
51	individuals	_	_	O
52	with	_	_	O
53	type	_	_	O
54	2	_	_	O
55	diabetes	_	_	O
56	mellitus	_	_	O
57	(	_	_	O
58	T2DM	_	_	O
59	)	_	_	O
60	and	_	_	O
61	low	_	_	O
62	habitual	_	_	O
63	Ca	_	_	O
64	consumption	_	_	O
65	(	_	_	O
66	<	_	_	O
67	600	_	_	O
68	mg/d	_	_	O
69	)	_	_	O
70	.	_	_	O

71	In	_	_	O
72	this	_	_	O
73	randomised	_	_	O
74	cross-over	_	_	O
75	design	_	_	O
76	,	_	_	O
77	fourteen	_	_	O
78	adults	_	_	O
79	with	_	_	O
80	T2DM	_	_	O
81	(	_	_	O
82	49·5	_	_	O
83	(	_	_	O
84	sd	_	_	O
85	8·6	_	_	O
86	)	_	_	O
87	years	_	_	O
88	,	_	_	O
89	BMI	_	_	O
90	29·4	_	_	O
91	(	_	_	O
92	sd	_	_	O
93	4·5	_	_	O
94	)	_	_	O
95	kg/m2	_	_	O
96	)	_	_	O
97	consumed	_	_	O
98	either	_	_	O
99	MD	_	_	O
100	or	_	_	O
101	CD	_	_	O
102	for	_	_	O
103	12	_	_	O
104	weeks	_	_	O
105	,	_	_	O
106	with	_	_	O
107	a	_	_	O
108	washout	_	_	O
109	of	_	_	O
110	18	_	_	O
111	weeks	_	_	O
112	between	_	_	O
113	phases	_	_	O
114	.	_	_	O

115	A	_	_	O
116	breakfast	_	_	O
117	shake	_	_	O
118	containing	_	_	O
119	700	_	_	O
120	mg	_	_	O
121	(	_	_	O
122	MD	_	_	O
123	)	_	_	O
124	or	_	_	O
125	6·4	_	_	O
126	mg	_	_	O
127	(	_	_	O
128	CD	_	_	O
129	)	_	_	O
130	of	_	_	O
131	Ca	_	_	O
132	was	_	_	O
133	consumed	_	_	O
134	in	_	_	O
135	the	_	_	O
136	laboratory	_	_	O
137	.	_	_	O

138	In	_	_	O
139	addition	_	_	O
140	,	_	_	O
141	energy-restricted	_	_	O
142	diets	_	_	O
143	were	_	_	O
144	prescribed	_	_	O
145	(	_	_	O
146	800	_	_	O
147	mg	_	_	O
148	of	_	_	O
149	dietary	_	_	O
150	Ca/d	_	_	O
151	)	_	_	O
152	.	_	_	O

153	Waist	_	_	O
154	circumference	_	_	O
155	(	_	_	O
156	WC	_	_	O
157	)	_	_	O
158	,	_	_	O
159	fasting	_	_	O
160	glucose	_	_	O
161	,	_	_	O
162	fasting	_	_	O
163	TAG	_	_	O
164	,	_	_	O
165	systolic	_	_	O
166	(	_	_	O
167	SBP	_	_	O
168	)	_	_	O
169	and	_	_	O
170	diastolic	_	_	O
171	blood	_	_	O
172	pressure	_	_	O
173	(	_	_	O
174	DBP	_	_	O
175	)	_	_	O
176	,	_	_	O
177	fasting	_	_	O
178	total	_	_	O
179	cholesterol	_	_	O
180	,	_	_	O
181	fasting	_	_	O
182	LDL-cholesterol	_	_	O
183	,	_	_	O
184	fasting	_	_	O
185	HDL-cholesterol	_	_	O
186	,	_	_	O
187	HDL	_	_	O
188	:	_	_	O
189	LDL	_	_	O
190	ratio	_	_	O
191	,	_	_	O
192	HDL	_	_	O
193	:	_	_	O
194	TAG	_	_	O
195	ratio	_	_	O
196	and	_	_	O
197	lipid	_	_	O
198	accumulation	_	_	O
199	product	_	_	O
200	(	_	_	O
201	LAP	_	_	O
202	)	_	_	O
203	index	_	_	O
204	were	_	_	O
205	assessed	_	_	O
206	at	_	_	O
207	baseline	_	_	O
208	and	_	_	O
209	after	_	_	O
210	each	_	_	O
211	phase	_	_	O
212	.	_	_	O

213	Ca	_	_	B-Premise
214	consumption	_	_	I-Premise
215	during	_	_	I-Premise
216	the	_	_	I-Premise
217	study	_	_	I-Premise
218	was	_	_	I-Premise
219	equivalent	_	_	I-Premise
220	to	_	_	I-Premise
221	1200	_	_	I-Premise
222	mg/d	_	_	I-Premise
223	during	_	_	I-Premise
224	MD	_	_	I-Premise
225	and	_	_	I-Premise
226	525	_	_	I-Premise
227	mg/d	_	_	I-Premise
228	during	_	_	I-Premise
229	CD	_	_	I-Premise
230	.	_	_	I-Premise

231	There	_	_	B-Premise
232	was	_	_	I-Premise
233	a	_	_	I-Premise
234	greater	_	_	I-Premise
235	reduction	_	_	I-Premise
236	in	_	_	I-Premise
237	WC	_	_	I-Premise
238	,	_	_	I-Premise
239	SBP	_	_	I-Premise
240	,	_	_	I-Premise
241	DBP	_	_	I-Premise
242	and	_	_	I-Premise
243	LAP	_	_	I-Premise
244	index	_	_	I-Premise
245	after	_	_	I-Premise
246	MD	_	_	I-Premise
247	compared	_	_	I-Premise
248	with	_	_	I-Premise
249	CD	_	_	I-Premise
250	.	_	_	I-Premise

251	HDL	_	_	B-Premise
252	:	_	_	I-Premise
253	LDL	_	_	I-Premise
254	ratio	_	_	I-Premise
255	increased	_	_	I-Premise
256	and	_	_	I-Premise
257	total	_	_	I-Premise
258	cholesterol	_	_	I-Premise
259	,	_	_	I-Premise
260	LDL-cholesterol	_	_	I-Premise
261	,	_	_	I-Premise
262	SBP	_	_	I-Premise
263	,	_	_	I-Premise
264	DBP	_	_	I-Premise
265	and	_	_	I-Premise
266	LAP	_	_	I-Premise
267	index	_	_	I-Premise
268	decreased	_	_	I-Premise
269	only	_	_	I-Premise
270	in	_	_	I-Premise
271	MD	_	_	I-Premise
272	.	_	_	I-Premise

273	The	_	_	B-Premise
274	consumption	_	_	I-Premise
275	of	_	_	I-Premise
276	approximately	_	_	I-Premise
277	1200	_	_	I-Premise
278	mg	_	_	I-Premise
279	of	_	_	I-Premise
280	Ca/d	_	_	I-Premise
281	(	_	_	I-Premise
282	700	_	_	I-Premise
283	mg	_	_	I-Premise
284	from	_	_	I-Premise
285	fat-free	_	_	I-Premise
286	milk+500mg	_	_	I-Premise
287	from	_	_	I-Premise
288	other	_	_	I-Premise
289	dietary	_	_	I-Premise
290	sources	_	_	I-Premise
291	)	_	_	I-Premise
292	associated	_	_	I-Premise
293	with	_	_	I-Premise
294	an	_	_	I-Premise
295	energy-restricted	_	_	I-Premise
296	diet	_	_	I-Premise
297	decreased	_	_	I-Premise
298	some	_	_	I-Premise
299	of	_	_	I-Premise
300	the	_	_	I-Premise
301	MetS	_	_	I-Premise
302	components	_	_	I-Premise
303	and	_	_	I-Premise
304	cardiometabolic	_	_	I-Premise
305	measures	_	_	I-Premise
306	in	_	_	I-Premise
307	adults	_	_	I-Premise
308	with	_	_	I-Premise
309	T2DM	_	_	I-Premise
310	.	_	_	I-Premise


0	This	_	_	O
1	study	_	_	O
2	aimed	_	_	O
3	to	_	_	O
4	propose	_	_	O
5	the	_	_	O
6	role	_	_	O
7	of	_	_	O
8	amniotic	_	_	O
9	membrane	_	_	O
10	transplantation	_	_	O
11	(	_	_	O
12	AMT	_	_	O
13	)	_	_	O
14	as	_	_	O
15	an	_	_	O
16	additional	_	_	O
17	modulator	_	_	O
18	in	_	_	O
19	primary	_	_	O
20	Mitomycin	_	_	O
21	C	_	_	O
22	(	_	_	O
23	MMC	_	_	O
24	)	_	_	O
25	-augmented	_	_	O
26	trabeculectomy	_	_	O
27	.	_	_	O

28	This	_	_	O
29	was	_	_	O
30	a	_	_	O
31	randomized	_	_	O
32	prospective	_	_	O
33	interventional	_	_	O
34	study	_	_	O
35	.	_	_	O

36	Forty	_	_	O
37	eyes	_	_	O
38	of	_	_	O
39	39	_	_	O
40	adult	_	_	O
41	patients	_	_	O
42	with	_	_	O
43	uncontrolled	_	_	O
44	primary	_	_	O
45	glaucoma	_	_	O
46	were	_	_	O
47	randomly	_	_	O
48	divided	_	_	O
49	into	_	_	O
50	two	_	_	O
51	equal	_	_	O
52	groups	_	_	O
53	.	_	_	O

54	Control	_	_	O
55	group	_	_	O
56	underwent	_	_	O
57	trabeculectomy	_	_	O
58	augmented	_	_	O
59	with	_	_	O
60	MMC	_	_	O
61	while	_	_	O
62	the	_	_	O
63	study	_	_	O
64	group	_	_	O
65	underwent	_	_	O
66	additional	_	_	O
67	AMT	_	_	O
68	.	_	_	O

69	Patients	_	_	O
70	were	_	_	O
71	followed	_	_	O
72	up	_	_	O
73	for	_	_	O
74	12	_	_	O
75	months	_	_	O
76	and	_	_	O
77	outcomes	_	_	O
78	measured	_	_	O
79	were	_	_	O
80	intraocular	_	_	O
81	pressure	_	_	O
82	(	_	_	O
83	IOP	_	_	O
84	)	_	_	O
85	,	_	_	O
86	need	_	_	O
87	for	_	_	O
88	additional	_	_	O
89	intervention	_	_	O
90	,	_	_	O
91	and	_	_	O
92	bleb	_	_	O
93	morphology	_	_	O
94	.	_	_	O

95	Complete	_	_	B-Premise
96	success	_	_	I-Premise
97	(	_	_	I-Premise
98	defined	_	_	I-Premise
99	as	_	_	I-Premise
100	IOP	_	_	I-Premise
101	<	_	_	I-Premise
102	16	_	_	I-Premise
103	mmHg	_	_	I-Premise
104	on	_	_	I-Premise
105	no	_	_	I-Premise
106	medication	_	_	I-Premise
107	)	_	_	I-Premise
108	could	_	_	I-Premise
109	be	_	_	I-Premise
110	achieved	_	_	I-Premise
111	in	_	_	I-Premise
112	85	_	_	I-Premise
113	%	_	_	I-Premise
114	eyes	_	_	I-Premise
115	in	_	_	I-Premise
116	study	_	_	I-Premise
117	group	_	_	I-Premise
118	while	_	_	I-Premise
119	it	_	_	I-Premise
120	was	_	_	I-Premise
121	60	_	_	I-Premise
122	%	_	_	I-Premise
123	in	_	_	I-Premise
124	control	_	_	I-Premise
125	group	_	_	I-Premise
126	(	_	_	I-Premise
127	P	_	_	I-Premise
128	=	_	_	I-Premise
129	0.04	_	_	I-Premise
130	)	_	_	I-Premise
131	.	_	_	I-Premise

132	IOP	_	_	B-Premise
133	reduced	_	_	I-Premise
134	by	_	_	I-Premise
135	71.1	_	_	I-Premise
136	%	_	_	I-Premise
137	in	_	_	I-Premise
138	study	_	_	I-Premise
139	group	_	_	I-Premise
140	from	_	_	I-Premise
141	41.9	_	_	I-Premise
142	±	_	_	I-Premise
143	10.6	_	_	I-Premise
144	to	_	_	I-Premise
145	12.1	_	_	I-Premise
146	±	_	_	I-Premise
147	2.7	_	_	I-Premise
148	mmHg	_	_	I-Premise
149	and	_	_	I-Premise
150	from	_	_	I-Premise
151	40.5	_	_	I-Premise
152	±	_	_	I-Premise
153	8.5	_	_	I-Premise
154	to	_	_	I-Premise
155	12.8	_	_	I-Premise
156	±	_	_	I-Premise
157	4.5	_	_	I-Premise
158	mmHg	_	_	I-Premise
159	in	_	_	I-Premise
160	control	_	_	I-Premise
161	group	_	_	I-Premise
162	,	_	_	I-Premise
163	a	_	_	I-Premise
164	decline	_	_	I-Premise
165	of	_	_	I-Premise
166	68.29	_	_	I-Premise
167	%	_	_	I-Premise
168	.	_	_	I-Premise

169	Blebs	_	_	B-Premise
170	in	_	_	I-Premise
171	AMT	_	_	I-Premise
172	group	_	_	I-Premise
173	showed	_	_	I-Premise
174	better	_	_	I-Premise
175	bleb	_	_	I-Premise
176	morphology	_	_	I-Premise
177	in	_	_	I-Premise
178	terms	_	_	I-Premise
179	of	_	_	I-Premise
180	significantly	_	_	I-Premise
181	better	_	_	I-Premise
182	extent	_	_	I-Premise
183	(	_	_	I-Premise
184	E3	_	_	I-Premise
185	)	_	_	I-Premise
186	on	_	_	I-Premise
187	day	_	_	I-Premise
188	1	_	_	I-Premise
189	(	_	_	I-Premise
190	P	_	_	I-Premise
191	=	_	_	I-Premise
192	0.03	_	_	I-Premise
193	)	_	_	I-Premise
194	and	_	_	I-Premise
195	better	_	_	I-Premise
196	height	_	_	I-Premise
197	(	_	_	I-Premise
198	H2	_	_	I-Premise
199	and	_	_	I-Premise
200	H3	_	_	I-Premise
201	)	_	_	I-Premise
202	(	_	_	I-Premise
203	P	_	_	I-Premise
204	=	_	_	I-Premise
205	0.04	_	_	I-Premise
206	)	_	_	I-Premise
207	,	_	_	I-Premise
208	according	_	_	I-Premise
209	to	_	_	I-Premise
210	the	_	_	I-Premise
211	Indiana	_	_	I-Premise
212	Bleb	_	_	I-Premise
213	Appearance	_	_	I-Premise
214	Grading	_	_	I-Premise
215	Scale	_	_	I-Premise
216	,	_	_	I-Premise
217	at	_	_	I-Premise
218	all	_	_	I-Premise
219	follow-up	_	_	I-Premise
220	visits	_	_	I-Premise
221	along	_	_	I-Premise
222	with	_	_	I-Premise
223	normal	_	_	I-Premise
224	vascularity	_	_	I-Premise
225	.	_	_	I-Premise

226	The	_	_	B-Premise
227	study	_	_	I-Premise
228	group	_	_	I-Premise
229	required	_	_	I-Premise
230	significantly	_	_	I-Premise
231	lesser	_	_	I-Premise
232	(	_	_	I-Premise
233	P	_	_	I-Premise
234	=	_	_	I-Premise
235	0.03	_	_	I-Premise
236	)	_	_	I-Premise
237	bleb	_	_	I-Premise
238	needlings	_	_	I-Premise
239	as	_	_	I-Premise
240	compared	_	_	I-Premise
241	to	_	_	I-Premise
242	control	_	_	I-Premise
243	group	_	_	I-Premise
244	.	_	_	I-Premise

245	Amnion	_	_	B-Claim
246	enhanced	_	_	I-Claim
247	the	_	_	I-Claim
248	efficacy	_	_	I-Claim
249	of	_	_	I-Claim
250	MMC-modulated	_	_	I-Claim
251	trabeculectomy	_	_	I-Claim
252	in	_	_	I-Claim
253	terms	_	_	I-Claim
254	of	_	_	I-Claim
255	eyes	_	_	I-Claim
256	with	_	_	I-Claim
257	complete	_	_	I-Claim
258	success	_	_	I-Claim
259	and	_	_	I-Claim
260	lesser	_	_	I-Claim
261	interventions	_	_	I-Claim
262	such	_	_	I-Claim
263	as	_	_	I-Claim
264	bleb	_	_	I-Claim
265	needling	_	_	I-Claim
266	.	_	_	I-Claim

267	This	_	_	B-Claim
268	reiterates	_	_	I-Claim
269	the	_	_	I-Claim
270	role	_	_	I-Claim
271	of	_	_	I-Claim
272	amnion	_	_	I-Claim
273	as	_	_	I-Claim
274	a	_	_	I-Claim
275	safe	_	_	I-Claim
276	and	_	_	I-Claim
277	effective	_	_	I-Claim
278	bleb	_	_	I-Claim
279	modulator	_	_	I-Claim
280	.	_	_	I-Claim

281	A	_	_	O
282	diffusely	_	_	O
283	elevated	_	_	O
284	bleb	_	_	O
285	with	_	_	O
286	healthier	_	_	O
287	conjunctiva	_	_	O
288	can	_	_	O
289	go	_	_	O
290	a	_	_	O
291	long	_	_	O
292	way	_	_	O
293	in	_	_	O
294	predicting	_	_	O
295	better	_	_	O
296	health	_	_	O
297	and	_	_	O
298	longevity	_	_	O
299	of	_	_	O
300	the	_	_	O
301	bleb	_	_	O
302	.	_	_	O


0	Methionine	_	_	B-Claim
1	aminopeptidase	_	_	I-Claim
2	2	_	_	I-Claim
3	(	_	_	I-Claim
4	MetAP2	_	_	I-Claim
5	)	_	_	I-Claim
6	inhibition	_	_	I-Claim
7	has	_	_	I-Claim
8	been	_	_	I-Claim
9	shown	_	_	I-Claim
10	to	_	_	I-Claim
11	result	_	_	I-Claim
12	in	_	_	I-Claim
13	significant	_	_	I-Claim
14	weight	_	_	I-Claim
15	loss	_	_	I-Claim
16	and	_	_	I-Claim
17	improved	_	_	I-Claim
18	glucose	_	_	I-Claim
19	control	_	_	I-Claim
20	.	_	_	I-Claim

21	This	_	_	O
22	Phase	_	_	O
23	1	_	_	O
24	clinical	_	_	O
25	trial	_	_	O
26	assessed	_	_	O
27	the	_	_	O
28	safety	_	_	O
29	and	_	_	O
30	tolerability	_	_	O
31	,	_	_	O
32	pharmacokinetics	_	_	O
33	,	_	_	O
34	and	_	_	O
35	preliminary	_	_	O
36	efficacy	_	_	O
37	of	_	_	O
38	a	_	_	O
39	novel	_	_	O
40	MetAP2	_	_	O
41	inhibitor	_	_	O
42	,	_	_	O
43	ZGN-1061	_	_	O
44	.	_	_	O

45	This	_	_	O
46	clinical	_	_	O
47	trial	_	_	O
48	included	_	_	O
49	a	_	_	O
50	single	_	_	O
51	ascending	_	_	O
52	dose	_	_	O
53	(	_	_	O
54	SAD	_	_	O
55	)	_	_	O
56	phase	_	_	O
57	in	_	_	O
58	healthy	_	_	O
59	subjects	_	_	O
60	(	_	_	O
61	BMI	_	_	O
62	23	_	_	O
63	to	_	_	O
64	<	_	_	O
65	30	_	_	O
66	kg/m2	_	_	O
67	)	_	_	O
68	and	_	_	O
69	a	_	_	O
70	multiple	_	_	O
71	ascending	_	_	O
72	dose	_	_	O
73	(	_	_	O
74	MAD	_	_	O
75	)	_	_	O
76	phase	_	_	O
77	in	_	_	O
78	otherwise	_	_	O
79	healthy	_	_	O
80	subjects	_	_	O
81	with	_	_	O
82	BMI	_	_	O
83	27	_	_	O
84	to	_	_	O
85	40	_	_	O
86	kg/m2	_	_	O
87	.	_	_	O

88	SAD	_	_	O
89	phase	_	_	O
90	doses	_	_	O
91	,	_	_	O
92	administered	_	_	O
93	subcutaneously	_	_	O
94	(	_	_	O
95	SC	_	_	O
96	)	_	_	O
97	were	_	_	O
98	0.2	_	_	O
99	,	_	_	O
100	0.6	_	_	O
101	,	_	_	O
102	1.2	_	_	O
103	,	_	_	O
104	2.4	_	_	O
105	,	_	_	O
106	3.6	_	_	O
107	,	_	_	O
108	and	_	_	O
109	4.8	_	_	O
110	mg	_	_	O
111	,	_	_	O
112	and	_	_	O
113	MAD	_	_	O
114	phase	_	_	O
115	evaluated	_	_	O
116	0.2	_	_	O
117	,	_	_	O
118	0.6	_	_	O
119	,	_	_	O
120	and	_	_	O
121	1.8	_	_	O
122	mg	_	_	O
123	twice	_	_	O
124	weekly	_	_	O
125	SC	_	_	O
126	for	_	_	O
127	4	_	_	O
128	weeks	_	_	O
129	.	_	_	O

130	SAD	_	_	O
131	phase	_	_	O
132	included	_	_	O
133	39	_	_	O
134	subjects	_	_	O
135	(	_	_	O
136	ZGN-1061	_	_	O
137	N=28	_	_	O
138	,	_	_	O
139	placebo	_	_	O
140	N=11	_	_	O
141	)	_	_	O
142	,	_	_	O
143	90	_	_	O
144	%	_	_	O
145	male	_	_	O
146	and	_	_	O
147	BMI	_	_	O
148	26.4	_	_	O
149	kg/m2	_	_	O
150	.	_	_	O

151	ZGN-1061	_	_	B-Premise
152	was	_	_	I-Premise
153	well	_	_	I-Premise
154	tolerated	_	_	I-Premise
155	across	_	_	I-Premise
156	all	_	_	I-Premise
157	doses	_	_	I-Premise
158	with	_	_	I-Premise
159	most	_	_	I-Premise
160	frequent	_	_	I-Premise
161	adverse	_	_	I-Premise
162	events	_	_	I-Premise
163	of	_	_	I-Premise
164	mild	_	_	I-Premise
165	headache	_	_	I-Premise
166	and	_	_	I-Premise
167	procedural-related	_	_	I-Premise
168	irritation	_	_	I-Premise
169	.	_	_	I-Premise

170	There	_	_	O
171	were	_	_	O
172	no	_	_	O
173	severe	_	_	O
174	or	_	_	O
175	serious	_	_	O
176	adverse	_	_	O
177	events	_	_	O
178	.	_	_	O

179	All	_	_	B-Premise
180	doses	_	_	I-Premise
181	of	_	_	I-Premise
182	ZGN-1061	_	_	I-Premise
183	were	_	_	I-Premise
184	rapidly	_	_	I-Premise
185	absorbed	_	_	I-Premise
186	and	_	_	I-Premise
187	cleared	_	_	I-Premise
188	,	_	_	I-Premise
189	resulting	_	_	I-Premise
190	in	_	_	I-Premise
191	short	_	_	I-Premise
192	duration	_	_	I-Premise
193	of	_	_	I-Premise
194	exposure	_	_	I-Premise
195	that	_	_	I-Premise
196	is	_	_	I-Premise
197	anticipated	_	_	I-Premise
198	to	_	_	I-Premise
199	minimize	_	_	I-Premise
200	potential	_	_	I-Premise
201	off-drug	_	_	I-Premise
202	target	_	_	I-Premise
203	risks	_	_	I-Premise
204	.	_	_	I-Premise

205	The	_	_	O
206	MAD	_	_	O
207	phase	_	_	O
208	included	_	_	O
209	29	_	_	O
210	subjects	_	_	O
211	(	_	_	O
212	ZGN-1061	_	_	O
213	N=22	_	_	O
214	,	_	_	O
215	placebo	_	_	O
216	N=7	_	_	O
217	)	_	_	O
218	,	_	_	O
219	76	_	_	O
220	%	_	_	O
221	male	_	_	O
222	and	_	_	O
223	BMI	_	_	O
224	33.5	_	_	O
225	kg/m2	_	_	O
226	.	_	_	O

227	Safety	_	_	B-Premise
228	observations	_	_	I-Premise
229	were	_	_	I-Premise
230	consistent	_	_	I-Premise
231	with	_	_	I-Premise
232	SAD	_	_	I-Premise
233	findings	_	_	I-Premise
234	.	_	_	I-Premise

235	Efficacy	_	_	B-Premise
236	measures	_	_	I-Premise
237	in	_	_	I-Premise
238	the	_	_	I-Premise
239	MAD	_	_	I-Premise
240	phase	_	_	I-Premise
241	indicated	_	_	I-Premise
242	trends	_	_	I-Premise
243	for	_	_	I-Premise
244	weight	_	_	I-Premise
245	change	_	_	I-Premise
246	(	_	_	I-Premise
247	-1.5	_	_	I-Premise
248	kg	_	_	I-Premise
249	total	_	_	I-Premise
250	ZGN-1061	_	_	I-Premise
251	vs	_	_	I-Premise
252	-0.2	_	_	I-Premise
253	kg	_	_	I-Premise
254	placebo	_	_	I-Premise
255	)	_	_	I-Premise
256	and	_	_	I-Premise
257	other	_	_	I-Premise
258	biomarker	_	_	I-Premise
259	changes	_	_	I-Premise
260	.	_	_	I-Premise

261	ZGN-1061	_	_	B-Claim
262	was	_	_	I-Claim
263	well	_	_	I-Claim
264	tolerated	_	_	I-Claim
265	with	_	_	I-Claim
266	no	_	_	I-Claim
267	safety	_	_	I-Claim
268	signals	_	_	I-Claim
269	in	_	_	I-Claim
270	all	_	_	I-Claim
271	doses	_	_	I-Claim
272	tested	_	_	I-Claim
273	.	_	_	I-Claim

274	In	_	_	O
275	addition	_	_	O
276	,	_	_	O
277	the	_	_	B-Claim
278	desired	_	_	I-Claim
279	pharmacokinetic	_	_	I-Claim
280	profile	_	_	I-Claim
281	and	_	_	I-Claim
282	preliminary	_	_	I-Claim
283	efficacy	_	_	I-Claim
284	observations	_	_	I-Claim
285	with	_	_	I-Claim
286	ZGN-1061	_	_	I-Claim
287	support	_	_	I-Claim
288	evaluation	_	_	I-Claim
289	in	_	_	I-Claim
290	larger	_	_	I-Claim
291	and	_	_	I-Claim
292	longer	_	_	I-Claim
293	clinical	_	_	I-Claim
294	trials	_	_	I-Claim
295	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	effect	_	_	O
4	of	_	_	O
5	selective	_	_	O
6	laser	_	_	O
7	trabeculoplasty	_	_	O
8	(	_	_	O
9	SLT	_	_	O
10	)	_	_	O
11	and	_	_	O
12	travoprost	_	_	O
13	on	_	_	O
14	24-hour	_	_	O
15	IOP	_	_	O
16	fluctuations	_	_	O
17	in	_	_	O
18	primary	_	_	O
19	open-angle	_	_	O
20	glaucoma	_	_	O
21	(	_	_	O
22	POAG	_	_	O
23	)	_	_	O
24	and	_	_	O
25	normal-tension	_	_	O
26	glaucoma	_	_	O
27	(	_	_	O
28	NTG	_	_	O
29	)	_	_	O
30	.	_	_	O

31	Sixty	_	_	O
32	eyes	_	_	O
33	were	_	_	O
34	included	_	_	O
35	.	_	_	O

36	Sixteen	_	_	O
37	and	_	_	O
38	14	_	_	O
39	eyes	_	_	O
40	of	_	_	O
41	POAG	_	_	O
42	patients	_	_	O
43	were	_	_	O
44	randomized	_	_	O
45	to	_	_	O
46	receive	_	_	O
47	360°	_	_	O
48	SLT	_	_	O
49	or	_	_	O
50	0.004	_	_	O
51	%	_	_	O
52	travoprost	_	_	O
53	,	_	_	O
54	respectively	_	_	O
55	.	_	_	O

56	Fourteen	_	_	O
57	and	_	_	O
58	16	_	_	O
59	eyes	_	_	O
60	of	_	_	O
61	NTG	_	_	O
62	patients	_	_	O
63	were	_	_	O
64	randomized	_	_	O
65	to	_	_	O
66	receive	_	_	O
67	either	_	_	O
68	SLT	_	_	O
69	or	_	_	O
70	travoprost	_	_	O
71	,	_	_	O
72	respectively	_	_	O
73	.	_	_	O

74	The	_	_	O
75	24-hour	_	_	O
76	IOP	_	_	O
77	data	_	_	O
78	were	_	_	O
79	collected	_	_	O
80	before	_	_	O
81	treatment	_	_	O
82	and	_	_	O
83	6	_	_	O
84	to	_	_	O
85	8	_	_	O
86	weeks	_	_	O
87	after	_	_	O
88	treatment	_	_	O
89	.	_	_	O

90	IOP	_	_	O
91	was	_	_	O
92	measured	_	_	O
93	at	_	_	O
94	2	_	_	O
95	hours	_	_	O
96	intervals	_	_	O
97	in	_	_	O
98	the	_	_	O
99	sitting	_	_	O
100	position	_	_	O
101	during	_	_	O
102	daytime	_	_	O
103	(	_	_	O
104	9	_	_	O
105	AM	_	_	O
106	to	_	_	O
107	7	_	_	O
108	PM	_	_	O
109	)	_	_	O
110	and	_	_	O
111	in	_	_	O
112	the	_	_	O
113	supine	_	_	O
114	position	_	_	O
115	during	_	_	O
116	nighttime	_	_	O
117	(	_	_	O
118	9	_	_	O
119	PM	_	_	O
120	to	_	_	O
121	7	_	_	O
122	AM	_	_	O
123	)	_	_	O
124	.	_	_	O

125	Main	_	_	O
126	outcome	_	_	O
127	measure	_	_	O
128	was	_	_	O
129	the	_	_	O
130	percentage	_	_	O
131	of	_	_	O
132	eyes	_	_	O
133	that	_	_	O
134	achieved	_	_	O
135	posttreatment	_	_	O
136	24-hour	_	_	O
137	IOP	_	_	O
138	fluctuations	_	_	O
139	<	_	_	O
140	3	_	_	O
141	mm	_	_	O
142	Hg	_	_	O
143	.	_	_	O

144	Success	_	_	O
145	in	_	_	O
146	fluctuation	_	_	O
147	reduction	_	_	O
148	was	_	_	O
149	defined	_	_	O
150	as	_	_	O
151	at	_	_	O
152	least	_	_	O
153	a	_	_	O
154	50	_	_	O
155	%	_	_	O
156	reduction	_	_	O
157	in	_	_	O
158	these	_	_	O
159	fluctuations	_	_	O
160	.	_	_	O

161	Fifty-eight	_	_	O
162	eyes	_	_	O
163	were	_	_	O
164	analyzed	_	_	O
165	.	_	_	O

166	Overall	_	_	O
167	,	_	_	O
168	eyes	_	_	B-Premise
169	in	_	_	I-Premise
170	the	_	_	I-Premise
171	SLT	_	_	I-Premise
172	and	_	_	I-Premise
173	the	_	_	I-Premise
174	travoprost	_	_	I-Premise
175	groups	_	_	I-Premise
176	achieved	_	_	I-Premise
177	a	_	_	I-Premise
178	significant	_	_	I-Premise
179	reduction	_	_	I-Premise
180	in	_	_	I-Premise
181	IOP	_	_	I-Premise
182	compared	_	_	I-Premise
183	with	_	_	I-Premise
184	the	_	_	I-Premise
185	baseline	_	_	I-Premise
186	IOP	_	_	I-Premise
187	values	_	_	I-Premise
188	(	_	_	I-Premise
189	-3.7	_	_	I-Premise
190	mm	_	_	I-Premise
191	Hg	_	_	I-Premise
192	[	_	_	I-Premise
193	P	_	_	I-Premise
194	=	_	_	I-Premise
195	0.002	_	_	I-Premise
196	]	_	_	I-Premise
197	vs	_	_	I-Premise
198	-4.1	_	_	I-Premise
199	mm	_	_	I-Premise
200	Hg	_	_	I-Premise
201	[	_	_	I-Premise
202	P	_	_	I-Premise
203	<	_	_	I-Premise
204	0.001	_	_	I-Premise
205	]	_	_	I-Premise
206	,	_	_	I-Premise
207	respectively	_	_	I-Premise
208	)	_	_	I-Premise
209	.	_	_	I-Premise

210	There	_	_	O
211	was	_	_	O
212	no	_	_	O
213	significant	_	_	O
214	difference	_	_	O
215	in	_	_	O
216	IOP	_	_	O
217	reduction	_	_	O
218	in	_	_	O
219	both	_	_	O
220	groups	_	_	O
221	according	_	_	O
222	to	_	_	O
223	type	_	_	O
224	of	_	_	O
225	glaucoma	_	_	O
226	.	_	_	O

227	During	_	_	O
228	the	_	_	O
229	diurnal	_	_	O
230	period	_	_	O
231	,	_	_	O
232	100	_	_	O
233	%	_	_	O
234	of	_	_	O
235	POAG	_	_	O
236	eyes	_	_	O
237	in	_	_	O
238	the	_	_	O
239	travoprost	_	_	O
240	group	_	_	O
241	achieved	_	_	O
242	posttreatment	_	_	O
243	IOP	_	_	O
244	fluctuations	_	_	O
245	<	_	_	O
246	3	_	_	O
247	mm	_	_	O
248	Hg	_	_	O
249	,	_	_	O
250	and	_	_	O
251	87	_	_	O
252	%	_	_	O
253	of	_	_	O
254	eyes	_	_	O
255	in	_	_	O
256	the	_	_	O
257	SLT	_	_	O
258	group	_	_	O
259	achieved	_	_	O
260	the	_	_	O
261	same	_	_	O
262	level	_	_	O
263	of	_	_	O
264	fluctuations	_	_	O
265	(	_	_	O
266	P	_	_	O
267	<	_	_	O
268	0.001	_	_	O
269	)	_	_	O
270	.	_	_	O

271	Ninety-six	_	_	B-Premise
272	percent	_	_	I-Premise
273	of	_	_	I-Premise
274	NTG	_	_	I-Premise
275	eyes	_	_	I-Premise
276	in	_	_	I-Premise
277	the	_	_	I-Premise
278	travoprost	_	_	I-Premise
279	group	_	_	I-Premise
280	,	_	_	I-Premise
281	and	_	_	I-Premise
282	82	_	_	I-Premise
283	%	_	_	I-Premise
284	of	_	_	I-Premise
285	eyes	_	_	I-Premise
286	in	_	_	I-Premise
287	the	_	_	I-Premise
288	SLT	_	_	I-Premise
289	group	_	_	I-Premise
290	had	_	_	I-Premise
291	IOP	_	_	I-Premise
292	fluctuations	_	_	I-Premise
293	<	_	_	I-Premise
294	3	_	_	I-Premise
295	mm	_	_	I-Premise
296	Hg	_	_	I-Premise
297	(	_	_	I-Premise
298	P	_	_	I-Premise
299	=	_	_	I-Premise
300	0.01	_	_	I-Premise
301	)	_	_	I-Premise
302	.	_	_	I-Premise

303	Success	_	_	B-Premise
304	in	_	_	I-Premise
305	fluctuation	_	_	I-Premise
306	reduction	_	_	I-Premise
307	was	_	_	I-Premise
308	75	_	_	I-Premise
309	%	_	_	I-Premise
310	and	_	_	I-Premise
311	92	_	_	I-Premise
312	%	_	_	I-Premise
313	for	_	_	I-Premise
314	the	_	_	I-Premise
315	SLT	_	_	I-Premise
316	and	_	_	I-Premise
317	travoprost	_	_	I-Premise
318	groups	_	_	I-Premise
319	,	_	_	I-Premise
320	respectively	_	_	I-Premise
321	(	_	_	I-Premise
322	P	_	_	I-Premise
323	=	_	_	I-Premise
324	0.005	_	_	I-Premise
325	)	_	_	I-Premise
326	.	_	_	I-Premise

327	The	_	_	B-Claim
328	effect	_	_	I-Claim
329	of	_	_	I-Claim
330	travoprost	_	_	I-Claim
331	on	_	_	I-Claim
332	IOP	_	_	I-Claim
333	reduction	_	_	I-Claim
334	in	_	_	I-Claim
335	POAG	_	_	I-Claim
336	and	_	_	I-Claim
337	NTG	_	_	I-Claim
338	patients	_	_	I-Claim
339	was	_	_	I-Claim
340	significant	_	_	I-Claim
341	both	_	_	I-Claim
342	during	_	_	I-Claim
343	the	_	_	I-Claim
344	daytime	_	_	I-Claim
345	and	_	_	I-Claim
346	the	_	_	I-Claim
347	nighttime	_	_	I-Claim
348	,	_	_	I-Claim
349	while	_	_	O
350	the	_	_	B-Claim
351	SLT	_	_	I-Claim
352	's	_	_	I-Claim
353	effect	_	_	I-Claim
354	was	_	_	I-Claim
355	significant	_	_	I-Claim
356	only	_	_	I-Claim
357	during	_	_	I-Claim
358	the	_	_	I-Claim
359	nighttime	_	_	I-Claim
360	.	_	_	I-Claim

361	Both	_	_	B-Claim
362	travoprost	_	_	I-Claim
363	and	_	_	I-Claim
364	SLT	_	_	I-Claim
365	can	_	_	I-Claim
366	significantly	_	_	I-Claim
367	reduce	_	_	I-Claim
368	the	_	_	I-Claim
369	IOP	_	_	I-Claim
370	in	_	_	I-Claim
371	patients	_	_	I-Claim
372	with	_	_	I-Claim
373	POAG	_	_	I-Claim
374	and	_	_	I-Claim
375	NTG	_	_	I-Claim
376	.	_	_	I-Claim

377	Based	_	_	O
378	on	_	_	O
379	habitual	_	_	O
380	positions	_	_	O
381	,	_	_	O
382	travoprost	_	_	B-Claim
383	better	_	_	I-Claim
384	controls	_	_	I-Claim
385	IOP	_	_	I-Claim
386	fluctuations	_	_	I-Claim
387	than	_	_	I-Claim
388	SLT	_	_	I-Claim
389	,	_	_	I-Claim
390	especially	_	_	I-Claim
391	during	_	_	I-Claim
392	the	_	_	I-Claim
393	daytime	_	_	I-Claim
394	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	additive	_	_	O
4	effects	_	_	O
5	and	_	_	O
6	safety	_	_	O
7	of	_	_	O
8	1	_	_	O
9	%	_	_	O
10	brinzolamide/0.5	_	_	O
11	%	_	_	O
12	timolol	_	_	O
13	fixed	_	_	O
14	combination	_	_	O
15	(	_	_	O
16	BTFC	_	_	O
17	)	_	_	O
18	versus	_	_	O
19	the	_	_	O
20	low-dose	_	_	O
21	regimen	_	_	O
22	of	_	_	O
23	1	_	_	O
24	%	_	_	O
25	dorzolamide/0.5	_	_	O
26	%	_	_	O
27	timolol	_	_	O
28	fixed	_	_	O
29	combination	_	_	O
30	(	_	_	O
31	DTFC	_	_	O
32	)	_	_	O
33	in	_	_	O
34	patients	_	_	O
35	with	_	_	O
36	open-angle	_	_	O
37	glaucoma	_	_	O
38	and	_	_	O
39	ocular	_	_	O
40	hypertension	_	_	O
41	(	_	_	O
42	OAG/OH	_	_	O
43	)	_	_	O
44	following	_	_	O
45	treatment	_	_	O
46	with	_	_	O
47	prostaglandin	_	_	O
48	analogues	_	_	O
49	(	_	_	O
50	PGAs	_	_	O
51	)	_	_	O
52	.	_	_	O

53	A	_	_	O
54	prospective	_	_	O
55	,	_	_	O
56	randomized	_	_	O
57	,	_	_	O
58	double-masked	_	_	O
59	,	_	_	O
60	multicentre	_	_	O
61	,	_	_	O
62	parallel-group	_	_	O
63	and	_	_	O
64	active-controlled	_	_	O
65	study	_	_	O
66	included	_	_	O
67	201	_	_	O
68	Japanese	_	_	O
69	OAG/OH	_	_	O
70	patients	_	_	O
71	who	_	_	O
72	had	_	_	O
73	been	_	_	O
74	treated	_	_	O
75	with	_	_	O
76	PGA	_	_	O
77	.	_	_	O

78	Efficacy	_	_	O
79	was	_	_	O
80	assessed	_	_	O
81	as	_	_	O
82	the	_	_	O
83	change	_	_	O
84	in	_	_	O
85	intra-ocular	_	_	O
86	pressure	_	_	O
87	(	_	_	O
88	IOP	_	_	O
89	)	_	_	O
90	from	_	_	O
91	baseline	_	_	O
92	after	_	_	O
93	weeks	_	_	O
94	4	_	_	O
95	and	_	_	O
96	8	_	_	O
97	.	_	_	O

98	Safety	_	_	O
99	was	_	_	O
100	assessed	_	_	O
101	with	_	_	O
102	adverse	_	_	O
103	event	_	_	O
104	rates	_	_	O
105	,	_	_	O
106	ocular	_	_	O
107	discomfort	_	_	O
108	score	_	_	O
109	,	_	_	O
110	blur	_	_	O
111	scale	_	_	O
112	,	_	_	O
113	blood	_	_	O
114	pressure	_	_	O
115	and	_	_	O
116	heart	_	_	O
117	rates	_	_	O
118	,	_	_	O
119	best-corrected	_	_	O
120	visual	_	_	O
121	acuity	_	_	O
122	(	_	_	O
123	BCVA	_	_	O
124	)	_	_	O
125	and	_	_	O
126	slit	_	_	O
127	lamp	_	_	O
128	examinations	_	_	O
129	.	_	_	O

130	Intra-ocular	_	_	B-Premise
131	pressure	_	_	I-Premise
132	(	_	_	I-Premise
133	IOP	_	_	I-Premise
134	)	_	_	I-Premise
135	change	_	_	I-Premise
136	from	_	_	I-Premise
137	baseline	_	_	I-Premise
138	at	_	_	I-Premise
139	9	_	_	I-Premise
140	AM/11	_	_	I-Premise
141	AM	_	_	I-Premise
142	pooled	_	_	I-Premise
143	over	_	_	I-Premise
144	the	_	_	I-Premise
145	8	_	_	I-Premise
146	weeks	_	_	I-Premise
147	was	_	_	I-Premise
148	-3.3/-3.3	_	_	I-Premise
149	mmHg	_	_	I-Premise
150	in	_	_	I-Premise
151	the	_	_	I-Premise
152	BTFC	_	_	I-Premise
153	group	_	_	I-Premise
154	and	_	_	I-Premise
155	-2.9/-3.4	_	_	I-Premise
156	mmHg	_	_	I-Premise
157	in	_	_	I-Premise
158	the	_	_	I-Premise
159	DTFC	_	_	I-Premise
160	group	_	_	I-Premise
161	,	_	_	I-Premise
162	demonstrating	_	_	O
163	non-inferiority	_	_	O
164	of	_	_	O
165	BTFC	_	_	O
166	to	_	_	O
167	DTFC	_	_	O
168	.	_	_	O

169	Ocular	_	_	B-Premise
170	irritation	_	_	I-Premise
171	was	_	_	I-Premise
172	frequently	_	_	I-Premise
173	seen	_	_	I-Premise
174	in	_	_	I-Premise
175	DTFC	_	_	I-Premise
176	group	_	_	I-Premise
177	.	_	_	I-Premise

178	Although	_	_	O
179	blurred	_	_	B-Premise
180	vision	_	_	I-Premise
181	was	_	_	I-Premise
182	frequently	_	_	I-Premise
183	seen	_	_	I-Premise
184	in	_	_	I-Premise
185	BTFC	_	_	I-Premise
186	group	_	_	I-Premise
187	,	_	_	I-Premise
188	it	_	_	O
189	was	_	_	O
190	transient	_	_	O
191	and	_	_	O
192	blurring	_	_	O
193	became	_	_	O
194	the	_	_	O
195	equivalent	_	_	O
196	3	_	_	O
197	min	_	_	O
198	after	_	_	O
199	instillation	_	_	O
200	between	_	_	O
201	two	_	_	O
202	groups	_	_	O
203	.	_	_	O

204	No	_	_	B-Premise
205	noteworthy	_	_	I-Premise
206	issue	_	_	I-Premise
207	was	_	_	I-Premise
208	observed	_	_	I-Premise
209	in	_	_	I-Premise
210	other	_	_	I-Premise
211	safety	_	_	I-Premise
212	outcome	_	_	I-Premise
213	.	_	_	I-Premise

214	Non-inferiority	_	_	B-Claim
215	of	_	_	I-Claim
216	BTFC	_	_	I-Claim
217	to	_	_	I-Claim
218	DTFC	_	_	I-Claim
219	in	_	_	I-Claim
220	IOP	_	_	I-Claim
221	reduction	_	_	I-Claim
222	was	_	_	I-Claim
223	demonstrated	_	_	I-Claim
224	after	_	_	I-Claim
225	adding	_	_	I-Claim
226	onto	_	_	I-Claim
227	PGA	_	_	I-Claim
228	therapy	_	_	I-Claim
229	in	_	_	I-Claim
230	Japanese	_	_	I-Claim
231	OAG/OH	_	_	I-Claim
232	patients	_	_	I-Claim
233	.	_	_	I-Claim

234	Although	_	_	O
235	the	_	_	B-Claim
236	score	_	_	I-Claim
237	of	_	_	I-Claim
238	blurred	_	_	I-Claim
239	vision	_	_	I-Claim
240	was	_	_	I-Claim
241	transiently	_	_	I-Claim
242	higher	_	_	I-Claim
243	in	_	_	I-Claim
244	BTFC	_	_	I-Claim
245	than	_	_	I-Claim
246	DTFC	_	_	I-Claim
247	,	_	_	I-Claim
248	treatment	_	_	B-Claim
249	difference	_	_	I-Claim
250	decreased	_	_	I-Claim
251	and	_	_	I-Claim
252	disappeared	_	_	I-Claim
253	with	_	_	I-Claim
254	time	_	_	I-Claim
255	.	_	_	I-Claim

256	Thus	_	_	O
257	,	_	_	O
258	BTFC	_	_	B-Claim
259	can	_	_	I-Claim
260	be	_	_	I-Claim
261	considered	_	_	I-Claim
262	as	_	_	I-Claim
263	a	_	_	I-Claim
264	safe	_	_	I-Claim
265	and	_	_	I-Claim
266	effective	_	_	I-Claim
267	agent	_	_	I-Claim
268	for	_	_	I-Claim
269	glaucoma	_	_	I-Claim
270	treatment	_	_	I-Claim
271	.	_	_	I-Claim


0	The	_	_	B-Claim
1	efficacy	_	_	I-Claim
2	of	_	_	I-Claim
3	switching	_	_	I-Claim
4	to	_	_	I-Claim
5	tenofovir	_	_	I-Claim
6	disoproxil	_	_	I-Claim
7	fumarate	_	_	I-Claim
8	(	_	_	I-Claim
9	TDF	_	_	I-Claim
10	)	_	_	I-Claim
11	monotherapy	_	_	I-Claim
12	from	_	_	I-Claim
13	lamivudine	_	_	I-Claim
14	(	_	_	I-Claim
15	LAM	_	_	I-Claim
16	)	_	_	I-Claim
17	plus	_	_	I-Claim
18	adefovir	_	_	I-Claim
19	dipivoxil	_	_	I-Claim
20	(	_	_	I-Claim
21	ADV	_	_	I-Claim
22	)	_	_	I-Claim
23	combination	_	_	I-Claim
24	therapy	_	_	I-Claim
25	(	_	_	I-Claim
26	stable	_	_	I-Claim
27	switching	_	_	I-Claim
28	)	_	_	I-Claim
29	in	_	_	I-Claim
30	patients	_	_	I-Claim
31	with	_	_	I-Claim
32	LAM-resistant	_	_	I-Claim
33	chronic	_	_	I-Claim
34	hepatitis	_	_	I-Claim
35	B	_	_	I-Claim
36	(	_	_	I-Claim
37	CHB	_	_	I-Claim
38	)	_	_	I-Claim
39	and	_	_	I-Claim
40	undetectable	_	_	I-Claim
41	hepatitis	_	_	I-Claim
42	B	_	_	I-Claim
43	virus	_	_	I-Claim
44	(	_	_	I-Claim
45	HBV	_	_	I-Claim
46	)	_	_	I-Claim
47	DNA	_	_	I-Claim
48	is	_	_	I-Claim
49	not	_	_	I-Claim
50	clear	_	_	I-Claim
51	.	_	_	I-Claim

52	In	_	_	O
53	this	_	_	O
54	non-inferiority	_	_	O
55	trial	_	_	O
56	,	_	_	O
57	patients	_	_	O
58	with	_	_	O
59	LAM-resistant	_	_	O
60	CHB	_	_	O
61	and	_	_	O
62	undetectable	_	_	O
63	serum	_	_	O
64	HBV	_	_	O
65	DNA	_	_	O
66	(	_	_	O
67	<	_	_	O
68	20	_	_	O
69	IU/mL	_	_	O
70	)	_	_	O
71	for	_	_	O
72	>	_	_	O
73	6	_	_	O
74	months	_	_	O
75	after	_	_	O
76	initiating	_	_	O
77	LAM+ADV	_	_	O
78	combination	_	_	O
79	therapy	_	_	O
80	were	_	_	O
81	randomized	_	_	O
82	(	_	_	O
83	1:2	_	_	O
84	)	_	_	O
85	either	_	_	O
86	to	_	_	O
87	continue	_	_	O
88	the	_	_	O
89	combination	_	_	O
90	therapy	_	_	O
91	(	_	_	O
92	LAM+ADV	_	_	O
93	group	_	_	O
94	,	_	_	O
95	n	_	_	O
96	=	_	_	O
97	58	_	_	O
98	)	_	_	O
99	or	_	_	O
100	switched	_	_	O
101	to	_	_	O
102	TDF	_	_	O
103	monotherapy	_	_	O
104	(	_	_	O
105	TDF	_	_	O
106	group	_	_	O
107	,	_	_	O
108	n	_	_	O
109	=	_	_	O
110	111	_	_	O
111	)	_	_	O
112	.	_	_	O

113	They	_	_	O
114	were	_	_	O
115	followed-up	_	_	O
116	with	_	_	O
117	serum	_	_	O
118	biochemistry	_	_	O
119	tests	_	_	O
120	and	_	_	O
121	HBV	_	_	O
122	DNA	_	_	O
123	measurement	_	_	O
124	at	_	_	O
125	12-week	_	_	O
126	intervals	_	_	O
127	for	_	_	O
128	96	_	_	O
129	weeks	_	_	O
130	.	_	_	O

131	The	_	_	O
132	primary	_	_	O
133	endpoint	_	_	O
134	of	_	_	O
135	this	_	_	O
136	study	_	_	O
137	was	_	_	O
138	the	_	_	O
139	proportion	_	_	O
140	of	_	_	O
141	patients	_	_	O
142	with	_	_	O
143	viral	_	_	O
144	reactivation	_	_	O
145	at	_	_	O
146	week	_	_	O
147	96	_	_	O
148	.	_	_	O

149	Patients	_	_	O
150	with	_	_	O
151	CHB	_	_	O
152	enrolled	_	_	O
153	in	_	_	O
154	this	_	_	O
155	study	_	_	O
156	(	_	_	O
157	n	_	_	O
158	=	_	_	O
159	169	_	_	O
160	)	_	_	O
161	included	_	_	O
162	74	_	_	O
163	patients	_	_	O
164	with	_	_	O
165	compensated	_	_	O
166	liver	_	_	O
167	cirrhosis	_	_	O
168	.	_	_	O

169	In	_	_	O
170	total	_	_	O
171	,	_	_	O
172	9	_	_	O
173	patients	_	_	O
174	(	_	_	O
175	4	_	_	O
176	in	_	_	O
177	the	_	_	O
178	LAM+ADV	_	_	O
179	group	_	_	O
180	and	_	_	O
181	5	_	_	O
182	in	_	_	O
183	the	_	_	O
184	TDF	_	_	O
185	group	_	_	O
186	)	_	_	O
187	dropped-out	_	_	O
188	from	_	_	O
189	the	_	_	O
190	study	_	_	O
191	.	_	_	O

192	After	_	_	B-Premise
193	a	_	_	I-Premise
194	mean	_	_	I-Premise
195	follow-up	_	_	I-Premise
196	period	_	_	I-Premise
197	of	_	_	I-Premise
198	96	_	_	I-Premise
199	weeks	_	_	I-Premise
200	,	_	_	I-Premise
201	the	_	_	I-Premise
202	proportion	_	_	I-Premise
203	of	_	_	I-Premise
204	HBV	_	_	I-Premise
205	reactivation	_	_	I-Premise
206	observed	_	_	I-Premise
207	was	_	_	I-Premise
208	6.8	_	_	I-Premise
209	%	_	_	I-Premise
210	(	_	_	I-Premise
211	4/58	_	_	I-Premise
212	)	_	_	I-Premise
213	in	_	_	I-Premise
214	the	_	_	I-Premise
215	LAM+ADV	_	_	I-Premise
216	group	_	_	I-Premise
217	and	_	_	I-Premise
218	4.5	_	_	I-Premise
219	%	_	_	I-Premise
220	(	_	_	I-Premise
221	5/111	_	_	I-Premise
222	)	_	_	I-Premise
223	in	_	_	I-Premise
224	the	_	_	I-Premise
225	TDF	_	_	I-Premise
226	group	_	_	I-Premise
227	by	_	_	I-Premise
228	using	_	_	I-Premise
229	intention-to-treat	_	_	I-Premise
230	analysis	_	_	I-Premise
231	(	_	_	I-Premise
232	difference	_	_	I-Premise
233	,	_	_	I-Premise
234	-2.3	_	_	I-Premise
235	%	_	_	I-Premise
236	;	_	_	I-Premise
237	95	_	_	I-Premise
238	%	_	_	I-Premise
239	CI	_	_	I-Premise
240	,	_	_	I-Premise
241	-9.84-5.24	_	_	I-Premise
242	%	_	_	I-Premise
243	)	_	_	I-Premise
244	.	_	_	I-Premise

245	None	_	_	B-Premise
246	of	_	_	I-Premise
247	the	_	_	I-Premise
248	subjects	_	_	I-Premise
249	in	_	_	I-Premise
250	either	_	_	I-Premise
251	group	_	_	I-Premise
252	experienced	_	_	I-Premise
253	viral	_	_	I-Premise
254	reactivation	_	_	I-Premise
255	based	_	_	I-Premise
256	on	_	_	I-Premise
257	per	_	_	I-Premise
258	protocol	_	_	I-Premise
259	analysis	_	_	I-Premise
260	.	_	_	I-Premise

261	No	_	_	B-Premise
262	serious	_	_	I-Premise
263	adverse	_	_	I-Premise
264	reactions	_	_	I-Premise
265	were	_	_	I-Premise
266	observed	_	_	I-Premise
267	.	_	_	I-Premise

268	In	_	_	B-Premise
269	the	_	_	I-Premise
270	subgroup	_	_	I-Premise
271	analysis	_	_	I-Premise
272	for	_	_	I-Premise
273	estimated	_	_	I-Premise
274	glomerular	_	_	I-Premise
275	filtration	_	_	I-Premise
276	rate	_	_	I-Premise
277	(	_	_	I-Premise
278	eGFR	_	_	I-Premise
279	)	_	_	I-Premise
280	before	_	_	I-Premise
281	and	_	_	I-Premise
282	after	_	_	I-Premise
283	treatment	_	_	I-Premise
284	,	_	_	I-Premise
285	decreased	_	_	I-Premise
286	eGFR	_	_	I-Premise
287	was	_	_	I-Premise
288	observed	_	_	I-Premise
289	only	_	_	I-Premise
290	in	_	_	I-Premise
291	the	_	_	I-Premise
292	TDF	_	_	I-Premise
293	group	_	_	I-Premise
294	with	_	_	I-Premise
295	cirrhosis	_	_	I-Premise
296	(	_	_	I-Premise
297	85.22	_	_	I-Premise
298	vs.	_	_	I-Premise
299	79.83	_	_	I-Premise
300	mL/min/1.73	_	_	I-Premise
301	m2	_	_	I-Premise
302	,	_	_	I-Premise
303	p	_	_	I-Premise
304	=	_	_	I-Premise
305	0.000	_	_	I-Premise
306	)	_	_	I-Premise
307	.	_	_	I-Premise

308	Stable	_	_	B-Claim
309	switching	_	_	I-Claim
310	to	_	_	I-Claim
311	TDF	_	_	I-Claim
312	monotherapy	_	_	I-Claim
313	yielded	_	_	I-Claim
314	non-inferior	_	_	I-Claim
315	results	_	_	I-Claim
316	at	_	_	I-Claim
317	96	_	_	I-Claim
318	weeks	_	_	I-Claim
319	compared	_	_	I-Claim
320	to	_	_	I-Claim
321	the	_	_	I-Claim
322	results	_	_	I-Claim
323	obtained	_	_	I-Claim
324	with	_	_	I-Claim
325	LAM+ADV	_	_	I-Claim
326	combination	_	_	I-Claim
327	therapy	_	_	I-Claim
328	in	_	_	I-Claim
329	patients	_	_	I-Claim
330	with	_	_	I-Claim
331	LAM-resistant	_	_	I-Claim
332	CHB	_	_	I-Claim
333	and	_	_	I-Claim
334	undetectable	_	_	I-Claim
335	HBV	_	_	I-Claim
336	DNA	_	_	I-Claim
337	.	_	_	I-Claim

338	However	_	_	B-Claim
339	,	_	_	I-Claim
340	TDF	_	_	I-Claim
341	monotherapy	_	_	I-Claim
342	in	_	_	I-Claim
343	patients	_	_	I-Claim
344	with	_	_	I-Claim
345	cirrhosis	_	_	I-Claim
346	requires	_	_	I-Claim
347	close	_	_	I-Claim
348	attention	_	_	I-Claim
349	with	_	_	I-Claim
350	respect	_	_	I-Claim
351	to	_	_	I-Claim
352	renal	_	_	I-Claim
353	function	_	_	I-Claim
354	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	the	_	_	O
3	long-term	_	_	O
4	safety	_	_	O
5	and	_	_	O
6	efficacy	_	_	O
7	of	_	_	O
8	a	_	_	O
9	single	_	_	O
10	trabecular	_	_	O
11	micro-bypass	_	_	O
12	stent	_	_	O
13	with	_	_	O
14	concomitant	_	_	O
15	cataract	_	_	O
16	surgery	_	_	O
17	versus	_	_	O
18	cataract	_	_	O
19	surgery	_	_	O
20	alone	_	_	O
21	for	_	_	O
22	mild	_	_	O
23	to	_	_	O
24	moderate	_	_	O
25	open-angle	_	_	O
26	glaucoma	_	_	O
27	.	_	_	O

28	Twenty-nine	_	_	O
29	investigational	_	_	O
30	sites	_	_	O
31	,	_	_	O
32	United	_	_	O
33	States	_	_	O
34	.	_	_	O

35	Prospective	_	_	O
36	randomized	_	_	O
37	controlled	_	_	O
38	multicenter	_	_	O
39	clinical	_	_	O
40	trial	_	_	O
41	.	_	_	O

42	Eyes	_	_	O
43	with	_	_	O
44	mild	_	_	O
45	to	_	_	O
46	moderate	_	_	O
47	glaucoma	_	_	O
48	with	_	_	O
49	an	_	_	O
50	unmedicated	_	_	O
51	intraocular	_	_	O
52	pressure	_	_	O
53	(	_	_	O
54	IOP	_	_	O
55	)	_	_	O
56	of	_	_	O
57	22	_	_	O
58	mm	_	_	O
59	Hg	_	_	O
60	or	_	_	O
61	higher	_	_	O
62	and	_	_	O
63	36	_	_	O
64	mm	_	_	O
65	Hg	_	_	O
66	or	_	_	O
67	lower	_	_	O
68	were	_	_	O
69	randomly	_	_	O
70	assigned	_	_	O
71	to	_	_	O
72	have	_	_	O
73	cataract	_	_	O
74	surgery	_	_	O
75	with	_	_	O
76	iStent	_	_	O
77	trabecular	_	_	O
78	micro-bypass	_	_	O
79	stent	_	_	O
80	implantation	_	_	O
81	(	_	_	O
82	stent	_	_	O
83	group	_	_	O
84	)	_	_	O
85	or	_	_	O
86	cataract	_	_	O
87	surgery	_	_	O
88	alone	_	_	O
89	(	_	_	O
90	control	_	_	O
91	group	_	_	O
92	)	_	_	O
93	.	_	_	O

94	Patients	_	_	O
95	were	_	_	O
96	followed	_	_	O
97	for	_	_	O
98	24	_	_	O
99	months	_	_	O
100	postoperatively	_	_	O
101	.	_	_	O

102	The	_	_	B-Premise
103	incidence	_	_	I-Premise
104	of	_	_	I-Premise
105	adverse	_	_	I-Premise
106	events	_	_	I-Premise
107	was	_	_	I-Premise
108	low	_	_	I-Premise
109	in	_	_	I-Premise
110	both	_	_	I-Premise
111	groups	_	_	I-Premise
112	through	_	_	I-Premise
113	24	_	_	I-Premise
114	months	_	_	I-Premise
115	of	_	_	I-Premise
116	follow-up	_	_	I-Premise
117	.	_	_	I-Premise

118	At	_	_	B-Premise
119	24	_	_	I-Premise
120	months	_	_	I-Premise
121	,	_	_	I-Premise
122	the	_	_	I-Premise
123	proportion	_	_	I-Premise
124	of	_	_	I-Premise
125	patients	_	_	I-Premise
126	with	_	_	I-Premise
127	an	_	_	I-Premise
128	IOP	_	_	I-Premise
129	of	_	_	I-Premise
130	21	_	_	I-Premise
131	mm	_	_	I-Premise
132	Hg	_	_	I-Premise
133	or	_	_	I-Premise
134	lower	_	_	I-Premise
135	without	_	_	I-Premise
136	ocular	_	_	I-Premise
137	hypotensive	_	_	I-Premise
138	medications	_	_	I-Premise
139	was	_	_	I-Premise
140	significantly	_	_	I-Premise
141	higher	_	_	I-Premise
142	in	_	_	I-Premise
143	the	_	_	I-Premise
144	stent	_	_	I-Premise
145	group	_	_	I-Premise
146	than	_	_	I-Premise
147	in	_	_	I-Premise
148	the	_	_	I-Premise
149	control	_	_	I-Premise
150	group	_	_	I-Premise
151	(	_	_	I-Premise
152	P=.036	_	_	I-Premise
153	)	_	_	I-Premise
154	.	_	_	I-Premise

155	Overall	_	_	O
156	,	_	_	O
157	the	_	_	B-Premise
158	mean	_	_	I-Premise
159	IOP	_	_	I-Premise
160	was	_	_	I-Premise
161	stable	_	_	I-Premise
162	between	_	_	I-Premise
163	12	_	_	I-Premise
164	months	_	_	I-Premise
165	and	_	_	I-Premise
166	24	_	_	I-Premise
167	months	_	_	I-Premise
168	(	_	_	I-Premise
169	17.0	_	_	I-Premise
170	mm	_	_	I-Premise
171	Hg	_	_	I-Premise
172	±	_	_	I-Premise
173	2.8	_	_	I-Premise
174	[	_	_	I-Premise
175	SD	_	_	I-Premise
176	]	_	_	I-Premise
177	and	_	_	I-Premise
178	17.1	_	_	I-Premise
179	±	_	_	I-Premise
180	2.9	_	_	I-Premise
181	mm	_	_	I-Premise
182	Hg	_	_	I-Premise
183	,	_	_	I-Premise
184	respectively	_	_	I-Premise
185	)	_	_	I-Premise
186	in	_	_	I-Premise
187	the	_	_	I-Premise
188	stent	_	_	I-Premise
189	group	_	_	I-Premise
190	but	_	_	I-Premise
191	increased	_	_	I-Premise
192	(	_	_	I-Premise
193	17.0	_	_	I-Premise
194	±	_	_	I-Premise
195	3.1	_	_	I-Premise
196	mm	_	_	I-Premise
197	Hg	_	_	I-Premise
198	to	_	_	I-Premise
199	17.8	_	_	I-Premise
200	±	_	_	I-Premise
201	3.3	_	_	I-Premise
202	mm	_	_	I-Premise
203	Hg	_	_	I-Premise
204	,	_	_	I-Premise
205	respectively	_	_	I-Premise
206	)	_	_	I-Premise
207	in	_	_	I-Premise
208	the	_	_	I-Premise
209	control	_	_	I-Premise
210	group	_	_	I-Premise
211	.	_	_	I-Premise

212	Ocular	_	_	B-Premise
213	hypotensive	_	_	I-Premise
214	medication	_	_	I-Premise
215	was	_	_	I-Premise
216	statistically	_	_	I-Premise
217	significantly	_	_	I-Premise
218	lower	_	_	I-Premise
219	in	_	_	I-Premise
220	the	_	_	I-Premise
221	stent	_	_	I-Premise
222	group	_	_	I-Premise
223	at	_	_	I-Premise
224	12	_	_	I-Premise
225	months	_	_	I-Premise
226	;	_	_	I-Premise
227	it	_	_	I-Premise
228	was	_	_	I-Premise
229	also	_	_	I-Premise
230	lower	_	_	I-Premise
231	at	_	_	I-Premise
232	24	_	_	I-Premise
233	months	_	_	I-Premise
234	,	_	_	I-Premise
235	although	_	_	I-Premise
236	the	_	_	I-Premise
237	difference	_	_	I-Premise
238	was	_	_	I-Premise
239	no	_	_	I-Premise
240	longer	_	_	I-Premise
241	statistically	_	_	I-Premise
242	significant	_	_	I-Premise
243	.	_	_	I-Premise

244	Patients	_	_	B-Claim
245	with	_	_	I-Claim
246	combined	_	_	I-Claim
247	single	_	_	I-Claim
248	trabecular	_	_	I-Claim
249	micro-bypass	_	_	I-Claim
250	stent	_	_	I-Claim
251	and	_	_	I-Claim
252	cataract	_	_	I-Claim
253	surgery	_	_	I-Claim
254	had	_	_	I-Claim
255	significantly	_	_	I-Claim
256	better	_	_	I-Claim
257	IOP	_	_	I-Claim
258	control	_	_	I-Claim
259	on	_	_	I-Claim
260	no	_	_	I-Claim
261	medication	_	_	I-Claim
262	through	_	_	I-Claim
263	24	_	_	I-Claim
264	months	_	_	I-Claim
265	than	_	_	I-Claim
266	patients	_	_	I-Claim
267	having	_	_	I-Claim
268	cataract	_	_	I-Claim
269	surgery	_	_	I-Claim
270	alone	_	_	I-Claim
271	.	_	_	I-Claim

272	Both	_	_	B-Claim
273	groups	_	_	I-Claim
274	had	_	_	I-Claim
275	a	_	_	I-Claim
276	similar	_	_	I-Claim
277	favorable	_	_	I-Claim
278	long-term	_	_	I-Claim
279	safety	_	_	I-Claim
280	profile	_	_	I-Claim
281	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	intraocular	_	_	O
4	pressure	_	_	O
5	(	_	_	O
6	IOP	_	_	O
7	)	_	_	O
8	-lowering	_	_	O
9	effect	_	_	O
10	and	_	_	O
11	safety	_	_	O
12	of	_	_	O
13	topical	_	_	O
14	brimonidine	_	_	O
15	to	_	_	O
16	that	_	_	O
17	of	_	_	O
18	timolol	_	_	O
19	,	_	_	O
20	and	_	_	O
21	to	_	_	O
22	study	_	_	O
23	the	_	_	O
24	additive	_	_	O
25	effect	_	_	O
26	of	_	_	O
27	topical	_	_	O
28	brimonidine	_	_	O
29	to	_	_	O
30	topical	_	_	O
31	prostaglandin	_	_	O
32	(	_	_	O
33	PG	_	_	O
34	)	_	_	O
35	analogues	_	_	O
36	in	_	_	O
37	475	_	_	O
38	patients	_	_	O
39	with	_	_	O
40	either	_	_	O
41	ocular	_	_	O
42	hypertension	_	_	O
43	or	_	_	O
44	primary	_	_	O
45	open	_	_	O
46	angle	_	_	O
47	glaucoma	_	_	O
48	.	_	_	O

49	The	_	_	O
50	primary	_	_	O
51	endpoint	_	_	O
52	was	_	_	O
53	the	_	_	O
54	mean	_	_	O
55	IOP	_	_	O
56	change	_	_	O
57	from	_	_	O
58	the	_	_	O
59	baseline	_	_	O
60	at	_	_	O
61	0	_	_	O
62	and	_	_	O
63	2	_	_	O
64	hours	_	_	O
65	at	_	_	O
66	week	_	_	O
67	4	_	_	O
68	.	_	_	O

69	The	_	_	B-Premise
70	mean	_	_	I-Premise
71	changes	_	_	I-Premise
72	were	_	_	I-Premise
73	-4.7	_	_	I-Premise
74	+/-	_	_	I-Premise
75	2.1	_	_	I-Premise
76	(	_	_	I-Premise
77	S.	_	_	I-Premise
78	D.	_	_	I-Premise
79	)	_	_	I-Premise
80	in	_	_	I-Premise
81	the	_	_	I-Premise
82	timolol	_	_	I-Premise
83	and	_	_	I-Premise
84	-4.0	_	_	I-Premise
85	+/-	_	_	I-Premise
86	2.0	_	_	I-Premise
87	mmHg	_	_	I-Premise
88	in	_	_	I-Premise
89	the	_	_	I-Premise
90	brimonidine	_	_	I-Premise
91	group	_	_	I-Premise
92	(	_	_	I-Premise
93	p	_	_	I-Premise
94	=	_	_	I-Premise
95	0.0138	_	_	I-Premise
96	)	_	_	I-Premise
97	.	_	_	I-Premise

98	The	_	_	B-Premise
99	95	_	_	I-Premise
100	%	_	_	I-Premise
101	confidence	_	_	I-Premise
102	interval	_	_	I-Premise
103	of	_	_	I-Premise
104	the	_	_	I-Premise
105	inter-group	_	_	I-Premise
106	difference	_	_	I-Premise
107	was	_	_	I-Premise
108	greater	_	_	I-Premise
109	than	_	_	I-Premise
110	the	_	_	I-Premise
111	pre-determined	_	_	I-Premise
112	criterion	_	_	I-Premise
113	of	_	_	I-Premise
114	non-inferiority	_	_	I-Premise
115	of	_	_	I-Premise
116	brimonidine	_	_	I-Premise
117	to	_	_	I-Premise
118	timolol	_	_	I-Premise
119	.	_	_	I-Premise

120	When	_	_	B-Premise
121	added	_	_	I-Premise
122	to	_	_	I-Premise
123	PG	_	_	I-Premise
124	analogues	_	_	I-Premise
125	,	_	_	I-Premise
126	the	_	_	I-Premise
127	IOP-lowering	_	_	I-Premise
128	effect	_	_	I-Premise
129	of	_	_	I-Premise
130	brimonidine	_	_	I-Premise
131	(	_	_	I-Premise
132	-2.9	_	_	I-Premise
133	+/-	_	_	I-Premise
134	1.8	_	_	I-Premise
135	mmHg	_	_	I-Premise
136	)	_	_	I-Premise
137	was	_	_	I-Premise
138	greater	_	_	I-Premise
139	than	_	_	I-Premise
140	that	_	_	I-Premise
141	of	_	_	I-Premise
142	the	_	_	I-Premise
143	placebo	_	_	I-Premise
144	(	_	_	I-Premise
145	-2.1	_	_	I-Premise
146	+/-	_	_	I-Premise
147	1.8	_	_	I-Premise
148	mmHg	_	_	I-Premise
149	)	_	_	I-Premise
150	(	_	_	I-Premise
151	p	_	_	I-Premise
152	=	_	_	I-Premise
153	0.0010	_	_	I-Premise
154	)	_	_	I-Premise
155	.	_	_	I-Premise

156	No	_	_	O
157	appreciable	_	_	O
158	adverse	_	_	O
159	side	_	_	O
160	effects	_	_	O
161	were	_	_	O
162	encountered	_	_	O
163	.	_	_	O

164	Topical	_	_	B-Claim
165	brimonidine	_	_	I-Claim
166	showed	_	_	I-Claim
167	an	_	_	I-Claim
168	additive	_	_	I-Claim
169	IOP-lowering	_	_	I-Claim
170	effect	_	_	I-Claim
171	to	_	_	I-Claim
172	topical	_	_	I-Claim
173	PG	_	_	I-Claim
174	analogues	_	_	I-Claim
175	,	_	_	I-Claim
176	although	_	_	B-Claim
177	its	_	_	I-Claim
178	IOP-lowering	_	_	I-Claim
179	effect	_	_	I-Claim
180	was	_	_	I-Claim
181	inferior	_	_	I-Claim
182	to	_	_	I-Claim
183	topical	_	_	I-Claim
184	timolol	_	_	I-Claim
185	as	_	_	I-Claim
186	monotherapy	_	_	I-Claim
187	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	blood	_	_	O
3	pressure	_	_	O
4	and	_	_	O
5	urine	_	_	O
6	albumin-creatinine	_	_	O
7	ratio	_	_	O
8	over	_	_	O
9	time	_	_	O
10	for	_	_	O
11	participants	_	_	O
12	receiving	_	_	O
13	aflibercept	_	_	O
14	,	_	_	O
15	bevacizumab	_	_	O
16	,	_	_	O
17	or	_	_	O
18	ranibizumab	_	_	O
19	.	_	_	O

20	Preplanned	_	_	O
21	secondary	_	_	O
22	analyses	_	_	O
23	from	_	_	O
24	a	_	_	O
25	randomized	_	_	O
26	trial	_	_	O
27	comparing	_	_	O
28	aflibercept	_	_	O
29	,	_	_	O
30	bevacizumab	_	_	O
31	,	_	_	O
32	and	_	_	O
33	ranibizumab	_	_	O
34	for	_	_	O
35	diabetic	_	_	O
36	macular	_	_	O
37	edema	_	_	O
38	(	_	_	O
39	DME	_	_	O
40	)	_	_	O
41	.	_	_	O

42	The	_	_	O
43	Diabetic	_	_	O
44	Retinopathy	_	_	O
45	Clinical	_	_	O
46	Research	_	_	O
47	Network	_	_	O
48	(	_	_	O
49	DRCR.net	_	_	O
50	)	_	_	O
51	enrolled	_	_	O
52	660	_	_	O
53	participants	_	_	O
54	with	_	_	O
55	DME	_	_	O
56	and	_	_	O
57	visual	_	_	O
58	acuity	_	_	O
59	20/32	_	_	O
60	or	_	_	O
61	worse	_	_	O
62	in	_	_	O
63	at	_	_	O
64	least	_	_	O
65	one	_	_	O
66	eye	_	_	O
67	.	_	_	O

68	Eyes	_	_	O
69	received	_	_	O
70	intravitreous	_	_	O
71	injections	_	_	O
72	of	_	_	O
73	2.0	_	_	O
74	mg	_	_	O
75	aflibercept	_	_	O
76	,	_	_	O
77	1.25	_	_	O
78	mg	_	_	O
79	bevacizumab	_	_	O
80	,	_	_	O
81	or	_	_	O
82	0.3	_	_	O
83	mg	_	_	O
84	ranibizumab	_	_	O
85	based	_	_	O
86	on	_	_	O
87	a	_	_	O
88	structured	_	_	O
89	retreatment	_	_	O
90	protocol	_	_	O
91	over	_	_	O
92	2	_	_	O
93	years	_	_	O
94	.	_	_	O

95	Main	_	_	O
96	outcome	_	_	O
97	measures	_	_	O
98	were	_	_	O
99	(	_	_	O
100	1	_	_	O
101	)	_	_	O
102	a	_	_	O
103	change	_	_	O
104	in	_	_	O
105	blood	_	_	O
106	pressure	_	_	O
107	at	_	_	O
108	2	_	_	O
109	years	_	_	O
110	,	_	_	O
111	and	_	_	O
112	(	_	_	O
113	2	_	_	O
114	)	_	_	O
115	a	_	_	O
116	change	_	_	O
117	in	_	_	O
118	urine	_	_	O
119	albumin-creatinine	_	_	O
120	ratio	_	_	O
121	(	_	_	O
122	UACR	_	_	O
123	)	_	_	O
124	at	_	_	O
125	1	_	_	O
126	year	_	_	O
127	.	_	_	O

128	At	_	_	O
129	baseline	_	_	O
130	,	_	_	O
131	95	_	_	O
132	participants	_	_	O
133	(	_	_	O
134	14	_	_	O
135	%	_	_	O
136	)	_	_	O
137	had	_	_	O
138	normal	_	_	O
139	blood	_	_	O
140	pressure	_	_	O
141	,	_	_	O
142	220	_	_	O
143	(	_	_	O
144	33	_	_	O
145	%	_	_	O
146	)	_	_	O
147	had	_	_	O
148	borderline	_	_	O
149	blood	_	_	O
150	pressure	_	_	O
151	elevation	_	_	O
152	,	_	_	O
153	206	_	_	O
154	(	_	_	O
155	31	_	_	O
156	%	_	_	O
157	)	_	_	O
158	had	_	_	O
159	mild	_	_	O
160	blood	_	_	O
161	pressure	_	_	O
162	elevation	_	_	O
163	,	_	_	O
164	and	_	_	O
165	139	_	_	O
166	(	_	_	O
167	21	_	_	O
168	%	_	_	O
169	)	_	_	O
170	had	_	_	O
171	moderate	_	_	O
172	blood	_	_	O
173	pressure	_	_	O
174	elevation	_	_	O
175	.	_	_	O

176	Average	_	_	B-Premise
177	change	_	_	I-Premise
178	in	_	_	I-Premise
179	mean	_	_	I-Premise
180	arterial	_	_	I-Premise
181	pressure	_	_	I-Premise
182	from	_	_	I-Premise
183	baseline	_	_	I-Premise
184	to	_	_	I-Premise
185	2	_	_	I-Premise
186	years	_	_	I-Premise
187	was	_	_	I-Premise
188	-1.2	_	_	I-Premise
189	±	_	_	I-Premise
190	15	_	_	I-Premise
191	,	_	_	I-Premise
192	-1.8	_	_	I-Premise
193	±	_	_	I-Premise
194	13.5	_	_	I-Premise
195	,	_	_	I-Premise
196	-2.6	_	_	I-Premise
197	±	_	_	I-Premise
198	14.4	_	_	I-Premise
199	mm	_	_	I-Premise
200	Hg	_	_	I-Premise
201	in	_	_	I-Premise
202	the	_	_	I-Premise
203	aflibercept	_	_	I-Premise
204	,	_	_	I-Premise
205	bevacizumab	_	_	I-Premise
206	,	_	_	I-Premise
207	and	_	_	I-Premise
208	ranibizumab	_	_	I-Premise
209	groups	_	_	I-Premise
210	,	_	_	I-Premise
211	respectively	_	_	I-Premise
212	(	_	_	I-Premise
213	global	_	_	I-Premise
214	P	_	_	I-Premise
215	=	_	_	I-Premise
216	0.69	_	_	I-Premise
217	)	_	_	I-Premise
218	.	_	_	I-Premise

219	At	_	_	O
220	baseline	_	_	O
221	247	_	_	O
222	participants	_	_	O
223	(	_	_	O
224	38	_	_	O
225	%	_	_	O
226	)	_	_	O
227	had	_	_	O
228	no	_	_	O
229	albuminuria	_	_	O
230	(	_	_	O
231	<	_	_	O
232	30	_	_	O
233	mg/g	_	_	O
234	)	_	_	O
235	,	_	_	O
236	195	_	_	O
237	(	_	_	O
238	30	_	_	O
239	%	_	_	O
240	)	_	_	O
241	had	_	_	O
242	microalbuminuria	_	_	O
243	(	_	_	O
244	30-300	_	_	O
245	mg/g	_	_	O
246	)	_	_	O
247	,	_	_	O
248	and	_	_	O
249	212	_	_	O
250	(	_	_	O
251	32	_	_	O
252	%	_	_	O
253	)	_	_	O
254	had	_	_	O
255	macroalbuminuria	_	_	O
256	(	_	_	O
257	>	_	_	O
258	300	_	_	O
259	mg/g	_	_	O
260	)	_	_	O
261	.	_	_	O

262	Changes	_	_	B-Premise
263	in	_	_	I-Premise
264	UACR	_	_	I-Premise
265	category	_	_	I-Premise
266	were	_	_	I-Premise
267	not	_	_	I-Premise
268	different	_	_	I-Premise
269	among	_	_	I-Premise
270	treatment	_	_	I-Premise
271	groups	_	_	I-Premise
272	at	_	_	I-Premise
273	the	_	_	I-Premise
274	52-week	_	_	I-Premise
275	visit	_	_	I-Premise
276	(	_	_	I-Premise
277	global	_	_	I-Premise
278	P	_	_	I-Premise
279	=	_	_	I-Premise
280	0.29	_	_	I-Premise
281	)	_	_	I-Premise
282	.	_	_	I-Premise

283	There	_	_	B-Claim
284	do	_	_	I-Claim
285	not	_	_	I-Claim
286	appear	_	_	I-Claim
287	to	_	_	I-Claim
288	be	_	_	I-Claim
289	treatment	_	_	I-Claim
290	group	_	_	I-Claim
291	differences	_	_	I-Claim
292	for	_	_	I-Claim
293	changes	_	_	I-Claim
294	in	_	_	I-Claim
295	blood	_	_	I-Claim
296	pressure	_	_	I-Claim
297	or	_	_	I-Claim
298	UACR	_	_	I-Claim
299	as	_	_	I-Claim
300	a	_	_	I-Claim
301	reflection	_	_	I-Claim
302	of	_	_	I-Claim
303	kidney	_	_	I-Claim
304	function	_	_	I-Claim
305	in	_	_	I-Claim
306	patients	_	_	I-Claim
307	with	_	_	I-Claim
308	DME	_	_	I-Claim
309	treated	_	_	I-Claim
310	with	_	_	I-Claim
311	aflibercept	_	_	I-Claim
312	,	_	_	I-Claim
313	bevacizumab	_	_	I-Claim
314	,	_	_	I-Claim
315	or	_	_	I-Claim
316	ranibizumab	_	_	I-Claim
317	.	_	_	I-Claim


0	Androgen	_	_	B-Claim
1	deprivation	_	_	I-Claim
2	therapy	_	_	I-Claim
3	is	_	_	I-Claim
4	a	_	_	I-Claim
5	common	_	_	I-Claim
6	treatment	_	_	I-Claim
7	in	_	_	I-Claim
8	men	_	_	I-Claim
9	with	_	_	I-Claim
10	prostate	_	_	I-Claim
11	cancer	_	_	I-Claim
12	that	_	_	I-Claim
13	may	_	_	I-Claim
14	cause	_	_	I-Claim
15	fatigue	_	_	I-Claim
16	,	_	_	I-Claim
17	functional	_	_	I-Claim
18	decline	_	_	I-Claim
19	,	_	_	I-Claim
20	increased	_	_	I-Claim
21	body	_	_	I-Claim
22	fatness	_	_	I-Claim
23	,	_	_	I-Claim
24	and	_	_	I-Claim
25	loss	_	_	I-Claim
26	of	_	_	I-Claim
27	lean	_	_	I-Claim
28	body	_	_	I-Claim
29	tissue	_	_	I-Claim
30	.	_	_	I-Claim

31	These	_	_	B-Claim
32	physical	_	_	I-Claim
33	changes	_	_	I-Claim
34	can	_	_	I-Claim
35	negatively	_	_	I-Claim
36	affect	_	_	I-Claim
37	health-related	_	_	I-Claim
38	quality	_	_	I-Claim
39	of	_	_	I-Claim
40	life	_	_	I-Claim
41	.	_	_	I-Claim

42	Resistance	_	_	B-Claim
43	exercise	_	_	I-Claim
44	may	_	_	I-Claim
45	help	_	_	I-Claim
46	to	_	_	I-Claim
47	counter	_	_	I-Claim
48	some	_	_	I-Claim
49	of	_	_	I-Claim
50	these	_	_	I-Claim
51	side	_	_	I-Claim
52	effects	_	_	I-Claim
53	by	_	_	I-Claim
54	reducing	_	_	I-Claim
55	fatigue	_	_	I-Claim
56	,	_	_	I-Claim
57	elevating	_	_	I-Claim
58	mood	_	_	I-Claim
59	,	_	_	I-Claim
60	building	_	_	I-Claim
61	muscle	_	_	I-Claim
62	mass	_	_	I-Claim
63	,	_	_	I-Claim
64	and	_	_	I-Claim
65	reducing	_	_	I-Claim
66	body	_	_	I-Claim
67	fat	_	_	I-Claim
68	.	_	_	I-Claim

69	In	_	_	O
70	a	_	_	O
71	two-site	_	_	O
72	study	_	_	O
73	,	_	_	O
74	155	_	_	O
75	men	_	_	O
76	with	_	_	O
77	prostate	_	_	O
78	cancer	_	_	O
79	who	_	_	O
80	were	_	_	O
81	scheduled	_	_	O
82	to	_	_	O
83	receive	_	_	O
84	androgen	_	_	O
85	deprivation	_	_	O
86	therapy	_	_	O
87	for	_	_	O
88	at	_	_	O
89	least	_	_	O
90	3	_	_	O
91	months	_	_	O
92	after	_	_	O
93	recruitment	_	_	O
94	were	_	_	O
95	randomly	_	_	O
96	assigned	_	_	O
97	to	_	_	O
98	an	_	_	O
99	intervention	_	_	O
100	group	_	_	O
101	that	_	_	O
102	participated	_	_	O
103	in	_	_	O
104	a	_	_	O
105	resistance	_	_	O
106	exercise	_	_	O
107	program	_	_	O
108	three	_	_	O
109	times	_	_	O
110	per	_	_	O
111	week	_	_	O
112	for	_	_	O
113	12	_	_	O
114	weeks	_	_	O
115	(	_	_	O
116	82	_	_	O
117	men	_	_	O
118	)	_	_	O
119	or	_	_	O
120	to	_	_	O
121	a	_	_	O
122	waiting	_	_	O
123	list	_	_	O
124	control	_	_	O
125	group	_	_	O
126	(	_	_	O
127	73	_	_	O
128	men	_	_	O
129	)	_	_	O
130	.	_	_	O

131	The	_	_	O
132	primary	_	_	O
133	outcomes	_	_	O
134	were	_	_	O
135	fatigue	_	_	O
136	and	_	_	O
137	disease-specific	_	_	O
138	quality	_	_	O
139	of	_	_	O
140	life	_	_	O
141	as	_	_	O
142	assessed	_	_	O
143	by	_	_	O
144	self-reported	_	_	O
145	questionnaires	_	_	O
146	after	_	_	O
147	12	_	_	O
148	weeks	_	_	O
149	.	_	_	O

150	Secondary	_	_	O
151	outcomes	_	_	O
152	were	_	_	O
153	muscular	_	_	O
154	fitness	_	_	O
155	and	_	_	O
156	body	_	_	O
157	composition	_	_	O
158	.	_	_	O

159	Men	_	_	B-Premise
160	assigned	_	_	I-Premise
161	to	_	_	I-Premise
162	resistance	_	_	I-Premise
163	exercise	_	_	I-Premise
164	had	_	_	I-Premise
165	less	_	_	I-Premise
166	interference	_	_	I-Premise
167	from	_	_	I-Premise
168	fatigue	_	_	I-Premise
169	on	_	_	I-Premise
170	activities	_	_	I-Premise
171	of	_	_	I-Premise
172	daily	_	_	I-Premise
173	living	_	_	I-Premise
174	(	_	_	I-Premise
175	P	_	_	I-Premise
176	=.002	_	_	I-Premise
177	)	_	_	I-Premise
178	and	_	_	I-Premise
179	higher	_	_	I-Premise
180	quality	_	_	I-Premise
181	of	_	_	I-Premise
182	life	_	_	I-Premise
183	(	_	_	I-Premise
184	P	_	_	I-Premise
185	=.001	_	_	I-Premise
186	)	_	_	I-Premise
187	than	_	_	I-Premise
188	men	_	_	I-Premise
189	in	_	_	I-Premise
190	the	_	_	I-Premise
191	control	_	_	I-Premise
192	group	_	_	I-Premise
193	.	_	_	I-Premise

194	Men	_	_	B-Premise
195	in	_	_	I-Premise
196	the	_	_	I-Premise
197	intervention	_	_	I-Premise
198	group	_	_	I-Premise
199	demonstrated	_	_	I-Premise
200	higher	_	_	I-Premise
201	levels	_	_	I-Premise
202	of	_	_	I-Premise
203	upper	_	_	I-Premise
204	body	_	_	I-Premise
205	(	_	_	I-Premise
206	P	_	_	I-Premise
207	=.009	_	_	I-Premise
208	)	_	_	I-Premise
209	and	_	_	I-Premise
210	lower	_	_	I-Premise
211	body	_	_	I-Premise
212	(	_	_	I-Premise
213	P	_	_	I-Premise
214	<	_	_	I-Premise
215	.001	_	_	I-Premise
216	)	_	_	I-Premise
217	muscular	_	_	I-Premise
218	fitness	_	_	I-Premise
219	than	_	_	I-Premise
220	men	_	_	I-Premise
221	in	_	_	I-Premise
222	the	_	_	I-Premise
223	control	_	_	I-Premise
224	group	_	_	I-Premise
225	.	_	_	I-Premise

226	The	_	_	B-Premise
227	12-week	_	_	I-Premise
228	resistance	_	_	I-Premise
229	exercise	_	_	I-Premise
230	intervention	_	_	I-Premise
231	did	_	_	I-Premise
232	not	_	_	I-Premise
233	improve	_	_	I-Premise
234	body	_	_	I-Premise
235	composition	_	_	I-Premise
236	as	_	_	I-Premise
237	measured	_	_	I-Premise
238	by	_	_	I-Premise
239	changes	_	_	I-Premise
240	in	_	_	I-Premise
241	body	_	_	I-Premise
242	weight	_	_	I-Premise
243	,	_	_	I-Premise
244	body	_	_	I-Premise
245	mass	_	_	I-Premise
246	index	_	_	I-Premise
247	,	_	_	I-Premise
248	waist	_	_	I-Premise
249	circumference	_	_	I-Premise
250	,	_	_	I-Premise
251	or	_	_	I-Premise
252	subcutaneous	_	_	I-Premise
253	skinfolds	_	_	I-Premise
254	.	_	_	I-Premise

255	Resistance	_	_	B-Claim
256	exercise	_	_	I-Claim
257	reduces	_	_	I-Claim
258	fatigue	_	_	I-Claim
259	and	_	_	I-Claim
260	improves	_	_	I-Claim
261	quality	_	_	I-Claim
262	of	_	_	I-Claim
263	life	_	_	I-Claim
264	and	_	_	I-Claim
265	muscular	_	_	I-Claim
266	fitness	_	_	I-Claim
267	in	_	_	I-Claim
268	men	_	_	I-Claim
269	with	_	_	I-Claim
270	prostate	_	_	I-Claim
271	cancer	_	_	I-Claim
272	receiving	_	_	I-Claim
273	androgen	_	_	I-Claim
274	deprivation	_	_	I-Claim
275	therapy	_	_	I-Claim
276	.	_	_	I-Claim

277	This	_	_	B-Claim
278	form	_	_	I-Claim
279	of	_	_	I-Claim
280	exercise	_	_	I-Claim
281	can	_	_	I-Claim
282	be	_	_	I-Claim
283	an	_	_	I-Claim
284	important	_	_	I-Claim
285	component	_	_	I-Claim
286	of	_	_	I-Claim
287	supportive	_	_	I-Claim
288	care	_	_	I-Claim
289	for	_	_	I-Claim
290	these	_	_	I-Claim
291	patients	_	_	I-Claim
292	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	protracted	_	_	O
3	venous	_	_	O
4	infusion	_	_	O
5	(	_	_	O
6	PVI	_	_	O
7	)	_	_	O
8	fluorouracil	_	_	O
9	(	_	_	O
10	5-FU	_	_	O
11	)	_	_	O
12	with	_	_	O
13	PVI	_	_	O
14	5-FU	_	_	O
15	plus	_	_	O
16	mitomycin	_	_	O
17	(	_	_	O
18	MMC	_	_	O
19	)	_	_	O
20	in	_	_	O
21	patients	_	_	O
22	with	_	_	O
23	advanced	_	_	O
24	pancreatic	_	_	O
25	cancer	_	_	O
26	in	_	_	O
27	a	_	_	O
28	multicenter	_	_	O
29	,	_	_	O
30	prospectively	_	_	O
31	randomized	_	_	O
32	study	_	_	O
33	.	_	_	O

34	Two	_	_	O
35	hundred	_	_	O
36	eight	_	_	O
37	patients	_	_	O
38	were	_	_	O
39	randomized	_	_	O
40	to	_	_	O
41	PVI	_	_	O
42	5-FU	_	_	O
43	(	_	_	O
44	300	_	_	O
45	mg/m	_	_	O
46	(	_	_	O
47	2	_	_	O
48	)	_	_	O
49	/d	_	_	O
50	for	_	_	O
51	a	_	_	O
52	maximum	_	_	O
53	of	_	_	O
54	24	_	_	O
55	weeks	_	_	O
56	)	_	_	O
57	or	_	_	O
58	PVI	_	_	O
59	5-FU	_	_	O
60	plus	_	_	O
61	MMC	_	_	O
62	(	_	_	O
63	7	_	_	O
64	mg/m	_	_	O
65	(	_	_	O
66	2	_	_	O
67	)	_	_	O
68	every	_	_	O
69	6	_	_	O
70	weeks	_	_	O
71	for	_	_	O
72	four	_	_	O
73	courses	_	_	O
74	)	_	_	O
75	.	_	_	O

76	The	_	_	O
77	major	_	_	O
78	end	_	_	O
79	points	_	_	O
80	were	_	_	O
81	tumor	_	_	O
82	response	_	_	O
83	,	_	_	O
84	survival	_	_	O
85	,	_	_	O
86	toxicity	_	_	O
87	,	_	_	O
88	and	_	_	O
89	quality	_	_	O
90	of	_	_	O
91	life	_	_	O
92	(	_	_	O
93	QOL	_	_	O
94	)	_	_	O
95	.	_	_	O

96	The	_	_	O
97	two	_	_	O
98	treatment	_	_	O
99	groups	_	_	O
100	were	_	_	O
101	balanced	_	_	O
102	for	_	_	O
103	baseline	_	_	O
104	demographic	_	_	O
105	factors	_	_	O
106	,	_	_	O
107	and	_	_	O
108	62	_	_	O
109	%	_	_	O
110	had	_	_	O
111	metastatic	_	_	O
112	disease	_	_	O
113	.	_	_	O

114	The	_	_	B-Premise
115	overall	_	_	I-Premise
116	response	_	_	I-Premise
117	rate	_	_	I-Premise
118	was	_	_	I-Premise
119	8.4	_	_	I-Premise
120	%	_	_	I-Premise
121	(	_	_	I-Premise
122	95	_	_	I-Premise
123	%	_	_	I-Premise
124	confidence	_	_	I-Premise
125	interval	_	_	I-Premise
126	[	_	_	I-Premise
127	CI	_	_	I-Premise
128	]	_	_	I-Premise
129	)	_	_	I-Premise
130	3.2	_	_	I-Premise
131	%	_	_	I-Premise
132	to	_	_	I-Premise
133	13.7	_	_	I-Premise
134	%	_	_	I-Premise
135	for	_	_	I-Premise
136	patients	_	_	I-Premise
137	treated	_	_	I-Premise
138	with	_	_	I-Premise
139	PVI	_	_	I-Premise
140	5-FU	_	_	I-Premise
141	alone	_	_	I-Premise
142	compared	_	_	I-Premise
143	with	_	_	I-Premise
144	17.6	_	_	I-Premise
145	%	_	_	I-Premise
146	;	_	_	I-Premise
147	95	_	_	I-Premise
148	%	_	_	I-Premise
149	CI	_	_	I-Premise
150	10.3	_	_	I-Premise
151	%	_	_	I-Premise
152	to	_	_	I-Premise
153	25.1	_	_	I-Premise
154	%	_	_	I-Premise
155	for	_	_	I-Premise
156	PVI	_	_	I-Premise
157	5-FU	_	_	I-Premise
158	plus	_	_	I-Premise
159	MMC	_	_	I-Premise
160	(	_	_	I-Premise
161	P	_	_	I-Premise
162	=.04	_	_	I-Premise
163	)	_	_	I-Premise
164	.	_	_	I-Premise

165	Median	_	_	B-Premise
166	failure-free	_	_	I-Premise
167	survival	_	_	I-Premise
168	was	_	_	I-Premise
169	2.8	_	_	I-Premise
170	months	_	_	I-Premise
171	for	_	_	I-Premise
172	PVI	_	_	I-Premise
173	5-FU	_	_	I-Premise
174	and	_	_	I-Premise
175	3.8	_	_	I-Premise
176	months	_	_	I-Premise
177	for	_	_	I-Premise
178	PVI	_	_	I-Premise
179	5-FU	_	_	I-Premise
180	plus	_	_	I-Premise
181	MMC	_	_	I-Premise
182	(	_	_	I-Premise
183	P	_	_	I-Premise
184	=.14	_	_	I-Premise
185	)	_	_	I-Premise
186	.	_	_	I-Premise

187	Median	_	_	B-Premise
188	survival	_	_	I-Premise
189	was	_	_	I-Premise
190	5.1	_	_	I-Premise
191	months	_	_	I-Premise
192	for	_	_	I-Premise
193	PVI	_	_	I-Premise
194	5-FU	_	_	I-Premise
195	and	_	_	I-Premise
196	6.5	_	_	I-Premise
197	months	_	_	I-Premise
198	for	_	_	I-Premise
199	PVI	_	_	I-Premise
200	5-FU	_	_	I-Premise
201	plus	_	_	I-Premise
202	MMC	_	_	I-Premise
203	(	_	_	I-Premise
204	P	_	_	I-Premise
205	=.34	_	_	I-Premise
206	)	_	_	I-Premise
207	.	_	_	I-Premise

208	Toxicities	_	_	B-Premise
209	in	_	_	I-Premise
210	both	_	_	I-Premise
211	arms	_	_	I-Premise
212	were	_	_	I-Premise
213	mild	_	_	I-Premise
214	.	_	_	I-Premise

215	There	_	_	B-Premise
216	was	_	_	I-Premise
217	an	_	_	I-Premise
218	increased	_	_	I-Premise
219	incidence	_	_	I-Premise
220	of	_	_	I-Premise
221	neutropenia	_	_	I-Premise
222	in	_	_	I-Premise
223	the	_	_	I-Premise
224	5-FU	_	_	I-Premise
225	plus	_	_	I-Premise
226	MMC	_	_	I-Premise
227	arm	_	_	I-Premise
228	(	_	_	I-Premise
229	P	_	_	I-Premise
230	<	_	_	I-Premise
231	.01	_	_	I-Premise
232	)	_	_	I-Premise
233	,	_	_	I-Premise
234	although	_	_	I-Premise
235	no	_	_	I-Premise
236	differences	_	_	I-Premise
237	in	_	_	I-Premise
238	infection	_	_	I-Premise
239	were	_	_	I-Premise
240	seen	_	_	I-Premise
241	.	_	_	I-Premise

242	No	_	_	B-Premise
243	patients	_	_	I-Premise
244	developed	_	_	I-Premise
245	hemolytic	_	_	I-Premise
246	uremic	_	_	I-Premise
247	syndrome	_	_	I-Premise
248	.	_	_	I-Premise

249	Global	_	_	B-Claim
250	QOL	_	_	I-Claim
251	improved	_	_	I-Claim
252	significantly	_	_	I-Claim
253	after	_	_	I-Claim
254	24	_	_	I-Claim
255	weeks	_	_	I-Claim
256	of	_	_	I-Claim
257	treatment	_	_	I-Claim
258	compared	_	_	I-Claim
259	with	_	_	I-Claim
260	baseline	_	_	I-Claim
261	for	_	_	I-Claim
262	patients	_	_	I-Claim
263	receiving	_	_	I-Claim
264	5-FU	_	_	I-Claim
265	plus	_	_	I-Claim
266	MMC	_	_	I-Claim
267	,	_	_	I-Claim
268	although	_	_	B-Premise
269	there	_	_	I-Premise
270	was	_	_	I-Premise
271	no	_	_	I-Premise
272	statistically	_	_	I-Premise
273	significant	_	_	I-Premise
274	difference	_	_	I-Premise
275	in	_	_	I-Premise
276	QOL	_	_	I-Premise
277	between	_	_	I-Premise
278	arms	_	_	I-Premise
279	.	_	_	I-Premise

280	PVI	_	_	B-Claim
281	5-FU	_	_	I-Claim
282	plus	_	_	I-Claim
283	MMC	_	_	I-Claim
284	resulted	_	_	I-Claim
285	in	_	_	I-Claim
286	a	_	_	I-Claim
287	superior	_	_	I-Claim
288	response	_	_	I-Claim
289	rate	_	_	I-Claim
290	in	_	_	I-Claim
291	comparison	_	_	I-Claim
292	with	_	_	I-Claim
293	PVI	_	_	I-Claim
294	5-FU	_	_	I-Claim
295	alone	_	_	I-Claim
296	in	_	_	I-Claim
297	advanced	_	_	I-Claim
298	pancreatic	_	_	I-Claim
299	cancer	_	_	I-Claim
300	,	_	_	I-Claim
301	but	_	_	B-Claim
302	this	_	_	I-Claim
303	did	_	_	I-Claim
304	not	_	_	I-Claim
305	translate	_	_	I-Claim
306	into	_	_	I-Claim
307	a	_	_	I-Claim
308	survival	_	_	I-Claim
309	advantage	_	_	I-Claim
310	.	_	_	I-Claim

311	These	_	_	B-Claim
312	results	_	_	I-Claim
313	emphasize	_	_	I-Claim
314	the	_	_	I-Claim
315	importance	_	_	I-Claim
316	of	_	_	I-Claim
317	chemotherapy	_	_	I-Claim
318	in	_	_	I-Claim
319	this	_	_	I-Claim
320	setting	_	_	I-Claim
321	and	_	_	I-Claim
322	the	_	_	I-Claim
323	continuing	_	_	I-Claim
324	value	_	_	I-Claim
325	of	_	_	I-Claim
326	the	_	_	I-Claim
327	fluoropyrimidines	_	_	I-Claim
328	in	_	_	I-Claim
329	pancreatic	_	_	I-Claim
330	cancer	_	_	I-Claim
331	.	_	_	I-Claim


0	Fracture	_	_	B-Claim
1	risk	_	_	I-Claim
2	is	_	_	I-Claim
3	increased	_	_	I-Claim
4	in	_	_	I-Claim
5	individuals	_	_	I-Claim
6	with	_	_	I-Claim
7	type	_	_	I-Claim
8	2	_	_	I-Claim
9	diabetes	_	_	I-Claim
10	(	_	_	I-Claim
11	T2D	_	_	I-Claim
12	)	_	_	I-Claim
13	.	_	_	I-Claim

14	The	_	_	O
15	pathophysiological	_	_	O
16	mechanisms	_	_	O
17	accentuating	_	_	O
18	fracture	_	_	O
19	risk	_	_	O
20	in	_	_	O
21	T2D	_	_	O
22	are	_	_	O
23	convoluted	_	_	O
24	,	_	_	O
25	incorporating	_	_	O
26	factors	_	_	O
27	such	_	_	O
28	as	_	_	O
29	hyperglycaemia	_	_	O
30	,	_	_	O
31	insulinopenia	_	_	O
32	,	_	_	O
33	and	_	_	O
34	antidiabetic	_	_	O
35	drugs	_	_	O
36	.	_	_	O

37	The	_	_	O
38	objectives	_	_	O
39	of	_	_	O
40	this	_	_	O
41	study	_	_	O
42	were	_	_	O
43	to	_	_	O
44	assess	_	_	O
45	whether	_	_	O
46	different	_	_	O
47	insulin	_	_	O
48	regimens	_	_	O
49	,	_	_	O
50	metformin	_	_	O
51	and	_	_	O
52	rosiglitazone	_	_	O
53	influence	_	_	O
54	bone	_	_	O
55	metabolism	_	_	O
56	.	_	_	O

57	We	_	_	O
58	explored	_	_	O
59	if	_	_	O
60	the	_	_	O
61	concentration	_	_	O
62	of	_	_	O
63	metformin	_	_	O
64	and	_	_	O
65	rosiglitazone	_	_	O
66	in	_	_	O
67	blood	_	_	O
68	or	_	_	O
69	improved	_	_	O
70	glycaemic	_	_	O
71	control	_	_	O
72	altered	_	_	O
73	bone	_	_	O
74	turnover	_	_	O
75	.	_	_	O

76	Two-year	_	_	O
77	clinical	_	_	O
78	trial	_	_	O
79	designed	_	_	O
80	to	_	_	O
81	investigate	_	_	O
82	effects	_	_	O
83	of	_	_	O
84	antidiabetic	_	_	O
85	treatment	_	_	O
86	in	_	_	O
87	371	_	_	O
88	T2D	_	_	O
89	patients	_	_	O
90	.	_	_	O

91	Participants	_	_	O
92	were	_	_	O
93	randomized	_	_	O
94	to	_	_	O
95	short	_	_	O
96	or	_	_	O
97	long-acting	_	_	O
98	human	_	_	O
99	insulin	_	_	O
100	(	_	_	O
101	non-blinded	_	_	O
102	)	_	_	O
103	and	_	_	O
104	then	_	_	O
105	further	_	_	O
106	randomized	_	_	O
107	to	_	_	O
108	metformin	_	_	O
109	+	_	_	O
110	placebo	_	_	O
111	,	_	_	O
112	rosiglitazone	_	_	O
113	+	_	_	O
114	placebo	_	_	O
115	,	_	_	O
116	metformin	_	_	O
117	+	_	_	O
118	rosiglitazone	_	_	O
119	or	_	_	O
120	placebo	_	_	O
121	+	_	_	O
122	placebo	_	_	O
123	(	_	_	O
124	blinded	_	_	O
125	)	_	_	O
126	.	_	_	O

127	Fasting	_	_	O
128	bone	_	_	O
129	turnover	_	_	O
130	markers	_	_	O
131	(	_	_	O
132	BTM	_	_	O
133	)	_	_	O
134	representing	_	_	O
135	bone	_	_	O
136	resorption	_	_	O
137	(	_	_	O
138	CTX	_	_	O
139	)	_	_	O
140	and	_	_	O
141	formation	_	_	O
142	(	_	_	O
143	PINP	_	_	O
144	)	_	_	O
145	including	_	_	O
146	HbA1c	_	_	O
147	were	_	_	O
148	measured	_	_	O
149	at	_	_	O
150	baseline	_	_	O
151	and	_	_	O
152	after	_	_	O
153	3	_	_	O
154	,	_	_	O
155	12	_	_	O
156	and	_	_	O
157	24	_	_	O
158	months	_	_	O
159	.	_	_	O

160	Trough	_	_	O
161	steady-state	_	_	O
162	plasma	_	_	O
163	concentrations	_	_	O
164	of	_	_	O
165	metformin	_	_	O
166	and	_	_	O
167	rosiglitazone	_	_	O
168	were	_	_	O
169	measured	_	_	O
170	after	_	_	O
171	3	_	_	O
172	,	_	_	O
173	6	_	_	O
174	and	_	_	O
175	9	_	_	O
176	months	_	_	O
177	of	_	_	O
178	treatment	_	_	O
179	.	_	_	O

180	Associations	_	_	O
181	between	_	_	O
182	treatments	_	_	O
183	and	_	_	O
184	BTMs	_	_	O
185	during	_	_	O
186	the	_	_	O
187	follow-up	_	_	O
188	of	_	_	O
189	the	_	_	O
190	trial	_	_	O
191	were	_	_	O
192	analysed	_	_	O
193	in	_	_	O
194	mixed-effects	_	_	O
195	models	_	_	O
196	that	_	_	O
197	included	_	_	O
198	adjustments	_	_	O
199	for	_	_	O
200	age	_	_	O
201	,	_	_	O
202	gender	_	_	O
203	,	_	_	O
204	BMI	_	_	O
205	,	_	_	O
206	renal	_	_	O
207	function	_	_	O
208	and	_	_	O
209	repeated	_	_	O
210	measures	_	_	O
211	of	_	_	O
212	HbA1c	_	_	O
213	.	_	_	O

214	BTMs	_	_	B-Premise
215	increased	_	_	I-Premise
216	from	_	_	I-Premise
217	baseline	_	_	I-Premise
218	to	_	_	I-Premise
219	month	_	_	I-Premise
220	12	_	_	I-Premise
221	and	_	_	I-Premise
222	remained	_	_	I-Premise
223	higher	_	_	I-Premise
224	at	_	_	I-Premise
225	month	_	_	I-Premise
226	24	_	_	I-Premise
227	,	_	_	I-Premise
228	with	_	_	I-Premise
229	CTX	_	_	I-Premise
230	and	_	_	I-Premise
231	PINP	_	_	I-Premise
232	increasing	_	_	I-Premise
233	28.5	_	_	I-Premise
234	%	_	_	I-Premise
235	and	_	_	I-Premise
236	23.0	_	_	I-Premise
237	%	_	_	I-Premise
238	(	_	_	I-Premise
239	all	_	_	I-Premise
240	:	_	_	I-Premise
241	p	_	_	I-Premise
242	<	_	_	I-Premise
243	0.001	_	_	I-Premise
244	)	_	_	I-Premise
245	,	_	_	I-Premise
246	respectively	_	_	I-Premise
247	.	_	_	I-Premise

248	Allocation	_	_	B-Premise
249	of	_	_	I-Premise
250	insulin	_	_	I-Premise
251	regimens	_	_	I-Premise
252	was	_	_	I-Premise
253	not	_	_	I-Premise
254	associated	_	_	I-Premise
255	with	_	_	I-Premise
256	different	_	_	I-Premise
257	levels	_	_	I-Premise
258	of	_	_	I-Premise
259	BTMs	_	_	I-Premise
260	.	_	_	I-Premise

261	Metformin	_	_	B-Premise
262	and	_	_	I-Premise
263	metformin	_	_	I-Premise
264	+	_	_	I-Premise
265	rosiglitazone	_	_	I-Premise
266	but	_	_	I-Premise
267	not	_	_	I-Premise
268	rosiglitazone	_	_	I-Premise
269	alone	_	_	I-Premise
270	were	_	_	I-Premise
271	associated	_	_	I-Premise
272	with	_	_	I-Premise
273	lower	_	_	I-Premise
274	bone	_	_	I-Premise
275	formation	_	_	I-Premise
276	(	_	_	I-Premise
277	PINP	_	_	I-Premise
278	)	_	_	I-Premise
279	.	_	_	I-Premise

280	Neither	_	_	B-Premise
281	metformin	_	_	I-Premise
282	nor	_	_	I-Premise
283	rosiglitazone	_	_	I-Premise
284	plasma	_	_	I-Premise
285	concentrations	_	_	I-Premise
286	was	_	_	I-Premise
287	associated	_	_	I-Premise
288	with	_	_	I-Premise
289	BTMs	_	_	I-Premise
290	.	_	_	I-Premise

291	HbA1c	_	_	B-Premise
292	was	_	_	I-Premise
293	inversely	_	_	I-Premise
294	associated	_	_	I-Premise
295	with	_	_	I-Premise
296	CTX	_	_	I-Premise
297	but	_	_	I-Premise
298	not	_	_	I-Premise
299	P1NP	_	_	I-Premise
300	.	_	_	I-Premise

301	The	_	_	B-Claim
302	choice	_	_	I-Claim
303	of	_	_	I-Claim
304	insulin	_	_	I-Claim
305	treatment	_	_	I-Claim
306	is	_	_	I-Claim
307	not	_	_	I-Claim
308	influencing	_	_	I-Claim
309	BTMs	_	_	I-Claim
310	,	_	_	I-Claim
311	metformin	_	_	B-Claim
312	treatment	_	_	I-Claim
313	may	_	_	I-Claim
314	decrease	_	_	I-Claim
315	BTMs	_	_	I-Claim
316	,	_	_	I-Claim
317	and	_	_	O
318	improvement	_	_	B-Claim
319	of	_	_	I-Claim
320	glycaemic	_	_	I-Claim
321	control	_	_	I-Claim
322	may	_	_	I-Claim
323	influence	_	_	I-Claim
324	bone	_	_	I-Claim
325	resorption	_	_	I-Claim
326	activity	_	_	I-Claim
327	.	_	_	I-Claim


0	To	_	_	O
1	investigate	_	_	O
2	the	_	_	O
3	clinical	_	_	O
4	effect	_	_	O
5	and	_	_	O
6	safety	_	_	O
7	of	_	_	O
8	long-acting	_	_	O
9	pegylated	_	_	O
10	interferon-α-2b	_	_	O
11	(	_	_	O
12	Peg-IFN-α-2b	_	_	O
13	)	_	_	O
14	(	_	_	O
15	Y	_	_	O
16	shape	_	_	O
17	,	_	_	O
18	40	_	_	O
19	kD	_	_	O
20	)	_	_	O
21	injection	_	_	O
22	(	_	_	O
23	180	_	_	O
24	μg/week	_	_	O
25	)	_	_	O
26	in	_	_	O
27	the	_	_	O
28	treatment	_	_	O
29	of	_	_	O
30	HBeAg-positive	_	_	O
31	chronic	_	_	O
32	hepatitis	_	_	O
33	B	_	_	O
34	(	_	_	O
35	CHB	_	_	O
36	)	_	_	O
37	patients	_	_	O
38	,	_	_	O
39	with	_	_	O
40	standard-dose	_	_	O
41	Peg-IFN-α-2a	_	_	O
42	as	_	_	O
43	positive	_	_	O
44	control	_	_	O
45	.	_	_	O

46	This	_	_	O
47	study	_	_	O
48	was	_	_	O
49	a	_	_	O
50	multicenter	_	_	O
51	,	_	_	O
52	randomized	_	_	O
53	,	_	_	O
54	open-label	_	_	O
55	,	_	_	O
56	and	_	_	O
57	positive-controlled	_	_	O
58	phase	_	_	O
59	III	_	_	O
60	clinical	_	_	O
61	trial	_	_	O
62	.	_	_	O

63	Eligible	_	_	O
64	HBeAg-positive	_	_	O
65	CHB	_	_	O
66	patients	_	_	O
67	were	_	_	O
68	screened	_	_	O
69	out	_	_	O
70	and	_	_	O
71	randomized	_	_	O
72	to	_	_	O
73	Peg-IFN-α-2b	_	_	O
74	(	_	_	O
75	Y	_	_	O
76	shape	_	_	O
77	,	_	_	O
78	40	_	_	O
79	kD	_	_	O
80	)	_	_	O
81	trial	_	_	O
82	group	_	_	O
83	and	_	_	O
84	Peg-IFN-α-2a	_	_	O
85	control	_	_	O
86	group	_	_	O
87	at	_	_	O
88	a	_	_	O
89	ratio	_	_	O
90	of	_	_	O
91	2:1	_	_	O
92	.	_	_	O

93	The	_	_	O
94	course	_	_	O
95	of	_	_	O
96	treatment	_	_	O
97	was	_	_	O
98	48	_	_	O
99	weeks	_	_	O
100	and	_	_	O
101	the	_	_	O
102	patients	_	_	O
103	were	_	_	O
104	followed	_	_	O
105	up	_	_	O
106	for	_	_	O
107	24	_	_	O
108	weeks	_	_	O
109	after	_	_	O
110	drug	_	_	O
111	withdrawal	_	_	O
112	.	_	_	O

113	Plasma	_	_	O
114	samples	_	_	O
115	were	_	_	O
116	collected	_	_	O
117	at	_	_	O
118	screening	_	_	O
119	,	_	_	O
120	baseline	_	_	O
121	,	_	_	O
122	and	_	_	O
123	12	_	_	O
124	,	_	_	O
125	24	_	_	O
126	,	_	_	O
127	36	_	_	O
128	,	_	_	O
129	48	_	_	O
130	,	_	_	O
131	60	_	_	O
132	,	_	_	O
133	and	_	_	O
134	72	_	_	O
135	weeks	_	_	O
136	for	_	_	O
137	centralized	_	_	O
138	detection	_	_	O
139	.	_	_	O

140	COBAS®	_	_	O
141	Ampliprep/COBAS®	_	_	O
142	TaqMan®	_	_	O
143	HBV	_	_	O
144	Test	_	_	O
145	was	_	_	O
146	used	_	_	O
147	to	_	_	O
148	measure	_	_	O
149	HBV	_	_	O
150	DNA	_	_	O
151	level	_	_	O
152	by	_	_	O
153	quantitative	_	_	O
154	real-time	_	_	O
155	PCR	_	_	O
156	.	_	_	O

157	Electrochemiluminescence	_	_	O
158	immunoassay	_	_	O
159	with	_	_	O
160	Elecsys	_	_	O
161	kit	_	_	O
162	was	_	_	O
163	used	_	_	O
164	to	_	_	O
165	measure	_	_	O
166	HBV	_	_	O
167	markers	_	_	O
168	(	_	_	O
169	HBsAg	_	_	O
170	,	_	_	O
171	anti-HBs	_	_	O
172	,	_	_	O
173	HBeAg	_	_	O
174	,	_	_	O
175	anti-HBe	_	_	O
176	)	_	_	O
177	.	_	_	O

178	Adverse	_	_	O
179	events	_	_	O
180	were	_	_	O
181	recorded	_	_	O
182	in	_	_	O
183	detail	_	_	O
184	.	_	_	O

185	The	_	_	O
186	primary	_	_	O
187	outcome	_	_	O
188	measure	_	_	O
189	was	_	_	O
190	HBeAg	_	_	O
191	seroconversion	_	_	O
192	rate	_	_	O
193	after	_	_	O
194	the	_	_	O
195	24-week	_	_	O
196	follow-up	_	_	O
197	,	_	_	O
198	and	_	_	O
199	non-inferiority	_	_	O
200	was	_	_	O
201	also	_	_	O
202	tested	_	_	O
203	.	_	_	O

204	The	_	_	O
205	difference	_	_	O
206	in	_	_	O
207	HBeAg	_	_	O
208	seroconversion	_	_	O
209	rate	_	_	O
210	after	_	_	O
211	treatment	_	_	O
212	between	_	_	O
213	the	_	_	O
214	trial	_	_	O
215	group	_	_	O
216	and	_	_	O
217	the	_	_	O
218	control	_	_	O
219	group	_	_	O
220	and	_	_	O
221	two-sided	_	_	O
222	confidence	_	_	O
223	interval	_	_	O
224	(	_	_	O
225	CI	_	_	O
226	)	_	_	O
227	were	_	_	O
228	calculated	_	_	O
229	,	_	_	O
230	and	_	_	O
231	non-inferiority	_	_	O
232	was	_	_	O
233	demonstrated	_	_	O
234	if	_	_	O
235	the	_	_	O
236	lower	_	_	O
237	limit	_	_	O
238	of	_	_	O
239	95	_	_	O
240	%	_	_	O
241	CI	_	_	O
242	was	_	_	O
243	>	_	_	O
244	-10	_	_	O
245	%	_	_	O
246	.	_	_	O

247	The	_	_	O
248	t-test	_	_	O
249	,	_	_	O
250	chi-square	_	_	O
251	test	_	_	O
252	,	_	_	O
253	or	_	_	O
254	rank	_	_	O
255	sum	_	_	O
256	test	_	_	O
257	was	_	_	O
258	used	_	_	O
259	according	_	_	O
260	to	_	_	O
261	the	_	_	O
262	types	_	_	O
263	and	_	_	O
264	features	_	_	O
265	of	_	_	O
266	data	_	_	O
267	.	_	_	O

268	A	_	_	O
269	total	_	_	O
270	of	_	_	O
271	855	_	_	O
272	HBeAg-positive	_	_	O
273	CHB	_	_	O
274	patients	_	_	O
275	were	_	_	O
276	enrolled	_	_	O
277	and	_	_	O
278	820	_	_	O
279	of	_	_	O
280	them	_	_	O
281	received	_	_	O
282	treatment	_	_	O
283	(	_	_	O
284	538	_	_	O
285	in	_	_	O
286	the	_	_	O
287	trial	_	_	O
288	group	_	_	O
289	and	_	_	O
290	282	_	_	O
291	in	_	_	O
292	the	_	_	O
293	control	_	_	O
294	group	_	_	O
295	)	_	_	O
296	.	_	_	O

297	The	_	_	B-Premise
298	data	_	_	I-Premise
299	of	_	_	I-Premise
300	the	_	_	I-Premise
301	full	_	_	I-Premise
302	analysis	_	_	I-Premise
303	set	_	_	I-Premise
304	showed	_	_	I-Premise
305	that	_	_	I-Premise
306	HBeAg	_	_	I-Premise
307	seroconversion	_	_	I-Premise
308	rate	_	_	I-Premise
309	at	_	_	I-Premise
310	week	_	_	I-Premise
311	72	_	_	I-Premise
312	was	_	_	I-Premise
313	27.32	_	_	I-Premise
314	%	_	_	I-Premise
315	in	_	_	I-Premise
316	the	_	_	I-Premise
317	trial	_	_	I-Premise
318	group	_	_	I-Premise
319	and	_	_	I-Premise
320	22.70	_	_	I-Premise
321	%	_	_	I-Premise
322	in	_	_	I-Premise
323	the	_	_	I-Premise
324	control	_	_	I-Premise
325	group	_	_	I-Premise
326	with	_	_	I-Premise
327	a	_	_	I-Premise
328	rate	_	_	I-Premise
329	difference	_	_	I-Premise
330	of	_	_	I-Premise
331	4.63	_	_	I-Premise
332	%	_	_	I-Premise
333	(	_	_	I-Premise
334	95	_	_	I-Premise
335	%	_	_	I-Premise
336	CI	_	_	I-Premise
337	-1.54	_	_	I-Premise
338	%	_	_	I-Premise
339	to	_	_	I-Premise
340	10.80	_	_	I-Premise
341	%	_	_	I-Premise
342	,	_	_	I-Premise
343	P	_	_	I-Premise
344	=	_	_	I-Premise
345	0.1493	_	_	I-Premise
346	)	_	_	I-Premise
347	.	_	_	I-Premise

348	The	_	_	B-Premise
349	data	_	_	I-Premise
350	of	_	_	I-Premise
351	the	_	_	I-Premise
352	per-protocol	_	_	I-Premise
353	set	_	_	I-Premise
354	showed	_	_	I-Premise
355	that	_	_	I-Premise
356	HBeAg	_	_	I-Premise
357	seroconversion	_	_	I-Premise
358	rate	_	_	I-Premise
359	at	_	_	I-Premise
360	week	_	_	I-Premise
361	72	_	_	I-Premise
362	was	_	_	I-Premise
363	30.75	_	_	I-Premise
364	%	_	_	I-Premise
365	in	_	_	I-Premise
366	the	_	_	I-Premise
367	trial	_	_	I-Premise
368	group	_	_	I-Premise
369	and	_	_	I-Premise
370	27.14	_	_	I-Premise
371	%	_	_	I-Premise
372	in	_	_	I-Premise
373	the	_	_	I-Premise
374	control	_	_	I-Premise
375	group	_	_	I-Premise
376	with	_	_	I-Premise
377	a	_	_	I-Premise
378	rate	_	_	I-Premise
379	difference	_	_	I-Premise
380	of	_	_	I-Premise
381	3.61	_	_	I-Premise
382	%	_	_	I-Premise
383	(	_	_	I-Premise
384	95	_	_	I-Premise
385	%	_	_	I-Premise
386	CI	_	_	I-Premise
387	-3.87	_	_	I-Premise
388	%	_	_	I-Premise
389	to	_	_	I-Premise
390	11.09	_	_	I-Premise
391	%	_	_	I-Premise
392	,	_	_	I-Premise
393	P	_	_	I-Premise
394	=	_	_	I-Premise
395	0.3436	_	_	I-Premise
396	)	_	_	I-Premise
397	.	_	_	I-Premise

398	95	_	_	B-Premise
399	%	_	_	I-Premise
400	CI	_	_	I-Premise
401	met	_	_	I-Premise
402	the	_	_	I-Premise
403	non-inferiority	_	_	I-Premise
404	criteria	_	_	I-Premise
405	,	_	_	I-Premise
406	and	_	_	I-Premise
407	the	_	_	I-Premise
408	trial	_	_	I-Premise
409	group	_	_	I-Premise
410	was	_	_	I-Premise
411	non-inferior	_	_	I-Premise
412	to	_	_	I-Premise
413	the	_	_	I-Premise
414	control	_	_	I-Premise
415	group	_	_	I-Premise
416	.	_	_	I-Premise

417	The	_	_	B-Premise
418	two	_	_	I-Premise
419	groups	_	_	I-Premise
420	had	_	_	I-Premise
421	similar	_	_	I-Premise
422	incidence	_	_	I-Premise
423	rates	_	_	I-Premise
424	of	_	_	I-Premise
425	adverse	_	_	I-Premise
426	events	_	_	I-Premise
427	,	_	_	I-Premise
428	serious	_	_	I-Premise
429	adverse	_	_	I-Premise
430	events	_	_	I-Premise
431	,	_	_	I-Premise
432	and	_	_	I-Premise
433	common	_	_	I-Premise
434	adverse	_	_	I-Premise
435	events	_	_	I-Premise
436	.	_	_	I-Premise

437	In	_	_	B-Claim
438	Peg-IFN-α	_	_	I-Claim
439	regimen	_	_	I-Claim
440	for	_	_	I-Claim
441	HBeAg-positive	_	_	I-Claim
442	CHB	_	_	I-Claim
443	patients	_	_	I-Claim
444	,	_	_	I-Claim
445	the	_	_	I-Claim
446	new	_	_	I-Claim
447	drug	_	_	I-Claim
448	Peg-IFN-α-2b	_	_	I-Claim
449	(	_	_	I-Claim
450	Y	_	_	I-Claim
451	shape	_	_	I-Claim
452	,	_	_	I-Claim
453	40	_	_	I-Claim
454	kD	_	_	I-Claim
455	)	_	_	I-Claim
456	has	_	_	I-Claim
457	comparable	_	_	I-Claim
458	effect	_	_	I-Claim
459	and	_	_	I-Claim
460	safety	_	_	I-Claim
461	to	_	_	I-Claim
462	the	_	_	I-Claim
463	control	_	_	I-Claim
464	drug	_	_	I-Claim
465	Peg-IFN-α-2a	_	_	I-Claim
466	.	_	_	I-Claim


0	Available	_	_	B-Claim
1	data	_	_	I-Claim
2	indicate	_	_	I-Claim
3	that	_	_	I-Claim
4	dietary	_	_	I-Claim
5	sodium	_	_	I-Claim
6	(	_	_	I-Claim
7	as	_	_	I-Claim
8	salt	_	_	I-Claim
9	)	_	_	I-Claim
10	relates	_	_	I-Claim
11	directly	_	_	I-Claim
12	to	_	_	I-Claim
13	blood	_	_	I-Claim
14	pressure	_	_	I-Claim
15	(	_	_	I-Claim
16	BP	_	_	I-Claim
17	)	_	_	I-Claim
18	.	_	_	I-Claim

19	Most	_	_	O
20	of	_	_	O
21	these	_	_	O
22	findings	_	_	O
23	are	_	_	O
24	from	_	_	O
25	studies	_	_	O
26	lacking	_	_	O
27	dietary	_	_	O
28	data	_	_	O
29	;	_	_	O
30	hence	_	_	O
31	,	_	_	O
32	it	_	_	O
33	is	_	_	O
34	unclear	_	_	O
35	whether	_	_	O
36	this	_	_	O
37	sodium-BP	_	_	O
38	relationship	_	_	O
39	is	_	_	O
40	modulated	_	_	O
41	by	_	_	O
42	other	_	_	O
43	dietary	_	_	O
44	factors	_	_	O
45	.	_	_	O

46	With	_	_	O
47	control	_	_	O
48	for	_	_	O
49	multiple	_	_	O
50	nondietary	_	_	O
51	factors	_	_	O
52	,	_	_	O
53	but	_	_	O
54	not	_	_	O
55	body	_	_	O
56	mass	_	_	O
57	index	_	_	O
58	,	_	_	O
59	there	_	_	O
60	were	_	_	O
61	direct	_	_	O
62	relations	_	_	O
63	to	_	_	O
64	BP	_	_	O
65	of	_	_	O
66	24-hour	_	_	O
67	urinary	_	_	O
68	sodium	_	_	O
69	excretion	_	_	O
70	and	_	_	O
71	the	_	_	O
72	urinary	_	_	O
73	sodium/potassium	_	_	O
74	ratio	_	_	O
75	among	_	_	O
76	4680	_	_	O
77	men	_	_	O
78	and	_	_	O
79	women	_	_	O
80	40	_	_	O
81	to	_	_	O
82	59	_	_	O
83	years	_	_	O
84	of	_	_	O
85	age	_	_	O
86	(	_	_	O
87	17	_	_	O
88	population	_	_	O
89	samples	_	_	O
90	in	_	_	O
91	China	_	_	O
92	,	_	_	O
93	Japan	_	_	O
94	,	_	_	O
95	United	_	_	O
96	Kingdom	_	_	O
97	,	_	_	O
98	and	_	_	O
99	United	_	_	O
100	States	_	_	O
101	)	_	_	O
102	in	_	_	O
103	the	_	_	O
104	INTERMAP	_	_	O
105	(	_	_	O
106	International	_	_	O
107	Study	_	_	O
108	on	_	_	O
109	Macro/Micronutrients	_	_	O
110	and	_	_	O
111	Blood	_	_	O
112	Pressure	_	_	O
113	)	_	_	O
114	,	_	_	O
115	and	_	_	O
116	among	_	_	O
117	its	_	_	O
118	2195	_	_	O
119	American	_	_	O
120	participants	_	_	O
121	,	_	_	O
122	for	_	_	O
123	example	_	_	O
124	,	_	_	O
125	2	_	_	O
126	SD	_	_	O
127	higher	_	_	O
128	24-hour	_	_	O
129	urinary	_	_	O
130	sodium	_	_	O
131	excretion	_	_	O
132	(	_	_	O
133	118.7	_	_	O
134	mmol	_	_	O
135	)	_	_	O
136	associated	_	_	O
137	with	_	_	O
138	systolic	_	_	O
139	BP	_	_	O
140	3.7	_	_	O
141	mm	_	_	O
142	Hg	_	_	O
143	higher	_	_	O
144	.	_	_	O

145	These	_	_	O
146	sodium-BP	_	_	O
147	relations	_	_	O
148	persisted	_	_	O
149	with	_	_	O
150	control	_	_	O
151	for	_	_	O
152	13	_	_	O
153	macronutrients	_	_	O
154	,	_	_	O
155	12	_	_	O
156	vitamins	_	_	O
157	,	_	_	O
158	7	_	_	O
159	minerals	_	_	O
160	,	_	_	O
161	and	_	_	O
162	18	_	_	O
163	amino	_	_	O
164	acids	_	_	O
165	,	_	_	O
166	for	_	_	O
167	both	_	_	O
168	sex	_	_	O
169	,	_	_	O
170	older	_	_	O
171	and	_	_	O
172	younger	_	_	O
173	,	_	_	O
174	blacks	_	_	O
175	,	_	_	O
176	Hispanics	_	_	O
177	,	_	_	O
178	whites	_	_	O
179	,	_	_	O
180	and	_	_	O
181	socioeconomic	_	_	O
182	strata	_	_	O
183	.	_	_	O

184	With	_	_	O
185	control	_	_	O
186	for	_	_	O
187	body	_	_	O
188	mass	_	_	O
189	index	_	_	O
190	,	_	_	O
191	sodium-BP-but	_	_	O
192	not	_	_	O
193	sodium/potassium-BP-relations	_	_	O
194	were	_	_	O
195	attenuated	_	_	O
196	.	_	_	O

197	Normal	_	_	B-Premise
198	weight	_	_	I-Premise
199	and	_	_	I-Premise
200	obese	_	_	I-Premise
201	participants	_	_	I-Premise
202	manifested	_	_	I-Premise
203	significant	_	_	I-Premise
204	positive	_	_	I-Premise
205	relations	_	_	I-Premise
206	to	_	_	I-Premise
207	BP	_	_	I-Premise
208	of	_	_	I-Premise
209	urinary	_	_	I-Premise
210	sodium	_	_	I-Premise
211	;	_	_	I-Premise
212	relations	_	_	I-Premise
213	were	_	_	I-Premise
214	weaker	_	_	I-Premise
215	for	_	_	I-Premise
216	overweight	_	_	I-Premise
217	people	_	_	I-Premise
218	.	_	_	I-Premise

219	At	_	_	B-Premise
220	lower	_	_	I-Premise
221	but	_	_	I-Premise
222	not	_	_	I-Premise
223	higher	_	_	I-Premise
224	levels	_	_	I-Premise
225	of	_	_	I-Premise
226	24-hour	_	_	I-Premise
227	sodium	_	_	I-Premise
228	excretion	_	_	I-Premise
229	,	_	_	I-Premise
230	potassium	_	_	I-Premise
231	intake	_	_	I-Premise
232	blunted	_	_	I-Premise
233	the	_	_	I-Premise
234	sodium-BP	_	_	I-Premise
235	relation	_	_	I-Premise
236	.	_	_	I-Premise

237	The	_	_	B-Claim
238	adverse	_	_	I-Claim
239	association	_	_	I-Claim
240	of	_	_	I-Claim
241	dietary	_	_	I-Claim
242	sodium	_	_	I-Claim
243	with	_	_	I-Claim
244	BP	_	_	I-Claim
245	is	_	_	I-Claim
246	minimally	_	_	I-Claim
247	attenuated	_	_	I-Claim
248	by	_	_	I-Claim
249	other	_	_	I-Claim
250	dietary	_	_	I-Claim
251	constituents	_	_	I-Claim
252	;	_	_	I-Claim
253	these	_	_	B-Claim
254	findings	_	_	I-Claim
255	underscore	_	_	I-Claim
256	the	_	_	I-Claim
257	importance	_	_	I-Claim
258	of	_	_	I-Claim
259	reducing	_	_	I-Claim
260	salt	_	_	I-Claim
261	intake	_	_	I-Claim
262	for	_	_	I-Claim
263	the	_	_	I-Claim
264	prevention	_	_	I-Claim
265	and	_	_	I-Claim
266	control	_	_	I-Claim
267	of	_	_	I-Claim
268	prehypertension	_	_	I-Claim
269	and	_	_	I-Claim
270	hypertension	_	_	I-Claim
271	.	_	_	I-Claim


0	Evidence	_	_	B-Claim
1	has	_	_	I-Claim
2	shown	_	_	I-Claim
3	that	_	_	I-Claim
4	long-term	_	_	I-Claim
5	sodium	_	_	I-Claim
6	reduction	_	_	I-Claim
7	can	_	_	I-Claim
8	not	_	_	I-Claim
9	only	_	_	I-Claim
10	reduce	_	_	I-Claim
11	blood	_	_	I-Claim
12	pressure	_	_	I-Claim
13	,	_	_	I-Claim
14	but	_	_	I-Claim
15	also	_	_	I-Claim
16	provide	_	_	I-Claim
17	cardiovascular	_	_	I-Claim
18	benefits	_	_	I-Claim
19	.	_	_	I-Claim

20	To	_	_	O
21	date	_	_	O
22	,	_	_	O
23	there	_	_	O
24	is	_	_	O
25	little	_	_	O
26	evidence	_	_	O
27	related	_	_	O
28	to	_	_	O
29	the	_	_	O
30	effects	_	_	O
31	of	_	_	O
32	salt	_	_	O
33	reduction	_	_	O
34	on	_	_	O
35	isolated	_	_	O
36	systolic	_	_	O
37	hypertension	_	_	O
38	(	_	_	O
39	ISH	_	_	O
40	)	_	_	O
41	.A	_	_	O
42	total	_	_	O
43	of	_	_	O
44	126	_	_	O
45	hypertensive	_	_	O
46	patients	_	_	O
47	were	_	_	O
48	divided	_	_	O
49	into	_	_	O
50	an	_	_	O
51	ISH	_	_	O
52	group	_	_	O
53	(	_	_	O
54	n	_	_	O
55	=	_	_	O
56	51	_	_	O
57	)	_	_	O
58	and	_	_	O
59	a	_	_	O
60	non-ISH	_	_	O
61	(	_	_	O
62	NISH	_	_	O
63	)	_	_	O
64	group	_	_	O
65	(	_	_	O
66	n	_	_	O
67	=	_	_	O
68	75	_	_	O
69	)	_	_	O
70	.	_	_	O

71	The	_	_	O
72	members	_	_	O
73	of	_	_	O
74	each	_	_	O
75	group	_	_	O
76	were	_	_	O
77	then	_	_	O
78	randomly	_	_	O
79	assigned	_	_	O
80	to	_	_	O
81	low	_	_	O
82	sodium	_	_	O
83	salt	_	_	O
84	(	_	_	O
85	LSSalt	_	_	O
86	)	_	_	O
87	or	_	_	O
88	normal	_	_	O
89	salt	_	_	O
90	(	_	_	O
91	NSalt	_	_	O
92	)	_	_	O
93	diets	_	_	O
94	for	_	_	O
95	6	_	_	O
96	months	_	_	O
97	.	_	_	O

98	Their	_	_	O
99	blood	_	_	O
100	pressure	_	_	O
101	was	_	_	O
102	measured	_	_	O
103	every	_	_	O
104	2	_	_	O
105	months	_	_	O
106	.	_	_	O

107	Serum	_	_	O
108	plasma	_	_	O
109	renin-angiotensin	_	_	O
110	activity	_	_	O
111	,	_	_	O
112	blood	_	_	O
113	biochemical	_	_	O
114	assays	_	_	O
115	and	_	_	O
116	urinary	_	_	O
117	measurements	_	_	O
118	were	_	_	O
119	determined	_	_	O
120	at	_	_	O
121	the	_	_	O
122	baseline	_	_	O
123	and	_	_	O
124	at	_	_	O
125	the	_	_	O
126	end	_	_	O
127	of	_	_	O
128	the	_	_	O
129	6	_	_	O
130	months	_	_	O
131	.	_	_	O

132	At	_	_	B-Premise
133	the	_	_	I-Premise
134	end	_	_	I-Premise
135	of	_	_	I-Premise
136	the	_	_	I-Premise
137	study	_	_	I-Premise
138	,	_	_	I-Premise
139	the	_	_	I-Premise
140	mean	_	_	I-Premise
141	systolic	_	_	I-Premise
142	blood	_	_	I-Premise
143	pressure	_	_	I-Premise
144	(	_	_	I-Premise
145	SBP	_	_	I-Premise
146	)	_	_	I-Premise
147	of	_	_	I-Premise
148	the	_	_	I-Premise
149	ISH	_	_	I-Premise
150	LSSalt	_	_	I-Premise
151	group	_	_	I-Premise
152	had	_	_	I-Premise
153	significantly	_	_	I-Premise
154	decreased	_	_	I-Premise
155	by	_	_	I-Premise
156	10.18	_	_	I-Premise
157	mm	_	_	I-Premise
158	Hg	_	_	I-Premise
159	(	_	_	I-Premise
160	95	_	_	I-Premise
161	%	_	_	I-Premise
162	confidence	_	_	I-Premise
163	interval	_	_	I-Premise
164	(	_	_	I-Premise
165	CI	_	_	I-Premise
166	)	_	_	I-Premise
167	:	_	_	I-Premise
168	3.13	_	_	I-Premise
169	to	_	_	I-Premise
170	17.2	_	_	I-Premise
171	,	_	_	I-Premise
172	P	_	_	I-Premise
173	=	_	_	I-Premise
174	.006	_	_	I-Premise
175	)	_	_	I-Premise
176	compared	_	_	I-Premise
177	with	_	_	I-Premise
178	that	_	_	I-Premise
179	of	_	_	I-Premise
180	the	_	_	I-Premise
181	ISH	_	_	I-Premise
182	NSalt	_	_	I-Premise
183	group	_	_	I-Premise
184	,	_	_	I-Premise
185	while	_	_	O
186	the	_	_	B-Premise
187	mean	_	_	I-Premise
188	SBP	_	_	I-Premise
189	only	_	_	I-Premise
190	decreased	_	_	I-Premise
191	by	_	_	I-Premise
192	5.10	_	_	I-Premise
193	mm	_	_	I-Premise
194	Hg	_	_	I-Premise
195	(	_	_	I-Premise
196	95	_	_	I-Premise
197	%	_	_	I-Premise
198	CI	_	_	I-Premise
199	:	_	_	I-Premise
200	-2.02	_	_	I-Premise
201	to	_	_	I-Premise
202	12.2	_	_	I-Premise
203	,	_	_	I-Premise
204	P	_	_	I-Premise
205	=	_	_	I-Premise
206	.158	_	_	I-Premise
207	)	_	_	I-Premise
208	in	_	_	I-Premise
209	the	_	_	I-Premise
210	NISH	_	_	I-Premise
211	LSSalt	_	_	I-Premise
212	group	_	_	I-Premise
213	compared	_	_	I-Premise
214	with	_	_	I-Premise
215	that	_	_	I-Premise
216	of	_	_	I-Premise
217	the	_	_	I-Premise
218	NISH	_	_	I-Premise
219	NSalt	_	_	I-Premise
220	group	_	_	I-Premise
221	.	_	_	I-Premise

222	The	_	_	B-Premise
223	mean	_	_	I-Premise
224	diastolic	_	_	I-Premise
225	blood	_	_	I-Premise
226	pressure	_	_	I-Premise
227	(	_	_	I-Premise
228	DBP	_	_	I-Premise
229	)	_	_	I-Premise
230	had	_	_	I-Premise
231	no	_	_	I-Premise
232	significant	_	_	I-Premise
233	differences	_	_	I-Premise
234	in	_	_	I-Premise
235	the	_	_	I-Premise
236	ISH	_	_	I-Premise
237	and	_	_	I-Premise
238	NISH	_	_	I-Premise
239	groups	_	_	I-Premise
240	.	_	_	I-Premise

241	No	_	_	B-Premise
242	obvious	_	_	I-Premise
243	renin	_	_	I-Premise
244	angiotensin	_	_	I-Premise
245	system	_	_	I-Premise
246	activation	_	_	I-Premise
247	was	_	_	I-Premise
248	found	_	_	I-Premise
249	after	_	_	I-Premise
250	LSSalt	_	_	I-Premise
251	intervention	_	_	I-Premise
252	.	_	_	I-Premise

253	Regarding	_	_	B-Premise
254	the	_	_	I-Premise
255	urinary	_	_	I-Premise
256	excretion	_	_	I-Premise
257	of	_	_	I-Premise
258	electrolytes	_	_	I-Premise
259	and	_	_	I-Premise
260	blood	_	_	I-Premise
261	biochemical	_	_	I-Premise
262	assays	_	_	I-Premise
263	,	_	_	I-Premise
264	the	_	_	I-Premise
265	LSSalt	_	_	I-Premise
266	treatment	_	_	I-Premise
267	had	_	_	I-Premise
268	the	_	_	I-Premise
269	same	_	_	I-Premise
270	effects	_	_	I-Premise
271	on	_	_	I-Premise
272	the	_	_	I-Premise
273	ISH	_	_	I-Premise
274	group	_	_	I-Premise
275	as	_	_	I-Premise
276	on	_	_	I-Premise
277	the	_	_	I-Premise
278	NISH	_	_	I-Premise
279	group	_	_	I-Premise
280	.	_	_	I-Premise

281	The	_	_	B-Claim
282	present	_	_	I-Claim
283	study	_	_	I-Claim
284	showed	_	_	I-Claim
285	that	_	_	I-Claim
286	the	_	_	I-Claim
287	SBP	_	_	I-Claim
288	of	_	_	I-Claim
289	ISH	_	_	I-Claim
290	patients	_	_	I-Claim
291	was	_	_	I-Claim
292	significantly	_	_	I-Claim
293	decreased	_	_	I-Claim
294	with	_	_	I-Claim
295	the	_	_	I-Claim
296	LSSalt	_	_	I-Claim
297	intervention	_	_	I-Claim
298	,	_	_	I-Claim
299	while	_	_	O
300	neither	_	_	B-Claim
301	the	_	_	I-Claim
302	SBP	_	_	I-Claim
303	of	_	_	I-Claim
304	the	_	_	I-Claim
305	NISH	_	_	I-Claim
306	patients	_	_	I-Claim
307	nor	_	_	I-Claim
308	the	_	_	I-Claim
309	DBP	_	_	I-Claim
310	of	_	_	I-Claim
311	either	_	_	I-Claim
312	group	_	_	I-Claim
313	were	_	_	I-Claim
314	similarly	_	_	I-Claim
315	decreased	_	_	I-Claim
316	,	_	_	I-Claim
317	which	_	_	I-Claim
318	indicated	_	_	I-Claim
319	that	_	_	I-Claim
320	ISH	_	_	I-Claim
321	patients	_	_	I-Claim
322	were	_	_	I-Claim
323	more	_	_	I-Claim
324	sensitive	_	_	I-Claim
325	to	_	_	I-Claim
326	salt	_	_	I-Claim
327	restriction	_	_	I-Claim
328	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	the	_	_	O
3	effects	_	_	O
4	of	_	_	O
5	exercise	_	_	O
6	training	_	_	O
7	on	_	_	O
8	cardiopulmonary	_	_	O
9	function	_	_	O
10	and	_	_	O
11	quality	_	_	O
12	of	_	_	O
13	life	_	_	O
14	(	_	_	O
15	QOL	_	_	O
16	)	_	_	O
17	in	_	_	O
18	postmenopausal	_	_	O
19	breast	_	_	O
20	cancer	_	_	O
21	survivors	_	_	O
22	who	_	_	O
23	had	_	_	O
24	completed	_	_	O
25	surgery	_	_	O
26	,	_	_	O
27	radiotherapy	_	_	O
28	,	_	_	O
29	and/or	_	_	O
30	chemotherapy	_	_	O
31	with	_	_	O
32	or	_	_	O
33	without	_	_	O
34	current	_	_	O
35	hormone	_	_	O
36	therapy	_	_	O
37	use	_	_	O
38	.	_	_	O

39	Fifty-three	_	_	O
40	postmenopausal	_	_	O
41	breast	_	_	O
42	cancer	_	_	O
43	survivors	_	_	O
44	were	_	_	O
45	randomly	_	_	O
46	assigned	_	_	O
47	to	_	_	O
48	an	_	_	O
49	exercise	_	_	O
50	(	_	_	O
51	n	_	_	O
52	=	_	_	O
53	25	_	_	O
54	)	_	_	O
55	or	_	_	O
56	control	_	_	O
57	(	_	_	O
58	n	_	_	O
59	=	_	_	O
60	28	_	_	O
61	)	_	_	O
62	group	_	_	O
63	.	_	_	O

64	The	_	_	O
65	exercise	_	_	O
66	group	_	_	O
67	trained	_	_	O
68	on	_	_	O
69	cycle	_	_	O
70	ergometers	_	_	O
71	three	_	_	O
72	times	_	_	O
73	per	_	_	O
74	week	_	_	O
75	for	_	_	O
76	15	_	_	O
77	weeks	_	_	O
78	at	_	_	O
79	a	_	_	O
80	power	_	_	O
81	output	_	_	O
82	that	_	_	O
83	elicited	_	_	O
84	the	_	_	O
85	ventilatory	_	_	O
86	equivalent	_	_	O
87	for	_	_	O
88	carbon	_	_	O
89	dioxide	_	_	O
90	.	_	_	O

91	The	_	_	O
92	control	_	_	O
93	group	_	_	O
94	did	_	_	O
95	not	_	_	O
96	train	_	_	O
97	.	_	_	O

98	The	_	_	O
99	primary	_	_	O
100	outcomes	_	_	O
101	were	_	_	O
102	changes	_	_	O
103	in	_	_	O
104	peak	_	_	O
105	oxygen	_	_	O
106	consumption	_	_	O
107	and	_	_	O
108	overall	_	_	O
109	QOL	_	_	O
110	from	_	_	O
111	baseline	_	_	O
112	to	_	_	O
113	postintervention	_	_	O
114	.	_	_	O

115	Peak	_	_	O
116	oxygen	_	_	O
117	consumption	_	_	O
118	was	_	_	O
119	assessed	_	_	O
120	by	_	_	O
121	a	_	_	O
122	graded	_	_	O
123	exercise	_	_	O
124	test	_	_	O
125	using	_	_	O
126	gas	_	_	O
127	exchange	_	_	O
128	analysis	_	_	O
129	.	_	_	O

130	Overall	_	_	O
131	QOL	_	_	O
132	was	_	_	O
133	assessed	_	_	O
134	by	_	_	O
135	the	_	_	O
136	Functional	_	_	O
137	Assessment	_	_	O
138	of	_	_	O
139	Cancer	_	_	O
140	Therapy-Breast	_	_	O
141	scale	_	_	O
142	.	_	_	O

143	Fifty-two	_	_	O
144	participants	_	_	O
145	completed	_	_	O
146	the	_	_	O
147	trial	_	_	O
148	.	_	_	O

149	The	_	_	O
150	exercise	_	_	O
151	group	_	_	O
152	completed	_	_	O
153	98.4	_	_	O
154	%	_	_	O
155	of	_	_	O
156	the	_	_	O
157	exercise	_	_	O
158	sessions	_	_	O
159	.	_	_	O

160	Baseline	_	_	O
161	values	_	_	O
162	for	_	_	O
163	peak	_	_	O
164	oxygen	_	_	O
165	consumption	_	_	O
166	(	_	_	O
167	P	_	_	O
168	=.254	_	_	O
169	)	_	_	O
170	and	_	_	O
171	overall	_	_	O
172	QOL	_	_	O
173	(	_	_	O
174	P	_	_	O
175	=.286	_	_	O
176	)	_	_	O
177	did	_	_	O
178	not	_	_	O
179	differ	_	_	O
180	between	_	_	O
181	groups	_	_	O
182	.	_	_	O

183	Peak	_	_	B-Premise
184	oxygen	_	_	I-Premise
185	consumption	_	_	I-Premise
186	increased	_	_	I-Premise
187	by	_	_	I-Premise
188	0.24	_	_	I-Premise
189	L/min	_	_	I-Premise
190	in	_	_	I-Premise
191	the	_	_	I-Premise
192	exercise	_	_	I-Premise
193	group	_	_	I-Premise
194	,	_	_	I-Premise
195	whereas	_	_	B-Premise
196	it	_	_	I-Premise
197	decreased	_	_	I-Premise
198	by	_	_	I-Premise
199	0.05	_	_	I-Premise
200	L/min	_	_	I-Premise
201	in	_	_	I-Premise
202	the	_	_	I-Premise
203	control	_	_	I-Premise
204	group	_	_	I-Premise
205	(	_	_	I-Premise
206	mean	_	_	I-Premise
207	difference	_	_	I-Premise
208	,	_	_	I-Premise
209	0.29	_	_	I-Premise
210	L/min	_	_	I-Premise
211	;	_	_	I-Premise
212	95	_	_	I-Premise
213	%	_	_	I-Premise
214	confidence	_	_	I-Premise
215	interval	_	_	I-Premise
216	[	_	_	I-Premise
217	CI	_	_	I-Premise
218	]	_	_	I-Premise
219	,	_	_	I-Premise
220	0.18	_	_	I-Premise
221	to	_	_	I-Premise
222	0.40	_	_	I-Premise
223	;	_	_	I-Premise
224	P	_	_	I-Premise
225	<	_	_	I-Premise
226	.001	_	_	I-Premise
227	)	_	_	I-Premise
228	.	_	_	I-Premise

229	Overall	_	_	B-Premise
230	QOL	_	_	I-Premise
231	increased	_	_	I-Premise
232	by	_	_	I-Premise
233	9.1	_	_	I-Premise
234	points	_	_	I-Premise
235	in	_	_	I-Premise
236	the	_	_	I-Premise
237	exercise	_	_	I-Premise
238	group	_	_	I-Premise
239	compared	_	_	I-Premise
240	with	_	_	I-Premise
241	0.3	_	_	I-Premise
242	points	_	_	I-Premise
243	in	_	_	I-Premise
244	the	_	_	I-Premise
245	control	_	_	I-Premise
246	group	_	_	I-Premise
247	(	_	_	I-Premise
248	mean	_	_	I-Premise
249	difference	_	_	I-Premise
250	,	_	_	I-Premise
251	8.8	_	_	I-Premise
252	points	_	_	I-Premise
253	;	_	_	I-Premise
254	95	_	_	I-Premise
255	%	_	_	I-Premise
256	CI	_	_	I-Premise
257	,	_	_	I-Premise
258	3.6	_	_	I-Premise
259	to	_	_	I-Premise
260	14.0	_	_	I-Premise
261	;	_	_	I-Premise
262	P	_	_	I-Premise
263	=.001	_	_	I-Premise
264	)	_	_	I-Premise
265	.	_	_	I-Premise

266	Pearson	_	_	B-Premise
267	correlations	_	_	I-Premise
268	indicated	_	_	I-Premise
269	that	_	_	I-Premise
270	change	_	_	I-Premise
271	in	_	_	I-Premise
272	peak	_	_	I-Premise
273	oxygen	_	_	I-Premise
274	consumption	_	_	I-Premise
275	correlated	_	_	I-Premise
276	with	_	_	I-Premise
277	change	_	_	I-Premise
278	in	_	_	I-Premise
279	overall	_	_	I-Premise
280	QOL	_	_	I-Premise
281	(	_	_	I-Premise
282	r	_	_	I-Premise
283	=	_	_	I-Premise
284	0.45	_	_	I-Premise
285	;	_	_	I-Premise
286	P	_	_	I-Premise
287	<	_	_	I-Premise
288	.01	_	_	I-Premise
289	)	_	_	I-Premise
290	.	_	_	I-Premise

291	Exercise	_	_	B-Claim
292	training	_	_	I-Claim
293	had	_	_	I-Claim
294	beneficial	_	_	I-Claim
295	effects	_	_	I-Claim
296	on	_	_	I-Claim
297	cardiopulmonary	_	_	I-Claim
298	function	_	_	I-Claim
299	and	_	_	I-Claim
300	QOL	_	_	I-Claim
301	in	_	_	I-Claim
302	postmenopausal	_	_	I-Claim
303	breast	_	_	I-Claim
304	cancer	_	_	I-Claim
305	survivors	_	_	I-Claim
306	.	_	_	I-Claim


0	This	_	_	O
1	randomized	_	_	O
2	,	_	_	O
3	double-blind	_	_	O
4	,	_	_	O
5	placebo-controlled	_	_	O
6	clinical	_	_	O
7	trial	_	_	O
8	assessed	_	_	O
9	the	_	_	O
10	effects	_	_	O
11	of	_	_	O
12	epoetin	_	_	O
13	alfa	_	_	O
14	on	_	_	O
15	transfusion	_	_	O
16	requirements	_	_	O
17	,	_	_	O
18	hematopoietic	_	_	O
19	parameters	_	_	O
20	,	_	_	O
21	quality	_	_	O
22	of	_	_	O
23	life	_	_	O
24	(	_	_	O
25	QOL	_	_	O
26	)	_	_	O
27	,	_	_	O
28	and	_	_	O
29	safety	_	_	O
30	in	_	_	O
31	anemic	_	_	O
32	cancer	_	_	O
33	patients	_	_	O
34	receiving	_	_	O
35	nonplatinum	_	_	O
36	chemotherapy	_	_	O
37	.	_	_	O

38	The	_	_	O
39	study	_	_	O
40	also	_	_	O
41	explored	_	_	O
42	a	_	_	O
43	possible	_	_	O
44	relationship	_	_	O
45	between	_	_	O
46	increased	_	_	O
47	hemoglobin	_	_	O
48	and	_	_	O
49	survival	_	_	O
50	.	_	_	O

51	Three	_	_	O
52	hundred	_	_	O
53	seventy-five	_	_	O
54	patients	_	_	O
55	with	_	_	O
56	solid	_	_	O
57	or	_	_	O
58	nonmyeloid	_	_	O
59	hematologic	_	_	O
60	malignancies	_	_	O
61	and	_	_	O
62	hemoglobin	_	_	O
63	levels	_	_	O
64	<	_	_	O
65	or	_	_	O
66	=	_	_	O
67	10.5	_	_	O
68	g/dL	_	_	O
69	,	_	_	O
70	or	_	_	O
71	greater	_	_	O
72	than	_	_	O
73	10.5	_	_	O
74	g/dL	_	_	O
75	but	_	_	O
76	<	_	_	O
77	or	_	_	O
78	=	_	_	O
79	12.0	_	_	O
80	g/dL	_	_	O
81	after	_	_	O
82	a	_	_	O
83	hemoglobin	_	_	O
84	decrease	_	_	O
85	of	_	_	O
86	>	_	_	O
87	or	_	_	O
88	=	_	_	O
89	1.5	_	_	O
90	g/dL	_	_	O
91	per	_	_	O
92	cycle	_	_	O
93	since	_	_	O
94	starting	_	_	O
95	chemotherapy	_	_	O
96	,	_	_	O
97	were	_	_	O
98	randomized	_	_	O
99	2:1	_	_	O
100	to	_	_	O
101	epoetin	_	_	O
102	alfa	_	_	O
103	150	_	_	O
104	to	_	_	O
105	300	_	_	O
106	IU/kg	_	_	O
107	(	_	_	O
108	n	_	_	O
109	=	_	_	O
110	251	_	_	O
111	)	_	_	O
112	or	_	_	O
113	placebo	_	_	O
114	(	_	_	O
115	n	_	_	O
116	=	_	_	O
117	124	_	_	O
118	)	_	_	O
119	three	_	_	O
120	times	_	_	O
121	per	_	_	O
122	week	_	_	O
123	subcutaneously	_	_	O
124	for	_	_	O
125	12	_	_	O
126	to	_	_	O
127	24	_	_	O
128	weeks	_	_	O
129	.	_	_	O

130	The	_	_	O
131	primary	_	_	O
132	end	_	_	O
133	point	_	_	O
134	was	_	_	O
135	proportion	_	_	O
136	of	_	_	O
137	patients	_	_	O
138	transfused	_	_	O
139	;	_	_	O
140	secondary	_	_	O
141	end	_	_	O
142	points	_	_	O
143	were	_	_	O
144	change	_	_	O
145	in	_	_	O
146	hemoglobin	_	_	O
147	and	_	_	O
148	QOL	_	_	O
149	.	_	_	O

150	The	_	_	O
151	protocol	_	_	O
152	was	_	_	O
153	amended	_	_	O
154	before	_	_	O
155	unblinding	_	_	O
156	to	_	_	O
157	prospectively	_	_	O
158	collect	_	_	O
159	and	_	_	O
160	assess	_	_	O
161	survival	_	_	O
162	data	_	_	O
163	12	_	_	O
164	months	_	_	O
165	after	_	_	O
166	the	_	_	O
167	last	_	_	O
168	patient	_	_	O
169	completed	_	_	O
170	the	_	_	O
171	study	_	_	O
172	.	_	_	O

173	Epoetin	_	_	B-Premise
174	alfa	_	_	I-Premise
175	,	_	_	I-Premise
176	compared	_	_	I-Premise
177	with	_	_	I-Premise
178	placebo	_	_	I-Premise
179	,	_	_	I-Premise
180	significantly	_	_	I-Premise
181	decreased	_	_	I-Premise
182	transfusion	_	_	I-Premise
183	requirements	_	_	I-Premise
184	(	_	_	I-Premise
185	P	_	_	I-Premise
186	=.0057	_	_	I-Premise
187	)	_	_	I-Premise
188	and	_	_	I-Premise
189	increased	_	_	I-Premise
190	hemoglobin	_	_	I-Premise
191	(	_	_	I-Premise
192	P	_	_	I-Premise
193	<	_	_	I-Premise
194	.001	_	_	I-Premise
195	)	_	_	I-Premise
196	.	_	_	I-Premise

197	Improvement	_	_	B-Premise
198	of	_	_	I-Premise
199	all	_	_	I-Premise
200	primary	_	_	I-Premise
201	cancer-	_	_	I-Premise
202	and	_	_	I-Premise
203	anemia-specific	_	_	I-Premise
204	QOL	_	_	I-Premise
205	domains	_	_	I-Premise
206	,	_	_	I-Premise
207	including	_	_	I-Premise
208	energy	_	_	I-Premise
209	level	_	_	I-Premise
210	,	_	_	I-Premise
211	ability	_	_	I-Premise
212	to	_	_	I-Premise
213	do	_	_	I-Premise
214	daily	_	_	I-Premise
215	activities	_	_	I-Premise
216	,	_	_	I-Premise
217	and	_	_	I-Premise
218	fatigue	_	_	I-Premise
219	,	_	_	I-Premise
220	was	_	_	I-Premise
221	significantly	_	_	I-Premise
222	(	_	_	I-Premise
223	P	_	_	I-Premise
224	<	_	_	I-Premise
225	.01	_	_	I-Premise
226	)	_	_	I-Premise
227	greater	_	_	I-Premise
228	for	_	_	I-Premise
229	epoetin	_	_	I-Premise
230	alfa	_	_	I-Premise
231	versus	_	_	I-Premise
232	placebo	_	_	I-Premise
233	patients	_	_	I-Premise
234	.	_	_	I-Premise

235	Although	_	_	O
236	the	_	_	O
237	study	_	_	O
238	was	_	_	O
239	not	_	_	O
240	powered	_	_	O
241	for	_	_	O
242	survival	_	_	O
243	as	_	_	O
244	an	_	_	O
245	end	_	_	O
246	point	_	_	O
247	,	_	_	O
248	Kaplan-Meier	_	_	B-Premise
249	estimates	_	_	I-Premise
250	showed	_	_	I-Premise
251	a	_	_	I-Premise
252	trend	_	_	I-Premise
253	in	_	_	I-Premise
254	overall	_	_	I-Premise
255	survival	_	_	I-Premise
256	favoring	_	_	I-Premise
257	epoetin	_	_	I-Premise
258	alfa	_	_	I-Premise
259	(	_	_	I-Premise
260	P	_	_	I-Premise
261	=.13	_	_	I-Premise
262	,	_	_	I-Premise
263	log-rank	_	_	I-Premise
264	test	_	_	I-Premise
265	)	_	_	I-Premise
266	,	_	_	I-Premise
267	and	_	_	O
268	Cox	_	_	B-Premise
269	regression	_	_	I-Premise
270	analysis	_	_	I-Premise
271	showed	_	_	I-Premise
272	an	_	_	I-Premise
273	estimated	_	_	I-Premise
274	hazards	_	_	I-Premise
275	ratio	_	_	I-Premise
276	of	_	_	I-Premise
277	1.309	_	_	I-Premise
278	(	_	_	I-Premise
279	P	_	_	I-Premise
280	=.052	_	_	I-Premise
281	)	_	_	I-Premise
282	favoring	_	_	I-Premise
283	epoetin	_	_	I-Premise
284	alfa	_	_	I-Premise
285	.	_	_	I-Premise

286	Adverse	_	_	B-Premise
287	events	_	_	I-Premise
288	were	_	_	I-Premise
289	comparable	_	_	I-Premise
290	between	_	_	I-Premise
291	groups	_	_	I-Premise
292	.	_	_	I-Premise

293	Epoetin	_	_	B-Claim
294	alfa	_	_	I-Claim
295	safely	_	_	I-Claim
296	and	_	_	I-Claim
297	effectively	_	_	I-Claim
298	ameliorates	_	_	I-Claim
299	anemia	_	_	I-Claim
300	and	_	_	I-Claim
301	significantly	_	_	I-Claim
302	improves	_	_	I-Claim
303	QOL	_	_	I-Claim
304	in	_	_	I-Claim
305	cancer	_	_	I-Claim
306	patients	_	_	I-Claim
307	receiving	_	_	I-Claim
308	nonplatinum	_	_	I-Claim
309	chemotherapy	_	_	I-Claim
310	.	_	_	I-Claim

311	Encouraging	_	_	B-Claim
312	results	_	_	I-Claim
313	regarding	_	_	I-Claim
314	increased	_	_	I-Claim
315	survival	_	_	I-Claim
316	warrant	_	_	I-Claim
317	another	_	_	I-Claim
318	trial	_	_	I-Claim
319	designed	_	_	I-Claim
320	to	_	_	I-Claim
321	confirm	_	_	I-Claim
322	these	_	_	I-Claim
323	findings	_	_	I-Claim
324	.	_	_	I-Claim


0	To	_	_	O
1	prospectively	_	_	O
2	evaluate	_	_	O
3	visual	_	_	O
4	outcomes	_	_	O
5	and	_	_	O
6	complications	_	_	O
7	during	_	_	O
8	and	_	_	O
9	after	_	_	O
10	cataract	_	_	O
11	surgery	_	_	O
12	with	_	_	O
13	or	_	_	O
14	without	_	_	O
15	prophylactic	_	_	O
16	sclerostomy	_	_	O
17	in	_	_	O
18	nanophthalmic	_	_	O
19	eyes	_	_	O
20	with	_	_	O
21	visually	_	_	O
22	significant	_	_	O
23	cataract.Sixty	_	_	O
24	nanophthalmic	_	_	O
25	eyes	_	_	O
26	of	_	_	O
27	60	_	_	O
28	patients	_	_	O
29	with	_	_	O
30	visually	_	_	O
31	significant	_	_	O
32	cataract	_	_	O
33	were	_	_	O
34	randomly	_	_	O
35	assigned	_	_	O
36	to	_	_	O
37	cataract	_	_	O
38	surgery	_	_	O
39	alone	_	_	O
40	(	_	_	O
41	control	_	_	O
42	group	_	_	O
43	,	_	_	O
44	n	_	_	O
45	=	_	_	O
46	31	_	_	O
47	)	_	_	O
48	or	_	_	O
49	cataract	_	_	O
50	surgery	_	_	O
51	with	_	_	O
52	concomitant	_	_	O
53	prophylactic	_	_	O
54	sclerostomy	_	_	O
55	(	_	_	O
56	sclerostomy	_	_	O
57	group	_	_	O
58	,	_	_	O
59	n	_	_	O
60	=	_	_	O
61	29	_	_	O
62	)	_	_	O
63	.	_	_	O

64	Surgery	_	_	O
65	was	_	_	O
66	performed	_	_	O
67	using	_	_	O
68	phacoemulsification	_	_	O
69	or	_	_	O
70	manual	_	_	O
71	small-incision	_	_	O
72	cataract	_	_	O
73	surgery	_	_	O
74	(	_	_	O
75	SICS	_	_	O
76	)	_	_	O
77	based	_	_	O
78	on	_	_	O
79	the	_	_	O
80	LOCS	_	_	O
81	III	_	_	O
82	grading	_	_	O
83	score	_	_	O
84	.	_	_	O

85	Group	_	_	O
86	differences	_	_	O
87	in	_	_	O
88	intraoperative	_	_	O
89	and	_	_	O
90	postoperative	_	_	O
91	complications	_	_	O
92	were	_	_	O
93	analyzed	_	_	O
94	and	_	_	O
95	risk	_	_	O
96	factors	_	_	O
97	assessed	_	_	O
98	.	_	_	O

99	Fewer	_	_	B-Premise
100	complications	_	_	I-Premise
101	were	_	_	I-Premise
102	noted	_	_	I-Premise
103	in	_	_	I-Premise
104	eyes	_	_	I-Premise
105	receiving	_	_	I-Premise
106	sclerostomy	_	_	I-Premise
107	(	_	_	I-Premise
108	5/29	_	_	I-Premise
109	,	_	_	I-Premise
110	17.2	_	_	I-Premise
111	%	_	_	I-Premise
112	)	_	_	I-Premise
113	as	_	_	I-Premise
114	compared	_	_	I-Premise
115	to	_	_	I-Premise
116	control	_	_	I-Premise
117	group	_	_	I-Premise
118	eyes	_	_	I-Premise
119	(	_	_	I-Premise
120	12/31	_	_	I-Premise
121	,	_	_	I-Premise
122	38.7	_	_	I-Premise
123	%	_	_	I-Premise
124	)	_	_	I-Premise
125	,	_	_	I-Premise
126	though	_	_	I-Premise
127	differences	_	_	I-Premise
128	were	_	_	I-Premise
129	marginally	_	_	I-Premise
130	significant	_	_	I-Premise
131	(	_	_	I-Premise
132	P	_	_	I-Premise
133	=	_	_	I-Premise
134	.065	_	_	I-Premise
135	)	_	_	I-Premise
136	.	_	_	I-Premise

137	Four	_	_	B-Premise
138	control	_	_	I-Premise
139	group	_	_	I-Premise
140	,	_	_	I-Premise
141	but	_	_	I-Premise
142	no	_	_	I-Premise
143	sclerostomy	_	_	I-Premise
144	group	_	_	I-Premise
145	,	_	_	I-Premise
146	eyes	_	_	I-Premise
147	developed	_	_	I-Premise
148	postoperative	_	_	I-Premise
149	uveal	_	_	I-Premise
150	effusions	_	_	I-Premise
151	(	_	_	I-Premise
152	P	_	_	I-Premise
153	=	_	_	I-Premise
154	.04	_	_	I-Premise
155	)	_	_	I-Premise
156	.	_	_	I-Premise

157	In	_	_	B-Premise
158	multivariable	_	_	I-Premise
159	models	_	_	I-Premise
160	,	_	_	I-Premise
161	sclerostomy	_	_	I-Premise
162	decreased	_	_	I-Premise
163	the	_	_	I-Premise
164	odds	_	_	I-Premise
165	of	_	_	I-Premise
166	an	_	_	I-Premise
167	intraoperative	_	_	I-Premise
168	or	_	_	I-Premise
169	postoperative	_	_	I-Premise
170	complication	_	_	I-Premise
171	by	_	_	I-Premise
172	80	_	_	I-Premise
173	%	_	_	I-Premise
174	(	_	_	I-Premise
175	odds	_	_	I-Premise
176	ratio	_	_	I-Premise
177	[	_	_	I-Premise
178	OR	_	_	I-Premise
179	]	_	_	I-Premise
180	=	_	_	I-Premise
181	0.2	_	_	I-Premise
182	,	_	_	I-Premise
183	95	_	_	I-Premise
184	%	_	_	I-Premise
185	confidence	_	_	I-Premise
186	interval	_	_	I-Premise
187	[	_	_	I-Premise
188	CI	_	_	I-Premise
189	]	_	_	I-Premise
190	=	_	_	I-Premise
191	0.04-0.92	_	_	I-Premise
192	,	_	_	I-Premise
193	P	_	_	I-Premise
194	=	_	_	I-Premise
195	.039	_	_	I-Premise
196	)	_	_	I-Premise
197	;	_	_	I-Premise
198	SICS	_	_	B-Premise
199	was	_	_	I-Premise
200	associated	_	_	I-Premise
201	with	_	_	I-Premise
202	a	_	_	I-Premise
203	significantly	_	_	I-Premise
204	higher	_	_	I-Premise
205	risk	_	_	I-Premise
206	of	_	_	I-Premise
207	complications	_	_	I-Premise
208	as	_	_	I-Premise
209	compared	_	_	I-Premise
210	to	_	_	I-Premise
211	phacoemulsification	_	_	I-Premise
212	(	_	_	I-Premise
213	OR	_	_	I-Premise
214	=	_	_	I-Premise
215	5.95	_	_	I-Premise
216	,	_	_	I-Premise
217	95	_	_	I-Premise
218	%	_	_	I-Premise
219	CI	_	_	I-Premise
220	=	_	_	I-Premise
221	1.49-23.73	_	_	I-Premise
222	,	_	_	I-Premise
223	P	_	_	I-Premise
224	=	_	_	I-Premise
225	.012	_	_	I-Premise
226	)	_	_	I-Premise
227	,	_	_	I-Premise
228	while	_	_	I-Premise
229	high	_	_	I-Premise
230	preoperative	_	_	I-Premise
231	intraocular	_	_	I-Premise
232	pressure	_	_	I-Premise
233	(	_	_	I-Premise
234	OR	_	_	I-Premise
235	=	_	_	I-Premise
236	4.54	_	_	I-Premise
237	,	_	_	I-Premise
238	95	_	_	I-Premise
239	%	_	_	I-Premise
240	CI	_	_	I-Premise
241	=	_	_	I-Premise
242	0.99-20.9	_	_	I-Premise
243	,	_	_	I-Premise
244	P	_	_	I-Premise
245	=	_	_	I-Premise
246	.052	_	_	I-Premise
247	)	_	_	I-Premise
248	and	_	_	I-Premise
249	greater	_	_	I-Premise
250	lens	_	_	I-Premise
251	thickness	_	_	I-Premise
252	(	_	_	I-Premise
253	OR	_	_	I-Premise
254	=	_	_	I-Premise
255	3.38	_	_	I-Premise
256	,	_	_	I-Premise
257	95	_	_	I-Premise
258	%	_	_	I-Premise
259	CI	_	_	I-Premise
260	=	_	_	I-Premise
261	0.88-12.91	_	_	I-Premise
262	,	_	_	I-Premise
263	P	_	_	I-Premise
264	=	_	_	I-Premise
265	.075	_	_	I-Premise
266	)	_	_	I-Premise
267	demonstrated	_	_	I-Premise
268	a	_	_	I-Premise
269	marginally	_	_	I-Premise
270	significant	_	_	I-Premise
271	association	_	_	I-Premise
272	.	_	_	I-Premise

273	Cataract	_	_	B-Claim
274	surgery	_	_	I-Claim
275	in	_	_	I-Claim
276	eyes	_	_	I-Claim
277	with	_	_	I-Claim
278	nanophthalmos	_	_	I-Claim
279	is	_	_	I-Claim
280	associated	_	_	I-Claim
281	with	_	_	I-Claim
282	a	_	_	I-Claim
283	high	_	_	I-Claim
284	risk	_	_	I-Claim
285	for	_	_	I-Claim
286	vision-threatening	_	_	I-Claim
287	complications	_	_	I-Claim
288	.	_	_	I-Claim

289	Performing	_	_	B-Claim
290	a	_	_	I-Claim
291	simultaneous	_	_	I-Claim
292	prophylactic	_	_	I-Claim
293	sclerostomy	_	_	I-Claim
294	with	_	_	I-Claim
295	cataract	_	_	I-Claim
296	surgery	_	_	I-Claim
297	reduces	_	_	I-Claim
298	complication	_	_	I-Claim
299	rates	_	_	I-Claim
300	,	_	_	I-Claim
301	particularly	_	_	I-Claim
302	uveal	_	_	I-Claim
303	effusions	_	_	I-Claim
304	.	_	_	I-Claim

305	Cataract	_	_	B-Claim
306	surgery	_	_	I-Claim
307	at	_	_	I-Claim
308	earlier	_	_	I-Claim
309	stages	_	_	I-Claim
310	by	_	_	I-Claim
311	phacoemulsification	_	_	I-Claim
312	may	_	_	I-Claim
313	be	_	_	I-Claim
314	more	_	_	I-Claim
315	beneficial	_	_	I-Claim
316	than	_	_	I-Claim
317	undergoing	_	_	I-Claim
318	manual	_	_	I-Claim
319	SICS	_	_	I-Claim
320	.	_	_	I-Claim


0	To	_	_	O
1	investigate	_	_	O
2	whether	_	_	O
3	the	_	_	O
4	relative	_	_	O
5	dose-intensity	_	_	O
6	of	_	_	O
7	cyclophosphamide	_	_	O
8	,	_	_	O
9	doxorubicin	_	_	O
10	,	_	_	O
11	vincristine	_	_	O
12	,	_	_	O
13	and	_	_	O
14	prednisone	_	_	O
15	(	_	_	O
16	CHOP	_	_	O
17	)	_	_	O
18	chemotherapy	_	_	O
19	could	_	_	O
20	be	_	_	O
21	improved	_	_	O
22	by	_	_	O
23	prophylactic	_	_	O
24	administration	_	_	O
25	of	_	_	O
26	granulocyte	_	_	O
27	colony-stimulating	_	_	O
28	factor	_	_	O
29	(	_	_	O
30	G-CSF	_	_	O
31	)	_	_	O
32	in	_	_	O
33	elderly	_	_	O
34	patients	_	_	O
35	with	_	_	O
36	aggressive	_	_	O
37	non-Hodgkin	_	_	O
38	's	_	_	O
39	lymphoma	_	_	O
40	(	_	_	O
41	NHL	_	_	O
42	)	_	_	O
43	.	_	_	O

44	Patients	_	_	O
45	aged	_	_	O
46	65	_	_	O
47	to	_	_	O
48	90	_	_	O
49	years	_	_	O
50	(	_	_	O
51	median	_	_	O
52	,	_	_	O
53	72	_	_	O
54	years	_	_	O
55	)	_	_	O
56	with	_	_	O
57	stage	_	_	O
58	II	_	_	O
59	to	_	_	O
60	IV	_	_	O
61	aggressive	_	_	O
62	NHL	_	_	O
63	were	_	_	O
64	randomly	_	_	O
65	assigned	_	_	O
66	to	_	_	O
67	receive	_	_	O
68	standard	_	_	O
69	CHOP	_	_	O
70	every	_	_	O
71	3	_	_	O
72	weeks	_	_	O
73	or	_	_	O
74	CHOP	_	_	O
75	plus	_	_	O
76	G-CSF	_	_	O
77	every	_	_	O
78	3	_	_	O
79	weeks	_	_	O
80	on	_	_	O
81	days	_	_	O
82	2	_	_	O
83	to	_	_	O
84	11	_	_	O
85	of	_	_	O
86	each	_	_	O
87	cycle	_	_	O
88	.	_	_	O

89	In	_	_	B-Premise
90	389	_	_	I-Premise
91	eligible	_	_	I-Premise
92	patients	_	_	I-Premise
93	,	_	_	I-Premise
94	the	_	_	I-Premise
95	relative	_	_	I-Premise
96	dose	_	_	I-Premise
97	intensities	_	_	I-Premise
98	(	_	_	I-Premise
99	RDIs	_	_	I-Premise
100	)	_	_	I-Premise
101	of	_	_	I-Premise
102	cyclophosphamide	_	_	I-Premise
103	(	_	_	I-Premise
104	median	_	_	I-Premise
105	,	_	_	I-Premise
106	96.3	_	_	I-Premise
107	%	_	_	I-Premise
108	v	_	_	I-Premise
109	93.9	_	_	I-Premise
110	%	_	_	I-Premise
111	;	_	_	I-Premise
112	P	_	_	I-Premise
113	=.01	_	_	I-Premise
114	)	_	_	I-Premise
115	and	_	_	I-Premise
116	doxorubicin	_	_	I-Premise
117	(	_	_	I-Premise
118	median	_	_	I-Premise
119	,	_	_	I-Premise
120	95.4	_	_	I-Premise
121	%	_	_	I-Premise
122	v	_	_	I-Premise
123	93.3	_	_	I-Premise
124	%	_	_	I-Premise
125	;	_	_	I-Premise
126	P	_	_	I-Premise
127	=.04	_	_	I-Premise
128	)	_	_	I-Premise
129	were	_	_	I-Premise
130	higher	_	_	I-Premise
131	in	_	_	I-Premise
132	patients	_	_	I-Premise
133	treated	_	_	I-Premise
134	with	_	_	I-Premise
135	CHOP	_	_	I-Premise
136	plus	_	_	I-Premise
137	G-CSF	_	_	I-Premise
138	.	_	_	I-Premise

139	The	_	_	B-Premise
140	complete	_	_	I-Premise
141	response	_	_	I-Premise
142	rates	_	_	I-Premise
143	were	_	_	I-Premise
144	55	_	_	I-Premise
145	%	_	_	I-Premise
146	and	_	_	I-Premise
147	52	_	_	I-Premise
148	%	_	_	I-Premise
149	for	_	_	I-Premise
150	CHOP	_	_	I-Premise
151	and	_	_	I-Premise
152	CHOP	_	_	I-Premise
153	plus	_	_	I-Premise
154	G-CSF	_	_	I-Premise
155	,	_	_	I-Premise
156	respectively	_	_	I-Premise
157	(	_	_	I-Premise
158	P	_	_	I-Premise
159	=.63	_	_	I-Premise
160	)	_	_	I-Premise
161	.	_	_	I-Premise

162	The	_	_	B-Premise
163	actuarial	_	_	I-Premise
164	overall	_	_	I-Premise
165	survival	_	_	I-Premise
166	at	_	_	I-Premise
167	5	_	_	I-Premise
168	years	_	_	I-Premise
169	was	_	_	I-Premise
170	22	_	_	I-Premise
171	%	_	_	I-Premise
172	with	_	_	I-Premise
173	CHOP	_	_	I-Premise
174	alone	_	_	I-Premise
175	,	_	_	I-Premise
176	compared	_	_	I-Premise
177	with	_	_	I-Premise
178	24	_	_	I-Premise
179	%	_	_	I-Premise
180	with	_	_	I-Premise
181	CHOP	_	_	I-Premise
182	plus	_	_	I-Premise
183	G-CSF	_	_	I-Premise
184	(	_	_	I-Premise
185	P	_	_	I-Premise
186	=.76	_	_	I-Premise
187	)	_	_	I-Premise
188	,	_	_	I-Premise
189	with	_	_	I-Premise
190	a	_	_	I-Premise
191	median	_	_	I-Premise
192	follow-up	_	_	I-Premise
193	of	_	_	I-Premise
194	33	_	_	I-Premise
195	months	_	_	I-Premise
196	.	_	_	I-Premise

197	Patients	_	_	B-Premise
198	treated	_	_	I-Premise
199	with	_	_	I-Premise
200	CHOP	_	_	I-Premise
201	plus	_	_	I-Premise
202	G-CSF	_	_	I-Premise
203	had	_	_	I-Premise
204	an	_	_	I-Premise
205	identical	_	_	I-Premise
206	incidence	_	_	I-Premise
207	of	_	_	I-Premise
208	infections	_	_	I-Premise
209	,	_	_	I-Premise
210	with	_	_	I-Premise
211	World	_	_	I-Premise
212	Health	_	_	I-Premise
213	Organization	_	_	I-Premise
214	grade	_	_	I-Premise
215	3	_	_	I-Premise
216	to	_	_	I-Premise
217	4	_	_	I-Premise
218	(	_	_	I-Premise
219	34	_	_	I-Premise
220	of	_	_	I-Premise
221	1,191	_	_	I-Premise
222	cycles	_	_	I-Premise
223	v	_	_	I-Premise
224	36	_	_	I-Premise
225	of	_	_	I-Premise
226	1,195	_	_	I-Premise
227	cycles	_	_	I-Premise
228	)	_	_	I-Premise
229	.	_	_	I-Premise

230	Only	_	_	B-Premise
231	the	_	_	I-Premise
232	cumulative	_	_	I-Premise
233	days	_	_	I-Premise
234	with	_	_	I-Premise
235	antibiotics	_	_	I-Premise
236	were	_	_	I-Premise
237	fewer	_	_	I-Premise
238	with	_	_	I-Premise
239	CHOP	_	_	I-Premise
240	plus	_	_	I-Premise
241	G-CSF	_	_	I-Premise
242	(	_	_	I-Premise
243	median	_	_	I-Premise
244	,	_	_	I-Premise
245	0	_	_	I-Premise
246	v	_	_	I-Premise
247	6	_	_	I-Premise
248	days	_	_	I-Premise
249	;	_	_	I-Premise
250	P	_	_	I-Premise
251	=.006	_	_	I-Premise
252	)	_	_	I-Premise
253	than	_	_	I-Premise
254	with	_	_	I-Premise
255	CHOP	_	_	I-Premise
256	alone	_	_	I-Premise
257	.	_	_	I-Premise

258	The	_	_	B-Premise
259	number	_	_	I-Premise
260	of	_	_	I-Premise
261	hospital	_	_	I-Premise
262	admissions	_	_	I-Premise
263	and	_	_	I-Premise
264	the	_	_	I-Premise
265	number	_	_	I-Premise
266	of	_	_	I-Premise
267	days	_	_	I-Premise
268	in	_	_	I-Premise
269	hospital	_	_	I-Premise
270	were	_	_	I-Premise
271	not	_	_	I-Premise
272	different	_	_	I-Premise
273	.	_	_	I-Premise

274	In	_	_	B-Claim
275	elderly	_	_	I-Claim
276	patients	_	_	I-Claim
277	,	_	_	I-Claim
278	G-CSF	_	_	I-Claim
279	improved	_	_	I-Claim
280	the	_	_	I-Claim
281	RDI	_	_	I-Claim
282	of	_	_	I-Claim
283	CHOP	_	_	I-Claim
284	,	_	_	I-Claim
285	but	_	_	B-Premise
286	this	_	_	I-Premise
287	did	_	_	I-Premise
288	not	_	_	I-Premise
289	lead	_	_	I-Premise
290	to	_	_	I-Premise
291	a	_	_	I-Premise
292	higher	_	_	I-Premise
293	complete	_	_	I-Premise
294	response	_	_	I-Premise
295	rate	_	_	I-Premise
296	or	_	_	I-Premise
297	better	_	_	I-Premise
298	overall	_	_	I-Premise
299	survival	_	_	I-Premise
300	.	_	_	I-Premise

301	G-CSF	_	_	B-Claim
302	did	_	_	I-Claim
303	not	_	_	I-Claim
304	prevent	_	_	I-Claim
305	serious	_	_	I-Claim
306	infections	_	_	I-Claim
307	.	_	_	I-Claim


0	The	_	_	O
1	study	_	_	O
2	was	_	_	O
3	designed	_	_	O
4	to	_	_	O
5	compare	_	_	O
6	the	_	_	O
7	effects	_	_	O
8	of	_	_	O
9	treatment	_	_	O
10	with	_	_	O
11	a	_	_	O
12	combination	_	_	O
13	of	_	_	O
14	trastuzumab	_	_	O
15	(	_	_	O
16	Herceptin	_	_	O
17	;	_	_	O
18	Genentech	_	_	O
19	,	_	_	O
20	Inc	_	_	O
21	,	_	_	O
22	South	_	_	O
23	San	_	_	O
24	Francisco	_	_	O
25	,	_	_	O
26	CA	_	_	O
27	)	_	_	O
28	and	_	_	O
29	chemotherapy	_	_	O
30	versus	_	_	O
31	chemotherapy	_	_	O
32	alone	_	_	O
33	on	_	_	O
34	health-related	_	_	O
35	quality	_	_	O
36	of	_	_	O
37	life	_	_	O
38	(	_	_	O
39	HRQL	_	_	O
40	)	_	_	O
41	in	_	_	O
42	patients	_	_	O
43	with	_	_	O
44	HER-2/neu	_	_	O
45	overexpressing	_	_	O
46	,	_	_	O
47	metastatic	_	_	O
48	breast	_	_	O
49	cancer	_	_	O
50	.	_	_	O

51	A	_	_	O
52	sample	_	_	O
53	of	_	_	O
54	400	_	_	O
55	patients	_	_	O
56	,	_	_	O
57	not	_	_	O
58	previously	_	_	O
59	treated	_	_	O
60	for	_	_	O
61	metastatic	_	_	O
62	disease	_	_	O
63	and	_	_	O
64	randomized	_	_	O
65	to	_	_	O
66	receive	_	_	O
67	either	_	_	O
68	trastuzumab	_	_	O
69	plus	_	_	O
70	chemotherapy	_	_	O
71	(	_	_	O
72	208	_	_	O
73	patients	_	_	O
74	)	_	_	O
75	or	_	_	O
76	chemotherapy	_	_	O
77	alone	_	_	O
78	(	_	_	O
79	192	_	_	O
80	patients	_	_	O
81	)	_	_	O
82	,	_	_	O
83	completed	_	_	O
84	the	_	_	O
85	European	_	_	O
86	Organization	_	_	O
87	for	_	_	O
88	Research	_	_	O
89	and	_	_	O
90	Treatment	_	_	O
91	Care	_	_	O
92	Quality	_	_	O
93	of	_	_	O
94	Life	_	_	O
95	Questionnaire	_	_	O
96	at	_	_	O
97	baseline	_	_	O
98	and	_	_	O
99	on	_	_	O
100	at	_	_	O
101	least	_	_	O
102	one	_	_	O
103	subsequent	_	_	O
104	occasion	_	_	O
105	at	_	_	O
106	8	_	_	O
107	,	_	_	O
108	20	_	_	O
109	,	_	_	O
110	32	_	_	O
111	,	_	_	O
112	44	_	_	O
113	,	_	_	O
114	and	_	_	O
115	56	_	_	O
116	weeks	_	_	O
117	.	_	_	O

118	HRQL	_	_	O
119	improvement	_	_	O
120	or	_	_	O
121	worsening	_	_	O
122	was	_	_	O
123	defined	_	_	O
124	as	_	_	O
125	a	_	_	O
126	>	_	_	O
127	or=	_	_	O
128	10-point	_	_	O
129	change	_	_	O
130	(	_	_	O
131	range	_	_	O
132	,	_	_	O
133	0	_	_	O
134	to	_	_	O
135	100	_	_	O
136	points	_	_	O
137	)	_	_	O
138	in	_	_	O
139	the	_	_	O
140	scores	_	_	O
141	of	_	_	O
142	six	_	_	O
143	preselected	_	_	O
144	domains	_	_	O
145	(	_	_	O
146	global	_	_	O
147	quality	_	_	O
148	of	_	_	O
149	life	_	_	O
150	[	_	_	O
151	QOL	_	_	O
152	]	_	_	O
153	,	_	_	O
154	physical	_	_	O
155	,	_	_	O
156	role	_	_	O
157	,	_	_	O
158	social	_	_	O
159	,	_	_	O
160	and	_	_	O
161	emotional	_	_	O
162	functioning	_	_	O
163	,	_	_	O
164	and	_	_	O
165	fatigue	_	_	O
166	)	_	_	O
167	.	_	_	O

168	Stable	_	_	O
169	HRQL	_	_	O
170	was	_	_	O
171	defined	_	_	O
172	as	_	_	O
173	a	_	_	O
174	change	_	_	O
175	of	_	_	O
176	less	_	_	O
177	than	_	_	O
178	10	_	_	O
179	.	_	_	O

180	A	_	_	O
181	Bonferroni	_	_	O
182	correction	_	_	O
183	was	_	_	O
184	applied	_	_	O
185	for	_	_	O
186	multiple	_	_	O
187	testing	_	_	O
188	.	_	_	O

189	After	_	_	B-Premise
190	completion	_	_	I-Premise
191	of	_	_	I-Premise
192	chemotherapy	_	_	I-Premise
193	,	_	_	I-Premise
194	patients	_	_	I-Premise
195	treated	_	_	I-Premise
196	with	_	_	I-Premise
197	trastuzumab	_	_	I-Premise
198	and	_	_	I-Premise
199	chemotherapy	_	_	I-Premise
200	reported	_	_	I-Premise
201	significant	_	_	I-Premise
202	improvement	_	_	I-Premise
203	in	_	_	I-Premise
204	fatigue	_	_	I-Premise
205	(	_	_	I-Premise
206	P	_	_	I-Premise
207	<	_	_	I-Premise
208	.05	_	_	I-Premise
209	)	_	_	I-Premise
210	as	_	_	I-Premise
211	compared	_	_	I-Premise
212	with	_	_	I-Premise
213	their	_	_	I-Premise
214	baseline	_	_	I-Premise
215	scores	_	_	I-Premise
216	.	_	_	I-Premise

217	Higher	_	_	B-Premise
218	proportions	_	_	I-Premise
219	of	_	_	I-Premise
220	patients	_	_	I-Premise
221	receiving	_	_	I-Premise
222	the	_	_	I-Premise
223	combined	_	_	I-Premise
224	therapy	_	_	I-Premise
225	achieved	_	_	I-Premise
226	improvement	_	_	I-Premise
227	in	_	_	I-Premise
228	global	_	_	I-Premise
229	QOL	_	_	I-Premise
230	(	_	_	I-Premise
231	P	_	_	I-Premise
232	<	_	_	I-Premise
233	.05	_	_	I-Premise
234	)	_	_	I-Premise
235	than	_	_	I-Premise
236	did	_	_	I-Premise
237	patients	_	_	I-Premise
238	treated	_	_	I-Premise
239	with	_	_	I-Premise
240	chemotherapy	_	_	I-Premise
241	alone	_	_	I-Premise
242	.	_	_	I-Premise

243	Higher	_	_	B-Premise
244	proportions	_	_	I-Premise
245	of	_	_	I-Premise
246	the	_	_	I-Premise
247	combined	_	_	I-Premise
248	therapy	_	_	I-Premise
249	group	_	_	I-Premise
250	also	_	_	I-Premise
251	achieved	_	_	I-Premise
252	improvement	_	_	I-Premise
253	in	_	_	I-Premise
254	physical	_	_	I-Premise
255	and	_	_	I-Premise
256	role	_	_	I-Premise
257	functioning	_	_	I-Premise
258	and	_	_	I-Premise
259	in	_	_	I-Premise
260	fatigue	_	_	I-Premise
261	as	_	_	I-Premise
262	compared	_	_	I-Premise
263	with	_	_	I-Premise
264	the	_	_	I-Premise
265	chemotherapy	_	_	I-Premise
266	group	_	_	I-Premise
267	,	_	_	I-Premise
268	but	_	_	B-Premise
269	the	_	_	I-Premise
270	differences	_	_	I-Premise
271	were	_	_	I-Premise
272	not	_	_	I-Premise
273	statistically	_	_	I-Premise
274	significant	_	_	I-Premise
275	.	_	_	I-Premise

276	There	_	_	B-Premise
277	were	_	_	I-Premise
278	no	_	_	I-Premise
279	differences	_	_	I-Premise
280	in	_	_	I-Premise
281	the	_	_	I-Premise
282	proportions	_	_	I-Premise
283	of	_	_	I-Premise
284	patients	_	_	I-Premise
285	in	_	_	I-Premise
286	the	_	_	I-Premise
287	two	_	_	I-Premise
288	groups	_	_	I-Premise
289	that	_	_	I-Premise
290	reported	_	_	I-Premise
291	worsening	_	_	I-Premise
292	.	_	_	I-Premise

293	Statistically	_	_	B-Claim
294	significantly	_	_	I-Claim
295	higher	_	_	I-Claim
296	proportions	_	_	I-Claim
297	of	_	_	I-Claim
298	patients	_	_	I-Claim
299	treated	_	_	I-Claim
300	with	_	_	I-Claim
301	a	_	_	I-Claim
302	combination	_	_	I-Claim
303	of	_	_	I-Claim
304	trastuzumab	_	_	I-Claim
305	and	_	_	I-Claim
306	chemotherapy	_	_	I-Claim
307	reported	_	_	I-Claim
308	improved	_	_	I-Claim
309	global	_	_	I-Claim
310	QOL	_	_	I-Claim
311	than	_	_	I-Claim
312	did	_	_	I-Claim
313	patients	_	_	I-Claim
314	treated	_	_	I-Claim
315	by	_	_	I-Claim
316	chemotherapy	_	_	I-Claim
317	alone	_	_	I-Claim
318	.	_	_	I-Claim


0	Pregnant	_	_	O
1	women	_	_	O
2	with	_	_	O
3	an	_	_	O
4	elevated	_	_	O
5	viral	_	_	O
6	load	_	_	O
7	of	_	_	O
8	hepatitis	_	_	O
9	B	_	_	O
10	virus	_	_	O
11	(	_	_	O
12	HBV	_	_	O
13	)	_	_	O
14	have	_	_	O
15	a	_	_	O
16	risk	_	_	O
17	of	_	_	O
18	transmitting	_	_	O
19	infection	_	_	O
20	to	_	_	O
21	their	_	_	O
22	infants	_	_	O
23	,	_	_	O
24	despite	_	_	O
25	the	_	_	O
26	infants	_	_	O
27	'	_	_	O
28	receiving	_	_	O
29	hepatitis	_	_	O
30	B	_	_	O
31	immune	_	_	O
32	globulin	_	_	O
33	.	_	_	O

34	In	_	_	O
35	this	_	_	O
36	multicenter	_	_	O
37	,	_	_	O
38	double-blind	_	_	O
39	clinical	_	_	O
40	trial	_	_	O
41	performed	_	_	O
42	in	_	_	O
43	Thailand	_	_	O
44	,	_	_	O
45	we	_	_	O
46	randomly	_	_	O
47	assigned	_	_	O
48	hepatitis	_	_	O
49	B	_	_	O
50	e	_	_	O
51	antigen	_	_	O
52	(	_	_	O
53	HBeAg	_	_	O
54	)	_	_	O
55	-positive	_	_	O
56	pregnant	_	_	O
57	women	_	_	O
58	with	_	_	O
59	an	_	_	O
60	alanine	_	_	O
61	aminotransferase	_	_	O
62	level	_	_	O
63	of	_	_	O
64	60	_	_	O
65	IU	_	_	O
66	or	_	_	O
67	less	_	_	O
68	per	_	_	O
69	liter	_	_	O
70	to	_	_	O
71	receive	_	_	O
72	tenofovir	_	_	O
73	disoproxil	_	_	O
74	fumarate	_	_	O
75	(	_	_	O
76	TDF	_	_	O
77	)	_	_	O
78	or	_	_	O
79	placebo	_	_	O
80	from	_	_	O
81	28	_	_	O
82	weeks	_	_	O
83	of	_	_	O
84	gestation	_	_	O
85	to	_	_	O
86	2	_	_	O
87	months	_	_	O
88	post	_	_	O
89	partum	_	_	O
90	.	_	_	O

91	Infants	_	_	O
92	received	_	_	O
93	hepatitis	_	_	O
94	B	_	_	O
95	immune	_	_	O
96	globulin	_	_	O
97	at	_	_	O
98	birth	_	_	O
99	and	_	_	O
100	hepatitis	_	_	O
101	B	_	_	O
102	vaccine	_	_	O
103	at	_	_	O
104	birth	_	_	O
105	and	_	_	O
106	at	_	_	O
107	1	_	_	O
108	,	_	_	O
109	2	_	_	O
110	,	_	_	O
111	4	_	_	O
112	,	_	_	O
113	and	_	_	O
114	6	_	_	O
115	months	_	_	O
116	.	_	_	O

117	The	_	_	O
118	primary	_	_	O
119	end	_	_	O
120	point	_	_	O
121	was	_	_	O
122	a	_	_	O
123	hepatitis	_	_	O
124	B	_	_	O
125	surface	_	_	O
126	antigen	_	_	O
127	(	_	_	O
128	HBsAg	_	_	O
129	)	_	_	O
130	-positive	_	_	O
131	status	_	_	O
132	in	_	_	O
133	the	_	_	O
134	infant	_	_	O
135	,	_	_	O
136	confirmed	_	_	O
137	by	_	_	O
138	the	_	_	O
139	HBV	_	_	O
140	DNA	_	_	O
141	level	_	_	O
142	at	_	_	O
143	6	_	_	O
144	months	_	_	O
145	of	_	_	O
146	age	_	_	O
147	.	_	_	O

148	We	_	_	O
149	calculated	_	_	O
150	that	_	_	O
151	a	_	_	O
152	sample	_	_	O
153	of	_	_	O
154	328	_	_	O
155	women	_	_	O
156	would	_	_	O
157	provide	_	_	O
158	the	_	_	O
159	trial	_	_	O
160	with	_	_	O
161	90	_	_	O
162	%	_	_	O
163	power	_	_	O
164	to	_	_	O
165	detect	_	_	O
166	a	_	_	O
167	difference	_	_	O
168	of	_	_	O
169	at	_	_	O
170	least	_	_	O
171	9	_	_	O
172	percentage	_	_	O
173	points	_	_	O
174	in	_	_	O
175	the	_	_	O
176	transmission	_	_	O
177	rate	_	_	O
178	(	_	_	O
179	expected	_	_	O
180	rate	_	_	O
181	,	_	_	O
182	3	_	_	O
183	%	_	_	O
184	in	_	_	O
185	the	_	_	O
186	TDF	_	_	O
187	group	_	_	O
188	vs.	_	_	O
189	12	_	_	O
190	%	_	_	O
191	in	_	_	O
192	the	_	_	O
193	placebo	_	_	O
194	group	_	_	O
195	)	_	_	O
196	.	_	_	O

197	From	_	_	O
198	January	_	_	O
199	2013	_	_	O
200	to	_	_	O
201	August	_	_	O
202	2015	_	_	O
203	,	_	_	O
204	we	_	_	O
205	enrolled	_	_	O
206	331	_	_	O
207	women	_	_	O
208	;	_	_	O
209	168	_	_	O
210	women	_	_	O
211	were	_	_	O
212	randomly	_	_	O
213	assigned	_	_	O
214	to	_	_	O
215	the	_	_	O
216	TDF	_	_	O
217	group	_	_	O
218	and	_	_	O
219	163	_	_	O
220	to	_	_	O
221	the	_	_	O
222	placebo	_	_	O
223	group	_	_	O
224	.	_	_	O

225	At	_	_	O
226	enrollment	_	_	O
227	,	_	_	O
228	the	_	_	O
229	median	_	_	O
230	gestational	_	_	O
231	age	_	_	O
232	was	_	_	O
233	28.3	_	_	O
234	weeks	_	_	O
235	,	_	_	O
236	and	_	_	O
237	the	_	_	O
238	median	_	_	O
239	HBV	_	_	O
240	DNA	_	_	O
241	level	_	_	O
242	was	_	_	O
243	8.0	_	_	O
244	log10	_	_	O
245	IU	_	_	O
246	per	_	_	O
247	milliliter	_	_	O
248	.	_	_	O

249	Among	_	_	O
250	322	_	_	O
251	deliveries	_	_	O
252	(	_	_	O
253	97	_	_	O
254	%	_	_	O
255	of	_	_	O
256	the	_	_	O
257	participants	_	_	O
258	)	_	_	O
259	,	_	_	O
260	there	_	_	O
261	were	_	_	O
262	319	_	_	O
263	singleton	_	_	O
264	births	_	_	O
265	,	_	_	O
266	two	_	_	O
267	twin	_	_	O
268	pairs	_	_	O
269	,	_	_	O
270	and	_	_	O
271	one	_	_	O
272	stillborn	_	_	O
273	infant	_	_	O
274	.	_	_	O

275	The	_	_	O
276	median	_	_	O
277	time	_	_	O
278	from	_	_	O
279	birth	_	_	O
280	to	_	_	O
281	administration	_	_	O
282	of	_	_	O
283	hepatitis	_	_	O
284	B	_	_	O
285	immune	_	_	O
286	globulin	_	_	O
287	was	_	_	O
288	1.3	_	_	O
289	hours	_	_	O
290	,	_	_	O
291	and	_	_	O
292	the	_	_	O
293	median	_	_	O
294	time	_	_	O
295	from	_	_	O
296	birth	_	_	O
297	to	_	_	O
298	administration	_	_	O
299	of	_	_	O
300	hepatitis	_	_	O
301	B	_	_	O
302	vaccine	_	_	O
303	was	_	_	O
304	1.2	_	_	O
305	hours	_	_	O
306	.	_	_	O

307	In	_	_	B-Premise
308	the	_	_	I-Premise
309	primary	_	_	I-Premise
310	analysis	_	_	I-Premise
311	,	_	_	I-Premise
312	none	_	_	I-Premise
313	of	_	_	I-Premise
314	the	_	_	I-Premise
315	147	_	_	I-Premise
316	infants	_	_	I-Premise
317	(	_	_	I-Premise
318	0	_	_	I-Premise
319	%	_	_	I-Premise
320	;	_	_	I-Premise
321	95	_	_	I-Premise
322	%	_	_	I-Premise
323	confidence	_	_	I-Premise
324	interval	_	_	I-Premise
325	[	_	_	I-Premise
326	CI	_	_	I-Premise
327	]	_	_	I-Premise
328	,	_	_	I-Premise
329	0	_	_	I-Premise
330	to	_	_	I-Premise
331	2	_	_	I-Premise
332	)	_	_	I-Premise
333	in	_	_	I-Premise
334	the	_	_	I-Premise
335	TDF	_	_	I-Premise
336	group	_	_	I-Premise
337	were	_	_	I-Premise
338	infected	_	_	I-Premise
339	,	_	_	I-Premise
340	as	_	_	I-Premise
341	compared	_	_	I-Premise
342	with	_	_	I-Premise
343	3	_	_	I-Premise
344	of	_	_	I-Premise
345	147	_	_	I-Premise
346	(	_	_	I-Premise
347	2	_	_	I-Premise
348	%	_	_	I-Premise
349	;	_	_	I-Premise
350	95	_	_	I-Premise
351	%	_	_	I-Premise
352	CI	_	_	I-Premise
353	,	_	_	I-Premise
354	0	_	_	I-Premise
355	to	_	_	I-Premise
356	6	_	_	I-Premise
357	)	_	_	I-Premise
358	in	_	_	I-Premise
359	the	_	_	I-Premise
360	placebo	_	_	I-Premise
361	group	_	_	I-Premise
362	(	_	_	I-Premise
363	P=0.12	_	_	I-Premise
364	)	_	_	I-Premise
365	.	_	_	I-Premise

366	The	_	_	B-Premise
367	rate	_	_	I-Premise
368	of	_	_	I-Premise
369	adverse	_	_	I-Premise
370	events	_	_	I-Premise
371	did	_	_	I-Premise
372	not	_	_	I-Premise
373	differ	_	_	I-Premise
374	significantly	_	_	I-Premise
375	between	_	_	I-Premise
376	groups	_	_	I-Premise
377	.	_	_	I-Premise

378	The	_	_	B-Premise
379	incidence	_	_	I-Premise
380	of	_	_	I-Premise
381	a	_	_	I-Premise
382	maternal	_	_	I-Premise
383	alanine	_	_	I-Premise
384	aminotransferase	_	_	I-Premise
385	level	_	_	I-Premise
386	of	_	_	I-Premise
387	more	_	_	I-Premise
388	than	_	_	I-Premise
389	300	_	_	I-Premise
390	IU	_	_	I-Premise
391	per	_	_	I-Premise
392	liter	_	_	I-Premise
393	after	_	_	I-Premise
394	discontinuation	_	_	I-Premise
395	of	_	_	I-Premise
396	the	_	_	I-Premise
397	trial	_	_	I-Premise
398	regimen	_	_	I-Premise
399	was	_	_	I-Premise
400	6	_	_	I-Premise
401	%	_	_	I-Premise
402	in	_	_	I-Premise
403	the	_	_	I-Premise
404	TDF	_	_	I-Premise
405	group	_	_	I-Premise
406	and	_	_	I-Premise
407	3	_	_	I-Premise
408	%	_	_	I-Premise
409	in	_	_	I-Premise
410	the	_	_	I-Premise
411	placebo	_	_	I-Premise
412	group	_	_	I-Premise
413	(	_	_	I-Premise
414	P=0.29	_	_	I-Premise
415	)	_	_	I-Premise
416	.	_	_	I-Premise

417	In	_	_	B-Claim
418	a	_	_	I-Claim
419	setting	_	_	I-Claim
420	in	_	_	I-Claim
421	which	_	_	I-Claim
422	the	_	_	I-Claim
423	rate	_	_	I-Claim
424	of	_	_	I-Claim
425	mother-to-child	_	_	I-Claim
426	HBV	_	_	I-Claim
427	transmission	_	_	I-Claim
428	was	_	_	I-Claim
429	low	_	_	I-Claim
430	with	_	_	I-Claim
431	the	_	_	I-Claim
432	administration	_	_	I-Claim
433	of	_	_	I-Claim
434	hepatitis	_	_	I-Claim
435	B	_	_	I-Claim
436	immune	_	_	I-Claim
437	globulin	_	_	I-Claim
438	and	_	_	I-Claim
439	hepatitis	_	_	I-Claim
440	B	_	_	I-Claim
441	vaccine	_	_	I-Claim
442	in	_	_	I-Claim
443	infants	_	_	I-Claim
444	born	_	_	I-Claim
445	to	_	_	I-Claim
446	HBeAg-positive	_	_	I-Claim
447	mothers	_	_	I-Claim
448	,	_	_	I-Claim
449	the	_	_	I-Claim
450	additional	_	_	I-Claim
451	maternal	_	_	I-Claim
452	use	_	_	I-Claim
453	of	_	_	I-Claim
454	TDF	_	_	I-Claim
455	did	_	_	I-Claim
456	not	_	_	I-Claim
457	result	_	_	I-Claim
458	in	_	_	I-Claim
459	a	_	_	I-Claim
460	significantly	_	_	I-Claim
461	lower	_	_	I-Claim
462	rate	_	_	I-Claim
463	of	_	_	I-Claim
464	transmission	_	_	I-Claim
465	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	effects	_	_	O
4	of	_	_	O
5	continuous	_	_	O
6	glucose	_	_	O
7	monitoring	_	_	O
8	(	_	_	O
9	CGM	_	_	O
10	)	_	_	O
11	on	_	_	O
12	nocturnal	_	_	O
13	and	_	_	O
14	daytime	_	_	O
15	hypoglycemia	_	_	O
16	in	_	_	O
17	persons	_	_	O
18	with	_	_	O
19	type	_	_	O
20	1	_	_	O
21	diabetes	_	_	O
22	treated	_	_	O
23	with	_	_	O
24	multiple	_	_	O
25	daily	_	_	O
26	insulin	_	_	O
27	injections	_	_	O
28	(	_	_	O
29	MDI	_	_	O
30	)	_	_	O
31	;	_	_	O
32	we	_	_	O
33	also	_	_	O
34	evaluated	_	_	O
35	factors	_	_	O
36	related	_	_	O
37	to	_	_	O
38	differences	_	_	O
39	in	_	_	O
40	hypoglycemia	_	_	O
41	confidence	_	_	O
42	in	_	_	O
43	this	_	_	O
44	population	_	_	O
45	.	_	_	O

46	Evaluations	_	_	O
47	were	_	_	O
48	performed	_	_	O
49	from	_	_	O
50	the	_	_	O
51	GOLD	_	_	O
52	randomized	_	_	O
53	trial	_	_	O
54	,	_	_	O
55	an	_	_	O
56	open-label	_	_	O
57	multicenter	_	_	O
58	crossover	_	_	O
59	randomized	_	_	O
60	clinical	_	_	O
61	trial	_	_	O
62	(	_	_	O
63	n	_	_	O
64	=	_	_	O
65	161	_	_	O
66	)	_	_	O
67	over	_	_	O
68	69	_	_	O
69	weeks	_	_	O
70	comparing	_	_	O
71	CGM	_	_	O
72	to	_	_	O
73	self-measurement	_	_	O
74	of	_	_	O
75	blood	_	_	O
76	glucose	_	_	O
77	(	_	_	O
78	SMBG	_	_	O
79	)	_	_	O
80	in	_	_	O
81	persons	_	_	O
82	with	_	_	O
83	type	_	_	O
84	1	_	_	O
85	diabetes	_	_	O
86	treated	_	_	O
87	with	_	_	O
88	MDI	_	_	O
89	.	_	_	O

90	Masked	_	_	O
91	CGM	_	_	O
92	and	_	_	O
93	the	_	_	O
94	hypoglycemia	_	_	O
95	confidence	_	_	O
96	questionnaire	_	_	O
97	were	_	_	O
98	used	_	_	O
99	for	_	_	O
100	evaluations	_	_	O
101	.	_	_	O

102	Time	_	_	B-Premise
103	with	_	_	I-Premise
104	nocturnal	_	_	I-Premise
105	hypoglycemia	_	_	I-Premise
106	,	_	_	I-Premise
107	glucose	_	_	I-Premise
108	levels	_	_	I-Premise
109	<	_	_	I-Premise
110	70	_	_	I-Premise
111	mg/dL	_	_	I-Premise
112	was	_	_	I-Premise
113	reduced	_	_	I-Premise
114	by	_	_	I-Premise
115	48	_	_	I-Premise
116	%	_	_	I-Premise
117	(	_	_	I-Premise
118	10.2	_	_	I-Premise
119	vs.	_	_	I-Premise
120	19.6	_	_	I-Premise
121	min	_	_	I-Premise
122	each	_	_	I-Premise
123	night	_	_	I-Premise
124	,	_	_	I-Premise
125	P	_	_	I-Premise
126	<	_	_	I-Premise
127	0.001	_	_	I-Premise
128	)	_	_	I-Premise
129	and	_	_	I-Premise
130	glucose	_	_	I-Premise
131	levels	_	_	I-Premise
132	<	_	_	I-Premise
133	54	_	_	I-Premise
134	mg/dL	_	_	I-Premise
135	by	_	_	I-Premise
136	65	_	_	I-Premise
137	%	_	_	I-Premise
138	.	_	_	I-Premise

139	(	_	_	I-Premise
140	3.1	_	_	I-Premise
141	vs.	_	_	I-Premise
142	8.9	_	_	I-Premise
143	min	_	_	I-Premise
144	,	_	_	I-Premise
145	P	_	_	I-Premise
146	<	_	_	I-Premise
147	0.001	_	_	I-Premise
148	)	_	_	I-Premise
149	.	_	_	I-Premise

150	For	_	_	B-Premise
151	the	_	_	I-Premise
152	corresponding	_	_	I-Premise
153	glucose	_	_	I-Premise
154	cutoffs	_	_	I-Premise
155	,	_	_	I-Premise
156	daytime	_	_	I-Premise
157	hypoglycemia	_	_	I-Premise
158	was	_	_	I-Premise
159	reduced	_	_	I-Premise
160	by	_	_	I-Premise
161	40	_	_	I-Premise
162	%	_	_	I-Premise
163	(	_	_	I-Premise
164	29	_	_	I-Premise
165	vs.	_	_	I-Premise
166	49	_	_	I-Premise
167	min	_	_	I-Premise
168	,	_	_	I-Premise
169	P	_	_	I-Premise
170	<	_	_	I-Premise
171	0.001	_	_	I-Premise
172	)	_	_	I-Premise
173	and	_	_	I-Premise
174	54	_	_	I-Premise
175	%	_	_	I-Premise
176	(	_	_	I-Premise
177	8	_	_	I-Premise
178	vs.	_	_	I-Premise
179	18	_	_	I-Premise
180	min.	_	_	I-Premise
181	,	_	_	I-Premise
182	P	_	_	I-Premise
183	<	_	_	I-Premise
184	0.001	_	_	I-Premise
185	)	_	_	I-Premise
186	,	_	_	I-Premise
187	respectively	_	_	I-Premise
188	.	_	_	I-Premise

189	Compared	_	_	B-Premise
190	with	_	_	I-Premise
191	SMBG	_	_	I-Premise
192	,	_	_	I-Premise
193	CGM	_	_	I-Premise
194	use	_	_	I-Premise
195	improved	_	_	I-Premise
196	hypoglycemia-related	_	_	I-Premise
197	confidence	_	_	I-Premise
198	in	_	_	I-Premise
199	social	_	_	I-Premise
200	situations	_	_	I-Premise
201	(	_	_	I-Premise
202	P	_	_	I-Premise
203	=	_	_	I-Premise
204	0.016	_	_	I-Premise
205	)	_	_	I-Premise
206	and	_	_	I-Premise
207	confidence	_	_	I-Premise
208	in	_	_	I-Premise
209	more	_	_	I-Premise
210	broadly	_	_	I-Premise
211	avoiding	_	_	I-Premise
212	serious	_	_	I-Premise
213	problems	_	_	I-Premise
214	due	_	_	I-Premise
215	to	_	_	I-Premise
216	hypoglycemia	_	_	I-Premise
217	(	_	_	I-Premise
218	P	_	_	I-Premise
219	=	_	_	I-Premise
220	0.0020	_	_	I-Premise
221	)	_	_	I-Premise
222	.	_	_	I-Premise

223	Persons	_	_	B-Premise
224	also	_	_	I-Premise
225	reported	_	_	I-Premise
226	greater	_	_	I-Premise
227	confidence	_	_	I-Premise
228	in	_	_	I-Premise
229	detecting	_	_	I-Premise
230	and	_	_	I-Premise
231	responding	_	_	I-Premise
232	to	_	_	I-Premise
233	decreasing	_	_	I-Premise
234	blood	_	_	I-Premise
235	glucose	_	_	I-Premise
236	levels	_	_	I-Premise
237	(	_	_	I-Premise
238	thereby	_	_	I-Premise
239	avoiding	_	_	I-Premise
240	hypoglycemia	_	_	I-Premise
241	)	_	_	I-Premise
242	during	_	_	I-Premise
243	CGM	_	_	I-Premise
244	use	_	_	I-Premise
245	(	_	_	I-Premise
246	P	_	_	I-Premise
247	=	_	_	I-Premise
248	0.0033	_	_	I-Premise
249	)	_	_	I-Premise
250	and	_	_	O
251	indicated	_	_	B-Premise
252	greater	_	_	I-Premise
253	conviction	_	_	I-Premise
254	that	_	_	I-Premise
255	they	_	_	I-Premise
256	could	_	_	I-Premise
257	more	_	_	I-Premise
258	freely	_	_	I-Premise
259	live	_	_	I-Premise
260	their	_	_	I-Premise
261	lives	_	_	I-Premise
262	despite	_	_	I-Premise
263	the	_	_	I-Premise
264	risk	_	_	I-Premise
265	of	_	_	I-Premise
266	hypoglycemia	_	_	I-Premise
267	(	_	_	I-Premise
268	P	_	_	I-Premise
269	=	_	_	I-Premise
270	0.022	_	_	I-Premise
271	)	_	_	I-Premise
272	.	_	_	I-Premise

273	CGM	_	_	B-Claim
274	reduced	_	_	I-Claim
275	time	_	_	I-Claim
276	in	_	_	I-Claim
277	both	_	_	I-Claim
278	nocturnal	_	_	I-Claim
279	and	_	_	I-Claim
280	daytime	_	_	I-Claim
281	hypoglycemia	_	_	I-Claim
282	in	_	_	I-Claim
283	persons	_	_	I-Claim
284	with	_	_	I-Claim
285	type	_	_	I-Claim
286	1	_	_	I-Claim
287	diabetes	_	_	I-Claim
288	treated	_	_	I-Claim
289	with	_	_	I-Claim
290	MDI	_	_	I-Claim
291	and	_	_	I-Claim
292	improved	_	_	I-Claim
293	hypoglycemia-related	_	_	I-Claim
294	confidence	_	_	I-Claim
295	,	_	_	I-Claim
296	especially	_	_	I-Claim
297	in	_	_	I-Claim
298	social	_	_	I-Claim
299	situations	_	_	I-Claim
300	,	_	_	I-Claim
301	thus	_	_	I-Claim
302	contributing	_	_	I-Claim
303	to	_	_	I-Claim
304	greater	_	_	I-Claim
305	well-being	_	_	I-Claim
306	and	_	_	I-Claim
307	quality	_	_	I-Claim
308	of	_	_	I-Claim
309	life	_	_	I-Claim
310	.	_	_	I-Claim


0	To	_	_	O
1	investigate	_	_	O
2	risk	_	_	O
3	factors	_	_	O
4	associated	_	_	O
5	with	_	_	O
6	visual	_	_	O
7	field	_	_	O
8	progression	_	_	O
9	in	_	_	O
10	the	_	_	O
11	Low-pressure	_	_	O
12	Glaucoma	_	_	O
13	Treatment	_	_	O
14	Study	_	_	O
15	,	_	_	O
16	a	_	_	O
17	prospective	_	_	O
18	trial	_	_	O
19	designed	_	_	O
20	to	_	_	O
21	compare	_	_	O
22	the	_	_	O
23	effects	_	_	O
24	of	_	_	O
25	the	_	_	O
26	alpha2-adrenergic	_	_	O
27	agonist	_	_	O
28	brimonidine	_	_	O
29	tartrate	_	_	O
30	0.2	_	_	O
31	%	_	_	O
32	to	_	_	O
33	the	_	_	O
34	beta-adrenergic	_	_	O
35	antagonist	_	_	O
36	timolol	_	_	O
37	maleate	_	_	O
38	0.5	_	_	O
39	%	_	_	O
40	on	_	_	O
41	visual	_	_	O
42	function	_	_	O
43	in	_	_	O
44	low-pressure	_	_	O
45	glaucoma	_	_	O
46	.	_	_	O

47	Prospective	_	_	O
48	cohort	_	_	O
49	study	_	_	O
50	.	_	_	O

51	Low-pressure	_	_	O
52	Glaucoma	_	_	O
53	Treatment	_	_	O
54	Study	_	_	O
55	patients	_	_	O
56	with	_	_	O
57	≥5	_	_	O
58	visual	_	_	O
59	field	_	_	O
60	tests	_	_	O
61	during	_	_	O
62	follow-up	_	_	O
63	were	_	_	O
64	included	_	_	O
65	.	_	_	O

66	Progression	_	_	O
67	was	_	_	O
68	determined	_	_	O
69	using	_	_	O
70	pointwise	_	_	O
71	linear	_	_	O
72	regression	_	_	O
73	analysis	_	_	O
74	,	_	_	O
75	defined	_	_	O
76	as	_	_	O
77	the	_	_	O
78	same	_	_	O
79	3	_	_	O
80	or	_	_	O
81	more	_	_	O
82	visual	_	_	O
83	field	_	_	O
84	locations	_	_	O
85	with	_	_	O
86	a	_	_	O
87	slope	_	_	O
88	more	_	_	O
89	negative	_	_	O
90	than	_	_	O
91	-1.0	_	_	O
92	dB/year	_	_	O
93	at	_	_	O
94	P	_	_	O
95	<	_	_	O
96	5	_	_	O
97	%	_	_	O
98	,	_	_	O
99	on	_	_	O
100	3	_	_	O
101	consecutive	_	_	O
102	tests	_	_	O
103	.	_	_	O

104	Ocular	_	_	O
105	and	_	_	O
106	systemic	_	_	O
107	risk	_	_	O
108	factors	_	_	O
109	were	_	_	O
110	analyzed	_	_	O
111	using	_	_	O
112	Cox	_	_	O
113	proportional	_	_	O
114	hazards	_	_	O
115	model	_	_	O
116	and	_	_	O
117	further	_	_	O
118	tested	_	_	O
119	for	_	_	O
120	independence	_	_	O
121	in	_	_	O
122	a	_	_	O
123	multivariate	_	_	O
124	model	_	_	O
125	.	_	_	O

126	A	_	_	O
127	total	_	_	O
128	of	_	_	O
129	253	_	_	O
130	eyes	_	_	O
131	of	_	_	O
132	127	_	_	O
133	subjects	_	_	O
134	(	_	_	O
135	mean	_	_	O
136	age	_	_	O
137	,	_	_	O
138	64.7	_	_	O
139	10.9	_	_	O
140	years	_	_	O
141	;	_	_	O
142	mean	_	_	O
143	follow-up	_	_	O
144	,	_	_	O
145	40.6	_	_	O
146	12	_	_	O
147	months	_	_	O
148	)	_	_	O
149	were	_	_	O
150	analyzed	_	_	O
151	.	_	_	O

152	Eyes	_	_	B-Premise
153	randomized	_	_	I-Premise
154	to	_	_	I-Premise
155	timolol	_	_	I-Premise
156	progressed	_	_	I-Premise
157	faster	_	_	I-Premise
158	than	_	_	I-Premise
159	those	_	_	I-Premise
160	randomized	_	_	I-Premise
161	to	_	_	I-Premise
162	brimonidine	_	_	I-Premise
163	(	_	_	I-Premise
164	mean	_	_	I-Premise
165	rates	_	_	I-Premise
166	of	_	_	I-Premise
167	progression	_	_	I-Premise
168	,	_	_	I-Premise
169	-0.38	_	_	I-Premise
170	0.9	_	_	I-Premise
171	vs	_	_	I-Premise
172	0.02	_	_	I-Premise
173	0.7	_	_	I-Premise
174	dB/y	_	_	I-Premise
175	,	_	_	I-Premise
176	P	_	_	I-Premise
177	<	_	_	I-Premise
178	.01	_	_	I-Premise
179	)	_	_	I-Premise
180	.	_	_	I-Premise

181	In	_	_	O
182	the	_	_	O
183	final	_	_	O
184	multivariate	_	_	O
185	model	_	_	O
186	adjusting	_	_	O
187	for	_	_	O
188	all	_	_	O
189	tested	_	_	O
190	covariates	_	_	O
191	,	_	_	O
192	older	_	_	B-Premise
193	age	_	_	I-Premise
194	(	_	_	I-Premise
195	hazard	_	_	I-Premise
196	ratio	_	_	I-Premise
197	[	_	_	I-Premise
198	HR	_	_	I-Premise
199	]	_	_	I-Premise
200	=	_	_	I-Premise
201	1.41/decade	_	_	I-Premise
202	older	_	_	I-Premise
203	,	_	_	I-Premise
204	95	_	_	I-Premise
205	%	_	_	I-Premise
206	confidence	_	_	I-Premise
207	interval	_	_	I-Premise
208	[	_	_	I-Premise
209	CI	_	_	I-Premise
210	]	_	_	I-Premise
211	=	_	_	I-Premise
212	1.05	_	_	I-Premise
213	to	_	_	I-Premise
214	1.90	_	_	I-Premise
215	,	_	_	I-Premise
216	P	_	_	I-Premise
217	=	_	_	I-Premise
218	.022	_	_	I-Premise
219	)	_	_	I-Premise
220	,	_	_	I-Premise
221	use	_	_	I-Premise
222	of	_	_	I-Premise
223	systemic	_	_	I-Premise
224	antihypertensives	_	_	I-Premise
225	(	_	_	I-Premise
226	HR	_	_	I-Premise
227	=	_	_	I-Premise
228	2.53	_	_	I-Premise
229	,	_	_	I-Premise
230	95	_	_	I-Premise
231	%	_	_	I-Premise
232	CI	_	_	I-Premise
233	=	_	_	I-Premise
234	1.32	_	_	I-Premise
235	to	_	_	I-Premise
236	4.87	_	_	I-Premise
237	,	_	_	I-Premise
238	P	_	_	I-Premise
239	=	_	_	I-Premise
240	.005	_	_	I-Premise
241	)	_	_	I-Premise
242	,	_	_	I-Premise
243	and	_	_	I-Premise
244	mean	_	_	I-Premise
245	ocular	_	_	I-Premise
246	perfusion	_	_	I-Premise
247	pressure	_	_	I-Premise
248	(	_	_	I-Premise
249	HR	_	_	I-Premise
250	=	_	_	I-Premise
251	1.21/mm	_	_	I-Premise
252	Hg	_	_	I-Premise
253	lower	_	_	I-Premise
254	,	_	_	I-Premise
255	95	_	_	I-Premise
256	%	_	_	I-Premise
257	CI	_	_	I-Premise
258	=	_	_	I-Premise
259	1.12	_	_	I-Premise
260	to	_	_	I-Premise
261	1.31	_	_	I-Premise
262	,	_	_	I-Premise
263	P	_	_	I-Premise
264	<	_	_	I-Premise
265	.001	_	_	I-Premise
266	)	_	_	I-Premise
267	were	_	_	I-Premise
268	associated	_	_	I-Premise
269	with	_	_	I-Premise
270	progression	_	_	I-Premise
271	whereas	_	_	O
272	randomization	_	_	B-Premise
273	to	_	_	I-Premise
274	brimonidine	_	_	I-Premise
275	revealed	_	_	I-Premise
276	a	_	_	I-Premise
277	protective	_	_	I-Premise
278	effect	_	_	I-Premise
279	(	_	_	I-Premise
280	HR	_	_	I-Premise
281	=	_	_	I-Premise
282	0.26	_	_	I-Premise
283	,	_	_	I-Premise
284	95	_	_	I-Premise
285	%	_	_	I-Premise
286	CI	_	_	I-Premise
287	=	_	_	I-Premise
288	0.12	_	_	I-Premise
289	to	_	_	I-Premise
290	0.55	_	_	I-Premise
291	,	_	_	I-Premise
292	P	_	_	I-Premise
293	<	_	_	I-Premise
294	.001	_	_	I-Premise
295	)	_	_	I-Premise
296	.	_	_	I-Premise

297	While	_	_	O
298	randomization	_	_	B-Premise
299	to	_	_	I-Premise
300	brimonidine	_	_	I-Premise
301	0.2	_	_	I-Premise
302	%	_	_	I-Premise
303	was	_	_	I-Premise
304	protective	_	_	I-Premise
305	compared	_	_	I-Premise
306	to	_	_	I-Premise
307	timolol	_	_	I-Premise
308	0.5	_	_	I-Premise
309	%	_	_	I-Premise
310	,	_	_	I-Premise
311	lower	_	_	B-Premise
312	mean	_	_	I-Premise
313	ocular	_	_	I-Premise
314	perfusion	_	_	I-Premise
315	pressure	_	_	I-Premise
316	increased	_	_	I-Premise
317	the	_	_	I-Premise
318	risk	_	_	I-Premise
319	for	_	_	I-Premise
320	reaching	_	_	I-Premise
321	a	_	_	I-Premise
322	progression	_	_	I-Premise
323	outcome	_	_	I-Premise
324	in	_	_	I-Premise
325	the	_	_	I-Premise
326	Low-pressure	_	_	I-Premise
327	Glaucoma	_	_	I-Premise
328	Treatment	_	_	I-Premise
329	Study	_	_	I-Premise
330	.	_	_	I-Premise

331	This	_	_	B-Claim
332	suggests	_	_	I-Claim
333	that	_	_	I-Claim
334	the	_	_	I-Claim
335	beneficial	_	_	I-Claim
336	effect	_	_	I-Claim
337	of	_	_	I-Claim
338	randomization	_	_	I-Claim
339	to	_	_	I-Claim
340	the	_	_	I-Claim
341	brimonidine	_	_	I-Claim
342	arm	_	_	I-Claim
343	was	_	_	I-Claim
344	independent	_	_	I-Claim
345	of	_	_	I-Claim
346	possible	_	_	I-Claim
347	differences	_	_	I-Claim
348	in	_	_	I-Claim
349	ocular	_	_	I-Claim
350	perfusion	_	_	I-Claim
351	pressures	_	_	I-Claim
352	between	_	_	I-Claim
353	the	_	_	I-Claim
354	2	_	_	I-Claim
355	treatment	_	_	I-Claim
356	arms	_	_	I-Claim
357	.	_	_	I-Claim

358	The	_	_	B-Claim
359	current	_	_	I-Claim
360	results	_	_	I-Claim
361	and	_	_	I-Claim
362	large	_	_	I-Claim
363	number	_	_	I-Claim
364	of	_	_	I-Claim
365	drop-outs	_	_	I-Claim
366	in	_	_	I-Claim
367	the	_	_	I-Claim
368	brimonidine	_	_	I-Claim
369	0.2	_	_	I-Claim
370	%	_	_	I-Claim
371	arm	_	_	I-Claim
372	suggest	_	_	I-Claim
373	that	_	_	I-Claim
374	more	_	_	I-Claim
375	research	_	_	I-Claim
376	is	_	_	I-Claim
377	necessary	_	_	I-Claim
378	before	_	_	I-Claim
379	altering	_	_	I-Claim
380	clinical	_	_	I-Claim
381	practice	_	_	I-Claim
382	paradigms	_	_	I-Claim
383	.	_	_	I-Claim
